Clustering O 0 7.72272323956713e-06
of O 0 4.8061203905547245e-09
missense O 0 1.4870410268486012e-05
mutations O 0 1.8060903812511242e-06
in O 0 1.1288449286439572e-07
the O 0 6.359129474731162e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999985694885254
telangiectasia I-Disease 1 0.9999996423721313
gene O 0 1.4575719433196355e-05
in O 0 9.326891259320291e-09
a O 0 4.966722144672531e-08
sporadic B-Disease 0 0.0019260277040302753
T I-Disease 1 0.9456891417503357
- I-Disease 0 0.003782155690714717
cell I-Disease 0 0.003256390802562237
leukaemia I-Disease 0 0.18724015355110168
. O 0 5.220570642450184e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.999998927116394
telangiectasia I-Disease 1 0.9999998807907104
( O 0 0.004053806886076927
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
) O 0 7.776205457332708e-09
is O 0 1.4744399035038214e-09
a O 0 3.632475209514041e-09
recessive B-Disease 0 4.945616456097923e-05
multi I-Disease 1 0.9519522786140442
- I-Disease 1 0.9999167919158936
system I-Disease 0 0.27230530977249146
disorder I-Disease 1 0.7703424096107483
caused O 0 5.6328122610693754e-08
by O 0 2.1369978009389e-10
mutations O 0 5.6328413045036996e-09
in O 0 2.852520997187469e-10
the O 0 2.905748697212829e-10
ATM O 0 3.999278703759046e-07
gene O 0 1.1395637322664243e-08
at O 0 2.4639305706841697e-08
11q22 O 0 6.747394110107052e-08
- O 0 3.357732339281938e-06
q23 O 0 3.0103672088444e-07
( O 0 8.803594520045976e-10
ref O 0 9.312910833614296e-07
. O 0 4.815082221831801e-10
3 O 0 9.924215893519772e-10
) O 0 1.0596419297570492e-09
. O 0 8.548786567530442e-09

The O 0 8.927480621423456e-08
risk O 0 3.366896407897002e-06
of O 0 8.703369691609453e-10
cancer B-Disease 0 1.0684912012948189e-06
, O 0 8.150524144490134e-10
especially O 0 2.1408745887185887e-09
lymphoid B-Disease 0 4.578631944696099e-07
neoplasias I-Disease 0 6.450069577113027e-06
, O 0 5.76271519392435e-09
is O 0 6.909733674120844e-09
substantially O 0 1.1145024814140925e-07
elevated O 0 9.709890491649276e-07
in O 0 4.462274461047855e-08
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 1.1973145774391014e-05
and O 0 2.9377090982052323e-07
has O 0 6.448818226090225e-07
long O 0 3.330774234200362e-08
been O 0 5.48849250492367e-08
associated O 0 8.842948773235548e-08
with O 0 5.554274480346066e-07
chromosomal O 1 0.9999998807907104
instability O 1 0.9999909400939941
. O 0 2.4502355699951295e-06

By O 0 9.678164758497587e-08
analysing O 0 4.908221308141947e-05
tumour B-Disease 1 0.9999960660934448
DNA O 0 2.9210245884314645e-06
from O 0 3.3026217316489692e-09
patients O 0 2.5962356708930656e-09
with O 0 3.3874200666694776e-10
sporadic B-Disease 0 4.180021278443746e-05
T I-Disease 1 0.566744863986969
- I-Disease 0 0.0004078488564118743
cell I-Disease 0 0.0009640128118917346
prolymphocytic I-Disease 0 0.03893212229013443
leukaemia I-Disease 1 0.7947655916213989
( O 0 1.7273173114062956e-08
T B-Disease 0 0.00046191702131181955
- I-Disease 0 1.9325325411045924e-06
PLL I-Disease 0 9.53477865550667e-07
) O 0 3.713561402829413e-10
, O 0 7.511791189074302e-11
a O 0 3.1213401308072264e-10
rare O 0 1.8541873814115206e-08
clonal B-Disease 0 1.8386411966275773e-06
malignancy I-Disease 0 1.2281109775358345e-05
with O 0 5.313833262299283e-10
similarities O 0 3.6784986168214573e-09
to O 0 5.726357721336228e-10
a O 0 2.9076199226096833e-08
mature B-Disease 0 1.0072010809381027e-05
T I-Disease 0 0.07609298080205917
- I-Disease 0 0.00039246282540261745
cell I-Disease 0 0.001724898349493742
leukaemia I-Disease 0 0.005668628495186567
seen O 0 1.0683928849175572e-05
in O 0 3.437750351054092e-08
A B-Disease 1 0.999992847442627
- I-Disease 1 0.999994158744812
T I-Disease 1 1.0
, O 0 1.0723377741328477e-08
we O 0 9.160490144211053e-10
demonstrate O 0 1.4474992038326917e-10
a O 0 3.130556230912518e-11
high O 0 2.0901637365344783e-10
frequency O 0 1.8540698976110548e-09
of O 0 4.236765452358959e-11
ATM O 0 2.878057330235606e-07
mutations O 0 1.2338224664176778e-08
in O 0 3.20644932827463e-09
T B-Disease 0 0.003382223891094327
- I-Disease 0 7.102603558450937e-05
PLL I-Disease 0 5.633298133034259e-05
. O 0 1.8933624801320548e-07

In O 0 3.172995732825257e-08
marked O 0 9.630416286654508e-08
contrast O 0 1.3008022214933135e-08
to O 0 1.3803792553446215e-09
the O 0 4.3345352307433416e-10
ATM O 0 6.37823222859879e-06
mutation O 0 2.2816990963292483e-08
pattern O 0 3.9100300455174875e-06
in O 0 7.058029893869389e-08
A B-Disease 1 0.9999958276748657
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
, O 0 2.5942421544300487e-08
the O 0 1.1348340323014128e-10
most O 0 9.32307564482926e-11
frequent O 0 9.396524669469386e-10
nucleotide O 0 1.0515101012131822e-09
changes O 0 2.2302786006900277e-10
in O 0 1.1247233699940296e-10
this O 0 2.1868751254316976e-09
leukaemia B-Disease 0 5.867686923011206e-05
were O 0 2.0430364955359437e-08
missense O 0 3.4184106425527716e-06
mutations O 0 9.242173177881341e-07
. O 0 7.978339766623321e-08

These O 0 2.5287150151598325e-08
clustered O 0 3.3767428249120712e-06
in O 0 1.9767063541564767e-09
the O 0 2.2406056177093348e-10
region O 0 2.1236106206856675e-09
corresponding O 0 2.1704021913038218e-10
to O 0 2.2192839232992867e-10
the O 0 6.850033734684402e-11
kinase O 0 9.948118773195347e-09
domain O 0 3.407269799637902e-09
, O 0 3.137324289248511e-10
which O 0 1.0370003744597511e-09
is O 0 7.90648158055518e-10
highly O 0 2.3034948948286171e-10
conserved O 0 1.252171810683933e-09
in O 0 4.039106271669368e-10
ATM O 0 3.883043973473832e-06
- O 0 1.1945974165428197e-06
related O 0 1.3395775155800038e-08
proteins O 0 2.8373545180038207e-10
in O 0 6.067847335700094e-10
mouse O 0 4.409742359712254e-06
, O 0 1.164657259522528e-09
yeast O 0 1.1242082109674811e-07
and O 0 9.713630788610317e-09
Drosophila O 0 1.1670555011278338e-07
. O 0 4.1954383078746105e-08

The O 0 9.691168401104733e-08
resulting O 0 8.408455443031926e-08
amino O 0 1.3625791162041878e-08
- O 0 1.699672793620266e-07
acid O 0 4.195738201318022e-10
substitutions O 0 6.871209712322468e-10
are O 0 8.283736890879467e-11
predicted O 0 2.4411157539816486e-09
to O 0 5.995504787081885e-11
interfere O 0 9.334437223174064e-09
with O 0 2.0944097844921572e-10
ATP O 0 1.1695864721161797e-08
binding O 0 2.720687852786341e-08
or O 0 4.674889453326614e-08
substrate O 0 6.640988431172445e-06
recognition O 0 1.0744776801629996e-07
. O 0 1.2036655050451373e-07

Two O 0 1.6936009927803752e-08
of O 0 4.210898851830791e-10
seventeen O 0 3.435619788660915e-08
mutated O 0 9.149337643066247e-07
T B-Disease 0 0.0007665455341339111
- I-Disease 0 3.924712018488208e-06
PLL I-Disease 0 2.607088163131266e-06
samples O 0 1.1301634117444337e-07
had O 0 1.167355545561577e-08
a O 0 1.6193307805778545e-09
previously O 0 3.535354267114599e-07
reported O 0 0.0003440768632572144
A B-Disease 1 0.9999545812606812
- I-Disease 1 0.9999608993530273
T I-Disease 1 0.999994158744812
allele O 0 7.163469035731396e-06
. O 0 1.4277179616328795e-07

In O 0 4.095312888807712e-08
contrast O 0 1.4930370184629282e-07
, O 0 2.9125415412778466e-09
no O 0 1.2919249003928712e-09
mutations O 0 2.1885611101168934e-09
were O 0 2.949978261668207e-09
detected O 0 3.8725463014088746e-07
in O 0 1.5423722021790098e-10
the O 0 5.5756916444993365e-11
p53 O 0 1.215307410262767e-09
gene O 0 3.75346953518374e-09
, O 0 3.8692266057793745e-10
suggesting O 0 2.5446411644480804e-09
that O 0 4.5653630875719386e-10
this O 0 2.355878603310657e-09
tumour B-Disease 1 0.9999991655349731
suppressor O 0 6.447849500545999e-06
is O 0 8.114466965025713e-08
not O 0 2.2964812274040014e-09
frequently O 0 1.9154764441253747e-09
altered O 0 1.92211633276429e-08
in O 0 1.3382642771730957e-09
this O 0 1.1943481759146835e-08
leukaemia B-Disease 0 0.0007570161833427846
. O 0 5.301923167166933e-08

Occasional O 0 3.083911360590719e-05
missense O 0 4.504004027694464e-05
mutations O 0 7.017116558927228e-07
in O 0 3.901837075659387e-09
ATM O 0 1.1117779649794102e-05
were O 0 2.1330788513296284e-07
also O 0 1.5278743603630573e-08
found O 0 1.7491057491270112e-08
in O 0 5.179634499086205e-09
tumour B-Disease 1 0.9999998807907104
DNA O 0 2.5101646770053776e-06
from O 0 1.401082583285529e-09
patients O 0 2.6132365160691506e-09
with O 0 6.025221988004148e-10
B B-Disease 0 3.080602255067788e-05
- I-Disease 0 1.736036028887611e-05
cell I-Disease 0 0.0001256081450264901
non I-Disease 0 0.00016705320740584284
- I-Disease 1 0.9959239959716797
Hodgkins I-Disease 1 0.9999724626541138
lymphomas I-Disease 0 0.273692786693573
( O 0 6.772353344786097e-09
B B-Disease 0 1.2832539141527377e-05
- I-Disease 0 9.980570894185803e-07
NHL I-Disease 0 3.943849247178832e-09
) O 0 1.5583223600401652e-10
and O 0 2.1274527972625634e-10
a O 0 4.330545699815502e-09
B B-Disease 0 3.5141140415362315e-06
- I-Disease 0 7.832982191757765e-07
NHL I-Disease 0 4.285749000132455e-08
cell O 0 2.770156015685643e-06
line O 0 2.2582238671020605e-05
. O 0 7.663231826882111e-08

The O 0 7.822305470028823e-09
evidence O 0 5.929120305836477e-09
of O 0 6.524764062376676e-11
a O 0 3.7893624349472077e-10
significant O 0 2.040438040751269e-09
proportion O 0 6.194932566927491e-09
of O 0 2.150769840003619e-10
loss O 0 2.530244955778471e-07
- O 0 1.8142549379263073e-05
of O 0 1.3137830379150728e-08
- O 0 0.0007991848397068679
function O 0 3.4804969573087874e-07
mutations O 0 7.399730606039157e-08
and O 0 5.7160156607949375e-09
a O 0 3.21752580134671e-09
complete O 0 3.018235474883113e-07
absence O 0 2.0316081261739782e-08
of O 0 6.726157825154289e-11
the O 0 9.026381031507213e-11
normal O 0 1.0443544917748682e-09
copy O 0 2.1124172633335547e-08
of O 0 8.865464612428653e-11
ATM O 0 4.534836648417695e-07
in O 0 2.636812435063973e-10
the O 0 1.289860857012215e-10
majority O 0 8.692370712104491e-10
of O 0 6.058433754674297e-10
mutated O 0 0.0001971207238966599
tumours B-Disease 1 0.9999983310699463
establishes O 0 2.332006943106535e-07
somatic O 0 3.068815956908111e-08
inactivation O 0 6.333339115371928e-07
of O 0 9.488189400830294e-11
this O 0 1.2777108537864734e-10
gene O 0 5.4124753567919015e-09
in O 0 2.0564284997082183e-10
the O 0 1.2508941105160432e-10
pathogenesis O 0 1.4171283702069104e-08
of O 0 3.9952025021605664e-10
sporadic B-Disease 0 6.801795825595036e-05
T I-Disease 0 0.06358497589826584
- I-Disease 0 1.4340963389258832e-05
PLL I-Disease 0 5.580749075306812e-06
and O 0 5.908461275794252e-09
suggests O 0 1.6161586513518955e-09
that O 0 2.0714388537790285e-10
ATM O 0 2.585598224413843e-07
acts O 0 2.084548178515888e-08
as O 0 2.4107302820652876e-09
a O 0 1.0418168727710508e-07
tumour B-Disease 1 0.999996542930603
suppressor O 0 6.788240716559812e-05
. O 0 1.9171685039509612e-07

As O 0 3.036490170416073e-08
constitutional O 0 2.105826846232617e-09
DNA O 0 3.153369476649459e-08
was O 0 1.4539511994371423e-07
not O 0 6.103482164121488e-10
available O 0 2.8058513290574183e-09
, O 0 9.517956423010787e-10
a O 0 3.0566169595402926e-09
putative O 0 4.386656200949801e-06
hereditary O 0 0.00016640458488836884
predisposition O 0 9.490241063758731e-05
to O 0 3.6216681564837927e-07
T B-Disease 0 0.4276353418827057
- I-Disease 0 5.168435109226266e-06
PLL I-Disease 0 1.3823344033880858e-06
will O 0 2.0932167110743194e-09
require O 0 2.0179888315929873e-10
further O 0 1.7523964224164246e-10
investigation O 0 3.73051634028343e-09
. O 0 1.0637994929396655e-09
. O 0 1.4683758209343978e-08

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999990463256836
protein O 0 1.1897906006197445e-05
kinase O 0 1.5514486221945845e-05
is O 0 2.1575022657316367e-08
involved O 0 2.508972807291343e-09
in O 0 2.781879240854046e-11
the O 0 7.811722622930173e-12
modulation O 0 7.134197121949626e-10
of O 0 4.024907490629559e-11
the O 0 4.546116261217037e-10
Ca2 O 0 8.719378996602245e-08
+ O 0 1.873399924079422e-06
homeostasis O 0 6.428863707697019e-05
in O 0 3.3571154745004606e-08
skeletal O 0 0.0102591123431921
muscle O 0 7.4737818067660555e-06
cells O 0 8.365757366846083e-07
. O 0 1.7091736026486615e-07

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
( O 0 5.758094266639091e-05
DM B-Disease 1 1.0
) O 0 3.5310949897393584e-07
, O 0 1.7527952422824455e-09
the O 0 1.1675035938019107e-10
most O 0 2.864265935542676e-09
prevalent O 0 6.979810859775171e-05
muscular B-Disease 0 0.03594876080751419
disorder I-Disease 0 0.0001815662399167195
in O 0 5.485776277680543e-10
adults O 0 1.5331850988786755e-07
, O 0 4.142882037427853e-09
is O 0 3.823401328872933e-08
caused O 0 1.2798537341041083e-08
by O 0 1.8552044622754948e-10
( O 0 3.4287492289841737e-10
CTG O 0 3.238053807308461e-07
) O 0 2.2237076069409056e-10
n O 0 5.077178570900287e-07
- O 0 6.00391331317951e-07
repeat O 0 9.678548629210582e-09
expansion O 0 1.600987009631183e-09
in O 0 1.317263745997943e-11
a O 0 2.4101347653737726e-11
gene O 0 1.8811122104445133e-10
encoding O 0 3.0760208269420275e-10
a O 0 1.8400730938950005e-09
protein O 0 5.369323474724297e-08
kinase O 0 2.819936526066158e-06
( O 0 5.457967944266784e-08
DM B-Disease 1 0.9999988079071045
protein O 0 3.5357084016141016e-07
kinase O 0 7.475325105588126e-07
; O 0 1.3324723546759287e-09
DMPK O 0 4.969384690411971e-07
) O 0 1.880886280059002e-10
and O 0 9.34964466958732e-11
involves O 0 1.260599125085804e-10
changes O 0 8.389508532324896e-11
in O 0 1.0529244837131913e-10
cytoarchitecture O 0 1.548310706311895e-06
and O 0 2.0160864977469828e-08
ion O 0 4.843503120355308e-06
homeostasis O 0 0.00010124399705091491
. O 0 2.9505264365070616e-07

To O 0 2.9037568793910395e-08
obtain O 0 2.3294456141798037e-08
clues O 0 1.3070850002350198e-07
to O 0 1.1419347689667347e-09
the O 0 1.9740603596218875e-10
normal O 0 2.6263184960129138e-09
biological O 0 3.032461748375681e-08
role O 0 1.3646122010158024e-09
of O 0 1.219390977080792e-10
DMPK O 0 4.673182445458224e-07
in O 0 3.5833741529600616e-10
cellular O 0 1.609659818768705e-07
ion O 0 1.4828485461748642e-07
homeostasis O 0 4.236277163727209e-06
, O 0 2.4644792873118604e-09
we O 0 5.432912786318411e-09
have O 0 4.1206482670475e-10
compared O 0 9.536873513127375e-10
the O 0 5.842338418604598e-11
resting O 0 9.569698988798336e-08
[ O 0 1.8491855824365189e-09
Ca2 O 0 9.812037848888622e-10
+ O 0 1.2639975288664118e-08
] O 0 3.811184257074274e-08
i O 0 1.221816319230129e-07
, O 0 2.324914739892936e-11
the O 0 3.3784218912008557e-12
amplitude O 0 5.331549091103227e-10
and O 0 4.3994449749895637e-10
shape O 0 2.5813058357471164e-08
of O 0 4.451760141077621e-11
depolarization O 0 1.525405046720607e-08
- O 0 6.624074558203574e-06
induced O 0 1.4769746030651731e-06
Ca2 O 0 4.519940688396673e-08
+ O 0 1.8021367509390984e-07
transients O 0 4.771760359290056e-06
, O 0 4.660482222362816e-09
and O 0 8.307363685844393e-10
the O 0 3.458586889104609e-11
content O 0 1.9780903581789744e-09
of O 0 5.466074814997057e-11
ATP O 0 7.991891592951106e-09
- O 0 4.0656956912243913e-07
driven O 0 7.398889465548564e-07
ion O 0 9.795479627427994e-08
pumps O 0 9.258020128299904e-08
in O 0 1.0291933971728895e-09
cultured O 0 3.833767550531775e-06
skeletal O 0 0.0001298312417929992
muscle O 0 1.0167033082097987e-07
cells O 0 4.512581863735932e-09
of O 0 1.2744444388701481e-10
wild O 0 4.265475084253012e-08
- O 0 4.143787464272464e-06
type O 0 2.1957279386697337e-05
and O 0 3.2961349205606894e-08
DMPK O 0 4.988514319848036e-06
[ O 0 2.684194555513386e-08
- O 0 5.9058438637293875e-06
/ O 0 1.8420303604216315e-05
- O 0 7.096262379491236e-06
] O 0 1.407295968647304e-07
knockout O 0 2.242383516204427e-06
mice O 0 3.1410152132593794e-06
. O 0 9.150160451554257e-08

In O 0 5.9359582138540645e-08
vitro O 0 2.620702980493661e-05
- O 0 1.2989154129172675e-05
differentiated O 0 1.0223266144748777e-06
DMPK O 0 8.641043677926064e-06
[ O 0 6.288087206485216e-08
- O 0 1.8350098116570734e-06
/ O 0 9.009903806145303e-06
- O 0 3.0550736482837237e-06
] O 0 2.3294767004244932e-08
myotubes O 0 2.375711716240403e-08
exhibit O 0 1.9564746267519695e-08
a O 0 2.0456440985583413e-09
higher O 0 1.9998123157449754e-09
resting O 0 9.630563369000811e-08
[ O 0 2.522624331646739e-09
Ca2 O 0 3.336393605835042e-09
+ O 0 5.798971614012771e-08
] O 0 4.1355022517564066e-08
i O 0 2.4540204535128396e-08
than O 0 4.1132511285901785e-10
do O 0 1.0802098104889524e-09
wild O 0 4.8390411677701195e-09
- O 0 2.502207507859566e-07
type O 0 2.2484073269879445e-06
myotubes O 0 1.4158349586068653e-06
because O 0 9.76646097328171e-10
of O 0 7.232121585626361e-12
an O 0 3.7764954358143754e-11
altered O 0 9.305496817546555e-09
open O 0 1.2624380429926418e-09
probability O 0 3.164229156471521e-10
of O 0 3.062613010418325e-11
voltage O 0 3.507400379021419e-07
- O 0 2.5817445248321746e-07
dependent O 0 5.428327654044551e-08
l O 0 5.275313128549897e-07
- O 0 6.651546158309429e-08
type O 0 1.3624470796003152e-07
Ca2 O 0 1.7048051859092084e-08
+ O 0 3.91748393724356e-08
and O 0 2.4220450089984524e-09
Na O 0 5.737809942729655e-07
+ O 0 4.161944389124983e-07
channels O 0 9.339361213278607e-07
. O 0 1.0833800700993379e-07

The O 0 1.663278581531813e-08
mutant O 0 4.944268994222512e-07
myotubes O 0 4.549569041500945e-07
exhibit O 0 3.782347590686186e-08
smaller O 0 7.849043193175476e-09
and O 0 7.313081251680842e-10
slower O 0 3.027837891522722e-08
Ca2 O 0 7.707089366704167e-08
+ O 0 1.1519045273189477e-07
responses O 0 3.34911964827711e-09
upon O 0 1.414329348081722e-10
triggering O 0 2.3947954730374477e-09
by O 0 8.644138876912066e-11
acetylcholine O 0 6.63827677271911e-08
or O 0 2.7561629423189515e-08
high O 0 7.502637799916556e-08
external O 0 6.952874542776044e-08
K O 0 1.65750577707513e-06
+ O 0 3.4925801628560293e-07
. O 0 6.624553350320639e-08

In O 0 1.91886346811998e-08
addition O 0 1.9830126429809525e-09
, O 0 2.1059302912629363e-10
we O 0 5.863560331720308e-11
observed O 0 2.906081209008704e-10
that O 0 1.4634916542521914e-11
these O 0 2.3043506339193165e-11
Ca2 O 0 5.678731707092766e-09
+ O 0 1.5271291431417922e-07
transients O 0 1.6856446336532827e-06
partially O 0 6.588073802049621e-07
result O 0 4.795962516013219e-10
from O 0 2.6766342614559235e-11
an O 0 1.5465899394495608e-11
influx O 0 7.613540353723636e-11
of O 0 8.127462244877925e-12
extracellular O 0 6.857017731398685e-10
Ca2 O 0 2.0426342839385825e-09
+ O 0 5.001665304149583e-09
through O 0 1.9012652563432653e-10
the O 0 1.353111789281769e-10
l O 0 1.6903489097330748e-07
- O 0 6.873313651567514e-08
type O 0 2.2807273580838228e-07
Ca2 O 0 6.638301641714861e-08
+ O 0 2.142350723488562e-07
channel O 0 5.378233254305087e-06
. O 0 9.113930588000585e-08

Neither O 0 8.298223974634311e-07
the O 0 6.049715728373428e-10
content O 0 2.4243757223985085e-08
nor O 0 1.1409165168174695e-08
the O 0 4.5040901563986324e-11
activity O 0 3.5652960583831828e-09
of O 0 1.9486247684885605e-11
Na O 0 3.921348934454727e-08
+ O 0 3.1637135577966546e-08
/ O 0 1.6480171893817896e-07
K O 0 1.2469247678836837e-07
+ O 0 2.693590239744026e-08
ATPase O 0 7.783032174302207e-07
and O 0 6.070165703420116e-09
sarcoplasmic O 0 1.4292643299995689e-06
reticulum O 0 9.094288770938874e-07
Ca2 O 0 3.1221145491144853e-07
+ O 0 1.1860485074066673e-06
- O 0 1.6147365613505826e-06
ATPase O 0 1.4838438801234588e-05
are O 0 7.210068098117972e-09
affected O 0 1.0561033825240429e-08
by O 0 1.0158670571414063e-09
DMPK O 0 5.490057446877472e-05
absence O 0 2.380234320753516e-07
. O 0 5.98767400106226e-08

In O 0 3.334092113504994e-08
conclusion O 0 1.8119600264654423e-09
, O 0 5.289886861881143e-10
our O 0 3.084722199897527e-10
data O 0 1.3493625106164586e-09
suggest O 0 1.044910380443298e-09
that O 0 2.833082379805063e-10
DMPK O 0 2.9779076271552185e-07
is O 0 5.539367298190712e-10
involved O 0 2.2061207027856966e-10
in O 0 1.3754605961147082e-11
modulating O 0 5.7172475642630616e-09
the O 0 2.3386498293476166e-10
initial O 0 1.5644281425863937e-09
events O 0 6.398712670829809e-10
of O 0 3.241236792850266e-11
excitation O 0 2.8643384553106443e-08
- O 0 1.393011916661635e-05
contraction O 0 9.997643246606458e-06
coupling O 0 4.400334887577628e-07
in O 0 3.97368227211814e-09
skeletal O 0 0.00018579885363578796
muscle O 0 5.127467943566444e-07
. O 0 5.924723378569752e-09
. O 0 2.612809346658196e-08

Constitutional O 0 1.1078640454798006e-05
RB1 O 0 0.005256345495581627
- O 0 4.074256867170334e-05
gene O 0 1.3776217429040116e-06
mutations O 0 4.5397607095765125e-07
in O 0 9.421960101008153e-09
patients O 0 1.2290350070998102e-07
with O 0 1.5123799101957047e-08
isolated O 0 0.0010312116937711835
unilateral B-Disease 0 0.008109187707304955
retinoblastoma I-Disease 0 0.006604640278965235
. O 0 4.97822668421577e-07

In O 0 3.061677489313297e-08
most O 0 4.7799466607045815e-09
patients O 0 1.1961150292449929e-08
with O 0 1.333733568031903e-09
isolated O 0 0.00020866311388090253
unilateral B-Disease 0 0.0006616251775994897
retinoblastoma I-Disease 0 0.000897508580237627
, O 0 1.254335657563388e-08
tumor B-Disease 0 1.6494716419401811e-06
development O 0 6.49467368774026e-09
is O 0 6.285408304940177e-10
initiated O 0 1.5663988994774058e-09
by O 0 5.796784233180752e-11
somatic O 0 2.644474417223819e-09
inactivation O 0 1.0039943987294464e-07
of O 0 1.4096755707182496e-10
both O 0 4.013602228347679e-10
alleles O 0 1.0827841956384532e-09
of O 0 1.4101973755398234e-10
the O 0 8.29069968233398e-09
RB1 O 0 2.4907134502427652e-05
gene O 0 3.373471315626375e-07
. O 0 1.5546315523806697e-07

However O 0 9.102690512463596e-08
, O 0 9.95113103030576e-10
some O 0 3.9497322079640185e-11
of O 0 2.9034203860578423e-11
these O 0 3.306946050329884e-09
patients O 0 9.07614516876265e-09
can O 0 3.119312141919295e-09
transmit O 0 0.0001638931134948507
retinoblastoma B-Disease 0 0.0020315477158874273
predisposition O 0 5.514745498658158e-05
to O 0 6.320578194163318e-08
their O 0 6.753548831284206e-08
offspring O 0 1.350496859231498e-06
. O 0 7.57253673100422e-08

To O 0 4.5990947938889803e-08
determine O 0 1.1092849305782693e-08
the O 0 1.3933799947185577e-10
frequency O 0 4.721252722106328e-08
and O 0 4.076637694083729e-09
nature O 0 1.2256787584874473e-08
of O 0 6.254634310476348e-11
constitutional O 0 2.27199734581518e-08
RB1 O 0 6.818076508352533e-05
- O 0 9.514722023595823e-07
gene O 0 3.653593694252777e-08
mutations O 0 3.238942625216623e-08
in O 0 2.947919464091342e-09
patients O 0 1.663814686025944e-08
with O 0 1.900041013414011e-09
isolated O 0 0.0042219022288918495
unilateral B-Disease 0 0.0015972248511388898
retinoblastoma I-Disease 0 3.987182572018355e-05
, O 0 2.2750750172662038e-09
we O 0 7.282222602711386e-10
analyzed O 0 8.157118314144896e-10
DNA O 0 6.291708043448807e-09
from O 0 3.873960041644864e-10
peripheral O 0 1.7369912939102505e-06
blood O 0 1.3712093505091616e-07
and O 0 9.740124262691552e-09
from O 0 5.561528126918347e-09
tumor B-Disease 0 9.364171273773536e-05
tissue O 0 2.7193522328161635e-05
. O 0 2.2243932562560076e-07

The O 0 4.650244189718933e-09
analysis O 0 1.2301567764438914e-08
of O 0 2.6658000251700287e-09
tumors B-Disease 1 0.9999992847442627
from O 0 2.186266279124993e-09
54 O 0 1.1327073501377072e-08
( O 0 1.0197919592114246e-10
71 O 0 2.8980342570150697e-09
% O 0 3.3932252840873645e-11
) O 0 3.1887468360247695e-11
of O 0 9.154197538885356e-11
76 O 0 2.2657397735770246e-08
informative O 0 1.3821518223267049e-05
patients O 0 2.3225165080020815e-07
showed O 0 8.496931513946038e-07
loss O 0 3.3125786558230175e-08
of O 0 3.346863897135677e-10
constitutional O 0 9.394937450224461e-08
heterozygosity O 0 5.50321965420153e-05
( O 0 6.562665362253028e-07
LOH O 1 0.9989176988601685
) O 0 2.6003801778529123e-08
at O 0 1.4032526962637348e-07
intragenic O 0 3.5326954730408033e-06
loci O 0 5.0393202855048e-07
. O 0 5.2198142697079675e-08

Three O 0 3.117588676104788e-08
of O 0 1.0140782658041303e-09
13 O 0 1.082113776362803e-08
uninformative O 0 0.0003077894216403365
patients O 0 9.785542260942748e-07
had O 0 3.3735865656581154e-08
constitutional O 0 2.962915424120638e-08
deletions O 0 2.696263436519075e-06
. O 0 2.6167873556914856e-07

For O 0 2.6302851452442155e-08
39 O 0 3.8888888553856304e-08
randomly O 0 4.27790851631471e-08
selected O 0 2.3594330400555918e-07
tumors B-Disease 1 0.9999996423721313
, O 0 2.4723810554405645e-08
SSCP O 0 3.504443520796485e-05
, O 0 3.1086508922584244e-09
hetero O 0 5.555270377044508e-07
- O 0 1.0525543814310367e-07
duplex O 0 4.853611244470812e-06
analysis O 0 4.044311552320323e-09
, O 0 3.7099701782894456e-11
sequencing O 0 4.941214659659465e-10
, O 0 3.6533112646175425e-10
and O 0 4.1209391454799515e-10
Southern O 0 1.055102227809357e-09
blot O 0 1.1928715366593678e-06
analysis O 0 1.9826684738433187e-09
were O 0 2.0465729111407427e-09
used O 0 1.1440756120251194e-09
to O 0 8.723878286431841e-10
identify O 0 2.604620306101424e-07
mutations O 0 4.267815256753238e-07
. O 0 8.381554295056048e-08

Mutations O 0 2.453364004395553e-06
were O 0 2.0067906447707173e-08
detected O 0 1.869400847454017e-07
in O 0 4.2208855854930505e-10
21 O 0 1.7743261304659086e-09
( O 0 9.674994833064332e-11
91 O 0 1.339781396936246e-09
% O 0 4.714568666019936e-11
) O 0 7.749678676560734e-11
of O 0 8.694210906767808e-10
23 O 0 2.309941191924736e-05
tumors B-Disease 1 0.9999998807907104
with O 0 2.3966347725945525e-05
LOH O 1 0.9999598264694214
. O 0 3.2143980206456035e-06

In O 0 1.2544218108700989e-08
6 O 0 5.367293720581756e-09
( O 0 7.199740109653519e-11
38 O 0 1.1931021726141466e-09
% O 0 4.6331261743803864e-11
) O 0 1.1718429004936581e-10
of O 0 1.0078807788360677e-09
16 O 0 7.382526746368967e-06
tumors B-Disease 1 1.0
without O 0 1.0824463060998823e-05
LOH O 1 0.9999823570251465
, O 0 1.3974589485599154e-08
one O 0 8.211911151079221e-10
mutation O 0 1.9129828832120666e-09
was O 0 1.5169069556009163e-08
detected O 0 4.6388589680645964e-07
, O 0 3.692274264111006e-10
and O 0 6.257811491217069e-10
in O 0 1.1699936852682669e-10
9 O 0 2.6166482314238237e-09
( O 0 5.862006019485833e-11
56 O 0 6.594442214513663e-10
% O 0 2.0931747654606703e-11
) O 0 1.1579187608745656e-10
of O 0 5.557824200863593e-10
the O 0 3.1463605409953743e-06
tumors B-Disease 1 1.0
without O 0 1.2629448974621482e-05
LOH O 1 0.9999774694442749
, O 0 6.863982271454461e-09
both O 0 2.1824281271065615e-10
mutations O 0 6.500671556608495e-09
were O 0 2.7515302036817957e-08
found O 0 2.0112516097015032e-07
. O 0 6.783590578152143e-08

Thus O 0 1.5096816241566557e-07
, O 0 1.9307060394879727e-09
a O 0 1.9393524286481778e-10
total O 0 5.230951227730429e-10
of O 0 3.4478968291562495e-11
45 O 0 1.279608863313797e-09
mutations O 0 2.8663371676174165e-09
were O 0 3.9430165799103634e-08
identified O 0 3.4605961900524562e-06
in O 0 5.346748466195095e-08
tumors B-Disease 1 0.9999995231628418
of O 0 2.3695376771826204e-09
36 O 0 5.024760412197793e-07
patients O 0 1.5673117559344973e-07
. O 0 4.247428009307441e-08

Thirty O 0 5.210262770560803e-06
- O 0 4.560958404908888e-05
nine O 0 1.0439646480620013e-08
of O 0 7.342764590800854e-11
the O 0 7.20258366837534e-11
mutations O 0 4.609859605153588e-09
- O 0 1.7949722064258822e-07
including O 0 4.14860679143203e-09
34 O 0 1.5757781746117416e-09
small O 0 1.787059167313032e-09
mutations O 0 3.0344156076722584e-09
, O 0 3.147880012210891e-10
2 O 0 1.3265327725164866e-10
large O 0 1.9464130307511596e-09
structural O 0 8.380274039154756e-07
alterations O 0 1.0020809213528992e-06
, O 0 5.950975712210038e-09
and O 0 2.9570705883941173e-09
hypermethylation O 0 1.0987019777530804e-05
in O 0 1.4664081504633941e-08
3 O 0 1.1496167644509114e-06
tumors O 1 0.9999998807907104
- O 0 0.0006500292802229524
were O 0 1.2821489008274511e-06
not O 0 2.3951243210973416e-09
detected O 0 2.3646855140668777e-08
in O 0 6.175660677287809e-11
the O 0 7.467391982540761e-11
corresponding O 0 1.1791644993763839e-08
peripheral O 0 4.633540811482817e-06
blood O 0 1.1899397378556387e-07
DNA O 0 3.212946921848925e-07
. O 0 5.052466889310381e-08

In O 0 2.5231743805420592e-08
6 O 0 6.905926053235589e-09
( O 0 1.3997943082433295e-10
17 O 0 5.42112077450696e-10
% O 0 8.42648433668769e-12
) O 0 7.509036795139146e-12
of O 0 7.221218414898978e-12
the O 0 4.6381329332767507e-10
36 O 0 1.49601522281273e-08
patients O 0 2.956534794762433e-09
, O 0 4.8760034204731184e-11
a O 0 4.963875976926602e-10
mutation O 0 2.509781715787085e-09
was O 0 4.941751967635355e-07
detected O 0 9.737682375998702e-07
in O 0 2.4487437078057894e-10
constitutional O 0 3.858268426970568e-10
DNA O 0 2.890450900849828e-08
, O 0 7.836160054175423e-10
and O 0 1.2046956765487948e-09
1 O 0 1.8765718146074306e-10
of O 0 1.4135573787876776e-11
these O 0 3.135900428219429e-10
mutations O 0 1.3486807226570363e-09
is O 0 6.490645243495408e-10
known O 0 3.1350826379394903e-09
to O 0 1.4458801933514565e-09
be O 0 1.9699474052004007e-08
associated O 0 7.62117569053089e-09
with O 0 4.114430129931179e-09
reduced O 0 4.417034915604745e-07
expressivity O 0 0.00029526068828999996
. O 0 3.741121190614649e-07

The O 0 4.0504122722495595e-08
presence O 0 3.092602085530416e-08
of O 0 1.1264066068772394e-10
a O 0 1.2666467874566933e-09
constitutional O 0 1.5625852833878184e-09
mutation O 0 2.2716161396374446e-08
was O 0 5.318564149092708e-07
not O 0 5.003583325446925e-09
associated O 0 5.89688786689635e-09
with O 0 3.1545693834900135e-10
an O 0 1.0982753595456529e-10
early O 0 1.4554461635896132e-08
age O 0 3.581997276569382e-08
at O 0 1.2178772124116222e-07
treatment O 0 1.9885611379777401e-07
. O 0 2.8473433388853664e-08

In O 0 4.4370256802039876e-08
1 O 0 4.203335990382584e-08
patient O 0 4.877155106441933e-07
, O 0 4.42593128813229e-10
somatic O 0 3.7706641364820825e-08
mosaicism O 0 3.545271101756953e-05
was O 0 2.875867266993737e-06
demonstrated O 0 1.1768995555883066e-08
by O 0 3.172440088405892e-11
molecular O 0 3.758568456468936e-10
analysis O 0 4.3839817887025845e-10
of O 0 7.82814854605185e-11
DNA O 0 1.6865422480805137e-07
and O 0 3.5522766950180085e-09
RNA O 0 1.4071465770371105e-08
from O 0 1.5740240222328339e-09
peripheral O 0 1.594850982655771e-05
blood O 0 1.7141881016868865e-06
. O 0 1.0881432643827793e-07

In O 0 1.0613460688091436e-07
2 O 0 2.129128091610255e-07
patients O 0 3.6297343797286885e-08
without O 0 3.7698838495359155e-10
a O 0 1.8409577196010218e-09
detectable O 0 1.5697876278863987e-06
mutation O 0 1.129417359635454e-08
in O 0 6.236101635082036e-10
peripheral O 0 0.0002578313578851521
blood O 0 6.204791134223342e-07
, O 0 9.488411167879462e-10
mosaicism O 0 8.634492587589193e-07
was O 0 3.324288400108344e-07
suggested O 0 8.923242234004647e-08
because O 0 8.954741947952982e-10
1 O 0 2.295687667741575e-10
of O 0 2.8842563754016837e-11
the O 0 2.6392943386355228e-09
patients O 0 4.203736736485553e-08
showed O 0 1.8398604879621416e-05
multifocal O 1 0.9996722936630249
tumors B-Disease 1 1.0
and O 0 8.493811947118957e-07
the O 0 9.55283963044451e-10
other O 0 3.6377773016127435e-10
later O 0 1.3175220914263264e-08
developed O 0 1.0261423710744566e-07
bilateral B-Disease 0 8.545771947865433e-07
retinoblastoma I-Disease 0 6.411390495486557e-05
. O 0 1.4601347686493682e-07

In O 0 2.0712986881221696e-08
conclusion O 0 3.2891689372149813e-09
, O 0 1.2449083985899279e-09
our O 0 3.1262614719196335e-10
results O 0 2.352765482438457e-10
emphasize O 0 4.359236083217866e-09
that O 0 6.836201604798475e-10
the O 0 6.280240216760546e-11
manifestation O 0 1.8914361632482724e-08
and O 0 4.569100375828583e-10
transmissibility O 0 1.8422865011302747e-08
of O 0 4.620788474074544e-11
retinoblastoma B-Disease 0 4.3774104341309794e-08
depend O 0 5.328745888988351e-09
on O 0 1.0498717273321745e-07
the O 0 2.7205915298367245e-10
nature O 0 6.373322491981526e-08
of O 0 3.505060477970723e-11
the O 0 5.310061765295693e-11
first O 0 3.8327946372263e-10
mutation O 0 1.083424572279057e-09
, O 0 9.916490545380796e-11
its O 0 1.42943518133265e-10
time O 0 4.173008327779115e-10
in O 0 1.666817933676512e-10
development O 0 4.549900900485682e-09
, O 0 6.001560359791824e-10
and O 0 9.575423787211435e-10
the O 0 6.912007077808369e-11
number O 0 2.782365005060683e-09
and O 0 3.720809216289922e-09
types O 0 9.571886394610374e-09
of O 0 2.298784253229602e-11
cells O 0 1.7770017679552552e-09
that O 0 1.2950328309724313e-10
are O 0 3.305954121568533e-10
affected O 0 2.0862851446423747e-09
. O 0 2.1579361908496963e-10
. O 0 1.0702801311879284e-08

Hereditary B-Disease 1 0.9999797344207764
deficiency I-Disease 1 0.9999457597732544
of I-Disease 0 1.0243253356634341e-08
the I-Disease 0 4.089035776644323e-09
fifth I-Disease 0 5.989981133325273e-08
component I-Disease 0 5.385384937994786e-08
of I-Disease 0 6.87899598394992e-11
complement I-Disease 0 1.2803543114614513e-08
in O 0 5.390603075028366e-09
man O 0 4.684994564740919e-06
. O 0 5.97925122747256e-08

I O 0 0.00034484395291656256
. O 0 1.1558103096831474e-06

Clinical O 0 1.0497808943910059e-05
, O 0 2.1218463430727752e-08
immunochemical O 0 1.5912413800833747e-05
, O 0 3.625852329491863e-08
and O 0 1.7582269862259636e-08
family O 0 2.767135640624474e-07
studies O 0 2.2537060218041916e-08
. O 0 4.411641896240326e-08

The O 0 7.720875316863385e-08
first O 0 2.5883162280138095e-08
recognized O 0 1.376859586343926e-07
human O 0 2.4812962351461465e-07
kindred O 0 9.670270083006471e-05
with O 0 1.2350193173915613e-05
hereditary B-Disease 1 0.999990701675415
deficiency I-Disease 1 0.9982858300209045
of I-Disease 0 2.768458573498833e-09
the I-Disease 0 3.6741794051664556e-09
fifth I-Disease 0 9.24064238461142e-08
component I-Disease 0 1.053858156296883e-07
of I-Disease 0 3.1031102687428813e-10
complement I-Disease 0 2.4356848982165502e-08
( O 0 1.5560895905153416e-09
C5 O 0 5.259308863969636e-07
) O 0 6.650931472229615e-10
is O 0 1.46355183527902e-09
described O 0 1.7793063022963906e-07
. O 0 2.3290102291184667e-08

The O 0 5.2739444811322755e-08
proband O 0 8.815741239232011e-06
, O 0 3.9680703167732645e-09
a O 0 1.5035894751491696e-09
20 O 0 2.7049567030701382e-09
- O 0 5.56921577299363e-07
year O 0 1.0966354047070581e-08
- O 0 1.7479391317465343e-05
old O 0 3.2695279514882714e-05
black O 0 4.419866570515296e-07
female O 0 5.801820179840433e-07
with O 0 1.1922417797904927e-05
systemic B-Disease 1 0.9999998807907104
lupus I-Disease 1 0.9995162487030029
erythematosus I-Disease 1 0.9999797344207764
since O 0 1.1625327260844642e-06
age O 0 9.019859703585098e-07
11 O 0 3.2359171342477566e-08
, O 0 7.004250957010072e-09
lacked O 0 1.7890930621433654e-06
serum O 0 7.831616130715702e-06
hemolytic O 0 0.0001065552860382013
complement O 0 1.1081472628404754e-08
activity O 0 6.817944608883408e-07
, O 0 7.687526171196168e-10
even O 0 8.121350258960547e-10
during O 0 4.2385153165014344e-09
remission O 0 3.2059375598691986e-07
. O 0 2.28558008075197e-08

C5 O 0 0.007564923260360956
was O 0 8.935060759540647e-05
undetectable O 0 0.0001924451789818704
in O 0 7.957363656885263e-09
her O 0 8.401769946431159e-08
serum O 0 2.3689408124027977e-07
by O 0 1.460428666888447e-09
both O 0 1.7387069561891622e-09
immunodiffusion O 0 9.847677574725822e-06
and O 0 3.096480156727921e-07
hemolytic O 0 0.0358290933072567
assays O 0 1.300474650633987e-05
. O 0 4.1067261236094055e-07

Other O 0 7.485628117365195e-08
complement O 0 6.796010154630494e-08
components O 0 2.688360893898789e-07
were O 0 5.526084034812584e-09
normal O 0 5.530766067352033e-09
during O 0 1.226679091637095e-09
remission O 0 7.176125471630712e-09
of O 0 3.077376409255095e-10
lupus O 0 5.04688932778663e-06
, O 0 2.3325568143661712e-09
but O 0 1.3851615854321153e-08
C1 O 0 1.74199649336515e-05
, O 0 1.940674509981477e-09
C4 O 0 7.913849913165905e-07
, O 0 1.8783213207029803e-08
C2 O 0 1.0629465577949304e-05
, O 0 4.034465206359528e-09
and O 0 3.81233284940663e-08
C3 O 0 0.00032385363010689616
levels O 0 1.9006478169103502e-07
fell O 0 9.98003815766424e-06
during O 0 2.7715561401464583e-08
exacerbations O 0 4.3656447815010324e-05
. O 0 9.280809365463938e-08

A O 0 1.2053178579662926e-06
younger O 0 1.3808650578539527e-07
half O 0 3.6528131630575444e-08
- O 0 0.0001254858070751652
sister O 0 0.0001881885400507599
, O 0 4.1556017293942205e-08
who O 0 2.556679135068407e-07
had O 0 3.6394997096067527e-06
no O 0 6.587297320947982e-06
underlying O 0 0.017416909337043762
disease O 0 6.785729055991396e-05
, O 0 1.5950191167846128e-09
was O 0 1.7538379779580282e-06
also O 0 5.37431361635754e-08
found O 0 3.859823127783102e-09
to O 0 2.257792397486469e-09
lack O 0 1.9880390667026404e-08
immunochemically O 0 1.5027513654786162e-05
detectable O 0 1.952536331373267e-05
C5 O 0 2.466925434418954e-05
. O 0 1.1675341937689154e-07

By O 0 5.219430363467836e-07
hemolytic O 1 0.7326879501342773
assay O 0 8.741609235585202e-06
, O 0 3.0818789298336924e-08
she O 0 4.375329876182832e-09
exhibited O 0 2.2357156126417976e-08
1 O 0 6.261011153974039e-10
- O 0 3.170490344928112e-06
2 O 0 2.9812867730072412e-09
% O 0 3.5086988869892366e-11
of O 0 2.4672658013868976e-11
the O 0 3.0499183734100654e-10
normal O 0 7.566703885686366e-08
serum O 0 6.484810199935964e-08
C5 O 0 2.531393761273648e-07
level O 0 9.187230531892965e-09
and O 0 2.9703306481110303e-10
normal O 0 3.7053118906449356e-10
concentrations O 0 4.445839807409868e-10
of O 0 5.72770650353327e-12
other O 0 6.055034945662285e-11
complement O 0 8.049918953645374e-09
components O 0 3.2797427707009774e-07
. O 0 4.885795235054502e-08

C5 O 0 0.0013221231056377292
levels O 0 1.8315080296815722e-06
of O 0 4.733673453216625e-10
other O 0 4.1023917596305637e-10
family O 0 6.5657679293451565e-09
members O 0 1.4081195931492374e-10
were O 0 6.837196586673144e-09
either O 0 6.52235265796719e-10
normal O 0 3.723009900369334e-09
or O 0 1.2968872642460383e-09
approximately O 0 6.748318348570592e-09
half O 0 8.404089868463416e-09
- O 0 2.9331004043342546e-06
normal O 0 8.324867195597108e-08
, O 0 1.143691696903204e-09
consistent O 0 5.396119462375282e-08
with O 0 1.9928898531418326e-09
autosomal O 0 2.0749401301145554e-05
codominant O 0 5.25831819686573e-06
inheritance O 0 1.0132922767525088e-07
of O 0 5.276353798322475e-10
the O 0 2.707496227216666e-09
gene O 0 5.545346994040301e-06
determining O 0 0.0038064392283558846
C5 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999994039535522
. O 0 1.0137343906535534e-06

Normal O 0 7.548904977738857e-05
hemolytic O 1 0.9835439324378967
titers O 0 0.0006842069560661912
were O 0 2.424480385343486e-07
restored O 0 4.319642528116674e-07
to O 0 2.8944271424080625e-09
both O 0 8.328738587692897e-09
homozygous O 0 0.01593232899904251
C5 B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999970197677612
deficient I-Disease 1 0.9999998807907104
( O 0 2.9601005735457875e-07
C5D B-Disease 1 0.9999991655349731
) O 0 1.1692831591858521e-08
sera O 0 5.642140877171187e-06
by O 0 1.3099134277272384e-10
addition O 0 4.202225512006663e-10
of O 0 1.0773903297289777e-10
highly O 0 4.819148458068412e-08
purified O 0 2.7463244123282493e-07
human O 0 6.954014963866939e-08
C5 O 0 8.898815394786652e-06
. O 0 9.66943645153151e-08

In O 0 2.2196037008370695e-08
specific O 0 3.401031989369585e-08
C5 O 0 4.442298632056918e-06
titrations O 0 9.875440809992142e-06
, O 0 3.587985464292842e-09
however O 0 1.957776607497408e-09
, O 0 1.1916255482358196e-10
it O 0 1.062625321068822e-09
was O 0 1.9781485605108173e-07
noted O 0 5.908281419664263e-09
that O 0 8.850039451280267e-11
when O 0 3.04931219163862e-11
limited O 0 2.1130681926440076e-10
amounts O 0 8.60131132984776e-11
of O 0 6.323318257894783e-11
C5 O 0 1.9845616350266937e-07
were O 0 8.858290101443345e-09
assayed O 0 9.514153020973026e-08
in O 0 1.5443060719100288e-10
the O 0 5.730014379645709e-11
presence O 0 6.633081861551204e-10
of O 0 5.576010486674221e-11
low O 0 3.955475236239181e-08
dilutions O 0 5.237515665612591e-08
of O 0 3.386534941363095e-10
either O 0 3.3020759815372003e-07
C5D B-Disease 1 0.9999994039535522
serum O 0 4.504682692640927e-06
, O 0 4.27126750635054e-10
curving O 0 2.4603945547596595e-08
rather O 0 6.591927559362887e-10
than O 0 5.459469334945233e-11
linear O 0 1.5759646920798787e-09
dose O 0 2.3596338216691493e-09
- O 0 1.3216174465924269e-07
response O 0 3.0361004821344295e-09
plots O 0 1.1807267696894996e-07
were O 0 3.0444294196740884e-08
consistently O 0 4.3250835801700305e-08
obtained O 0 2.535947563053753e-10
, O 0 3.03724441430564e-11
suggesting O 0 2.0339674389191487e-10
some O 0 3.0817039892161446e-11
inhibitory O 0 8.720855149135787e-09
effect O 0 1.2020522355271623e-08
. O 0 1.9197567979745145e-08

Further O 0 3.181995822387762e-08
studies O 0 4.358221783462568e-09
suggested O 0 1.4676365900356814e-08
that O 0 1.014234918272905e-09
low O 0 2.1374529524109676e-07
dilutions O 0 1.563403657200979e-06
of O 0 7.359347620194967e-08
C5D B-Disease 1 0.9999996423721313
serum O 0 4.5371307351160794e-06
contain O 0 1.3671452414598662e-08
a O 0 1.1196470417473847e-09
factor O 0 2.1623209889298778e-09
( O 0 7.765230125578171e-11
or O 0 1.172945851557472e-09
factors O 0 3.334896803153242e-10
) O 0 4.878812631670115e-11
interfering O 0 6.195865598357386e-09
at O 0 1.4469099696157173e-08
some O 0 1.3491739669913017e-10
step O 0 7.715910577132945e-09
in O 0 3.0154784225189246e-10
the O 0 9.438844150722048e-10
hemolytic O 0 1.1678448572638445e-05
assay O 0 2.6864276136961962e-08
of O 0 3.9745290392190213e-10
C5 O 0 1.1752169939427404e-06
, O 0 5.918429080153942e-10
rather O 0 4.133431930064546e-10
than O 0 2.745409455329195e-10
a O 0 2.201170357096771e-09
true O 0 1.1497292717876917e-07
C5 O 0 3.7952324873913312e-06
inhibitor O 0 1.554412136783867e-07
or O 0 3.7261802532384536e-08
inactivator O 0 3.429656544540194e-06
. O 0 6.208466629686882e-08

Of O 0 2.661462694675265e-08
clinical O 0 7.782074931128591e-07
interest O 0 1.5843748712995875e-07
are O 0 4.7901234090375056e-09
( O 0 2.3131015158828205e-10
a O 0 2.1460586641097734e-09
) O 0 1.296552726293143e-10
the O 0 6.29841387378427e-11
documentation O 0 1.364634272249532e-07
of O 0 1.563742912935595e-08
membranous O 1 0.9613951444625854
glomerulonephritis B-Disease 1 1.0
, O 0 0.00018071025260724127
vasculitis B-Disease 1 0.9999997615814209
, O 0 2.4267401386168785e-05
and O 0 0.10100086778402328
arthritis B-Disease 1 1.0
in O 0 7.959447145822196e-08
an O 0 3.865439168748708e-08
individual O 0 2.4985967073121174e-08
lacking O 0 2.2370981866970396e-07
C5 O 0 5.62135619475157e-06
( O 0 1.3631398232405445e-09
and O 0 8.436303322589822e-10
its O 0 2.9327867911987937e-10
biologic O 0 7.860477069243643e-08
functions O 0 1.3285921252048638e-09
) O 0 7.548112829214304e-11
, O 0 2.1673492167639807e-10
and O 0 1.0089175050964627e-09
( O 0 1.7866254309328866e-10
b O 0 3.070684329031792e-07
) O 0 3.638587695031781e-11
a O 0 3.3948713284992493e-10
remarkable O 0 2.3541593563436436e-08
propensity O 0 7.096323315636255e-06
to O 0 2.4974019652290735e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 7.995535789007135e-09
the O 0 7.613631392011655e-10
proband O 0 1.9707194951479323e-06
, O 0 6.00871963296612e-10
even O 0 2.644917063143737e-10
during O 0 1.0486835011480622e-10
periods O 0 6.87592927040015e-10
of O 0 8.125234512990076e-11
low O 0 4.182088275683782e-07
- O 0 3.18389055564694e-07
dose O 0 1.3149963784542251e-08
or O 0 1.1798073629165629e-09
alternate O 0 1.1278991074448186e-09
- O 0 3.2831914609232626e-07
day O 0 4.18993657547162e-08
corticosteroid O 0 2.271964149258565e-06
therapy O 0 2.294762566634745e-07
. O 0 1.1546206657442326e-08

Other O 0 1.5802577024714992e-08
observations O 0 5.5649795882573017e-08
indicate O 0 2.3564730611269624e-08
that O 0 1.0145657647342432e-09
the O 0 1.2132321813851377e-09
C5D B-Disease 1 0.999997615814209
state O 0 3.794232039666667e-09
is O 0 3.4908862467375457e-09
compatible O 0 1.6476738196047336e-08
with O 0 3.5829778033402704e-10
normal O 0 6.29771168547677e-09
coagulation O 0 2.586460823295056e-08
function O 0 3.608549192790633e-08
and O 0 3.044003715757526e-09
the O 0 2.522151931749761e-10
capacity O 0 8.055848432775292e-09
to O 0 1.912329850028982e-09
mount O 0 5.3540676162810996e-05
a O 0 5.511581093742279e-07
neutrophilic O 0 0.026512181386351585
leukocytosis O 0 0.0011222417233511806
during O 0 7.476337486878037e-07
pyogenic B-Disease 0 0.03396013006567955
infection I-Disease 0 0.00027677047182805836
. O 0 7.382753075546589e-09
. O 0 7.123896494931614e-08

Susceptibility O 0 0.13400143384933472
to O 0 0.0001767784997355193
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00021037415717728436
twins O 0 0.000322323408909142
: O 0 1.1190427473550812e-09
the O 0 5.898658644865051e-11
role O 0 2.4706908741123357e-10
of O 0 1.0365781150101228e-11
genes O 0 3.2611063849330435e-10
, O 0 3.53374551842478e-10
HLA O 0 8.320817528328917e-07
, O 0 4.21033075070909e-09
and O 0 3.3376919006400385e-09
the O 0 1.6246394229924022e-09
environment O 0 8.671643740854051e-07
. O 0 3.4655123215543426e-08

OBJECTIVE O 0 2.4810315153445117e-06
To O 0 9.997861205590652e-09
determine O 0 9.156844171798184e-09
the O 0 4.4225476059089885e-10
relative O 0 2.9853111982447444e-08
effects O 0 1.5611680836968844e-08
of O 0 1.5937623443207372e-10
genetic O 0 4.4222656470083166e-07
and O 0 3.5460894221017725e-09
environmental O 0 3.4412384053439382e-09
factors O 0 1.0465219801858439e-09
in O 0 2.1095334368226304e-09
susceptibility O 0 9.643592784414068e-05
to O 0 0.0006261347443796694
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 8.453038026345894e-05
AS B-Disease 1 0.9998444318771362
) O 0 2.457683478951367e-08
. O 0 2.9460100137157497e-08

METHODS O 0 5.1040300604654476e-05
Twins O 0 3.7206926208455116e-05
with O 0 1.5424538446495717e-07
AS B-Disease 1 0.9995606541633606
were O 0 1.2069713761775347e-07
identified O 0 1.3027568002144108e-07
from O 0 1.429511509165593e-10
the O 0 1.6762614907239737e-10
Royal O 0 1.063212238250344e-07
National O 0 7.564885606825555e-08
Hospital O 0 6.244657470233506e-06
for O 0 1.2800873605556262e-07
Rheumatic B-Disease 1 0.9988875985145569
Diseases I-Disease 0 9.185214730678126e-05
database O 0 3.6211713450029492e-06
. O 0 1.98685313534952e-07

Clinical O 0 1.3020209735259414e-05
and O 0 3.2882795153454936e-08
radiographic O 0 6.254491836443776e-06
examinations O 0 9.905709674740137e-08
were O 0 1.2974570751111969e-08
performed O 0 3.5334188908109354e-08
to O 0 5.196365004955794e-10
establish O 0 3.43064073149435e-07
diagnoses O 0 0.00017544352158438414
, O 0 3.510417911911645e-08
and O 0 8.548551022613537e-07
disease O 0 0.0001127252253354527
severity O 0 8.45605995891674e-07
was O 0 4.2459740257072554e-07
assessed O 0 7.043399108397352e-08
using O 0 6.470883384679382e-09
a O 0 1.0799919181181394e-08
combination O 0 1.2142074012899684e-08
of O 0 6.786211592668678e-10
validated O 0 1.2302605512104492e-07
scoring O 0 1.1672447186583668e-07
systems O 0 1.5982958530003089e-06
. O 0 9.384926613620337e-08

HLA O 0 0.00017287064110860229
typing O 0 3.1490203582507093e-06
for O 0 1.0472833267272108e-08
HLA O 0 5.888780833629426e-06
- O 0 1.6738449630793184e-06
B27 O 0 1.6113402523387776e-07
, O 0 9.827996194644584e-10
HLA O 0 3.2239967140412773e-07
- O 0 3.2818235240483773e-07
B60 O 0 1.2891125322767039e-07
, O 0 3.2637326174977943e-10
and O 0 6.805330188264236e-10
HLA O 0 3.2525799724680837e-06
- O 0 1.6596504792687483e-05
DR1 O 0 0.10915013402700424
was O 0 5.424502091955219e-07
performed O 0 1.0910294001575949e-08
by O 0 1.0399273803196607e-10
polymerase O 0 8.725201894321799e-08
chain O 0 8.058807452471228e-07
reaction O 0 9.78344627533545e-10
with O 0 3.751948404739913e-11
sequence O 0 1.2769465485007458e-09
- O 0 2.095167062066139e-08
specific O 0 1.3464933612539198e-09
primers O 0 8.930785355687476e-08
, O 0 7.512166999568137e-10
and O 0 8.319573363557708e-10
zygosity O 0 2.253594999501729e-07
was O 0 4.435341693920236e-08
assessed O 0 4.3312585518151536e-08
using O 0 2.427540657379268e-08
microsatellite O 0 4.074509706697427e-05
markers O 0 3.113358252448961e-05
. O 0 2.562735801348026e-07

Genetic O 0 8.107556823233608e-06
and O 0 1.2520983361241633e-08
environmental O 0 1.840329333369084e-09
variance O 0 6.672395524986996e-09
components O 0 5.080733558315842e-07
were O 0 3.65459698059567e-08
assessed O 0 3.7856611356801295e-07
with O 0 1.2754227673994478e-09
the O 0 4.423239552409086e-10
program O 0 1.6403426172928448e-08
Mx O 0 2.924891759903403e-07
, O 0 1.3991262141910266e-11
using O 0 4.28241678229746e-11
data O 0 1.3186024494515891e-09
from O 0 7.124534469327148e-12
this O 0 1.970015817143178e-11
and O 0 7.682249281160125e-10
previous O 0 5.281902137888039e-10
studies O 0 1.4916599899716942e-10
of O 0 3.9024061759818096e-11
twins O 0 7.161879125305859e-07
with O 0 4.19373407112289e-08
AS B-Disease 1 0.9999213218688965
. O 0 1.908771025682654e-07

RESULTS O 0 9.61294290391379e-07
Six O 0 1.099265656279158e-08
of O 0 7.596398510223423e-10
8 O 0 2.0988148108358473e-08
monozygotic O 0 5.581920049735345e-06
( O 0 3.261582648406147e-08
MZ O 1 0.9989954829216003
) O 0 6.786165585026538e-08
twin O 0 0.010355887934565544
pairs O 0 1.1284073480055667e-06
were O 0 6.558437689818675e-06
disease O 0 2.800626589305466e-06
concordant O 0 2.031684402936662e-07
, O 0 9.031362879774463e-10
compared O 0 7.139114632792598e-09
with O 0 4.326613789462641e-10
4 O 0 9.061005834531954e-10
of O 0 7.739767160508393e-11
15 O 0 1.2967883433745442e-09
B27 O 0 3.8391860357478436e-08
- O 0 5.064227934781229e-07
positive O 0 1.3901375162106433e-08
dizygotic O 0 2.1686173568014055e-07
( O 0 3.4291286477028393e-10
DZ O 0 0.00010313870006939396
) O 0 1.2492804568609017e-09
twin O 0 1.160187935056456e-06
pairs O 0 1.1420719925325784e-09
( O 0 9.749016871563043e-11
27 O 0 3.028602924004531e-10
% O 0 9.113184165632227e-12
) O 0 2.3118963340951204e-11
and O 0 3.146577165491493e-10
4 O 0 3.243711965694729e-10
of O 0 3.5577332746505874e-10
32 O 0 3.652974100987194e-07
DZ O 1 0.9939242005348206
twin O 0 0.0006282565300352871
pairs O 0 4.01233357649744e-09
overall O 0 7.702354309913062e-09
( O 0 1.1124811488683051e-10
12 O 0 1.647691150186148e-10
. O 0 3.9488582542768214e-11
5 O 0 3.349130694996205e-10
% O 0 1.7332461854646652e-10
) O 0 9.679983481447607e-10
. O 0 1.538090543817816e-08

Nonsignificant O 0 0.00019152277673128992
increases O 0 8.762189622757433e-07
in O 0 1.455381593018501e-09
similarity O 0 7.2813790552572755e-09
with O 0 3.4378186408723366e-10
regard O 0 6.465837198987856e-09
to O 0 3.080014465695058e-09
age O 0 2.317907359383753e-07
at O 0 4.638368409359828e-06
disease O 0 8.08737149782246e-06
onset O 0 1.1906798391692064e-07
and O 0 3.2648252101807884e-08
all O 0 5.342206677028116e-10
of O 0 3.0115815397024903e-10
the O 0 1.827740447879478e-08
disease O 0 2.6263549443683587e-05
severity O 0 1.8055531825211801e-07
scores O 0 2.7692310666793674e-08
assessed O 0 1.6941834246608778e-07
were O 0 6.354860460078271e-08
noted O 0 5.1247930343834014e-08
in O 0 1.4110650425891436e-08
disease O 0 5.05063399032224e-05
- O 0 0.007526564411818981
concordant O 0 0.38868647813796997
MZ O 1 0.9998289346694946
twins O 0 1.4815052054473199e-05
compared O 0 2.472287121690897e-07
with O 0 6.642645900001298e-08
concordant O 0 0.0017916167853400111
DZ O 1 0.9174681901931763
twins O 0 2.3149365006247535e-05
. O 0 1.4576860962733917e-07

HLA O 0 0.0019652487244457006
- O 0 0.00013063420192338526
B27 O 0 2.848723397619324e-06
and O 0 1.0322017907071768e-08
B60 O 0 8.134239948276445e-08
were O 0 6.282522946321478e-09
associated O 0 1.2057101095308553e-08
with O 0 3.932642211879056e-09
the O 0 1.4889327992761991e-08
disease O 0 2.816501591951237e-06
in O 0 8.206990642634082e-11
probands O 0 1.2156995126133552e-06
, O 0 7.102751720111655e-10
and O 0 1.556074824549114e-09
the O 0 5.789064227990082e-10
rate O 0 7.993226972757839e-06
of O 0 5.986572348959385e-10
disease O 0 5.922692025706056e-07
concordance O 0 1.754023415401207e-08
was O 0 1.8369360077485908e-07
significantly O 0 1.3199895398940953e-08
increased O 0 3.670874804129198e-08
among O 0 1.1161379376289915e-08
DZ O 1 0.9916389584541321
twin O 0 0.004330831579864025
pairs O 0 2.8933524021113044e-08
in O 0 1.253196768580267e-09
which O 0 1.1852722536787041e-07
the O 0 4.768009542743812e-09
co O 0 7.432948768837377e-05
- O 0 0.0019458167953416705
twin O 0 0.002682681893929839
was O 0 5.25892744462908e-07
positive O 0 2.2258941356767536e-09
for O 0 7.219693592963594e-11
both O 0 3.15982656706737e-10
B27 O 0 1.1099012198201308e-07
and O 0 2.1794644311512457e-08
DR1 O 0 0.0006838567787781358
. O 0 4.3980985964253705e-08

Additive O 0 6.061125532141887e-06
genetic O 0 1.617011093912879e-06
effects O 0 1.654961323538373e-07
were O 0 8.517601735036351e-09
estimated O 0 2.672433607742164e-09
to O 0 4.871541364748211e-11
contribute O 0 3.7137029562650525e-10
97 O 0 3.9002001628318794e-09
% O 0 4.7909589490080506e-11
of O 0 1.7496502510705447e-11
the O 0 1.4802269132641044e-10
population O 0 1.6469221542081414e-09
variance O 0 5.619109444410242e-08
. O 0 5.162210214848528e-08

CONCLUSION O 0 6.219376587068837e-07
Susceptibility O 0 6.6631532718020026e-06
to O 0 3.3233280305466906e-07
AS B-Disease 1 0.9999665021896362
is O 0 1.3453901104298893e-08
largely O 0 5.831408689260797e-10
genetically O 0 1.185939457748475e-09
determined O 0 3.184983654591633e-07
, O 0 4.6092267780295515e-09
and O 0 3.272542237198195e-09
the O 0 4.812676923648951e-10
environmental O 0 3.1564987068577466e-08
trigger O 0 9.925757638029609e-08
for O 0 1.4651271307286606e-09
the O 0 3.905777745671912e-08
disease O 0 2.3457754650735296e-05
is O 0 2.37001240854795e-09
probably O 0 5.9005586194871285e-08
ubiquitous O 0 4.884630584456318e-07
. O 0 4.5659341196824244e-08

HLA O 0 0.0007261587306857109
- O 0 4.178594463155605e-05
B27 O 0 1.448176817575586e-06
accounts O 0 6.743765368355525e-08
for O 0 4.473348080846762e-10
a O 0 4.223343896825327e-09
minority O 0 1.486815737195002e-08
of O 0 7.148386049760092e-11
the O 0 2.9040750360032064e-10
overall O 0 2.5272106185525445e-08
genetic O 0 1.299746088534448e-07
susceptibility O 0 7.956242598083918e-07
to O 0 3.21542358960869e-07
AS B-Disease 1 0.9999746084213257
. O 0 3.2061700494523393e-07

Cell O 0 0.00036002122214995325
cycle O 0 3.0342949685291387e-05
- O 0 1.6766243788879365e-05
dependent O 0 7.270591595442966e-07
colocalization O 0 2.6225111469102558e-06
of O 0 1.5752372739541443e-09
BARD1 O 0 4.445064041647129e-05
and O 0 8.093812731146954e-09
BRCA1 O 0 7.899253517962279e-08
proteins O 0 3.353521904614354e-10
in O 0 2.8640020910408737e-10
discrete O 0 5.432630132418126e-07
nuclear O 0 0.0009116042638197541
domains O 0 9.102992066800653e-07
. O 0 7.969153870135415e-08

Germ O 0 0.1077207624912262
- O 0 0.013295075856149197
line O 0 6.767486047465354e-05
mutations O 0 1.6377111933252309e-07
of O 0 4.204919468175916e-10
the O 0 2.011871336193849e-09
BRCA1 O 0 4.502396393490926e-07
gene O 0 4.253378449448064e-08
predispose O 0 1.2411446448368224e-07
women O 0 2.0445363180243703e-09
to O 0 6.232296900776646e-10
early O 0 1.8380997346412187e-07
- O 1 0.990230143070221
onset O 1 0.9963096976280212
breast B-Disease 1 0.9999984502792358
and I-Disease 1 0.9999974966049194
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
by O 0 1.524602311064882e-08
compromising O 0 2.6409319616504945e-05
the O 0 3.056314090699175e-09
genes O 0 4.8481339831596415e-08
presumptive O 0 2.134516535079456e-06
function O 0 9.877071249775327e-08
as O 0 1.5886008064569523e-09
a O 0 1.1615387762731189e-08
tumor B-Disease 0 5.385166332416702e-06
suppressor O 0 8.892343430488836e-06
. O 0 2.1294304985985946e-07

Although O 0 7.109494504220493e-08
the O 0 4.764434402559914e-10
biochemical O 0 5.808236736015715e-08
properties O 0 6.37944026493642e-07
of O 0 6.49279907616318e-10
BRCA1 O 0 2.9314236371646984e-07
polypeptides O 0 2.2896685436535336e-08
are O 0 3.377215840316694e-09
not O 0 2.781627372883122e-09
understood O 0 9.506965881200813e-09
, O 0 2.732917503411869e-10
their O 0 1.8660675782378178e-10
expression O 0 1.8021817371760562e-09
pattern O 0 4.1374437387275975e-07
and O 0 9.208266149585143e-09
subcellular O 0 3.9818251025280915e-06
localization O 0 1.585671896009444e-07
suggest O 0 9.116500443440145e-09
a O 0 9.146958745986922e-10
role O 0 2.8733546653114672e-09
in O 0 5.35334554463418e-10
cell O 0 8.08740992397361e-07
- O 0 4.548453580355272e-05
cycle O 0 1.391046680510044e-06
regulation O 0 5.60094015611412e-08
. O 0 4.6508940698686274e-08

When O 0 5.490732633006701e-07
resting O 0 1.0534363354963716e-05
cells O 0 2.3082250777406443e-08
are O 0 4.880369441906396e-10
induced O 0 7.265871460049311e-08
to O 0 4.6138332043810237e-10
proliferate O 0 5.467776986733952e-07
, O 0 3.402455817091976e-10
the O 0 7.395190015913045e-11
steady O 0 1.547796955492231e-06
- O 0 6.889831070111541e-07
state O 0 1.4412078197523215e-09
levels O 0 6.542275610144088e-10
of O 0 7.328196209577253e-12
BRCA1 O 0 5.598982610877101e-09
increase O 0 2.793461295613753e-10
in O 0 5.3552724754712955e-11
late O 0 4.049128143890357e-09
G1 O 0 6.650169552813168e-07
and O 0 1.6863767049457579e-09
reach O 0 5.428839600085666e-10
a O 0 1.868649956993096e-10
maximum O 0 2.862310832796311e-09
during O 0 3.46451267674297e-09
S O 0 4.5043389036436565e-06
phase O 0 7.677745372802747e-08
. O 0 2.7209475561562613e-08

Moreover O 0 1.0880462468776386e-06
, O 0 5.014570536587826e-09
in O 0 3.513422053291748e-10
S O 0 6.301621851889649e-06
phase O 0 4.4049404124280045e-08
cells O 0 1.0952223128413152e-08
, O 0 2.263465526120001e-10
BRCA1 O 0 9.95299664907634e-09
polypeptides O 0 5.4076356725829555e-09
are O 0 1.0417046114596928e-09
hyperphosphorylated O 0 5.564342018260504e-07
and O 0 4.592413116455418e-09
accumulate O 0 5.798341007334784e-08
into O 0 5.988399220946405e-10
discrete O 0 5.100229714116722e-07
subnuclear O 0 5.904092176933773e-05
foci O 0 3.305853533674963e-05
termed O 0 1.1176353837072384e-05
" O 0 1.6443450476799626e-06
BRCA1 O 0 1.1862218343594577e-05
nuclear O 0 3.0476727260975167e-05
dots O 0 1.3187411241233349e-05
. O 0 1.9211638857541402e-07

" O 0 1.8642853319761343e-05
BRCA1 O 0 5.461171531351283e-05
associates O 0 2.916498669947032e-05
in O 0 2.2668840138351243e-09
vivo O 0 7.970415754243731e-05
with O 0 3.911143409141005e-09
a O 0 4.2136182543117684e-08
structurally O 0 0.0002342030347790569
related O 0 6.875686153762217e-07
protein O 0 1.804836955443534e-07
termed O 0 4.550438461592421e-06
BARD1 O 0 7.537252531619743e-05
. O 0 8.784648741766432e-08

Here O 0 5.72701821965893e-07
we O 0 5.247041912070927e-09
show O 0 8.756656733055479e-09
that O 0 9.800511097113329e-11
the O 0 4.4191556664019416e-11
steady O 0 5.680640242644586e-07
- O 0 4.071193870913703e-07
state O 0 2.9178670590823685e-10
levels O 0 1.7282580921929025e-10
of O 0 2.9504914136890825e-12
BARD1 O 0 9.978717940839488e-08
, O 0 3.50177942198826e-11
unlike O 0 6.074121067234373e-11
those O 0 2.670973511809116e-11
of O 0 2.2524048598482338e-11
BRCA1 O 0 1.2088167977708508e-07
, O 0 1.0826644025740961e-09
remain O 0 5.273921743764731e-09
relatively O 0 1.2751357747475822e-09
constant O 0 5.206566289217562e-09
during O 0 2.9511375565505205e-09
cell O 0 2.0188144844723865e-06
cycle O 0 2.814168510667514e-06
progression O 0 6.695142474200111e-06
. O 0 1.446322954734569e-07

However O 0 1.2826744466565287e-07
, O 0 5.6994027275436565e-09
immunostaining O 0 1.1735785392374964e-06
revealed O 0 5.026600433666317e-07
that O 0 4.320900970355979e-09
BARD1 O 0 2.7803704142570496e-05
resides O 0 2.1865308497126534e-07
within O 0 4.685885457433869e-09
BRCA1 O 0 8.011901400095667e-07
nuclear O 0 8.555184649594594e-06
dots O 0 4.0546876789449016e-07
during O 0 1.7653409400963938e-08
S O 0 5.161145509191556e-06
phase O 0 4.032665312792005e-09
of O 0 6.470678853842671e-11
the O 0 2.5236532308348103e-10
cell O 0 4.957347528034006e-07
cycle O 0 2.6337548320043425e-07
, O 0 6.178609290863335e-10
but O 0 1.8803984758175574e-10
not O 0 4.270841666431657e-11
during O 0 5.026180513456602e-11
the O 0 1.1134024258119268e-10
G1 O 0 2.3306508012410632e-07
phase O 0 5.999037000492535e-08
. O 0 2.2375285624320895e-08

Nevertheless O 0 4.304047706682468e-06
, O 0 1.235998858817311e-08
BARD1 O 0 1.2484649687394267e-06
polypeptides O 0 2.368937934704718e-08
are O 0 1.5159719035651165e-09
found O 0 5.694846816339805e-10
exclusively O 0 3.33944938368802e-09
in O 0 5.120351920240296e-10
the O 0 3.616828225805335e-10
nuclear O 0 1.1430820023861088e-07
fractions O 0 3.458799635591703e-10
of O 0 9.955677775230765e-12
both O 0 6.027931626073624e-11
G1 O 0 1.0782922288399277e-07
- O 0 3.522844167491712e-07
and O 0 1.7700713783597166e-08
S O 0 2.181961463065818e-05
- O 0 1.1035937319547884e-07
phase O 0 5.9200381485879916e-08
cells O 0 3.355156863449338e-08
. O 0 9.707537884651174e-09

Therefore O 0 1.6759504717356322e-07
, O 0 1.750292910607243e-09
progression O 0 9.075612439346514e-08
to O 0 3.097057055256869e-09
S O 0 1.4199581528373528e-05
phase O 0 7.454567452214178e-08
is O 0 5.1506314768801076e-09
accompanied O 0 3.2679075001595947e-09
by O 0 1.0782248704988007e-10
the O 0 7.522716477526004e-11
aggregation O 0 8.179058319512933e-09
of O 0 8.191434197613034e-10
nuclear O 0 3.2672436645952985e-05
BARD1 O 0 5.72364911022305e-07
polypeptides O 0 4.453134394566405e-08
into O 0 4.685813514981874e-09
BRCA1 O 0 2.4724527065700386e-06
nuclear O 0 7.05054162608576e-06
dots O 0 3.6468234156927792e-06
. O 0 1.4312841756236594e-07

This O 0 1.02934309964553e-08
cell O 0 8.972972409537761e-07
cycle O 0 1.3517609431801247e-06
- O 0 2.470030040058191e-06
dependent O 0 5.6760811162348546e-08
colocalization O 0 7.944975095597329e-07
of O 0 7.540015833917835e-10
BARD1 O 0 4.743139652418904e-05
and O 0 2.5901236710978992e-08
BRCA1 O 0 4.495643111113168e-07
indicates O 0 5.768785893423001e-09
a O 0 8.112169269658409e-10
role O 0 1.366005530911707e-09
for O 0 5.734719366046193e-10
BARD1 O 0 6.29218811809551e-06
in O 0 2.642548402320699e-09
BRCA1 O 0 1.0051255230791867e-05
- O 0 0.00013250652409624308
mediated O 0 0.0005785597604699433
tumor B-Disease 0 0.0011712678242474794
suppression O 0 1.428202995157335e-05
. O 0 3.0948504559091816e-07

Ethnic O 0 6.528801804961404e-06
differences O 0 1.118880959438684e-06
in O 0 3.6740670505963635e-09
the O 0 5.006237202564989e-09
HFE O 0 3.164351437590085e-05
codon O 0 4.617236584181228e-07
282 O 0 4.3574388541856024e-07
( O 0 1.2095936696709941e-08
Cys O 0 4.6492928959196433e-05
/ O 0 1.040865754475817e-05
Tyr O 0 5.656763278238941e-06
) O 0 8.51126813472547e-09
polymorphism O 0 2.2123733742773766e-06
. O 0 7.904829857352524e-08

Recent O 0 1.5557884580630343e-07
studies O 0 2.277064581335253e-08
have O 0 4.447317625277947e-09
shown O 0 1.0775438852306252e-07
that O 0 1.7048600057023577e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 9.014192983158864e-06
HH B-Disease 1 0.9999780654907227
) O 0 7.236547361344492e-09
is O 0 1.3205360360757368e-08
likely O 0 5.211852283082408e-09
to O 0 3.7980815714711014e-10
be O 0 7.859229711471016e-09
caused O 0 1.2074262700778604e-09
by O 0 6.155375514849126e-11
homozygosity O 0 1.9750798685436166e-07
for O 0 6.29176544197918e-10
a O 0 3.974705897746844e-09
Cys282Tyr O 0 7.514050821555429e-07
mutation O 0 1.5670502673259534e-09
in O 0 5.3612822514814695e-11
the O 0 1.1025191176683435e-10
HFE O 0 5.367991775528935e-07
gene O 0 1.4357322442037912e-08
located O 0 2.729097730025387e-07
4 O 0 7.034429927443853e-08
. O 0 7.930140100143035e-08

5 O 0 1.8681618030313984e-06
Mb O 0 2.6851250368054025e-05
telomeric O 0 6.958484300412238e-05
to O 0 5.1054072969236586e-08
HLA O 0 0.00010602640395518392
- O 0 1.2329082892392762e-05
A O 0 2.396255069925246e-07
. O 0 7.937267554325445e-08

Population O 0 5.079424880705119e-08
studies O 0 7.927743461699777e-10
of O 0 2.283101832589729e-11
this O 0 3.404596049527697e-11
polymorphism O 0 3.385027369517957e-08
are O 0 2.6470567404679457e-10
facilitated O 0 1.570827734553859e-08
by O 0 3.8590705631058597e-10
the O 0 4.381423834853848e-10
fact O 0 2.1803738814440976e-09
that O 0 1.7941108321206656e-10
the O 0 2.378053032270344e-10
Cys282Tyr O 0 3.588572781154653e-07
mutation O 0 6.5430776352570774e-09
creates O 0 4.090712657500717e-09
a O 0 1.9244483784319755e-09
Rsal O 0 1.728295046632411e-06
restriction O 0 3.277316409366904e-07
site O 0 9.709755431686062e-06
. O 0 7.26924014315955e-08

We O 0 3.5977257084596204e-07
have O 0 6.444152989004692e-10
studied O 0 3.4736885590191946e-10
the O 0 3.13929784945266e-11
codon O 0 2.0095829000865706e-08
282 O 0 1.8041120597445115e-08
( O 0 1.751689016060709e-09
Cys O 0 1.2881044312962331e-05
/ O 0 1.76607886714919e-06
Tyr O 0 1.7461664469919924e-07
) O 0 9.350393376239552e-11
polymorphism O 0 6.752000292209459e-09
in O 0 5.1017006591491665e-11
different O 0 8.954907648739407e-11
ethnic O 0 2.9198281570330664e-09
groups O 0 1.2473762467379856e-08
. O 0 2.067044313491806e-08

In O 0 8.532207118605584e-08
agreement O 0 4.036730061329763e-08
with O 0 5.908785682962048e-10
previous O 0 2.4149180433141737e-09
observations O 0 2.2097108143270816e-08
the O 0 3.612636301220107e-10
Tyr O 0 7.448654315567182e-08
allele O 0 5.691830562426503e-09
appeared O 0 2.635955276275581e-08
to O 0 1.1179696057794786e-09
be O 0 8.084755975801272e-09
rare O 0 1.0776524561606493e-08
or O 0 3.7922294637837695e-08
absent O 0 6.586890588522465e-09
in O 0 2.680682065214768e-10
Asiatic O 0 8.264334105945181e-09
( O 0 1.3783869878825072e-10
Indian O 0 4.063128999920451e-10
, O 0 3.8403519947438625e-11
Chinese O 0 2.410286380205573e-11
) O 0 6.673000346735236e-11
populations O 0 2.268783161341048e-09
. O 0 5.767311073157089e-09

The O 0 3.814784221845002e-08
highest O 0 2.7674515123976562e-08
allele O 0 2.029547729875958e-08
frequency O 0 2.6937751584910075e-08
( O 0 1.3043337243612285e-10
7 O 0 2.8652805128537295e-10
. O 0 1.0573979192241012e-11
5 O 0 9.373195275497181e-11
% O 0 3.538046244866422e-11
) O 0 6.837176658169852e-11
was O 0 1.6772905553352757e-07
found O 0 1.2474381527738387e-08
in O 0 1.0580364362411387e-09
Swedes O 0 3.450913084179774e-07
. O 0 3.018157102019359e-08

Saamis O 0 1.8790609829011373e-05
( O 0 4.960839738998857e-09
2 O 0 7.159907111642383e-10
% O 0 7.601265450407624e-11
) O 0 3.8944871633139755e-11
and O 0 7.146945257829884e-10
Mordvinians O 0 6.71803874752186e-08
( O 0 1.3106225306425134e-11
1 O 0 1.751055724030781e-11
. O 0 7.389307048188964e-12
8 O 0 1.1432155916368814e-10
% O 0 6.0824648269453e-12
) O 0 1.4738254019985852e-11
had O 0 9.453529070668765e-10
significantly O 0 2.855378711252854e-10
lower O 0 3.1188879257015856e-10
frequencies O 0 1.5182898271959289e-09
of O 0 7.230525206347593e-11
the O 0 1.8696275638774296e-09
Tyr O 0 2.1291371012921445e-06
allele O 0 2.79946277714771e-07
. O 0 4.107265993980036e-08

Comparisons O 0 4.269170688075974e-07
with O 0 2.7961866155834514e-09
allele O 0 3.80543845324155e-08
frequencies O 0 1.3869302151192642e-08
based O 0 4.736005365657547e-09
on O 0 7.143407998455586e-08
prevalence O 0 2.5251172701246105e-05
estimates O 0 6.092054860573626e-08
of O 0 5.254670587540033e-10
HH B-Disease 1 0.9998766183853149
showed O 0 2.1448895495268516e-05
some O 0 1.0277653172963142e-09
disagreements O 0 2.9813057267347176e-07
with O 0 5.037633088456062e-10
the O 0 3.0461627664735147e-10
RFLP O 0 1.4857927510547597e-07
data O 0 3.564747075301966e-08
, O 0 5.433646310670781e-10
particularly O 0 7.856707506803673e-10
in O 0 4.497671124426006e-10
Finns O 0 3.181704926191742e-07
. O 0 3.3109614605564275e-08

The O 0 1.4769942424663896e-07
newly O 0 2.6983423140336527e-07
described O 0 1.1830413768620929e-06
HFE O 0 0.00015661574434489012
marker O 0 6.90204615239054e-05
provides O 0 6.457395063108606e-09
a O 0 3.10218101207127e-10
new O 0 2.4587173963475095e-10
approach O 0 5.896843013886155e-09
to O 0 1.5095225069927665e-10
the O 0 2.3729816722717345e-11
screening O 0 1.6852899076269523e-09
of O 0 1.3090591111097893e-10
HH B-Disease 1 0.5143251419067383
as O 0 4.420745103317358e-09
well O 0 1.4968792871883352e-09
as O 0 7.097710613690467e-11
studies O 0 9.548494807332109e-12
of O 0 5.788251822291812e-12
the O 0 9.258995653516067e-11
relationship O 0 1.2612954236601581e-08
between O 0 1.261944548858196e-09
the O 0 1.3972821788499346e-09
HFE O 0 4.045834793942049e-05
Tyr O 0 7.129849564080359e-07
allele O 0 9.198350880978978e-08
and O 0 6.048945788705851e-09
different O 0 2.4193267833538812e-08
disorders O 0 0.0032677522394806147
including O 0 1.151132892118767e-06
cancer B-Disease 0 0.0035468656569719315

Autosomal B-Disease 1 0.9998437166213989
dominant I-Disease 1 0.9987295269966125
neurohypophyseal I-Disease 1 0.9999737739562988
diabetes I-Disease 1 0.999997615814209
insipidus I-Disease 1 0.9997565150260925
associated O 0 2.2673109924653545e-05
with O 0 1.0162357177989634e-08
a O 0 1.9072638579586965e-08
missense O 0 4.242984687152784e-06
mutation O 0 8.964045861148406e-08
encoding O 0 7.0557689468842e-08
Gly23 O 0 2.2875285139889456e-05
- O 0 8.667659858474508e-05
- O 0 0.00017900728562381119
> O 0 4.7178141926451644e-07
Val O 0 5.621384843834676e-05
in O 0 1.5780409867716116e-08
neurophysin O 0 0.00013323922757990658
II O 0 0.00032517933868803084
. O 0 2.3308417951284355e-07

Autosomal B-Disease 1 0.9997720122337341
dominant I-Disease 1 0.9973352551460266
neurohypophyseal I-Disease 1 0.9998716115951538
diabetes I-Disease 1 0.9999958276748657
insipidus I-Disease 1 0.9997709393501282
( O 0 7.429626407429168e-07
ADNDI B-Disease 0 0.0005584165919572115
) O 0 2.36556072508165e-08
is O 0 1.5128653103602119e-06
an O 0 4.744637408293784e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.405071816407144e-05
by O 0 1.930290771667842e-08
progressive O 0 7.391902181552723e-05
degeneration O 0 0.0005909986793994904
of O 0 7.263869505891307e-10
the O 0 1.806311322738452e-09
magnocellular O 0 9.266619827030809e-07
neurons O 0 2.996629433482667e-08
of O 0 3.2612931799569367e-10
the O 0 4.82321682593323e-10
hypothalamus O 0 5.5174933066837184e-08
leading O 0 2.993282066654501e-08
to O 0 6.892385329138051e-09
decreased O 0 3.5418304378254106e-06
ability O 0 9.319119698147915e-09
to O 0 1.0353697899034842e-09
produce O 0 2.829493972456021e-08
the O 0 1.9885006974362796e-09
hormone O 0 3.828502315172955e-08
arginine O 0 4.2421408608106503e-08
vasopressin O 0 8.442025034582912e-08
( O 0 2.087981121334792e-09
AVP O 0 3.893223663453682e-07
) O 0 4.090579874826972e-09
. O 0 1.2229839363442352e-08

Affected O 0 2.033691998803988e-06
individuals O 0 1.8782136734785126e-08
are O 0 1.2076127875459974e-09
not O 0 1.6699118754459619e-09
symptomatic O 0 3.67360712516529e-07
at O 0 8.548053642698505e-07
birth O 0 5.236676656750205e-07
, O 0 3.5615712601355654e-09
but O 0 4.341280668285208e-09
usually O 0 1.304325536466422e-07
develop O 0 7.6003780122846365e-06
diabetes B-Disease 0 0.001654587802477181
insipidus I-Disease 0 0.00037572323344647884
at O 0 8.37596815017605e-07
1 O 0 5.3446584047378565e-08
- O 0 0.0004146744904574007
6 O 0 3.620859843067592e-07
yr O 0 3.825566454906948e-05
of O 0 2.6421451693181552e-09
age O 0 1.4227296674107492e-07
. O 0 7.246136135563574e-08

The O 0 2.770372198312998e-08
genetic O 0 4.1423476204727194e-07
locus O 0 2.741658704508154e-07
of O 0 6.122537143937734e-09
the O 0 2.2737405913630937e-07
disease O 0 0.00010355299309594557
is O 0 7.244226107872009e-09
the O 0 5.684992476773232e-10
AVP O 0 1.1193143109267112e-05
- O 0 2.8275086151552387e-05
neurophysin O 0 3.1066429073689505e-05
II O 0 6.460529675678117e-06
( O 0 4.844856738017711e-10
NPII O 0 2.1805605854297028e-07
) O 0 6.992416368145626e-11
gene O 0 2.3407127347496726e-09
, O 0 7.080730446418215e-10
and O 0 3.3264808685373737e-09
mutations O 0 2.6177328749099615e-08
that O 0 4.060419556140005e-09
cause O 0 1.1906725383425965e-08
ADNDI B-Disease 0 5.094078915135469e-06
have O 0 3.346330856857094e-08
been O 0 2.325242043355047e-08
found O 0 1.6785570267074945e-08
in O 0 8.532650280779208e-11
both O 0 6.512727857010958e-11
the O 0 7.957401404468101e-11
signal O 0 6.487665960008826e-09
peptide O 0 1.4184681207396466e-10
of O 0 5.417807261848262e-12
the O 0 7.767940457537037e-11
prepro O 0 1.2819064920677192e-07
- O 0 3.2213841905104346e-07
AVP O 0 1.2043481092405273e-06
- O 0 4.387148351270298e-07
NPII O 0 4.470503824904881e-07
precursor O 0 5.404006575560061e-09
and O 0 1.8762831288654525e-09
within O 0 2.7432649485348293e-09
NPII O 0 4.613795226759976e-06
itself O 0 3.700580464283121e-07
. O 0 2.7908438227086663e-08

An O 0 1.3150659583516244e-07
affected O 0 1.4061116644370486e-06
girl O 0 0.0005418889923021197
who O 0 4.401295683464923e-08
presented O 0 9.718931437419087e-09
at O 0 1.5705586520198267e-07
9 O 0 4.9421782222225374e-09
months O 0 8.902103498797942e-10
of O 0 8.2346025831459e-11
age O 0 1.3625250971927017e-07
and O 0 1.496189838690043e-07
her O 0 4.61722748923421e-08
similarly O 0 8.745278279320701e-08
affected O 0 3.972289874809576e-08
younger O 0 5.30866230974425e-08
brother O 0 3.081426029893919e-06
and O 0 3.7237933270262147e-07
father O 0 8.309319241561752e-07
were O 0 5.094570809660581e-08
all O 0 3.0243257898021625e-10
found O 0 5.282831949671163e-09
to O 0 2.391435938164932e-09
have O 0 4.808183629023688e-09
a O 0 6.956038522965002e-10
novel O 0 1.2830824402954022e-08
missense O 0 1.806123322012354e-07
mutation O 0 1.974516994351916e-09
( O 0 7.014872016597451e-11
G1758 O 0 1.0058609944962882e-08
- O 0 2.6866434836847475e-06
- O 0 1.5222321962937713e-05
> O 0 5.96635558736125e-08
T O 0 6.391242095560301e-07
) O 0 1.807950143761783e-11
encoding O 0 6.859918882939908e-11
the O 0 1.033658054983011e-11
amino O 0 3.06191218213403e-11
acid O 0 4.758127052084671e-12
substitution O 0 3.4303827139980925e-11
Gly23 O 0 2.936590526303462e-08
- O 0 2.442873778818466e-07
- O 0 1.5646103292965563e-06
> O 0 1.187348317444048e-07
Val O 0 6.146482974145329e-06
within O 0 3.5171197509953345e-08
NPII O 0 2.250407123938203e-05
. O 0 9.694829827822105e-08

The O 0 3.5545426158023474e-08
mutation O 0 1.2826328088522132e-07
was O 0 5.990723650484142e-08
confirmed O 0 1.7188577672300198e-08
by O 0 2.9375119003915984e-10
restriction O 0 2.417822919653645e-08
endonuclease O 0 3.098355955444276e-05
analysis O 0 5.720817171095405e-07
. O 0 1.9780372895183973e-07

A O 0 2.611348008940695e-06
T1 O 0 0.0002791361475829035
- O 0 4.0071586226986255e-07
weighted O 0 3.618998789534089e-08
magnetic O 0 2.066366278086207e-08
resonance O 0 2.6848089973441347e-08
imaging O 0 2.3360544219031e-06
of O 0 1.1685156176000078e-09
the O 0 1.1101294106197201e-08
fathers O 0 1.2136341865698341e-05
pituitary O 0 1.3047306310909335e-05
gland O 0 8.657218131702393e-06
demonstrates O 0 3.174146172568726e-07
an O 0 1.3232237527915913e-08
attenuated O 0 0.0025900197215378284
posterior O 0 0.0001019784394884482
pituitary O 0 0.0002135162940248847
bright O 0 5.636601599690039e-06
spot O 0 1.166978654509876e-05
. O 0 1.948460948142383e-07

This O 0 1.3325696990307279e-08
mutation O 0 1.1504948815854732e-07
may O 0 7.309096439200857e-09
be O 0 1.4724045593883517e-10
valuable O 0 2.4188123726176514e-10
for O 0 6.214606607102269e-11
developing O 0 5.872251129801498e-09
models O 0 2.0195855654492334e-07
of O 0 1.3970370416060973e-09
dominantly B-Disease 0 0.011334553360939026
inherited I-Disease 1 0.7294875979423523
neurodegeneration I-Disease 1 0.9999998807907104
, O 0 2.724520982155809e-07
as O 0 1.2415294348144812e-09
the O 0 3.230214012939214e-11
early O 0 1.5304314482378345e-09
age O 0 3.5714078361337442e-09
of O 0 9.929360111904373e-11
onset O 0 5.675701686413959e-07
of O 0 1.9346835244959948e-09
symptoms O 0 8.602477805652597e-07
suggests O 0 2.6128379460033102e-09
that O 0 2.681265209858452e-10
this O 0 7.135567831051404e-11
mutation O 0 5.743106434863421e-09
may O 0 4.6673140907671495e-09
be O 0 6.124636353632695e-10
particularly O 0 6.595662349617726e-10
deleterious O 0 1.733029719730439e-08
to O 0 9.599342432053959e-10
the O 0 8.36881564048042e-10
magnocellular O 0 1.3666182212546119e-06
neuron O 0 3.429836112900375e-07
. O 0 3.0272706563749807e-09
. O 0 2.236440543867957e-08

Frequent O 0 9.329452041129116e-06
inactivation O 0 8.811673978925683e-06
of O 0 1.1535772337367689e-08
PTEN O 0 0.00014869832375552505
/ O 0 7.823410851415247e-05
MMAC1 O 0 0.0004154810740146786
in O 0 4.130339732455468e-07
primary O 1 0.7344773411750793
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
. O 0 1.9683977825479815e-06

Sporadic B-Disease 1 0.9993093013763428
prostate I-Disease 1 0.9999936819076538
carcinoma I-Disease 1 1.0
is O 0 0.00018532908870838583
the O 0 1.4574184525883993e-08
most O 0 2.647110264319963e-08
common O 0 1.8697642190090846e-06
male B-Disease 0 5.962117484159535e-06
cancer I-Disease 0 5.330238082024152e-07
in O 0 1.3040358792792972e-09
the O 0 4.184700919118711e-10
Western O 0 1.2873945465230463e-08
world O 0 3.010361027122599e-08
, O 0 9.182811733232654e-10
yet O 0 1.0018625928864822e-09
many O 0 1.0433818739552514e-11
of O 0 1.1814274385180124e-11
the O 0 9.164417835716421e-11
major O 0 9.501178732662652e-10
genetic O 0 1.1974543578929797e-09
events O 0 6.27882967840776e-10
involved O 0 9.875917861279504e-09
in O 0 4.014337195989981e-10
the O 0 2.7315627537660703e-10
progression O 0 2.845449671440292e-07
of O 0 6.692692927634525e-11
this O 0 5.340456965541307e-09
often O 0 1.0160341844311915e-05
fatal O 0 0.000105658735265024
cancer B-Disease 0 7.847008305361669e-07
remain O 0 4.9920227951361085e-08
to O 0 1.8191247397325583e-09
be O 0 6.056752255290121e-08
elucidated O 0 7.159890174079919e-06
. O 0 4.258695440739757e-08

Numerous O 0 2.3145178147387924e-06
cytogenetic O 0 0.0007997200009413064
and O 0 2.0983809179142554e-07
allelotype O 0 2.881643695218372e-06
studies O 0 7.249064015724116e-09
have O 0 2.9066591356041727e-09
reported O 0 2.3870242671364394e-07
frequent O 0 5.357651033932598e-08
loss O 0 2.345634442235678e-08
of O 0 3.6305478068321406e-10
heterozygosity O 0 1.8457792521076044e-06
on O 0 5.50040738289681e-07
chromosomal O 0 0.12151293456554413
arm O 0 0.006596858613193035
10q O 0 1.991935050682514e-06
in O 0 6.788314266259476e-08
sporadic B-Disease 1 0.9975466132164001
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999955892562866
. O 0 7.354281592597545e-07

Deletion O 0 4.5580345613416284e-06
mapping O 0 2.0428849893505685e-05
studies O 0 1.7710920019453624e-07
have O 0 1.1286098278162626e-08
unambiguously O 0 2.316413701919373e-05
identified O 0 2.3921616048028227e-06
a O 0 1.0679106487998524e-08
region O 0 6.459368506739338e-08
of O 0 9.774227260894719e-11
chromosome O 0 8.196753356060071e-07
10q23 O 0 1.4127434155852825e-07
to O 0 2.590724967888036e-09
be O 0 2.9400695211734273e-09
the O 0 5.794396559788417e-11
minimal O 0 1.3174465962606519e-08
area O 0 9.702302605774094e-08
of O 0 1.625612755518091e-09
loss O 0 6.47987747015577e-07
. O 0 8.870500778357382e-08

A O 0 1.1483069783935207e-07
new O 0 8.029294562561518e-09
tumor B-Disease 0 8.716457955415535e-07
suppressor O 0 7.134883048820484e-07
gene O 0 8.506857795964606e-08
, O 0 1.4025638428449838e-09
PTEN O 0 2.5695956082927296e-06
/ O 0 1.7912725525093265e-05
MMAC1 O 0 0.0001175928846350871
, O 0 2.0524533184129723e-08
was O 0 2.115411774639142e-07
isolated O 0 1.7994036170421168e-05
recently O 0 1.4236636616260512e-06
at O 0 8.67353193712006e-08
this O 0 1.406106758805592e-10
region O 0 2.266257181915421e-09
of O 0 3.152210090173746e-11
chromosome O 0 8.816085141916119e-07
10q23 O 0 2.7685504733199195e-07
and O 0 1.8343200736126164e-08
found O 0 1.4033191497730968e-08
to O 0 1.184840558998701e-09
be O 0 1.4851709861929407e-09
inactivated O 0 2.1417580597926644e-08
by O 0 2.2649337960700677e-10
mutation O 0 1.7678983610380783e-08
in O 0 1.1559097679025854e-08
three O 0 7.738726708339527e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
cell O 0 0.0003081261820625514
lines O 0 7.528128480771556e-05
. O 0 5.301994292494783e-07

We O 0 1.3848493836121634e-06
screened O 0 4.577023355523124e-05
80 O 0 4.042617729282938e-05
prostate B-Disease 1 0.9960877895355225
tumors I-Disease 1 0.9999997615814209
by O 0 1.0902534874901448e-08
microsatellite O 0 2.0757893253176007e-06
analysis O 0 6.908721417175911e-08
and O 0 1.649733682995702e-08
found O 0 9.202418382869837e-09
chromosome O 0 4.7623586851841537e-07
10q23 O 0 6.025342713655846e-08
to O 0 1.2707266350275859e-09
be O 0 1.0193899058208444e-09
deleted O 0 6.338203206723847e-08
in O 0 4.264985253854547e-09
23 O 0 3.5444955415186996e-08
cases O 0 9.894526975529061e-09
. O 0 3.970858131197019e-08

We O 0 3.23361291520996e-07
then O 0 1.085499246045174e-09
proceeded O 0 8.492097025580847e-10
with O 0 1.524588441603747e-11
sequence O 0 1.5918909246348534e-10
analysis O 0 2.1327467569776104e-10
of O 0 1.729546714179797e-11
the O 0 2.0700485769964416e-10
entire O 0 5.162682725767809e-08
PTEN O 0 1.1317805729049724e-05
/ O 0 1.4534687579725869e-05
MMAC1 O 0 1.2919206710648723e-05
coding O 0 5.138793767400784e-06
region O 0 2.4503335680492455e-06
and O 0 2.2316935854860276e-08
tested O 0 1.5361196403773647e-07
for O 0 2.744650340336108e-10
homozygous O 0 8.287319985811337e-08
deletion O 0 3.5167108336509045e-08
with O 0 2.7168178817760236e-09
new O 0 3.0744269352567244e-09
intragenic O 0 2.0866123122686986e-06
markers O 0 4.875094873568742e-06
in O 0 6.531166718559689e-10
these O 0 4.1316031151872323e-10
23 O 0 2.7603281882448982e-09
cases O 0 6.44444775321773e-10
with O 0 1.2164970142336529e-09
10q23 O 0 3.8773578125983477e-07
loss O 0 8.391776873395429e-08
of O 0 3.733049869225624e-09
heterozygosity O 0 2.3553109713247977e-05
. O 0 2.4675856025169196e-07

The O 0 1.6781664058385104e-08
identification O 0 2.4103728790692003e-08
of O 0 3.528653480522337e-10
the O 0 5.076475351195597e-10
second O 0 2.9534688028576284e-09
mutational O 0 5.606807462754659e-07
event O 0 1.0020197116489271e-08
in O 0 1.595776011331651e-10
10 O 0 2.342310512215562e-10
( O 0 3.163859799149016e-11
43 O 0 3.833322992363719e-09
% O 0 2.3708353058538023e-09
) O 0 1.518840093694962e-07
tumors B-Disease 1 0.9999991655349731
establishes O 0 5.240991413302254e-06
PTEN O 0 3.156732054776512e-05
/ O 0 2.7085077817901038e-05
MMAC1 O 0 2.2442178305936977e-05
as O 0 3.4200637877290774e-09
a O 0 3.940909376609625e-09
main O 0 1.7899294846301927e-07
inactivation O 0 6.604178111047077e-07
target O 0 6.723627166138613e-08
of O 0 9.69285623986238e-11
10q O 0 1.1657461840286487e-07
loss O 0 2.0571407688407817e-08
in O 0 7.49648343401077e-09
sporadic B-Disease 1 0.9994431138038635
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
. O 0 3.718193042345774e-08
. O 0 1.2581027419855673e-07

Risk O 0 2.0160336134722456e-05
reversals O 0 5.273773808767146e-07
in O 0 2.4438737700194224e-09
predictive O 0 1.183265908366593e-06
testing O 0 2.8459155601012753e-06
for O 0 2.5288509277743287e-06
Huntington B-Disease 1 0.9999997615814209
disease I-Disease 1 0.9999980926513672
. O 0 5.583813731391274e-07

The O 0 3.6917056078777932e-09
first O 0 1.0904525060695391e-09
predictive O 0 2.8034381216457405e-07
testing O 0 8.891766469787399e-07
for O 0 9.958484952221625e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999986886978149
( O 0 8.652539240650015e-10
HD B-Disease 0 0.00029318913584575057
) O 0 1.7512246097695083e-09
was O 0 4.692962818353408e-08
based O 0 2.2906021523994013e-09
on O 0 9.479624196728764e-09
analysis O 0 1.053662268546418e-09
of O 0 6.889500081541655e-11
linked O 0 6.41512485799467e-07
polymorphic O 0 1.5079642423643236e-08
DNA O 0 1.9408531670705997e-08
markers O 0 1.4981947060732637e-07
to O 0 9.765342978695912e-10
estimate O 0 6.729888468726131e-08
the O 0 2.319627268043689e-10
likelihood O 0 2.6698352417753313e-09
of O 0 3.8770403554266863e-11
inheriting O 0 3.014400462575395e-08
the O 0 3.059350828227281e-10
mutation O 0 5.801436220309597e-09
for O 0 3.5269462905773707e-09
HD B-Disease 0 0.0018665172392502427
. O 0 4.1515303905725887e-07

Limits O 0 3.609813177263277e-07
to O 0 3.134903225898711e-09
accuracy O 0 6.639695016019687e-08
included O 0 2.788404229736585e-10
recombination O 0 5.931880764364905e-09
between O 0 1.8531612910877016e-09
the O 0 1.1923803611146866e-10
DNA O 0 1.2943925753461372e-07
markers O 0 9.682716154202353e-06
and O 0 1.8286471004103078e-08
the O 0 7.065553142560077e-10
mutation O 0 2.6087858984169543e-08
, O 0 2.29186492006761e-09
pedigree O 0 7.780405439916649e-07
structure O 0 6.973466497584013e-07
, O 0 1.7610689573288596e-09
and O 0 5.512491019210586e-10
whether O 0 2.597571879814353e-10
DNA O 0 2.158229595039529e-09
samples O 0 3.3010723043958023e-09
were O 0 5.81721426584636e-09
available O 0 1.026887463950743e-09
from O 0 2.4868410108958017e-10
family O 0 1.7598912549487977e-08
members O 0 7.451176342598842e-10
. O 0 9.929219224602548e-09

With O 0 3.079152577356581e-08
direct O 0 4.10971878750388e-08
tests O 0 7.106633148623587e-08
for O 0 1.975480196092505e-10
the O 0 2.0880597251249355e-10
HD B-Disease 0 2.170066727558151e-05
mutation O 0 3.5075049531485547e-09
, O 0 9.337864509406657e-11
we O 0 4.0945435930694885e-10
have O 0 5.392489926814292e-11
assessed O 0 1.305887731284372e-09
the O 0 4.418548860130045e-11
accuracy O 0 1.5441303276020335e-06
of O 0 5.0941067336607304e-11
results O 0 1.1469420968523991e-09
obtained O 0 7.572371063524486e-10
by O 0 2.468759363605244e-10
linkage O 0 2.98793132458286e-08
approaches O 0 7.65627383714218e-09
when O 0 2.1513196779565646e-10
requested O 0 3.9597891632325855e-10
to O 0 6.818868802938027e-10
do O 0 9.908295517391252e-09
so O 0 2.6395799435086076e-10
by O 0 2.6629564872648892e-11
the O 0 1.0241191922277793e-10
test O 0 8.341540080891718e-08
individuals O 0 1.4502220535561605e-09
. O 0 1.1263925792093232e-08

For O 0 2.3934907389389082e-08
six O 0 1.6668315616641394e-09
such O 0 2.0600558758854248e-10
individuals O 0 5.042102846353202e-10
, O 0 3.0428642938673534e-10
there O 0 2.155937872672098e-09
was O 0 6.177035771770534e-08
significant O 0 8.713734178655841e-10
disparity O 0 1.557393103368554e-09
between O 0 6.578713684923798e-10
the O 0 3.6755370969032697e-10
tests O 0 6.848436839845817e-08
. O 0 1.0140594142171722e-08

Three O 0 1.5292773980490892e-07
went O 0 6.70971473937243e-08
from O 0 3.027003370181802e-10
a O 0 1.8032648707588805e-09
decreased O 0 3.0493597478198353e-06
risk O 0 8.706527943047604e-09
to O 0 1.342896766010071e-10
an O 0 1.0508579423307296e-10
increased O 0 3.854123775681728e-08
risk O 0 1.9734041245556e-07
, O 0 4.5659989678092927e-10
while O 0 1.556754614107092e-09
in O 0 3.383287816571823e-10
another O 0 1.7069613500453329e-09
three O 0 2.0704711556351896e-10
the O 0 5.970379746145227e-10
risk O 0 8.862011924293256e-08
was O 0 6.882469278934877e-07
decreased O 0 1.7143350987680606e-06
. O 0 3.4073689647584615e-08

Knowledge O 0 3.4370884804957313e-07
of O 0 2.0471506712027576e-09
the O 0 9.17593112603754e-10
potential O 0 4.536780728869871e-09
reasons O 0 3.9363096115963003e-10
for O 0 2.062594713081456e-11
these O 0 2.2476839833807105e-11
changes O 0 1.5450987711496111e-10
in O 0 1.7305935851030796e-10
results O 0 1.538075800056049e-08
and O 0 7.242374255866935e-09
impact O 0 1.400208837765149e-09
of O 0 1.518224608532126e-11
these O 0 3.6870947961453737e-10
risk O 0 2.189604941804646e-09
reversals O 0 2.364738405091771e-09
on O 0 1.2439909369277302e-07
both O 0 4.5982946339506725e-09
patients O 0 5.0671138396296556e-09
and O 0 9.197992367759866e-10
the O 0 1.2832108986504664e-10
counseling O 0 2.088236028541246e-09
team O 0 2.055216968832596e-10
can O 0 1.6324475105022884e-10
assist O 0 1.1915982089938382e-10
in O 0 1.5774193062867425e-10
the O 0 6.243882494372244e-11
development O 0 1.0513014903068552e-09
of O 0 1.2594448921265933e-11
strategies O 0 5.710360184707497e-09
for O 0 1.354278772458528e-10
the O 0 2.0134904854529623e-10
prevention O 0 2.3996618025989847e-08
and O 0 2.444274782575917e-09
, O 0 2.0695867242181976e-10
where O 0 4.3682898964725325e-10
necessary O 0 2.1549471096449224e-09
, O 0 1.892506013012607e-10
management O 0 8.233397852386304e-10
of O 0 1.0134604093436916e-11
a O 0 1.4537668846514862e-09
risk O 0 9.240886278405469e-09
reversal O 0 2.652678521286589e-09
in O 0 1.1357997875549586e-10
any O 0 3.364676315342763e-10
predictive O 0 2.717773206484253e-08
testing O 0 2.5826352612057235e-08
program O 0 1.9836292608488293e-09
. O 0 1.481028910621518e-10
. O 0 3.276158011544794e-09

A O 0 2.1937651126791025e-06
novel O 0 5.388250770010927e-07
common O 0 6.370831329149951e-08
missense O 0 4.536256710707676e-06
mutation O 0 8.517264404872549e-08
G301C O 0 1.8746997909602214e-07
in O 0 7.144382307977537e-10
the O 0 3.534837422769499e-10
N O 0 1.1841332707263064e-05
- O 0 7.502317657781532e-06
acetylgalactosamine O 0 3.941393515560776e-05
- O 0 2.3124275685404427e-05
6 O 0 6.347519132532398e-08
- O 0 7.323526006075554e-06
sulfate O 0 1.2207021882204572e-06
sulfatase O 0 1.7813483736972557e-06
gene O 0 2.3574980190232964e-08
in O 0 2.502783091884453e-09
mucopolysaccharidosis B-Disease 0 2.570311880845111e-05
IVA I-Disease 0 0.0009962004842236638
. O 0 4.464641278900672e-07

Mucopolysaccharidosis B-Disease 0 0.15668094158172607
IVA I-Disease 1 0.9914095997810364
( O 0 7.270997593877837e-05
MPS B-Disease 1 0.9999957084655762
IVA I-Disease 1 0.9999996423721313
) O 0 4.772834358846012e-07
is O 0 3.778850725666416e-07
an O 0 4.3576923758337216e-07
autosomal B-Disease 1 0.999996542930603
recessive I-Disease 1 0.999998927116394
lysosomal I-Disease 1 0.9999996423721313
storage I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999972581863403
caused O 0 1.6234007489401847e-05
by O 0 1.024980100794437e-08
a O 0 1.1110466402897146e-05
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999994039535522
in O 0 1.6562601956593426e-08
N O 0 0.00044839957263320684
- O 0 1.393826551066013e-05
acetylgalactosamine O 0 0.0001754508848534897
- O 0 7.346324855461717e-05
6 O 0 1.165636192013153e-07
- O 0 6.470335938502103e-05
sulfate O 0 1.0473718248249497e-05
sulfatase O 0 3.575081109374878e-06
( O 0 5.254069401772199e-10
GALNS O 0 2.086907784359937e-07
) O 0 1.044764941227072e-09
. O 0 3.813589444234822e-09

In O 0 6.114697015391357e-08
previous O 0 1.5668957686898466e-08
studies O 0 2.328103043680585e-09
, O 0 6.512296257810135e-10
we O 0 2.2966828439052733e-09
have O 0 3.340250576133741e-10
found O 0 8.878481838614505e-10
two O 0 5.6105332185696355e-11
common O 0 2.9956320757307253e-10
mutations O 0 2.119744796358347e-10
in O 0 4.1140965634234306e-11
Caucasians O 0 8.784041050091673e-09
and O 0 5.761989552155455e-09
Japanese O 0 2.2212454098280432e-07
, O 0 6.184504020012582e-10
respectively O 0 1.2922631853484745e-08
. O 0 2.2335928662187143e-08

To O 0 3.479958721186449e-08
characterize O 0 5.906678097744589e-07
the O 0 3.222875299968564e-09
mutational O 0 1.2380713769744034e-06
spectrum O 0 1.82527088554707e-07
in O 0 7.297698001451636e-10
various O 0 2.1637887315240079e-10
ethnic O 0 1.8135539736618966e-09
groups O 0 9.174198623007612e-10
, O 0 1.3180685709546225e-10
mutations O 0 5.30398114317876e-10
in O 0 5.2531649169518246e-11
the O 0 3.6780409273795556e-10
GALNS O 0 6.025228458383936e-07
gene O 0 7.929683576435309e-09
in O 0 5.864494667662257e-09
Colombian O 0 3.5538861993700266e-05
MPS B-Disease 1 0.9999946355819702
IVA I-Disease 1 0.9999995231628418
patients O 0 5.873514510312816e-06
were O 0 7.581106586940223e-08
investigated O 0 2.1048358576081228e-06
, O 0 6.3140688233431774e-09
and O 0 4.569311595759018e-09
genetic O 0 9.92387949594331e-09
backgrounds O 0 7.306085958447284e-09
were O 0 3.922902891417834e-09
extensively O 0 2.0318562832244424e-08
analyzed O 0 1.326713849891803e-08
to O 0 4.172594492146686e-10
identify O 0 3.383542690471586e-08
racial O 0 6.298564336759682e-09
origin O 0 2.831927581325999e-09
, O 0 1.6313675410550843e-10
based O 0 5.404560687871651e-10
on O 0 5.407512215782617e-09
mitochondrial O 0 3.818468314875645e-07
DNA O 0 7.331257734222163e-08
( O 0 2.2380855502213137e-10
mtDNA O 0 6.933642549000751e-09
) O 0 1.0125862370813365e-09
lineages O 0 2.5701044847892263e-08
. O 0 2.7274838387825184e-08

Three O 0 1.257296702306121e-07
novel O 0 3.558511423307209e-07
missense O 0 2.2438412997871637e-05
mutations O 0 1.0151740070796222e-06
never O 0 3.316283709864365e-07
identified O 0 4.0533808487452916e-07
previously O 0 1.8569257065337297e-07
in O 0 9.748389873109886e-10
other O 0 4.4006701060972375e-10
populations O 0 1.9632333092545196e-08
and O 0 9.141295720382914e-09
found O 0 2.1739591460345764e-08
in O 0 3.428108352743209e-10
16 O 0 9.32373844797496e-10
out O 0 8.165585985153712e-10
of O 0 1.1443194308791149e-10
19 O 0 3.92284498218487e-08
Colombian O 0 1.5167802303039934e-06
MPS B-Disease 1 0.9996299743652344
IVA I-Disease 1 0.9998788833618164
unrelated O 0 1.5825341392883274e-07
alleles O 0 2.925035857970215e-08
account O 0 3.2039441322240236e-08
for O 0 1.2162215234923224e-08
84 O 0 5.902517159483978e-07
. O 0 1.5595452396155451e-07

2 O 0 1.4765124944915442e-07
% O 0 2.0773114339789345e-09
of O 0 6.904549154640449e-11
the O 0 1.4495547817627852e-10
alleles O 0 1.6976202665830442e-09
in O 0 1.8549781155563494e-10
this O 0 3.1893507279612265e-10
study O 0 5.697956773076385e-09
. O 0 1.9361129588446602e-08

The O 0 6.51436451448717e-08
G301C O 0 1.5963461237333831e-06
and O 0 1.7696864418326186e-08
S162F O 0 2.0015656332361687e-07
mutations O 0 4.51002861723282e-08
account O 0 7.002059820848672e-09
for O 0 3.7629606097766555e-09
68 O 0 3.6672994951914006e-07
. O 0 1.2968291684956057e-07

4 O 0 4.053720772390079e-07
% O 0 1.8351670405536424e-08
and O 0 1.835272023242851e-08
10 O 0 1.8297845016945757e-08
. O 0 2.713546543020584e-08

5 O 0 7.86731675361807e-08
% O 0 1.5585728263545207e-09
of O 0 5.110261172558417e-11
mutations O 0 8.72022276610096e-09
, O 0 1.0592641208617692e-09
respectively O 0 6.476934100163589e-09
, O 0 7.205925856013096e-10
whereas O 0 1.2788574643707307e-09
the O 0 1.572420943452002e-10
remaining O 0 5.197418051494651e-09
F69V O 0 5.695227628166322e-06
is O 0 3.682823157546977e-09
limited O 0 2.0976169690101187e-09
to O 0 3.6685612880837937e-10
a O 0 2.2827295609317844e-09
single O 0 5.56729418121904e-08
allele O 0 5.927144570705423e-07
. O 0 4.4515800823319296e-08

The O 0 1.6636686694937453e-08
skewed O 0 9.928775170919835e-07
prevalence O 0 1.653001891099848e-05
of O 0 2.537021703830078e-10
G301C O 0 7.972894167096456e-08
in O 0 5.208390940758534e-10
only O 0 6.371481675593316e-10
Colombian O 0 1.7822774367459715e-08
patients O 0 1.1319680748300698e-09
and O 0 5.364278812813872e-11
haplotype O 0 5.443742345789815e-09
analysis O 0 5.80253955995147e-10
by O 0 8.257077660500656e-11
restriction O 0 1.8753000929905284e-08
fragment O 0 1.0173318543138521e-07
length O 0 2.5419294047424046e-07
polymorphisms O 0 1.238800109604199e-06
in O 0 1.629741896991277e-09
the O 0 3.536766157719029e-10
GALNS O 0 3.610932139963552e-07
gene O 0 4.765145611429489e-09
suggest O 0 3.982643548283704e-09
that O 0 2.808473453796978e-10
G301C O 0 1.7291368337168933e-08
originated O 0 2.7061022311869465e-09
from O 0 2.428867384995925e-10
a O 0 3.0631071012976463e-09
common O 0 1.9449256427606088e-08
ancestor O 0 2.5659835500846384e-07
. O 0 1.0241109293929185e-07

Investigation O 0 1.1926003651296924e-07
of O 0 8.29129709334353e-10
the O 0 5.967875083001672e-10
genetic O 0 1.621551461994386e-07
background O 0 5.058049623585248e-08
by O 0 7.102534671510341e-10
means O 0 2.1662840410385797e-09
of O 0 2.300494864049263e-11
mtDNA O 0 2.3126176529331133e-09
lineages O 0 1.723436504619258e-09
indicate O 0 3.127880887632273e-08
that O 0 1.9986570176655505e-09
all O 0 6.952921571823367e-10
our O 0 5.9826485987457545e-09
patients O 0 4.457370306187869e-10
are O 0 4.320394042522935e-11
probably O 0 1.942566996149253e-09
of O 0 3.901371933845432e-11
native O 0 7.702603888048998e-09
American O 0 9.385141197526536e-08
descent O 0 0.0003450539370533079

Low O 0 2.6506070298637496e-06
frequency O 0 4.772242618855671e-07
of O 0 5.350122567193694e-09
BRCA1 O 0 3.853319412883138e-06
germline O 0 1.0322291927877814e-06
mutations O 0 1.368110957855606e-07
in O 0 3.696856598622844e-09
45 O 0 7.222485010061064e-07
German O 1 0.9962528944015503
breast B-Disease 1 0.9999992847442627
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 8.538589099771343e-06
. O 0 4.007009408724116e-07

In O 0 3.884780053198256e-09
this O 0 7.763526627124762e-11
study O 0 9.594157412973203e-11
we O 0 3.9965591946966583e-10
investigated O 0 2.975681034911304e-08
45 O 0 9.900836772658295e-08
German O 1 0.9716046452522278
breast B-Disease 1 0.9999982118606567
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 2.001483636604462e-07
for O 0 1.6583963091676424e-09
germline O 0 8.455197075818432e-07
mutations O 0 6.082372294713423e-08
in O 0 6.761585180647955e-10
the O 0 1.3262095865940182e-09
BRCA1 O 0 7.283867944352096e-07
gene O 0 4.0303339687852713e-07
. O 0 8.421231001420892e-08

We O 0 4.353866813744389e-07
identified O 0 2.3136340132623445e-07
four O 0 1.8254331379807809e-09
germline O 0 4.3761667711805785e-07
mutations O 0 1.2628220247279387e-07
in O 0 1.7876327973453954e-08
three O 0 1.0450812624185346e-06
breast B-Disease 1 0.9815309047698975
cancer I-Disease 0 0.0017018010839819908
families O 0 4.8991488199590094e-08
and O 0 1.4874375153794972e-07
in O 0 7.029762372212645e-08
one O 0 0.014687636867165565
breast B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 5.092092578706797e-06
. O 0 1.21035226285926e-09
among O 0 2.494156270405057e-10
these O 0 1.7839831001342787e-10
were O 0 2.7501764421344888e-08
one O 0 2.698438139603354e-09
frameshift O 0 1.0155283689528005e-06
mutation O 0 9.581091475752146e-09
, O 0 6.571929112020314e-10
one O 0 2.558950829012474e-09
nonsense O 0 1.3029885849391576e-05
mutation O 0 2.8954723063634447e-08
, O 0 2.4139235055287145e-09
one O 0 1.0407036343806908e-09
novel O 0 3.391489755699695e-08
splice O 0 2.6132311177207157e-05
site O 0 3.1127197871683165e-05
mutation O 0 2.227934601251036e-07
, O 0 5.126745694639112e-09
and O 0 4.258425612135852e-09
one O 0 1.9619005087179175e-08
missense O 0 1.4844750694464892e-05
mutation O 0 1.761988983162155e-06
. O 0 3.648360973329545e-07

The O 0 6.319529433085336e-08
missense O 0 1.375104966427898e-05
mutation O 0 5.550371611207083e-07
was O 0 1.455316578358179e-06
also O 0 1.7266652108105518e-08
found O 0 5.961097837570151e-09
in O 0 1.1652061537859026e-09
2 O 0 2.919829711345301e-08
. O 0 3.047502517006251e-08

8 O 0 8.30662685302741e-08
% O 0 1.2668932569681601e-09
of O 0 7.235684967854539e-11
the O 0 5.934624319747783e-11
general O 0 1.4125554892441272e-10
population O 0 4.2968267832677043e-10
, O 0 1.0587707099940502e-10
suggesting O 0 5.894481347468172e-09
that O 0 6.540841201996273e-10
it O 0 4.330099834248813e-09
is O 0 2.1934766891718027e-08
not O 0 4.9813131397513644e-08
disease O 0 4.811048484043567e-07
associated O 0 5.3721201709322486e-08
. O 0 8.754590652415573e-08

The O 0 1.6965140403613077e-08
average O 0 3.1207426332002797e-07
age O 0 6.114510853194588e-08
of O 0 2.9221234321141765e-09
disease O 0 0.0002174208202632144
onset O 0 2.576588940428337e-06
in O 0 5.5922053654455794e-09
those O 0 1.5581962387045678e-08
families O 0 1.6283102866054833e-08
harbouring O 0 0.00013975435285829008
causative O 0 5.46274486623588e-06
mutations O 0 1.0347035583890829e-07
was O 0 5.190447041059087e-07
between O 0 2.0753006424456544e-08
32 O 0 1.4561103967025701e-07
. O 0 5.8635471589241206e-08

3 O 0 1.0028085171143175e-06
and O 0 7.916749922287636e-08
37 O 0 2.679650492609653e-07
. O 0 8.900923376131686e-08

4 O 0 5.098478936815809e-07
years O 0 2.7255703471951165e-08
, O 0 4.2380446374501446e-10
whereas O 0 1.0068604838764372e-09
the O 0 4.89004170489693e-10
family O 0 1.6579073758293816e-07
harbouring O 0 8.149569475790486e-05
the O 0 1.310241359853137e-09
missense O 0 5.857772862327693e-07
mutation O 0 1.3483932193025794e-08
had O 0 3.869341469453502e-08
an O 0 1.7062966317649142e-10
average O 0 1.6318396944825508e-07
age O 0 5.8780900147326065e-09
of O 0 8.668342432738285e-11
onset O 0 1.4598563780054974e-07
of O 0 1.5000375386264864e-09
51 O 0 8.237196880145348e-07
. O 0 1.4143071780381433e-07

2 O 0 1.2373880053928588e-06
years O 0 6.27478868864273e-08
. O 0 1.240684355252597e-07

These O 0 2.5453076091253024e-08
findings O 0 8.438833631885245e-09
show O 0 1.7733466961544764e-07
that O 0 2.9769282594571678e-09
BRCA1 O 0 4.83956057450996e-07
is O 0 6.691334153430262e-09
implicated O 0 3.869828191227498e-08
in O 0 5.943449205014772e-11
a O 0 4.3124762094670643e-10
small O 0 2.3932704706908225e-09
fraction O 0 6.321759826732887e-08
of O 0 1.3740881286139484e-06
breast B-Disease 1 0.9999991655349731
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.297126849905908e-07
suggesting O 0 5.348084641809692e-08
the O 0 2.9835151016399664e-10
involvement O 0 6.875303437681168e-09
of O 0 4.100058834111131e-11
another O 0 3.514482704858324e-09
susceptibility O 0 6.356157200571033e-07
gene O 0 2.8946448082933784e-07
( O 0 5.3407756439582954e-08
s O 0 0.0003055419656448066
) O 0 3.620372979185049e-07

Paternal O 0 0.07170233130455017
transmission O 1 0.7443934679031372
of O 0 6.283140828600153e-05
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999996423721313
. O 0 7.828164234524593e-05

We O 0 1.4736751836608164e-06
report O 0 2.105281815545368e-08
a O 0 2.0163508640536065e-09
rare O 0 6.895791049288391e-09
case O 0 8.314993138469617e-09
of O 0 8.306940024738196e-09
paternally O 1 0.9867373108863831
transmitted O 1 0.999984860420227
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007513099117204547
DM B-Disease 1 0.9999997615814209
) O 0 2.044215534624527e-06
. O 0 2.8707492560897663e-07

The O 0 4.391845109807946e-08
proband O 0 1.2378610335872509e-05
is O 0 2.624487116520413e-08
a O 0 2.8709987720532126e-09
23 O 0 6.145925990352907e-09
year O 0 1.6296858307285333e-09
old O 0 0.00012895927648060024
, O 0 3.919086793757742e-06
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999997615814209
male O 0 0.00036716071190312505
who O 0 2.726958700804971e-05
suffers O 1 0.8108496069908142
severe O 0 0.00018338403606321663
muscular B-Disease 0 0.028403261676430702
weakness I-Disease 0 0.03647735342383385
. O 0 6.414384188246913e-07

He O 0 8.798824069344846e-07
presented O 0 8.839986662678712e-07
with O 0 5.021439392294269e-06
respiratory O 1 0.7756919860839844
and O 0 5.946451437921496e-07
feeding O 0 9.89310719887726e-05
difficulties O 0 2.2464912490249844e-06
at O 0 6.430272492252698e-07
birth O 0 1.1267019317529048e-06
. O 0 6.481521097612131e-08

His O 0 8.579615496273618e-06
two O 0 1.4816739621892339e-06
sibs O 1 0.9600442051887512
suffer O 0 0.00028670780011452734
from O 0 3.0512829596318625e-08
childhood O 0 7.108282443368807e-05
onset O 0 0.11567690968513489
DM B-Disease 1 0.9999997615814209
. O 0 8.665048881084658e-06

Their O 0 7.593958173401916e-08
late O 0 1.0630134283928783e-07
father O 0 4.102967920971423e-07
had O 0 1.4561292616122046e-08
the O 0 4.086739280317886e-11
adult O 0 3.743959808844011e-09
type O 0 6.484019081653969e-07
of O 0 5.269798819540483e-09
DM B-Disease 1 1.0
, O 0 3.404095139103447e-08
with O 0 1.4672916215374698e-09
onset O 0 1.6351486920029856e-07
around O 0 1.8596193740449962e-07
30 O 0 5.6982178975317765e-09
years O 0 2.9473516960365487e-09
. O 0 1.2300816365495848e-08

Only O 0 3.05867722261155e-08
six O 0 1.4861145647415697e-09
other O 0 5.1239935905389444e-11
cases O 0 2.1824657359115207e-10
of O 0 2.582735969536287e-10
paternal O 0 0.0007097407360561192
transmission O 0 0.4759669303894043
of O 0 3.071409537369618e-06
congenital B-Disease 1 0.9999997615814209
DM I-Disease 1 1.0
have O 0 7.342065509874374e-05
been O 0 1.5798409549461212e-06
reported O 0 8.427451575698797e-06
recently O 0 7.650751285837032e-07
. O 0 4.145998389049055e-08

We O 0 1.4023643757354876e-07
review O 0 8.289877229117337e-09
the O 0 1.8371860976973409e-10
sex O 0 3.886056276769523e-08
related O 0 3.455150476838753e-08
effects O 0 5.440309536197674e-08
on O 0 1.925125445723097e-07
transmission O 0 0.05883416533470154
of O 0 1.2862994935858296e-06
congenital B-Disease 1 0.9999982118606567
DM I-Disease 1 0.9999998807907104
. O 0 2.2812109818914905e-05

Decreased O 0 0.00012354596401564777
fertility O 0 1.2464759038266493e-06
of O 0 2.779398655672338e-10
males O 0 4.737966019519035e-09
with O 0 1.505799374079686e-09
adult O 0 1.778031787580403e-06
onset O 0 0.0012963715707883239
DM B-Disease 1 1.0
and O 0 4.809933670912869e-06
contraction O 0 7.165730949054705e-06
of O 0 5.055025842359839e-10
the O 0 1.1793932497283777e-09
repeat O 0 4.5035129403458996e-08
upon O 0 1.089114021191051e-09
male O 0 1.258313453433857e-08
transmission O 0 3.0360271807694517e-07
contribute O 0 1.4730568986820458e-09
to O 0 2.957578404405581e-09
the O 0 1.6817480741337931e-09
almost O 0 1.0348649048808056e-08
absent O 0 3.98141297708321e-09
occurrence O 0 1.192151888318449e-08
of O 0 8.001359574905109e-10
paternal O 0 1.2424014130374417e-05
transmission O 0 0.0008796431357041001
of O 0 2.0138975287409266e-06
congenital B-Disease 1 0.999998927116394
DM I-Disease 1 0.9999998807907104
. O 0 3.658109562820755e-05

Also O 0 1.818497935346386e-06
the O 0 2.036332436006205e-09
fathers O 0 7.858585782116734e-09
of O 0 5.966790950218126e-11
the O 0 8.062177037082563e-10
reported O 0 3.653733801911585e-05
congenitally O 0 0.00034766682074405253
affected O 0 4.429686271123501e-07
children O 0 1.2523299730560211e-08
showed O 0 1.4430493422423751e-07
, O 0 1.6591610030314285e-10
on O 0 4.956706600722782e-09
average O 0 2.3882469690761354e-07
, O 0 2.424262457445536e-10
shorter O 0 7.986135130977345e-08
CTG O 0 3.364280701134703e-06
repeat O 0 9.61648467523446e-08
lengths O 0 4.517609397680644e-07
and O 0 1.523945236669988e-08
hence O 0 2.1708927988584037e-08
less O 0 4.649075791007817e-08
severe O 0 1.5228982874759822e-06
clinical O 0 1.8840318034563097e-06
symptoms O 0 7.901512049102166e-07
than O 0 4.05175448747741e-09
the O 0 2.76608336235995e-09
mothers O 0 6.701235122363869e-08
of O 0 3.1337718531254666e-10
children O 0 1.754623184524462e-07
with O 0 1.6518171150892158e-06
congenital B-Disease 1 0.9999979734420776
DM I-Disease 1 0.9999998807907104
. O 0 1.980686647584662e-05

We O 0 1.8111271060661238e-07
conclude O 0 4.3622161882694854e-08
that O 0 1.0575643694110681e-09
paternal O 0 2.3333959688898176e-06
transmission O 0 0.00790385715663433
of O 0 6.019416218805418e-07
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
is O 0 2.925267290265765e-05
rare O 0 4.975018441655266e-07
and O 0 4.552070720365009e-09
preferentially O 0 3.023048478212331e-08
occurs O 0 1.296951546159164e-09
with O 0 1.595946430565931e-10
onset O 0 4.974733158746858e-08
of O 0 2.9637843290686305e-09
DM B-Disease 1 1.0
past O 0 1.0334307262382936e-05
30 O 0 1.428387452762081e-08
years O 0 2.6673549480271674e-10
in O 0 1.1168097696634405e-10
the O 0 3.00821728638212e-10
father O 0 4.120346019931276e-08
. O 0 5.775619427161871e-10
. O 0 8.218653313463165e-09

The O 0 2.8988935696361295e-07
RB1 O 0 0.00024724937975406647
gene O 0 8.355311820196221e-07
mutation O 0 6.461956303382976e-08
in O 0 1.2364839152567697e-09
a O 0 3.384698032959932e-08
child O 0 2.6879793949774466e-05
with O 0 1.4461396631304524e-06
ectopic B-Disease 1 0.9999947547912598
intracranial I-Disease 1 0.99997878074646
retinoblastoma I-Disease 1 0.980878472328186
. O 0 1.1823481145256665e-05

The O 0 2.0944443690495973e-07
RB1 O 0 0.0001176451551145874
gene O 0 7.271388540175394e-07
mutation O 0 2.1516014214739698e-07
was O 0 1.368612032592864e-07
investigated O 0 9.27550559026713e-07
in O 0 8.758423986066077e-10
a O 0 3.606994170013422e-08
child O 0 0.0001479747297707945
with O 0 1.512095082034648e-06
ectopic B-Disease 1 0.999976396560669
intracranial I-Disease 1 0.99958735704422
retinoblastoma I-Disease 0 0.00015868886839598417
using O 0 8.44255652054926e-08
DNA O 0 2.383978312536783e-07
obtained O 0 4.474033143964107e-09
from O 0 7.232349163999174e-10
both O 0 2.947175836709448e-10
the O 0 3.879298549058774e-10
pineal B-Disease 0 7.3515716394467745e-06
and I-Disease 0 7.317824497476977e-07
retinal I-Disease 0 0.00013694008521270007
tumours I-Disease 1 0.9999990463256836
of O 0 7.3063084471414186e-09
the O 0 5.19836298451537e-08
patient O 0 1.0283686606271658e-05
. O 0 8.401081430520208e-08

A O 0 6.910275942573207e-07
nonsense O 0 2.2855836050439393e-06
mutation O 0 3.179084018256617e-08
in O 0 6.758233417336612e-10
exon O 0 6.719576362002044e-08
17 O 0 2.1798884475288105e-08
( O 0 3.3228267359852737e-10
codon O 0 5.1414739132837894e-09
556 O 0 2.9512388088903663e-09
) O 0 4.3487515671847277e-11
of O 0 1.5215381038435893e-11
the O 0 1.1736660254779707e-10
RB1 O 0 4.3603404265013523e-07
gene O 0 4.986938417772535e-09
was O 0 2.0125389710301533e-07
found O 0 1.5654201490633568e-08
to O 0 1.2207319599610855e-09
be O 0 4.250213070378095e-09
present O 0 1.2193404064220204e-09
homozygously O 0 2.9360901976360765e-07
in O 0 4.473570125451687e-10
both O 0 2.0984884663288739e-10
the O 0 1.9100213077827277e-10
retinal B-Disease 0 8.704738974074644e-08
and I-Disease 0 2.7736289709423545e-08
the I-Disease 0 2.2980380265380518e-08
pineal I-Disease 0 0.04312553629279137
tumours I-Disease 1 0.9999934434890747
. O 0 7.994751172191172e-07

The O 0 1.820024486676175e-08
same O 0 4.429953737172809e-09
mutation O 0 1.4725829444728333e-08
was O 0 3.586783137166094e-08
present O 0 3.6712441975339516e-09
heterozygously O 0 1.0294696721757646e-06
in O 0 8.352405989064948e-10
the O 0 1.6266850366708496e-10
DNA O 0 3.7457759560766135e-08
from O 0 1.2986738073816895e-10
the O 0 5.3806948480117356e-11
constitutional O 0 3.4903982482070717e-10
cells O 0 6.217621417725638e-10
of O 0 1.2772765484170279e-11
the O 0 1.5248603491002655e-09
patient O 0 7.893362976574281e-07
, O 0 1.9738193024476658e-10
proving O 0 8.148538732655197e-09
it O 0 5.022119942132974e-10
to O 0 3.7900563243375984e-10
be O 0 5.248981249650342e-10
of O 0 5.895172544567728e-11
germline O 0 1.4382543156443717e-07
origin O 0 4.7140900960584986e-08
. O 0 4.529969288569191e-08

The O 0 1.152484152555644e-08
initial O 0 1.5421472099319544e-08
mutation O 0 1.0655200277653876e-08
was O 0 2.085617900604575e-08
shown O 0 4.471524484017664e-09
to O 0 4.66312932712043e-10
have O 0 3.5847089741025684e-09
occurred O 0 8.94576590582119e-09
in O 0 7.864844886462663e-11
the O 0 1.0831022745350083e-09
paternally O 0 8.618186484454782e-07
derived O 0 1.2559736717321357e-07
RB1 O 0 4.7180572437355295e-05
allele O 0 2.3089883143256884e-06
. O 0 2.1392047244717105e-07

The O 0 3.182978858262686e-08
mutation O 0 1.1591467341531825e-07
is O 0 1.0677497108702028e-08
in O 0 2.566917511881428e-10
an O 0 2.2732564441962921e-10
area O 0 6.740100957358663e-07
of O 0 5.773942435283175e-11
the O 0 7.886084840702523e-11
gene O 0 2.1184809462226895e-09
that O 0 2.1652253601178728e-10
encodes O 0 3.332130960043145e-10
the O 0 9.255623351078768e-11
protein O 0 3.0991962329807166e-09
- O 0 1.4700718509175204e-07
binding O 0 3.5589792446444335e-08
region O 0 2.4400650389111433e-08
known O 0 2.956147326926839e-08
as O 0 1.0062729538518056e-09
the O 0 2.2443738534327906e-10
pocket O 0 0.0004836957377847284
region O 0 1.680466652942414e-06
and O 0 2.1098911417993804e-07
has O 0 6.588979317712074e-08
been O 0 4.434138389797226e-09
detected O 0 1.91219946543697e-08
in O 0 2.982887548075297e-11
other O 0 3.081181143560485e-11
cases O 0 2.945748367455536e-10
of O 0 4.429349595436172e-11
retinoblastoma B-Disease 0 1.0888921906371252e-06
. O 0 6.872982627470492e-09
. O 0 4.123349128803966e-08

Low O 0 0.0001044634627760388
levels O 0 2.9538702150944118e-08
of O 0 5.422710197544589e-11
beta O 0 7.848604544058446e-10
hexosaminidase O 0 5.00561867511351e-08
A O 0 2.81471690399826e-09
in O 0 2.9957233915745007e-10
healthy O 0 1.1816774758699466e-07
individuals O 0 2.4101556306277416e-09
with O 0 3.467727438533075e-08
apparent O 0 0.0018842777935788035
deficiency O 0 0.000710381253156811
of O 0 4.181148482995667e-11
this O 0 1.1018113088567816e-09
enzyme O 0 5.559707005886594e-08
. O 0 1.137811000972988e-08

Appreciable O 0 2.7673289878293872e-05
beta O 0 9.05578417587094e-07
hexosaminidase O 0 2.4225690140156075e-05
A O 0 1.2773105595442757e-07
( O 0 8.104606985526175e-10
hex O 0 8.946127394438008e-08
A O 0 1.896087509223321e-09
) O 0 2.496249214278823e-11
activity O 0 1.5090748206603166e-08
has O 0 6.378484962432651e-10
been O 0 4.406810194534927e-10
detected O 0 8.703257670106268e-09
in O 0 8.044661464756686e-11
cultured O 0 1.8972443740494782e-06
skin O 0 6.325084541458637e-05
fibroblasts O 0 8.954260920290835e-06
and O 0 7.231789641082287e-05
melanoma B-Disease 0 0.40940800309181213
tissue O 0 8.645461639389396e-05
from O 0 7.75582353895743e-09
healthy O 0 6.055262815607421e-07
individuals O 0 3.1765181596199454e-09
previously O 0 1.7529674778415938e-07
reported O 0 0.00010148534784093499
as O 0 1.1538961643964285e-06
having O 0 0.0002157345588784665
deficiency B-Disease 0 0.004457058385014534
of I-Disease 0 2.498322659860719e-10
hex I-Disease 0 1.822413082663843e-06
A I-Disease 0 8.215268465505687e-09
activity O 0 3.998202302568643e-08
indistinguishable O 0 1.4925800595477767e-09
from O 0 2.669369066066185e-11
that O 0 3.467960293934702e-11
of O 0 4.5078461796688174e-11
patients O 0 6.532341334519742e-09
with O 0 6.184207904880168e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.3755098879337311
( O 0 1.632804114137798e-08
TSD B-Disease 0 3.5050685255555436e-05
) O 0 2.2912061581337184e-08
. O 0 4.739432668543486e-08

Identification O 0 3.968964847445022e-06
and O 0 4.0294839465104815e-08
quantitation O 0 2.5795420697249938e-06
of O 0 1.1942337119208446e-09
hex O 0 1.985994231290533e-06
A O 0 1.3846438662312721e-08
, O 0 4.2217873641448023e-10
amounting O 0 1.2495425805170157e-09
to O 0 5.603359998218593e-10
3 O 0 1.1338053163001405e-08
. O 0 2.988923242241981e-08

5 O 0 4.794248411599256e-07
% O 0 4.1838749353928506e-08
- O 0 4.5068100007483736e-05
6 O 0 2.1634902225287078e-07
. O 0 8.346553670435242e-08

9 O 0 1.5744068093681562e-07
% O 0 8.448669541749609e-10
of O 0 4.5710421558986525e-11
total O 0 1.5103498451907171e-09
beta O 0 6.476040814717976e-10
hexosaminidase O 0 5.662229796143947e-08
activity O 0 1.19646458074385e-07
, O 0 3.151399974310465e-10
has O 0 1.4143408666456025e-09
been O 0 6.32614405304821e-10
obtained O 0 9.33550015069784e-10
by O 0 2.329933357358982e-09
cellulose O 0 6.534968269988894e-05
acetate O 0 9.449781828152481e-06
gel O 0 6.571886387973791e-06
electrophoresis O 0 3.411986995160987e-07
, O 0 6.1011808938360446e-09
DEAE O 0 1.761217959028727e-06
- O 0 3.956909893076954e-07
cellulose O 0 6.091573254707328e-07
ion O 0 2.080310821384046e-07
- O 0 1.3462868082569912e-06
exchange O 0 5.079212073155759e-08
chromatography O 0 1.0592630417249893e-07
, O 0 1.9040233278921903e-10
radial O 0 2.1358346202760004e-08
immunodiffusion O 0 3.671792683235253e-07
, O 0 1.9963519726218237e-09
and O 0 7.692796621938669e-09
radioimmunoassay O 0 1.1001844541169703e-05
. O 0 8.555967667689401e-08

Previous O 0 4.760397132486105e-06
family O 0 5.456832354866492e-07
studies O 0 2.5712800777455413e-09
suggested O 0 2.3916562952308595e-08
that O 0 6.274842867526331e-10
these O 0 1.914642749900608e-10
individuals O 0 6.154204368336025e-10
may O 0 2.599054749197194e-09
be O 0 8.608258550424353e-10
compound O 0 2.9568068882213083e-08
heterozygotes O 0 1.6901029908922283e-08
for O 0 1.3792600395134968e-10
the O 0 1.744286520777294e-10
common O 0 2.843304480748543e-09
mutant O 0 6.617442949163888e-08
TSD B-Disease 0 5.477050990521093e-07
gene O 0 1.0364847646826547e-08
and O 0 2.865604642465769e-09
a O 0 2.7049256168254487e-09
rare O 0 1.5891863824890606e-08
( O 0 2.9923541422505195e-10
allelic O 0 2.7589821982587637e-08
) O 0 4.715595691706653e-10
mutant O 0 8.435056031430577e-08
gene O 0 7.987262762298997e-08
. O 0 6.900135218756986e-08

Thus O 0 1.7109300642914604e-07
, O 0 1.5468628600245893e-09
the O 0 5.083061402344491e-11
postulated O 0 1.4933695169361272e-08
rate O 0 3.68684531792951e-08
mutant O 0 1.3345866634040249e-08
gene O 0 4.506620854272114e-09
appears O 0 1.353681078342106e-08
to O 0 3.8693523385369133e-10
code O 0 6.071934621765251e-10
for O 0 1.646805053434619e-10
the O 0 1.6598764029929214e-10
expression O 0 1.0967979857667842e-09
of O 0 5.462229626940207e-11
low O 0 1.9412793506035086e-07
amounts O 0 2.2055579584900897e-09
of O 0 5.8965249349896e-10
hex O 0 3.581875716918148e-06
A O 0 5.607139641483627e-08
. O 0 2.9797702083556032e-08

Heterozygotes O 0 1.684328162809834e-05
for O 0 1.3250219588201162e-08
the O 0 5.129051627861259e-10
rare O 0 1.0574196629420385e-08
mutant O 0 7.325456294893229e-07
may O 0 6.604354751971186e-08
be O 0 1.0013543327858088e-09
indistinguishable O 0 2.7655400192116986e-09
from O 0 9.234339681807313e-11
heterozygotes O 0 1.9092183833890886e-08
for O 0 2.1095324098663326e-10
the O 0 9.315543891830202e-10
common O 0 2.19718661043089e-08
TSD B-Disease 0 6.748553005309077e-06
mutant O 0 1.0004060868595843e-06
. O 0 3.2453801424026096e-08

However O 0 1.94896657035315e-07
, O 0 5.991255824788766e-10
direct O 0 2.5657294067116254e-09
visualization O 0 8.526640726813639e-07
and O 0 2.0181639470706614e-08
quantitation O 0 4.525540589384036e-06
of O 0 1.3907732743234646e-09
hex O 0 7.829218702681828e-06
A O 0 2.064120963041205e-08
by O 0 7.406326940628816e-11
the O 0 3.794959138603282e-11
methods O 0 1.8523634182088244e-08
described O 0 1.485311372562137e-06
may O 0 2.214060401684037e-08
prevent O 0 1.1591440696179234e-08
false O 0 7.448768002404904e-08
- O 0 3.0576968583773123e-06
positive O 0 6.567648824784555e-08
prenatal O 0 1.1234669727855362e-05
diagnosis O 0 3.879128144035349e-06
of O 0 6.216672732151096e-10
TSD B-Disease 0 3.7344176234910265e-05
in O 0 4.817509946519749e-09
fetuses O 0 1.2130878985772142e-06
having O 0 5.336221686746967e-09
the O 0 6.096035898295327e-10
incomplete O 0 1.1576216820685659e-06
hex B-Disease 0 0.0002380722580710426
A I-Disease 0 1.3854536518920213e-05
deficiency I-Disease 0 0.00047499893116764724
of O 0 6.190036677677924e-11
the O 0 7.352451980580099e-10
type O 0 6.680963451799471e-06
described O 0 6.851342959635076e-07
in O 0 2.032219503789179e-09
the O 0 1.0162857222439925e-09
four O 0 1.5232711092494355e-08
healthy O 0 3.3444025575590786e-06
individuals O 0 2.2142404532132787e-07

The O 0 1.8814807845046744e-07
tumor B-Disease 0 6.023692094458966e-06
suppressor O 0 6.471746473835083e-06
gene O 0 6.448510703194188e-07
Smad4 O 0 9.098487680603284e-06
/ O 0 1.3966155165689997e-05
Dpc4 O 0 7.143766652006889e-06
is O 0 4.9332125051648745e-09
required O 0 2.506680418790097e-10
for O 0 4.6954981569591325e-11
gastrulation O 0 3.66817374697348e-07
and O 0 1.1176718217598136e-08
later O 0 3.8178904482322196e-09
for O 0 1.246110548080992e-09
anterior O 0 4.4615170224915346e-08
development O 0 3.4051712560767555e-09
of O 0 8.567287851368732e-11
the O 0 1.4461477571003911e-09
mouse O 0 7.3781347964541055e-06
embryo O 0 2.969795332319336e-06
. O 0 1.0501020852871079e-07

Mutations O 0 4.519950380199589e-06
in O 0 5.197537067402891e-09
the O 0 2.8046098776712824e-09
SMAD4 O 0 0.00047678168630227447
/ O 0 0.00024373545602429658
DPC4 O 0 0.0001980853994609788
tumor B-Disease 0 1.2245463040017057e-05
suppressor O 0 6.819784630351933e-07
gene O 0 6.453210943391241e-08
, O 0 1.1408984867955496e-09
a O 0 1.4011278803849336e-09
key O 0 4.097656969292984e-08
signal O 0 1.3475735727297433e-07
transducer O 0 4.088808225333196e-07
in O 0 6.152948150983661e-10
most O 0 9.118965582644023e-10
TGFbeta O 0 6.1580949477502145e-06
- O 0 1.310061907133786e-05
related O 0 4.630858541077032e-07
pathways O 0 6.271484220832235e-09
, O 0 8.477592239319875e-11
are O 0 8.391167968802016e-12
involved O 0 7.620572228805855e-11
in O 0 5.7925070989783833e-11
50 O 0 1.7061672075158185e-09
% O 0 5.273063652388998e-10
of O 0 1.866703058794883e-08
pancreatic B-Disease 1 0.9989873766899109
cancers I-Disease 0 0.022095706313848495
. O 0 4.526376642388641e-07

Homozygous O 0 0.0005783431115560234
Smad4 O 0 0.0008065825677476823
mutant O 0 6.938103615539148e-05
mice O 0 0.0012928831856697798
die O 0 6.401186965376837e-06
before O 0 1.8290926551145503e-09
day O 0 2.3074239408060748e-08
7 O 0 2.4994546876655477e-08
. O 0 1.3196799208969878e-08

5 O 0 2.3545462113361282e-07
of O 0 1.1881724937268245e-08
embryogenesis O 0 1.0855249456653837e-05
. O 0 4.366823986856616e-07

Mutant O 0 4.059929324284894e-06
embryos O 0 4.782867790709133e-07
have O 0 4.2316168347156236e-09
reduced O 0 1.5748257142789157e-09
size O 0 3.9664610085310414e-07
, O 0 3.694729500125504e-08
fail O 0 1.925904058452943e-07
to O 0 1.772425095580843e-09
gastrulate O 0 1.3774450053460896e-05
or O 0 1.3556633859934664e-07
express O 0 2.0129627742448974e-08
a O 0 1.0688802065672576e-09
mesodermal O 0 5.084514214104274e-07
marker O 0 2.8836513592978008e-05
, O 0 1.3997950576438711e-09
and O 0 1.987287445714969e-09
show O 0 6.944438268874364e-07
abnormal O 0 1.2608693396032322e-06
visceral O 0 1.746879405573054e-07
endoderm O 0 1.9275078102509724e-06
development O 0 2.535496435029927e-07
. O 0 5.708446337848727e-08

Growth B-Disease 1 0.9999988079071045
retardation I-Disease 1 0.9999998807907104
of O 0 1.2333613241821695e-08
the O 0 4.611900195072849e-09
Smad4 O 0 0.0002215901913587004
- O 0 0.0007939934730529785
deficient O 0 3.818568438873626e-05
embryos O 0 5.10619635463172e-08
results O 0 3.2436393571089184e-09
from O 0 1.8873404228347823e-10
reduced O 0 2.086233408249427e-09
cell O 0 1.9202170165044663e-07
proliferation O 0 3.8071598851274757e-07
rather O 0 8.302548648586594e-10
than O 0 7.156220616089115e-10
increased O 0 4.5916510593713156e-09
apoptosis O 0 1.0344569290055006e-07
. O 0 5.2347093770777064e-08

Aggregation O 0 5.694445462722797e-06
of O 0 1.2158852591426239e-08
mutant O 0 4.529971192823723e-06
Smad4 O 0 0.00020414979371707886
ES O 0 8.455732313450426e-06
cells O 0 5.784765022553984e-08
with O 0 4.004787168554458e-09
wild O 0 4.933261834594305e-07
- O 0 0.00013714523811358958
type O 0 0.00011809552233899012
tetraploid O 0 1.202487874252256e-05
morulae O 0 4.892077049589716e-05
rescues O 0 5.854863502463559e-06
the O 0 8.484653868379155e-09
gastrulation B-Disease 0 5.1845858251908794e-05
defect I-Disease 0 5.05158313899301e-05
. O 0 6.490328985364613e-08

These O 0 3.395923897642206e-08
results O 0 6.86093271085042e-09
indicate O 0 9.41349931338209e-09
that O 0 1.831968743370993e-10
Smad4 O 0 3.3405441968170635e-07
is O 0 1.1306755531848012e-09
initially O 0 8.469499546137627e-10
required O 0 4.976652423493988e-11
for O 0 3.6699799449424475e-11
the O 0 2.8355730957718706e-11
differentiation O 0 1.6153820503461702e-09
of O 0 3.596176134657014e-11
the O 0 3.4997377218459746e-10
visceral O 0 1.481143385717587e-08
endoderm O 0 2.319842451470322e-07
and O 0 2.0375455989096736e-08
that O 0 1.0781555648264884e-09
the O 0 3.8085859466185923e-10
gastrulation B-Disease 0 2.011544211200089e-06
defect I-Disease 0 1.994052581721917e-06
in O 0 1.1318315035202531e-10
the O 0 2.9176167037903156e-10
epiblast O 0 8.9392443669567e-07
is O 0 3.6978862194558815e-09
secondary O 0 2.9636033627156166e-09
and O 0 2.8784890027111487e-09
non O 0 2.5704116524138954e-07
- O 0 6.688711437163875e-05
cell O 0 4.4712658564094454e-05
autonomous O 0 8.892750429367879e-07
. O 0 1.221806940066017e-07

Rescued O 0 0.00010158633085666224
embryos O 0 2.0186729670967907e-05
show O 0 0.0002050643670372665
severe O 0 2.7920747015741654e-05
anterior O 0 5.082573352410691e-06
truncations O 0 9.344214959128294e-06
, O 0 7.706736226964495e-08
indicating O 0 2.0972585446088488e-07
a O 0 6.850379818956753e-09
second O 0 6.588247725147767e-09
important O 0 2.4101050044578187e-09
role O 0 2.233540685736557e-09
for O 0 6.611457492589068e-10
Smad4 O 0 8.418747938776505e-07
in O 0 1.9007477813914875e-09
anterior O 0 1.6158642779373622e-07
patterning O 0 1.6843799812704674e-06
during O 0 5.932449553824881e-08
embryogenesis O 0 2.2714266378898174e-06
. O 0 1.591668592482165e-07

Prevalence O 0 0.0005080775590613484
of O 0 6.570553434670501e-09
p16 O 0 1.852245304689859e-06
and O 0 5.3695284663035636e-08
CDK4 O 0 8.955054909165483e-06
germline O 0 7.413984235427051e-07
mutations O 0 2.0957111246389104e-07
in O 0 2.683261612901333e-09
48 O 0 2.071038124995539e-06
melanoma B-Disease 1 0.9987543821334839
- O 1 0.9991681575775146
prone O 1 0.9833266139030457
families O 0 5.602307169283449e-07
in O 0 7.693103931671885e-09
France O 0 4.3063344492111355e-05
. O 0 2.612431444504182e-07

The O 0 2.2168033808611654e-07
French O 0 3.348228710819967e-05
Familial B-Disease 0 0.1554277390241623
Melanoma I-Disease 1 0.5610913038253784
Study O 0 1.5456683399861504e-07
Group O 0 6.342817187032779e-07
. O 0 7.203691865242945e-08

Germline O 0 0.00010113630560226738
mutations O 0 2.7049686650570948e-06
in O 0 2.943295607238383e-09
the O 0 1.4903803191579357e-10
p16 O 0 9.923353871954532e-08
and O 0 8.638081361311833e-09
CDK4 O 0 2.482832769601373e-06
genes O 0 4.32471880529306e-09
have O 0 2.3092854295470033e-09
been O 0 6.7901120281987914e-09
reported O 0 3.1799726230019587e-07
in O 0 7.749945130086644e-11
a O 0 3.033337747648801e-10
subset O 0 1.4330674424911649e-08
of O 0 6.638574689965537e-10
melanoma B-Disease 0 0.00015425744641106576
pedigrees O 0 3.186893309248262e-06
, O 0 2.2770949570372068e-08
but O 0 7.76331265939234e-09
their O 0 1.1798140242547106e-09
prevalence O 0 2.187633072026074e-06
is O 0 3.5753200400279184e-09
not O 0 6.869165236622621e-10
well O 0 1.7019290421416144e-09
known O 0 3.166399764609196e-08
. O 0 2.0853553550637116e-08

We O 0 2.881429850276618e-07
searched O 0 1.1240708630566587e-07
for O 0 2.1106309755491992e-10
such O 0 2.5352947519152735e-10
germline O 0 1.1002225619449746e-07
mutations O 0 3.300098327940759e-08
in O 0 3.0359323943685013e-09
48 O 0 1.0929018117167288e-06
French O 0 0.003993093501776457
melanoma B-Disease 1 0.9998980760574341
- O 1 0.9949989318847656
prone O 1 0.7151980400085449
families O 0 3.310865137606811e-09
selected O 0 7.517269584589314e-10
according O 0 5.911862666074796e-10
to O 0 1.6132082336639542e-09
two O 0 7.309441385494608e-10
major O 0 1.0227401148199533e-08
criteria O 0 4.984693990905953e-09
families O 0 3.258644465375937e-10
with O 0 3.514233071211237e-10
at O 0 1.922149976962828e-07
least O 0 1.0728425925421448e-09
three O 0 1.1733390647972186e-10
affected O 0 6.038486932702369e-10
members O 0 5.61822940600698e-12
( O 0 4.409262885363141e-11
n O 0 3.7651739148714114e-07
= O 0 1.3314102886852197e-07
20 O 0 4.659280183894055e-10
) O 0 2.2107950886640637e-11
or O 0 6.33273544714541e-10
families O 0 5.785509293865232e-10
with O 0 5.905777533676826e-10
two O 0 4.718060941932833e-10
affected O 0 8.240251148095012e-09
members O 0 2.5666175781924316e-11
, O 0 1.7458774703715818e-10
one O 0 1.0645073017512274e-10
of O 0 1.2944443260332061e-11
them O 0 1.212331762756591e-10
affected O 0 6.067314983759786e-10
before O 0 1.1079368672506362e-10
the O 0 1.3727087175285924e-11
age O 0 9.744369894315597e-11
of O 0 2.3072171343591075e-12
50 O 0 1.784370845525629e-10
( O 0 1.6738898461765572e-11
n O 0 3.659316405446589e-07
= O 0 2.419585598545382e-07
28 O 0 2.7129860580288323e-09
) O 0 2.2262995266753016e-11
, O 0 6.878759367667797e-11
and O 0 1.6304001204670016e-10
one O 0 1.574209373966795e-10
additional O 0 6.102551242115339e-10
minor O 0 4.249202589790002e-08
criterion O 0 6.114645429988741e-07
. O 0 5.2945559048112045e-08

Sixteen O 0 3.536527515279886e-07
different O 0 8.70662830720903e-09
p16 O 0 5.35466824658215e-07
germline O 0 6.193363901729754e-07
mutations O 0 1.6951223358319112e-07
were O 0 2.7919833556211415e-08
found O 0 1.3135825760457465e-08
in O 0 5.239578770854791e-10
21 O 0 6.071810165764191e-09
families O 0 1.3205454507669856e-09
, O 0 3.343360865937228e-10
while O 0 1.0190828181322331e-09
one O 0 4.999583524956108e-10
germline O 0 1.6871913643967673e-08
mutation O 0 1.357828072201528e-09
, O 0 2.901688889167531e-10
Arg24His O 0 1.972839527297765e-07
, O 0 1.915191560897256e-09
was O 0 1.5821387933101505e-07
detected O 0 1.9575465159960004e-07
in O 0 1.3475048854516558e-10
the O 0 6.727854384713794e-10
CDK4 O 0 2.1676073629350867e-06
gene O 0 4.222460248115567e-08
. O 0 3.0186463106929295e-08

The O 0 3.589662789238446e-09
frequency O 0 7.073731467244215e-08
of O 0 2.389980158223892e-10
p16 O 0 5.708642447643797e-08
gene O 0 2.1818518547433996e-08
mutation O 0 8.583194599509625e-09
in O 0 5.549985471198227e-10
our O 0 1.6772440103451913e-09
sample O 0 1.8267566348484365e-09
( O 0 4.170189540908531e-11
44 O 0 8.153753366935135e-11
% O 0 1.791333227585401e-11
) O 0 5.4525692988471874e-11
is O 0 3.504876833204662e-09
among O 0 1.5093928884546415e-10
the O 0 2.998776227336464e-10
highest O 0 9.02746108977226e-08
rates O 0 3.2731495025473123e-07
yet O 0 5.789619450524697e-09
reported O 0 4.7084427023946773e-07
and O 0 1.8473418350595239e-09
the O 0 7.601990564820582e-11
CDK4 O 0 7.881778856244637e-07
mutation O 0 4.086766480781989e-09
is O 0 1.2954458616931674e-09
the O 0 7.124864587204627e-11
second O 0 2.48980391859277e-09
mutation O 0 5.653744583611342e-09
detected O 0 1.2197997989460418e-07
in O 0 6.702900040567172e-11
this O 0 1.2611450772581634e-10
gene O 0 1.8795290657180885e-08
worldwide O 0 3.9945284413533955e-08
. O 0 6.471848479350228e-08

In O 0 6.224901483165013e-08
summary O 0 3.72497265743732e-06
, O 0 1.7596127221963798e-08
our O 0 1.5790727614373168e-09
results O 0 6.01534710931162e-10
show O 0 3.5249236418621877e-08
frequent O 0 2.441988122825478e-08
involvement O 0 2.7694740722949973e-08
of O 0 9.355138885780434e-11
the O 0 1.8599201345725902e-10
p16 O 0 3.1465443584011155e-08
gene O 0 2.680848432135008e-08
in O 0 4.4307228996842696e-09
familial B-Disease 0 0.00028691915213130414
melanoma I-Disease 0 0.34769168496131897
and O 0 4.431908564583864e-07
confirm O 0 7.318073585338425e-06
the O 0 7.964481851807648e-10
role O 0 3.159906558636294e-09
of O 0 6.183062395415106e-11
the O 0 1.7975565480554678e-10
CDK4 O 0 2.5007616955008416e-07
gene O 0 2.850395697251429e-09
as O 0 6.643831040875625e-10
a O 0 2.6353017545943658e-08
melanoma B-Disease 0 0.0024888762272894382
- O 0 1.7550948541611433e-05
predisposing O 0 1.5501944972129422e-06
gene O 0 9.817981094784045e-08
. O 0 3.4078808663906557e-09
. O 0 2.3555744022019098e-08

Progression O 0 3.2859257771633565e-05
of O 0 8.346836999351126e-09
somatic O 0 3.0329995297506684e-06
CTG O 0 0.00021062724408693612
repeat O 0 1.3478412483891589e-06
length O 0 3.4839709428524657e-07
heterogeneity O 0 4.496770884543366e-07
in O 0 3.097258005624326e-09
the O 0 1.7267004492893534e-09
blood O 0 3.830361947620986e-07
cells O 0 4.958789645570505e-08
of O 0 1.4278758442287653e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
patients O 0 3.86037390853744e-05
. O 0 2.309555924284723e-07

The O 0 1.5626635985199755e-08
genetic O 0 3.4497151091272826e-07
basis O 0 2.50760876951972e-07
of O 0 6.831833729847858e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.5239796084642876e-05
DM B-Disease 1 1.0
) O 0 4.537388775815998e-08
is O 0 3.6119078838936503e-09
the O 0 3.9599455659011795e-11
expansion O 0 3.650693747303535e-09
of O 0 2.2406439204036843e-10
an O 0 1.3696919154426723e-09
unstable O 0 4.5096472604200244e-05
CTG O 0 4.500187060330063e-06
repeat O 0 4.456252611362288e-08
in O 0 1.4318446428518428e-10
the O 0 1.1240436359472028e-10
34 O 0 6.729163892771339e-10
UTR O 0 9.306917014839655e-09
of O 0 7.066600776761689e-11
the O 0 3.830998629439364e-09
DM B-Disease 1 0.9999995231628418
protein O 0 5.2155940011289204e-08
kinase O 0 1.5348705062478984e-07
gene O 0 2.2652860920402418e-08
on O 0 5.335918729088007e-08
chromosome O 0 1.5736768546048552e-05
19 O 0 2.1567497299201932e-07
. O 0 6.125529949940756e-08

One O 0 8.535707252121938e-08
of O 0 5.312384421252148e-10
the O 0 9.049347382550366e-10
principal O 0 1.337453436889291e-08
features O 0 2.7392768942036128e-08
of O 0 4.2951880940833576e-10
the O 0 3.422010408371534e-08
DM B-Disease 1 1.0
mutation O 0 6.413357027668098e-07
is O 0 1.5606023140435354e-08
an O 0 5.489271814873575e-10
extraordinarily O 0 6.125617915131443e-07
high O 0 4.208349935197475e-07
level O 0 5.472005959461512e-09
of O 0 3.787178209924136e-11
somatic O 0 2.038684598915097e-08
mosaicism O 0 5.965552645648131e-06
, O 0 1.9918335869562043e-09
due O 0 1.0490460722323292e-09
to O 0 4.1964345887102183e-10
an O 0 4.2711209569112896e-10
extremely O 0 1.8099062515375408e-07
high O 0 1.525250858946947e-08
degree O 0 1.2119849568392738e-10
of O 0 2.906722952611407e-11
somatic O 0 5.4806360338943705e-08
instability O 0 2.94192858518727e-07
both O 0 3.9696351761264737e-10
within O 0 6.67407240584339e-10
and O 0 1.7946011343639157e-09
between O 0 8.849874721938988e-10
different O 0 2.1955266493733916e-09
tissues O 0 6.950951387807436e-07
. O 0 4.5211475452333616e-08

This O 0 4.820527621518522e-08
instability O 0 4.314035777497338e-07
appears O 0 2.0682273671468465e-08
to O 0 1.2320434950030545e-10
be O 0 1.453125814121492e-10
biased O 0 6.664763851915723e-09
towards O 0 2.4762011885393065e-10
further O 0 8.133809598076525e-11
expansion O 0 2.113480279675173e-09
and O 0 2.9441307725086574e-10
continuous O 0 1.014415396127788e-08
throughout O 0 1.4948793314317754e-09
the O 0 2.1142210204772027e-10
life O 0 1.9144099638879197e-09
of O 0 5.4292924323018354e-11
an O 0 3.463625497523992e-10
individual O 0 1.6901369193078608e-10
, O 0 1.8707967119890867e-10
features O 0 1.6988771278647619e-07
that O 0 6.548211217705102e-08
could O 0 9.380037795381213e-07
be O 0 1.9584348365242477e-08
associated O 0 1.0643114833897016e-08
with O 0 1.3894739803177458e-09
the O 0 1.4149399429896903e-09
progressive O 0 1.69552507145454e-07
nature O 0 1.2961663742316887e-07
of O 0 2.714646285539857e-10
the O 0 6.447453415603377e-08
disease O 0 2.0139985281275585e-05
. O 0 3.2614956069210166e-08

Although O 0 1.231091459885647e-07
increasing O 0 9.665708233796977e-09
measured O 0 2.2910582231361332e-07
allele O 0 6.751513836888989e-08
size O 0 3.4737189480438246e-07
between O 0 7.019044545586439e-08
patients O 0 2.1296351349064935e-08
clearly O 0 1.28615758043793e-08
correlates O 0 2.533861476194943e-08
with O 0 1.0108108794426585e-09
an O 0 8.161848974452823e-10
increased O 0 2.327319066353084e-07
severity O 0 1.9731209249584936e-05
of O 0 3.3958269085587744e-08
symptoms O 0 1.729040377540514e-05
and O 0 2.831507650569165e-08
an O 0 7.847691940732204e-10
earlier O 0 5.72917109309401e-08
age O 0 7.83416087557498e-09
of O 0 1.215160749801214e-10
onset O 0 6.464224355795523e-08
, O 0 9.238884657314372e-11
this O 0 6.9408302889872875e-12
correlation O 0 2.5336377440510205e-09
is O 0 4.5679326987624336e-10
not O 0 1.206886812710195e-10
precise O 0 3.428229788937642e-08
and O 0 6.51131859541465e-09
measured O 0 3.0827309274172876e-06
allele O 0 3.666214709596716e-08
length O 0 5.850721436218009e-07
cannot O 0 1.1286409744570847e-06
be O 0 9.18566722685199e-10
used O 0 2.2981421210488406e-09
as O 0 5.118535595372009e-10
an O 0 2.5582307106031266e-11
accurate O 0 4.059225773289654e-07
predictor O 0 1.3342910278879572e-06
of O 0 3.206741261418955e-10
age O 0 1.0128145433441205e-08
of O 0 1.0943572714694483e-09
onset O 0 4.444065780262463e-06
. O 0 1.1842452352084365e-07

In O 0 1.2652373371224712e-08
order O 0 2.1898221014282626e-09
to O 0 1.5576924472515685e-10
further O 0 3.1712257819727085e-10
characterize O 0 5.8316924622658917e-08
the O 0 6.102120475581785e-10
dynamics O 0 2.809269972203765e-07
of O 0 2.6859153123837132e-08
DM B-Disease 1 0.9999997615814209
CTG O 0 0.0022165554109960794
repeat O 0 1.6234558870564797e-06
somatic O 0 6.961525400583923e-07
instability O 0 1.0893679700529901e-06
, O 0 1.5503955896889465e-09
we O 0 1.6309856798457645e-09
have O 0 7.566259424551802e-11
studied O 0 4.0185274552406725e-10
repeat O 0 2.4278496990604026e-09
length O 0 2.3466892873358347e-09
changes O 0 4.3605061228468855e-10
over O 0 6.228969007260332e-10
time O 0 7.689828773749241e-10
in O 0 3.220472777343275e-09
111 O 0 0.0002383718965575099
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
patients O 0 5.871436769666616e-06
with O 0 1.507644342702008e-09
varying O 0 4.859493429876238e-08
clinical O 0 2.049294607786578e-06
severity O 0 8.712986527825706e-06
and O 0 3.6411201165265084e-08
CTG O 0 6.852206752228085e-06
repeat O 0 5.2148383389294395e-08
size O 0 2.8935122742268504e-08
over O 0 5.905723465815527e-09
time O 0 1.0705777375719094e-09
intervals O 0 4.914138873601814e-09
of O 0 2.7866693327882608e-11
1 O 0 8.463330591901297e-10
- O 0 4.104721256226185e-07
7 O 0 2.3564763473871153e-09
years O 0 1.108700575791488e-09
. O 0 5.3902944330275204e-09

We O 0 1.7597488977116882e-06
have O 0 5.4826410078590015e-09
found O 0 8.784656890803433e-10
a O 0 6.665523688553776e-10
direct O 0 1.235942281851976e-08
progression O 0 1.1882991657330422e-06
of O 0 5.440913344867404e-11
the O 0 9.140972007104509e-11
size O 0 1.625725332132788e-08
heterogeneity O 0 1.373048608144245e-08
over O 0 4.695915212238333e-09
time O 0 6.653558259905878e-10
related O 0 5.0582880106730954e-09
to O 0 4.114726337434149e-10
initial O 0 9.656274002622922e-09
CTG O 0 6.419261922019359e-07
repeat O 0 6.530024077022745e-09
size O 0 9.201825434956845e-08
and O 0 3.911396984079829e-09
the O 0 7.668762846968491e-11
time O 0 4.568255218551087e-10
interval O 0 1.0655708315709944e-08
and O 0 7.675439173127074e-10
always O 0 2.1473196554211427e-09
biased O 0 6.5240359781171264e-09
towards O 0 1.959203466128656e-09
further O 0 2.428989009928273e-09
expansion O 0 4.5597197129154665e-08
. O 0 3.777661561343848e-08

Attempts O 0 1.5996896536307759e-06
to O 0 1.2016807993120437e-08
mathematically O 0 1.7354683734538412e-07
model O 0 9.085472356673563e-07
the O 0 2.0333672523520363e-09
dynamics O 0 4.245340733177727e-06
have O 0 1.5333459657540516e-07
proved O 0 4.311658301503485e-07
only O 0 2.344707317192274e-09
partially O 0 2.0899470598578773e-07
successful O 0 2.1513577586063093e-09
suggesting O 0 1.577017805232117e-08
that O 0 2.2689290724020594e-10
individual O 0 2.978362348415864e-11
specific O 0 4.5913334245639703e-10
genetic O 0 7.721185113496176e-08
and O 0 6.941982633179578e-08
/ O 0 0.0013733177911490202
or O 0 7.306339284696151e-07
environmental O 0 6.776154748422414e-08
factors O 0 7.549862068856328e-09
also O 0 3.222661959512152e-08
play O 0 4.336944137151022e-09
a O 0 1.7026952070509083e-09
role O 0 1.8114727495799343e-09
in O 0 4.4266321164165845e-10
somatic O 0 1.0901936775553622e-07
mosaicism O 0 4.389296464069048e-06
. O 0 4.736005365657547e-09
. O 0 3.2607616162749764e-08

Aspartylglucosaminuria B-Disease 1 0.9990668892860413
among O 0 3.197179694325314e-06
Palestinian O 0 2.0127428797422908e-05
Arabs O 0 4.068991984240711e-06
. O 0 2.9303336646080425e-07

Aspartylglucosaminuria B-Disease 1 0.9999960660934448
( O 0 0.00012021038128295913
AGU B-Disease 1 0.9999808073043823
) O 0 5.1418588498108875e-08
is O 0 5.968174399129111e-09
a O 0 5.02948482861143e-09
rare O 0 4.565517429000465e-06
disorder B-Disease 0 0.02361331321299076
of I-Disease 0 1.6769848842912438e-09
glycoprotein I-Disease 0 0.09786175936460495
metabolism I-Disease 0 0.0012442582519724965
caused O 0 7.255076184264908e-07
by O 0 7.558290882059282e-09
the O 0 2.3391345393974916e-07
deficiency B-Disease 0 0.0040214695036411285
of I-Disease 0 2.661597053865705e-10
the I-Disease 0 4.399933750676155e-09
lysosomal I-Disease 0 0.0005417846259661019
enzyme I-Disease 0 2.0297032676808158e-07
aspartylglucosaminidase I-Disease 0 3.0257192520366516e-06
( O 0 7.090627196504329e-09
AGA O 0 3.000850767875818e-07
) O 0 1.264479809748309e-08
. O 0 2.8089639059203364e-08

AGU B-Disease 1 0.9999914169311523
is O 0 0.00011584706953726709
inherited O 0 0.00703037204220891
as O 0 2.5223707567079146e-08
an O 0 1.5020882315752715e-08
autosomal O 1 0.9968221187591553
recessive O 1 0.9993743300437927
trait O 0 0.06006772443652153
and O 0 1.5321838873205706e-06
occurs O 0 2.438846102847947e-08
with O 0 3.235802459311543e-10
a O 0 1.028928497959214e-09
high O 0 6.776643246553249e-09
frequency O 0 6.931423968126182e-08
in O 0 3.5058729253023557e-09
Finland O 0 5.345795557332167e-07
because O 0 2.2906194718785855e-09
of O 0 4.341557668929852e-11
a O 0 6.890821246940959e-09
founder O 0 4.4898590090269863e-07
effect O 0 3.5053528080197793e-08
. O 0 1.6370826472211775e-08

While O 0 2.8205610647091817e-07
very O 0 3.865660147539529e-08
few O 0 1.424706042030266e-08
patients O 0 4.4357815198736716e-08
with O 0 3.570864492985493e-08
AGU B-Disease 1 0.9999982118606567
have O 0 1.8133928847419156e-07
been O 0 6.125950591240326e-08
reported O 0 4.499469241636689e-07
from O 0 3.255662406331794e-10
non O 0 1.4713425855461537e-07
- O 0 1.2784365026163869e-05
Finnish O 0 7.02697377619188e-07
origin O 0 4.829119770732859e-09
, O 0 2.152646727537899e-09
we O 0 1.7734886625930812e-07
diagnosed O 0 1.3350190783967264e-06
the O 0 4.834804223641243e-10
disorder O 0 7.063342309265863e-06
in O 0 5.286094895140536e-10
8 O 0 1.6103900435382457e-08
patients O 0 6.324865076123842e-10
originating O 0 4.992208313403523e-10
from O 0 2.1219212498202467e-10
3 O 0 8.644818749736771e-10
unrelated O 0 4.118505536609973e-09
families O 0 2.376703056583551e-09
, O 0 8.133933110388014e-11
all O 0 5.648274209457682e-11
Palestinian O 0 1.0984947351744268e-07
Arabs O 0 9.503159148493978e-09
from O 0 1.7088859494140962e-10
the O 0 2.25557877930882e-10
region O 0 6.273458197370019e-09
of O 0 3.577528273623898e-10
Jerusalem O 0 0.00011979808914475143
. O 0 1.858715137359468e-07

The O 0 7.136693369602654e-08
clinical O 0 9.86309169093147e-06
diagnosis O 0 0.005518446210771799
of O 0 4.7298377126026026e-07
AGU B-Disease 1 0.9999997615814209
is O 0 3.227788283766131e-06
often O 0 5.367726174654308e-08
difficult O 0 1.475988824495289e-07
, O 0 3.0748828483417867e-10
in O 0 1.1813643813196606e-11
particular O 0 1.0571665071124059e-10
early O 0 1.487030387714583e-09
in O 0 3.4390190695177125e-10
the O 0 1.3255008202150975e-10
course O 0 1.3666168570125592e-06
of O 0 1.9614533608436346e-10
the O 0 1.4978196460901927e-08
disease O 0 3.2400942018284695e-06
, O 0 7.202710095022269e-10
and O 0 2.7382882628046445e-09
most O 0 1.4385788393855847e-10
of O 0 4.160195105074038e-11
the O 0 1.275731742467201e-09
patients O 0 5.937529135024988e-09
are O 0 5.560722105002469e-09
diagnosed O 0 6.22341715939001e-08
after O 0 2.1776130898487622e-10
the O 0 6.286999393312342e-11
age O 0 7.40521532982541e-10
of O 0 5.361179902796387e-11
5 O 0 2.189972425625797e-09
years O 0 2.3822490646807637e-09
. O 0 1.7936814700192372e-08

However O 0 1.2052737474732567e-07
, O 0 3.104597912084728e-09
since O 0 7.961140080503526e-10
these O 0 2.8654939532302137e-10
patients O 0 2.706085355796972e-10
excrete O 0 3.6135044956253637e-10
early O 0 1.0294971819480025e-10
large O 0 1.18163520634873e-10
amounts O 0 3.7312328227123714e-10
of O 0 9.926198057952362e-11
aspartylglucosamine O 0 2.757662059593713e-06
in O 0 1.6110988099171664e-09
urine O 0 7.818266567483079e-08
, O 0 1.8578673322000583e-10
biochemical O 0 1.0261963501179139e-09
screening O 0 3.4581550956147566e-09
is O 0 3.24600368806216e-09
easy O 0 4.438879486201586e-08
by O 0 8.822538810626668e-10
urine O 0 3.0783777305032345e-08
chromatography O 0 1.927352002439875e-07
. O 0 2.826412659473476e-09
. O 0 2.5102712797320237e-08

Detection O 0 6.337315312521241e-07
of O 0 1.872975552430489e-09
heterozygous O 0 2.271837615808181e-07
carriers O 0 2.1655292670175186e-08
of O 0 1.4184500241043452e-09
the O 0 1.9400022210902534e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 2.1101828906466835e-07
ATM O 0 3.7440090636664536e-06
) O 0 1.591915210763517e-10
gene O 0 1.4402514736389094e-09
by O 0 3.175868457105935e-10
G2 O 0 4.835850972995104e-07
phase O 0 5.401639313618034e-08
chromosomal O 0 1.6268910258077085e-05
radiosensitivity O 0 6.467741513915826e-06
of O 0 1.1838563906962918e-08
peripheral O 0 0.0008347227121703327
blood O 0 1.667493961576838e-05
lymphocytes O 0 5.5331729527097195e-05
. O 0 2.4233636963799654e-07

In O 0 0.0006634322926402092
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.0006724254926666617
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
) O 0 7.092253184737274e-08
patients O 0 5.8689288096047676e-08
, O 0 1.3826262357241603e-10
mutations O 0 1.984764574913811e-09
in O 0 1.6757371879005944e-10
a O 0 1.2553690309502485e-09
single O 0 9.863305727719762e-09
gene O 0 8.190016664855193e-09
, O 0 1.6633824317935364e-09
ATM O 0 1.1306372016406385e-06
, O 0 4.044009016546113e-10
result O 0 8.803325846074017e-10
in O 0 2.2833186008597295e-08
an O 0 0.05651283636689186
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 4.066027941007633e-06
embraces O 0 5.856354050592927e-07
a O 0 6.347371073189834e-09
variety O 0 1.894620815789949e-08
of O 0 3.814096538601319e-10
clinical O 0 3.8440040839304856e-07
features O 0 1.9117283954983577e-05
and O 0 6.661804263785598e-07
manifests O 0 3.77386271566138e-07
extreme O 0 2.9992688155289216e-07
radiosensitivity O 0 1.228612381964922e-05
and O 0 1.2886032685344162e-08
a O 0 2.527999809487369e-09
strong O 0 2.850265357068338e-09
pre O 0 3.3289056773355696e-06
- O 0 9.950184903573245e-05
disposition O 0 5.1883147534681484e-05
to O 0 7.208873853414843e-08
malignancy B-Disease 0 0.0002407537103863433
. O 0 7.394115186798444e-08

Heterozygotes O 0 3.511324757710099e-05
for O 0 1.6697820015565412e-08
the O 0 1.6531125357488463e-09
ATM O 0 5.730749421672954e-07
gene O 0 1.9690158836738192e-08
have O 0 1.4422920635581704e-08
no O 0 2.7510681732678677e-08
clinical O 0 1.659745052506878e-08
expression O 0 2.1313296016955974e-08
of O 0 8.883500157708113e-09
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
but O 0 1.1288065252301749e-05
may O 0 2.1240507521724794e-06
be O 0 1.9144347334076883e-06
cancer B-Disease 0 2.515446112738573e-06
prone O 0 6.128304448793642e-06
with O 0 2.4749688409819726e-10
a O 0 3.5497302874887282e-09
moderate O 0 4.475409411952569e-07
increase O 0 7.485709829779807e-09
in O 0 6.372198879667224e-10
in O 0 1.2551584216424772e-09
vitro O 0 1.2323016562731937e-05
radiosensitivity O 0 3.232973540434614e-05
. O 0 9.862368699486979e-08

We O 0 1.2277608902877546e-06
performed O 0 3.8187923223631515e-07
a O 0 1.0411886464112285e-08
blind O 0 1.6628922594463802e-07
chromosomal O 0 4.788746991835069e-06
analysis O 0 3.235373924326268e-08
on O 0 2.7733539909036153e-08
G2 O 0 1.7312773934463621e-06
- O 0 6.420161469122831e-08
phase O 0 2.8633660775767567e-08
lymphocytes O 0 8.575998577953214e-08
from O 0 9.973053632927886e-11
7 O 0 2.475687432834661e-09
unrelated O 0 8.285500712190697e-07
A B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 7.554041872026573e-07
, O 0 1.3374987783976167e-09
13 O 0 3.599913256380205e-09
obligate O 0 3.873713581015181e-07
A B-Disease 1 0.9999932050704956
- I-Disease 1 0.9999877214431763
T I-Disease 1 0.9999996423721313
heterozygotes O 0 4.0560439629189204e-06
( O 0 1.711891295386181e-09
parents O 0 1.760430801134305e-09
of O 0 2.7038758385056205e-11
the O 0 4.67917593560685e-10
patients O 0 4.78257100589019e-10
) O 0 2.1910816910830633e-11
, O 0 2.5766791478254447e-10
and O 0 1.0617440260318745e-09
14 O 0 2.1868659660917444e-10
normal O 0 1.724090870069972e-09
controls O 0 1.3359955630676268e-07
following O 0 7.004620772299575e-10
X O 0 5.982690709060989e-06
- O 0 2.1551356610416406e-07
irradiation O 0 2.5803212011510368e-08
with O 0 1.7358970927361383e-09
1 O 0 2.52747911488882e-09
Gy O 0 1.4351293202707893e-06
in O 0 2.1367776992242682e-10
order O 0 4.066726677631749e-10
to O 0 1.3491661954301293e-10
evaluate O 0 5.042124495702183e-09
this O 0 3.521182304067061e-11
cytogenetic O 0 6.939004038031271e-08
method O 0 4.6802042241722575e-09
as O 0 1.823900752651042e-10
a O 0 1.630807572317039e-10
tool O 0 7.172622495943415e-09
for O 0 2.134039646384256e-11
detection O 0 1.0063094801893158e-09
of O 0 2.0100983377790982e-10
ATM O 0 1.8992775494552916e-06
carriers O 0 7.214527641963286e-08
. O 0 2.430839529665718e-08

Both O 0 1.6976199503915268e-06
A B-Disease 1 0.9987319111824036
- I-Disease 1 0.999914288520813
T I-Disease 1 0.9999991655349731
homozygotes O 0 8.80650713952491e-06
and O 0 3.159924544249293e-09
heterozygotes O 0 1.0853159437829163e-07
showed O 0 2.1906254588088814e-08
significantly O 0 3.5086424876595856e-09
increased O 0 1.5011079046445275e-09
levels O 0 9.24736953678007e-10
of O 0 5.0411775448511165e-11
radiation O 0 3.3138474009319907e-06
- O 0 4.663013169192709e-05
induced O 0 0.00010196123912464827
chromatid O 0 0.0018045797478407621
damage O 0 2.0198245692881756e-05
relative O 0 2.3949612071305637e-08
to O 0 9.289957136893179e-10
that O 0 2.0315131521453367e-10
of O 0 8.446023047614659e-11
normal O 0 2.3551788075337754e-08
controls O 0 4.216069100948516e-06
. O 0 4.249202589790002e-08

These O 0 1.8319495254104368e-08
results O 0 7.425699610763559e-09
show O 0 1.6418520942806936e-07
that O 0 9.70992175552965e-10
the O 0 5.432485572498535e-10
G2 O 0 4.844630439038156e-06
- O 0 5.252011305856286e-07
phase O 0 1.5978889678081032e-07
chromosomal O 0 3.049923361686524e-05
radiosensitivity O 0 4.019991138193291e-06
assay O 0 1.6769672583905049e-07
can O 0 1.4107952583941596e-09
be O 0 1.6852631790076344e-10
used O 0 1.9548986041062477e-10
for O 0 7.481363445416278e-11
the O 0 4.6568877226649263e-11
detection O 0 7.742003482746895e-09
of O 0 6.922896145233892e-10
A B-Disease 1 0.9998944997787476
- I-Disease 1 0.9999687671661377
T I-Disease 1 0.9999971389770508
heterozygotes O 0 2.9652914236066863e-05
. O 0 8.100533932520193e-08

In O 0 6.29542000751826e-08
combination O 0 1.20073735843107e-07
with O 0 1.8111133703868632e-09
molecular O 0 1.6085451193248446e-08
genetic O 0 5.422408122512934e-08
analyses O 0 2.268555476803158e-07
, O 0 3.3997977766375698e-09
this O 0 4.210039539209731e-10
test O 0 1.9839296783175087e-07
may O 0 2.131279819295173e-09
be O 0 2.6419522125564754e-10
of O 0 3.3056541445114496e-12
value O 0 6.699520049835428e-09
in O 0 7.348915226357278e-11
studies O 0 1.0856499033096156e-10
of O 0 3.7282787967996e-11
familial B-Disease 0 4.0248141885967925e-07
and I-Disease 0 6.624464532478669e-08
sporadic I-Disease 0 9.453128586756065e-05
cancers I-Disease 0 1.374158455291763e-05
aimed O 0 6.011728146404494e-07
at O 0 4.952447625328205e-07
determination O 0 2.4747588867057857e-08
of O 0 2.92788397693311e-11
the O 0 3.0576985388108824e-11
potential O 0 2.513478869481389e-10
involvement O 0 1.2230182422356961e-09
of O 0 1.1574197156249966e-10
ATM O 0 8.917335435398854e-06
mutations O 0 3.826458083722173e-08
in O 0 2.926730857666371e-09
tumor B-Disease 0 9.200958447763696e-05
risk O 0 4.39285457787264e-07
or O 0 5.394542590408946e-09
development O 0 5.487840848417136e-09
. O 0 1.316295628051023e-09
. O 0 1.4858716035348607e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999936819076538
telangiectasia I-Disease 1 0.9999994039535522
: O 0 3.404998381029145e-07
identification O 0 2.167108021922104e-07
and O 0 4.471746528622589e-09
detection O 0 3.547038218698617e-08
of O 0 4.058497149461715e-10
founder O 0 2.1245734842523234e-06
- O 0 1.3522972039936576e-05
effect O 0 2.4375996332537397e-08
mutations O 0 1.3162209988593077e-08
in O 0 3.186401975607822e-10
the O 0 4.61727572842463e-10
ATM O 0 4.659213743707369e-07
gene O 0 1.2003041227615086e-08
in O 0 1.425656703801792e-09
ethnic O 0 2.1429183760801607e-08
populations O 0 2.784071284622769e-07
. O 0 8.336609624848279e-08

To O 0 2.4057339231831065e-08
facilitate O 0 2.6381078654935664e-08
the O 0 4.764943439816705e-10
evaluation O 0 3.009854143698476e-09
of O 0 1.1008864653216932e-10
ATM O 0 1.7261685343328281e-06
heterozygotes O 0 5.818005277546945e-08
for O 0 4.5833190021049575e-10
susceptibility O 0 3.394512759768986e-07
to O 0 1.4298129791256997e-08
other O 0 8.406659190995924e-08
diseases O 0 6.852668593637645e-05
, O 0 1.0800038641178844e-09
such O 0 1.5064895109162535e-08
as O 0 3.150290922349086e-06
breast B-Disease 0 0.038472697138786316
cancer I-Disease 0 9.131370461545885e-06
, O 0 8.2629147968305e-09
we O 0 7.101484555960269e-08
have O 0 1.3858056924220818e-09
attempted O 0 1.493876666813776e-08
to O 0 6.234710525632181e-10
define O 0 2.9013765612262432e-08
the O 0 2.245992419824816e-10
most O 0 1.7760723447501903e-10
common O 0 4.0741796047960577e-10
mutations O 0 5.689027582356232e-10
and O 0 3.0632574254951805e-10
their O 0 2.1820160955865475e-10
frequencies O 0 7.307413056878431e-07
in O 0 1.0822461263160221e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
( O 0 0.00012811871420126408
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999951124191284
T I-Disease 1 0.9999995231628418
) O 0 4.445858792223589e-09
homozygotes O 0 1.3434494405828445e-07
from O 0 5.498629884748141e-10
10 O 0 1.4312255824933118e-09
ethnic O 0 6.997520785034794e-09
populations O 0 8.057219957890993e-08
. O 0 3.6228247068947894e-08

Both O 0 9.507768083949486e-08
genomic O 0 8.692923643138784e-07
mutations O 0 1.3381586541072465e-06
and O 0 4.9109274868897046e-08
their O 0 1.4955094940205527e-09
effects O 0 1.5585083446012504e-08
on O 0 8.059459766229793e-09
cDNA O 0 2.1414761519622516e-08
were O 0 3.1495947183657336e-08
characterized O 0 2.4018603994591103e-07
. O 0 2.9942469836896635e-08

Protein O 0 5.047631361776439e-07
- O 0 7.805644486325036e-07
truncation O 0 4.301632827719004e-07
testing O 0 1.473485440328659e-07
of O 0 5.7102454709134776e-11
the O 0 4.901552774772e-11
entire O 0 2.6016289123020897e-09
ATM O 0 1.1454211801265046e-08
cDNA O 0 2.8030109344712173e-09
detected O 0 1.666972160307978e-08
92 O 0 8.303578380441934e-10
( O 0 3.645381219108401e-11
66 O 0 7.426063652893333e-10
% O 0 7.003655294601785e-11
) O 0 5.482739956486071e-11
truncating O 0 3.519045677080612e-08
mutations O 0 5.8889302323450465e-09
in O 0 2.180601532675297e-10
140 O 0 8.316896504823035e-09
mutant O 0 4.472243517739116e-07
alleles O 0 4.0493085862181033e-07
screened O 0 5.503259217221057e-06
. O 0 3.217129176391609e-07

The O 0 2.5218801269488722e-08
haplotyping O 0 8.999059900816064e-06
of O 0 7.526312018057979e-09
patients O 0 1.4006481308115326e-07
with O 0 2.140049915055897e-09
identical O 0 4.7484268179687206e-06
mutations O 0 2.115655775014602e-07
indicates O 0 2.5510192358524364e-07
that O 0 1.724019327298265e-08
almost O 0 5.52876233683719e-09
all O 0 1.1494645513199231e-10
of O 0 1.0290411751878725e-11
these O 0 1.6271443914472883e-10
represent O 0 5.68150193558381e-10
common O 0 8.66504468177709e-09
ancestry O 0 3.0764823577555944e-07
and O 0 1.6298582750096102e-07
that O 0 1.1040839353881893e-08
very O 0 8.079268809524365e-09
few O 0 2.8167526089362127e-09
spontaneously O 0 1.4030086425975696e-08
recurring O 0 2.0322016780482954e-07
ATM O 0 6.498549737443682e-06
mutations O 0 2.7430473892309237e-07
exist O 0 4.547109710983932e-07
. O 0 1.1889528650499415e-07

Assays O 0 3.0634876111435005e-06
requiring O 0 4.932189057171854e-08
minimal O 0 6.256408369154087e-08
amounts O 0 3.2923634929460377e-09
of O 0 3.142593130167626e-11
genomic O 0 6.595842094725413e-09
DNA O 0 1.881915068224771e-07
were O 0 8.829529996035035e-09
designed O 0 1.1356758022884605e-07
to O 0 3.001568715799152e-10
allow O 0 9.284466528924895e-10
rapid O 0 8.121167738295298e-09
screening O 0 9.248414478690847e-09
for O 0 5.691111470973453e-10
common O 0 5.927763613300385e-09
ethnic O 0 1.6095702548568624e-08
mutations O 0 3.8997302453935845e-07
. O 0 7.844885629992859e-08

These O 0 1.6960417070777112e-08
rapid O 0 6.851689704490127e-08
assays O 0 2.4284491928483476e-07
detected O 0 9.88619390795975e-08
mutations O 0 5.7747193693558074e-09
in O 0 2.3106455637744716e-10
76 O 0 1.3138581778093794e-08
% O 0 3.542342807971721e-10
of O 0 3.6285263682600544e-10
Costa O 0 1.1592484838729433e-07
Rican O 0 8.871921863828902e-08
patients O 0 3.784640156823116e-09
( O 0 1.729411405748671e-11
3 O 0 1.1070284966496757e-10
) O 0 3.9838243814926955e-11
, O 0 9.146553653360812e-11
50 O 0 3.311747820422539e-10
% O 0 2.227357014106257e-11
of O 0 5.4395748322333404e-11
Norwegian O 0 0.001764714834280312
patients O 0 8.544124519005436e-09
( O 0 2.1012268314191118e-11
1 O 0 7.063002960272513e-11
) O 0 6.251890671826743e-11
, O 0 1.7447955580340846e-10
25 O 0 1.6310004735675676e-10
% O 0 2.803975975018691e-11
of O 0 7.81092204804601e-11
Polish O 0 4.4206768507137895e-05
patients O 0 1.0968570940406153e-08
( O 0 2.1445180700685462e-11
4 O 0 1.8740430041130907e-10
) O 0 1.0281451384708262e-10
, O 0 5.262915658832412e-10
and O 0 2.2617274719749503e-09
14 O 0 4.446365498012028e-10
% O 0 4.408245296572133e-11
of O 0 1.1462789745175783e-10
Italian O 0 4.982189057045616e-05
patients O 0 1.712574793089061e-08
( O 0 3.301031323288406e-11
1 O 0 3.706230322642057e-10
) O 0 2.6225277505176336e-10
, O 0 3.858945385459833e-10
as O 0 4.079545312674071e-10
well O 0 1.2187452158585188e-09
as O 0 2.168209223274431e-10
in O 0 9.837181069727308e-11
patients O 0 8.770422582626836e-11
of O 0 1.7279309927342723e-11
Amish O 0 1.6282657497868058e-06
/ O 0 1.701173277979251e-05
Mennonite O 0 1.6603678432147717e-06
and O 0 1.6343800268714404e-07
Irish O 0 2.1454994225678092e-07
English O 0 7.280146263610732e-08
backgrounds O 0 2.557835330208036e-07
. O 0 4.2342350070612156e-08

Additional O 0 9.258655353505674e-08
mutations O 0 2.2790204923239799e-07
were O 0 5.480382814226914e-09
observed O 0 6.8414491849466685e-09
in O 0 1.764615259469693e-10
Japanese O 0 1.0584407128533257e-08
, O 0 1.4517759390486606e-11
Utah O 0 3.8914132333145446e-11
Mormon O 0 1.7260805285079783e-10
, O 0 9.797632843921988e-11
and O 0 6.220515769150836e-10
African O 0 6.847725164682572e-10
American O 0 3.1767424246709197e-09
patients O 0 1.2987618980275784e-08
. O 0 1.8561122416826947e-08

These O 0 4.141404552626682e-09
assays O 0 9.060978811703535e-08
should O 0 1.186127196461939e-09
facilitate O 0 1.2478847954966454e-09
screening O 0 1.131398885689805e-08
for O 0 5.416513459977068e-09
A B-Disease 1 0.9999499320983887
- I-Disease 1 0.999863862991333
T I-Disease 1 0.9999991655349731
heterozygotes O 0 3.8064771956669574e-07
in O 0 3.864882303084016e-10
the O 0 1.20447679607949e-10
populations O 0 5.7777818085469335e-09
studied O 0 7.363669229931702e-09
. O 0 1.4862477915045247e-09
. O 0 2.0011871271208292e-08

The O 0 9.341009103991382e-07
von B-Disease 1 0.9895334839820862
Hippel I-Disease 1 0.9989216327667236
- I-Disease 1 0.984104573726654
Lindau I-Disease 1 0.9637734293937683
tumor I-Disease 0 0.0004935383913107216
suppressor O 0 4.464689482119866e-06
gene O 0 2.2453679093814571e-07
is O 0 1.1092997631578783e-08
required O 0 2.0296047065215816e-09
for O 0 6.92594648299405e-10
cell O 0 3.282306806795532e-06
cycle O 0 1.7517502328701084e-06
exit O 0 2.024779064413451e-07
upon O 0 9.73026459405446e-09
serum O 0 8.236874577960407e-07
withdrawal O 0 2.2955994154472137e-06
. O 0 1.0677379691514943e-07

The O 0 8.886924085516057e-09
inactivation O 0 1.3358570640775724e-06
of O 0 1.5941280517850487e-09
the O 0 1.2783484493184005e-08
von B-Disease 1 0.9988313317298889
Hippel I-Disease 1 0.9996286630630493
- I-Disease 1 0.9995601773262024
Lindau I-Disease 1 0.9996368885040283
( I-Disease 0 5.476121600622719e-07
VHL I-Disease 0 4.734359390567988e-05
) I-Disease 0 8.027487119477428e-09
tumor I-Disease 0 7.361621783275041e-07
suppressor O 0 4.05027378747036e-07
gene O 0 5.69652556237088e-08
predisposes O 0 9.180365623251419e-07
affected O 0 2.1893247037496621e-07
individuals O 0 2.1305686104255983e-09
to O 0 5.092790633653976e-09
the O 0 3.135509132334846e-07
human O 1 0.7083711624145508
VHL B-Disease 1 0.9999963045120239
cancer I-Disease 1 0.9999897480010986
syndrome I-Disease 1 0.9999854564666748
and O 0 2.762878992257356e-08
is O 0 3.5998322545083283e-08
associated O 0 1.9348198065927136e-07
with O 0 3.5307181178723113e-07
sporadic B-Disease 1 0.9999508857727051
renal I-Disease 1 0.9999972581863403
cell I-Disease 1 0.9998966455459595
carcinomas I-Disease 1 1.0
( O 0 1.940266656674794e-06
RCC B-Disease 0 0.004425982013344765
) O 0 4.600656566822181e-08
and O 0 2.6695420274336357e-07
brain B-Disease 0 9.553360541758593e-06
hemangioblastomas I-Disease 0 7.639062096131966e-05
. O 0 2.996407033606374e-07

VHL O 0 0.0004088649293407798
- O 0 9.164042239717674e-06
negative O 0 5.727143843614613e-07
786 O 0 1.3637162510349299e-06
- O 0 5.106946628075093e-05
0 O 0 2.1291070240181398e-08
RCC B-Disease 0 1.0784285677800654e-06
cells O 0 7.962313475218252e-09
are O 0 5.385976109550938e-10
tumorigenic O 0 4.353299573267577e-06
in O 0 6.899803839388596e-09
nude O 1 0.7558190226554871
mice O 0 0.00019151272135786712
which O 0 2.7792538048743154e-07
is O 0 1.080985256862732e-08
suppressed O 0 5.627075250203006e-09
by O 0 9.330831940435047e-11
the O 0 7.507823529540048e-11
reintroduction O 0 4.8987843115355645e-08
of O 0 3.0860423105849577e-09
VHL B-Disease 0 7.94843890616903e-06
. O 0 5.002268821385769e-08

Remarkably O 0 2.2922980861039832e-05
, O 0 3.752338884055462e-09
this O 0 6.429073245994843e-11
occurs O 0 2.8040522681571645e-10
without O 0 2.911006158345941e-11
affecting O 0 1.7378871952633546e-10
the O 0 6.126783108628686e-11
growth O 0 4.2783901221810083e-07
rate O 0 3.1571935323881917e-06
and O 0 2.991351388814678e-09
cell O 0 3.0418001983889553e-07
cycle O 0 2.100409091099209e-07
profile O 0 4.0621024766096525e-08
of O 0 4.168694209272239e-11
these O 0 1.9331959644208752e-10
cells O 0 9.57502188647652e-10
in O 0 2.0815781043292958e-10
culture O 0 7.14313586058779e-08
. O 0 5.5182930225328164e-08

The O 0 3.569080675447367e-08
786 O 0 1.0509151024962193e-06
- O 0 1.3927396139479242e-05
0 O 0 2.3586943953546324e-08
cell O 0 4.995393737772247e-06
line O 0 0.00014200089208316058
, O 0 1.3300829326823305e-09
like O 0 3.033235440597082e-09
many O 0 6.410439956638925e-10
cancer B-Disease 0 5.34045980771225e-08
cells O 0 2.1300645691724185e-09
, O 0 4.787280016849138e-10
fails O 0 1.685149086938509e-08
to O 0 3.372785384314625e-10
exit O 0 2.326422645637649e-07
the O 0 2.0767607633587204e-09
cell O 0 5.248656407275121e-07
cycle O 0 1.337209027951758e-07
upon O 0 1.958979201077682e-09
serum O 0 3.912511488124437e-07
withdrawal O 0 5.92079516081867e-07
. O 0 5.1569550407748466e-08

Here O 0 4.05701200634212e-07
, O 0 2.3341055754855233e-09
it O 0 6.460816326381291e-10
is O 0 4.0364644959822726e-10
shown O 0 7.227688447741798e-10
that O 0 4.352966945231351e-11
reintroduction O 0 1.222885237517346e-09
of O 0 1.3737773939259679e-11
the O 0 1.262964871573402e-10
wild O 0 2.961701568438002e-07
- O 0 3.529759851517156e-05
type O 0 5.6503962696297094e-05
VHL B-Disease 0 6.978016813263821e-07
gene O 0 1.5417677801110585e-08
restores O 0 7.169957427777263e-08
the O 0 5.680158565724014e-10
ability O 0 1.2506209401408341e-08
of O 0 3.0293656472224484e-10
VHL O 0 1.2153298484918196e-05
- O 0 3.867331179208122e-05
negative O 0 2.997807678184472e-05
RCC B-Disease 0 0.004274945240467787
cancer I-Disease 0 1.1366763601472485e-06
cells O 0 3.963410932783518e-09
to O 0 4.709932999169553e-10
exit O 0 4.983042956041572e-08
the O 0 6.040422606545803e-10
cell O 0 2.763412112471997e-07
cycle O 0 1.788168617622432e-07
and O 0 1.8533027335010388e-09
enter O 0 7.144876690290403e-09
G0 O 0 1.0637136256264057e-06
/ O 0 2.3282338190711016e-07
quiescence O 0 3.479667327610514e-07
in O 0 4.878715209599704e-09
low O 0 7.246871973620728e-06
serum O 0 3.3168446407216834e-06
. O 0 3.5539322595923295e-08

Both O 0 2.3987973918337957e-07
VHL O 0 2.19438206841005e-05
- O 0 2.334915188839659e-05
positive O 0 1.1202952521216503e-07
and O 0 5.960415716543821e-09
VHL O 0 3.121411054962664e-06
- O 0 3.4121146654797485e-06
negative O 0 4.825375299333245e-07
RCC B-Disease 0 2.4979544832604006e-06
cells O 0 8.468937551242561e-09
exit O 0 3.2179567455159486e-08
the O 0 5.465848329500034e-10
cell O 0 1.8990604644386622e-07
cycle O 0 9.849698301422904e-08
by O 0 1.4251183566571513e-09
contact O 0 5.730913699153461e-07
inhibition O 0 1.5803246355972078e-07
. O 0 6.619588788225883e-08

The O 0 1.04919308796525e-07
cyclin O 0 0.00010577306238701567
- O 0 4.5697161112912e-06
dependent O 0 3.6485209875536384e-07
kinase O 0 1.2179368695797166e-06
inhibitor O 0 5.25922807526058e-08
, O 0 2.1064243405088945e-10
p27 O 0 7.1609211893530755e-09
, O 0 1.1134767413656377e-10
accumulates O 0 1.4854061314295564e-09
upon O 0 1.2429718365680742e-10
serum O 0 1.4364307077130434e-08
withdrawal O 0 1.2196228738048376e-07
, O 0 8.629547632033052e-10
only O 0 2.779886321135905e-10
in O 0 8.122089112383435e-11
the O 0 8.884440405587668e-11
presence O 0 4.853942581206638e-09
of O 0 1.1897587082199124e-10
VHL B-Disease 0 1.0520968629634808e-07
, O 0 3.728010677939153e-10
as O 0 2.2688510792345795e-10
a O 0 1.26280111367727e-10
result O 0 9.684041069046856e-11
of O 0 6.377725170897408e-12
the O 0 4.828857452787716e-11
stabilization O 0 1.2535057436480201e-08
of O 0 2.9503465642788385e-11
the O 0 2.788510533591193e-10
protein O 0 6.567170807159073e-09
. O 0 1.4521935653988294e-08

We O 0 6.054627021967462e-08
propose O 0 1.6947611314321875e-08
that O 0 3.4508132462640617e-10
the O 0 4.9187286188523416e-11
loss O 0 4.287283861259539e-09
of O 0 5.293578422826961e-11
wild O 0 1.5700151152486796e-06
- O 0 0.05462903901934624
type O 0 0.004477350972592831
VHL B-Disease 0 4.0244535171041207e-07
gene O 0 1.0725628385443997e-08
results O 0 6.010349551388572e-09
in O 0 2.3028842721650733e-10
a O 0 1.807700211742258e-09
specific O 0 1.1174867609042849e-07
cellular O 0 0.0003232376475352794
defect O 0 0.00015970985987223685
in O 0 4.33416547096499e-09
serum O 0 1.1710550325005897e-06
- O 0 5.373951807996491e-06
dependent O 0 2.4266711307063815e-07
growth O 0 3.7052100765322393e-07
control O 0 1.6309294323946233e-06
, O 0 1.7210155522917603e-09
which O 0 4.370875217318826e-09
may O 0 5.6542837079121e-09
initiate O 0 4.3445218977922195e-08
tumor B-Disease 0 8.545559921913082e-07
formation O 0 2.9711893390071964e-08
. O 0 4.778026507779032e-08

This O 0 2.4158962830256314e-08
is O 0 1.1944871758373665e-08
corrected O 0 1.002949403527964e-07
by O 0 9.43815581244678e-11
the O 0 2.226613685096801e-11
reintroduction O 0 5.558367988101054e-09
of O 0 1.1715144132562472e-10
wild O 0 8.181321504707739e-07
- O 0 0.052176471799612045
type O 1 0.5014541745185852
VHL B-Disease 0 8.069408067967743e-05
, O 0 1.7205110225404496e-08
implicating O 0 7.220609404612333e-06
VHL B-Disease 0 7.343593324549147e-07
as O 0 1.0766738611778237e-09
the O 0 2.979669289082665e-11
first O 0 4.5438622309212917e-10
tumor B-Disease 0 4.3381540137943375e-08
suppressor O 0 1.3588391745145145e-08
involved O 0 3.1135107825264186e-09
in O 0 1.3364168105489682e-10
the O 0 5.0003633178530293e-11
regulation O 0 2.102310270313268e-10
of O 0 5.569601030375182e-11
cell O 0 2.760051529548946e-07
cycle O 0 2.6245751882925106e-07
exit O 0 2.6012565967903356e-07
, O 0 1.4009035043116569e-09
which O 0 1.3732816661615743e-08
is O 0 2.8065164414670107e-08
consistent O 0 1.146937762541711e-07
with O 0 5.71015068562275e-10
its O 0 4.6541575038361316e-09
gatekeeper O 0 5.225641643846757e-07
function O 0 9.211128748631836e-09
in O 0 1.8587499595046353e-10
the O 0 2.3001593962845845e-09
kidney O 0 4.377014306555793e-07
. O 0 1.6293377758103134e-09
. O 0 3.680788651649891e-08

Piebaldism B-Disease 1 0.9999988079071045
with O 0 0.14864251017570496
deafness B-Disease 1 1.0
: O 0 5.447224538102091e-08
molecular O 0 4.08983318322953e-08
evidence O 0 1.46057983485548e-08
for O 0 1.7269574659195541e-09
an O 0 3.474924525903589e-08
expanded O 0 0.07888884842395782
syndrome O 1 0.999907374382019
. O 0 1.549337156347974e-07

In O 0 5.2612147527497655e-08
a O 0 2.4236314288827998e-08
South O 0 7.010240210547636e-08
African O 0 2.2445931779913053e-09
girl O 0 8.039785370783648e-07
of O 0 4.6271056430846613e-10
Xhosa O 0 1.072466966434149e-05
stock O 0 1.8844721125788055e-06
with O 0 7.96249555179429e-09
severe O 0 1.1857068784593139e-06
piebaldism B-Disease 0 0.001001878408715129
and O 0 5.25766154169105e-06
profound O 0 0.00023706271895207465
congenital O 1 0.9999997615814209
sensorineural B-Disease 1 0.9999985694885254
deafness I-Disease 1 1.0
we O 0 0.0032321603503078222
identified O 0 1.1975234883720987e-05
a O 0 6.9227010790484655e-09
novel O 0 2.2184270420666508e-08
missense O 0 3.688013237024279e-07
substitution O 0 8.626210856732541e-09
at O 0 6.970707744358151e-08
a O 0 5.268700475902222e-10
highly O 0 5.037757988546332e-10
conserved O 0 9.451130988935574e-10
residue O 0 1.9807341544719748e-08
in O 0 4.675596021463946e-11
the O 0 6.992429552044044e-11
intracellular O 0 2.9276800983524254e-09
kinase O 0 3.972396100948572e-08
domain O 0 5.225538668440777e-09
of O 0 8.669401307948021e-11
the O 0 8.883292990091718e-10
KIT O 0 8.431455171376001e-06
proto O 0 7.648134669580031e-06
- O 0 1.863116085587535e-05
oncogene O 0 3.62660421160399e-06
, O 0 1.0097052971502762e-08
R796G O 0 6.501405778180924e-07
. O 0 4.485005433707556e-08

Though O 0 1.3029969068156788e-06
auditory B-Disease 0 1.1871528613482951e-06
anomalies I-Disease 0 0.00011931572953471914
have O 0 2.3269588922403273e-08
been O 0 2.847635238723001e-09
observed O 0 3.375247104031587e-08
in O 0 3.025849015791948e-10
mice O 0 3.567842554730305e-07
with O 0 1.8642931642887106e-09
dominant O 0 5.364888238545973e-06
white O 0 3.0491619327221997e-06
spotting O 0 4.2827199649764225e-05
( O 0 5.1376409793135736e-09
W O 0 0.037875209003686905
) O 0 6.463774515630405e-10
due O 0 1.598552068493575e-09
to O 0 7.442743754637604e-09
KIT O 0 0.022718127816915512
mutations O 0 1.5770961908856407e-05
, O 0 4.54270730188e-06
deafness B-Disease 1 1.0
is O 0 3.528443130562664e-06
not O 0 1.9882930857306746e-08
typical O 0 1.1754451634260477e-07
in O 0 2.8758326831024306e-09
human O 0 1.278711039276459e-07
piebaldism B-Disease 0 1.6272106222459115e-05
. O 0 6.526290974306903e-08

Thus O 0 2.4658447728143074e-07
, O 0 3.601314135792677e-09
the O 0 1.988579301226423e-10
occurrence O 0 2.953234741198685e-07
of O 0 5.91145976613916e-09
sensorineural B-Disease 1 0.9999427795410156
deafness I-Disease 1 1.0
in O 0 1.8052966765935707e-07
this O 0 2.067399229588318e-08
patient O 0 1.1595496971494867e-06
extends O 0 2.1844085651423484e-08
considerably O 0 7.333254448127491e-09
the O 0 1.3301075518779015e-10
phenotypic O 0 5.890235854622006e-08
range O 0 8.471606065540982e-07
of O 0 2.845527424799599e-10
piebaldism B-Disease 0 1.0875056659642723e-06
due O 0 3.2833269436594037e-09
to O 0 7.886269415280367e-10
KIT O 0 3.592826487874845e-06
gene O 0 1.6668927571572567e-08
mutation O 0 7.504409538228174e-09
in O 0 2.1505729141946262e-10
humans O 0 4.173376311200627e-09
and O 0 1.2934591175906007e-08
tightens O 0 1.7710221072775312e-05
the O 0 1.5289259858164428e-09
clinical O 0 1.3169919377276074e-08
similarity O 0 5.127919422420746e-09
between O 0 7.14923853450955e-09
piebaldism B-Disease 0 3.283652040408924e-05
and O 0 2.4981106960808575e-08
the O 0 9.307084963827705e-11
various O 0 2.241186819462726e-10
forms O 0 2.4004764398455336e-08
of O 0 2.711381739572971e-06
Waardenburg B-Disease 1 0.9999921321868896
syndrome I-Disease 1 0.9996830224990845
. O 0 8.487923253142071e-09
. O 0 9.82303802743445e-08

Cycloheximide O 0 3.476327037787996e-05
facilitates O 0 3.7933369867459987e-07
the O 0 8.685625552118381e-10
identification O 0 7.271885760218311e-09
of O 0 2.11049011600295e-10
aberrant O 0 2.751299916781136e-06
transcripts O 0 1.3327597798706847e-06
resulting O 0 4.950718945906374e-08
from O 0 1.033672925032647e-09
a O 0 4.505839257262778e-09
novel O 0 4.5478987686919936e-08
splice O 0 0.0003586523234844208
- O 0 4.982345853932202e-05
site O 0 5.653550033457577e-05
mutation O 0 2.130809306777337e-08
in O 0 4.877903636568703e-10
COL17A1 O 0 2.206671297244611e-06
in O 0 5.09496389522468e-10
a O 0 1.3464374504223997e-08
patient O 0 5.233391675574239e-07
with O 0 2.080286165551115e-08
generalized O 0 0.0018556612776592374
atrophic B-Disease 1 0.99962317943573
benign I-Disease 1 0.996743381023407
epidermolysis I-Disease 1 0.9842772483825684
bullosa I-Disease 1 0.8317152261734009
. O 0 1.1597274351515807e-05

Patients O 0 3.817810647888109e-05
with O 0 7.759836506693318e-08
generalized O 0 0.00202589831314981
atrophic B-Disease 1 0.9998843669891357
benign I-Disease 1 0.9994593262672424
epidermolysis I-Disease 1 0.9975722432136536
bullosa I-Disease 1 0.9228902459144592
often O 0 1.0792406101245433e-05
show O 0 2.389386963841389e-06
decreased O 0 1.0826855714185513e-06
expression O 0 3.844790263940467e-09
of O 0 1.6054139961863e-10
type O 0 1.6920350390137173e-05
XVII O 0 1.3305018910614308e-05
collagen O 0 1.414372309227474e-05
, O 0 2.063199922019976e-08
a O 0 2.835772150433513e-08
transmembrane O 0 5.289378464112815e-07
hemidesmosomal O 0 4.822738901566481e-07
protein O 0 8.983452204347486e-09
encoded O 0 7.100939836135467e-09
by O 0 2.2363200180564036e-09
COL17A1 O 0 6.259563178900862e-06
. O 0 2.1455848653317844e-08

This O 0 4.014831134213637e-08
report O 0 3.513472535132678e-08
documents O 0 3.1710055026223927e-08
a O 0 4.7112114209824085e-09
novel O 0 4.9374509814015255e-08
splice O 0 0.00020997495448682457
- O 0 7.47656958992593e-05
site O 0 3.1372761441161856e-05
mutation O 0 1.735487487053433e-08
in O 0 4.4768819207341437e-10
COL17A1 O 0 1.9970134417235386e-06
in O 0 4.150187693507945e-10
a O 0 1.0924141591317493e-08
patient O 0 5.240843279352703e-07
with O 0 1.2857773512564563e-08
generalized O 0 0.0004863459907937795
atrophic B-Disease 1 0.9993674159049988
benign I-Disease 1 0.9893353581428528
epidermolysis I-Disease 0 0.10215866565704346
bullosa I-Disease 0 0.041157856583595276
, O 0 5.719049340768834e-07
and O 0 7.365368759337798e-09
applies O 0 2.131194332122277e-09
a O 0 3.416951999124507e-10
new O 0 1.4772484624447912e-10
methodology O 0 3.3074127880894366e-09
to O 0 2.1488344437159412e-10
define O 0 1.5959633614670565e-08
and O 0 3.73688280319584e-09
characterize O 0 5.693005959983566e-07
the O 0 3.233552314796384e-09
resulting O 0 3.013572325016867e-08
mRNA O 0 6.398706631216555e-08
splice O 0 4.2639035200409126e-06
variants O 0 8.497482895108988e-07
. O 0 1.8598801432290202e-07

Mutational O 0 5.001950194127858e-05
analysis O 0 1.289437108198399e-07
of O 0 3.771381429373832e-09
COL17A1 O 0 0.00011009196896338835
identified O 0 1.1691213330777828e-06
a O 0 9.963518898814527e-09
maternally O 0 4.428934335010126e-05
inherited O 0 0.000353560404619202
G O 0 0.0019040856277570128
- O 0 4.38099232269451e-05
to O 0 2.0515459198122699e-07
- O 0 6.094064883654937e-05
T O 0 2.3055266865412705e-05
transversion O 0 1.034162906421443e-07
at O 0 3.71829789180822e-09
the O 0 8.110911942083021e-11
- O 0 4.0301831205624694e-08
1 O 0 2.384843711400464e-10
position O 0 1.6094219290607725e-09
of O 0 6.033982341557831e-11
exon O 0 5.2817966889051604e-08
32 O 0 4.9679343305797374e-08
. O 0 3.619896205009354e-08

This O 0 1.185564624250901e-08
acceptor O 0 5.195339980446079e-08
splice O 0 7.022926183708478e-06
- O 0 6.684271284029819e-06
site O 0 5.44261001778068e-06
mutation O 0 1.2534317583856591e-08
led O 0 9.937853873154268e-10
to O 0 4.40123243405921e-10
the O 0 8.75664887822758e-11
formation O 0 1.5656043128586816e-09
of O 0 3.809150564415553e-11
aberrant O 0 5.254856461078816e-08
transcripts O 0 3.0026942710037474e-08
present O 0 5.38223998702847e-09
at O 0 5.375553868702809e-08
extremely O 0 4.0915975318966957e-07
low O 0 5.753685400122777e-06
levels O 0 7.531600232368874e-08
. O 0 1.2510885660788063e-08

Based O 0 5.641101097353385e-07
on O 0 1.8131559897938132e-07
our O 0 4.603875947140068e-09
recent O 0 5.986389162160322e-10
finding O 0 5.23827980991598e-10
that O 0 2.1146365214441687e-10
cycloheximide O 0 7.779099178151228e-07
stabilized O 0 1.061949569702847e-05
mutant O 0 6.984348743799274e-08
COL17A1 O 0 3.3849246960926394e-07
transcripts O 0 1.4826725625027848e-08
in O 0 1.4474799137076388e-10
keratinocytes O 0 1.4752902011139213e-08
homozygous O 0 7.722216111005764e-08
for O 0 9.317320248669603e-10
a O 0 2.6852392309706374e-08
frameshift O 0 2.5738097974681295e-05
mutation O 0 3.1311579107295984e-08
, O 0 9.476727180768307e-10
the O 0 1.3795599385080237e-10
effects O 0 2.697230172543641e-08
of O 0 8.051815464371614e-11
the O 0 5.147809956085325e-10
splice O 0 1.2980090104974806e-05
- O 0 4.145297225477407e-06
site O 0 3.520876589391264e-06
mutation O 0 3.94086407951022e-09
on O 0 8.116178285000331e-10
splicing O 0 1.862526799456532e-09
of O 0 1.82652573621489e-10
COL17A1 O 0 2.964287091344886e-07
transcripts O 0 2.0354635310582125e-08
were O 0 2.2544444089334092e-09
determined O 0 1.8660080147725466e-09
using O 0 2.809782184698406e-09
reverse O 0 4.007017082585662e-07
transcriptase O 0 8.294418876175769e-07
polymerase O 0 1.1750450568115411e-07
chain O 0 1.4909909396010335e-07
reaction O 0 4.029480082934356e-10
of O 0 8.59805976416439e-12
total O 0 1.2797889137328156e-10
RNA O 0 1.1351549700222563e-09
from O 0 1.1744535031998904e-11
keratinocytes O 0 2.4658006747557693e-09
incubated O 0 9.767825659423579e-09
for O 0 4.5269762938282554e-10
2 O 0 1.4306259288332512e-08
. O 0 2.4028219414162777e-08

5 O 0 2.721646410464018e-07
h O 0 5.294695256452542e-06
in O 0 9.923458721416978e-10
the O 0 1.7448455180701927e-10
presence O 0 9.099354159047834e-09
or O 0 2.7685114201148053e-09
absence O 0 6.550479603184556e-10
of O 0 3.565768513791312e-11
10 O 0 6.060930646256679e-10
microg O 0 1.7621593428884808e-07
cycloheximide O 0 2.78721131508064e-07
per O 0 6.223002202432326e-08
ml O 0 8.94918957783375e-06
. O 0 1.0548998830017808e-07

Using O 0 1.4426937866574008e-08
this O 0 5.362644772688441e-10
approach O 0 4.8839780220077955e-08
, O 0 1.5327129565534392e-09
an O 0 3.080765087482007e-10
abnormally O 0 6.155055984891078e-07
spliced O 0 3.8071739254519343e-06
transcript O 0 4.585174974636175e-05
was O 0 5.488807073561475e-05
identified O 0 9.050509675034846e-07
that O 0 1.0663361860174803e-10
contains O 0 2.983452374039075e-10
an O 0 2.710903897196193e-11
extra O 0 3.236191037370162e-10
264 O 0 1.8113172073341843e-09
bases O 0 4.672640940839301e-09
upstream O 0 7.369383991928657e-10
from O 0 9.918187798829692e-12
exon O 0 8.012476793162193e-10
32 O 0 1.6844349248756885e-09
, O 0 7.263062373752405e-11
resulting O 0 2.3684476602170434e-10
in O 0 1.7150769693330403e-10
a O 0 7.316140138158289e-09
premature O 0 1.7392659401593846e-07
termination O 0 1.7992221046370105e-08
codon O 0 1.3556473277276382e-08
27 O 0 3.0323445976421226e-09
bp O 0 6.131094210104493e-08
downstream O 0 3.55682807651192e-08
from O 0 1.431377794069988e-10
the O 0 6.06193650831699e-10
cryptic O 0 3.729896036475111e-07
splice O 0 7.891007953730877e-06
site O 0 3.619265498855384e-06
. O 0 4.062474445731823e-08

Three O 0 9.532589473337794e-08
other O 0 1.309084840528385e-09
splice O 0 8.68938457188051e-07
variants O 0 1.409588890055602e-07
, O 0 3.913934509824912e-09
including O 0 4.4589179570841964e-10
one O 0 8.267451723220631e-10
derived O 0 3.3589697689961895e-10
from O 0 3.9458467743225256e-11
the O 0 4.741369449834387e-11
skipping O 0 1.1305656411053633e-09
of O 0 1.8379105529153783e-11
exon O 0 1.6569544625255617e-09
32 O 0 8.421356056942386e-09
, O 0 6.578851907690364e-10
were O 0 2.156366640804208e-08
also O 0 1.5452151558292826e-08
identified O 0 4.182187751666788e-07
. O 0 1.686496453601194e-08

These O 0 1.1313938585999495e-07
results O 0 1.6792711221569334e-08
indicate O 0 3.156823780159357e-08
the O 0 2.86321022446856e-10
usefulness O 0 1.680623284983085e-08
of O 0 1.0499283387144231e-10
cycloheximide O 0 1.2859806020060205e-06
treatment O 0 2.090700057522099e-08
in O 0 4.231185193881437e-11
evaluating O 0 4.1019951879661676e-09
the O 0 1.6902851340816483e-10
abnormal O 0 3.5164557488087667e-08
processing O 0 1.2894613377056885e-08
of O 0 4.1303249015411936e-11
mRNA O 0 3.890398558858976e-10
due O 0 3.3936928267586097e-10
to O 0 3.4389990855032693e-10
splice O 0 8.890257049642969e-06
- O 0 6.892913461342687e-06
site O 0 1.5959891243255697e-05
mutations O 0 3.193834174908261e-08
, O 0 2.148458522199803e-09
because O 0 1.1747504080616977e-09
( O 0 5.070746600388532e-10
i O 0 1.2767431201154977e-07
) O 0 1.0765398295031758e-10
aberrant O 0 8.346374258394462e-09
splicing O 0 7.453284212033395e-09
often O 0 5.46567369141826e-09
generates O 0 2.117143793611831e-09
a O 0 8.15467582349072e-10
premature O 0 3.254237768146595e-08
termination O 0 1.20692265070943e-08
codon O 0 1.095305890430609e-08
, O 0 1.9441931398134216e-10
( O 0 2.1340233399835817e-11
ii O 0 3.344920784797978e-08
) O 0 1.646481700978697e-10
transcripts O 0 4.428460798067135e-08
with O 0 3.3351972295037058e-09
premature O 0 2.4847415147633e-07
termination O 0 1.2957580786121525e-08
codons O 0 1.0932875049718405e-08
can O 0 1.1609158079295412e-09
occur O 0 1.4924227131896117e-10
at O 0 2.3781007385537123e-08
low O 0 3.32211902787094e-06
or O 0 2.710228841351636e-07
undetectable O 0 3.2357368127122754e-06
levels O 0 3.2699400964730785e-09
due O 0 3.653255198354799e-10
to O 0 1.0562096752764205e-09
nonsense O 0 1.2688337847066578e-05
- O 0 6.969111723265087e-07
mediated O 0 1.1225004215020817e-07
mRNA O 0 2.430410595000154e-10
decay O 0 3.0399827100069388e-09
, O 0 7.472207574910072e-11
and O 0 5.796463656282391e-11
( O 0 1.2830707850353118e-11
iii O 0 1.913022851240953e-09
) O 0 1.940999166949453e-10
the O 0 2.1126610183497263e-10
levels O 0 2.5056683394808488e-09
of O 0 5.503996564071301e-12
these O 0 2.133815867055855e-11
transcripts O 0 3.8853138484284955e-09
can O 0 1.5524965757407472e-09
be O 0 1.1430897339792523e-09
increased O 0 9.86194681473762e-10
by O 0 1.30931454567218e-09
cycloheximide O 0 9.290987691201735e-06
. O 0 1.2149723715992877e-07

A O 0 4.451232484825596e-07
deletion O 0 1.4969936046327348e-06
mutation O 0 2.404597125860164e-07
in O 0 2.383930830518466e-09
COL17A1 O 0 3.793252835748717e-05
in O 0 2.0916162135620198e-09
five O 0 2.9916253918571556e-09
Austrian O 0 6.083219545871543e-07
families O 0 8.88075657456966e-09
with O 0 6.7426575434126335e-09
generalized O 0 0.0013030916452407837
atrophic B-Disease 1 0.9998655319213867
benign I-Disease 1 0.9971926808357239
epidermolysis I-Disease 1 0.8866605162620544
bullosa I-Disease 0 0.011526564136147499
represents O 0 2.1406638950338674e-07
propagation O 0 1.710695016754471e-07
of O 0 1.2191520015747415e-09
an O 0 4.53500703656573e-09
ancestral O 0 1.663659350015223e-05
allele O 0 7.997222382982727e-06
. O 0 1.8965032211326616e-07

Patients O 0 6.521285831695423e-05
with O 0 1.4853650043278321e-07
generalized O 0 0.0008087796159088612
atrophic B-Disease 1 0.9998636245727539
benign I-Disease 1 0.9997068047523499
epidermolysis I-Disease 1 0.998285710811615
bullosa I-Disease 1 0.9697839617729187
, O 0 1.1306678970868234e-07
a O 0 5.857697438216292e-09
usually O 0 3.603677578567499e-09
nonlethal O 0 1.5239575645864534e-07
form O 0 1.1942184130475653e-08
of O 0 1.2471812027570195e-08
junctional B-Disease 1 0.7546229958534241
epidermolysis I-Disease 1 0.8386197090148926
bullosa I-Disease 0 0.11895977705717087
, O 0 1.0907114500469106e-07
have O 0 1.4137779835721176e-08
generalized O 0 8.285374519800826e-07
blistering B-Disease 0 0.0010735997930169106
, O 0 4.2888891016445996e-07
nail B-Disease 1 0.9999319314956665
dystrophy I-Disease 1 0.9756431579589844
, O 0 7.505213517333686e-08
patchy B-Disease 1 0.6514589786529541
alopecia I-Disease 1 0.9995111227035522
, O 0 3.837180599930434e-07
and O 0 1.9559058728191303e-06
dental B-Disease 0 0.015952255576848984
abnormalities I-Disease 1 0.8624317646026611
. O 0 6.748732630512677e-07

Skin B-Disease 1 0.9757601618766785
fragility I-Disease 0 0.004386928863823414
in O 0 2.2593097170897636e-08
most O 0 1.4818293259111215e-09
cases O 0 3.109397850309392e-09
is O 0 2.1112842585324643e-09
due O 0 9.868005301783e-10
to O 0 3.512658219850806e-10
mutations O 0 7.209792762807865e-09
in O 0 3.245888974268141e-11
the O 0 3.818148575085445e-11
gene O 0 3.5213674198786293e-09
encoding O 0 1.7593711376662213e-08
type O 0 1.869728475867305e-05
XVII O 0 6.342518645396922e-06
collagen O 0 3.983629540016409e-06
( O 0 3.041451890339886e-08
COL17A1 O 0 1.1975863344559912e-05
) O 0 1.1055800719361741e-08
. O 0 3.177022733780177e-08

Recently O 0 2.0253139155101962e-05
, O 0 1.9560268071927567e-08
we O 0 9.098504172300181e-09
reported O 0 1.4883016774547286e-07
five O 0 8.437622267543077e-10
Austrian O 0 5.997492849019181e-07
families O 0 8.485010027925455e-09
with O 0 3.74351705190179e-09
generalized O 0 0.00020086010044906288
atrophic B-Disease 1 0.9996609687805176
benign I-Disease 1 0.9703980684280396
epidermolysis I-Disease 1 0.6884911060333252
bullosa I-Disease 0 0.12883853912353516
who O 0 1.4750363561688573e-06
share O 0 3.94626660238373e-08
the O 0 7.34324434592537e-10
same O 0 2.7764924581674677e-08
COL17A1 O 0 3.3534532121848315e-05
mutation O 0 6.16602449099446e-07
. O 0 5.744534092855247e-08

Affected O 0 2.107797990902327e-05
individuals O 0 6.083253367705765e-08
in O 0 1.279130690257091e-09
three O 0 1.0625826885046763e-09
families O 0 1.6982745210114558e-09
are O 0 2.395488807316326e-10
homozygous O 0 1.223025858365645e-08
for O 0 4.6522383168046133e-10
4003delTC O 0 3.7374337580331485e-07
, O 0 4.5782166946395364e-10
whereas O 0 5.511996414853115e-10
those O 0 1.8701973303336672e-10
in O 0 1.0419545087847482e-10
two O 0 1.8274212698621284e-10
others O 0 1.328394394484178e-09
are O 0 2.784211194928332e-10
compound O 0 7.765284948391127e-08
heterozygotes O 0 5.068479822512018e-07
. O 0 2.5546167847778634e-08

To O 0 9.89894886060938e-08
determine O 0 6.36486703342598e-08
if O 0 2.6868260949441947e-09
the O 0 6.16612733095323e-11
occurrence O 0 1.7793631457152514e-08
of O 0 6.87723697434528e-11
4003delTC O 0 1.407846355050424e-07
in O 0 2.585461567061742e-10
these O 0 2.132771043106274e-10
unrelated O 0 1.139570215968888e-08
families O 0 7.85742693132363e-10
signifies O 0 2.946064725506403e-09
propagation O 0 1.2151248007796767e-08
of O 0 1.608196770197523e-10
an O 0 4.5585415997528855e-10
ancestral O 0 3.977593223680742e-06
allele O 0 2.1198970046043542e-07
or O 0 1.7216304826206397e-08
a O 0 7.944398028314481e-09
mutational O 0 5.725910341425333e-06
hot O 0 2.112001493514981e-05
spot O 0 8.465826795145404e-06
, O 0 1.1399131638611948e-09
haplotypes O 0 3.196576869868295e-08
were O 0 1.1882948847130592e-08
determined O 0 8.589303490680322e-09
for O 0 3.3170705071583484e-10
polymorphisms O 0 1.693839067229419e-06
both O 0 1.5219226989771073e-09
within O 0 4.067123970941111e-09
and O 0 1.1724760184961269e-07
flanking O 0 0.0007345371413975954
COL17A1 O 0 0.00052679079817608
. O 0 2.1333576682991406e-07

Five O 0 2.507556189357274e-07
intragenic O 0 3.1937177027430153e-06
polymorphisms O 0 2.0429486085049575e-06
were O 0 1.8232871212831014e-08
chosen O 0 1.2954706196666166e-09
based O 0 1.5993512070267002e-09
on O 0 2.7181773276652166e-08
their O 0 9.199487394084827e-09
informativeness O 0 6.782031960028689e-06
. O 0 4.803382580575999e-08

One O 0 1.7104601113260287e-07
of O 0 2.4358684513892115e-10
these O 0 4.6101300554823865e-10
, O 0 2.432056778189917e-10
not O 0 3.813492577275923e-10
previously O 0 3.421625294208752e-08
reported O 0 3.2399705105490284e-06
, O 0 1.1005868438829225e-09
was O 0 2.6207135306322016e-07
2988 O 0 5.6540063297916276e-08
A O 0 1.2914672886665812e-08
or O 0 1.7365934468216437e-08
C O 0 6.100800078456814e-07
that O 0 1.831004514674106e-10
introduces O 0 4.854643353979782e-10
a O 0 9.719236526706254e-11
new O 0 5.0142494323335285e-11
restriction O 0 2.574047419656722e-09
site O 0 5.685041770675525e-08
for O 0 4.678434861737912e-10
Eco0109 O 0 3.403310131488979e-07
I O 0 1.292619003834261e-06
. O 0 1.2714352237708226e-08

All O 0 1.0627738689095168e-08
the O 0 5.298854133251041e-10
4003delTC O 0 1.3616001126592892e-07
alleles O 0 1.2724759912430272e-08
showed O 0 8.602669510082706e-08
the O 0 6.394159507427943e-11
same O 0 1.943707417240148e-10
haplotype O 0 1.2599705279114914e-08
for O 0 1.6910139954973147e-10
these O 0 1.9862479716525883e-10
five O 0 1.3210744720382195e-09
polymorphic O 0 9.187907039631682e-07
markers O 0 1.687271833361592e-05
. O 0 1.046277446903332e-07

Fourteen O 0 2.206048520747572e-06
microsatellite O 0 1.6557709386688657e-05
polymorphisms O 0 5.2526047511491925e-06
were O 0 3.687885907766031e-08
selected O 0 2.8735738233365282e-09
based O 0 6.986744516268573e-09
on O 0 1.918351841823096e-07
their O 0 3.6407501458057823e-09
high O 0 1.3923909136792645e-07
heterozygosity O 0 1.6268502633920434e-07
and O 0 2.8549336228422817e-09
their O 0 1.6261514357296392e-10
location O 0 5.0572101173429473e-08
within O 0 9.049053728560352e-10
10q23 O 0 1.0413817363996714e-07
- O 0 4.2574670260364655e-06
q25 O 0 2.0397383195813745e-06
near O 0 1.0595671483315527e-05
COL17A1 O 0 2.431074062769767e-05
. O 0 8.701270104438663e-08

Three O 0 5.791245598629757e-07
families O 0 1.0338730049852529e-07
shared O 0 1.3523520081548668e-08
microsatellite O 0 7.058991741359932e-06
polymorphisms O 0 3.813816874753684e-06
covering O 0 6.943027528905077e-06
at O 0 6.956475431252329e-07
most O 0 6.862565515852737e-10
19 O 0 1.7793418960465601e-09
cM O 0 1.803843652226078e-08
, O 0 2.775382978992269e-10
whereas O 0 9.39799460475399e-10
the O 0 3.3350430750367366e-10
others O 0 6.438271249464833e-09
shared O 0 6.227318105622714e-10
smaller O 0 1.4530940006807214e-08
regions O 0 2.605792204235513e-08
consistent O 0 7.858241133362753e-07
with O 0 1.7842978650151053e-08
cross O 0 1.6307352780131623e-05
- O 0 9.573198622092605e-05
over O 0 4.09381328836389e-08
events O 0 5.741003672454781e-09
during O 0 9.382770116417305e-10
passage O 0 2.1544856176891614e-10
of O 0 1.0908884039151356e-11
this O 0 1.0024354263338253e-10
mutation O 0 5.857013207766215e-10
through O 0 6.98977681290458e-11
several O 0 5.497685640065697e-10
generations O 0 1.3583753677437471e-08
. O 0 1.3810094401378592e-08

These O 0 2.7073220110196416e-08
results O 0 6.4242011710291536e-09
indicate O 0 2.356805595127298e-08
that O 0 6.543736108532983e-10
4003delTC O 0 2.002569914338892e-07
occurs O 0 1.267608795707531e-09
on O 0 2.1769497315915487e-09
a O 0 1.4086387611911277e-09
single O 0 1.369225088865278e-08
ancestral O 0 1.384216943733918e-06
allele O 0 1.0250938231592954e-07
. O 0 4.02746858085834e-09
. O 0 3.2397768023884055e-08

The O 0 1.0930335747616482e-07
haptoglobin O 0 3.258173819631338e-05
- O 0 3.4594677345012315e-06
gene O 0 1.6007351177904638e-07
deletion O 0 5.126465225657739e-07
responsible O 0 3.094543501447333e-07
for O 0 9.585826354907567e-09
anhaptoglobinemia B-Disease 0 6.99793963576667e-05
. O 0 1.534225049226734e-07

We O 0 1.260160047422687e-06
have O 0 6.471500224591864e-09
found O 0 6.447312128621263e-10
an O 0 4.1481991452929634e-11
allelic O 0 2.1904206448652985e-08
deletion O 0 6.129877760940872e-08
of O 0 5.592287743994007e-10
the O 0 1.7934547180686877e-09
haptoglobin O 0 1.3175355206840322e-06
( O 0 1.8239251775575838e-10
Hp O 0 2.711568525270991e-09
) O 0 3.264652090329001e-11
gene O 0 9.59546109235987e-10
from O 0 2.1832567698165661e-10
an O 0 7.341675600791575e-10
individual O 0 1.9191701561283026e-09
with O 0 1.5338981640411475e-08
anhaptoglobinemia B-Disease 0 0.0001374771527480334
. O 0 2.746486984506191e-07

The O 0 6.571684707523673e-08
Hp O 0 1.4210834820005402e-07
gene O 0 3.3909014263144854e-08
cluster O 0 3.7582967138405365e-07
consists O 0 3.8283398673399915e-09
of O 0 2.7889468512398707e-10
coding O 0 8.755657177061948e-07
regions O 0 1.9015645946751647e-08
of O 0 2.027379236713145e-10
the O 0 2.3194503262491395e-10
alpha O 0 1.3326095782417724e-09
chain O 0 1.1908302894880762e-06
and O 0 1.1212711870101089e-09
beta O 0 3.9959113795617895e-10
chain O 0 4.598586045290176e-08
of O 0 2.625223996521875e-11
the O 0 1.4932398373357358e-10
haptoglobin O 0 7.273997226775464e-08
gene O 0 2.045550395735063e-09
( O 0 8.16869766273598e-11
Hp O 0 1.7856555123429985e-09
) O 0 2.011939503887561e-10
and O 0 1.5353754934110952e-09
of O 0 3.614543733765352e-11
the O 0 2.5999311037416817e-10
alpha O 0 8.135318529944868e-10
chain O 0 6.879312763885537e-07
and O 0 4.539703890582558e-10
beta O 0 1.7567940158169648e-10
chain O 0 2.621170125394201e-08
of O 0 7.179961486469821e-12
the O 0 1.3311761415391032e-10
haptoglobin O 0 5.714164785786124e-07
- O 0 5.696182370229508e-07
related O 0 8.163880949041413e-08
gene O 0 2.5262274050419364e-08
( O 0 4.547755505512896e-10
Hpr O 0 1.6964955307230412e-07
) O 0 8.234999349099326e-10
, O 0 3.250400504306583e-10
in O 0 3.1885905027451145e-10
tandem O 0 2.1153603029233636e-06
from O 0 1.210299194198683e-09
the O 0 1.5930337049496757e-09
5 O 0 1.7599683488356277e-08
side O 0 1.5641329582649632e-06
. O 0 4.999760250257168e-08

Southern O 0 1.1109195838798769e-06
blot O 0 5.318162584444508e-05
and O 0 2.5568054340396884e-08
PCR O 0 1.4258482394780003e-07
analyses O 0 3.818729865656678e-08
have O 0 1.7572506783025688e-09
indicated O 0 2.527605680313627e-08
that O 0 1.9265114503674852e-10
the O 0 7.927769551940855e-11
individual O 0 1.6437924632572987e-10
with O 0 1.9792820160624558e-10
anhaptoglobinemia B-Disease 0 1.2470596857383498e-06
was O 0 1.1365165875076855e-07
homozygous O 0 1.851745423664397e-08
for O 0 1.8809472035474784e-10
the O 0 6.543769692779478e-11
gene O 0 2.3708668361877017e-09
deletion O 0 8.864746270376145e-09
and O 0 1.9246256144356266e-08
that O 0 5.914817524654836e-10
the O 0 2.373456986504152e-11
gene O 0 1.5594381341799135e-09
deletion O 0 3.4289338035620176e-09
was O 0 4.138339591008844e-07
included O 0 4.382061380425739e-09
at O 0 1.1306248381970363e-07
least O 0 5.613286502281767e-10
from O 0 3.830753769751283e-11
the O 0 7.96979635064865e-11
promoter O 0 9.015981277116225e-07
region O 0 6.877821867590228e-09
of O 0 9.825554259101921e-11
Hp O 0 8.371773496662627e-09
to O 0 8.822168551247955e-10
Hpr O 0 7.186880424114861e-08
alpha O 0 3.11633135963163e-10
but O 0 1.5760479032955743e-10
not O 0 9.014114454863886e-11
to O 0 2.0805977773985518e-10
Hpr O 0 3.21856219898109e-07
beta O 0 4.715760226758903e-09
( O 0 8.23567491980981e-10
Hpdel O 0 3.042493403881963e-07
) O 0 4.49671233582194e-09
. O 0 1.327060505929012e-08

In O 0 2.7467793373148197e-08
addition O 0 5.561613392046638e-09
, O 0 2.0520765087184145e-09
we O 0 2.599942483527684e-09
found O 0 6.119965645368097e-10
seven O 0 9.341481060909373e-11
individuals O 0 5.3130909394294434e-11
with O 0 6.789962342379496e-11
hypohaptoglobinemia B-Disease 0 6.448585168072896e-07
in O 0 7.638882859595242e-10
three O 0 1.0446752352066824e-09
families O 0 5.959199356198042e-09
, O 0 1.3329578552045973e-09
and O 0 3.3544258482010036e-09
the O 0 1.2813179683934806e-10
genotypes O 0 1.27721273557313e-08
of O 0 8.895903458316923e-11
six O 0 2.0075017204135293e-09
of O 0 5.815123035879388e-11
the O 0 2.641352692123178e-10
seven O 0 3.311962371022048e-10
individuals O 0 9.188588778741291e-11
were O 0 1.481984757134569e-09
found O 0 4.4416950673031863e-10
to O 0 2.5837165740227874e-10
be O 0 2.0517839871558863e-08
Hp2 O 0 5.418553882918786e-06
/ O 0 3.256515265093185e-05
Hpdel O 0 1.2209537089802325e-05
. O 0 1.4521360469643696e-07

The O 0 5.348165998952936e-08
phenotypes O 0 1.1349236956448294e-05
and O 0 2.610916460810131e-08
genotypes O 0 3.393448082533723e-07
in O 0 2.7053641549201757e-09
one O 0 1.5799735963994976e-09
of O 0 2.558762576820861e-11
these O 0 2.7803423452432696e-10
three O 0 3.597755982021056e-10
families O 0 1.3139752619295564e-09
showed O 0 3.95255000285033e-07
the O 0 2.8980440269776864e-10
father O 0 2.5593230645881704e-08
to O 0 5.884727705129933e-10
be O 0 4.250010565698403e-09
hypohaptoglobinemic B-Disease 0 2.0136889133937075e-07
( O 0 9.94672330612012e-11
Hp2 O 0 2.073148586134721e-08
) O 0 1.4325494956946017e-10
and O 0 3.3875946492401e-10
Hp2 O 0 2.873477455977991e-07
/ O 0 7.60926070597634e-07
Hpdel O 0 2.601442702143686e-06
, O 0 4.692056077004736e-09
the O 0 4.035479450603674e-10
mother O 0 1.8254694111874414e-07
to O 0 4.3797360183006617e-10
be O 0 1.235748281480653e-09
Hp2 O 0 1.901129991210837e-07
- O 0 3.893346161021327e-07
1 O 0 9.95340920795229e-10
and O 0 1.18203713483922e-09
Hp1 O 0 2.1260520099986024e-07
/ O 0 2.4151916022674413e-07
Hp2 O 0 4.776632067660103e-07
, O 0 1.5342455084166318e-09
one O 0 2.5825538929602487e-10
of O 0 4.4465327253551123e-11
the O 0 3.0619839996859355e-10
two O 0 8.075227708737032e-10
children O 0 4.637179973343564e-09
to O 0 7.386833922318203e-10
be O 0 1.6207096109610575e-08
hypohaptoglobinemic B-Disease 0 1.6438920624750608e-07
( O 0 1.0036101116828178e-10
Hp2 O 0 1.6601502395019452e-08
) O 0 5.248077666886175e-11
and O 0 3.7650835227331925e-10
Hp2 O 0 1.6457211415854545e-07
/ O 0 1.022919491333596e-06
Hpdel O 0 2.09747554436035e-06
, O 0 4.517094254197218e-09
and O 0 2.1935342431333993e-09
the O 0 5.7415457804799175e-11
other O 0 1.3707888990577288e-10
child O 0 3.0712755005879444e-08
to O 0 1.6285135739924073e-10
be O 0 4.383465590507285e-09
Hp1 O 0 1.1861045834393735e-07
and O 0 2.4615431915009367e-09
Hp1 O 0 2.7885459985554917e-07
/ O 0 1.852761101872602e-06
Hpdel O 0 5.679166861227714e-07
, O 0 6.280842512751406e-10
showing O 0 1.0691521623584777e-07
an O 0 2.7279545289360385e-10
anomalous O 0 1.8087881414885487e-07
inheritance O 0 1.2248214886767528e-07
of O 0 3.084294375454988e-09
Hp O 0 7.447474672517274e-07
phenotypes O 0 2.6384131501799857e-07
in O 0 8.162133191547127e-09
the O 0 1.123943960124052e-08
child O 0 4.45485238742549e-06
with O 0 2.2662195675593466e-08
Hp1 O 0 4.894984158454463e-05
. O 0 1.233277089340845e-07

The O 0 4.480166282405662e-08
Hp2 O 0 8.301094567286782e-06
/ O 0 5.226920166023774e-06
Hpdel O 0 8.478148629365023e-06
individuals O 0 2.9397851264434394e-08
had O 0 8.117856964418024e-08
an O 0 1.333239491030369e-10
extremely O 0 5.389392754295841e-08
low O 0 9.864237426882028e-07
level O 0 6.821240017274022e-09
of O 0 3.680677637674101e-11
Hp O 0 2.8041444721793596e-09
( O 0 7.162115345238362e-11
mean O 0 1.6571914951413191e-09
+ O 0 1.164100371653376e-08
/ O 0 1.7033498522778245e-07
- O 0 3.0893716029822826e-07
SD O 0 1.536614718133933e-06
= O 0 5.924421131453528e-08
0 O 0 3.323701314172922e-10
. O 0 1.666734458782848e-11
049 O 0 9.129307976252221e-09
+ O 0 2.854802838569981e-09
/ O 0 2.441908719674757e-08
- O 0 1.65671814045254e-08
0 O 0 4.5866682674144954e-10
. O 0 5.3278562117675676e-11
043 O 0 5.797100133264621e-09
mg O 0 1.0184963983306261e-08
/ O 0 1.6543973302418635e-08
ml O 0 3.339355458820137e-08
; O 0 1.1262132199041375e-10
n O 0 6.839911748102168e-08
= O 0 1.787595316216084e-08
6 O 0 1.7949117192550545e-10
) O 0 1.4303890537303854e-11
, O 0 1.053174995130357e-11
compared O 0 6.990553136354549e-10
with O 0 2.383256647586762e-10
the O 0 1.1674501643188506e-10
level O 0 1.7668694285433162e-09
( O 0 4.142187894767835e-12
1 O 0 8.327725661838592e-12
. O 0 9.780357947131169e-12
64 O 0 1.5771124683983118e-10
+ O 0 9.164439207509645e-10
/ O 0 3.1500391628469515e-08
- O 0 1.1220188866900571e-07
1 O 0 1.1201270466720814e-10
. O 0 1.9610557969174103e-11
07 O 0 4.665139941018026e-10
mg O 0 3.1782210196951155e-09
/ O 0 2.105956475872972e-08
ml O 0 1.2932765969253524e-08
) O 0 1.0882200522643881e-11
obtained O 0 5.852911905135372e-11
from O 0 5.1395075695293e-11
52 O 0 4.783768492444551e-09
healthy O 0 1.2551804928762067e-08
volunteers O 0 1.7110719507940075e-09
having O 0 2.365902140866183e-09
phenotype O 0 3.244099033850034e-08
Hp2 O 0 4.0864185280042875e-07
, O 0 7.723534589665348e-10
whereas O 0 1.131894689088142e-09
the O 0 1.622371958998059e-10
serum O 0 4.820269694505441e-08
Hp O 0 1.2840837726457721e-08
level O 0 4.309534507029866e-09
of O 0 4.0803523754240345e-11
an O 0 2.867473203327364e-10
individual O 0 5.157884119810774e-10
with O 0 1.1696305035613364e-09
Hp1 O 0 6.38414167042356e-06
/ O 0 1.5151095794863068e-05
Hpdel O 0 4.393941253511002e-06
was O 0 9.394182711730537e-07
0 O 0 9.782726806406572e-08
. O 0 2.8614332236998052e-08

50 O 0 3.507560961679701e-07
mg O 0 4.372700175281352e-07
/ O 0 1.3859565797247342e-06
ml O 0 4.593187441059854e-06
, O 0 2.145551070142915e-09
which O 0 1.692221474058897e-09
was O 0 1.4642338008741262e-08
approximately O 0 1.2946481664499743e-09
half O 0 4.871962278052422e-10
the O 0 1.1464253851789508e-10
level O 0 7.828734327475217e-10
of O 0 1.049323301860472e-11
Hp O 0 1.964037599222479e-09
in O 0 3.9054537381844057e-10
control O 0 3.385568106750725e-06
sera O 0 0.00010398620361229405
from O 0 2.062996995455535e-10
the O 0 1.2810100202820252e-10
Hp1 O 0 8.087782532584242e-08
phenotype O 0 5.1212531992916865e-09
( O 0 2.912527510834373e-11
1 O 0 3.8670334295831665e-11
. O 0 8.239469002913058e-12
26 O 0 5.6484896621133984e-11
+ O 0 6.224942783461529e-10
/ O 0 9.370220155346942e-09
- O 0 1.6335455654825637e-08
0 O 0 8.346494329014575e-11
. O 0 4.21974651401702e-12
33 O 0 8.585412242245738e-11
mg O 0 1.337284505353864e-09
/ O 0 1.1424734935872038e-08
ml O 0 3.124655023611922e-08
; O 0 2.453278691305627e-10
n O 0 1.945030163597039e-07
= O 0 8.321707412051182e-08
9 O 0 3.404879267421279e-09
) O 0 6.128501178759294e-11
, O 0 4.222582700164068e-11
showing O 0 8.1514919259007e-09
a O 0 7.488519804255134e-10
gene O 0 1.8937392098905548e-08
- O 0 1.2763441645802232e-06
dosage O 0 1.4083891528571257e-06
effect O 0 1.3766442918949906e-07
. O 0 5.461331298306504e-08

The O 0 3.2840617336660216e-08
other O 0 1.3210089688797666e-09
allele O 0 3.746176346908214e-08
( O 0 1.4610715415308562e-10
Hp2 O 0 4.5039509899424957e-08
) O 0 3.808584003728299e-11
of O 0 3.8603419072469336e-11
individuals O 0 3.17638942926024e-10
with O 0 6.539643271352702e-10
Hp2 O 0 8.48386662255507e-06
/ O 0 1.351154969597701e-05
Hpdel O 0 1.0697030120354611e-05
was O 0 2.1030321022408316e-06
found O 0 4.805930231555067e-08
to O 0 5.243660172737918e-09
have O 0 2.459418624312093e-08
, O 0 2.0879323270328598e-10
in O 0 3.7745150754942e-11
all O 0 9.773108711197409e-11
exons O 0 3.455992381162787e-09
, O 0 6.138693997570499e-10
no O 0 1.5065088065924215e-09
mutation O 0 5.551563098116219e-10
, O 0 1.8586391106745204e-11
by O 0 2.9662924894147125e-11
DNA O 0 6.32961150159872e-09
sequencing O 0 2.402684629032592e-08
. O 0 4.3341589872625264e-08

On O 0 5.900794803892495e-07
the O 0 4.693727628790612e-10
basis O 0 5.484146914369603e-09
of O 0 5.989127249694803e-11
the O 0 1.3428583245378434e-10
present O 0 7.277903835145594e-10
study O 0 5.690525828327964e-10
, O 0 6.794807771992595e-11
the O 0 8.682237220836164e-12
mechanism O 0 6.178102474052594e-10
of O 0 3.951495380905001e-11
anhaptoglobinemia B-Disease 0 1.8614074406286818e-06
and O 0 1.0439825892660792e-08
the O 0 1.940814176037975e-10
mechanism O 0 2.46514697543887e-09
of O 0 1.560864978933374e-11
anomalous O 0 2.7920311396201214e-08
inheritance O 0 4.279344878455049e-08
of O 0 9.907855647028896e-10
Hp O 0 1.2167743079771753e-07
phenotypes O 0 7.142876512489238e-08
were O 0 9.983477866626345e-08
well O 0 9.601200190445525e-08
explained O 0 4.2651993226172635e-07
. O 0 4.1667291839075915e-08

However O 0 3.6804939895773714e-07
, O 0 3.6593594820999442e-09
the O 0 3.115267488418283e-10
mechanism O 0 1.2641904412191707e-08
of O 0 5.514447232179975e-10
hypohaptoglobinemia B-Disease 0 7.293803355423734e-05
remains O 0 1.2884828720416408e-05
unknown O 0 5.6216026678157505e-06

ATM O 0 0.0015972498804330826
mutations O 0 7.383131742244586e-05
and O 0 5.55494693799119e-07
phenotypes O 0 0.0007640247349627316
in O 0 0.0002980288991238922
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
families O 0 0.00023149166372604668
in O 0 4.421658417186336e-08
the O 0 5.7629456762242626e-09
British O 0 3.49199831362057e-06
Isles O 0 9.769254575076047e-06
: O 0 3.9208064572804346e-10
expression O 0 4.2430917113200906e-10
of O 0 1.2410617672431457e-11
mutant O 0 3.177434848566918e-08
ATM O 0 2.071014478133293e-06
and O 0 1.4608111165159698e-08
the O 0 9.381982968292846e-10
risk O 0 7.696601045381612e-08
of O 0 2.3999762177595585e-09
leukemia B-Disease 1 0.8052423596382141
, O 0 2.185243647545576e-05
lymphoma B-Disease 1 1.0
, O 0 5.814155429106904e-06
and O 0 0.0008367717382498085
breast B-Disease 1 0.9812907576560974
cancer I-Disease 0 0.00011892487236764282
. O 0 1.652171732757779e-07

We O 0 1.938511786647723e-07
report O 0 5.816293224825131e-09
the O 0 8.311654836612448e-11
spectrum O 0 7.3620682883301924e-09
of O 0 7.780603938911668e-11
59 O 0 5.0959387820626034e-09
ATM O 0 1.393734237353783e-06
mutations O 0 6.665694485263884e-08
observed O 0 1.6858697335919715e-06
in O 0 1.1476458894321695e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0005622515454888344
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
) O 0 9.896075070514598e-09
patients O 0 6.1079457047696906e-09
in O 0 3.151947036705849e-10
the O 0 1.7771913940478612e-09
British O 0 3.490439894449082e-06
Isles O 0 9.308750304626301e-05
. O 0 2.179913991540161e-07

Of O 0 1.2097417823042633e-07
51 O 0 2.7576227239478612e-06
ATM O 0 5.5605891247978434e-05
mutations O 0 4.923330720885133e-07
identified O 0 2.3722241166979074e-06
in O 0 2.298567336467272e-09
families O 0 3.3925298126291636e-09
native O 0 4.347876725319111e-09
to O 0 1.3235367468666936e-08
the O 0 5.676370928853203e-09
British O 0 9.715886335470714e-06
Isles O 0 4.0906630601966754e-05
, O 0 2.2393473741999514e-08
11 O 0 1.6751883213927954e-09
were O 0 8.293910447321196e-09
founder O 0 1.9797369077423355e-08
mutations O 0 2.944048116404474e-09
, O 0 2.9597663209202096e-10
and O 0 9.395234590314772e-10
2 O 0 1.8521142952643288e-10
of O 0 3.136574680540072e-11
these O 0 7.097483711859809e-10
11 O 0 9.556593294490767e-10
conferred O 0 2.3650348346393457e-10
a O 0 1.0320377885619791e-09
milder O 0 2.680895363482705e-07
clinical O 0 1.2817450567581545e-07
phenotype O 0 9.522685928686769e-08
with O 0 8.879328938782294e-10
respect O 0 5.014178405815528e-09
to O 0 2.203397819755537e-08
both O 0 1.0629202051859465e-07
cerebellar B-Disease 0 0.00024518428836017847
degeneration I-Disease 0 0.000738987815566361
and O 0 1.8908325216671074e-07
cellular O 0 5.8936916502716485e-06
features O 0 1.1668273145915009e-05
. O 0 1.0822271860888577e-06

We O 0 1.694921706985042e-06
report O 0 4.423657173902029e-08
, O 0 5.220704424324651e-10
in O 0 2.2904697583037148e-10
two O 0 1.2581670816302903e-08
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
families O 0 1.837209282484764e-07
, O 0 5.116817525241402e-10
an O 0 1.0411836670609631e-10
ATM O 0 1.035397986015596e-06
mutation O 0 5.501559208198614e-09
( O 0 5.197373781351544e-11
7271T O 0 1.9331906742081628e-08
- O 0 3.928194473701296e-06
- O 0 2.250561556138564e-05
> O 0 3.495038569667486e-08
G O 0 3.4317235986236483e-07
) O 0 1.3883660887614724e-10
that O 0 3.2991195886289404e-10
may O 0 3.0969979913919587e-09
be O 0 2.903454976443953e-10
associated O 0 2.01189842563565e-09
with O 0 3.736389253550243e-10
an O 0 1.6659034152155527e-09
increased O 0 1.918378984555602e-06
risk O 0 5.134149432706181e-06
of O 0 2.246148866902331e-08
breast B-Disease 1 0.5851984024047852
cancer I-Disease 0 1.1911371984751895e-05
in O 0 1.179382036475829e-09
both O 0 3.03762393016882e-09
homozygotes O 0 1.4018003184901318e-06
and O 0 5.530470748027483e-09
heterozygotes O 0 1.3031245771344402e-07
( O 0 5.543013825715093e-10
relative O 0 2.872632798300856e-08
risk O 0 1.1442682357198919e-08
12 O 0 9.643454090824122e-11
. O 0 2.4911742807498527e-11
7 O 0 4.922522944816876e-10
; O 0 3.1485522522523013e-10
P O 0 0.00029991354676894844
= O 0 1.7961725973236753e-07
. O 0 1.4508465262519366e-10
0025 O 0 5.052309681730094e-09
) O 0 1.297202623096183e-11
, O 0 1.322068843290225e-11
although O 0 5.473294734104073e-11
there O 0 2.694199030539579e-10
is O 0 3.6563782557230695e-10
a O 0 9.702794123711556e-10
less O 0 3.9653635042213864e-08
severe O 0 2.633422627695836e-05
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
phenotype O 0 3.1315069008996943e-06
in O 0 9.28510379694103e-10
terms O 0 1.4017882410399807e-09
of O 0 3.2162522645151626e-11
the O 0 2.0661514166242512e-10
degree O 0 5.096803867843391e-09
of O 0 1.035340790878081e-08
cerebellar B-Disease 0 0.001734056044369936
degeneration I-Disease 0 0.0018171187257394195
. O 0 5.047612603448215e-07

This O 0 1.262874604890385e-08
mutation O 0 3.293778405577541e-08
( O 0 4.992398716652247e-10
7271T O 0 4.429593047916569e-08
- O 0 6.209998900885694e-06
- O 0 7.258257028297521e-06
> O 0 4.260498798203116e-08
G O 0 2.3304839658067067e-07
) O 0 1.0191055638264501e-10
also O 0 2.414147770579689e-10
allows O 0 9.153219848734295e-11
expression O 0 3.4597169573657993e-10
of O 0 2.3258105510959304e-11
full O 0 5.419644732995721e-09
- O 0 8.314566457556793e-07
length O 0 3.0333066547427734e-07
ATM O 0 7.277250801962509e-07
protein O 0 1.794789428188892e-09
at O 0 4.75234784858003e-09
a O 0 7.026445536517656e-10
level O 0 4.204633086146714e-09
comparable O 0 9.638847942028406e-09
with O 0 1.359338197559623e-10
that O 0 2.851884284282846e-10
in O 0 9.480921603355341e-10
unaffected O 0 9.93033722807013e-07
individuals O 0 3.7533909313935965e-09
. O 0 1.8617818398070085e-08

In O 0 9.573894566017316e-09
addition O 0 4.983534473979034e-09
, O 0 1.3967066392339689e-09
we O 0 1.1159883017697325e-09
have O 0 8.64038007808432e-11
studied O 0 2.8802187301835147e-09
18 O 0 7.003758639712032e-08
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
patients O 0 4.3264699911560456e-07
, O 0 2.7419452819366086e-10
in O 0 9.791468330577757e-11
15 O 0 9.230153308337208e-10
families O 0 1.2403862381660247e-09
, O 0 2.102808593917871e-09
who O 0 6.344747305320197e-08
developed O 0 0.0009461012086831033
leukemia B-Disease 1 0.972851574420929
, O 0 1.1182387424923945e-05
lymphoma B-Disease 1 1.0
, O 0 6.791759687985177e-08
preleukemic O 0 0.0005193459801375866
T O 0 0.4179067611694336
- O 0 4.786976205650717e-05
cell O 0 0.00013130872684996575
proliferation O 0 0.011777764186263084
, O 0 6.222278159384587e-08
or O 0 0.014635391533374786
Hodgkin B-Disease 1 0.9999998807907104
lymphoma I-Disease 1 1.0
, O 0 2.1061538291178294e-07
mostly O 0 1.2099444113289337e-08
in O 0 4.65623495315981e-09
childhood O 0 4.254898158251308e-06
. O 0 1.1859813042747192e-07

A O 0 2.2061958588892594e-06
wide O 0 8.156657145264035e-07
variety O 0 4.346668447396951e-08
of O 0 5.111540635205358e-10
ATM O 0 9.30624173633987e-06
mutation O 0 1.1885260775557072e-08
types O 0 6.734408231068301e-08
, O 0 6.914093741983152e-10
including O 0 1.0650399451250792e-09
missense O 0 2.183137667088886e-06
mutations O 0 1.859259270986513e-07
and O 0 1.0026203511870335e-07
in O 0 1.0385388549138952e-08
- O 0 0.0002279993932461366
frame O 0 0.00042732275323942304
deletions O 0 4.049783228765591e-07
, O 0 4.3372271107955385e-08
were O 0 4.6123776797912797e-08
seen O 0 2.8932097961842373e-07
in O 0 1.4066835196668848e-10
these O 0 8.779933446945165e-10
patients O 0 6.960063636540781e-09
. O 0 6.874805169587717e-09

We O 0 3.7614881875924766e-07
also O 0 3.3712883595882204e-09
show O 0 1.9576503973439685e-08
that O 0 1.3012574351378703e-10
25 O 0 8.728966854887332e-11
% O 0 8.490242363323741e-12
of O 0 2.8754677458553424e-11
all O 0 1.5441361256307573e-07
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
patients O 0 7.503989536417066e-07
carried O 0 2.3998546794246067e-07
in O 0 1.948337047252835e-09
- O 0 1.0290907994203735e-05
frame O 0 0.0005377477500587702
deletions O 0 6.16800093666825e-07
or O 0 3.432313064877235e-07
missense O 0 5.891853902539879e-07
mutations O 0 1.4172742979212671e-08
, O 0 9.315828108924507e-10
many O 0 2.8366333587603876e-11
of O 0 2.7191117413227772e-11
which O 0 5.585002682551021e-08
were O 0 3.472553373740084e-07
also O 0 2.8170227039936435e-08
associated O 0 1.3123555575589307e-08
with O 0 2.8538432728097973e-10
expression O 0 2.4338122628364545e-09
of O 0 1.863695170412072e-10
mutant O 0 2.3886684630269883e-07
ATM O 0 2.1369689875427866e-06
protein O 0 1.1243775333014128e-07
. O 0 4.953297505494447e-08

The O 0 6.16946493892101e-08
DMPK O 0 7.393433861579979e-06
gene O 0 2.846288111868489e-07
of O 0 2.2602407057092933e-08
severely O 1 0.7676486372947693
affected O 0 0.2596083879470825
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00022928928956389427
is O 0 3.781337909458671e-08
hypermethylated O 0 2.356033974137972e-06
proximal O 0 6.246021257538814e-06
to O 0 3.6389817381632383e-08
the O 0 3.5739156079017675e-09
largely O 0 2.049577929597035e-08
expanded O 0 1.9597356981648772e-07
CTG O 0 4.041234205942601e-05
repeat O 0 2.306567239429569e-06
. O 0 7.859308226443318e-08

Using O 0 6.04011631821777e-08
methylation O 0 1.2158525350969285e-06
- O 0 2.137057344953064e-05
sensitive O 0 3.7056604924146086e-05
restriction O 0 3.540617399266921e-08
enzymes O 0 9.12655639950799e-09
, O 0 2.6752933202089935e-10
we O 0 4.648929574635474e-10
characterized O 0 4.481093551778059e-10
the O 0 5.132823853448709e-12
methylation O 0 6.083692216662939e-09
pattern O 0 4.0026745296017907e-07
on O 0 4.831407451888481e-08
the O 0 3.805383785859817e-10
5 O 0 1.6620917975274097e-09
side O 0 4.294684785577374e-08
of O 0 3.9073216884233375e-11
the O 0 4.2147477175014103e-10
CTG O 0 2.015352038142737e-06
repeat O 0 1.9466142475721426e-08
in O 0 9.695370201123765e-11
the O 0 6.743371139261711e-11
DMPK O 0 7.977502747280596e-08
gene O 0 1.158820706059771e-09
of O 0 5.216879706004818e-11
normal O 0 4.978992773629898e-09
individuals O 0 8.320668598571501e-10
and O 0 2.1757833312818775e-09
of O 0 1.1838692248744564e-09
patients O 0 1.9784995686222828e-07
affected O 0 3.893713653724262e-07
with O 0 9.641776159696747e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 2.178400393404445e-08
showing O 0 8.227706871366536e-08
expansions O 0 2.0506500675310235e-07
of O 0 3.5876276949231567e-10
the O 0 2.516694186383006e-09
repetitive O 0 5.1608749345177785e-06
sequence O 0 2.1049048370969103e-07
. O 0 8.714690125088964e-08

The O 0 8.609116974866993e-09
gene O 0 3.3693424938974204e-08
segment O 0 5.0557733999312404e-08
analyzed O 0 1.355644752010221e-08
corresponds O 0 6.624474746530495e-09
to O 0 2.0558912905421778e-10
the O 0 2.812493848924902e-10
genomic O 0 1.9614147106494784e-07
SacI O 0 8.783148587099276e-06
- O 0 1.7468839814682724e-06
HindIII O 0 1.0847628573174006e-06
fragment O 0 2.6681470899347914e-07
carrying O 0 4.855815305404576e-08
exons O 0 3.18248716268954e-08
11 O 0 1.1831069457457488e-08
- O 0 2.3832287752156844e-06
15 O 0 2.2517209430361618e-08
. O 0 4.1007844231444324e-08

There O 0 6.28856753337459e-08
is O 0 5.997223273546126e-10
constitutive O 0 4.855127411218518e-09
methylation O 0 3.879539178797131e-08
in O 0 6.011826036989021e-10
intron O 0 2.1646512777806493e-06
12 O 0 2.0687629387339257e-09
at O 0 7.615272856753563e-10
restriction O 0 5.613275955163033e-10
sites O 0 3.07207059790926e-09
of O 0 2.1169638958484782e-11
SacII O 0 1.036247994079531e-07
and O 0 1.3050460712094036e-09
HhaI O 0 1.1286479661976045e-07
, O 0 7.652383587908318e-11
localized O 0 2.774225515977946e-09
1 O 0 3.6093167343764776e-10
, O 0 1.0224992380569731e-10
159 O 0 2.434086043834327e-09
- O 0 6.732109341101022e-07
1 O 0 7.265975598969021e-10
, O 0 7.199300877669401e-11
232 O 0 1.383096415175089e-09
bp O 0 3.4997011510995435e-08
upstream O 0 3.431773532014404e-09
of O 0 4.0306001591883245e-11
the O 0 9.404880207952715e-10
CTG O 0 3.0954402063798625e-06
repeat O 0 3.80337041860912e-08
, O 0 7.496132881090745e-11
whereas O 0 7.607603436099453e-11
most O 0 5.0090306902284e-11
, O 0 8.780297322541486e-11
if O 0 1.50855536396044e-10
not O 0 4.1570169528881706e-10
all O 0 4.2627439772457976e-11
, O 0 2.508735753858904e-11
of O 0 1.7149377621109019e-12
the O 0 1.1137927385940216e-11
other O 0 1.3128591963562641e-11
sites O 0 1.519858017218212e-08
of O 0 3.047526814237145e-11
SacII O 0 8.202730583661832e-08
, O 0 3.044942908925208e-10
HhaI O 0 5.2266681649371094e-08
, O 0 2.8205734969866114e-10
and O 0 1.6853766160451755e-09
HpaII O 0 9.324173078084641e-08
in O 0 1.8043545824131257e-10
this O 0 3.157856198754416e-10
region O 0 3.5100347073324656e-09
are O 0 1.9270186835118608e-10
unmethylated O 0 4.006661527000688e-07
, O 0 2.1466470268016735e-10
in O 0 2.4199184323059342e-11
normal O 0 3.6205847209203057e-09
individuals O 0 3.0574143217165783e-10
and O 0 1.143696026773e-09
most O 0 2.2827154055882204e-10
of O 0 2.647934302379973e-11
the O 0 1.4360326261453338e-09
patients O 0 1.133217342186299e-08
. O 0 7.31208071869105e-09

In O 0 3.8501120513956266e-08
a O 0 4.539403519743246e-09
number O 0 1.0422511742547158e-09
of O 0 2.0691763580327205e-10
young O 0 4.5167347195729235e-08
and O 0 7.21785866630853e-08
severely O 0 0.0009084498160518706
affected O 0 3.314864045478316e-07
patients O 0 8.996997813426333e-09
, O 0 1.3002848797682987e-10
however O 0 3.8358516363246054e-10
, O 0 3.36545132040289e-11
complete O 0 2.770501328352992e-10
methylation O 0 9.775559917102328e-09
of O 0 2.155002391812655e-11
these O 0 4.257194596846148e-11
restriction O 0 2.9507323251465323e-09
sites O 0 1.3220790151535766e-07
was O 0 4.4078069549868815e-07
found O 0 8.735021594930004e-09
in O 0 4.954792479083814e-11
the O 0 1.8085133390854935e-10
mutated O 0 4.866682346005291e-08
allele O 0 1.437006744708924e-07
. O 0 4.51029507075873e-08

In O 0 1.341451660863413e-08
most O 0 5.74220559990124e-10
of O 0 6.86288872953078e-11
these O 0 1.5310708256777161e-09
patients O 0 3.137816673159932e-09
, O 0 7.271600682701163e-11
the O 0 7.987311506640893e-11
onset O 0 7.748388952677487e-08
of O 0 4.873058623289239e-10
the O 0 5.469357233778283e-07
disease O 0 0.019264226779341698
was O 0 0.0032439955975860357
congenital O 1 0.9998602867126465
. O 0 6.128025233920198e-07

Preliminary O 0 5.645008513965877e-07
in O 0 7.7907991169468e-09
vivo O 0 5.019538548367564e-06
footprinting O 0 2.8988408303121105e-05
data O 0 1.1770436714186872e-07
gave O 0 4.451560897678064e-09
evidence O 0 3.442998108837969e-09
for O 0 3.282091820544508e-10
protein O 0 2.6051845125607542e-09
- O 0 4.682341057105077e-07
DNA O 0 1.8896753317676485e-07
contact O 0 2.060263142311669e-07
in O 0 2.626467376920516e-10
normal O 0 7.817085645456245e-09
genes O 0 8.038135490551213e-09
at O 0 7.013932190602645e-08
an O 0 1.0391546512167338e-09
Sp1 O 0 1.3996067593780026e-07
consensus O 0 1.121741699527945e-09
binding O 0 5.958506132941466e-09
site O 0 9.410959478373115e-07
upstream O 0 2.3508166080432602e-08
of O 0 1.2756508349642814e-10
the O 0 2.799093457017676e-10
CTG O 0 1.3357284842641093e-06
repeat O 0 7.8582587548226e-08
and O 0 6.894117499101071e-10
for O 0 2.626235513780717e-11
a O 0 1.6681346581837175e-10
significant O 0 2.6201529834679604e-10
reduction O 0 9.88254700295954e-10
of O 0 8.365296302881298e-12
this O 0 1.838134852660822e-11
interaction O 0 7.630491377641491e-11
in O 0 4.147107657281879e-11
cells O 0 4.6427534039494844e-10
with O 0 7.633839393950126e-11
a O 0 6.524745632674467e-09
hypermethylated O 0 6.682474122499116e-06
DMPK O 0 1.611046286598139e-06
gene O 0 2.937010812331664e-08
. O 0 2.9080786667634584e-09
. O 0 2.204621019075148e-08

The O 0 1.2599292631421122e-06
hemochromatosis B-Disease 1 0.9999872446060181
gene O 0 8.920134177969885e-07
product O 0 9.829267355598859e-07
complexes O 0 7.325358524212788e-07
with O 0 1.530521820392039e-09
the O 0 7.900391452153599e-10
transferrin O 0 1.321128593190224e-07
receptor O 0 5.242420275664017e-09
and O 0 2.164470824794762e-09
lowers O 0 1.5835017563858855e-07
its O 0 1.3246870267380473e-10
affinity O 0 1.4891100852398864e-10
for O 0 3.454967215099636e-11
ligand O 0 2.557194234142912e-09
binding O 0 3.8261006807260856e-08
. O 0 1.954926531766432e-08

We O 0 5.144075885255006e-07
recently O 0 1.424694318075126e-07
reported O 0 9.815659041123581e-08
the O 0 1.0226786084643891e-10
positional O 0 2.7045556905136436e-08
cloning O 0 1.1708212355188152e-07
of O 0 1.1056611182169718e-10
a O 0 2.909721130706089e-09
candidate O 0 3.373727963662532e-08
gene O 0 1.7276786365982844e-06
for O 0 0.00013067906547803432
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.8268157243728638
HFE O 1 0.9015605449676514
. O 0 2.914449396484997e-06

The O 0 2.527075437797066e-08
gene O 0 1.2201115850984934e-07
product O 0 4.3645736695907544e-06
, O 0 6.32830809976781e-09
a O 0 1.9472223833361113e-09
member O 0 2.9588800853908026e-10
of O 0 5.077383652407619e-11
the O 0 1.0668148586745474e-09
major O 0 2.12125144116726e-08
histocompatibility O 0 4.946556941831659e-07
complex O 0 7.865918973948283e-07
class O 0 1.186636922057005e-08
I O 0 2.1481971543835243e-06
- O 0 9.111129770644766e-07
like O 0 1.2051421194314571e-08
family O 0 2.4045915480996882e-08
, O 0 1.7453191114569222e-09
was O 0 7.204063194876653e-07
found O 0 2.518039643462089e-08
to O 0 2.3627635403755676e-09
have O 0 1.9978223519956373e-09
a O 0 5.85088366644726e-10
mutation O 0 1.8069247209595574e-09
, O 0 1.4172782392130046e-10
Cys O 0 2.886066567953094e-07
- O 0 1.8702139925608208e-07
282 O 0 1.2200767685044411e-07
- O 0 6.1403311519825365e-06
- O 0 7.729347998974845e-06
> O 0 3.565433814856078e-08
Tyr O 0 1.1895959062258044e-07
( O 0 6.957773246440979e-11
C282Y O 0 9.386009747203161e-10
) O 0 6.611261451489048e-12
, O 0 2.293540791314941e-12
in O 0 2.7582029542283504e-12
85 O 0 3.9576070198776847e-10
% O 0 1.4309846363413925e-10
of O 0 6.770038418757451e-10
patient O 0 2.2637498204858275e-06
chromosomes O 0 7.44888097869989e-07
. O 0 2.417849032099184e-07

This O 0 5.6873923348632616e-09
mutation O 0 6.560462395555078e-08
eliminates O 0 1.1459952986569988e-07
the O 0 5.8471152364347745e-09
ability O 0 2.1905918856646167e-08
of O 0 2.966350498567749e-10
HFE O 0 1.8208012988907285e-05
to O 0 8.05443534090955e-09
associate O 0 6.464998758559659e-09
with O 0 1.0049208132301146e-09
beta2 O 0 1.956204323505517e-05
- O 0 6.0130110796308145e-05
microglobulin O 0 5.284782218950568e-06
( O 0 3.842837714707059e-10
beta2m O 0 1.0187143573148205e-07
) O 0 1.419973305605282e-10
and O 0 2.4553664657034346e-10
prevents O 0 3.6076390763639665e-09
cell O 0 5.587228315562243e-07
- O 0 2.3306125513045117e-05
surface O 0 9.40150857786648e-05
expression O 0 1.6686412891431246e-06
. O 0 1.1197440841215212e-07

A O 0 4.707100060841185e-07
second O 0 5.869966734906029e-09
mutation O 0 1.1613416894817874e-08
that O 0 1.5923896645730906e-09
has O 0 6.88430787931793e-08
no O 0 7.373675892097253e-09
effect O 0 1.922408676691134e-09
on O 0 8.731927181315768e-08
beta2m O 0 8.182935744116548e-06
association O 0 2.4611255255990727e-09
, O 0 9.600398948039768e-11
H63D O 0 3.5154073430021526e-07
, O 0 4.757823024448271e-10
was O 0 3.160402854973654e-07
found O 0 1.3507793994449457e-08
in O 0 3.4565114659379503e-10
eight O 0 2.490592398984859e-09
out O 0 5.020638127462007e-09
of O 0 9.138740458825012e-11
nine O 0 2.4512123442121947e-09
patients O 0 3.9347933245004185e-10
heterozygous O 0 1.2349096190078512e-09
for O 0 2.2093082918672735e-10
the O 0 9.086411623115964e-10
C282Y O 0 3.927086709154537e-07
mutant O 0 1.2509093494372792e-06
. O 0 8.461353218081058e-08

In O 0 2.2723570580751584e-08
this O 0 7.243863286987562e-10
report O 0 7.419455716473067e-09
, O 0 7.529879497703007e-11
we O 0 1.3640702456463316e-10
demonstrate O 0 3.2457481147218914e-10
in O 0 1.6785961509668823e-11
cultured O 0 3.236207035683947e-08
293 O 0 2.5062526276542485e-08
cells O 0 5.896775512326258e-09
overexpressing O 0 1.6538237446184212e-07
wild O 0 2.594534187494446e-08
- O 0 3.247583663323894e-06
type O 0 1.3889355614082888e-05
or O 0 4.943906262155906e-08
mutant O 0 4.3725788145820843e-07
HFE O 0 2.205770897489856e-06
proteins O 0 1.1510249420254581e-09
that O 0 4.454420998722952e-10
both O 0 8.644698845650112e-11
the O 0 6.007020575404809e-11
wild O 0 2.568174579664628e-07
- O 0 6.243059760890901e-05
type O 0 0.0004448327817954123
and O 0 4.190508207102539e-07
H63D O 0 0.0002278526808368042
HFE O 0 1.276506736758165e-05
proteins O 0 3.0339641909904458e-09
form O 0 1.625780288172507e-09
stable O 0 3.608274710131809e-07
complexes O 0 3.827458172622755e-08
with O 0 2.058539727567421e-10
the O 0 4.5689871330800713e-10
transferrin O 0 2.2667236976303684e-07
receptor O 0 1.0141328665724814e-08
( O 0 1.0234655345442434e-09
TfR O 0 2.0057859728694893e-06
) O 0 2.293268464015341e-09
. O 0 7.530705836700236e-09

The O 0 6.962800824794613e-08
C282Y O 0 1.6684790580256958e-06
mutation O 0 4.828072519558191e-07
nearly O 0 3.835518924688586e-08
completely O 0 9.892135466316176e-08
prevents O 0 6.217601100644288e-09
the O 0 3.7288211407471294e-10
association O 0 4.6050066537794976e-10
of O 0 1.5535791403342714e-11
the O 0 2.7760607701488027e-10
mutant O 0 4.031691105410573e-07
HFE O 0 4.980951416655444e-06
protein O 0 1.077374900404493e-08
with O 0 1.1345272499241332e-09
the O 0 1.704356478171576e-08
TfR O 0 0.0004486894467845559
. O 0 7.435085080942372e-08

Studies O 0 9.070039652669948e-08
on O 0 2.7119217094195847e-08
cell O 0 2.5874137463688385e-06
- O 0 2.589020596133196e-06
associated O 0 1.9414454044408558e-08
transferrin O 0 4.012243692841366e-08
at O 0 3.1396962807406226e-09
37 O 0 6.636549088057109e-10
degrees O 0 2.9622471142687345e-09
C O 0 1.1292486590264161e-07
suggest O 0 2.3832715800864435e-09
that O 0 1.0746441930775674e-10
the O 0 1.120522355457787e-10
overexpressed O 0 4.3088382994938e-07
wild O 0 8.966832609758058e-08
- O 0 1.128884014178766e-05
type O 0 3.103306153207086e-05
HFE O 0 8.543044714315329e-06
protein O 0 1.2688285089268447e-08
decreases O 0 1.480533295961095e-08
the O 0 2.661017066418747e-11
affinity O 0 3.3722966086280337e-10
of O 0 2.744560134715357e-11
the O 0 1.3455998537637015e-09
TfR O 0 7.999358786037192e-06
for O 0 1.989411080316472e-09
transferrin O 0 1.4802673149461043e-06
. O 0 2.2452923076343723e-08

The O 0 6.290883192150432e-08
overexpressed O 0 1.5730000086477958e-05
H63D O 0 9.208371011482086e-06
protein O 0 1.1870444183159634e-08
does O 0 4.318272850412086e-09
not O 0 3.0399754935572787e-10
have O 0 6.791024687036185e-11
this O 0 9.582868353008589e-12
effect O 0 6.488627413148151e-10
, O 0 1.969538594714937e-11
providing O 0 4.640457809679255e-11
the O 0 4.824030931660506e-12
first O 0 5.647294090693755e-11
direct O 0 5.892881738134292e-10
evidence O 0 8.473301171818548e-09
for O 0 2.7672167335346387e-10
a O 0 1.7210023406377672e-09
functional O 0 2.700390666632302e-08
consequence O 0 2.4123307795775872e-09
of O 0 7.324160722355089e-11
the O 0 3.6468383868282217e-09
H63D O 0 8.618708307039924e-06
mutation O 0 1.0633500835410814e-07
. O 0 3.52823974480998e-08

Addition O 0 6.671100294397547e-08
of O 0 7.574811888844124e-10
soluble O 0 1.743071749160663e-07
wild O 0 5.944818326497625e-07
- O 0 0.0001448074181098491
type O 0 0.0007977422210387886
HFE O 0 0.0015134498244151473
/ O 0 3.5580982512328774e-05
beta2m O 0 7.884245860623196e-06
heterodimers O 0 2.2076829964134959e-07
to O 0 1.7762493698114667e-09
cultured O 0 1.3653814789904573e-07
cells O 0 1.4199042830398412e-08
also O 0 3.0691305052954476e-09
decreased O 0 6.878716618530234e-08
the O 0 4.6535313796836064e-11
apparent O 0 6.74749456308632e-09
affinity O 0 4.1131728578669424e-10
of O 0 5.600376065673096e-11
the O 0 3.6459463226279354e-10
TfR O 0 1.5197674656519666e-06
for O 0 8.045674543266657e-11
its O 0 5.824692117517571e-11
ligand O 0 2.5699253836108937e-10
under O 0 3.471032627988535e-10
steady O 0 3.740871363788756e-07
- O 0 2.5111481249950884e-07
state O 0 5.134855873833999e-10
conditions O 0 5.466927177621983e-07
, O 0 1.0155333518557796e-10
both O 0 7.185140069726481e-12
in O 0 4.575726256228485e-11
293 O 0 1.8178657468226334e-09
cells O 0 5.128386049157996e-10
and O 0 3.565933659466225e-10
in O 0 6.794513285335313e-10
HeLa O 0 2.049464819720015e-05
cells O 0 7.740353424878776e-08
. O 0 2.2926313292259692e-08

Furthermore O 0 5.345677891455125e-07
, O 0 4.846762990950992e-09
at O 0 4.223698724103997e-09
4 O 0 3.421628258504228e-10
degrees O 0 8.847752752672022e-09
C O 0 1.8712233895712416e-06
, O 0 5.237260625179374e-10
the O 0 1.767616747416767e-10
added O 0 1.1116741305272626e-08
soluble O 0 2.9663576039951067e-09
complex O 0 5.123431900955211e-09
of O 0 1.536476362806738e-10
HFE O 0 4.190314939478412e-06
/ O 0 1.5576069927192293e-06
beta2m O 0 4.992432423023274e-07
inhibited O 0 3.1662910515706244e-08
binding O 0 4.6921728724669265e-09
of O 0 2.427052170350663e-10
transferrin O 0 2.4327465553142247e-07
to O 0 3.4173057716913036e-09
HeLa O 0 2.032827615039423e-05
cell O 0 4.855315182794584e-06
TfR O 0 8.904290552891325e-06
in O 0 5.123537150097945e-10
a O 0 3.3082456774025104e-09
concentration O 0 1.262806790691684e-06
- O 0 1.053739742928883e-05
dependent O 0 1.3098231192998355e-06
manner O 0 2.4907208171498496e-06
. O 0 9.045627535897438e-08

Scatchard O 0 8.842416718835011e-05
plots O 0 2.8990149075980298e-05
of O 0 2.297589674071787e-09
these O 0 4.636540873459438e-10
data O 0 1.0904884994999975e-08
indicate O 0 8.170263576801062e-09
that O 0 2.927388331741554e-10
the O 0 1.3606740734140033e-10
added O 0 2.245917585241841e-08
heterodimer O 0 1.1176718217598136e-08
substantially O 0 1.0235441827433078e-08
reduced O 0 8.891208880257295e-10
the O 0 6.281006270647538e-11
affinity O 0 8.910885918034239e-10
of O 0 4.5525547220925944e-10
TfR O 0 5.509781203727471e-06
for O 0 5.818445725225274e-09
transferrin O 0 1.7985499880524003e-06
. O 0 4.0513008059406275e-08

These O 0 6.751049852482538e-08
results O 0 1.345479905268121e-08
establish O 0 1.5413560205956855e-08
a O 0 4.0315040195082474e-09
molecular O 0 1.8098199916494195e-07
link O 0 3.131566336378455e-05
between O 0 3.1204388051264687e-07
HFE O 0 0.000681387260556221
and O 0 5.9148462128177925e-08
a O 0 1.0876571643336774e-08
key O 0 8.348432345428591e-08
protein O 0 2.5734131492427537e-10
involved O 0 5.257457802443355e-10
in O 0 4.492595462313176e-10
iron O 0 5.388361842051381e-06
transport O 0 7.198540856734326e-07
, O 0 6.042047417942342e-10
the O 0 6.359276993883611e-11
TfR O 0 1.827482719818363e-06
, O 0 6.635840210655886e-10
and O 0 1.5938421693562077e-09
raise O 0 2.2176009917274087e-09
the O 0 3.629888056799757e-11
possibility O 0 5.095984745295823e-10
that O 0 4.0982446602999545e-11
alterations O 0 2.8184614642157158e-09
in O 0 3.454868335861505e-11
this O 0 5.446800302455479e-11
regulatory O 0 1.7406913688233772e-09
mechanism O 0 1.1379455600035726e-08
may O 0 2.37091679622381e-09
play O 0 3.3237140817377053e-10
a O 0 5.344622522329701e-10
role O 0 1.3348787630818038e-09
in O 0 1.4315798546604697e-10
the O 0 7.482580666184901e-10
pathogenesis O 0 1.7172363868667162e-06
of O 0 5.090748800284928e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.015200152527541e-06
. O 0 2.385497452905838e-07

Genomic O 0 2.2171466298459563e-06
organization O 0 7.746364616423307e-08
of O 0 8.284499197763751e-10
the O 0 2.207056093439519e-09
UBE3A O 0 5.4365420510293916e-05
/ O 0 8.096253623079974e-06
E6 O 0 4.72891770186834e-06
- O 0 0.00013507904077414423
AP O 0 4.854611233895412e-06
gene O 0 6.997389334628679e-08
and O 0 8.38097502509072e-09
related O 0 2.161572183467797e-07
pseudogenes O 0 4.7444618758163415e-06
. O 0 2.0570354308802052e-07

The O 0 1.0138664663372765e-07
UBE3A O 0 4.360456296126358e-05
gene O 0 2.0374120879296242e-07
encodes O 0 3.648537827416476e-08
the O 0 2.128200504714073e-09
E6 O 0 5.0676949285843875e-06
- O 0 0.0003143016074318439
AP O 0 6.474302153947065e-06
ubiquitin O 0 1.3333684023564274e-07
- O 0 3.54398906665665e-07
protein O 0 1.273028904513751e-09
ligase O 0 1.2226060164266528e-08
and O 0 3.831195805048537e-09
has O 0 2.6779496398177116e-09
recently O 0 1.1055147020044842e-08
been O 0 7.432355286773884e-10
shown O 0 5.091282395675023e-10
to O 0 1.5219714377678883e-10
be O 0 1.7924538298075277e-08
mutated O 0 2.142227822332643e-05
in O 0 0.003643008414655924
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.9455903384368867e-05
who O 0 2.5877140430452528e-08
lack O 0 8.635347548135996e-09
15q11 O 0 7.894356031101779e-07
- O 0 1.5558132872683927e-05
q13 O 0 1.7875631783681456e-06
deletions O 0 1.2945434946232126e-06
or O 0 1.7774011666915612e-06
chromosome O 0 0.00016520573990419507
15 O 0 4.2705022451627883e-07
paternal O 0 0.0002420878445263952
uniparental B-Disease 0 0.02411642111837864
disomy I-Disease 0 0.0018466066103428602
. O 0 1.2759765013470314e-06

Previous O 0 7.295581667676743e-07
UBE3A O 0 1.5785541108925827e-05
cDNA O 0 1.9034993670175027e-07
analysis O 0 1.0379551440564683e-07
has O 0 1.0921413107212175e-08
shown O 0 1.7974204347126488e-09
a O 0 7.495021270287339e-10
coding O 0 9.058283012564061e-08
region O 0 9.821854440872357e-09
of O 0 1.2020762163444942e-10
approximately O 0 1.367403434926473e-08
2 O 0 2.401067256130318e-08
. O 0 5.000237379704231e-08

6 O 0 1.7074887637136271e-06
kb O 0 0.0001409067481290549
and O 0 1.0971064767772987e-07
a O 0 2.2911798680524953e-08
3 O 0 2.488530981281656e-07
- O 0 0.08044254034757614
untranslated O 0 0.004358069971203804
region O 0 2.6639847874321276e-06
( O 0 8.467173628901037e-10
UTR O 0 9.266212686043218e-09
) O 0 8.224912938226137e-12
of O 0 2.0656054991463613e-12
< O 0 7.509163069130409e-09
50 O 0 5.462451047044681e-10
bp O 0 1.4623638300292896e-08
, O 0 4.04228699124598e-11
whereas O 0 1.4217023391882577e-10
Northern O 0 4.676329323771711e-10
analysis O 0 7.363047949127122e-10
has O 0 3.869339515460979e-09
indicated O 0 2.0595500860309812e-09
mRNA O 0 3.3494741702444486e-11
sizes O 0 4.799202146799075e-10
of O 0 3.05762290486733e-11
5 O 0 1.4547321125490953e-09
- O 0 3.1849517654336523e-06
8 O 0 7.640420562893269e-08
kb O 0 1.6043439245549962e-05
. O 0 1.2904656898626854e-07

We O 0 4.37986614088004e-07
have O 0 1.4082681687455079e-09
analyzed O 0 2.7385023138037923e-09
additional O 0 9.934588568460967e-11
cDNA O 0 6.839179000905915e-09
clones O 0 4.901055490336148e-07
and O 0 2.510107233177905e-09
provide O 0 3.79957426632771e-10
evidence O 0 4.6150833155067517e-10
for O 0 7.881167940482214e-11
an O 0 6.905655908218122e-11
additional O 0 1.645295788499368e-09
0 O 0 4.701178113464266e-08
. O 0 4.999626668222845e-08

5 O 0 3.0871626677253516e-07
kb O 0 2.527891183490283e-06
of O 0 3.083529653835626e-09
5 O 0 3.38093606444545e-08
- O 0 2.8230306270415895e-05
UTR O 0 6.009080379953957e-07
and O 0 2.080689842642869e-09
> O 0 4.285166443906974e-09
2 O 0 1.768022284132087e-09
kb O 0 3.467112890120916e-07
of O 0 1.0513737658257583e-09
3 O 0 5.803142855143051e-08
- O 0 0.0008615234401077032
UTR O 0 4.871244163950905e-05
. O 0 6.37907504597024e-08

We O 0 2.0403281268954743e-06
have O 0 2.475196270168567e-09
established O 0 3.2426170082366923e-10
the O 0 1.5858170679394767e-11
genomic O 0 3.526166025835664e-09
organization O 0 8.250186089853173e-10
of O 0 4.0784150362460636e-11
UBE3A O 0 2.806329575832933e-06
and O 0 1.0264331606890664e-09
the O 0 3.398173409330241e-11
sequence O 0 1.0068798017570657e-09
of O 0 2.3855534214689555e-10
intron O 0 6.7499045144359116e-06
- O 0 1.2747670552926138e-05
exon O 0 1.6956169019977096e-06
borders O 0 2.5462093162786914e-06
. O 0 1.495419610364479e-07

We O 0 1.4949847582101938e-06
have O 0 1.67841616161013e-08
also O 0 1.6422295745499582e-09
mapped O 0 7.241704224725254e-06
two O 0 1.5776216999441317e-09
highly O 0 5.248903978127828e-09
homologous O 0 6.210572944809201e-09
processed O 0 5.0157879627477087e-08
pseudogenes O 0 6.10022894420581e-08
, O 0 2.0144517165476827e-09
UBE3AP1 O 0 6.85362408603396e-07
and O 0 2.669590770665309e-09
UBE3AP2 O 0 7.465180260624038e-07
, O 0 2.317606107027359e-10
to O 0 3.981318053014604e-11
chromosomes O 0 9.777215703721254e-10
2 O 0 1.8931929357535182e-09
and O 0 4.4855703151824855e-08
21 O 0 1.0298635721994742e-08
, O 0 3.0587676835835964e-10
respectively O 0 2.138409671559316e-09
, O 0 7.773205967787078e-10
and O 0 1.9334587264552283e-09
determined O 0 2.2647718367352354e-08
their O 0 1.9919615956709436e-10
genomic O 0 3.075713195244134e-08
organization O 0 1.0818536289036729e-08
. O 0 1.266502547281334e-08

These O 0 6.478654057673339e-08
results O 0 3.5383621366236184e-08
will O 0 3.6592544550018147e-09
form O 0 1.5618335791334204e-10
the O 0 3.7388037110730465e-11
basis O 0 2.3802324555788346e-09
for O 0 6.145439018778731e-11
studies O 0 1.120428333445389e-10
of O 0 1.2303801207036447e-11
mutation O 0 2.603058435468597e-09
and O 0 6.148161979524502e-10
imprinting O 0 2.4144915755641705e-07
of O 0 4.571159895050414e-09
UBE3A O 0 0.00017774327716324478
. O 0 1.7106232519381592e-07

Mutation O 0 4.037380222143838e-06
spectrum O 0 2.1012976958445506e-06
and O 0 4.3006849637095e-08
genotype O 0 1.1951344276894815e-05
- O 0 2.7337180654285476e-05
phenotype O 0 2.315626261406578e-06
analyses O 0 5.033440970692027e-07
in O 0 9.677441070721216e-09
Cowden B-Disease 1 0.9898035526275635
disease I-Disease 0 0.002586026443168521
and O 0 4.892514198218123e-07
Bannayan B-Disease 1 0.9978920817375183
- I-Disease 1 0.999998927116394
Zonana I-Disease 1 0.999998927116394
syndrome I-Disease 1 0.9999994039535522
, O 0 4.691593602501598e-08
two O 0 8.843168330940898e-08
hamartoma B-Disease 1 0.979089617729187
syndromes I-Disease 0 0.038265883922576904
with O 0 5.232133659660576e-08
germline O 0 0.00012611412967089564
PTEN O 0 0.0011853520991280675
mutation O 0 8.551057362637948e-06
. O 0 3.6834472894042847e-07

The O 0 6.285485483203956e-07
tumour B-Disease 1 0.9999862909317017
suppressor O 0 3.2716929126763716e-05
gene O 0 2.0091861188120674e-06
PTEN O 0 3.3678847103146836e-05
, O 0 1.9115202753994254e-09
which O 0 6.453205192435973e-10
maps O 0 8.001623541531444e-07
to O 0 1.8220877251451384e-08
10q23 O 0 3.10224891109101e-06
. O 0 5.7749208082213954e-08

3 O 0 4.489987475153612e-07
and O 0 8.176219701283571e-09
encodes O 0 1.708333563499309e-08
a O 0 1.4162089279068368e-09
403 O 0 5.257670743219478e-09
amino O 0 1.0655905047229908e-09
acid O 0 2.6211474657422684e-10
dual O 0 1.268827931610872e-09
specificity O 0 1.829072715509028e-08
phosphatase O 0 0.00013871585542801768
( O 0 1.5187416879669513e-09
protein O 0 3.529018854919741e-09
tyrosine O 0 2.9172245064046365e-08
phosphatase O 0 3.949885012843879e-06
; O 0 3.886986565948547e-10
PTPase O 0 7.733521556474443e-08
) O 0 1.5705595157733399e-10
, O 0 1.1536354510566227e-10
was O 0 2.8004953023241796e-08
shown O 0 9.29300991714399e-09
recently O 0 6.329940305249693e-08
to O 0 1.5525527530257932e-09
play O 0 6.422828935370717e-09
a O 0 3.735956433104093e-09
broad O 0 1.782961618346235e-07
role O 0 7.357239262262283e-09
in O 0 1.8972523552207576e-09
human O 0 1.3437235679703008e-07
malignancy B-Disease 0 1.1999412890872918e-05
. O 0 3.158823247417786e-08

Somatic O 0 5.2021572628291324e-05
PTEN O 0 9.774187492439523e-05
deletions O 0 1.8966366042150185e-06
and O 0 4.848245183097788e-08
mutations O 0 4.104994744125179e-08
were O 0 4.6289794219944724e-09
observed O 0 3.34976029137124e-08
in O 0 3.2600946386907026e-09
sporadic B-Disease 0 0.008240882307291031
breast I-Disease 0 0.39072659611701965
, I-Disease 0 9.291849778492178e-07
brain I-Disease 0 0.0005956857348792255
, I-Disease 0 7.99405768248107e-07
prostate I-Disease 1 0.9299212694168091
and I-Disease 0 0.10223644971847534
kidney I-Disease 1 0.9887692928314209
cancer I-Disease 0 8.817652997095138e-05
cell O 0 0.00026085058925673366
lines O 0 0.012159226462244987
and O 0 6.443974598369095e-07
in O 0 1.7188471757023649e-09
several O 0 4.5945331983432425e-09
primary O 0 2.1646452296408825e-05
tumours B-Disease 1 0.9999939203262329
such O 0 4.3313328035310406e-08
as O 0 1.0292831575497985e-05
endometrial B-Disease 1 0.9988430738449097
carcinomas I-Disease 1 1.0
, O 1 0.9832395911216736
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9993758797645569
thyroid B-Disease 1 0.9999982118606567
tumours I-Disease 1 0.9999991655349731
. O 0 6.071955795050599e-06

In O 0 1.6999832652686564e-08
addition O 0 8.98021390582926e-09
, O 0 1.77869041717571e-09
PTEN O 0 1.6638725810480537e-06
was O 0 6.67345432248112e-07
identified O 0 4.909560402666102e-07
as O 0 4.675776432705447e-10
the O 0 3.9984404676118857e-11
susceptibility O 0 4.175257473093552e-08
gene O 0 2.4504098306010746e-08
for O 0 3.750235233468402e-09
two O 0 1.0580106390989386e-06
hamartoma B-Disease 1 0.9997735619544983
syndromes I-Disease 1 0.9998425245285034
Cowden B-Disease 1 0.9998216032981873
disease I-Disease 0 0.47225385904312134
( O 0 2.152030775803837e-09
CD B-Disease 0 1.2918098946101964e-05
; O 0 1.6936528624000857e-08
MIM O 0 1.5212003745546099e-05
158350 O 0 1.2710538044302666e-07
) O 0 5.104379696696526e-10
and O 0 3.205183674026557e-09
Bannayan B-Disease 0 1.2348898053460289e-05
- I-Disease 0 0.00045860264799557626
Zonana I-Disease 0 0.00010815955465659499
( I-Disease 0 1.4188504815493275e-09
BZS I-Disease 0 1.8681087965433107e-07
) I-Disease 0 1.790446124694256e-10
or I-Disease 0 1.1103956643054858e-09
Ruvalcaba I-Disease 0 9.664197477832204e-07
- I-Disease 0 5.519552360055968e-06
Riley I-Disease 0 5.924425295233959e-06
- I-Disease 1 0.9902922511100769
Smith I-Disease 1 0.7664853930473328
syndrome I-Disease 1 0.9993398785591125
( O 0 7.855378569843197e-09
MIM O 0 6.858141568955034e-05
153480 O 0 1.343709982393193e-06
) O 0 9.979761017575584e-09
. O 0 1.1556847923088753e-08

Constitutive O 0 2.5253998501284514e-06
DNA O 0 6.346871259665932e-07
from O 0 2.5606399223221388e-09
37 O 0 8.90604745507062e-09
CD B-Disease 0 1.9537806110747624e-06
families O 0 3.040941365384242e-08
and O 0 7.519797229349479e-09
seven O 0 5.224831234329486e-09
BZS B-Disease 0 1.7917413970280904e-06
families O 0 5.222639209989666e-09
was O 0 2.1663471017063785e-08
screened O 0 1.5276798137620062e-07
for O 0 3.5785949759059577e-09
germline O 0 6.71547695674235e-06
PTEN O 0 3.248261418775655e-05
mutations O 0 1.3688121498489636e-06
. O 0 1.2563043583213584e-07

PTEN O 0 0.00018012621148955077
mutations O 0 1.2623949032786186e-06
were O 0 4.6931237562830574e-08
identified O 0 8.181901023363025e-08
in O 0 2.4329060988037554e-10
30 O 0 4.1334791145430927e-10
of O 0 3.004201748479929e-11
37 O 0 1.2322249887120051e-09
( O 0 3.184492253227589e-11
81 O 0 2.4218047567359235e-09
% O 0 4.4601149162826204e-11
) O 0 5.42202775732914e-11
CD B-Disease 0 1.1815124025815749e-06
families O 0 9.891979679821361e-09
, O 0 2.381416730479202e-10
including O 0 7.560911896575817e-10
missense O 0 1.7815148112276802e-06
and O 0 5.6432433837017015e-08
nonsense O 0 9.435067113372497e-06
point O 0 1.196402905634386e-07
mutations O 0 1.2712411567861182e-08
, O 0 1.0928173643787176e-10
deletions O 0 2.037591206871525e-09
, O 0 3.9427869302777196e-10
insertions O 0 3.5505649975675624e-08
, O 0 1.2949616934321284e-09
a O 0 2.8495912296477854e-09
deletion O 0 4.1489025193186535e-07
/ O 0 1.870463165687397e-05
insertion O 0 3.861062793930614e-07
and O 0 1.2883948841135862e-07
splice O 0 0.00019917059398721904
site O 0 0.00014864133845549077
mutations O 0 2.966460897368961e-06
. O 0 2.394359057689144e-07

These O 0 6.866643076364198e-08
mutations O 0 1.3076410709800257e-07
were O 0 3.9803293105933335e-08
scattered O 0 5.432676744021592e-07
over O 0 1.3628850581426377e-07
the O 0 1.5719298085414835e-09
entire O 0 5.1034795944815414e-08
length O 0 1.0278465367719036e-07
of O 0 4.636664385770928e-10
PTEN O 0 2.08621804631548e-06
, O 0 1.6660306467741748e-09
with O 0 2.612413063651786e-10
the O 0 1.716271430529659e-10
exception O 0 1.4549069726754738e-09
of O 0 2.8015969752437364e-11
the O 0 4.2068207251055867e-10
first O 0 9.624610441960613e-09
, O 0 4.737288339384804e-09
fourth O 0 9.12979842837558e-08
and O 0 2.096482099034347e-08
last O 0 3.43478774311734e-08
exons O 0 7.556635637229192e-07
. O 0 6.582597933402212e-08

A O 0 9.550467439112253e-07
hot O 0 5.922595391893992e-06
spot O 0 9.29085672396468e-07
for O 0 1.3399781284562096e-09
PTEN O 0 2.494816726539284e-06
mutation O 0 4.049993229671145e-09
in O 0 8.248215305206585e-11
CD B-Disease 0 3.288127800260554e-06
was O 0 6.204126748343697e-06
identified O 0 2.42771506009376e-07
in O 0 1.169429275638123e-10
exon O 0 4.961890009980152e-09
5 O 0 1.0885531365190104e-09
that O 0 2.4870022707901285e-10
contains O 0 2.171078206103516e-09
the O 0 2.071905147449371e-10
PTPase O 0 2.0572041137256747e-07
core O 0 1.207360469379637e-07
motif O 0 7.861193473956973e-09
, O 0 1.0243302039913971e-10
with O 0 1.0686670298687417e-11
13 O 0 2.7082268719280655e-11
of O 0 4.2565755607737454e-12
30 O 0 1.7272495933529086e-10
( O 0 1.9148535188029392e-11
43 O 0 3.1373842412918407e-10
% O 0 4.850568557923651e-11
) O 0 8.460260270126696e-11
CD B-Disease 0 2.9887698360653303e-07
mutations O 0 7.3922077348242965e-09
identified O 0 9.060888928047461e-09
in O 0 1.2384850089919297e-10
this O 0 1.1885118444965315e-09
exon O 0 2.9026617198724125e-07
. O 0 1.7287584341829643e-07

Seven O 0 1.0574683528830064e-07
of O 0 3.5322222924349944e-10
30 O 0 1.919364001068402e-09
( O 0 6.420311504662379e-11
23 O 0 4.3837561358728294e-10
% O 0 3.297544876046388e-11
) O 0 3.9012081759493e-11
were O 0 2.4638602269533294e-08
within O 0 2.377771868289358e-10
the O 0 8.73546304736017e-11
core O 0 9.85050292001688e-07
motif O 0 2.675321653100582e-08
, O 0 2.503221241401121e-10
the O 0 6.170763205970431e-11
majority O 0 2.6113519679960007e-10
( O 0 3.9662197137690924e-11
five O 0 1.414224293228017e-10
of O 0 3.3635712270996265e-11
seven O 0 3.642825208149958e-10
) O 0 2.0735092462476068e-11
of O 0 2.029722744045781e-11
which O 0 1.3340954119200887e-08
were O 0 6.38949870790384e-08
missense O 0 3.6366509448271245e-07
mutations O 0 1.1172710756568449e-08
, O 0 4.882995119359634e-10
possibly O 0 3.4371123724952213e-09
pointing O 0 1.4147942692943616e-06
to O 0 2.1478645528816287e-09
the O 0 3.007752380490558e-10
functional O 0 1.0572986930412753e-08
significance O 0 1.6262982072134946e-09
of O 0 8.155309760837781e-11
this O 0 1.1526133381067893e-09
region O 0 1.5356171445546352e-07
. O 0 3.0259442951319215e-08

Germline O 0 0.0004694176896009594
PTEN O 0 0.00031641998793929815
mutations O 0 2.507475301172235e-06
were O 0 2.1872692457236553e-07
identified O 0 6.205247018442606e-07
in O 0 1.3001169030246729e-09
four O 0 5.95794635849245e-10
of O 0 8.692664643650261e-11
seven O 0 1.3049663571962355e-09
( O 0 1.690620421435085e-10
57 O 0 7.378065269847411e-09
% O 0 2.2609025762676538e-10
) O 0 5.084538345911938e-10
BZS B-Disease 0 8.344840694007871e-07
families O 0 3.1883913287344967e-09
studied O 0 1.3578858037988084e-08
. O 0 2.196319393021895e-08

Interestingly O 0 2.8678591661446262e-06
, O 0 1.950635741820861e-08
none O 0 2.6386048901372305e-09
of O 0 1.9092298922385176e-11
these O 0 8.745298929468959e-11
mutations O 0 5.35404254264904e-09
was O 0 9.030767955664487e-08
observed O 0 3.459614816847534e-08
in O 0 2.828908496343985e-10
the O 0 6.489295767408976e-10
PTPase O 0 3.7879681258345954e-06
core O 0 8.186910349650134e-07
motif O 0 5.544689543057757e-07
. O 0 2.938411469699531e-08

It O 0 1.5142741460749676e-07
is O 0 9.702798564603654e-09
also O 0 7.719145878049005e-10
worthy O 0 2.1681691997343933e-09
of O 0 4.8494770699125667e-11
note O 0 1.3406119592218602e-07
that O 0 5.407406744595278e-10
a O 0 1.192776766245629e-09
single O 0 2.187527883279472e-07
nonsense O 0 1.2859466551162768e-05
point O 0 3.774779955278973e-08
mutation O 0 2.236644203179594e-09
, O 0 1.5279544296475933e-10
R233X O 0 1.1957546064422786e-08
, O 0 3.3828487233655835e-10
was O 0 1.044534325700397e-08
observed O 0 2.6713799172739527e-08
in O 0 1.8484370978288922e-10
the O 0 2.3009173732990718e-10
germline O 0 2.180345859414956e-08
DNA O 0 8.897981906841324e-09
from O 0 1.177554026510208e-10
two O 0 1.395103199630654e-10
unrelated O 0 7.289202130777994e-09
CD B-Disease 0 8.85229655978037e-06
families O 0 6.794143558863652e-08
and O 0 9.653400745435192e-09
one O 0 2.1933388438810653e-08
BZS B-Disease 0 1.4049458513909485e-05
family O 0 2.5836533268375206e-07
. O 0 4.647151996550747e-08

Genotype O 0 0.0007832875708118081
- O 0 0.00026211736258119345
phenotype O 0 1.524877802694391e-06
studies O 0 1.0889046997419882e-08
were O 0 2.9218128361208073e-08
not O 0 8.317764810250594e-10
performed O 0 8.895895575733448e-09
on O 0 2.6512927409072518e-09
this O 0 7.26214782753587e-11
small O 0 2.3085411360312946e-09
group O 0 2.690651701442448e-09
of O 0 6.010587583205051e-10
BZS B-Disease 0 4.036663995066192e-06
families O 0 8.599515766150034e-09
. O 0 2.409292676475161e-08

However O 0 1.3260374487344961e-07
, O 0 2.737484017245606e-09
genotype O 0 9.703965133667225e-07
- O 0 8.746812454774044e-06
phenotype O 0 3.213749835140334e-07
analysis O 0 4.9975938942736775e-09
inthe O 0 1.8949268110191042e-07
group O 0 1.9753617408468926e-08
of O 0 1.2514309033484494e-10
CD B-Disease 0 1.2539893759822007e-05
families O 0 4.894291905088721e-08
revealed O 0 4.3174105712751043e-07
two O 0 3.422555017174034e-10
possible O 0 1.0576333586698183e-08
associations O 0 3.0253008431735395e-10
worthy O 0 8.647820237683845e-10
of O 0 6.209843750326627e-11
follow O 0 6.606015290344658e-09
- O 0 5.4027077567297965e-06
up O 0 1.4335341802507173e-07
in O 0 7.104553612080622e-10
independent O 0 1.683170403055101e-08
analyses O 0 3.2961168017209275e-07
. O 0 4.7915420964272926e-08

The O 0 5.582829842865067e-08
first O 0 4.4191541093141495e-08
was O 0 1.385654559271643e-05
an O 0 2.7456152906779607e-09
association O 0 1.0573283359960328e-09
noted O 0 2.054764181025348e-08
in O 0 1.6087091381233876e-10
the O 0 2.2030005597528657e-10
group O 0 6.2792997468363865e-09
of O 0 1.3466845694143359e-11
CD B-Disease 0 2.7580421374295838e-05
families O 0 1.3431267120722623e-07
with O 0 6.314974143606378e-07
breast B-Disease 1 0.9986293315887451
disease I-Disease 0 0.010142290964722633
. O 0 2.388019311183598e-07

A O 0 1.255856290072188e-07
correlation O 0 1.6893368126602581e-07
was O 0 6.587898582210983e-08
observed O 0 1.8981836547027342e-08
between O 0 3.909977897009753e-10
the O 0 1.427312990021079e-10
presence O 0 1.4813411830516543e-08
/ O 0 7.72281907757133e-07
absence O 0 1.394332427295808e-09
of O 0 3.7515546225108665e-11
a O 0 2.690805578353661e-09
PTEN O 0 8.996998985821847e-07
mutation O 0 6.534696783688787e-09
and O 0 1.6201308072893994e-09
the O 0 1.509191382975672e-10
type O 0 3.816607204498723e-06
of O 0 1.664921978061784e-09
breast O 0 0.0003122762427665293
involvement O 0 5.759761734225322e-07
( O 0 4.920216678527822e-09
unaffected O 0 2.970146624647896e-06
versus O 0 1.3441738246910973e-06
benign O 0 0.0001886628451757133
versus O 0 4.635759523807792e-06
malignant O 0 0.002909296890720725
) O 0 2.496281581443327e-08
. O 0 4.8237374983273185e-08

Specifically O 0 4.73646878162981e-07
and O 0 1.9043522314632355e-08
more O 0 9.403158252041521e-10
directly O 0 4.8122572593456425e-09
, O 0 2.989126945962539e-09
an O 0 4.660568597714132e-10
association O 0 2.9362923203990476e-09
was O 0 3.56285499947262e-06
also O 0 4.5555996308621616e-08
observed O 0 3.183148677976533e-08
between O 0 2.481047034486039e-10
the O 0 6.922944856269098e-11
presence O 0 1.273546157420924e-09
of O 0 2.2187156625830262e-11
a O 0 7.1927610534316955e-09
PTEN O 0 0.00020341260824352503
mutation O 0 2.1798277884954587e-06
and O 0 1.8652708604349755e-05
malignant B-Disease 1 0.9999895095825195
breast I-Disease 1 0.9999189376831055
disease I-Disease 1 0.6458196640014648
. O 0 8.061437029027729e-07

Secondly O 0 0.00029604884912259877
, O 0 5.424373838991414e-08
there O 0 7.084827391423687e-09
appeared O 0 6.801560203939516e-08
to O 0 3.6290472849032085e-09
be O 0 3.227638600833416e-08
an O 0 1.4965795269716864e-09
interdependent O 0 6.7886003307648934e-06
association O 0 2.2061805715622995e-09
between O 0 6.844029787345107e-10
mutations O 0 1.2130916715591411e-08
upstream O 0 2.945425592315587e-08
and O 0 5.501527677864715e-09
within O 0 1.950585526433457e-10
the O 0 3.8162284443643557e-10
PTPase O 0 6.439728963414382e-07
core O 0 4.3124066451127874e-07
motif O 0 1.9525143102328002e-07
, O 0 5.631742849843135e-10
the O 0 1.208335653757331e-10
core O 0 3.9096056525522727e-07
motif O 0 5.2786241155899916e-08
containing O 0 8.230025549949005e-09
the O 0 5.084780374531306e-10
majority O 0 4.831107736080753e-10
of O 0 1.0528341393145624e-10
missense O 0 2.3067843812896172e-07
mutations O 0 3.069922627219057e-08
, O 0 6.566281740560953e-09
and O 0 1.0567905661673649e-08
the O 0 3.6493066901677196e-10
involvement O 0 1.3454054759165501e-08
of O 0 9.269508771669877e-11
all O 0 7.459936002263134e-10
major O 0 2.6628896421243553e-08
organ O 0 5.38397534910473e-06
systems O 0 2.0266852516215295e-06
( O 0 6.264164742475486e-10
central O 0 2.1129775262807016e-08
nervous O 0 4.4144871935714036e-07
system O 0 2.5727536012709606e-07
, O 0 4.854704016565847e-08
thyroid O 0 0.0015501242596656084
, O 0 5.814910153389974e-08
breast O 0 0.007770750671625137
, O 0 2.0310230866016354e-06
skin O 1 0.999451220035553
and O 0 0.23324856162071228
gastrointestinal O 1 0.9988480806350708
tract O 1 0.9992371797561646
) O 0 1.1465947409305954e-06
. O 0 7.015797791609657e-07

However O 0 1.4863029207390355e-07
, O 0 3.898569245208705e-10
these O 0 6.678624667189048e-12
observations O 0 5.742501474337303e-10
would O 0 2.8273292596026067e-09
need O 0 4.3543313399396766e-10
to O 0 3.4945216165205295e-10
be O 0 3.3831732970668327e-09
confirmed O 0 3.4702665185903925e-09
by O 0 4.919533530545195e-12
studying O 0 4.084993454611663e-11
a O 0 8.867037659676669e-11
larger O 0 3.7053257684327434e-10
number O 0 2.578960378585293e-10
of O 0 1.182419856471384e-10
CD B-Disease 0 1.7590440620551817e-05
families O 0 8.317502420140954e-08
. O 0 3.7269622055191576e-08

Molecular O 0 0.003909370396286249
defects O 1 0.9972361922264099
leading O 0 5.382427161748637e-07
to O 0 1.5542543252422547e-08
human O 0 2.3819373495825857e-07
complement B-Disease 0 8.812602027319372e-05
component I-Disease 1 0.9997021555900574
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.577930479143788e-09
an O 0 6.650462403001711e-10
African O 0 3.6562686211993878e-09
- O 0 5.789925580756972e-06
American O 0 3.138554660608861e-08
family O 0 5.143124326423276e-07
. O 0 3.7364642935244774e-08

Complement B-Disease 0 0.0016855875728651881
component I-Disease 1 0.9989956021308899
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.105921102061984e-08
C6D B-Disease 0 9.701404633233324e-05
) O 0 1.0086351309723796e-08
was O 0 1.1112967513327021e-05
diagnosed O 0 1.5587242160108872e-05
in O 0 5.079129339335964e-10
a O 0 2.5779501200418053e-08
16 O 0 1.0810306427799787e-08
- O 0 1.4286551959230565e-06
year O 0 1.5475011494459068e-08
- O 0 4.933374839311e-06
old O 0 2.9741602247668197e-06
African O 0 4.65587968179193e-09
- O 0 4.55418785350048e-07
American O 0 1.5949559895034326e-08
male O 0 6.262796432565665e-07
with O 0 9.379661491948355e-07
meningococcal B-Disease 1 0.9999992847442627
meningitis I-Disease 1 0.9999969005584717
. O 0 5.450107778415259e-07

The O 0 2.603800624001451e-07
patients O 0 1.0417617204439011e-06
father O 0 1.0076968237626716e-06
and O 0 5.970339600480656e-08
two O 0 9.606930362338062e-09
brothers O 0 1.5754261767142452e-05
also O 0 2.4183009372791275e-07
had O 0 4.2238539776917605e-07
C6D B-Disease 0 9.601841156836599e-06
, O 0 8.751877556001375e-10
but O 0 5.287768556350159e-10
gave O 0 1.3711688451323312e-09
no O 0 4.170018552684951e-09
history O 0 2.1767170288455873e-09
of O 0 9.900152697639442e-09
meningitis B-Disease 1 0.9999961853027344
or O 0 6.112947659175916e-08
other O 0 1.1904000452034325e-08
neisserial B-Disease 0 0.0016580848023295403
infection I-Disease 0 0.0002256558946100995
. O 0 8.953792729471388e-08

By O 0 7.962799308813828e-09
using O 0 8.242578175554627e-09
exon O 0 2.546857160723448e-07
- O 0 4.962229240845772e-07
specific O 0 6.952288522654726e-09
polymerase O 0 2.652933801527979e-07
chain O 0 1.22759695386776e-06
reaction O 0 7.711802862964134e-10
( O 0 1.8651129252145182e-11
PCR O 0 4.4942516375101604e-09
) O 0 4.055275906744704e-11
/ O 0 9.63024771039045e-09
single O 0 6.143265451896696e-09
- O 0 2.666460545697191e-07
strand O 0 5.1076380458425774e-08
conformation O 0 8.924089023309989e-09
polymorphism O 0 1.3976507950985706e-08
as O 0 7.896063664025732e-11
a O 0 2.940245963367616e-11
screening O 0 4.991465574200049e-10
step O 0 2.3514432623272796e-09
and O 0 1.664351816088594e-11
nucleotide O 0 8.422632036264588e-11
sequencing O 0 1.3740662774264223e-10
of O 0 2.772588235389062e-11
target O 0 1.4010671733899471e-08
exons O 0 1.324505727318126e-09
, O 0 1.269359756195243e-10
we O 0 4.381373597261984e-10
determined O 0 1.0851058940275493e-09
that O 0 6.78879660820364e-11
the O 0 6.380793809990237e-11
proband O 0 3.1179399684333475e-07
was O 0 4.168652978364662e-08
a O 0 5.147702264451937e-10
compound O 0 1.3829758671590753e-08
heterozygote O 0 6.676940778049811e-09
for O 0 2.4175392243641625e-10
two O 0 1.404504623714331e-09
C6 O 0 6.8023582571186125e-06
gene O 0 1.6618173503957223e-07
mutations O 0 4.446357593224093e-07
. O 0 6.577540290209072e-08

The O 0 6.1884959379199245e-09
first O 0 8.624347347385708e-10
, O 0 1.4702659922871675e-10
1195delC O 0 9.960364977246172e-09
located O 0 3.163315298593261e-08
in O 0 6.219409709462553e-11
exon O 0 6.020538290130162e-09
7 O 0 6.051971723763927e-08
, O 0 6.103811678315196e-09
is O 0 7.394294954110592e-09
a O 0 6.8124339502873e-10
novel O 0 4.318956747795255e-09
mutation O 0 2.7864277551969963e-09
, O 0 5.827672233671422e-10
while O 0 1.361149748468904e-09
the O 0 9.841009257494093e-11
second O 0 4.074228510120292e-09
, O 0 3.928711522771522e-10
1936delG O 0 5.342484676873482e-09
in O 0 5.839041056221461e-11
exon O 0 1.4579905061040677e-09
12 O 0 7.052321837619502e-09
, O 0 4.105900952566799e-09
has O 0 3.5301518153119105e-08
been O 0 1.1048653547618414e-08
described O 0 6.532617646826111e-08
before O 0 1.0210906564722677e-09
to O 0 2.524154885108487e-09
cause O 0 5.31479926735301e-09
C6D B-Disease 0 1.0527899121370865e-06
in O 0 3.425219552433134e-10
an O 0 2.212141719803995e-10
unrelated O 0 1.916219183328849e-08
African O 0 3.3017022449399747e-09
- O 0 3.844451384793501e-06
American O 0 1.0215684298486849e-08
individual O 0 1.4697572048305574e-08
. O 0 4.437287870473483e-08

Both O 0 1.7360592607928993e-07
mutations O 0 5.527109010472486e-07
result O 0 8.725247191421204e-09
in O 0 2.8506077498491322e-09
premature O 0 8.236073654188658e-07
termination O 0 1.7563343135407194e-07
codons O 0 2.2396555721115874e-07
and O 0 2.4975246759595393e-08
C6 O 0 4.2447474697837606e-05
null O 0 6.141104677226394e-06
alleles O 0 2.784634034469491e-07
. O 0 6.300597021891008e-08

Allele O 0 7.836785698600579e-06
- O 0 1.6339934063580586e-06
specific O 0 2.0165826342122273e-08
PCR O 0 3.7000614838689216e-07
indicated O 0 1.6435582494978007e-07
that O 0 1.8743326335446397e-10
the O 0 1.0941814121423477e-10
probands O 0 1.609737864782801e-06
two O 0 8.90453577540029e-09
brothers O 0 4.588227966451086e-05
also O 0 1.8618250408053427e-07
inherited O 0 9.847103683569003e-07
the O 0 5.760052990133602e-10
1195delC O 0 3.722607573308778e-07
mutation O 0 5.337168484942367e-09
from O 0 2.0726641236645804e-10
their O 0 1.001896898777943e-09
heterozygous O 0 3.7256759810588846e-07
mother O 0 2.518770770620904e-06
and O 0 7.666210777301785e-09
the O 0 5.931538038517203e-10
1936delG O 0 2.7612861686066026e-07
mutation O 0 4.471661263494298e-09
from O 0 3.3722966086280337e-10
their O 0 1.708309937953345e-09
homozygous O 0 3.5328534409018175e-07
father O 0 1.4871140763261792e-07
. O 0 9.656194732698964e-10
. O 0 2.688806333139837e-08

PAX6 O 0 0.012975454330444336
mutations O 0 0.00010270000348100439
reviewed O 0 2.089025110763032e-05
. O 0 1.0507085335120792e-06

Mutations O 0 2.753742410277482e-05
in O 0 1.5297406008585313e-08
PAX6 O 0 4.385205465951003e-05
are O 0 7.990077932618078e-09
responsible O 0 1.0381055659536287e-07
for O 0 6.28719787343357e-09
human O 0 8.225445640164253e-07
aniridia B-Disease 1 0.9999998807907104
and O 0 1.2016842447337694e-05
have O 0 2.2412879729927226e-07
also O 0 2.2414242906165782e-08
been O 0 2.045754321500226e-08
found O 0 2.8423172704350463e-09
in O 0 1.7754729630947708e-10
patients O 0 3.005030002611875e-09
with O 0 2.0034022440995614e-08
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999997615814209
, O 0 3.782059366130852e-06
with O 0 0.00010405058128526434
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999704360961914
, O 0 2.6722443635662785e-06
with O 0 7.255000014083635e-07
autosomal B-Disease 1 0.6930643916130066
dominant I-Disease 0 0.031093018129467964
keratitis I-Disease 1 0.8634421229362488
, O 0 6.066915716473886e-07
and O 0 2.3022724349175405e-07
with O 0 1.26125166843849e-06
isolated B-Disease 1 0.9987437129020691
foveal I-Disease 1 0.9999995231628418
hypoplasia I-Disease 1 0.9999994039535522
. O 0 5.3520407163887285e-06

No O 0 4.799582029590965e-07
locus O 0 2.634958207181626e-07
other O 0 4.4391228470885835e-09
than O 0 5.009303638559004e-09
chromosome O 0 3.69100757779961e-06
11p13 O 0 4.264680228516227e-06
has O 0 5.471590611705324e-07
been O 0 6.069149094400927e-08
implicated O 0 3.063193787511409e-07
in O 0 9.170529224888924e-09
aniridia B-Disease 1 0.9999997615814209
, O 0 5.829301485960059e-08
and O 0 1.505010516211769e-08
PAX6 O 0 8.755183444009162e-06
is O 0 2.8445642286101247e-08
clearly O 0 1.0176789189131341e-08
the O 0 2.153445304020618e-11
major O 0 1.0447449572126288e-09
, O 0 3.2048577680576784e-10
if O 0 4.3751607892161815e-10
not O 0 4.656961483107125e-10
only O 0 1.3258397157933643e-10
, O 0 1.367999463708358e-10
gene O 0 6.951758280138165e-09
responsible O 0 2.726532670749293e-07
. O 0 4.590331315057483e-08

Twenty O 0 2.980727686008322e-06
- O 0 1.6208654415095225e-05
eight O 0 3.4942985394081916e-08
percent O 0 3.922029634395585e-08
of O 0 1.0177245157727555e-10
identified O 0 2.821688553922286e-07
PAX6 O 0 4.6568334255425725e-06
mutations O 0 5.421643223257888e-08
are O 0 5.161823413146749e-09
C O 0 1.550065826450009e-05
- O 0 9.74293943727389e-05
T O 0 1.2461425285437144e-05
changes O 0 9.89346604640673e-10
at O 0 4.211053283853516e-09
CpG O 0 1.776913620687992e-07
dinucleotides O 0 7.946144364723295e-08
, O 0 1.6755742626717307e-10
20 O 0 3.833692044374892e-11
% O 0 3.228463069798737e-12
are O 0 1.0234664678254735e-11
splicing O 0 9.54766710137278e-10
errors O 0 5.0290839936906195e-08
, O 0 7.233743049006591e-10
and O 0 4.520608609670518e-10
more O 0 4.763377886574105e-11
than O 0 2.8946078867164715e-10
30 O 0 1.8552753777711928e-10
% O 0 3.6456941632234674e-11
are O 0 1.2578826869003024e-10
deletion O 0 7.487281017404257e-09
or O 0 3.662934622283842e-09
insertion O 0 2.8645786187553313e-08
events O 0 1.7193799806136667e-07
. O 0 1.6086133314274775e-07

There O 0 2.6375903416919755e-07
is O 0 1.1073401751104939e-08
a O 0 4.231810457611118e-09
noticeably O 0 1.1501409744596458e-06
elevated O 0 1.5004180795585853e-06
level O 0 1.2934838089506684e-08
of O 0 6.768188093309035e-11
mutation O 0 3.2361251456336504e-09
in O 0 1.1903557306514045e-10
the O 0 9.212648005574309e-11
paired O 0 2.3317472397366146e-09
domain O 0 5.262456692634032e-09
compared O 0 2.8230628501546562e-08
with O 0 9.642575626855887e-10
the O 0 3.6677638703963567e-10
rest O 0 1.2487944012207208e-09
of O 0 3.076025545389882e-11
the O 0 2.423541090035286e-10
gene O 0 3.599214437599585e-08
. O 0 2.1031826946682486e-08

Increased O 0 3.949742506392795e-07
mutation O 0 1.0821368334745785e-07
in O 0 2.684806266195494e-10
the O 0 3.073897802963188e-10
homeodomain O 0 1.3516795149826066e-07
is O 0 2.0971611114362076e-09
accounted O 0 9.967514813524758e-08
for O 0 2.6358418225846947e-10
by O 0 6.819948494829475e-10
the O 0 1.4555064931087713e-09
hypermutable O 0 6.716073130519362e-06
CpG O 0 9.25437780097127e-06
dinucleotide O 0 1.6479701514526823e-07
in O 0 6.368954252877757e-10
codon O 0 2.296772407817116e-07
240 O 0 7.745182983853738e-08
. O 0 2.445936253536729e-08

Very O 0 6.709068429699983e-07
nearly O 0 1.8767241982686755e-08
all O 0 3.3912081476294986e-10
mutations O 0 6.763730464598439e-09
appear O 0 1.1717546044565097e-08
to O 0 1.6344307240956368e-08
cause O 0 3.2533262128708884e-07
loss O 0 5.881378584149388e-08
of O 0 1.0017225243741379e-10
function O 0 1.702647445256389e-08
of O 0 8.213207197682593e-11
the O 0 7.140128766014442e-11
mutant O 0 8.241226367999843e-09
allele O 0 3.819951466255134e-09
, O 0 8.395306116959489e-10
and O 0 7.144028146832682e-10
more O 0 3.9945529523022216e-11
than O 0 3.3637523322305185e-10
80 O 0 4.890591820405632e-10
% O 0 4.042140580584608e-11
of O 0 3.730611999874789e-11
exonic O 0 3.125877583443071e-07
substitutions O 0 1.562371565455578e-08
result O 0 3.9669654228191575e-09
in O 0 1.6661513280169515e-09
nonsense O 0 4.510881808528211e-06
codons O 0 6.897739694977645e-07
. O 0 3.361011025049265e-08

In O 0 1.5807188447070075e-08
a O 0 1.667861959653294e-09
gene O 0 9.426543989832226e-09
with O 0 3.951271532187661e-10
such O 0 1.682986638940065e-09
extraordinarily O 0 3.378498149686493e-06
high O 0 1.0014946383307688e-07
sequence O 0 8.626782621590223e-10
conservation O 0 3.507369117361492e-10
throughout O 0 1.5446794884854675e-11
evolution O 0 1.6155476956214443e-10
, O 0 2.200711834987601e-10
there O 0 3.3561922130331823e-09
are O 0 7.372748189737877e-09
presumed O 0 2.4035498427110724e-06
undiscovered O 0 9.253724783775397e-06
missense O 0 7.42044960588828e-07
mutations O 0 4.2322568560848595e-08
, O 0 6.158971666003765e-10
these O 0 6.558539822343334e-11
are O 0 1.6216417098036118e-10
hypothesized O 0 1.1632320662258167e-09
to O 0 7.495593035145021e-10
exist O 0 1.2491499390421268e-08
in O 0 3.7125980067997943e-10
as O 0 6.668133600840065e-09
- O 0 2.1176805603317916e-05
yet O 0 3.9395555972987495e-07
unidentified O 0 4.595158316078596e-07
phenotypes O 0 4.070634318509292e-08
. O 0 1.2835811302736033e-09
. O 0 1.2743388566605063e-08

Genetic O 0 4.8083198635140434e-05
heterogeneity O 0 5.551967205974506e-06
and O 0 1.01232444649213e-07
penetrance O 0 3.2426319194200914e-06
analysis O 0 2.112816410715368e-08
of O 0 5.469686370496163e-10
the O 0 6.180592926341433e-09
BRCA1 O 0 3.410580393392593e-05
and O 0 2.586846221674932e-07
BRCA2 O 0 7.20613661542302e-06
genes O 0 2.93973556608762e-07
in O 0 4.0921864297160937e-07
breast B-Disease 1 0.9838009476661682
cancer I-Disease 0 0.0015546829672530293
families O 0 3.837583051335969e-07
. O 0 3.1379502729578235e-07

The O 0 0.0001328392536379397
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999923706054688
Linkage O 0 0.005464234855026007
Consortium O 0 2.4362612748518586e-05
. O 0 3.4781078284140676e-07

The O 0 6.966664134466782e-09
contribution O 0 1.455396247962426e-08
of O 0 9.849783211279828e-10
BRCA1 O 0 1.7322325220447965e-05
and O 0 9.09220773337438e-07
BRCA2 O 0 0.029646098613739014
to O 0 0.09628207236528397
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0014349109260365367
assessed O 0 2.8719792680931278e-05
by O 0 1.2587479503167742e-08
linkage O 0 8.886279101716354e-05
and O 0 2.2302810265273365e-08
mutation O 0 3.498858536232774e-09
analysis O 0 9.946254930781606e-10
in O 0 2.8739011170841877e-10
237 O 0 9.496418762466874e-09
families O 0 3.905284540195453e-09
, O 0 9.962539820884686e-11
each O 0 3.5512232043899417e-11
with O 0 1.1955464396251614e-09
at O 0 1.55569935600397e-07
least O 0 1.420033535204368e-09
four O 0 3.5682876098341865e-10
cases O 0 4.174618428720578e-09
of O 0 7.88353649028295e-09
breast B-Disease 0 0.3629428744316101
cancer I-Disease 0 1.876412716228515e-05
, O 0 7.406458224501478e-10
collected O 0 2.321482783784745e-09
by O 0 9.879441265070454e-09
the O 0 5.287361273076385e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999837875366211
Linkage O 0 7.203666609711945e-05
Consortium O 0 2.005969463425572e-06
. O 0 1.032893450769734e-07

Families O 0 1.7110716044044239e-06
were O 0 3.2407839967163454e-08
included O 0 3.7108018879905558e-09
without O 0 7.825479708678529e-10
regard O 0 1.2819199035618567e-09
to O 0 2.1821243423314485e-10
the O 0 7.268910473534618e-11
occurrence O 0 7.929896241876122e-07
of O 0 1.3962067058059802e-08
ovarian B-Disease 0 0.0013886892702430487
or I-Disease 0 6.648565431532916e-08
other I-Disease 0 1.516117364985803e-08
cancers I-Disease 0 8.79537474247627e-05
. O 0 1.2846159336277196e-07

Overall O 0 4.458798503037542e-05
, O 0 4.42595046479255e-06
disease O 0 0.0009313990012742579
was O 0 3.6950368667021394e-06
linked O 0 0.00018101651221513748
to O 0 3.254362113125353e-08
BRCA1 O 0 4.343200430412253e-07
in O 0 8.172363896719048e-10
an O 0 7.888732722616254e-11
estimated O 0 1.462916277006343e-08
52 O 0 1.0655342386201028e-08
% O 0 1.0980952258599075e-10
of O 0 7.781479627322341e-11
families O 0 8.439123178050068e-09
, O 0 6.065093982599024e-10
to O 0 1.0965950369978827e-09
BRCA2 O 0 3.063745523945727e-08
in O 0 4.6248291307726674e-10
32 O 0 3.1925233567875466e-09
% O 0 3.7458276064272766e-11
of O 0 1.305204833101925e-10
families O 0 2.9140879931333075e-08
, O 0 5.056917995460708e-09
and O 0 4.977132039840626e-09
to O 0 9.022169122907542e-10
neither O 0 8.538124096624244e-10
gene O 0 2.424160594483027e-10
in O 0 4.663074093524955e-11
16 O 0 8.412325697149114e-11
% O 0 2.4038084023292328e-11
( O 0 3.5677547721713054e-11
95 O 0 2.2394956999960414e-09
% O 0 5.800447899773076e-10
confidence O 0 8.132502671287511e-08
interval O 0 1.0248905368825945e-07
[ O 0 1.6305698125052004e-08
CI O 0 1.0958032135022222e-06
] O 0 2.7615867370656133e-09
6 O 0 1.2624108702841141e-10
% O 0 1.1443804931454693e-10
- O 0 8.879927690941258e-07
28 O 0 5.771724431724579e-09
% O 0 3.1632925445723714e-11
) O 0 3.78032223580238e-11
, O 0 4.122642852100178e-11
suggesting O 0 1.9760995062512166e-09
other O 0 8.54825987772756e-10
predisposition O 0 1.1583327932385146e-06
genes O 0 6.489871395842783e-08
. O 0 6.209757685837758e-08

The O 0 1.037260055625211e-08
majority O 0 4.485927629360731e-09
( O 0 3.7029801447374666e-10
81 O 0 2.7862046003690466e-09
% O 0 2.7343344602415165e-11
) O 0 3.5621179617084664e-11
of O 0 3.489832589576025e-10
the O 0 8.418752258876339e-06
breast B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.610541318086689e-07
were O 0 1.1171990621505756e-07
due O 0 8.605258727811815e-09
to O 0 3.1912323894545125e-09
BRCA1 O 0 7.913683361948642e-07
, O 0 1.8117941591455633e-09
with O 0 2.0357839025653135e-10
most O 0 1.31818500559433e-09
others O 0 1.2503651447559605e-09
( O 0 2.7977684405322556e-11
14 O 0 2.6580354584027077e-10
% O 0 6.112695072335583e-11
) O 0 1.793573622954625e-10
due O 0 3.1454805426989196e-09
to O 0 2.34344792460206e-08
BRCA2 O 0 1.5379020624095574e-05
. O 0 9.815004631263946e-08

Conversely O 0 6.867855063319439e-06
, O 0 2.6695921917507803e-08
the O 0 4.00995986415964e-10
majority O 0 1.0127561012041042e-09
of O 0 1.2605774757368238e-10
families O 0 2.3699458395753936e-08
with O 0 1.534978188999503e-08
male B-Disease 0 7.354398985626176e-05
and I-Disease 0 3.484764965833165e-05
female I-Disease 0 0.00030715568573214114
breast I-Disease 0 0.04404359683394432
cancer I-Disease 0 4.193501354166074e-06
were O 0 5.74763561189684e-08
due O 0 1.4514070834081849e-08
to O 0 3.683146454491748e-09
BRCA2 O 0 6.386769086930144e-07
( O 0 6.703632648985547e-10
76 O 0 2.085824668540681e-08
% O 0 1.1680409972569805e-09
) O 0 5.9499201121582246e-09
. O 0 4.363372596571935e-08

The O 0 1.42197498220753e-08
largest O 0 2.5770603429009498e-08
proportion O 0 6.861390566825776e-09
( O 0 2.840462587361259e-10
67 O 0 2.7948057201854226e-09
% O 0 2.524219895605473e-11
) O 0 2.819872807480195e-11
of O 0 4.5974390960878964e-11
families O 0 8.473365120664766e-09
due O 0 2.3544994842694678e-09
to O 0 2.1347175138686225e-09
other O 0 2.3025065187809446e-10
genes O 0 5.49470069444169e-09
was O 0 6.68293296257616e-06
found O 0 2.1243799608328118e-07
in O 0 2.2011872324867454e-09
families O 0 7.692869452569084e-09
with O 0 1.7901533588826624e-09
four O 0 3.6322880259120893e-09
or O 0 2.90956698734135e-08
five O 0 2.1378550041362132e-09
cases O 0 4.2057157756403285e-09
of O 0 3.6866607544538965e-09
female O 0 7.926809485070407e-05
breast B-Disease 0 0.06625909358263016
cancer I-Disease 0 1.5182930837909225e-05
only O 0 5.1294282599201324e-08
. O 0 1.1832653257215497e-07

These O 0 1.177887742898065e-08
estimates O 0 2.7637486965659264e-08
were O 0 6.7959557981112084e-09
not O 0 6.90824120130884e-10
substantially O 0 8.047985389225687e-09
affected O 0 1.1360625773448874e-09
either O 0 2.6679858322609107e-10
by O 0 1.65706101618035e-10
changing O 0 5.270854419592297e-09
the O 0 3.3254704545626623e-10
assumed O 0 2.2017594858425582e-08
penetrance O 0 1.4279956417340145e-07
model O 0 1.3159014145003312e-07
for O 0 1.896232282305732e-09
BRCA1 O 0 1.369959790054054e-07
or O 0 5.6815916416042e-09
by O 0 3.1185073967598953e-10
including O 0 1.378030134446817e-09
or O 0 3.243053470214363e-08
excluding O 0 7.679691975681635e-07
BRCA1 O 0 3.2974357964121737e-06
mutation O 0 9.866734274055489e-08
data O 0 8.487521085953631e-07
. O 0 1.7852075018254254e-07

Among O 0 4.6372707629416254e-07
those O 0 3.484528221520122e-08
families O 0 1.7313058719992114e-07
with O 0 3.6795958635593706e-07
disease O 0 0.000308345741359517
due O 0 1.4877405085655937e-08
to O 0 2.050590808266861e-08
BRCA1 O 0 2.784718844850431e-06
that O 0 5.56934374174034e-08
were O 0 1.1173710845469031e-06
tested O 0 5.728192604692595e-07
by O 0 2.0566208458472346e-10
one O 0 4.150290666693479e-10
of O 0 1.426816911148654e-11
the O 0 3.577315180192109e-11
standard O 0 1.286655004761883e-09
screening O 0 4.708244349949098e-10
methods O 0 4.170949363668797e-09
, O 0 1.1502254704254256e-10
mutations O 0 5.465118357861343e-10
were O 0 4.979619827594206e-09
detected O 0 5.251876018519397e-07
in O 0 2.536997278923536e-10
the O 0 2.4208338111897376e-10
coding O 0 3.119403046980551e-08
sequence O 0 7.2787131877305455e-09
or O 0 1.6175989436817417e-09
splice O 0 8.173010002110459e-08
sites O 0 2.593416752461053e-07
in O 0 1.051377249150498e-10
an O 0 6.64475349743121e-11
estimated O 0 3.4127918269177826e-09
63 O 0 1.550339301381598e-09
% O 0 2.3682928881885168e-11
( O 0 2.0508653802986387e-11
95 O 0 1.532014404226345e-09
% O 0 3.772948065083881e-10
CI O 0 5.316998795024119e-06
51 O 0 2.516292063603487e-08
% O 0 7.879112917663633e-10
- O 0 6.698118340864312e-06
77 O 0 6.323448076273053e-08
% O 0 8.696267039809413e-10
) O 0 3.8916252442788846e-09
. O 0 1.701562979405935e-08

The O 0 6.817613495968544e-08
estimated O 0 4.283575094632397e-07
sensitivity O 0 4.907832931166922e-07
was O 0 4.002270088676596e-07
identical O 0 3.1114524290387635e-08
for O 0 5.337294495255662e-11
direct O 0 4.755700278025188e-10
sequencing O 0 6.36026609157625e-09
and O 0 2.8515487748848045e-09
other O 0 2.1604978917011408e-10
techniques O 0 1.3822406685903843e-07
. O 0 2.8757739300999674e-08

The O 0 7.471648189039115e-08
penetrance O 0 1.6927870092331432e-05
of O 0 6.843067446027362e-09
BRCA2 O 0 4.561291461868677e-06
was O 0 2.909104921400285e-07
estimated O 0 1.4805502601689113e-08
by O 0 3.7039690758966515e-10
maximizing O 0 2.6862636559599196e-08
the O 0 1.4231028577782467e-09
LOD O 0 0.00013481885252986103
score O 0 1.0434116859414644e-07
in O 0 2.0189987459673375e-09
BRCA2 O 0 1.6850403881107923e-06
- O 0 6.509088052553125e-06
mutation O 0 4.512618545504665e-08
families O 0 3.0992435284815656e-09
, O 0 2.0544134449185236e-10
over O 0 3.093048706048762e-09
all O 0 8.77261818743591e-10
possible O 0 4.4550372280127704e-08
penetrance O 0 1.8993191588378977e-06
functions O 0 2.3519557856843676e-08
. O 0 4.298929923152173e-08

The O 0 2.260327036651688e-08
estimated O 0 6.295096000030753e-08
cumulative O 0 4.411381269164849e-07
risk O 0 1.7448427342969808e-06
of O 0 2.7460131946099864e-09
breast B-Disease 0 0.15830405056476593
cancer I-Disease 0 3.02668286167318e-05
reached O 0 1.2747806010793283e-07
28 O 0 1.1439119651512897e-09
% O 0 5.3322478377193505e-11
( O 0 5.437437652910937e-11
95 O 0 2.052350511760892e-09
% O 0 4.953812360319887e-10
CI O 0 2.8591696263902122e-06
9 O 0 4.126029740092463e-09
% O 0 1.958544854074873e-10
- O 0 4.690068067247921e-07
44 O 0 2.442196223029214e-09
% O 0 3.286443686634222e-11
) O 0 1.1203166866424752e-11
by O 0 3.534147974271207e-11
age O 0 1.2732352949740289e-09
50 O 0 3.804715986710505e-10
years O 0 1.663115201111509e-10
and O 0 1.8100869414450216e-10
84 O 0 2.3278977356877562e-10
% O 0 1.1869135882469628e-11
( O 0 6.683402963003626e-12
95 O 0 6.071830260800937e-10
% O 0 1.1749336226163365e-10
CI O 0 2.243427388748387e-06
43 O 0 4.4179633285068576e-09
% O 0 2.660348330518758e-10
- O 0 2.5819809934546356e-07
95 O 0 1.3858011627121414e-08
% O 0 1.0645175019252662e-10
) O 0 5.882390408107341e-11
by O 0 3.1096811237141253e-10
age O 0 6.209695868619747e-09
70 O 0 4.4438412949432404e-09
years O 0 8.273544516157472e-09
. O 0 2.3981701957609403e-08

The O 0 1.0828217682501418e-06
corresponding O 0 0.46919798851013184
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
risks O 0 5.689130921382457e-05
were O 0 9.161738745433468e-08
0 O 0 5.118482349075748e-08
. O 0 5.4114359215873264e-08

4 O 0 1.0500018987613657e-07
% O 0 2.5121236202352293e-09
( O 0 1.5015538812335194e-10
95 O 0 1.6392471824389077e-09
% O 0 2.6831833976892483e-10
CI O 0 3.4588736070872983e-06
0 O 0 2.037521040776369e-09
% O 0 2.3431370732573953e-10
- O 0 3.421417034132901e-07
1 O 0 4.742403136859252e-10
% O 0 1.9030856751589553e-11
) O 0 8.747195676117592e-12
by O 0 1.9977630660861223e-11
age O 0 5.102023803438271e-10
50 O 0 2.0920062904217218e-10
years O 0 1.7494641846305115e-10
and O 0 4.4182055236596796e-10
27 O 0 1.917661585082442e-10
% O 0 6.031413649770778e-12
( O 0 4.4554451274214646e-12
95 O 0 2.861179349000764e-10
% O 0 1.0267869887670145e-10
CI O 0 3.4499487355788006e-07
0 O 0 2.5037988349296825e-10
% O 0 1.993542830813766e-10
- O 0 1.1629441587501788e-06
47 O 0 7.296991899607974e-09
% O 0 6.50925077727571e-11
) O 0 1.6262748092632506e-11
by O 0 1.1100945163100562e-10
age O 0 7.094848264443954e-09
70 O 0 5.254573220980774e-09
years O 0 3.314978735957652e-09
. O 0 1.4999296027440323e-08

The O 0 1.6248424117293325e-07
lifetime O 0 8.370832347281976e-07
risk O 0 1.198807694891002e-05
of O 0 1.513776837214209e-08
breast B-Disease 1 0.9633598327636719
cancer I-Disease 0 0.00012391136260703206
appears O 0 2.92132369850151e-07
similar O 0 7.884649377842834e-09
to O 0 5.139659808861552e-09
the O 0 1.226541623822186e-08
risk O 0 2.704641417494713e-07
in O 0 1.5179096868322972e-10
BRCA1 O 0 3.366875489518861e-08
carriers O 0 4.889829430254622e-09
, O 0 9.329804706581513e-10
but O 0 1.925862136431533e-09
there O 0 1.8552620550948973e-09
was O 0 5.494253230153845e-08
some O 0 6.580166272973642e-11
suggestion O 0 6.024808429927475e-10
of O 0 1.7886362529973e-11
a O 0 2.069694415851586e-09
lower O 0 2.2598621285396803e-07
risk O 0 4.071495851576401e-08
in O 0 1.1760950546779725e-10
BRCA2 O 0 1.870263410808093e-08
carriers O 0 1.0476723932839604e-09
< O 0 2.9132209533599962e-08
50 O 0 5.340009323617778e-09
years O 0 5.577810990864407e-10
of O 0 3.3397598575568566e-10
age O 0 5.778291978231209e-08
. O 0 3.924012403899724e-08

Eye B-Disease 1 0.6073250770568848
movement I-Disease 0 0.0002585604670457542
abnormalities I-Disease 0 0.24205686151981354
correlate O 0 3.2399643714597914e-06
with O 0 1.9331240608266853e-08
genotype O 0 0.0001614549255464226
in O 0 1.623322987143183e-07
autosomal O 1 0.9991657733917236
dominant O 1 0.993575394153595
cerebellar B-Disease 1 0.9989527463912964
ataxia I-Disease 1 0.999968409538269
type I-Disease 1 0.9991375207901001
I I-Disease 0 0.024741902947425842
. O 0 5.455474365589907e-07

We O 0 3.8794695456090267e-07
compared O 0 4.0860604144654644e-07
horizontal O 0 0.0002312551805516705
eye O 0 0.09356776624917984
movements O 0 0.0004651391936931759
( O 0 1.8455537542649836e-08
visually O 0 1.5509871218455373e-06
guided O 0 8.516190632690268e-07
saccades O 0 7.429870038322406e-06
, O 0 1.40739542242585e-09
antisaccades O 0 1.2675566551934025e-07
, O 0 8.309851695642578e-10
and O 0 6.528065310540399e-10
smooth O 0 2.6855420287574816e-07
pursuit O 0 6.848502209777507e-08
) O 0 8.155683073329811e-11
in O 0 7.58957410806893e-11
control O 0 1.550000803263174e-07
subjects O 0 2.159704770576809e-08
( O 0 2.0057935867789922e-10
n O 0 1.2192616622996866e-06
= O 0 3.095682927778398e-07
14 O 0 8.659984951364663e-10
) O 0 1.8932209966404656e-10
and O 0 2.071057814134747e-08
patients O 0 2.2097854657232574e-09
with O 0 4.482928958604582e-11
three O 0 2.5165680650474087e-10
forms O 0 3.436701234704742e-08
of O 0 1.25678791818018e-08
autosomal O 0 0.35963261127471924
dominant O 0 0.0013085384853184223
cerebellar B-Disease 0 0.00015059583529364318
ataxias I-Disease 0 0.0008455523056909442
type I-Disease 0 0.07045599818229675
I I-Disease 0 9.329793101642281e-05
spinocerebellar B-Disease 0 0.049723610281944275
ataxias I-Disease 0 6.3948414208425675e-06
1 I-Disease 0 8.718792798845243e-09
and I-Disease 0 2.7820041825776798e-09
2 I-Disease 0 1.1749610173694691e-09
( O 0 1.0242246634151186e-10
SCA1 B-Disease 0 3.353103750214359e-07
, O 0 3.587532215743039e-10
n O 0 1.3745847127211164e-07
= O 0 2.60574246624401e-08
11 O 0 3.2491115353749933e-10
; O 0 1.886058496880505e-11
SCA2 B-Disease 0 2.8274330432509487e-08
, O 0 3.7676320396862195e-11
n O 0 3.079099641922767e-08
= O 0 1.5648348394847744e-08
10 O 0 1.501823110316991e-10
) O 0 5.838305533467647e-11
and O 0 1.3356326045155242e-09
SCA3 B-Disease 1 0.9999964237213135
/ O 0 7.275249663507566e-05
Machado B-Disease 0 4.19522251604576e-07
- I-Disease 0 0.00018353624909650534
Joseph I-Disease 0 0.0002768560079857707
disease I-Disease 0 4.788871228811331e-05
( O 0 7.352844444419304e-10
MJD B-Disease 1 0.9999845027923584
) O 0 5.669399394392372e-10
( O 0 2.2111167063965098e-10
n O 0 1.0687490430427715e-06
= O 0 8.448740231870033e-07
16 O 0 7.484054265205486e-09
) O 0 1.471955890508525e-09
. O 0 9.947644485919227e-09

In O 0 6.637745286752761e-08
SCA1 B-Disease 0 5.304262231220491e-06
, O 0 2.5685644722273082e-09
saccade O 0 1.4112890767137287e-07
amplitude O 0 1.600102628174227e-08
was O 0 9.94734072889969e-09
significantly O 0 1.1484400097572234e-08
increased O 0 4.032788325503134e-09
, O 0 1.8150375646897032e-10
resulting O 0 9.736107475788458e-10
in O 0 2.894333439584784e-09
hypermetria B-Disease 0 3.056160130654462e-05
. O 0 1.533673525955237e-07

The O 0 3.670748682793601e-08
smooth O 0 8.709611165613751e-07
pursuit O 0 1.4055164001547382e-06
gain O 0 7.582435728181736e-07
was O 0 2.103513452311745e-06
decreased O 0 4.444714249984827e-06
. O 0 4.095117489555378e-08

In O 0 1.1005457878354719e-07
SCA2 B-Disease 0 8.776474714977667e-06
, O 0 3.417260252547294e-09
saccade O 0 3.9694580777904775e-07
velocity O 0 1.9245490534558485e-07
was O 0 2.114836661348818e-07
markedly O 0 8.391070309698989e-07
decreased O 0 7.590394375256437e-07
. O 0 2.89511863371672e-08

The O 0 1.0314204601513666e-08
percentage O 0 1.9441678489329206e-07
of O 0 3.460812469935348e-10
errors O 0 7.456031170249844e-08
in O 0 4.054520608143264e-10
antisaccades O 0 5.044090016781411e-07
was O 0 4.154000876610553e-08
greatly O 0 1.2294524287526087e-09
increased O 0 1.3600649495515427e-09
and O 0 1.04950237389545e-09
was O 0 1.9860227240542372e-08
significantly O 0 1.8752848163217095e-09
correlated O 0 2.2930806142795745e-09
with O 0 4.709402867675294e-10
age O 0 8.05167346129565e-08
at O 0 3.844660568574909e-06
disease O 0 7.868931425036862e-05
onset O 0 3.0836779387755087e-06
. O 0 1.3757571082351205e-07

In O 0 1.5199335123838864e-08
addition O 0 3.5739360360054206e-09
, O 0 1.9912400894828153e-10
a O 0 2.4075355598007775e-10
correlation O 0 1.4362033340376001e-08
between O 0 1.721823239542175e-09
smooth O 0 6.423465038096765e-06
pursuit O 0 2.327657284695306e-06
gain O 0 1.705410568320076e-06
and O 0 2.4083876226654866e-08
the O 0 2.908249197020041e-10
number O 0 9.53136347625616e-10
of O 0 1.5716652979058665e-10
trinucleotide O 0 1.28978933844337e-06
repeats O 0 2.4597193259978667e-07
was O 0 6.847195095360803e-07
found O 0 4.3034091845584044e-08
. O 0 1.8312858784952368e-08

In O 0 1.2267988722669543e-06
SCA3 B-Disease 1 0.9999876022338867
, O 0 1.5669172626076033e-07
gaze B-Disease 0 1.151622291217791e-05
- I-Disease 0 0.00017147553444374353
evoked I-Disease 0 1.2051708836224861e-05
nystagmus I-Disease 0 0.0003459866566117853
was O 0 7.436346436406893e-07
often O 0 4.913239148862658e-09
present O 0 1.468501209522799e-09
as O 0 6.770890514928851e-10
was O 0 2.1085972079504245e-08
saccade O 0 2.1132339611540374e-07
hypometria O 0 4.373767694687558e-07
and O 0 4.2828864899036034e-09
smooth O 0 2.3183297059858887e-07
pursuit O 0 3.12721937234528e-07
gain O 0 2.291851615154883e-07
was O 0 7.188977519945183e-07
markedly O 0 1.2206415931359516e-06
decreased O 0 6.48862112484494e-07
. O 0 1.772277258282884e-08

Three O 0 9.349728458118989e-08
major O 0 3.3515945574436046e-08
criteria O 0 7.1550094737915515e-09
, O 0 9.457961497316703e-11
saccade O 0 7.760947084989311e-08
amplitude O 0 6.677373765029415e-09
, O 0 1.9810345031068266e-10
saccade O 0 2.0486087493054583e-08
velocity O 0 3.278660187788773e-08
, O 0 4.741969039656624e-10
and O 0 2.2912563513166617e-10
presence O 0 8.633910253408317e-10
of O 0 1.8935458756530466e-10
gaze B-Disease 0 5.257897100818809e-06
- I-Disease 0 3.667393684736453e-05
evoked I-Disease 0 2.467473223077832e-06
nystagmus I-Disease 0 8.378632628591731e-06
, O 0 4.769135086846177e-10
permitted O 0 2.049119540714628e-09
the O 0 4.1223597452288985e-11
correct O 0 1.587144815573538e-08
assignment O 0 4.052264745979528e-09
of O 0 1.0734268508783007e-11
90 O 0 3.0468830236607403e-10
% O 0 2.1936575819725412e-11
of O 0 1.179619249502828e-11
the O 0 1.7026197118852338e-10
SCA1 B-Disease 0 3.5239764883954194e-07
, O 0 8.014062330419236e-11
90 O 0 9.645183263184975e-11
% O 0 1.5853481721839202e-11
of O 0 1.3176959523519827e-11
the O 0 6.866361923485442e-10
SCA2 B-Disease 0 3.224880629204563e-06
, O 0 5.54620793735694e-10
and O 0 7.991598494072605e-10
93 O 0 3.4511093982558805e-10
% O 0 2.5354725263770916e-11
of O 0 1.8390185207994847e-11
the O 0 1.54689896447735e-08
patients O 0 3.802238879302422e-08
with O 0 1.72261920283745e-08
SCA3 B-Disease 1 0.9999998807907104
to O 0 2.413260062894551e-07
their O 0 2.747207572539878e-09
genetically O 0 1.4236579204407462e-07
confirmed O 0 1.2213390618853737e-06
patient O 0 1.0377606258771266e-06
group O 0 6.268652441576705e-08
and O 0 3.564223405305711e-08
, O 0 9.358213093335621e-10
therefore O 0 6.010690833946342e-10
, O 0 2.9934443812607014e-10
may O 0 1.115273318141874e-09
help O 0 1.0088193613810859e-09
orient O 0 1.627097481105011e-05
diagnoses O 0 1.863833972493012e-06
of O 0 5.896885202361091e-10
SCA1 B-Disease 0 1.4684699635836296e-05
, O 0 2.0297170610916737e-09
SCA2 B-Disease 0 2.4916021175158676e-06
, O 0 3.067023746083919e-09
and O 0 5.322745266767015e-08
SCA3 B-Disease 1 0.9999980926513672
at O 0 4.098595809409744e-07
early O 0 3.616402288741938e-09
clinical O 0 2.5254806246266526e-08
stages O 0 4.948613607780317e-08
of O 0 2.993387204774933e-10
the O 0 1.6135631497604663e-08
diseases O 0 8.168673957698047e-06
. O 0 1.33277222591488e-09
. O 0 3.242589485807912e-08

Genetic O 0 7.587942945974646e-06
basis O 0 2.471094262546103e-07
and O 0 1.0949110951230523e-08
molecular O 0 4.001117304142099e-07
mechanism O 0 3.338424448884325e-06
for O 0 1.3888799003325403e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999802112579346
fibrillation I-Disease 1 0.9999984502792358
. O 0 8.675365097587928e-05

Ventricular B-Disease 1 0.996936559677124
fibrillation I-Disease 1 0.974276602268219
causes O 0 2.2512522264150903e-06
more O 0 2.971051626943222e-09
than O 0 2.2709520930419558e-09
300 O 0 3.847379304033893e-09
, O 0 1.718692133056976e-10
000 O 0 2.3035093832390885e-09
sudden O 0 4.13613898686549e-09
deaths O 0 1.9027510234082e-08
each O 0 9.465631056748691e-11
year O 0 7.164510651413991e-10
in O 0 1.860395726360764e-10
the O 0 1.1209055905680998e-09
USA O 0 1.0471978839632357e-07
alone O 0 9.161301761650975e-08
. O 0 1.1696087653945142e-08

In O 0 1.9864243583356256e-08
approximately O 0 1.8900585985193175e-08
5 O 0 5.152360760263264e-09
- O 0 1.399434836457658e-06
12 O 0 7.728869211298672e-10
% O 0 1.2093056590833928e-11
of O 0 2.9502494197641838e-12
these O 0 4.0421813118918237e-10
cases O 0 3.973129381051876e-09
, O 0 1.499001339722028e-10
there O 0 1.7663167595216578e-09
are O 0 6.185211787190781e-10
no O 0 1.1074520855913761e-08
demonstrable O 0 1.8508753782953136e-05
cardiac O 0 9.599370059731882e-06
or O 0 2.1174462006001704e-07
non O 0 1.7623939129407518e-05
- O 1 0.883038341999054
cardiac O 0 0.01379796676337719
causes O 0 4.930402397462785e-08
to O 0 3.6638778677655637e-09
account O 0 4.1608441136986585e-08
for O 0 3.71926045517057e-10
the O 0 2.7605268071440037e-10
episode O 0 1.3415161959073885e-07
, O 0 8.074981239225565e-10
which O 0 1.861042653317213e-09
is O 0 1.4795559222235966e-09
therefore O 0 1.6450447670735002e-09
classified O 0 1.0084755786010646e-06
as O 0 3.84669237973867e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999722242355347
fibrillation I-Disease 1 0.9999997615814209
( O 0 7.0778801273263525e-06
IVF B-Disease 1 0.9999939203262329
) O 0 3.4870788567786803e-07
. O 0 8.666140161039948e-08

A O 0 3.0902558023626625e-07
distinct O 0 4.138753340043877e-08
group O 0 7.715075867054111e-08
of O 0 2.047404468186187e-09
IVF B-Disease 1 0.9999998807907104
patients O 0 2.1931185983703472e-05
has O 0 8.263737782954195e-08
been O 0 3.131540182721437e-08
found O 0 1.3323002256981908e-08
to O 0 8.144478425009538e-10
present O 0 5.267035696476796e-09
with O 0 9.257057898004462e-10
a O 0 2.2035111513218908e-08
characteristic O 0 1.888377710201894e-06
electrocardiographic O 0 9.322266123490408e-06
pattern O 0 1.0416422810521908e-05
. O 0 2.3397569748340175e-07

Because O 0 7.396329237963073e-08
of O 0 3.9397801687712786e-10
the O 0 1.0204612849173955e-10
small O 0 1.7463580581633664e-09
size O 0 3.679202364992307e-08
of O 0 1.1831485791091723e-10
most O 0 5.756680687696303e-10
pedigrees O 0 2.828485889949661e-07
and O 0 2.078239802472126e-08
the O 0 8.206055834847348e-10
high O 0 1.2712820307569928e-06
incidence O 0 1.6028836398618296e-05
of O 0 7.42149008914339e-10
sudden B-Disease 0 3.564625217222783e-07
death I-Disease 0 1.9879750823292852e-07
, O 0 6.714420131004317e-10
however O 0 4.948920717673388e-10
, O 0 4.778137260852411e-11
molecular O 0 6.009567288245421e-10
genetic O 0 2.1709829489680033e-09
studies O 0 6.106137262484879e-10
of O 0 7.821913672323433e-10
IVF B-Disease 1 0.9999966621398926
have O 0 6.306524937826907e-07
not O 0 9.148516610935076e-09
yet O 0 6.96622581841666e-09
been O 0 6.43822195556254e-09
done O 0 3.515403079745738e-08
. O 0 1.2673773142068967e-08

Because O 0 1.1692489351844415e-05
IVF B-Disease 1 0.9999948740005493
causes O 0 0.00039809977170079947
cardiac O 0 0.0020312489941716194
rhythm O 0 0.00019675512157846242
disturbance O 0 2.7603126000030898e-05
, O 0 3.2270028871295153e-09
we O 0 2.489395578564313e-09
investigated O 0 2.4209748872294767e-08
whether O 0 2.974992918680641e-09
malfunction O 0 1.97734607354505e-06
of O 0 2.323692210870476e-10
ion O 0 2.3019123318590573e-07
channels O 0 2.301607673871331e-05
could O 0 2.546033101680223e-05
cause O 0 4.181330552910367e-07
the O 0 1.2466912835407129e-08
disorder O 0 4.4761573008145206e-06
by O 0 3.878053780881352e-11
studying O 0 7.859285444666853e-10
mutations O 0 4.165145561785266e-09
in O 0 1.525741061270125e-10
the O 0 5.740442565738135e-10
cardiac O 0 2.3179715924470656e-07
sodium O 0 1.9254370542398647e-08
channel O 0 2.815814241330372e-06
gene O 0 1.1610225101321703e-06
SCN5A O 0 6.280691741267219e-05
. O 0 4.670032467402052e-07

We O 0 3.3233072826988064e-06
have O 0 1.805688754075163e-08
now O 0 1.0985466758484108e-08
identified O 0 3.056035424719994e-08
a O 0 4.273094766915619e-09
missense O 0 4.8673132369003724e-06
mutation O 0 5.134253910910047e-08
, O 0 6.582918654629566e-10
a O 0 2.916672237063267e-09
splice O 0 0.0001444875670131296
- O 0 7.28972809156403e-05
donor O 0 1.552720192421475e-07
mutation O 0 9.739551387610845e-08
, O 0 5.9525535611726355e-09
and O 0 6.586840850530962e-09
a O 0 2.3549318939330988e-08
frameshift O 0 2.8302523787715472e-05
mutation O 0 2.275349508806812e-08
in O 0 6.173614397475546e-10
the O 0 5.837016980869691e-10
coding O 0 2.932874849648215e-07
region O 0 1.8483508057443032e-08
of O 0 3.078603760808818e-10
SCN5A O 0 2.6847583285416476e-06
in O 0 1.6241251676873958e-09
three O 0 1.6091741272816762e-08
IVF B-Disease 1 0.9999910593032837
families O 0 2.0841831371853914e-07
. O 0 4.276521892165874e-08

We O 0 1.9094811420927726e-07
show O 0 5.199443720016461e-08
that O 0 1.864132320728018e-10
sodium O 0 7.092598175439946e-10
channels O 0 5.0477053648023684e-09
with O 0 3.0140293039160326e-10
the O 0 3.6774094880343e-10
missense O 0 7.431284529957338e-07
mutation O 0 1.5423148980175938e-08
recover O 0 1.545527616997333e-08
from O 0 6.530316565278582e-11
inactivation O 0 1.0702845543164585e-07
more O 0 3.733817421913699e-10
rapidly O 0 1.5314270962463183e-09
than O 0 1.1702593061269084e-10
normal O 0 2.1741073386039034e-09
and O 0 1.0716767473439859e-09
that O 0 6.54032938918192e-10
the O 0 4.162372391203206e-10
frameshift O 0 9.63994625635678e-06
mutation O 0 7.035098725793887e-09
causes O 0 7.268221025036325e-10
the O 0 4.167605496818716e-11
sodium O 0 1.444942943074068e-09
channel O 0 2.393436773218127e-07
to O 0 5.556290538777375e-09
be O 0 1.1739670568999827e-08
non O 0 3.215502886178001e-08
- O 0 1.54217150338809e-06
functional O 0 5.15239321430272e-07
. O 0 2.8748143421353234e-08

Our O 0 4.6500073835886724e-07
results O 0 8.539823070918828e-09
indicate O 0 3.3714233627080148e-09
that O 0 1.0229030122932414e-10
mutations O 0 4.115058072073907e-09
in O 0 1.2767753521103486e-10
cardiac O 0 7.419020420229572e-08
ion O 0 2.9368939635787683e-07
- O 0 3.672153252409771e-05
channel O 0 1.3172429135011043e-05
genes O 0 6.396471352587696e-09
contribute O 0 9.31531296544108e-10
to O 0 1.8148230140901944e-10
the O 0 1.890063938692066e-10
risk O 0 3.6886864673846276e-09
of O 0 2.7919312695079412e-11
developing O 0 5.663590485482928e-08
IVF B-Disease 1 0.9998422861099243
. O 0 1.0627515756311823e-08
. O 0 4.355647931220119e-08

Molecular O 0 1.9236624666518765e-06
heterogeneity O 0 1.4845396663076826e-06
in O 0 9.568417169703025e-09
mucopolysaccharidosis B-Disease 0 0.00018400620319880545
IVA I-Disease 0 0.0004624256689567119
in O 0 1.0777078784940386e-08
Australia O 0 3.7634286798038374e-08
and O 0 1.4514625057415742e-08
Northern O 0 1.1225069584952507e-07
Ireland O 0 1.308082602236027e-07
: O 0 2.7003518865420517e-10
nine O 0 4.640106354703022e-10
novel O 0 3.4470457599411475e-09
mutations O 0 5.1617741192444555e-09
including O 0 4.942600217994197e-10
T312S O 0 1.1297194646431308e-07
, O 0 1.0349454626634724e-09
a O 0 5.615439224726515e-10
common O 0 2.308321089827814e-09
allele O 0 1.8957123870677606e-08
that O 0 1.095708634935022e-09
confers O 0 4.718605950415622e-08
a O 0 3.8459212703401136e-08
mild O 0 2.4237868274212815e-05
phenotype O 0 1.2857652109232731e-05
. O 0 2.598174830836797e-07

Mucopolysaccharidosis B-Disease 0 0.24717912077903748
IVA I-Disease 1 0.9957452416419983
( O 0 0.00021544717310462147
MPS B-Disease 1 0.9999967813491821
IVA I-Disease 1 0.9999996423721313
) O 0 3.6465522157413943e-07
is O 0 3.100877279393899e-07
an O 0 3.811780686646671e-07
autosomal B-Disease 1 0.9999909400939941
recessive I-Disease 1 0.999997615814209
lysosomal I-Disease 1 0.9999996423721313
storage I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9999932050704956
caused O 0 1.8369959434494376e-05
by O 0 2.569942658681157e-08
a O 0 1.736029480525758e-05
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999997615814209
in O 0 4.181066870501127e-08
N O 0 0.0022863810881972313
- O 0 0.0001111629098886624
acetylgalactosamine O 0 0.0002584416652098298
- O 0 7.042551442282274e-05
6 O 0 2.4419421151833376e-07
- O 0 0.0001415179285686463
sulfate O 0 5.427378710010089e-05
sulfatase O 0 2.2695650841342285e-05
( O 0 2.8738367241487595e-09
GALNS O 0 9.330148031949648e-07
) O 0 5.500552013870674e-09
. O 0 8.472299306561126e-09

Previous O 0 1.6169464345239248e-07
studies O 0 1.5383017526460208e-08
of O 0 9.63924717822806e-10
patients O 0 6.0409672819616844e-09
from O 0 1.3976067525511837e-10
a O 0 4.738878622845277e-09
British O 0 2.207458692282671e-06
- O 0 0.0013316788244992495
Irish O 0 1.1180255796716665e-06
population O 0 4.079733884054804e-09
showed O 0 8.714164323464502e-07
that O 0 4.203019043913514e-10
the O 0 1.1497013757688634e-10
I113F O 0 1.6967955929203526e-08
mutation O 0 2.660349718297539e-09
is O 0 1.0233738301224093e-09
the O 0 3.658979022547193e-11
most O 0 2.0451554338940525e-10
common O 0 7.672511515011138e-10
single O 0 1.7238679816955482e-08
mutation O 0 1.5501042582855007e-07
among O 0 7.876789140937035e-07
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 1.0
patients O 0 6.968126399442554e-05
and O 0 4.4994344250426366e-08
produces O 0 7.671156936339685e-07
a O 0 8.950992480549758e-08
severe O 0 5.011187568015885e-06
clinical O 0 9.466670007896028e-07
phenotype O 0 1.5360259567387402e-05
. O 0 2.785922390557971e-07

We O 0 2.6787662932292733e-07
studied O 0 1.0747334577843048e-08
mutations O 0 1.5551291809856593e-08
in O 0 3.636730083744766e-10
the O 0 2.577367208544956e-10
GALNS O 0 2.876183202715765e-07
gene O 0 3.370433265814654e-09
from O 0 6.402497421120756e-10
23 O 0 4.059133917877489e-09
additional O 0 9.513427556839815e-08
MPS B-Disease 1 0.9999994039535522
IVA I-Disease 1 0.9999998807907104
patients O 0 8.601907211414073e-06
( O 0 7.295958281972048e-10
15 O 0 6.051262269046731e-10
from O 0 1.938779137233837e-10
Australia O 0 1.7786293549093557e-09
, O 0 7.705579230243842e-11
8 O 0 2.3801313697724424e-10
from O 0 4.551302043576122e-11
Northern O 0 6.1798148820457754e-09
Ireland O 0 2.9975939508375404e-09
) O 0 4.444667550673742e-11
, O 0 3.528301956157165e-11
with O 0 6.060557611320405e-11
various O 0 6.622803416789225e-10
clinical O 0 3.389411347143323e-07
phenotypes O 0 4.298856310924748e-07
( O 0 2.8648505789874434e-09
severe O 0 2.3199619647584768e-07
, O 0 6.301360544469503e-10
16 O 0 3.7721781254163034e-10
cases O 0 3.982086882459157e-10
; O 0 1.2351210332273155e-10
intermediate O 0 7.206273355819803e-09
, O 0 3.089639100117836e-10
4 O 0 1.3252589026180317e-09
cases O 0 3.837324680233678e-09
; O 0 2.315482028336646e-09
mild O 0 1.547689180370071e-06
, O 0 2.8029414345098758e-09
3 O 0 1.76028314147203e-09
cases O 0 2.6248359041858293e-09
) O 0 6.206629432625732e-09
. O 0 4.1424335961437464e-08

We O 0 1.8290259049535962e-06
found O 0 1.9674279982950793e-08
two O 0 1.4749566845662088e-10
common O 0 5.622641241487258e-10
mutations O 0 1.967141782799331e-09
that O 0 1.178942776736136e-10
together O 0 2.907712737254542e-09
accounted O 0 1.766173625128431e-07
for O 0 1.9542237272851537e-10
32 O 0 4.6382303553471615e-10
% O 0 3.27044849535163e-11
of O 0 2.6291625127017326e-11
the O 0 3.0668234618502765e-10
44 O 0 1.642267211110493e-09
unrelated O 0 2.1718860043762334e-09
alleles O 0 7.076626507007688e-10
in O 0 3.911454771188261e-10
these O 0 4.501732764339295e-09
patients O 0 3.202917753242218e-08
. O 0 2.0283440704815803e-08

One O 0 4.145485377193836e-07
is O 0 1.5144179243975486e-08
the O 0 4.4490461315049856e-10
T312S O 0 1.617193277070328e-07
mutation O 0 3.783191360184901e-08
, O 0 1.0802633232387393e-09
a O 0 1.377898795063004e-09
novel O 0 1.5284571830420646e-08
mutation O 0 1.3848445945541243e-08
found O 0 2.4639106310786474e-09
exclusively O 0 7.588553785353724e-09
in O 0 1.966732776637059e-09
milder O 0 3.5641700378619134e-05
patients O 0 9.320924618805293e-07
. O 0 1.1483178496973778e-07

The O 0 3.512701951535746e-08
other O 0 2.4411250798550554e-09
is O 0 4.0520173882896415e-09
the O 0 2.511494623380628e-10
previously O 0 3.9718884181638714e-08
described O 0 1.1702541513614051e-07
I113F O 0 7.181002104061918e-08
that O 0 5.834746574784333e-10
produces O 0 4.182861701451657e-08
a O 0 4.6459206259896746e-08
severe O 0 3.188623168171034e-06
phenotype O 0 1.010013420454925e-05
. O 0 1.581009030360292e-07

The O 0 3.055138364516097e-08
I113F O 0 3.216043182874273e-07
and O 0 3.754286215240654e-09
T312S O 0 7.000193136263988e-08
mutations O 0 9.349101048883313e-09
accounted O 0 3.183088281843993e-08
for O 0 1.418614392623141e-10
8 O 0 1.1261686028163354e-09
( O 0 4.898730379676586e-11
18 O 0 2.9154803571351806e-10
% O 0 1.0772397730784977e-11
) O 0 3.000204945591278e-11
and O 0 2.7736910546138915e-09
6 O 0 4.703469835831697e-10
( O 0 2.8423742526317852e-11
14 O 0 9.925801153221059e-11
% O 0 7.74976350453871e-12
) O 0 6.041303741988191e-12
of O 0 1.0209825172802223e-11
44 O 0 4.598248448672848e-10
unrelated O 0 4.764264094347936e-09
alleles O 0 8.297075027030587e-09
, O 0 4.35546265720177e-09
respectively O 0 8.388271766079924e-08
. O 0 1.1425262158581972e-07

The O 0 2.0807942036071836e-08
relatively O 0 1.3979653878948284e-08
high O 0 1.547560124492975e-08
residual O 0 1.0125638283398075e-07
GALNS O 0 2.156483333237702e-06
activity O 0 1.621497318637921e-07
seen O 0 3.649052970899902e-08
when O 0 8.824485586700348e-11
the O 0 1.7518743400390946e-11
T312S O 0 3.0075417711827868e-09
mutant O 0 4.013022358861917e-09
cDNA O 0 2.710818680640159e-09
is O 0 8.010292429361243e-10
overexpressed O 0 6.405288388577901e-08
in O 0 1.8364328113751327e-10
mutant O 0 1.0582452603102865e-07
cells O 0 7.433649251709085e-09
provides O 0 2.503155682731517e-09
an O 0 6.549039088810105e-11
explanation O 0 1.5195152913705101e-09
for O 0 4.110466966800175e-10
the O 0 1.0993111976276282e-09
mild O 0 2.678740656847367e-06
phenotype O 0 1.1044639904866926e-06
in O 0 6.189640799902918e-09
patients O 0 1.8874143137281862e-08
with O 0 1.4345208354527017e-10
this O 0 2.719135361317626e-09
mutation O 0 3.012480931374739e-07
. O 0 6.706324029437383e-08

The O 0 1.9964444319953145e-08
distribution O 0 1.0992619081662269e-07
and O 0 1.0910017333998212e-09
relative O 0 1.2904767254795502e-09
frequencies O 0 1.9807409046279645e-09
of O 0 4.564655597949496e-11
the O 0 1.7488037407087376e-10
I113F O 0 5.055898810724102e-08
and O 0 1.5476714354534238e-09
T312S O 0 1.8149147962276402e-08
mutations O 0 1.4892274080580137e-09
in O 0 2.759726613899005e-10
Australia O 0 5.542939995883955e-10
corresponded O 0 1.450197184560409e-09
to O 0 2.03158295741801e-10
those O 0 7.513367011879879e-11
observed O 0 3.408212156941204e-09
in O 0 2.0449487936335942e-10
Northern O 0 3.1953756973734926e-08
Ireland O 0 7.841519789053564e-08
and O 0 2.6044903123079166e-08
are O 0 2.7118363110645305e-10
unique O 0 1.8863688389103572e-10
to O 0 4.535636310976088e-10
these O 0 3.8991790352049804e-10
two O 0 1.292313617229368e-10
populations O 0 1.7036340116405313e-09
, O 0 9.278743051677196e-11
suggesting O 0 3.0173898935004217e-09
that O 0 4.931375308103725e-10
both O 0 1.0806131683915865e-10
mutations O 0 1.065702415203873e-09
were O 0 3.880203269801541e-09
probably O 0 5.162197336261443e-09
introduced O 0 6.934512408740545e-10
to O 0 1.0840488506858037e-09
Australia O 0 2.4983857205285176e-09
by O 0 3.651095814571903e-10
Irish O 0 7.555033931794242e-09
migrants O 0 1.516596626061073e-09
during O 0 7.687673275746931e-10
the O 0 1.3275401611334559e-10
19th O 0 1.7900314119856375e-08
century O 0 1.3518766195375065e-07
. O 0 2.988005576298747e-08

Haplotype O 0 1.3308203961059917e-05
analysis O 0 1.655164965086442e-07
using O 0 5.600545094353038e-08
6 O 0 6.79515199664138e-09
RFLPs O 0 1.833077334367772e-07
provides O 0 1.2026272200316157e-09
additional O 0 1.185812142923126e-10
data O 0 1.2663818438340968e-08
that O 0 1.888716127940171e-10
the O 0 1.1370179797687285e-10
I113F O 0 2.064026460857349e-08
mutation O 0 3.040307339219339e-09
originated O 0 2.5535922265618183e-09
from O 0 1.282799838575599e-10
a O 0 2.8469075985526615e-09
common O 0 9.467951755937065e-09
ancestor O 0 2.2461154003394768e-07
. O 0 1.388638111166074e-07

The O 0 2.6727407842486173e-08
other O 0 3.6754410626116396e-09
9 O 0 1.1825338930293583e-08
novel O 0 8.213372204579628e-09
mutations O 0 4.997548330720747e-08
identified O 0 3.8228841958698467e-07
in O 0 3.570445883394058e-10
these O 0 1.287185247278444e-09
23 O 0 1.135255267570301e-08
patients O 0 6.1542393403613e-10
were O 0 1.365575652556572e-09
each O 0 4.699897762638905e-11
limited O 0 1.1915381570304362e-08
to O 0 4.783522022933084e-09
a O 0 1.5709025191767978e-08
single O 0 6.558585710081388e-07
family O 0 1.3719943581236294e-06
. O 0 8.144315444269523e-08

These O 0 9.525789046449518e-09
data O 0 2.7085306442131696e-08
provide O 0 1.9011647811595367e-09
further O 0 1.6390307167046814e-10
evidence O 0 1.1533984878298043e-09
for O 0 2.4884305727113087e-10
extensive O 0 7.06207003986492e-08
allelic O 0 3.8881182717886986e-07
heterogeneity O 0 1.1505127304189955e-06
in O 0 8.340297767972515e-07
MPS B-Disease 1 0.9999948740005493
IVA I-Disease 1 0.9999991655349731
in O 0 1.5553018783975858e-07
British O 0 1.8340373571845703e-05
- O 0 0.054232072085142136
Irish O 0 1.956947016878985e-05
patients O 0 2.1152683871150657e-07
and O 0 2.0095511921169873e-09
provide O 0 6.929937179656065e-10
evidence O 0 5.201385100406242e-09
for O 0 7.02424785004041e-10
their O 0 8.815658758543066e-10
transmission O 0 1.4226444591258769e-06
to O 0 1.0095912994501077e-09
Australia O 0 1.5944868758666075e-09
by O 0 1.2332401766457224e-10
British O 0 2.3138062488214928e-07
- O 0 1.874947702162899e-05
Irish O 0 6.515918471450277e-08
migrants O 0 3.2859897025616647e-09
. O 0 4.055502600408545e-10
. O 0 2.6431985489239196e-09

Identification O 0 1.8008447568718111e-06
of O 0 9.400508815815556e-09
constitutional O 0 1.1347707129516493e-07
WT1 O 0 0.00010044794180430472
mutations O 0 6.106574232944695e-07
, O 0 2.0602179962025957e-09
in O 0 9.669207656770595e-10
patients O 0 1.12306111077487e-08
with O 0 8.758979319622995e-09
isolated O 1 0.6422374844551086
diffuse B-Disease 1 0.9974937438964844
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.238315653992686e-08
and O 0 4.075034754080775e-10
analysis O 0 1.0777937431427631e-09
of O 0 4.0462619366188335e-10
genotype O 0 8.874120794644114e-06
/ O 0 2.8411586754373275e-05
phenotype O 0 1.4181347296471358e-07
correlations O 0 3.812921889334575e-08
by O 0 3.4174083007876277e-10
use O 0 4.2352992224437e-09
of O 0 2.831936907199406e-10
a O 0 1.6599635443981242e-08
computerized O 0 1.1021020327461883e-05
mutation O 0 5.027947622693318e-07
database O 0 9.940504241967574e-07
. O 0 1.219209053715531e-07

Constitutional O 0 2.7378806066735706e-07
mutations O 0 2.1523239013276907e-07
of O 0 2.1956396700772984e-09
the O 0 1.2236085478178893e-09
WT1 O 0 1.938483592311968e-06
gene O 0 1.2474571597920203e-08
, O 0 1.3006817844996021e-10
encoding O 0 1.7892965997745591e-09
a O 0 2.1639724678834682e-08
zinc O 0 0.00010627025039866567
- O 0 4.835929212276824e-05
finger O 0 3.099091918556951e-05
transcription O 0 1.9381268145934882e-08
factor O 0 9.555098934299622e-10
involved O 0 4.076684767539973e-09
in O 0 2.459531245335711e-08
renal O 1 0.6312786936759949
and O 0 3.52163823436058e-07
gonadal O 0 0.0007948853308334947
development O 0 7.678476094952202e-07
, O 0 1.917252800964775e-09
are O 0 1.1095801361049595e-10
found O 0 4.5561424077966706e-10
in O 0 2.653536071428597e-11
most O 0 4.810492559848001e-10
patients O 0 1.1524462495415833e-09
with O 0 5.013298665090815e-09
Denys B-Disease 1 0.9999104738235474
- I-Disease 1 0.9999988079071045
Drash I-Disease 1 0.9999967813491821
syndrome I-Disease 1 0.9999974966049194
( O 0 5.574997885560151e-08
DDS B-Disease 1 0.9999963045120239
) O 0 4.173471790380745e-09
, O 0 9.890466223794192e-10
or O 0 6.911251944075048e-07
diffuse B-Disease 1 0.9661507606506348
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.061283327885576e-07
DMS B-Disease 0 0.0014843286480754614
) O 0 8.154302788554446e-10
associated O 0 4.6045172119590916e-09
with O 0 2.82321765965321e-09
pseudohermaphroditism B-Disease 1 0.9999995231628418
and O 0 4.470709427550901e-06
/ O 0 0.0040962728671729565
or O 0 6.5150129557878245e-06
Wilms B-Disease 1 0.5241600871086121
tumor I-Disease 0 0.010605024173855782
( O 0 4.333184335791884e-07
WT B-Disease 1 0.9998762607574463
) O 0 5.764466237678789e-08
. O 0 1.1370672581278995e-07

Most O 0 1.1316755177404048e-07
mutations O 0 3.3314972824882716e-06
in O 0 1.8555147107690573e-07
DDS B-Disease 1 0.9999998807907104
patients O 0 0.0001371881371596828
lie O 0 6.2054937188804615e-06
in O 0 5.270640590637754e-10
exon O 0 2.7431928728560706e-08
8 O 0 7.3563133362597455e-09
or O 0 2.499868312355602e-09
exon O 0 1.0777901238157028e-08
9 O 0 1.991538134404891e-08
, O 0 3.5386421570748894e-10
encoding O 0 1.996463439013496e-08
zinc O 0 0.00015493878163397312
finger O 0 0.003251738380640745
2 O 0 2.501390916620494e-08
or O 0 3.094047826834867e-07
zinc O 0 1.958212669705972e-05
finger O 0 0.000481765455333516
3 O 0 2.6840549782747303e-09
, O 0 5.769872357674899e-10
respectively O 0 1.7465080492939933e-09
, O 0 3.0230509762141367e-10
with O 0 1.3811791987894395e-10
a O 0 1.2121988746116585e-08
hot O 0 2.276964187331032e-05
spot O 0 6.7584842327050865e-06
( O 0 4.751048998663521e-10
R394W O 0 7.455331463290804e-09
) O 0 6.388344020447079e-11
in O 0 6.048363199173679e-11
exon O 0 5.596199059709761e-08
9 O 0 2.0272656797715172e-07
. O 0 8.37177722701199e-08

We O 0 1.8168965709719487e-07
analyzed O 0 2.6710079481517823e-08
a O 0 7.618773945061719e-10
series O 0 2.047549019223993e-09
of O 0 5.5087254202668134e-11
24 O 0 2.3494615142283237e-09
patients O 0 1.0588803167621563e-09
, O 0 1.2194142917643092e-10
10 O 0 4.5491349576209927e-10
with O 0 8.377491589328656e-09
isolated B-Disease 0 0.05171522498130798
DMS I-Disease 1 0.6213276982307434
( O 0 3.985196617151132e-09
IDMS B-Disease 0 3.3969138257816667e-06
) O 0 2.836456347576899e-10
, O 0 3.048615526690668e-10
10 O 0 2.7023355775313007e-10
with O 0 7.203551977141842e-09
DDS B-Disease 1 0.9999998807907104
, O 0 3.756028021939528e-08
and O 0 1.570827734553859e-08
4 O 0 6.455129319959951e-09
with O 0 5.659203772268029e-09
urogenital B-Disease 0 0.019015034660696983
abnormalities I-Disease 1 0.8794220089912415
and O 0 8.183155841834377e-07
/ O 0 0.16027021408081055
or O 0 0.004100967198610306
WT B-Disease 1 0.99998939037323
. O 0 1.8789842215483077e-06

We O 0 1.880518766483874e-06
report O 0 1.5090525096184138e-07
WT1 O 0 3.0452822102233768e-05
heterozygous O 0 6.495345132861985e-07
mutations O 0 1.3571327883710183e-07
in O 0 3.029858586245382e-09
16 O 0 1.524131398866757e-08
patients O 0 1.4897991285067747e-08
, O 0 3.9069811275105337e-10
4 O 0 1.9308126208983367e-09
of O 0 7.625665099375567e-10
whom O 0 2.0022453384171968e-07
presented O 0 1.8963061165777617e-07
with O 0 4.120944083751965e-07
IDMS B-Disease 0 0.010377250611782074
. O 0 2.0454994853480457e-07

One O 0 6.185996994645393e-07
male O 0 3.0761877951590577e-06
and O 0 5.145586712274053e-08
two O 0 7.1447674443447795e-09
female O 0 4.7900302888592705e-06
IDMS B-Disease 0 0.3846447169780731
patients O 0 2.355543529120041e-07
with O 0 1.1088554963123443e-08
WT1 O 0 0.002489368664100766
mutations O 0 3.0872383831592742e-06
underwent O 0 1.8447973388902028e-06
normal O 0 1.1734922509276657e-06
puberty O 0 8.205042831832543e-06
. O 0 8.366812664917234e-08

Two O 0 2.1969901808915893e-07
mutations O 0 9.745300530994427e-07
associated O 0 3.0372200399142457e-07
with O 0 6.338844826814238e-08
IDMS B-Disease 0 0.001766258617863059
are O 0 1.7638186466939487e-09
different O 0 1.8816900815288307e-10
from O 0 2.3034728291460027e-10
those O 0 7.33389460272349e-10
described O 0 2.4356762651223107e-07
in O 0 3.5163552070116566e-08
DDS B-Disease 1 0.9999994039535522
patients O 0 5.731662326979858e-07
. O 0 1.886665756956063e-08

No O 0 1.9520596197253326e-06
WT1 O 0 3.514708441798575e-05
mutations O 0 2.002883121576815e-07
were O 0 2.660980413793368e-08
detected O 0 6.40923587980069e-07
in O 0 4.2887698947779995e-10
the O 0 2.563917966824647e-10
six O 0 3.788323876818822e-09
other O 0 6.375059147245565e-09
IDMS B-Disease 0 0.013195907697081566
patients O 0 1.4002791814959892e-08
, O 0 1.3652884378601016e-10
suggesting O 0 5.419716675447717e-09
genetic O 0 1.739782717891103e-08
heterogeneity O 0 3.501003220662824e-08
of O 0 1.4744623300089188e-09
this O 0 2.1846507536338322e-07
disease O 0 0.00019669004541356117
. O 0 8.203434020970235e-08

We O 0 3.048220946766378e-07
analyzed O 0 5.512291068043851e-07
genotype O 0 5.474740191857563e-06
/ O 0 8.525343218934722e-06
phenotype O 0 4.058285014707508e-07
correlations O 0 8.19956767372787e-07
, O 0 6.9863448359797076e-09
on O 0 2.7403636693179578e-08
the O 0 1.8877509277981375e-10
basis O 0 1.269307770002115e-08
of O 0 1.5963817767694621e-10
the O 0 9.711829118685955e-10
constitution O 0 1.0643412817756825e-09
of O 0 1.6479269338010027e-10
a O 0 7.311955041444662e-09
WT1 O 0 2.5490837742836447e-06
mutation O 0 9.003280787567292e-09
database O 0 9.703687631201774e-09
of O 0 1.4970355510790512e-10
84 O 0 6.236226823830293e-08
germ O 0 0.00021453337103594095
- O 0 0.002044382970780134
line O 0 0.0021301901433616877
mutations O 0 3.1532852773352715e-08
, O 0 1.8136014912073506e-10
to O 0 1.034783023157182e-10
compare O 0 3.919118807260702e-09
the O 0 8.79179368196148e-11
distribution O 0 1.927068922213948e-07
and O 0 7.148747815932666e-09
type O 0 1.5554604715362075e-06
of O 0 6.122963247534585e-11
mutations O 0 1.5748865322962047e-08
, O 0 3.639928913834467e-10
according O 0 1.7252280160029443e-10
to O 0 5.347732257021676e-10
the O 0 7.032117110838954e-10
different O 0 2.2634633722873332e-08
symptoms O 0 1.1830684343294706e-06
. O 0 2.902716111918835e-08

This O 0 1.2286513140224997e-08
demonstrated O 0 2.4552472055461294e-08
( O 0 1.4422905925126628e-10
1 O 0 2.0971518965851033e-10
) O 0 4.5978779811273185e-11
the O 0 8.802246431738325e-11
association O 0 7.944848112728664e-10
between O 0 3.8764952359215954e-10
mutations O 0 1.977543462317044e-09
in O 0 6.280120173896009e-11
exons O 0 7.130880774752768e-09
8 O 0 1.6573091343730084e-08
and O 0 1.1836893243355462e-08
9 O 0 4.625716343298336e-08
and O 0 2.396204124011092e-08
DMS B-Disease 0 4.558780346997082e-05
; O 0 2.4797883191318704e-10
( O 0 4.803989497870198e-11
2 O 0 2.2363019769322534e-10
) O 0 1.151632747498077e-10
among O 0 3.404922732652693e-10
patients O 0 3.892461908350242e-10
with O 0 2.6377580675251977e-10
DMS B-Disease 0 0.0004481786454562098
, O 0 1.1081714712535273e-10
a O 0 5.722129020613309e-11
higher O 0 1.2081996514368143e-10
frequency O 0 1.4820441540663865e-09
of O 0 4.01852544296144e-11
exon O 0 6.761343929184704e-09
8 O 0 8.023063990947321e-09
mutations O 0 1.8148247349358826e-08
among O 0 5.71162406259873e-09
46 O 0 3.045222172204376e-07
, O 0 6.293834786674779e-08
XY O 0 0.043771084398031235
patients O 0 4.0806628476275364e-07
with O 0 5.086053356251341e-09
female O 0 5.9593503465293907e-08
phenotype O 0 6.852761913478389e-08
than O 0 1.1580657321985655e-08
among O 0 4.281318410903623e-09
46 O 0 1.0504185610216155e-07
, O 0 3.6612952669656806e-08
XY O 0 0.03823598474264145
patients O 0 4.35806668974692e-07
with O 0 3.129162262638374e-09
sexual O 0 7.124113494683115e-07
ambiguity O 0 1.5281285641322029e-06
or O 0 2.1472937987709884e-06
male O 0 2.125399163332986e-07
phenotype O 0 8.631167958128572e-08
; O 0 2.2679524924740235e-09
and O 0 2.005130106397246e-08
( O 0 1.8160695169910923e-10
3 O 0 1.5458002933232962e-10
) O 0 1.9681679896965676e-11
statistically O 0 5.221401644384116e-10
significant O 0 9.063300110412342e-11
evidence O 0 6.540070707217183e-09
that O 0 4.674965414785959e-10
mutations O 0 3.0838238629371517e-09
in O 0 2.129178083842831e-10
exons O 0 1.7588408951496604e-08
8 O 0 1.4272735882059351e-08
and O 0 2.952184496862742e-09
9 O 0 2.323959469308079e-09
preferentially O 0 3.590903929762135e-08
affect O 0 6.148658027171905e-09
amino O 0 3.151700567194382e-10
acids O 0 5.987562529119472e-11
with O 0 2.7154889448155473e-11
different O 0 2.824017235336651e-11
functions O 0 3.560577943595433e-10
. O 0 3.2231872726384836e-10
. O 0 8.845593590933731e-09

The O 0 1.6458214702197438e-07
185delAG O 0 1.5698109564254992e-05
BRCA1 O 0 2.539881961638457e-06
mutation O 0 4.3678110017708605e-08
originated O 0 1.5906358896700112e-08
before O 0 1.983159053642325e-10
the O 0 1.2010923505778592e-11
dispersion O 0 2.5949006499104144e-08
of O 0 1.1181434250717714e-11
Jews O 0 7.85921050461269e-10
in O 0 8.708064824780593e-11
the O 0 4.4710599805819484e-11
diaspora O 0 2.4915567387040483e-09
and O 0 4.330678038400038e-09
is O 0 1.3851292335331777e-09
not O 0 3.7717678980087044e-10
limited O 0 2.3771291601804023e-09
to O 0 6.453873435674495e-09
Ashkenazim O 0 1.18031339297886e-05
. O 0 7.853284245129544e-08

The O 0 2.180532909790145e-08
185delAG O 0 2.2302356228465214e-06
mutation O 0 1.0181529574992965e-07
in O 0 1.7429404586266628e-09
BRCA1 O 0 1.1796298622357426e-06
is O 0 7.887898334502097e-09
detected O 0 1.4722043317760836e-07
in O 0 2.638060048187896e-10
Ashkenazi O 0 4.281075405287993e-08
Jews O 0 2.045094094071942e-09
both O 0 4.717169987955572e-10
in O 0 2.839809987165154e-08
familial B-Disease 1 0.9985425472259521
breast I-Disease 1 0.9999969005584717
and I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.3222835377746378e-06
in O 0 1.1685913348102872e-09
the O 0 2.2930181364788638e-10
general O 0 1.1481415818082041e-09
population O 0 6.892608706010606e-09
. O 0 2.1724254395394382e-08

All O 0 6.392521640918858e-07
tested O 0 9.186671263705648e-07
Ashkenazi O 0 3.1382884913000453e-07
mutation O 0 3.909072177066264e-08
carriers O 0 7.401617985181019e-09
share O 0 2.593266268391403e-09
the O 0 2.1359057578163032e-10
same O 0 1.5660582830534509e-09
allelic O 0 1.677604046790293e-07
pattern O 0 5.203340606385609e-06
at O 0 1.5360653549123526e-07
the O 0 6.1310099219724634e-09
BRCA1 O 0 2.535636895117932e-06
locus O 0 4.439482381712878e-06
. O 0 4.7212347453751136e-07

Our O 0 1.007804485197994e-06
previous O 0 1.0455030619027639e-08
study O 0 1.308083863449383e-09
showed O 0 5.5691739220264935e-08
that O 0 1.6319183504531765e-10
this O 0 1.1507939046140336e-10
Ashkenazi O 0 5.580700346285994e-08
mutation O 0 5.48377032671965e-09
also O 0 4.243433604500524e-09
occurs O 0 3.720651287064669e-10
in O 0 7.48884426693408e-11
Iraqi O 0 2.6385306384213436e-08
Jews O 0 1.5044787637918944e-09
with O 0 4.1105377435179946e-10
a O 0 4.622953131416807e-09
similar O 0 2.3070015231496654e-08
allelic O 0 2.1181581359996926e-06
pattern O 0 5.328574843588285e-05
. O 0 4.5492694766835484e-07

We O 0 7.019378358563699e-07
extended O 0 2.3763325529557733e-08
our O 0 1.0426806085206408e-09
analysis O 0 2.5811061621361375e-10
to O 0 1.4174729445759482e-10
other O 0 5.6398555964287667e-11
non O 0 1.1456790183217436e-08
- O 0 1.2516380820670747e-07
Ashkenazi O 0 9.627125763245203e-09
subsets O 0 6.568273036577921e-09
354 O 0 1.275953920298889e-08
of O 0 8.208884960669849e-11
Moroccan O 0 3.5351241933767596e-08
origin O 0 2.298102597109164e-09
, O 0 1.6652322576415912e-10
200 O 0 3.9948902519348906e-10
Yemenites O 0 2.8335607638041438e-08
and O 0 1.7804757668216098e-09
150 O 0 2.7043065564669178e-09
Iranian O 0 3.944581195014507e-08
Jews O 0 1.2937873883345219e-08
. O 0 1.4413020998915727e-08

Heteroduplex O 0 4.78049369121436e-05
analysis O 0 2.7785011980085983e-07
complemented O 0 1.0413162243594343e-07
by O 0 3.4456304476293553e-10
direct O 0 1.8723649297669454e-09
DNA O 0 1.5442134682075448e-08
sequencing O 0 1.0963530527874354e-08
of O 0 4.169523615260573e-10
abnormally O 0 1.0388701099373066e-07
migrating O 0 1.834774110420767e-09
bands O 0 6.4324527926373776e-09
were O 0 1.0822313711855713e-08
employed O 0 2.33733729260166e-07
. O 0 2.7162080584730575e-08

Four O 0 7.153852266128524e-08
of O 0 3.800552927923917e-10
Moroccan O 0 1.6093498800273665e-07
origin O 0 1.7780085181939853e-09
( O 0 2.7961516782526452e-11
1 O 0 2.2199643165410343e-11
. O 0 1.0567768882197015e-11
1 O 0 3.431017275845605e-11
% O 0 9.38419307539018e-12
) O 0 4.253379939922475e-11
and O 0 6.708240629649254e-09
none O 0 1.0786862514322593e-09
of O 0 1.2781416550144975e-11
the O 0 2.373911067721224e-10
Yemenites O 0 4.429254829574347e-08
or O 0 2.725989878271662e-09
Iranians O 0 3.2585902864923355e-09
was O 0 4.4124750075980046e-08
a O 0 1.5160066535457872e-09
carrier O 0 1.0868650868189889e-08
of O 0 7.537279828051524e-11
the O 0 1.2638907698203639e-09
185delAG O 0 1.6790073686934193e-06
mutation O 0 2.520986299714423e-07
. O 0 5.462664631750158e-08

BRCA1 O 0 8.216576679842547e-05
allelic O 0 5.595671609626152e-06
patterns O 0 7.682559044042137e-06
were O 0 1.0437580755251474e-07
determined O 0 1.6017459358863562e-07
for O 0 1.9296455544548508e-09
four O 0 2.3153837180878156e-10
of O 0 1.6365993629752218e-11
these O 0 2.6139979070194386e-10
individuals O 0 3.1791655419333154e-10
and O 0 8.480475210959071e-10
for O 0 1.7025708620721502e-10
12 O 0 2.495360307275263e-10
additional O 0 6.41711905835507e-10
non O 0 3.003399058343348e-07
- O 0 6.901286724314559e-06
Ashkenazi O 0 2.789317363749433e-07
185delAG O 0 1.7126049556281941e-07
mutation O 0 1.5740697634214484e-08
carriers O 0 2.0257035160398118e-08
who O 0 6.737363378306327e-08
had O 0 0.0006146564846858382
breast B-Disease 1 0.999985933303833
/ I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
. O 0 1.300087546951545e-06

Six O 0 2.2481456198875094e-06
non O 0 1.4272077351051848e-05
- O 0 0.0012468628119677305
Ashkenazi O 0 5.088269608677365e-05
individuals O 0 7.083276898356416e-08
shared O 0 1.1295574253722407e-08
the O 0 8.366053960706665e-10
common O 0 6.687876030753159e-09
Ashkenazi O 0 1.1211567141344858e-07
haplotype O 0 4.160742150816077e-07
, O 0 4.115733087672879e-09
four O 0 3.3616507355560543e-09
had O 0 6.08584187489214e-08
a O 0 1.0082672474709398e-09
closely O 0 6.944657826579714e-08
related O 0 1.4283716609497787e-07
pattern O 0 3.896104681189172e-05
, O 0 7.681081548582824e-09
and O 0 8.278228658120668e-10
the O 0 5.665289071199453e-11
rest O 0 1.3684749999853807e-09
( O 0 9.529432104526947e-11
n O 0 1.5263617569871712e-06
= O 0 9.422643643119955e-07
6 O 0 5.0015507291334416e-09
) O 0 3.604651854782759e-10
displayed O 0 4.5283627514436375e-08
a O 0 4.404299591698191e-09
distinct O 0 3.157016337240748e-08
BRCA1 O 0 4.340523446444422e-06
allelic O 0 3.3471019378339406e-06
pattern O 0 3.264132101321593e-05
. O 0 4.75155246704162e-07

We O 0 1.1998548643532558e-07
conclude O 0 4.6266336539702024e-08
that O 0 6.946187514067503e-10
the O 0 3.978268270365959e-10
185delAG O 0 2.7541218514670618e-06
BRCA1 O 0 5.669123765983386e-07
mutation O 0 7.85714693307682e-09
occurs O 0 5.782068157600406e-10
in O 0 5.228045774074985e-11
some O 0 2.3348881161844304e-10
non O 0 9.311003168477328e-08
- O 0 9.07798130356241e-06
Ashkenazi O 0 1.9510345339313062e-07
populations O 0 1.7728995160837258e-08
at O 0 1.3346045157902608e-08
rates O 0 1.9519310612281515e-08
comparable O 0 1.0183682341846634e-08
with O 0 2.531549969653213e-10
that O 0 4.151034793675734e-10
of O 0 6.714778177929759e-10
Ashkenazim O 0 4.585331225825939e-06
. O 0 4.5940712567471564e-08

The O 0 4.0535809375796816e-08
majority O 0 1.029034990551736e-08
of O 0 1.748410166646508e-10
Jewish O 0 5.5483290850588673e-08
185delAG O 0 7.242197739287803e-07
mutation O 0 4.75882657724469e-08
carriers O 0 1.8067844109737052e-08
have O 0 2.2943098532124395e-09
a O 0 1.8555097458516912e-09
common O 0 3.736597697923116e-09
allelic O 0 9.029940883920062e-08
pattern O 0 0.00015549734234809875
, O 0 6.035646205049261e-09
supporting O 0 8.309443799703331e-09
the O 0 5.592991625391619e-10
founder O 0 1.89761539814981e-08
effect O 0 7.817856917391452e-10
notion O 0 1.289915729785207e-09
, O 0 5.746303433085131e-10
but O 0 3.5061253900181555e-10
dating O 0 4.2167780378576936e-08
the O 0 4.645816023551852e-11
mutations O 0 2.954205213789862e-10
origin O 0 1.7451716460836764e-10
to O 0 7.546720470763546e-10
an O 0 9.433188952190363e-11
earlier O 0 1.7065968638263485e-09
date O 0 3.3176370095588936e-08
than O 0 7.924417233518e-10
currently O 0 5.573952854831532e-09
estimated O 0 4.1077203860595546e-08
. O 0 2.404426524549308e-08

However O 0 2.3086661826710042e-07
, O 0 2.6183157864068107e-09
the O 0 6.690689668964467e-11
different O 0 7.028639475992193e-11
allelic O 0 6.071766023296732e-08
pattern O 0 1.441808581148507e-05
at O 0 4.0375471144216135e-07
the O 0 3.2258828941422735e-09
BRCA1 O 0 3.2629489510327403e-07
locus O 0 5.460977092752728e-08
even O 0 2.5871020881140794e-08
in O 0 2.7845242778212764e-10
some O 0 1.4344497811791257e-10
Jewish O 0 4.804058040264181e-09
mutation O 0 1.5441626866063984e-09
carriers O 0 7.255948619722119e-10
, O 0 1.4790810243248131e-10
might O 0 1.8394975542790348e-09
suggest O 0 4.500719796851627e-09
that O 0 4.5580458851723904e-10
the O 0 2.956759004302256e-10
mutation O 0 4.647779050515055e-09
arose O 0 1.2717231712144894e-09
independently O 0 1.9481928958953176e-08
. O 0 2.2933079879550178e-09
. O 0 4.386788177157541e-08

Crystal O 0 0.0029508459847420454
structure O 0 7.977561836014502e-06
of O 0 8.54979731457206e-09
the O 0 1.2643440072679368e-07
hemochromatosis B-Disease 1 0.9999998807907104
protein O 0 1.9439059997239383e-06
HFE O 0 6.329356256173924e-05
and O 0 2.7196554341912815e-08
characterization O 0 2.06918286949076e-07
of O 0 1.9361073855250766e-10
its O 0 1.975277719168389e-09
interaction O 0 2.292166678685703e-09
with O 0 5.505976230502085e-10
transferrin O 0 2.958094285077095e-07
receptor O 0 3.557404681941989e-08
. O 0 8.131041617787105e-09

HFE O 0 0.034910209476947784
is O 0 1.8783553059620317e-06
an O 0 3.1603766270649203e-09
MHC O 0 1.4526723361996119e-06
- O 0 2.171346204704605e-05
related O 0 2.3609005950220308e-07
protein O 0 1.6032085659034578e-09
that O 0 1.460698229038826e-10
is O 0 2.369107410249427e-10
mutated O 0 2.056864900623623e-09
in O 0 4.1678854811877386e-10
the O 0 2.4280131682985484e-08
iron B-Disease 1 0.9992486834526062
- I-Disease 1 0.9999908208847046
overload I-Disease 1 0.9999841451644897
disease I-Disease 1 0.9999721050262451
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00017747670062817633

HFE O 0 0.0003727058647200465
binds O 0 3.3752701256162254e-07
to O 0 1.9358360248133977e-08
transferrin O 0 1.0406129149487242e-06
receptor O 0 2.2894413476137743e-08
( O 0 1.2522100023559801e-09
TfR O 0 3.574422464680538e-07
) O 0 1.5975240574839233e-10
and O 0 1.599356341808189e-10
reduces O 0 5.950723247494238e-10
its O 0 1.2898954127038564e-10
affinity O 0 6.064607704914238e-10
for O 0 1.529068871519712e-09
iron O 0 5.397874701884575e-05
- O 0 8.721574886294547e-06
loaded O 0 5.102136810819502e-07
transferrin O 0 1.5633051475560933e-07
, O 0 4.739816872323388e-10
implicating O 0 5.607042794508743e-07
HFE O 0 1.28020792544703e-05
in O 0 6.96030211244647e-09
iron O 0 0.00031924681388773024
metabolism O 0 1.4519973774440587e-05
. O 0 8.166123421915472e-08

The O 0 1.3448517677261407e-07
2 O 0 1.76077520563922e-07
. O 0 6.856226519857955e-08

6 O 0 3.994123744632816e-06
A O 0 4.925543066747196e-07
crystal O 0 0.00020287763618398458
structure O 0 1.8822412357621943e-06
of O 0 3.4341240962021402e-09
HFE O 0 6.061653039068915e-05
reveals O 0 3.660489085177687e-07
the O 0 5.648750911468881e-10
locations O 0 1.3351269956274336e-07
of O 0 1.9788876315374182e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 6.957323785172775e-05
and O 0 4.989024660062569e-07
a O 0 7.731500772933941e-08
patch O 0 0.44997429847717285
of O 0 3.4747571486803963e-09
histidines O 0 1.7268635929212905e-05
that O 0 1.2194247389629709e-08
could O 0 1.697825169344469e-08
be O 0 2.5066229647485727e-10
involved O 0 5.522372559241262e-10
in O 0 9.378261500714302e-10
pH O 0 2.0028912331326865e-05
- O 0 4.76002514915308e-06
dependent O 0 7.635509291503695e-07
interactions O 0 9.398378608693747e-08
. O 0 7.154233827577627e-08

We O 0 4.7086399490581243e-07
also O 0 6.024903687062988e-09
demonstrate O 0 1.0968236097141926e-08
that O 0 5.888006193721651e-10
soluble O 0 5.510519827112148e-07
TfR O 0 9.081503230845556e-05
and O 0 6.594772727908094e-09
HFE O 0 2.2793103653384605e-06
bind O 0 8.76909300728812e-09
tightly O 0 1.911215434802216e-07
at O 0 1.7112955674747354e-07
the O 0 3.2980876363275513e-10
basic O 0 7.368448962097318e-08
pH O 0 3.6614915188692976e-07
of O 0 2.42940355332788e-11
the O 0 3.6584432705488723e-10
cell O 0 1.7541012198307726e-07
surface O 0 4.6372274482564535e-06
, O 0 1.1689013090787626e-09
but O 0 2.9000346568608393e-10
not O 0 4.4947809363371505e-10
at O 0 7.416697034301478e-09
the O 0 4.2996470273060083e-10
acidic O 0 2.050060857072822e-06
pH O 0 1.526248297523125e-06
of O 0 7.050247052831082e-10
intracellular O 0 4.622849871793733e-07
vesicles O 0 3.277368250564905e-06
. O 0 1.5051834623136529e-07

TfR O 0 0.015894459560513496
HFE O 0 0.0004589257878251374
stoichiometry O 0 2.5148440272459993e-06
( O 0 1.4503638290364051e-08
2 O 0 2.350411865137403e-09
1 O 0 6.118646700414843e-10
) O 0 9.565780806353175e-11
differs O 0 3.743374499265428e-09
from O 0 1.7533101637212667e-09
TfR O 0 1.6380268789362162e-05
transferrin O 0 2.401704080057243e-08
stoichiometry O 0 2.162453105469808e-09
( O 0 1.0251237358982479e-10
2 O 0 2.081633615480527e-10
2 O 0 2.411446597960776e-10
) O 0 6.389794249272995e-11
, O 0 5.810045153320509e-11
implying O 0 6.71162903032041e-10
a O 0 7.060996232155503e-11
different O 0 1.9895609465470088e-11
mode O 0 4.0476608731410124e-09
of O 0 8.596846325092944e-12
binding O 0 2.2469062166408094e-09
for O 0 1.2182199693455686e-09
HFE O 0 1.9477549358271062e-05
and O 0 2.7172859518032055e-08
transferrin O 0 1.9446999033334578e-07
to O 0 5.321615592634998e-09
TfR O 0 3.9267622923944145e-05
, O 0 8.962259823164231e-10
consistent O 0 1.585000042325646e-08
with O 0 2.750630001546739e-10
our O 0 1.0192012789289606e-09
demonstration O 0 2.9516623811787213e-08
that O 0 4.433070854847898e-10
HFE O 0 6.446887823585712e-07
, O 0 6.256176132701796e-10
transferrin O 0 2.011646138555534e-08
, O 0 1.343240629836373e-09
and O 0 1.9283405094938644e-08
TfR O 0 4.9187641707248986e-05
form O 0 1.3239904728123975e-09
a O 0 8.312217580908055e-09
ternary O 0 1.5547576595054124e-06
complex O 0 4.410701421875274e-06
. O 0 9.008197565663068e-08

Identification O 0 9.94848960544914e-07
of O 0 6.845678246492071e-09
three O 0 5.026549843023531e-09
novel O 0 5.0962231767925914e-08
mutations O 0 6.330350288408226e-08
and O 0 5.634238409157888e-09
a O 0 1.5862421376411362e-09
high O 0 6.3047300713492405e-09
frequency O 0 1.4390934666153044e-08
of O 0 9.60402521399395e-11
the O 0 4.448469370643693e-10
Arg778Leu O 0 3.641033856638387e-07
mutation O 0 5.934528868323241e-09
in O 0 2.7289914772410384e-09
Korean O 0 6.437091542466078e-06
patients O 0 1.1669481381204605e-08
with O 0 2.8231477156026585e-09
Wilson B-Disease 0 5.0998896767850965e-05
disease I-Disease 0 4.075356628163718e-05
. O 0 6.725051093781076e-08

Four O 0 1.1820021228459154e-07
mutations O 0 6.374149279508856e-07
- O 0 2.7870655685546808e-05
- O 0 2.57311749010114e-05
R778L O 0 3.710121347921813e-07
, O 0 7.03541669366814e-10
A874V O 0 3.6606646602876936e-09
, O 0 6.654315987120185e-11
L1083F O 0 3.426619654689489e-09
, O 0 1.2834949769668924e-10
and O 0 1.2812592653510535e-10
2304delC O 0 8.451772259832069e-08
- O 0 4.441388227860443e-06
- O 0 3.5483894862409215e-06
in O 0 8.412425755999209e-10
the O 0 5.906655720089304e-10
copper O 0 6.300633117461985e-07
- O 0 1.748025191261604e-08
transporting O 0 6.2662466326912636e-09
enzyme O 0 7.74903197164889e-10
, O 0 1.5521552099162506e-10
P O 0 3.73763327843335e-07
- O 0 5.024079641202661e-08
type O 0 4.311452812544303e-07
ATPase O 0 8.833034712552035e-07
( O 0 4.045737078683942e-10
ATP7B O 0 1.0939470485027414e-07
) O 0 5.088144489073798e-11
, O 0 2.233257329065097e-11
were O 0 5.377045475540854e-10
identified O 0 9.191984418066568e-08
in O 0 3.7139598063617996e-09
Korean O 0 2.7254558517597616e-05
Patients O 0 7.64996777036231e-09
with O 0 3.87810228374974e-09
Wilson B-Disease 0 6.361051055137068e-05
disease I-Disease 0 3.70145462511573e-05
. O 0 3.8018761472358165e-08

Arg778Leu O 0 0.0002570846409071237
, O 0 2.9109047616771022e-08
the O 0 2.250327563180221e-10
most O 0 2.0496072894449213e-10
frequently O 0 2.990759639942553e-08
reported O 0 1.4395992309346184e-07
mutation O 0 8.498740600160204e-10
of O 0 7.932317996894866e-12
this O 0 5.350249410174257e-11
enzyme O 0 5.679898218424739e-10
, O 0 2.553362243862267e-10
was O 0 3.5524928421182267e-07
found O 0 1.3695829359505751e-08
in O 0 3.4889272026994433e-10
six O 0 7.817826941369788e-10
of O 0 5.7896906019427874e-11
eight O 0 1.2898615509016054e-09
unrelated O 0 4.216810012280803e-08
patients O 0 8.007710050605965e-10
studied O 0 8.817929164628424e-10
, O 0 1.761547678558184e-11
an O 0 4.802887688254431e-12
allele O 0 1.250272108066497e-09
frequency O 0 7.0085941494824056e-09
of O 0 7.81896047907793e-10
37 O 0 1.22706154570551e-07
. O 0 5.6384337199233414e-08

5 O 0 1.3902122475428769e-07
% O 0 5.0866355572054545e-09
, O 0 8.531125250677007e-10
which O 0 9.507216125470563e-10
is O 0 3.5019681599024466e-10
considerably O 0 9.362605135621038e-10
higher O 0 2.3248893088467781e-10
than O 0 2.1369365998946677e-10
those O 0 2.65270617971769e-11
in O 0 2.399621473747615e-11
other O 0 5.6250195473728226e-11
Asian O 0 4.254079866150562e-10
populations O 0 8.376661142506237e-09
. O 0 1.3231379547562483e-08

The O 0 3.677097737408985e-08
novel O 0 2.656700281988833e-08
single O 0 6.1664628958624235e-09
nucleotide O 0 2.1203291566962434e-08
deletion O 0 2.400632226340349e-08
, O 0 6.965637511235911e-10
2304delC O 0 8.056404965373076e-08
, O 0 7.701145277039245e-10
was O 0 8.077607560608158e-08
found O 0 6.974481880916983e-09
in O 0 5.272832725999876e-10
one O 0 2.1251066684158104e-08
patient O 0 5.247500212135492e-07
. O 0 2.258168052549081e-08

Since O 0 6.690520137908607e-08
a O 0 3.976995621712831e-09
mutation O 0 1.5938185882191647e-08
at O 0 4.415116272582509e-09
cDNA O 0 6.966866550328632e-08
nucleotide O 0 2.504210385723127e-07
2302 O 0 2.226582410003175e-06
( O 0 3.730621089825803e-10
2302insC O 0 2.0046902804438105e-08
) O 0 3.496161971039413e-10
had O 0 4.382654683610099e-09
been O 0 1.6627449417327966e-09
previously O 0 1.707649310844772e-08
described O 0 4.531559341103275e-07
, O 0 7.395786205677268e-10
this O 0 2.0910807807528187e-10
region O 0 4.3619228229374585e-09
of O 0 6.737752022978327e-11
the O 0 5.332261299173524e-10
ATP7B O 0 3.647915946203284e-06
gene O 0 3.140740290064059e-08
may O 0 1.9063255862761253e-08
be O 0 2.799297682543056e-09
susceptible O 0 8.0805968138975e-08
to O 0 2.150114752907939e-09
gene O 0 1.94096242012165e-06
rearrangements O 0 0.0007714765961281955
causing O 0 0.00024651005514897406
Wilson B-Disease 0 0.000544062873814255
disease I-Disease 0 0.0007124229450710118
. O 0 1.761310812753436e-07

Disruption O 0 7.186658876889851e-06
of O 0 1.7278865005465605e-09
splicing O 0 1.2986137676307408e-07
regulated O 0 4.859809337176557e-07
by O 0 2.9278253155240463e-09
a O 0 2.444826208147788e-08
CUG O 0 0.00017008392023853958
- O 0 1.3090004358673468e-05
binding O 0 5.768094979430316e-07
protein O 0 3.5087720107185305e-07
in O 0 3.728270598912786e-07
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999961853027344
. O 0 2.4969924652396003e-06

Myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.00020261626923456788
DM B-Disease 1 1.0
) O 0 1.091232320504787e-06
is O 0 1.8777541299641598e-07
caused O 0 1.3780492302828407e-08
by O 0 1.7876956859286253e-10
a O 0 6.444533795502139e-10
CTG O 0 7.715876222391671e-07
expansion O 0 9.229453645787089e-09
in O 0 3.771307710564997e-10
the O 0 2.752393590821356e-10
3 O 0 4.274203657672615e-09
untranslated O 0 1.6726498870411888e-06
region O 0 2.0630976038660265e-08
of O 0 4.464491831779327e-10
the O 0 5.574912975703228e-08
DM B-Disease 1 0.9999984502792358
gene O 0 6.305006536422297e-06
. O 0 3.7755654602733557e-07

One O 0 1.0426636976035297e-07
model O 0 7.026055754977278e-07
of O 0 3.255976110949632e-08
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 4.890962372883223e-05
suggests O 0 6.272084362990427e-08
that O 0 7.751486119644824e-10
RNAs O 0 2.189548098385785e-07
from O 0 3.2428024154818047e-10
the O 0 7.419886927095831e-11
expanded O 0 1.429485085857607e-09
allele O 0 3.3073748184619944e-09
create O 0 1.0375998948930487e-09
a O 0 2.662111198148409e-09
gain O 0 1.7491164783223212e-07
- O 0 3.119973598586512e-06
of O 0 1.9226507053105024e-09
- O 0 2.4470653443131596e-05
function O 0 5.115710877134916e-08
mutation O 0 6.102504612748305e-10
by O 0 4.0247999377740484e-11
the O 0 9.461208899663731e-11
inappropriate O 0 8.820695995837013e-08
binding O 0 9.931108158056645e-10
of O 0 1.2822756745300978e-11
proteins O 0 1.7108393868259242e-10
to O 0 3.7536754260436567e-10
the O 0 3.4688039107777513e-09
CUG O 0 1.091028480004752e-05
repeats O 0 8.322706435137661e-07
. O 0 4.043696577582523e-08

Data O 0 2.0045831661263946e-06
presented O 0 4.4563375212192113e-08
here O 0 6.274822439422678e-09
indicate O 0 1.7817948005927065e-08
that O 0 3.5778421891841106e-10
the O 0 9.055852595585279e-11
conserved O 0 1.796320958646902e-08
heterogeneous O 0 9.054517136064533e-08
nuclear O 0 5.820773822051706e-06
ribonucleoprotein O 0 2.0220485907884722e-07
, O 0 3.132636372527031e-10
CUG O 0 3.495859175473015e-07
- O 0 1.3966892709049716e-07
binding O 0 9.160110003847421e-09
protein O 0 2.2334598615003642e-09
( O 0 6.058534923747416e-11
CUG O 0 2.3446555985628947e-07
- O 0 6.814817652411875e-07
BP O 0 3.217883772776986e-07
) O 0 6.982008027289766e-11
, O 0 9.515646604008055e-11
may O 0 1.089450529789815e-09
mediate O 0 1.365128952102168e-07
the O 0 1.132672178272287e-09
trans O 0 1.4149655669370986e-07
- O 0 6.110422873462085e-06
dominant O 0 2.325916739209788e-07
effect O 0 3.3903175822302956e-09
of O 0 7.354790387825716e-11
the O 0 7.883863006874492e-10
RNA O 0 5.810630199221123e-08
. O 0 1.0543483419667155e-08

CUG O 0 0.00037827639607712626
- O 0 0.000395341805415228
BP O 0 6.23187079327181e-05
was O 0 1.7926866746620362e-07
found O 0 1.333303689676768e-09
to O 0 3.691272634775977e-11
bind O 0 7.72568564677556e-10
to O 0 3.741423837411162e-10
the O 0 5.157618776507888e-10
human O 0 5.4394483584019326e-08
cardiac O 0 1.560244413667533e-06
troponin O 0 2.3019983927952126e-05
T O 0 2.0399122149683535e-05
( O 0 3.9438022292337394e-10
cTNT O 0 1.7692240561473227e-08
) O 0 9.265709033368097e-11
pre O 0 2.296242485044786e-07
- O 0 1.9423141566221602e-06
messenger O 0 3.911592827421373e-08
RNA O 0 3.4622007483164907e-09
and O 0 1.2151560313533594e-10
regulate O 0 3.5265290687647166e-09
its O 0 5.150559978517322e-10
alternative O 0 8.436837894976179e-09
splicing O 0 1.77832234271591e-07
. O 0 3.244748825181887e-08

Splicing O 0 2.0619036149582826e-06
of O 0 1.9464398093305135e-08
cTNT O 0 7.004425697232364e-06
was O 0 7.05517663845967e-07
disrupted O 0 1.2307725228311028e-05
in O 0 4.324258640053813e-08
DM B-Disease 1 0.9999998807907104
striated O 0 0.0018095752457156777
muscle O 0 5.5851192882983014e-05
and O 0 7.210592656292647e-08
in O 0 6.305953537122377e-10
normal O 0 1.703589447288323e-08
cells O 0 9.433557934812598e-09
expressing O 0 2.162098500235743e-09
transcripts O 0 6.749466052724529e-08
that O 0 4.23002743943357e-09
contain O 0 4.055074214193155e-07
CUG O 0 4.196773443254642e-05
repeats O 0 4.355242708697915e-06
. O 0 7.408669233655019e-08

Altered O 0 8.099859769572504e-06
expression O 0 2.830855407864874e-07
of O 0 6.037116917489982e-10
genes O 0 3.03459692929664e-08
regulated O 0 7.543690827560567e-08
posttranscriptionally O 0 4.130544368763367e-07
by O 0 2.844389168643602e-09
CUG O 0 3.8102447433630005e-05
- O 0 1.783792322385125e-05
BP O 0 2.365298087170231e-06
therefore O 0 1.6407142311436473e-09
may O 0 5.505671474281826e-10
contribute O 0 7.193717843634317e-10
to O 0 1.1388336496054308e-08
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 2.6558738682069816e-05
. O 0 7.325621886877798e-09
. O 0 2.9637405418725393e-08

Identification O 0 8.891146876521816e-07
of O 0 5.4033053586977076e-09
a O 0 3.571314266537229e-08
novel O 0 3.2419654871773673e-07
nonsense O 0 0.00021115245181135833
mutation O 0 8.849208654737595e-08
and O 0 7.994052642068539e-10
a O 0 7.736656870704905e-10
missense O 0 3.829561379120605e-08
substitution O 0 1.4476712051347818e-09
in O 0 1.670357047123261e-10
the O 0 1.4805204284762397e-10
vasopressin O 0 7.570251980837384e-09
- O 0 8.960564628068823e-07
neurophysin O 0 8.631701007288939e-07
II O 0 2.0322463001321012e-07
gene O 0 4.502256789606918e-09
in O 0 4.932917962996441e-10
two O 0 1.061175036731754e-09
Spanish O 0 4.188769509028134e-08
kindreds O 0 7.021560577413766e-06
with O 0 3.6003680037310914e-08
familial B-Disease 0 0.0674414411187172
neurohypophyseal I-Disease 1 0.9983075857162476
diabetes I-Disease 1 0.9997623562812805
insipidus I-Disease 1 0.9910818338394165
. O 0 3.1400836633110885e-06

Familial B-Disease 1 0.999106228351593
neurohypophyseal I-Disease 1 0.9998997449874878
diabetes I-Disease 1 0.9999979734420776
insipidus I-Disease 1 0.9999706745147705
( O 0 4.854448343394324e-05
FNDI B-Disease 1 0.9999994039535522
) O 0 9.835918035605573e-08
is O 0 1.3099251816584e-07
an O 0 7.427458825759459e-08
autosomal B-Disease 1 0.9999604225158691
dominant I-Disease 1 0.999984622001648
disease I-Disease 1 0.9999630451202393
caused O 0 6.857330299681053e-05
by O 0 3.859571279463125e-06
deficiency O 1 0.7469666600227356
in O 0 4.541681253300567e-09
the O 0 1.402468274847024e-08
antidiuretic O 0 0.00023001186491455883
hormone O 0 1.393676853922443e-07
arginine O 0 5.7616961868234284e-08
vasopressin O 0 3.514028890094778e-08
( O 0 5.563286498144748e-10
AVP O 0 1.9203245216203868e-08
) O 0 6.667274371485732e-11
encoded O 0 1.640844821126919e-10
by O 0 9.158214464566328e-11
the O 0 2.5446594831279867e-10
AVP O 0 1.7338913949060952e-06
- O 0 3.4371844321867684e-06
neurophysin O 0 4.6434674914053176e-06
II O 0 2.6682719180826098e-06
( O 0 1.1706438041159117e-09
AVP O 0 7.367352736764587e-07
- O 0 3.2674909107299754e-06
NPII O 0 1.0089527222589822e-06
) O 0 1.2211272271134277e-10
gene O 0 1.5888279580877906e-09
on O 0 5.638334243940335e-09
chromosome O 0 9.824143489822745e-06
20p13 O 0 4.082673967786832e-06
. O 0 1.394155475509251e-07

In O 0 7.458361039880401e-09
this O 0 1.4403661596773532e-10
study O 0 2.7678659364482883e-10
, O 0 1.3792206265961227e-10
we O 0 3.3380215258560497e-10
analyzed O 0 2.531343579192935e-09
two O 0 1.2165753127124646e-10
families O 0 1.1768136465306611e-09
with O 0 1.7482243430677613e-09
FNDI B-Disease 1 0.9999325275421143
using O 0 8.222385439182744e-09
direct O 0 1.1425060897352068e-08
automated O 0 6.025376819707162e-08
fluorescent O 0 9.08556696543883e-09
, O 0 3.4540859061849005e-10
solid O 0 3.8411469560628575e-09
phase O 0 9.328901207084073e-09
, O 0 4.920852059164815e-10
single O 0 1.0426234986482541e-08
- O 0 4.349783182533429e-07
stranded O 0 9.823072133485766e-09
DNA O 0 5.306591277509654e-10
sequencing O 0 5.608610242902046e-10
of O 0 9.271401008037472e-11
PCR O 0 1.1906480779089179e-07
- O 0 9.793200206331676e-08
amplified O 0 1.974503476276368e-07
AVP O 0 1.920447402881109e-06
- O 0 1.6081147578006494e-06
NPII O 0 6.02471527599846e-06
DNA O 0 2.3493021217291243e-07
. O 0 2.989082759086159e-08

In O 0 6.446420286465582e-08
one O 0 3.4654512592879883e-09
of O 0 1.251087289322328e-10
the O 0 5.388339219258853e-10
families O 0 4.791137264703593e-09
, O 0 1.7178638511694544e-09
affected O 0 1.8087325415194755e-08
individuals O 0 4.627793981359929e-10
presented O 0 1.1754571538347136e-08
a O 0 1.8947508451105932e-08
novel O 0 1.0943895745185728e-07
nonsense O 0 4.8690594667277765e-06
mutation O 0 2.748455019130347e-09
in O 0 4.691335861450874e-11
exon O 0 1.7258213746984552e-09
3 O 0 1.5175515288845531e-09
of O 0 5.164723163031404e-11
the O 0 8.471498502693464e-11
gene O 0 2.1624200208236743e-09
, O 0 1.1533780874817268e-10
consisting O 0 7.261317241935572e-11
in O 0 6.564008364629004e-11
a O 0 3.78370934583927e-09
G O 0 3.5015425510209752e-06
to O 0 3.120224079111722e-08
T O 0 2.3374885131488554e-05
transition O 0 6.8710557243889525e-09
at O 0 8.875845836087137e-09
nucleotide O 0 7.54247864165336e-09
2101 O 0 4.969110136698873e-07
, O 0 3.988106789254431e-10
which O 0 2.0708543213565633e-10
produces O 0 8.55478410333177e-10
a O 0 1.8938565993220635e-10
stop O 0 6.9152314985387875e-09
signal O 0 1.930014725814999e-08
in O 0 1.0653380261294032e-10
codon O 0 2.0077171924981485e-08
82 O 0 9.67804947293871e-09
( O 0 6.366986937678121e-10
Glu O 0 1.2228192645125091e-06
) O 0 1.0506641112684179e-09
of O 0 1.2676377725284738e-09
NPII O 0 1.1498829735501204e-05
. O 0 6.555609388669836e-08

The O 0 3.6433917216527334e-08
premature O 0 6.834212626927183e-07
termination O 0 1.1589013837465245e-07
eliminates O 0 3.320162988984521e-08
part O 0 6.504591087974632e-09
of O 0 9.978456949610859e-11
the O 0 1.3086354222480168e-09
C O 0 7.62736817705445e-06
- O 0 1.7598276826902293e-06
terminal O 0 2.712563968998438e-07
domain O 0 2.7257560653026758e-09
of O 0 3.835476727886977e-11
NPII O 0 1.3077698213237454e-06
, O 0 1.8355326980579179e-10
including O 0 3.337879625475715e-11
a O 0 7.908573795845086e-11
cysteine O 0 2.1414289785859353e-10
residue O 0 3.2399605220945205e-09
in O 0 7.840641330636444e-11
position O 0 3.14007353452439e-09
85 O 0 4.956118293542033e-10
, O 0 4.9248306821514376e-11
which O 0 4.2718542592190545e-10
could O 0 3.3572549185123535e-09
be O 0 4.80114281664612e-10
involved O 0 6.370849958692304e-10
in O 0 2.0295999603181514e-10
the O 0 2.8882107816485814e-10
correct O 0 2.995806426042691e-06
folding O 0 3.066745080104738e-07
of O 0 2.1177283537898717e-10
the O 0 3.070196097354483e-09
prohormone O 0 5.2242303354432806e-05
. O 0 1.2984985175990005e-07

In O 0 6.803415431022586e-08
the O 0 3.1804101574550714e-09
second O 0 7.603926377441894e-09
family O 0 1.1334770988469245e-07
, O 0 2.556734546299566e-10
a O 0 1.633556484526011e-10
G279A O 0 2.5303443784707724e-09
substitution O 0 6.639498950633538e-10
at O 0 2.334053306185524e-08
position O 0 2.9737803330931456e-08
- O 0 8.856098077103525e-08
1 O 0 1.7071526137169002e-10
of O 0 7.0313321137716045e-12
the O 0 2.9699156328666376e-11
signal O 0 1.0280658102601592e-08
peptide O 0 1.1601337945865708e-10
was O 0 2.220918449147291e-10
observed O 0 3.346040389207161e-10
in O 0 2.1838843233812355e-11
all O 0 9.423154617715923e-11
affected O 0 6.052223611163754e-09
individuals O 0 1.233021906799081e-09
. O 0 7.699416215700694e-09

This O 0 1.725687326370462e-08
missense O 0 1.0266752724419348e-05
mutation O 0 7.054604225231742e-07
, O 0 8.491906733354426e-09
which O 0 3.027572503810916e-08
replaces O 0 1.3105153584547224e-06
Ala O 0 1.5004237639004714e-06
with O 0 2.2860104920141566e-09
Thr O 0 4.332118987804279e-05
, O 0 4.55606663507524e-09
is O 0 3.1356388596748275e-09
frequent O 0 1.2108498026464076e-07
among O 0 5.9285806486286674e-08
FNDI B-Disease 1 1.0
patients O 0 1.6992008795568836e-06
and O 0 7.92671972504877e-09
is O 0 3.284623462107561e-09
thought O 0 9.524384614323367e-10
to O 0 8.750555141601168e-11
reduce O 0 1.1524903253956609e-09
the O 0 4.1435733316719237e-11
efficiency O 0 4.737649828001622e-09
of O 0 8.065587087102699e-11
cleavage O 0 1.5914622508717002e-07
by O 0 3.8700681548320404e-10
signal O 0 1.555904134420416e-07
peptidases O 0 3.7895003401899885e-07
. O 0 9.828428071401163e-10
. O 0 1.3104645368855472e-08

Genetic O 0 3.1437782581633655e-06
heterogeneity O 0 1.26212887607835e-06
of O 0 2.1095184266073375e-08
Saethre B-Disease 1 0.83622145652771
- I-Disease 1 0.9999812841415405
Chotzen I-Disease 1 0.9999885559082031
syndrome I-Disease 1 0.9999966621398926
, O 0 6.090855819707031e-09
due O 0 3.3812634914198725e-09
to O 0 2.577530855418786e-09
TWIST O 0 2.089337976940442e-05
and O 0 1.3033209711466043e-07
FGFR O 0 8.775344031164423e-05
mutations O 0 9.678170727056568e-07
. O 0 5.406029757182296e-08

Thirty O 0 3.880830263369717e-06
- O 0 4.4288877688813955e-05
two O 0 8.581918287120516e-09
unrelated O 0 5.114881673762284e-07
patients O 0 9.171508885685853e-09
with O 0 8.976385607040172e-11
features O 0 4.1646799786576594e-07
of O 0 1.2973432106377913e-08
Saethre B-Disease 1 0.9526472687721252
- I-Disease 1 0.9999943971633911
Chotzen I-Disease 1 0.9999963045120239
syndrome I-Disease 1 0.9999979734420776
, O 0 6.0219162989483266e-09
a O 0 1.1891541973341191e-08
common O 0 7.512861657232861e-07
autosomal B-Disease 0 0.04024146869778633
dominant I-Disease 0 0.022102054208517075
condition I-Disease 0 0.07789868861436844
of O 0 4.672669717820099e-08
craniosynostosis B-Disease 1 0.9462692737579346
and O 0 2.816952928696992e-06
limb B-Disease 0 0.02301533706486225
anomalies I-Disease 0 0.008429191075265408
, O 0 1.1355713702698722e-08
were O 0 1.2677278782291523e-08
screened O 0 1.716735624768262e-07
for O 0 1.1681768885551946e-09
mutations O 0 1.7174421884647018e-08
in O 0 4.879522341738607e-10
TWIST O 0 3.017406413619028e-07
, O 0 4.830907229802506e-09
FGFR2 O 0 1.2112071772207855e-06
, O 0 1.4543493076502045e-09
and O 0 1.5359855609631268e-08
FGFR3 O 0 3.2272437238134444e-05
. O 0 1.1854215387074873e-07

Nine O 0 2.551267698436277e-06
novel O 0 5.062846639702911e-07
and O 0 2.2029696822301048e-07
three O 0 1.503013891124283e-08
recurrent O 0 9.58269665716216e-05
TWIST O 0 4.375296612124657e-06
mutations O 0 7.609254737417359e-08
were O 0 2.9681080704335727e-08
found O 0 7.771268073497595e-09
in O 0 4.305284739825055e-10
12 O 0 3.784062840850311e-09
families O 0 1.305963159836665e-08
. O 0 2.5883657883696287e-08

Seven O 0 3.0077157475716376e-07
families O 0 6.812881991891118e-08
were O 0 1.3287118072469184e-08
found O 0 1.705139252017318e-09
to O 0 5.307876915772169e-10
have O 0 1.0020827723167258e-08
the O 0 1.67469552114774e-10
FGFR3 O 0 2.205926421083859e-06
P250R O 0 2.4388274511011332e-08
mutation O 0 1.6858300311284324e-09
, O 0 4.4322082115577643e-10
and O 0 3.3295532997357213e-09
one O 0 2.3565256412894087e-09
individual O 0 4.987334989436931e-10
was O 0 9.256921202904778e-07
found O 0 1.725921094930527e-08
to O 0 1.4619782051639163e-09
have O 0 3.914158330786677e-09
an O 0 3.4094521650374077e-10
FGFR2 O 0 1.94018502952531e-06
VV269 O 0 1.880691513633792e-07
- O 0 5.855354174855165e-07
270 O 0 1.0119344295844712e-07
deletion O 0 1.172776251223695e-06
. O 0 1.7163834797884192e-07

To O 0 1.8980822247272044e-08
date O 0 1.380859799837708e-07
, O 0 9.72918301478387e-10
our O 0 4.436132572394058e-10
detection O 0 5.347878140327111e-09
rate O 0 1.8371842713804654e-08
for O 0 5.535382568977454e-11
TWIST O 0 9.166545567040885e-08
or O 0 1.29706858587042e-08
FGFR O 0 4.2392818500047724e-07
mutations O 0 2.4117052799255134e-09
is O 0 8.982488086672902e-10
68 O 0 3.3429736756573902e-09
% O 0 1.3341959481660837e-10
in O 0 4.373425233072936e-10
our O 0 1.520778027952474e-07
Saethre B-Disease 0 0.007063966244459152
- I-Disease 1 0.9999139308929443
Chotzen I-Disease 1 0.9999727010726929
syndrome I-Disease 1 0.9999911785125732
patients O 0 1.1144449985067695e-07
, O 0 6.651730832807345e-10
including O 0 9.116744692505563e-09
our O 0 3.536729309416842e-08
five O 0 5.178535933403339e-10
patients O 0 6.365918348016919e-10
elsewhere O 0 2.5324444763441534e-09
reported O 0 1.1887691186984739e-07
with O 0 1.043275466017235e-09
TWIST O 0 5.4139309213496745e-06
mutations O 0 8.69384393809014e-07
. O 0 1.186956666288097e-07

More O 0 1.1147209377782019e-08
than O 0 1.4692351779643786e-09
35 O 0 2.524511266699392e-09
different O 0 8.669070322708805e-11
TWIST O 0 2.7313049599797523e-08
mutations O 0 6.437829380701032e-09
are O 0 1.2924744607900607e-09
now O 0 6.026420695803836e-09
known O 0 1.4758474442544411e-08
in O 0 5.344367726145549e-10
the O 0 4.1577860598884797e-10
literature O 0 1.530884752298789e-08
. O 0 2.5917842094713706e-08

The O 0 3.5446642954184426e-08
most O 0 4.0221950214913704e-09
common O 0 1.87282545027756e-09
phenotypic O 0 7.590931261347578e-08
features O 0 5.3874473451287486e-06
, O 0 1.1179063008626144e-08
present O 0 2.5381070578589515e-09
in O 0 1.0298173425127288e-10
more O 0 7.002719931703538e-11
than O 0 3.3345087802061357e-10
a O 0 2.5441220241617657e-09
third O 0 2.1699904095839884e-08
of O 0 9.966955039075742e-10
our O 0 5.435309731183224e-07
patients O 0 1.8803170132031255e-09
with O 0 9.859458388605802e-11
TWIST O 0 2.8039755761710694e-07
mutations O 0 3.078518417964915e-08
, O 0 3.5574418411066233e-10
are O 0 4.795121522072066e-10
coronal B-Disease 0 6.826402909609897e-07
synostosis I-Disease 0 2.032805923590786e-06
, O 0 2.0230424002676273e-09
brachycephaly B-Disease 0 3.801322009167052e-06
, O 0 4.3808935146216754e-08
low B-Disease 0 0.007176664192229509
frontal I-Disease 1 0.9999796152114868
hairline I-Disease 1 0.9999790191650391
, O 0 5.205477577874262e-07
facial B-Disease 0 0.0025217554066330194
asymmetry I-Disease 0 5.5509670346509665e-05
, O 0 1.9830444841772987e-07
ptosis B-Disease 0 0.059317175298929214
, O 0 7.86395659702066e-08
hypertelorism B-Disease 0 0.00022496179735753685
, O 0 5.1618361140981506e-08
broad B-Disease 0 1.2216000868647825e-05
great I-Disease 0 8.71374322741758e-06
toes I-Disease 0 0.048936035484075546
, O 0 8.762504499770785e-09
and O 0 1.2097089552298712e-08
clinodactyly B-Disease 0 1.693549165793229e-05
. O 0 1.0364436775489594e-07

Significant O 0 4.549616789972788e-07
intra O 0 1.3528981980925892e-05
- O 0 0.0001710005453787744
and O 0 3.6150524351796776e-08
interfamilial O 0 5.873889108443109e-07
phenotypic O 0 1.3596381620573084e-07
variability O 0 2.2959759462537477e-06
is O 0 3.786531976857077e-09
present O 0 9.689847813021402e-10
for O 0 1.7888007741717615e-10
either O 0 8.784795113569999e-09
TWIST O 0 1.857111215031182e-06
mutations O 0 4.243962052896677e-07
or O 0 1.1186446613464796e-07
FGFR O 0 7.265203748829663e-05
mutations O 0 1.2556088222481776e-06
. O 0 2.621883368192357e-07

The O 0 2.0845998704999147e-08
overlap O 0 8.928672912134061e-08
in O 0 2.059707293611268e-09
clinical O 0 1.0033109987261923e-07
features O 0 1.0014532563218381e-05
and O 0 2.3274878913071007e-07
the O 0 2.457446746095826e-10
presence O 0 1.5402921604845687e-08
, O 0 1.9251816807397404e-10
in O 0 9.279715884602524e-11
the O 0 6.767155585896134e-11
same O 0 5.064870189919191e-10
genes O 0 5.927466295574391e-10
, O 0 3.49400022803259e-11
of O 0 4.97144122743598e-12
mutations O 0 1.4987726337789553e-10
for O 0 6.743113706297876e-11
more O 0 2.6261468000221555e-10
than O 0 1.562266427335146e-09
one O 0 2.436580492926055e-09
craniosynostotic B-Disease 0 3.6851904496870702e-06
condition I-Disease 0 1.304684246861143e-06
- O 0 8.497792691741779e-08
such O 0 1.0731741051372978e-09
as O 0 3.212191179713386e-09
Saethre B-Disease 0 1.9601226597387722e-07
- I-Disease 0 6.184959033816995e-07
Chotzen I-Disease 0 4.2741490346998035e-07
, I-Disease 0 5.787529344658537e-10
Crouzon I-Disease 0 1.676078369428069e-07
, I-Disease 0 2.681517230485042e-09
and I-Disease 0 1.0466547450960206e-07
Pfeiffer I-Disease 0 0.0005403539980761707
syndromes I-Disease 0 3.917396315955557e-05
- O 0 1.727398921502754e-05
support O 0 2.318435399217833e-08
the O 0 6.735195734464128e-11
hypothesis O 0 3.930452407985285e-09
that O 0 3.327126352203891e-10
TWIST O 0 2.8423295717061592e-08
and O 0 1.206233890549413e-09
FGFRs O 0 4.553305998911128e-08
are O 0 1.4731826869507358e-10
components O 0 6.598106949695648e-09
of O 0 1.4378894776234663e-11
the O 0 2.5882580800828947e-11
same O 0 1.5941271913622046e-10
molecular O 0 6.00572869213778e-10
pathway O 0 5.818409642976974e-10
involved O 0 1.9898656333783293e-10
in O 0 2.129059081812379e-11
the O 0 1.889399747767584e-11
modulation O 0 1.0346142609307662e-08
of O 0 3.81205467192558e-09
craniofacial O 0 0.436208575963974
and O 0 1.3660866216014256e-06
limb O 0 0.012346050702035427
development O 0 1.9634022407899465e-07
in O 0 1.6933773272498343e-09
humans O 0 4.3081209710749135e-09
. O 0 9.8426855554834e-10
. O 0 2.7515879352790762e-08

Mutation O 0 2.73131604444643e-06
analysis O 0 1.3917815522290766e-07
of O 0 8.741125867572919e-08
UBE3A O 1 0.9959824085235596
in O 0 0.3578771948814392
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0006974575808271766
. O 0 5.178531523597485e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00010668574395822361
AS B-Disease 1 0.9999862909317017
) O 0 7.4133876815096755e-09
is O 0 9.617417084939461e-09
caused O 0 1.1423492374262878e-08
by O 0 9.994366445553737e-10
chromosome O 0 2.5400113372597843e-05
15q11 O 0 3.5957334603153868e-06
- O 0 1.2311059435887728e-05
q13 O 0 3.195553119894612e-07
deletions O 0 5.788418633301262e-08
of O 0 3.4921248115438175e-09
maternal O 0 1.1317202961436124e-06
origin O 0 4.045808577046728e-09
, O 0 1.2703461615970468e-09
by O 0 3.3164966328769196e-09
paternal O 0 1.898887421702966e-05
uniparental B-Disease 0 0.0005920474068261683
disomy I-Disease 0 0.002504189731553197
( O 0 2.1624072132908623e-07
UPD B-Disease 1 0.9999943971633911
) O 0 7.626076659050796e-09
15 O 0 2.2461006388141413e-09
, O 0 3.8979894312340946e-10
by O 0 1.047378739293947e-09
imprinting O 0 0.008991091512143612
defects O 1 0.9939163327217102
, O 0 1.0748626877443712e-08
and O 0 1.5427260580125335e-09
by O 0 3.4924294012306234e-10
mutations O 0 1.2635227086832401e-08
in O 0 5.109805356617869e-10
the O 0 3.9412926255977254e-09
UBE3A O 0 5.028512896387838e-05
gene O 0 5.658391160068277e-07
. O 0 7.932908374641556e-08

UBE3A O 0 0.004563577938824892
encodes O 0 5.833600425830809e-06
a O 0 9.253023591782039e-08
ubiquitin O 0 2.0832660538872005e-06
- O 0 5.1262968554510735e-06
protein O 0 1.072736655061135e-08
ligase O 0 2.898284634511583e-08
and O 0 2.621083794451806e-09
shows O 0 1.8608220386795438e-07
brain O 0 2.1190614916122286e-06
- O 0 8.802642810223915e-07
specific O 0 5.021397342375167e-08
imprinting O 0 1.3828005648974795e-05
. O 0 1.8430426962368074e-07

Here O 0 5.115905992170156e-07
we O 0 3.164280570899791e-08
describe O 0 2.1212156298133777e-07
UBE3A O 0 6.680546357529238e-05
coding O 0 2.4449964257655665e-05
- O 0 0.00013102006050758064
region O 0 3.268941668466141e-07
mutations O 0 9.899344632913198e-08
detected O 0 1.8316076477731258e-07
by O 0 1.7456909529034448e-10
SSCP O 0 1.2331477705629368e-07
analysis O 0 1.1740246552705003e-09
in O 0 1.1550936873661044e-09
13 O 0 5.598921504201826e-08
AS B-Disease 1 0.9999332427978516
individuals O 0 1.0368565561691412e-08
or O 0 5.175114736744035e-08
families O 0 2.2479875738667943e-08
. O 0 4.941190923091199e-08

Two O 0 1.4060364605938958e-07
identical O 0 1.8330177908865153e-06
de O 0 1.2320962241574307e-06
novo O 0 3.0567125008928997e-07
5 O 0 8.613961988146457e-09
- O 0 6.813439767938689e-07
bp O 0 5.182790019375716e-08
duplications O 0 2.6035218425590756e-08
in O 0 3.409315607605379e-10
exon O 0 2.6022657806379357e-08
16 O 0 4.148393184522092e-09
were O 0 8.373562287999903e-09
found O 0 2.358447126482588e-08
. O 0 3.6584260953986814e-08

Among O 0 1.3947777688372298e-07
the O 0 1.0579799258891853e-09
other O 0 3.70511371583504e-10
11 O 0 4.3642672808985594e-10
unique O 0 4.807896858416427e-10
mutations O 0 9.794429267628857e-09
, O 0 4.5206949295106824e-10
8 O 0 2.1431583174802427e-09
were O 0 9.76391412166322e-09
small O 0 8.723366917706699e-09
deletions O 0 3.179890484261705e-08
or O 0 1.2474333566103724e-08
insertions O 0 1.208194362334325e-07
predicted O 0 5.499030521605164e-06
to O 0 1.0344564316255855e-08
cause O 0 1.8019111536204946e-08
frameshifts O 0 3.0769126624363707e-06
, O 0 3.001329851315404e-09
1 O 0 1.8811527890960633e-09
was O 0 5.944296503912483e-07
a O 0 2.7456781293011545e-09
mutation O 0 1.2274982141846635e-09
to O 0 1.22361037968588e-10
a O 0 4.5526937775264287e-10
stop O 0 2.9325605055419146e-08
codon O 0 3.382734314882896e-09
, O 0 9.392577687838966e-11
1 O 0 5.890384013884642e-11
was O 0 1.2263803306211685e-08
a O 0 1.1147160972058145e-09
missense O 0 1.661627209159633e-07
mutation O 0 5.888413312504781e-09
, O 0 6.318776057945286e-10
and O 0 2.3046078378996526e-09
1 O 0 1.7187913314842262e-09
was O 0 2.2311887732939795e-06
predicted O 0 9.613667089070077e-07
to O 0 3.4478608856858273e-09
cause O 0 1.804617122402874e-09
insertion O 0 2.1449331200074084e-09
of O 0 3.6824840399241054e-10
an O 0 4.262496577922548e-09
isoleucine O 0 0.000122089812066406
in O 0 2.035936308431019e-09
the O 0 2.9007812818448997e-10
hect O 0 9.556128333088054e-08
domain O 0 5.1679212020872e-09
of O 0 1.1037858127505018e-10
the O 0 5.207874687052083e-10
UBE3A O 0 1.3068397493043449e-06
protein O 0 1.8011474534063154e-09
, O 0 1.3618293992490038e-10
which O 0 1.1282772632847937e-10
functions O 0 1.178933894951939e-10
in O 0 5.909672751158723e-11
E2 O 0 4.4123570575038684e-08
binding O 0 4.458630797898877e-09
and O 0 1.2187475473268705e-09
ubiquitin O 0 9.332784145499318e-08
transfer O 0 7.64216991910871e-08
. O 0 5.5248857933065665e-08

Eight O 0 8.269367413049622e-08
of O 0 5.728629792756124e-10
the O 0 4.885967186396556e-10
cases O 0 3.322232711155948e-09
were O 0 3.7226140392476736e-08
familial O 0 7.014653419901151e-06
, O 0 2.4574772439223125e-08
and O 0 8.12477729539296e-09
five O 0 3.431680217769184e-10
were O 0 1.4814994564460449e-08
sporadic O 0 2.960198344226228e-06
. O 0 6.562603260817923e-08

In O 0 5.159257199238709e-08
two O 0 7.136010893304956e-09
familial O 0 2.6004503524745815e-05
cases O 0 8.859747424594389e-08
and O 0 1.1763834351086189e-08
one O 0 3.601485776272284e-09
sporadic O 0 9.310111636295915e-06
case O 0 6.371706007257671e-08
, O 0 1.2042293828784523e-09
mosaicism O 0 3.914646242719755e-07
for O 0 2.343616412048277e-09
UBE3A O 0 2.743715958786197e-05
mutations O 0 8.629473313703784e-08
was O 0 1.7577652045019931e-07
detected O 0 1.4691246406073333e-06
in O 0 2.4861024350286698e-09
the O 0 2.980553137632569e-09
mother O 0 9.070399755728431e-07
of O 0 3.947520088587453e-10
three O 0 1.778095111149014e-07
AS B-Disease 1 0.9999997615814209
sons O 0 0.00013702183787245303
, O 0 5.178340423128702e-09
in O 0 5.46956091529438e-10
the O 0 3.7174749945023677e-09
maternal O 0 1.7626898625167087e-06
grandfather O 0 1.3597008319266024e-06
of O 0 6.041978029003303e-10
two O 0 8.251516447899121e-08
AS B-Disease 1 0.9999927282333374
first O 0 3.736542808496779e-08
cousins O 0 1.5790335510246223e-06
, O 0 1.7091581483441587e-08
and O 0 1.7342664193620294e-08
in O 0 3.833227957272811e-09
the O 0 4.879087800446769e-09
mother O 0 1.8542956468081684e-06
of O 0 4.020060950793436e-10
an O 0 9.52344834104224e-08
AS B-Disease 1 0.9999980926513672
daughter O 0 0.026359478011727333
. O 0 2.7774945010605734e-07

The O 0 7.682224634208978e-09
frequencies O 0 3.7695567556284004e-08
with O 0 9.667621148068406e-10
which O 0 2.633491424930412e-09
we O 0 7.572140137135364e-10
detected O 0 2.8916515848464996e-09
mutations O 0 3.456946395807847e-10
were O 0 3.6553324256338726e-10
5 O 0 2.3489585276870173e-10
( O 0 1.8329324169563677e-11
14 O 0 5.676873554572026e-11
% O 0 6.98388265621408e-12
) O 0 6.054673255817544e-12
of O 0 4.923400662854016e-12
35 O 0 6.609905955912154e-10
in O 0 4.807124143191288e-11
sporadic O 0 1.5861270412642625e-06
cases O 0 7.3760393348720754e-09
and O 0 4.717020107847247e-09
8 O 0 5.902916488942367e-10
( O 0 1.788370146416085e-11
80 O 0 2.547709265776632e-10
% O 0 1.116459875938336e-11
) O 0 6.7358085255320166e-12
of O 0 2.3181885230871835e-11
10 O 0 7.114968059163118e-10
in O 0 8.778610616211324e-10
familial O 0 2.240370122308377e-06
cases O 0 4.3087641898864604e-08
. O 0 6.482816949926473e-09
. O 0 1.5298054734103061e-07

The O 0 6.567304353666259e-07
hemochromatosis B-Disease 1 0.9999725818634033
845 O 0 5.676547880284488e-05
G O 0 0.0005854099290445447
- O 0 5.895793219679035e-05
- O 0 5.028618488722714e-06
> O 0 1.995675447119538e-08
A O 0 3.539453841128193e-09
and O 0 3.032545325964975e-10
187 O 0 3.781645663281097e-09
C O 0 1.0617935686241253e-07
- O 0 7.025365675872308e-07
- O 0 8.008594704733696e-06
> O 0 5.442364425789492e-08
G O 0 3.738460634394869e-07
mutations O 0 1.734620447280122e-08
: O 0 2.0226438579573625e-10
prevalence O 0 3.159595109991642e-07
in O 0 1.1248676434760796e-09
non O 0 1.3375475873544929e-06
- O 0 0.0005024343845434487
Caucasian O 0 1.2510748092608992e-05
populations O 0 8.503741355525563e-07
. O 0 4.326040681235099e-08

Hemochromatosis B-Disease 1 0.9972834587097168
, O 0 1.0784156074805651e-05
the O 0 2.1720918084611185e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 3.121462839317246e-07
iron I-Disease 1 0.9485582113265991
metabolism I-Disease 0 5.193096149014309e-05
, O 0 2.9736497708654497e-08
leads O 0 2.2459904158722566e-08
, O 0 5.094160204777154e-09
if O 0 2.7824247794683288e-08
untreated O 0 2.0412181811479968e-07
, O 0 2.868140447365164e-10
to O 0 6.327788515392285e-09
progressive O 0 8.25533497845754e-05
iron B-Disease 1 0.9786141514778137
overload I-Disease 0 0.0031458239536732435
and O 0 7.409418003589963e-07
premature B-Disease 0 2.068382855213713e-05
death I-Disease 0 2.618445194002561e-07
. O 0 3.558829675398556e-08

The O 0 9.790825288291671e-07
hemochromatosis B-Disease 1 0.9999949932098389
gene O 0 7.076267138472758e-06
, O 0 2.6274218356547863e-08
HFE O 0 2.5523930162307806e-05
, O 0 1.3630261364028229e-08
recently O 0 1.6855659623615793e-06
has O 0 1.1410018174728975e-07
been O 0 2.8064523149851084e-08
identified O 0 1.31115916701674e-06
, O 0 7.02952862585704e-10
and O 0 1.0037637387938503e-09
characterization O 0 2.783783870086154e-08
of O 0 1.015695513806314e-11
this O 0 4.297201483538515e-11
gene O 0 7.70908581415597e-09
has O 0 8.72962928610832e-08
shown O 0 1.497776835890363e-08
that O 0 2.611750538061841e-10
it O 0 1.6022264071047232e-10
contains O 0 3.8605427188365127e-10
two O 0 1.2208059563256768e-10
mutations O 0 1.7706308641507462e-09
that O 0 1.641395769302889e-10
result O 0 9.532122313693492e-11
in O 0 8.796132225374897e-12
amino O 0 1.0039049452847948e-10
acid O 0 3.4841376311822714e-11
substitutions O 0 2.1411755701805646e-10
- O 0 1.1324431392623069e-09
cDNA O 0 9.57158907688438e-10
nucleotides O 0 5.545202630408141e-10
845 O 0 4.5718575591990884e-09
G O 0 5.624609755727761e-08
- O 0 1.295906884024589e-07
- O 0 3.637358361174847e-07
> O 0 3.5738474402080556e-09
A O 0 7.323354700439211e-10
( O 0 1.2981629660124838e-11
C282Y O 0 6.366051574779874e-10
) O 0 6.777899855953118e-12
and O 0 1.7880051605967395e-11
187 O 0 3.149164817806138e-10
C O 0 2.248335029264581e-08
- O 0 3.4882961585935846e-07
- O 0 2.1803766685479786e-06
> O 0 2.372166285624644e-08
G O 0 4.146932610638032e-07
( O 0 1.1874016214719063e-09
H63D O 0 5.42329701147537e-07
) O 0 1.7695911402881848e-09
. O 0 7.3201462669203465e-09

Although O 0 2.688107269932516e-05
hemochromatosis B-Disease 1 0.9999990463256836
is O 0 9.762558050852022e-08
common O 0 1.2141749827776493e-08
in O 0 2.3672280802244927e-10
Caucasians O 0 1.9097063486128718e-08
, O 0 1.9237245130199199e-10
affecting O 0 1.425273343791389e-09
> O 0 3.7362983817956774e-09
= O 0 5.0246356408933934e-08
1 O 0 8.874079804321866e-10
/ O 0 1.829237135098083e-07
300 O 0 3.603567888532666e-09
individuals O 0 1.791252285388012e-10
of O 0 1.2303637275667967e-11
northern O 0 2.533286469486029e-08
European O 0 2.2544015543246587e-09
origin O 0 6.568310340071548e-09
, O 0 2.1300727848228007e-09
it O 0 8.221992864321237e-09
has O 0 1.7688631004375566e-08
not O 0 1.1804105470858417e-09
been O 0 1.77555836700094e-09
recognized O 0 1.7121419559895656e-10
in O 0 3.909252782596795e-11
other O 0 1.4399927084074449e-10
populations O 0 1.6560390392328372e-08
. O 0 1.5241720774383793e-08

The O 0 1.7188087397812524e-08
present O 0 5.403656189173489e-09
study O 0 3.316785734952532e-10
used O 0 5.020434623581593e-10
PCR O 0 3.821935834480428e-08
and O 0 5.944177927652561e-10
restriction O 0 5.824464022197162e-09
- O 0 3.589185126884331e-08
enzyme O 0 8.725126732223032e-10
digestion O 0 2.6965703003867247e-09
to O 0 1.1090320328754899e-10
analyze O 0 2.9339521923077427e-09
the O 0 2.4447664379034784e-11
frequency O 0 1.822142436935792e-09
of O 0 1.3157722307532982e-11
the O 0 8.582105859300526e-11
845 O 0 6.97585189612937e-09
G O 0 2.412401727269753e-07
- O 0 7.759642244309362e-07
- O 0 4.5823361460861634e-07
> O 0 1.5420200671911743e-09
A O 0 8.063530398949581e-10
and O 0 3.1907682052079167e-10
187 O 0 1.239416569376317e-09
C O 0 4.971934686182067e-08
- O 0 4.664362052153592e-07
- O 0 7.969972557475558e-07
> O 0 1.5391000474096472e-08
G O 0 6.272897934422872e-08
mutations O 0 3.0769495840132777e-09
in O 0 4.5695361383657485e-10
HLA O 0 1.2129178230679827e-06
- O 0 6.79868037423148e-07
typed O 0 4.2622545493031794e-08
samples O 0 6.23163431967555e-09
from O 0 2.002452648142139e-10
non O 0 3.341661880540414e-08
- O 0 3.7863464967813343e-06
Caucasian O 0 9.457414762437111e-08
populations O 0 9.361663444451551e-09
, O 0 2.2016732881269263e-10
comprising O 0 2.5935023573175897e-10
Australian O 0 1.2366349055881187e-09
Aboriginal O 0 4.894560312607155e-09
, O 0 2.556617417770468e-10
Chinese O 0 3.881731741595118e-11
, O 0 4.3881124428546414e-11
and O 0 7.089352438427454e-10
Pacific O 0 1.2368478685687023e-08
Islanders O 0 3.1429873814659004e-08
. O 0 2.407207233545705e-08

Results O 0 7.156321544243838e-07
showed O 0 5.134440357323911e-07
that O 0 6.325009960228556e-10
the O 0 1.6363724264500945e-10
845 O 0 4.7918710777139495e-08
G O 0 9.503390174359083e-06
- O 0 1.969821641978342e-05
- O 0 2.8469488825066946e-05
> O 0 1.2395779513951766e-08
A O 0 1.6345109710158567e-09
mutation O 0 2.8273616781149258e-09
was O 0 5.874595743193822e-08
present O 0 2.330324377908255e-09
in O 0 9.255852334577597e-11
these O 0 3.6761101107618543e-11
populations O 0 2.2375222508141945e-10
( O 0 2.9953888761730108e-12
allele O 0 1.065490473628472e-10
frequency O 0 1.7850186884160735e-09
0 O 0 1.4410367343842267e-10
. O 0 1.9360287678571453e-11
32 O 0 1.4379834822886295e-10
% O 0 1.7641702335091658e-11
) O 0 3.7644498629418877e-11
, O 0 4.5372286483491564e-10
and O 0 7.159186576899401e-09
, O 0 5.283191661931141e-10
furthermore O 0 7.398015533510716e-10
, O 0 1.124170131983071e-10
it O 0 2.296604018070525e-09
was O 0 4.758608724841906e-07
always O 0 2.1354516377414257e-08
seen O 0 1.01960431209136e-08
in O 0 2.766961659794731e-11
conjunction O 0 4.970450717678432e-10
with O 0 8.527774042477176e-10
HLA O 0 1.8167005464420072e-06
haplotypes O 0 9.645564347238178e-08
common O 0 1.342186273234347e-08
in O 0 6.735879631847297e-10
Caucasians O 0 1.584126430032029e-08
, O 0 1.894445433858749e-10
suggesting O 0 1.6086271203974434e-09
that O 0 1.4362265543521602e-10
845 O 0 2.1189345389416303e-08
G O 0 9.58830878516892e-06
- O 0 3.630009450716898e-05
- O 0 8.034134953049943e-05
> O 0 2.651652941665361e-08
A O 0 1.202119079835029e-07
may O 0 3.87470286966618e-08
have O 0 7.876002627860146e-10
been O 0 3.54608120645139e-10
introduced O 0 1.1313717324101802e-10
into O 0 1.940950004886144e-11
these O 0 4.797542918488773e-11
populations O 0 2.3258650561075456e-10
by O 0 2.1024867957741833e-10
Caucasian O 0 3.072020149375021e-07
admixture O 0 8.352938039024593e-07
. O 0 1.0797246119409465e-07

187 O 0 2.0646111806854606e-06
C O 0 1.220645117427921e-05
- O 0 7.431082394759869e-06
- O 0 4.8575520850135945e-06
> O 0 4.0179415350394265e-08
G O 0 6.716577445331495e-07
was O 0 6.626714110780085e-08
present O 0 7.59464546806754e-10
at O 0 6.236672844828206e-10
an O 0 8.835867801315622e-12
allele O 0 1.6110158762572269e-09
frequency O 0 9.93469395638158e-09
of O 0 7.903435683687121e-10
2 O 0 5.049075824103966e-08
. O 0 5.350584331154096e-08

68 O 0 1.0203639249084517e-05
% O 0 2.9141881796590496e-08
in O 0 9.615284124464551e-10
the O 0 3.2588370890707097e-10
two O 0 3.686025928928416e-10
populations O 0 1.798840298938842e-09
analyzed O 0 9.955654967086502e-09
( O 0 1.1785471210057352e-10
Australian O 0 3.124337677462563e-09
Aboriginal O 0 2.0140532797086053e-08
and O 0 4.952576571071177e-09
Chinese O 0 7.670594714959122e-10
) O 0 8.676948604069423e-10
. O 0 4.817574339455177e-09

In O 0 2.2297832913409366e-08
the O 0 1.0471330469385975e-09
Australian O 0 2.2651509556936844e-09
Aboriginal O 0 2.734723336672573e-09
samples O 0 1.1912125730262346e-09
, O 0 3.5730668423994416e-11
187 O 0 4.075983162099561e-10
C O 0 5.3698869351137546e-08
- O 0 8.828890827317082e-07
- O 0 3.9522660699731205e-06
> O 0 8.70882033154885e-09
G O 0 1.3902798912113212e-07
was O 0 3.188612254234613e-07
found O 0 4.0458241201690726e-09
to O 0 7.278053160142406e-11
be O 0 6.287242393376857e-10
associated O 0 1.818330375158439e-09
with O 0 1.3065429849135057e-09
HLA O 0 1.5513953258050606e-05
haplotypes O 0 5.86590687134958e-08
common O 0 6.315176825921753e-09
in O 0 3.099691059382792e-10
Caucasians O 0 1.2539170590741833e-08
, O 0 9.669792744304573e-11
suggesting O 0 3.0864013567111215e-09
that O 0 6.083213377472418e-10
it O 0 7.914342514681039e-10
was O 0 6.892451054341109e-09
introduced O 0 2.739613813584896e-10
by O 0 2.143259458797786e-10
recent O 0 7.630295506544371e-09
admixture O 0 3.400932087060937e-07
. O 0 5.964967186855574e-08

In O 0 3.1275408929332116e-08
the O 0 4.177690970941228e-10
Chinese O 0 9.917360682676346e-11
samples O 0 1.7068400859354682e-10
analyzed O 0 6.054818313394605e-10
, O 0 2.4831711339934337e-11
187 O 0 4.3141049066441894e-10
C O 0 4.619808535721859e-08
- O 0 5.763480999121384e-07
- O 0 4.6372715587494895e-06
> O 0 2.7917755218709317e-08
G O 0 1.942573589985841e-06
was O 0 2.317959342690301e-06
present O 0 3.300205264622491e-08
in O 0 4.434959066657029e-09
association O 0 2.3585582376028924e-09
with O 0 2.9967406334208135e-10
a O 0 3.796323699845061e-09
wide O 0 4.341671910879086e-08
variety O 0 4.625264171664867e-09
of O 0 2.395799392207465e-10
HLA O 0 8.688058983352676e-07
haplotypes O 0 4.822127408488086e-08
, O 0 8.667751516533428e-10
showing O 0 6.570530786120798e-08
this O 0 1.4412951387932083e-10
mutation O 0 1.4625304300963649e-09
to O 0 3.5633293538062105e-10
be O 0 2.6007707099040545e-09
widespread O 0 3.5324803082659173e-09
and O 0 1.5577564127511323e-08
likely O 0 6.876509583975121e-09
to O 0 1.6435448835228073e-10
predate O 0 2.5265357805892563e-08
the O 0 1.1238977803973427e-10
more O 0 4.241147363859277e-11
genetically O 0 5.264862990017605e-10
restricted O 0 3.6477012521629604e-09
845 O 0 2.6643578010521196e-08
G O 0 2.2981359961704584e-06
- O 0 2.4613376808702014e-05
- O 0 2.7950263756792992e-05
> O 0 9.832335479131871e-08
A O 0 3.312881702299819e-08
mutation O 0 2.2968555413171998e-07
. O 0 5.1984919480219105e-08

Genotype O 0 0.0015382715500891209
- O 0 0.002185087651014328
phenotype O 0 0.00014427142741624266
correlations O 0 0.00020082370610907674
in O 0 3.814595174844726e-06
attenuated B-Disease 1 0.9997928738594055
adenomatous I-Disease 1 0.9999979734420776
polyposis I-Disease 1 0.9999498128890991
coli I-Disease 1 0.999955415725708
. O 0 1.4301042938313913e-05

Germ O 0 0.08456043154001236
- O 0 0.0023541199043393135
line O 0 4.3915919377468526e-05
mutations O 0 2.3716059160960867e-07
of O 0 2.1985091525067446e-10
the O 0 8.307443621902166e-10
tumor B-Disease 0 4.746873855765443e-06
suppressor O 0 2.416012648609467e-06
APC O 0 4.3920670123043237e-07
are O 0 1.019411755009969e-08
implicated O 0 1.3968999610369792e-06
in O 0 4.6636014872092346e-07
attenuated B-Disease 1 0.9999315738677979
adenomatous I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999903440475464
coli I-Disease 1 0.9999986886978149
( O 0 2.6094232453033328e-05
AAPC B-Disease 1 0.9999960660934448
) O 0 4.670549103025223e-08
, O 0 1.180450959203938e-09
a O 0 2.0016328594607558e-09
variant O 0 3.4352844522800297e-05
of O 0 2.2097397049947176e-06
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999289512634277
polyposis I-Disease 1 0.9999966621398926
( O 0 1.3116768968757242e-06
FAP B-Disease 0 1.356600841972977e-05
) O 0 5.520524481994471e-08
. O 0 5.8035968919512015e-08

AAPC B-Disease 1 0.9999700784683228
is O 0 2.106713509419933e-06
recognized O 0 3.243418333909176e-08
by O 0 4.679068799084973e-10
the O 0 1.36315472798465e-10
occurrence O 0 6.111886818871426e-08
of O 0 3.5869024417323203e-10
< O 0 1.0667399692465551e-06
100 O 0 1.8920928823717986e-08
colonic B-Disease 0 7.940915565995965e-06
adenomas I-Disease 0 2.242463597212918e-05
and O 0 1.685965678177581e-08
a O 0 3.6875045239526116e-09
later O 0 4.304443379510303e-08
onset O 0 4.952889867126942e-05
of O 0 2.957683136628475e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
( O 0 3.4666014503415e-09
age O 0 3.500128542555103e-08
> O 0 1.304449526173812e-08
40 O 0 1.386039016892937e-08
years O 0 2.482671845882578e-09
) O 0 1.495449541977223e-09
. O 0 1.2874706634136146e-08

The O 0 5.2601510702743326e-08
aim O 0 8.66409024524728e-08
of O 0 3.063320083707133e-11
this O 0 3.070825538298294e-11
study O 0 1.1941328481590574e-10
was O 0 2.4891628758183515e-09
to O 0 2.5927060498531773e-10
assess O 0 1.5300358313652396e-07
genotype O 0 2.9114326025592163e-06
- O 0 2.474288339726627e-05
phenotype O 0 1.5040225207485491e-06
correlations O 0 1.5419318515341729e-06
in O 0 2.3175296348654228e-07
AAPC B-Disease 1 0.9999929666519165
families O 0 1.1899072660526144e-06
. O 0 1.4270645465330745e-07

By O 0 3.7101454353205554e-08
protein O 0 3.216557686869237e-08
- O 0 2.3341920041275444e-07
truncation O 0 3.522041254200303e-07
test O 0 2.2243530395371636e-07
( O 0 1.6294177118680864e-10
PTT O 0 8.37972891076788e-09
) O 0 1.2352617193012172e-11
assay O 0 2.126013809444771e-09
, O 0 6.086204457078637e-11
the O 0 1.115682893293446e-11
entire O 0 4.575957834873634e-09
coding O 0 1.0729375787832396e-07
region O 0 1.1080500073035182e-08
of O 0 6.693152976300354e-11
the O 0 1.3673628895816137e-10
APC B-Disease 0 4.208275061756694e-09
gene O 0 1.6452769147079493e-09
was O 0 2.878858218480218e-08
screened O 0 1.9597432299178763e-07
in O 0 2.3749673339068522e-09
affected O 0 2.5715559459627002e-08
individuals O 0 5.732236907363131e-10
from O 0 1.7654883111006825e-09
11 O 0 3.810316115959722e-07
AAPC B-Disease 1 0.999992847442627
kindreds O 0 7.156900392146781e-05
, O 0 1.1120070197989662e-08
and O 0 3.5611298354609744e-09
their O 0 1.6157148952089528e-09
phenotypic O 0 1.7376147809500253e-07
differences O 0 2.7720776074602327e-07
were O 0 2.2171670366333274e-07
examined O 0 7.17743978384533e-06
. O 0 8.944216745021549e-08

Five O 0 5.190041179048421e-07
novel O 0 5.652237291542406e-07
germ O 0 0.002085448009893298
- O 0 0.00378807308152318
line O 0 0.00016680365661159158
APC B-Disease 0 2.133579499741245e-07
mutations O 0 2.3462476406166388e-08
were O 0 6.623022130725076e-09
identified O 0 7.911165056384561e-08
in O 0 6.047408129816745e-10
seven O 0 2.3658945025317735e-08
kindreds O 0 2.535684143367689e-05
. O 0 1.1136778965692429e-07

Mutations O 0 1.7489958281657891e-06
were O 0 1.322246703239216e-07
located O 0 1.7973993635678198e-06
in O 0 4.3979347941203173e-10
three O 0 1.3663982445510925e-10
different O 0 3.7862539492561353e-11
regions O 0 7.235095300650585e-10
of O 0 3.829467992710889e-11
the O 0 1.7318417533385144e-10
APC B-Disease 0 1.5699223032683562e-09
gene O 0 4.0107245302678507e-10
( O 0 1.960367805586838e-11
1 O 0 7.126577106220111e-11
) O 0 5.219785714771774e-11
at O 0 1.0377269710204473e-08
the O 0 2.688700928565879e-10
5 O 0 7.992177475379947e-10
end O 0 5.7111226858808095e-09
spanning O 0 4.097670647240648e-09
exons O 0 1.737490373798778e-09
4 O 0 5.265546332289261e-10
and O 0 1.7069060609387066e-09
5 O 0 3.1966282398876444e-10
, O 0 1.3679837818081353e-10
( O 0 7.477635698138752e-12
2 O 0 3.225325909128607e-11
) O 0 9.212977603034744e-12
within O 0 1.5026847821619782e-11
exon O 0 6.380748707179862e-10
9 O 0 1.6217423848274848e-08
, O 0 1.0540923689461579e-09
and O 0 1.4241510193357954e-09
( O 0 1.7480758160437482e-11
3 O 0 4.972534189962019e-11
) O 0 2.291368830786844e-11
at O 0 3.981291296639711e-09
the O 0 1.946099184579886e-11
3 O 0 1.850836012229351e-10
distal O 0 8.770116721734666e-08
end O 0 1.1641409258800195e-07
of O 0 1.8619114583451335e-10
the O 0 5.730083074695358e-10
gene O 0 7.174403293674914e-08
. O 0 4.6357410354858075e-08

Variability O 0 5.9604531998047605e-05
in O 0 7.596431927936464e-09
the O 0 1.028449658768693e-09
number O 0 9.42926234870356e-08
of O 0 1.9398376025492325e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.05713384971022606
most O 0 1.1705818536711377e-08
apparent O 0 7.935314982887576e-08
in O 0 3.142295035285514e-10
individuals O 0 6.624711335057043e-10
with O 0 4.432639255647075e-10
mutations O 0 1.613984679238456e-08
in O 0 2.123651032803764e-09
region O 0 8.182525590427758e-08
1 O 0 1.3139032972731002e-08
, O 0 2.2605210148185506e-08
and O 0 7.251410352182575e-07
upper O 0 0.17975552380084991
- O 1 0.9992743134498596
gastrointestinal O 0 0.0022712640929967165
manifestations O 0 1.4369987866302836e-06
were O 0 4.493611243105988e-07
more O 0 2.8364521842405566e-09
severe O 0 2.3717319663774106e-08
in O 0 1.6006533598567074e-10
them O 0 2.233413010088725e-09
. O 0 1.9691697161761113e-08

In O 0 3.67177115379036e-08
individuals O 0 9.100378228765749e-09
with O 0 5.211939213545236e-10
mutations O 0 1.8801779688715214e-08
in O 0 1.1704026636749632e-09
either O 0 4.764621053254814e-08
region O 0 1.73274798953571e-07
2 O 0 1.2500056101316659e-08
or O 0 1.2173128993708815e-07
region O 0 4.2364806773775854e-08
3 O 0 1.1712736336377816e-09
, O 0 1.7699108845192768e-10
the O 0 3.500510645237931e-11
average O 0 1.2694797213441689e-08
number O 0 1.900732210513567e-10
of O 0 5.331414129616796e-11
adenomas B-Disease 0 2.9481387286978133e-07
tended O 0 9.387378696601445e-08
to O 0 2.81422862791203e-09
be O 0 5.611020092999297e-09
lower O 0 3.852328678277672e-09
than O 0 8.847951260548825e-10
those O 0 2.328723602840199e-10
in O 0 1.9118036320708853e-10
individuals O 0 2.0794194144357903e-10
with O 0 1.6668846858358677e-10
mutations O 0 4.332528558137483e-09
in O 0 4.3867254273521894e-10
region O 0 3.499794587469296e-08
1 O 0 7.466427476288118e-10
, O 0 2.800311094119934e-10
although O 0 9.527165723000053e-10
age O 0 4.626631522341995e-09
at O 0 9.35682891167744e-08
diagnosis O 0 1.6086024743344751e-06
was O 0 1.531463595938476e-07
similar O 0 2.1542042816236062e-08
. O 0 8.082508173856695e-08

In O 0 3.1071263606463617e-07
all O 0 1.8335825302528974e-07
AAPC B-Disease 1 0.9999816417694092
kindreds O 0 0.00019608279399108142
, O 0 8.404218654334272e-09
a O 0 1.2546365057986009e-09
predominance O 0 2.9678145097022934e-07
of O 0 4.371459194629779e-09
right O 0 0.03278898820281029
- O 1 0.9999833106994629
sided O 1 0.9999995231628418
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.006995631847530603
rectal B-Disease 1 0.999861478805542
polyp I-Disease 0 0.11406821757555008
sparing O 0 6.484995651589998e-07
was O 0 1.266871777261258e-06
observed O 0 7.609035606037651e-07
. O 0 9.185605165384914e-08

No O 0 7.769330841256306e-05
desmoid B-Disease 1 0.6684889793395996
tumors I-Disease 1 0.9999997615814209
were O 0 2.8848937745351577e-06
found O 0 4.446590651241422e-08
in O 0 9.742330275841482e-10
these O 0 8.078852253845525e-09
kindreds O 0 1.817711745388806e-05
. O 0 1.783160712420795e-07

Our O 0 1.892884000653794e-07
data O 0 4.030790634601544e-08
suggest O 0 6.777406191815771e-09
that O 0 7.35621119574148e-10
, O 0 6.89768187012163e-10
in O 0 3.1753251139576832e-09
AAPC B-Disease 1 0.9999994039535522
families O 0 3.834955819570496e-08
, O 0 1.9684692764698752e-10
the O 0 2.37256100182881e-11
location O 0 4.5785924385199905e-07
of O 0 1.9006742013605304e-10
the O 0 4.656954377679767e-09
APC B-Disease 0 5.020037292524648e-07
mutation O 0 3.307073725977716e-08
may O 0 8.319863020744833e-09
partially O 0 1.241138676277842e-07
predict O 0 3.543434345942842e-08
specific O 0 9.613969176314185e-09
phenotypic O 0 1.6372565596611821e-06
expression O 0 8.46122190978349e-07
. O 0 1.839477903331499e-07

This O 0 1.853013742447729e-08
should O 0 5.9546887420935946e-09
help O 0 1.011352779300978e-09
in O 0 1.3619748384652297e-10
the O 0 9.166882530831089e-11
design O 0 1.2223773637742852e-06
of O 0 1.0710679010372814e-09
tailored O 0 2.6325897124479525e-06
clinical O 0 2.652746388775995e-06
- O 0 4.585525311995298e-05
management O 0 2.2532682919518265e-07
protocols O 0 7.159036474746472e-09
in O 0 3.1011089529631164e-11
this O 0 8.627020105234084e-12
subset O 0 1.6393754131982519e-09
of O 0 1.1974719826834956e-10
FAP B-Disease 0 9.188548943939168e-08
patients O 0 5.9976383859350335e-09
. O 0 4.087762628390834e-10
. O 0 4.123766217389857e-08

Wilms B-Disease 0 0.38271236419677734
' I-Disease 0 2.0545410734484904e-05
tumor I-Disease 0 1.0715591997723095e-05
1 O 0 1.3742877946754106e-08
and O 0 4.962420252496713e-09
Dax O 1 0.9018993973731995
- O 0 6.846888572908938e-05
1 O 0 5.025323268625925e-09
modulate O 0 6.727706391984611e-08
the O 0 7.15829562292214e-10
orphan O 0 4.772488750859338e-07
nuclear O 0 4.354934048933501e-07
receptor O 0 3.496156697480046e-09
SF O 0 2.177274291170761e-05
- O 0 5.801975362373923e-07
1 O 0 4.0202449702597676e-10
in O 0 6.147795467148498e-11
sex O 0 5.866253971475999e-08
- O 0 4.441242040797988e-08
specific O 0 2.1132826599767895e-09
gene O 0 3.316232621841664e-08
expression O 0 3.981627472171567e-08
. O 0 2.320908443209646e-08

Products O 0 1.6788152379376697e-06
of O 0 2.1144881401369275e-09
steroidogenic O 0 1.5676752127546933e-06
factor O 0 3.155728123260815e-08
1 O 0 4.4730090742461925e-09
( O 0 4.0940750789530966e-10
SF O 0 0.028730330988764763
- O 0 1.516449628979899e-05
1 O 0 1.3966693357403415e-09
) O 0 9.742771867049527e-11
and O 0 3.3888629680234317e-09
Wilms B-Disease 0 0.00016094632155727595
tumor I-Disease 0 7.850542715459596e-06
1 O 0 2.398132359360261e-09
( O 0 5.276364345441209e-10
WT1 O 0 5.189368152969109e-07
) O 0 7.902015153327113e-11
genes O 0 3.8872682850410456e-10
are O 0 1.026414994664826e-10
essential O 0 4.36878977438937e-10
for O 0 4.481954737900473e-11
mammalian O 0 6.833076771073365e-09
gonadogenesis O 0 1.0900646429945482e-07
prior O 0 1.5249417284479705e-09
to O 0 2.0174433235098377e-09
sexual O 0 4.3222961210176436e-08
differentiation O 0 2.004863119964284e-07
. O 0 3.3198588766936155e-08

In O 0 2.278898136864882e-08
males O 0 3.991040387063549e-08
, O 0 4.281400123318235e-09
SF O 1 0.8125407099723816
- O 0 0.0003361844574101269
1 O 0 3.2459170906662393e-09
participates O 0 1.9003889573099286e-09
in O 0 1.9446269594602938e-10
sexual O 0 3.6535778846769063e-09
development O 0 5.324485852220562e-10
by O 0 5.0534135903612665e-11
regulating O 0 1.844927233207727e-08
expression O 0 9.109373699800472e-09
of O 0 5.886027082402379e-11
the O 0 1.4726972974443697e-09
polypeptide O 0 2.3213451640913263e-05
hormone O 0 1.4728250619100436e-07
Mullerian O 0 1.0580166645013378e-06
inhibiting O 0 1.348022067304555e-07
substance O 0 3.7045953149572597e-07
( O 0 4.746386839116212e-09
MIS O 0 2.5153449314530008e-05
) O 0 1.2727649156829557e-08
. O 0 3.608934662224783e-08

Here O 0 6.425680680877122e-07
, O 0 4.394297814513948e-09
we O 0 6.89127754860408e-10
show O 0 1.2995572618024198e-08
that O 0 9.530636280175031e-10
WT1 O 0 3.4234967642987613e-06
- O 0 2.3361926650977693e-06
KTS O 0 4.0378154153586365e-06
isoforms O 0 5.752271992065516e-09
associate O 0 3.4739153775831255e-09
and O 0 6.015989373331365e-10
synergize O 0 2.1219634618319105e-06
with O 0 1.5925788687809472e-08
SF O 1 0.9633774161338806
- O 0 0.00011108831677120179
1 O 0 3.1106497377919595e-09
to O 0 6.872494240361959e-10
promote O 0 1.3369974283250485e-07
MIS O 0 0.0015019465936347842
expression O 0 4.3892325152228295e-07
. O 0 4.4861092618475595e-08

In O 0 1.0840208375384464e-07
contrast O 0 2.1837112740286102e-07
, O 0 2.0859362237501955e-08
WT1 O 0 3.615444802562706e-05
missense O 0 1.978040199901443e-05
mutations O 0 7.52041728446784e-07
, O 0 2.7687330206305205e-09
associated O 0 1.5470494219016473e-08
with O 0 3.104540269305289e-08
male B-Disease 0 2.3121629055822268e-05
pseudohermaphroditism I-Disease 1 0.9999994039535522
in O 0 6.041711912985193e-06
Denys B-Disease 1 0.9999908208847046
- I-Disease 1 0.9999983310699463
Drash I-Disease 1 0.9999963045120239
syndrome I-Disease 1 0.9999990463256836
, O 0 4.9734428131387176e-08
fail O 0 1.9620246405338548e-07
to O 0 2.588818270865545e-09
synergize O 0 2.0075000065844506e-05
with O 0 1.166241005989832e-07
SF O 1 0.9980477094650269
- O 0 0.0011591563234105706
1 O 0 1.2201779497900134e-07
. O 0 3.6900672739648144e-08

Additionally O 0 6.029079031577567e-07
, O 0 7.808888646820833e-09
the O 0 6.903262406154909e-10
X O 0 0.03441701829433441
- O 0 0.020251745358109474
linked O 0 0.042664337903261185
, O 0 2.1056740795444284e-09
candidate O 0 2.3128778892100854e-09
dosage O 0 3.0314643595374946e-07
- O 0 4.5151239191909553e-07
sensitive O 0 6.439786830014782e-06
sex O 0 1.418410704445705e-07
- O 0 1.764519552693855e-08
reversal O 0 1.9379149396314688e-09
gene O 0 1.6046004525094304e-09
, O 0 2.3185213471332844e-10
Dax O 0 0.00019807161879725754
- O 0 2.6862412596528884e-06
1 O 0 2.38621455928012e-09
, O 0 4.926759000767333e-10
antagonizes O 0 1.0007518369548052e-07
synergy O 0 1.0272307449099571e-08
between O 0 1.9055428346348435e-09
SF O 0 0.20247770845890045
- O 0 3.5938574001193047e-05
1 O 0 7.1749481911354e-09
and O 0 4.510430695603418e-09
WT1 O 0 1.0034514161816332e-06
, O 0 4.587700774827397e-10
most O 0 3.0888892138536406e-11
likely O 0 2.0846216419734276e-10
through O 0 1.6955993900613642e-11
a O 0 1.5208656556353617e-10
direct O 0 8.909696314063353e-10
interaction O 0 1.5292846988756992e-09
with O 0 1.1928678045336483e-09
SF O 1 0.9485433101654053
- O 0 0.0011920914985239506
1 O 0 1.1619226114589765e-07
. O 0 3.083348687482612e-08

We O 0 1.2771255342158838e-07
propose O 0 6.266727581305531e-08
that O 0 1.4491657873705321e-09
WT1 O 0 2.2767706013837596e-06
and O 0 1.2626914625002428e-08
Dax O 1 0.9015456438064575
- O 0 0.00011558191908989102
1 O 0 4.816242515914837e-09
functionally O 0 5.831114435750351e-08
oppose O 0 1.0089910240651534e-08
each O 0 2.1312908382586926e-10
other O 0 1.0074728551412448e-10
in O 0 2.1102125602467936e-10
testis O 0 5.978487820357259e-07
development O 0 7.926896361531988e-10
by O 0 1.16428811036684e-10
modulating O 0 1.2206096755562612e-07
SF O 0 0.250296413898468
- O 0 9.763837442733347e-05
1 O 0 5.171947137228017e-08
- O 0 4.725991857412737e-06
mediated O 0 6.852186743344646e-06
transactivation O 0 1.5099441043275874e-05
. O 0 3.3576392777234787e-09
. O 0 1.3495175643640778e-08

A O 0 5.466458219416381e-07
mouse O 0 1.6215672076214105e-05
model O 0 1.1976389032497536e-05
for O 0 1.4913798622728791e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
imprinting O 0 0.13380305469036102
- O 0 0.08336155861616135
centre O 0 0.0002406855346634984
mutations O 0 1.70226539921714e-05
. O 0 2.9225608955130156e-07

Imprinting O 0 1.2487014828366227e-05
in O 0 8.169951826175748e-09
the O 0 1.786278791549023e-09
15q11 O 0 8.686948262948135e-07
- O 0 8.266863915196154e-06
q13 O 0 1.1713119647538406e-06
region O 0 1.644995428762286e-08
involves O 0 2.2980326530586126e-09
an O 0 1.7703566390636638e-10
imprinting O 0 3.5351351357348904e-07
centre O 0 1.4035514368515578e-06
( O 0 2.6550764364863255e-10
IC O 0 2.8556975451010658e-08
) O 0 5.57841446646723e-11
, O 0 2.7705476801642703e-11
mapping O 0 2.693898437655662e-08
in O 0 5.007839143367221e-10
part O 0 4.709737488894916e-09
to O 0 1.726815801461612e-09
the O 0 1.814110112130507e-10
promoter O 0 1.8562559489510022e-06
and O 0 1.8563345305366852e-09
first O 0 5.832432314889502e-10
exon O 0 2.9178533367257842e-08
of O 0 1.4753240407117119e-08
SNRPN O 0 0.0001324598997598514
. O 0 1.3395474240951444e-07

Deletion O 0 4.118144715903327e-06
of O 0 6.679080399862869e-09
this O 0 1.0826050278467392e-08
IC O 0 5.282489382807398e-06
abolishes O 0 1.1380516298231669e-06
local O 0 6.205090663513602e-09
paternally O 0 1.4579363494249264e-07
derived O 0 2.319827441255029e-09
gene O 0 1.4940875203706128e-08
expression O 0 2.4409681387282944e-08
and O 0 1.3244786600807856e-08
results O 0 2.6774867478707165e-07
in O 0 2.4180655600503087e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.6116340450244024e-05
PWS B-Disease 1 0.9999967813491821
) O 0 2.5560942162883293e-07
. O 0 1.2984997965759248e-07

We O 0 1.2866860288340831e-06
have O 0 2.4481379146124027e-09
created O 0 6.864646628912396e-10
two O 0 1.7368434468423288e-10
deletion O 0 9.6324924925284e-08
mutations O 0 5.5130854548224306e-08
in O 0 1.719932640753541e-09
mice O 0 2.983944568768493e-06
to O 0 5.77252023958863e-08
understand O 0 1.051556409947807e-05
PWS B-Disease 1 0.9999996423721313
and O 0 7.884005981395603e-08
the O 0 2.618843752966171e-10
mechanism O 0 4.808165421366084e-09
of O 0 3.490829153518504e-11
this O 0 1.0105101200252875e-09
IC O 0 1.923988975249813e-06
. O 0 3.4377041657762675e-08

Mice O 0 0.0042638834565877914
harbouring O 0 0.000630143447779119
an O 0 8.970010512143745e-09
intragenic O 0 2.475767814758001e-06
deletion O 0 1.7587277056918538e-07
in O 0 1.3887905270237866e-09
Snrpn O 0 7.352770353463711e-06
are O 0 2.5186916996489117e-09
phenotypically O 0 1.0182189669194486e-07
normal O 0 2.1200058597514726e-08
, O 0 3.7536251884517924e-10
suggesting O 0 9.795829924996724e-09
that O 0 2.1775881098307082e-10
mutations O 0 1.6219829923613815e-09
of O 0 3.136072304621429e-11
SNRPN O 0 1.4182688801156473e-06
are O 0 1.9269092987883596e-09
not O 0 6.545433639537634e-10
sufficient O 0 1.7710937161297124e-09
to O 0 5.00143659820651e-09
induce O 0 8.701602382643614e-06
PWS B-Disease 1 0.9999761581420898
. O 0 7.33331319224817e-07

Mice O 0 0.00018368804012425244
with O 0 1.2476736976907432e-08
a O 0 3.4614611177374854e-09
larger O 0 9.058089389668567e-09
deletion O 0 7.419048841939002e-08
involving O 0 2.776423713157783e-08
both O 0 2.2571033930773865e-09
Snrpn O 0 1.2846106073993724e-05
and O 0 7.869568463547694e-08
the O 0 1.3825220968044505e-08
putative O 0 0.00012019296991638839
PWS O 1 0.9999974966049194
- O 0 0.0009755428181961179
IC O 0 2.9455681215040386e-05
lack O 0 1.4644014001419237e-08
expression O 0 3.65210062192034e-09
of O 0 1.0921422100018674e-10
the O 0 6.718724465670789e-10
imprinted O 0 1.7822150084612076e-06
genes O 0 2.2390697296259532e-08
Zfp127 O 0 3.170007971675659e-07
( O 0 5.123507174076281e-10
mouse O 0 1.6638153965686797e-07
homologue O 0 1.3677012589141668e-07
of O 0 1.4033610939989671e-09
ZNF127 O 0 8.748573236516677e-06
) O 0 2.1857535781322213e-09
, O 0 1.5470811298712306e-09
Ndn O 0 4.918952072330285e-07
and O 0 1.5767162020452474e-09
Ipw O 0 1.1366119423428245e-07
, O 0 3.5326688241354987e-09
and O 0 5.670938385549107e-09
manifest O 0 7.67673427048976e-08
several O 0 1.1825918022623227e-09
phenotypes O 0 1.7128499507634842e-07
common O 0 9.034247483441504e-08
to O 0 1.510793936176924e-05
PWS B-Disease 1 0.9999997615814209
infants O 0 0.0017218563007190824
. O 0 1.8110009136762528e-07

These O 0 1.623184608945394e-08
data O 0 5.041838946340249e-08
demonstrate O 0 1.7251311490440457e-08
that O 0 3.935596570858735e-10
both O 0 5.4844236790918544e-11
the O 0 9.338647910528408e-11
position O 0 2.464382475864113e-07
of O 0 1.0723019000513645e-10
the O 0 3.3635921825592163e-10
IC O 0 4.523381846865959e-07
and O 0 3.243101343031185e-09
its O 0 8.20937373635644e-10
role O 0 1.0421139506888721e-09
in O 0 4.715522070042333e-11
the O 0 4.8101047450677115e-11
coordinate O 0 2.0630490382700373e-07
expression O 0 7.827723358388994e-09
of O 0 2.75669487237451e-11
genes O 0 2.190753578545923e-09
is O 0 3.9904274329316536e-10
conserved O 0 1.7322852041701253e-09
between O 0 1.9234944748092175e-09
mouse O 0 0.00015809547039680183
and O 0 5.231306090536236e-07
human O 0 2.9185658334540676e-08
, O 0 1.194557119887918e-09
and O 0 9.623485341947458e-10
indicate O 0 1.006421346261277e-08
that O 0 3.35902750059347e-10
the O 0 2.349715977345568e-10
mouse O 0 2.322120053577237e-05
is O 0 9.73702185547154e-09
a O 0 3.6736166886264243e-10
suitable O 0 1.326115892652524e-07
model O 0 3.905238372681197e-07
system O 0 5.692188942418852e-09
in O 0 2.1126086990896908e-10
which O 0 3.6313181350777768e-09
to O 0 8.954416652606767e-10
investigate O 0 2.9768731479862254e-08
the O 0 5.889429222083464e-11
molecular O 0 1.0976142217344886e-09
mechanisms O 0 6.928086992985527e-10
of O 0 1.53702068433903e-11
imprinting O 0 5.712890427389539e-08
in O 0 4.978952250489499e-10
this O 0 2.586660330372581e-10
region O 0 5.410400572003482e-09
of O 0 2.6415480913755118e-11
the O 0 2.1285202767007405e-10
genome O 0 1.0955691465142081e-08
. O 0 1.6873161756691957e-09
. O 0 2.2837454594082374e-08

Mutations O 0 3.3959063330257777e-06
of O 0 2.1779298364776878e-09
the O 0 2.258141229560806e-09
ATM O 0 1.0400424343970371e-06
gene O 0 4.5945533599933697e-08
detected O 0 7.650554039173585e-07
in O 0 1.705348218195013e-08
Japanese O 0 0.4345804750919342
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 0 0.003464665962383151
: O 0 2.355914574536655e-09
possible O 0 1.199301813414877e-08
preponderance O 0 8.940941853552431e-08
of O 0 5.646909051471027e-10
the O 0 1.1372940367238016e-09
two O 0 2.6265287722537778e-09
founder O 0 2.1622814472266327e-07
mutations O 0 3.013411387087217e-08
4612del165 O 0 9.538355527638487e-08
and O 0 1.2199691035164051e-08
7883del5 O 0 2.3391173726849956e-06
. O 0 1.0227698510334449e-07

The O 0 2.160566339171055e-07
ATM O 0 0.0001022766373353079
( O 0 6.624995307902282e-08
A O 1 0.9999613761901855
- O 1 0.9999958276748657
T O 1 1.0
, O 0 3.6893474941734894e-09
mutated O 0 3.437460094346534e-09
) O 0 3.054003577807052e-11
gene O 0 1.198381949230054e-09
on O 0 1.214925582360138e-08
human O 0 4.782584994700301e-08
chromosome O 0 1.0571398888714612e-05
11q22 O 0 8.597962732892483e-06
. O 0 2.320457639370943e-07

3 O 0 5.973016641291906e-07
has O 0 1.0989704435360181e-07
recently O 0 8.201478607361423e-08
been O 0 2.5218175991881253e-08
identified O 0 9.906144526894423e-08
as O 0 1.4795324687622013e-10
the O 0 1.2699428314499883e-11
gene O 0 1.2672630722576628e-09
responsible O 0 1.3445640156817262e-08
for O 0 1.9525323025071373e-10
the O 0 3.9369649762477366e-09
human O 0 3.630909850471653e-05
recessive B-Disease 1 0.9999698400497437
disease I-Disease 1 0.9999885559082031
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.006281393114477396
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999985694885254
T I-Disease 1 0.9999998807907104
) O 0 1.026751306199003e-07
. O 0 6.46230091660982e-08

In O 0 1.4209446952406779e-08
order O 0 4.653109897390095e-09
to O 0 3.427428341140626e-10
define O 0 1.560188778171323e-08
the O 0 1.4567277939470102e-10
types O 0 1.1574854141827018e-07
of O 0 6.842022948205795e-09
disease O 0 0.0004558478540275246
- O 0 0.00014284941426012665
causing O 0 8.811907719064038e-07
ATM O 0 5.575163413595874e-06
mutations O 0 7.641980204198262e-08
in O 0 6.5008207705830046e-09
Japanese O 0 0.00010211329936282709
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
patients O 0 1.3162407412892208e-06
as O 0 1.9425188124699844e-09
well O 0 1.6034806815667935e-09
as O 0 2.87794399422836e-10
to O 0 1.9165388720487897e-10
look O 0 5.257851487527887e-09
for O 0 7.293200071645245e-11
possible O 0 3.738322984503384e-09
mutational O 0 4.0171758541873714e-07
hotspots O 0 2.503656560293166e-06
, O 0 1.5651923090942432e-09
reverse O 0 1.1659579968181788e-06
- O 0 2.015457766901818e-06
transcribed O 0 1.8554263192527287e-07
RNA O 0 6.398789942352323e-09
derived O 0 2.9548588575956103e-10
from O 0 5.75101528899058e-11
ten O 0 5.231629573998475e-10
patients O 0 6.025188126201897e-10
belonging O 0 2.9829361203326243e-09
to O 0 4.2911263431477664e-10
eight O 0 1.545913175249325e-09
unrelated O 0 2.0395017941154947e-07
Japanese O 0 0.00011923623969778419
A B-Disease 1 0.9999780654907227
- I-Disease 1 0.9999905824661255
T I-Disease 1 1.0
families O 0 1.3537511733829888e-07
was O 0 8.277004326373572e-08
analyzed O 0 1.8274720403610445e-08
for O 0 1.31847602280466e-10
mutations O 0 8.992190325685101e-10
by O 0 1.8371394683303066e-11
the O 0 5.23713815370197e-11
restriction O 0 9.012214974291055e-09
endonuclease O 0 5.69787232507224e-07
fingerprinting O 0 1.3831569845024205e-07
method O 0 5.794769819544854e-08
. O 0 6.347204362100456e-08

As O 0 1.3255861119887413e-07
has O 0 3.888547439601098e-08
been O 0 5.62185054064912e-09
reported O 0 1.682670500713357e-07
by O 0 4.498778016781557e-10
others O 0 2.6630608829236735e-09
, O 0 9.485837115796869e-11
mutations O 0 7.383565980845219e-10
that O 0 1.3917436647581383e-10
lead O 0 2.5385318846993243e-10
to O 0 3.724755504030952e-10
exon O 0 1.8484424657572163e-08
skipping O 0 1.9238628112816514e-07
or O 0 1.6136806380018243e-07
premature O 0 3.4885317745647626e-08
protein O 0 1.0372456227258908e-09
truncation O 0 8.560440534211011e-08
were O 0 8.678959773078532e-08
also O 0 3.12165138183218e-09
predominant O 0 3.118956826142494e-08
in O 0 7.58247298282555e-10
our O 0 6.7011560744845156e-09
mutants O 0 5.8186373053104035e-08
. O 0 1.3658680408923374e-08

Six O 0 9.142902968051203e-08
different O 0 1.149188855187333e-09
mutations O 0 1.440513308637037e-08
were O 0 1.3680634403101521e-08
identified O 0 1.6552438353301113e-07
on O 0 4.610477688515857e-08
12 O 0 6.337496638586515e-10
of O 0 4.5688539757060553e-11
the O 0 6.258646934043099e-10
16 O 0 2.685786038014726e-09
alleles O 0 2.9469147122540562e-08
examined O 0 7.779048019074253e-07
. O 0 8.563249309645471e-08

Four O 0 6.257506868223572e-08
were O 0 5.034552330585029e-09
deletions O 0 4.475016623928241e-08
involving O 0 9.045541560226411e-08
a O 0 4.530185293560862e-08
loss O 0 1.9219481828258722e-07
of O 0 1.323237491801521e-10
a O 0 1.414626860096746e-09
single O 0 5.59338930727904e-09
exon O 0 6.636907023960248e-09
exon O 0 1.9495347558518006e-08
7 O 0 1.3014822108914359e-08
, O 0 2.0009713330715329e-10
exon O 0 4.351958793336053e-09
16 O 0 1.3093894857263422e-09
, O 0 1.6103300637393403e-10
exon O 0 5.023291560490861e-09
33 O 0 1.3681417776467697e-08
or O 0 1.4058695541052657e-08
exon O 0 1.9107891091607598e-07
35 O 0 3.92888836131533e-07
. O 0 1.86410801461534e-07

The O 0 2.510213903406111e-08
others O 0 1.3009412214159966e-08
were O 0 5.485347176481525e-10
minute O 0 1.0268796923895707e-09
deletions O 0 1.9660022942957767e-08
, O 0 7.390935641282681e-10
4649delA O 0 9.57320089867153e-09
in O 0 1.2772284618822738e-10
exon O 0 1.3675077070729458e-08
33 O 0 1.4674994552876797e-08
and O 0 1.2130308979507731e-09
7883del5 O 0 1.384031289575205e-08
in O 0 5.294126248500675e-10
exon O 0 1.9565797515497252e-07
55 O 0 1.3687974842468975e-07
. O 0 6.893176873745688e-08

The O 0 3.286586647277545e-08
mutations O 0 1.8957872782721097e-07
4612del165 O 0 3.067491149977286e-07
and O 0 4.139082854237586e-09
7883del5 O 0 3.586578145586827e-08
were O 0 1.598479570930067e-08
found O 0 3.73386210839044e-09
in O 0 4.0324917016665296e-11
more O 0 3.9593415351868444e-11
than O 0 8.326443701189845e-11
two O 0 3.229918416058908e-11
unrelated O 0 1.6851997575173527e-09
families O 0 2.337512683414644e-10
; O 0 2.399534390629121e-11
44 O 0 3.4062414000501917e-10
% O 0 5.427491095444381e-11
( O 0 5.4835767870908825e-11
7 O 0 2.2559070167460504e-09
of O 0 2.2825019652117362e-10
16 O 0 1.2348624345293047e-09
) O 0 2.5001662198875785e-11
of O 0 5.2991422014314615e-12
the O 0 6.244632588803256e-11
mutant O 0 1.3624023686986675e-08
alleles O 0 1.1687786294345415e-09
had O 0 2.7705314664672187e-07
one O 0 1.6817384151934789e-09
of O 0 9.153394014971283e-11
the O 0 5.965962723841756e-10
two O 0 1.86644233401978e-09
mutations O 0 1.6471280162022595e-07
. O 0 4.8365706106778816e-08

The O 0 2.528888565223042e-08
4612del165 O 0 5.281112294142076e-07
mutations O 0 2.0023217928155645e-07
in O 0 1.1801718491355473e-09
three O 0 1.0925006038720042e-10
different O 0 1.0196850308563654e-10
families O 0 7.388257783347285e-10
were O 0 5.326947327688458e-09
all O 0 7.364434062573366e-11
ascribed O 0 1.7431167620429733e-09
to O 0 8.866770651039246e-10
the O 0 4.229807337718938e-10
same O 0 1.0846822995347338e-08
T O 0 3.759939136216417e-05
- O 0 1.0134328931599157e-06
- O 0 9.357763133266417e-07
> O 0 7.258053047465296e-10
A O 0 7.392369355541106e-11
substitution O 0 9.263022987537894e-11
at O 0 1.5776487893859326e-09
the O 0 2.540468009570862e-11
splice O 0 5.8080814824279514e-08
donor O 0 1.2064087506757915e-09
site O 0 4.403058895263712e-08
in O 0 9.829964620067244e-10
intron O 0 1.324875029240502e-05
33 O 0 2.3236198387621698e-07
. O 0 5.343333242535664e-08

Microsatellite O 0 0.00024368712911382318
genotyping O 0 4.999556404072791e-05
around O 0 1.4000861483509652e-06
the O 0 3.941217574521261e-09
ATM O 0 1.3958132285551983e-06
locus O 0 1.6513997991296492e-07
also O 0 4.520095586713069e-08
indicated O 0 2.2403733623832522e-07
that O 0 1.7549151021256648e-10
a O 0 9.60318824461126e-10
common O 0 4.768082373374227e-09
haplotype O 0 1.2435419876055676e-06
was O 0 5.654832420987077e-06
shared O 0 5.621164422819902e-09
by O 0 2.704682033893846e-10
the O 0 1.4381536239671533e-10
mutant O 0 3.178362462108453e-08
alleles O 0 3.046954466512375e-09
in O 0 8.896145486936291e-10
both O 0 5.398515856569475e-09
mutations O 0 6.175034172883898e-07
. O 0 1.1687217238431913e-07

This O 0 7.897412501733925e-09
suggests O 0 1.7581767153274086e-08
that O 0 6.052497392161627e-10
these O 0 2.7418670112133725e-10
two O 0 4.4071379878829475e-10
founder O 0 2.1131351957137667e-07
mutations O 0 4.465680092380353e-08
may O 0 6.040483224722948e-09
be O 0 1.0999487987106704e-09
predominant O 0 3.489682853796694e-08
among O 0 1.0014651330436664e-09
Japanese O 0 5.659919111167255e-08
ATM O 0 5.946457122263382e-07
mutant O 0 5.260262128103932e-07
alleles O 0 4.1659353655632003e-07
. O 0 1.1027479018821396e-07

W474C O 0 4.356188219389878e-05
amino O 0 1.5297236188871466e-07
acid O 0 1.070770139222077e-08
substitution O 0 1.2455616538176173e-09
affects O 0 2.1373656178269584e-09
early O 0 1.0264854244379507e-10
processing O 0 3.786178037756827e-09
of O 0 9.154611964323767e-12
the O 0 8.941829048036976e-12
alpha O 0 4.086848220952177e-11
- O 0 2.633680773467262e-10
subunit O 0 4.701171049670272e-11
of O 0 7.576047428292654e-12
beta O 0 2.6397359298435674e-10
- O 0 5.189169982600106e-08
hexosaminidase O 0 7.835927817723132e-08
A O 0 4.742568116000712e-09
and O 0 1.0675170747376228e-09
is O 0 1.3087053662985682e-09
associated O 0 7.61575602581388e-09
with O 0 7.79921371929504e-09
subacute O 0 0.005452700424939394
G B-Disease 0 0.0001846962986746803
( I-Disease 0 1.3193175441017502e-08
M2 I-Disease 0 4.174651621724479e-05
) I-Disease 0 1.7247296923983413e-08
gangliosidosis I-Disease 0 3.608367933338741e-06
. O 0 5.987993034750616e-08

Mutations O 0 3.5784851206699386e-06
in O 0 7.501704146761767e-09
the O 0 1.0260925442651114e-09
HEXA O 0 1.5991932741599157e-05
gene O 0 2.442663493695818e-08
, O 0 6.65629634744036e-11
encoding O 0 2.473463378560581e-10
the O 0 3.384060393019084e-11
alpha O 0 1.2318907005592905e-10
- O 0 1.1713048309047736e-09
subunit O 0 1.9996512778952535e-10
of O 0 1.6868640165257354e-11
beta O 0 1.6645186340369378e-09
- O 0 5.53329016383941e-07
hexosaminidase O 0 1.0983885658788495e-06
A O 0 1.1026465074337466e-08
( O 0 1.426510159996397e-10
Hex O 0 1.63565943012145e-08
A O 0 9.431357916867e-10
) O 0 2.2164190621731805e-11
, O 0 1.049205167191758e-11
that O 0 2.0390899038713606e-11
abolish O 0 4.746060877636182e-09
Hex O 0 2.9073316198946486e-08
A O 0 4.355219795915133e-10
enzyme O 0 1.0007667583522561e-08
activity O 0 2.291531018272508e-06
cause O 0 4.622885171556845e-05
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 0 0.4247454106807709
( O 0 1.3396024289846764e-09
TSD B-Disease 0 6.401052814908326e-06
) O 0 2.1810224737350836e-09
, O 0 1.1442676806083796e-09
the O 0 2.071424143323952e-09
fatal O 0 0.00015324848936870694
infantile B-Disease 0 0.00020633844542317092
form I-Disease 0 9.293789737796487e-09
of I-Disease 0 1.147775985366195e-09
G I-Disease 0 6.459371434175409e-06
( I-Disease 0 4.407591791544263e-10
M2 I-Disease 0 1.9806602722383104e-06
) I-Disease 0 7.375698385381213e-10
gangliosidosis I-Disease 0 1.2729061893423932e-07
, I-Disease 0 4.558932953369066e-10
Type I-Disease 0 2.3309641505875334e-07
1 I-Disease 0 6.5961947015580336e-09
. O 0 4.292833821750719e-08

Less O 0 2.6052437078760704e-06
severe O 0 3.375814776518382e-05
, O 0 1.93599483111484e-08
subacute O 0 0.009634102694690228
( O 0 9.301808745476592e-08
juvenile O 0 0.022272620350122452
- O 0 0.0363970622420311
onset O 0 0.00023929000599309802
) O 0 1.0204626477161582e-07
and O 0 4.415878265717765e-06
chronic O 0 0.0020607069600373507
( O 0 1.0031915298469585e-09
adult O 0 3.75142508346471e-06
- O 0 0.01500749308615923
onset O 0 5.5855307437013835e-06
) O 0 5.259082613839894e-10
variants O 0 1.3353428585105576e-08
are O 0 1.5960751609256363e-09
characterized O 0 1.6964170512778765e-08
by O 0 1.3044655633454028e-10
a O 0 8.448964194940345e-09
broad O 0 2.594139232314774e-07
spectrum O 0 2.720027225677768e-07
of O 0 1.255749837447695e-09
clinical O 0 8.308749954721861e-08
manifestations O 0 9.083561280931463e-08
and O 0 1.3869354553719404e-08
are O 0 3.388079261590349e-10
associated O 0 1.6800808522177135e-09
with O 0 4.86889639716992e-10
residual O 0 2.7907565254281508e-06
levels O 0 2.119892528185119e-08
of O 0 2.6342786285660225e-10
Hex O 0 1.4618457555570785e-07
A O 0 9.48642053799631e-10
enzyme O 0 4.4048542591212936e-09
activity O 0 7.154888947979998e-08
. O 0 1.2975066354670162e-08

We O 0 8.440831607003929e-07
identified O 0 6.384199480180541e-08
a O 0 2.4785176133690356e-09
1422 O 0 1.7523783526485204e-06
G O 0 3.143142384942621e-05
- O 0 8.754774171393365e-05
- O 0 0.00013307022163644433
> O 0 2.9783478794342955e-07
C O 0 2.4352100354008144e-06
( O 0 2.5969079664456274e-10
amino O 0 1.3360142159246635e-10
acid O 0 5.3489945112117354e-11
W474C O 0 2.8900842830026363e-10
) O 0 8.918098464566482e-13
substitution O 0 5.672844572562896e-12
in O 0 9.81536033006769e-12
the O 0 6.330156884781779e-12
first O 0 1.1508378278124454e-10
position O 0 1.2725700493376735e-09
of O 0 9.184729365951938e-12
exon O 0 2.4473070237007732e-09
13 O 0 1.5600243319369156e-09
of O 0 1.8788998135121915e-10
HEXA O 0 5.399810106609948e-05
of O 0 5.71183822462018e-10
a O 0 2.2678367628259366e-08
non O 0 2.912577485858492e-07
- O 0 5.894382411497645e-06
Jewish O 0 6.225750439625699e-07
proband O 0 4.3594165617832914e-05
who O 0 2.295510448391269e-08
manifested O 0 4.419668186983472e-08
a O 0 7.150793734922445e-09
subacute O 0 1.7119176845881157e-05
variant O 0 4.1537364836585766e-07
of O 0 2.9206748131116456e-09
G B-Disease 0 1.5134515706449747e-05
( I-Disease 0 3.4078222466149555e-09
M2 I-Disease 0 2.7476096875034273e-05
) I-Disease 0 1.4011581228601244e-08
gangliosidosis I-Disease 0 4.414008799358271e-06
. O 0 8.061831380246076e-08

On O 0 9.592575906935963e-07
the O 0 3.471550824585279e-09
second O 0 1.152297368633981e-08
maternally O 0 1.4887026736687403e-05
inherited O 0 5.496513949765358e-06
allele O 0 2.2266515031788003e-07
, O 0 9.814102419625215e-09
we O 0 6.568385835237223e-09
identified O 0 8.716967414557075e-08
the O 0 1.6084644727243358e-09
common O 0 6.123210368969012e-06
infantile O 1 0.998946487903595
disease O 0 0.08666250854730606
- O 0 0.00023693597177043557
causing O 0 1.5027652580101858e-06
4 O 0 8.817496066626518e-09
- O 0 1.4432959005716839e-06
bp O 0 1.221131213924309e-07
insertion O 0 1.399000382207305e-08
, O 0 8.641405924159073e-10
+ O 0 5.165637873005835e-08
TATC O 0 1.2053684486090788e-06
1278 O 0 1.2772171658070874e-06
, O 0 1.3757873729147718e-09
in O 0 4.821478771788179e-10
exon O 0 2.1675421635336534e-07
11 O 0 9.070541295841394e-08
. O 0 7.816731084631101e-08

Pulse O 0 5.846233761985786e-05
- O 0 5.86065061725094e-06
chase O 0 4.2909633179988305e-07
analysis O 0 1.01134700614125e-09
using O 0 1.2445785513293117e-09
proband O 0 2.3261763715254347e-07
fibroblasts O 0 5.539130043530349e-08
revealed O 0 2.4604537429695483e-07
that O 0 5.079361931059623e-10
the O 0 6.664426649427568e-11
W474C O 0 2.3764412659943446e-08
- O 0 2.182093261637874e-08
containing O 0 3.2799218896428783e-09
alpha O 0 4.2720660342610017e-10
- O 0 1.0340258649321754e-09
subunit O 0 1.0639145814339557e-10
precursor O 0 5.782332390680267e-10
was O 0 9.91585746845658e-09
normally O 0 4.0410247370559205e-10
synthesized O 0 5.167534178340816e-10
, O 0 7.079430097700623e-11
but O 0 7.930552742285712e-11
not O 0 2.7622211809519293e-11
phosphorylated O 0 2.48819798098765e-10
or O 0 8.004061302635535e-10
secreted O 0 3.132201831235193e-09
, O 0 8.589872702025048e-10
and O 0 1.103268698621207e-09
the O 0 2.9350982755360633e-10
mature O 0 1.570282570639847e-08
lysosomal O 0 4.499254657730489e-08
alpha O 0 2.973947477169503e-10
- O 0 2.568177226436319e-09
subunit O 0 3.0798838479562107e-10
was O 0 1.70758429618445e-08
not O 0 1.982320751992006e-09
detected O 0 2.435039903048164e-07
. O 0 1.844441754883519e-08

When O 0 1.794811339550506e-07
the O 0 3.6051697183125953e-09
W474C O 0 1.5761600025143707e-07
- O 0 3.720364105674889e-08
containing O 0 3.824595751211746e-09
alpha O 0 5.058469199070714e-10
- O 0 2.7613813458060577e-09
subunit O 0 1.119909720515011e-09
was O 0 1.4152240268572314e-08
transiently O 0 7.831221182641457e-08
co O 0 2.97440521990211e-07
- O 0 7.856173169784597e-07
expressed O 0 8.213446589522277e-10
with O 0 4.819564192182213e-11
the O 0 2.986713307229216e-11
beta O 0 7.375722255176242e-11
- O 0 1.0657267290881123e-09
subunit O 0 1.7012302677699154e-10
to O 0 1.49336806809508e-10
produce O 0 4.462902047919215e-09
Hex O 0 1.0949386819447682e-07
A O 0 3.6104821354854266e-09
( O 0 4.161782723999252e-11
alphabeta O 0 9.714928417281499e-09
) O 0 3.3150638484302775e-11
in O 0 8.855544769703627e-11
COS O 0 1.9822608010144904e-05
- O 0 3.999120508524356e-06
7 O 0 3.772712364735753e-09
cells O 0 1.3805451226645005e-09
, O 0 9.887877322478644e-11
the O 0 1.8671383883450687e-11
mature O 0 2.3048309094608754e-10
alpha O 0 2.4515839011640672e-11
- O 0 3.964104045017791e-10
subunit O 0 1.7052650957971593e-10
was O 0 1.161153395656811e-08
present O 0 5.053348850481143e-10
, O 0 1.3463540005087538e-10
but O 0 1.2015557993017012e-10
its O 0 2.5005630899244125e-10
level O 0 1.9751309476845336e-09
was O 0 1.1068649996559543e-08
much O 0 2.196815646060557e-10
lower O 0 1.0667069449965538e-09
than O 0 1.168853763777733e-10
that O 0 2.270399666881584e-11
from O 0 4.465637061523697e-12
normal O 0 4.937735290089229e-11
alpha O 0 2.0780306295153927e-11
- O 0 2.062922332957129e-10
subunit O 0 9.03751032343969e-11
transfections O 0 1.3985495428414652e-08
, O 0 3.359647282596967e-11
although O 0 1.7097587234893297e-11
higher O 0 4.025713790101193e-11
than O 0 5.073588424386877e-11
in O 0 5.253996890330903e-11
those O 0 1.4581956475634428e-10
cells O 0 4.845023271471405e-10
transfected O 0 2.1112088077757107e-08
with O 0 1.0192650196083619e-10
an O 0 1.1495565610530889e-10
alpha O 0 6.508124039683594e-10
- O 0 1.917747560753469e-08
subunit O 0 7.462872098074058e-09
associated O 0 3.7134093133772694e-08
with O 0 4.6418545451842874e-08
infantile O 0 0.31071707606315613
TSD B-Disease 0 0.002914884826168418
. O 0 4.499597707763314e-07

Furthermore O 0 1.872146185633028e-06
, O 0 7.73722153013523e-09
the O 0 6.365502569494197e-11
precursor O 0 1.5698984334733268e-09
level O 0 2.9714937177516276e-09
of O 0 9.97318113510337e-12
the O 0 3.7287482129721994e-11
W474C O 0 1.5974183087408278e-09
alpha O 0 1.0128019950483846e-10
- O 0 3.2599559163237757e-10
subunit O 0 4.7851052981107145e-11
was O 0 2.2943098532124395e-09
found O 0 3.442497120698107e-10
to O 0 1.3204187743198759e-10
accumulate O 0 1.2847943153815322e-08
in O 0 5.999028357406289e-11
comparison O 0 1.2513766689536965e-09
to O 0 3.269389758919772e-10
the O 0 7.922871386734087e-11
normal O 0 5.399655722548857e-10
alpha O 0 2.545212651750006e-10
- O 0 1.7320077594362715e-09
subunit O 0 7.913587563024294e-10
precursor O 0 4.18900736320893e-09
levels O 0 6.88246704072526e-09
. O 0 4.492554772639323e-09

We O 0 1.3401479748154088e-07
conclude O 0 3.89036536319054e-08
that O 0 9.78829378661672e-11
the O 0 1.0790128512905284e-10
1422 O 0 2.0211616913456965e-07
G O 0 5.754420271841809e-06
- O 0 6.887772178743035e-05
- O 0 5.708216122002341e-05
> O 0 7.195233564516457e-08
C O 0 7.585979915347707e-07
mutation O 0 6.45255626707808e-09
is O 0 9.94593185588144e-10
the O 0 7.614005259615197e-11
cause O 0 2.87610135707439e-09
of O 0 2.030560164456574e-10
Hex B-Disease 0 0.0004657668177969754
A I-Disease 0 0.0003163204819429666
enzyme I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999990463256836
in O 0 1.244599756589082e-09
the O 0 2.124554532301204e-09
proband O 0 1.5902931409073062e-05
. O 0 1.2431489437858545e-07

The O 0 3.46536026540889e-08
resulting O 0 1.6196867846929308e-08
W474C O 0 4.4503575935550543e-08
substitution O 0 6.030422383673795e-09
clearly O 0 2.6323428770069768e-08
interferes O 0 2.4066885373486002e-08
with O 0 6.602569185831797e-11
alpha O 0 2.1355757440222334e-10
- O 0 5.837596517288546e-10
subunit O 0 8.525606609577352e-11
processing O 0 1.0678862238933107e-08
, O 0 1.214393724469076e-10
but O 0 4.424621086185354e-11
because O 0 8.203371142101457e-12
the O 0 9.953052921771177e-13
base O 0 4.699461375601288e-10
substitution O 0 3.607692200535695e-10
falls O 0 4.205381003430375e-07
at O 0 1.6406985769990001e-09
the O 0 1.9448114993436683e-11
first O 0 2.906679896774733e-10
position O 0 4.158961619538104e-09
of O 0 1.3111125032883031e-11
exon O 0 2.454978886845538e-09
13 O 0 1.3105213580999475e-09
, O 0 1.4857766406084494e-10
aberrant O 0 9.264091715976974e-09
splicing O 0 1.0757896795610122e-08
may O 0 1.7164270005309845e-08
also O 0 1.1757231854758743e-09
contribute O 0 1.408370198241471e-09
to O 0 1.6175720318756248e-08
Hex B-Disease 0 0.000213887746213004
A I-Disease 0 1.0885209121624939e-05
deficiency I-Disease 0 0.00013319641584530473
in O 0 4.6782185764149276e-11
this O 0 2.039588775648582e-10
proband O 0 5.249207220003882e-07
. O 0 1.7785819483862042e-09
. O 0 1.3615191640781177e-08

Two O 0 2.913644436830509e-07
frequent O 0 1.4302174349722918e-05
missense O 0 0.0010598818771541119
mutations O 0 0.0003621373325586319
in O 0 6.922618922544643e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.089830432960298e-06

Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
is O 0 0.0020169089548289776
an O 0 0.26873672008514404
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.964539647102356
by O 0 7.414662945848249e-07
early O 0 0.00017066970758605748
childhood O 1 0.9998420476913452
deafness B-Disease 1 1.0
and O 1 0.8607710599899292
goiter B-Disease 1 0.9999998807907104
. O 0 1.2979978237126488e-05

A O 0 5.194037271394336e-07
century O 0 6.812388164689764e-08
after O 0 5.490154109111245e-09
its O 0 1.14539211448772e-09
recognition O 0 1.8808801183212154e-09
as O 0 5.698750360494387e-09
a O 0 3.8477085695376445e-07
syndrome O 0 0.015391673892736435
by O 0 4.4995329684383023e-10
Vaughan O 0 1.550034880892781e-06
Pendred O 0 5.582814537774539e-06
, O 0 3.6575940054461853e-09
the O 0 3.564718076276563e-09
disease O 0 2.962872940770467e-06
gene O 0 1.7549069752931246e-08
( O 0 2.3747090960313244e-09
PDS O 0 1.896321919048205e-06
) O 0 1.7079286873666888e-09
was O 0 9.567271064270244e-08
mapped O 0 1.046455236064503e-05
to O 0 2.3753990774366684e-08
chromosome O 0 2.1121826648595743e-05
7q22 O 0 5.1973593144793995e-06
- O 0 3.430929791647941e-05
q31 O 0 1.1824066859844606e-05
. O 0 1.46574620885076e-07

1 O 0 5.702824523723393e-07
and O 0 1.3141871590960363e-07
, O 0 4.10326261857108e-09
recently O 0 2.614654590615828e-07
, O 0 4.0256006861305593e-10
found O 0 4.755083549135009e-10
to O 0 1.2386149050858108e-10
encode O 0 2.8532257445590403e-08
a O 0 1.198186510009691e-07
putative O 0 6.562948783539468e-06
sulfate O 0 7.3580240496085025e-06
transporter O 0 5.2983850764576346e-05
. O 0 1.37625960405785e-07

We O 0 3.7378507045104925e-07
performed O 0 3.7790162110695746e-08
mutation O 0 2.195685633310518e-09
analysis O 0 1.6060027752118344e-09
of O 0 8.661400763276816e-11
the O 0 4.998697011870945e-10
PDS B-Disease 0 2.2922274922621e-07
gene O 0 6.4051390857855495e-09
in O 0 1.064877408474274e-09
patients O 0 4.230939154581392e-09
from O 0 2.7079491426995617e-10
14 O 0 3.4549445526721456e-09
Pendred B-Disease 0 8.474474384456698e-07
families O 0 1.1536779309651024e-09
originating O 0 1.492528767244039e-09
from O 0 2.9881735974512935e-10
seven O 0 8.236523130200624e-10
countries O 0 1.2401893401126074e-10
and O 0 7.677093405433766e-10
identified O 0 3.898841072214054e-08
all O 0 8.305304777245226e-10
mutations O 0 4.896701355505684e-08
. O 0 1.586282394328009e-08

The O 0 2.6363977667642757e-08
mutations O 0 1.5174227030456677e-07
include O 0 4.668257780338081e-09
three O 0 7.526479994801605e-10
single O 0 5.037820827169526e-08
base O 0 3.544008819744704e-08
deletions O 0 3.0417186991371636e-08
, O 0 3.0203555212438005e-09
one O 0 9.913015963647354e-10
splice O 0 9.695670996734407e-06
site O 0 6.896924332977505e-06
mutation O 0 1.4809513615432479e-08
and O 0 2.1608328459876702e-09
10 O 0 2.5689905758241594e-09
missense O 0 1.6269680145342136e-06
mutations O 0 5.690747570952226e-07
. O 0 1.3658164732532896e-07

One O 0 9.702706620373647e-07
missense O 0 3.07072295981925e-05
mutation O 0 2.865306498733844e-07
( O 0 1.4303578321772648e-09
L236P O 0 5.853289053447952e-08
) O 0 8.017399522053381e-10
was O 0 2.221052710638105e-07
found O 0 7.951856062504703e-09
in O 0 9.701419528829192e-11
a O 0 6.078666459075066e-10
homozygous O 0 3.934842496278179e-08
state O 0 6.528153018159344e-10
in O 0 4.579954471228831e-10
two O 0 5.542612480091691e-10
consanguineous O 0 2.8148608635092387e-06
families O 0 1.0637310587924276e-08
and O 0 7.021532244522177e-09
in O 0 4.282851573389479e-10
a O 0 1.5698174982148316e-09
heterozygous O 0 1.960984086224471e-08
state O 0 2.0649300325192854e-10
in O 0 5.999005459056406e-11
five O 0 1.0416206785990312e-10
additional O 0 6.169906252573298e-10
non O 0 1.769511754901032e-07
- O 0 3.277595169492997e-05
consanguineous O 0 0.00010955265315715224
families O 0 1.3051767666638625e-07
. O 0 6.373383598656801e-08

Another O 0 6.407915407180553e-07
missense O 0 9.085687634069473e-05
mutation O 0 8.521519703208469e-07
( O 0 1.3555535582909783e-09
T416P O 0 8.311333488109085e-08
) O 0 2.210215566122997e-09
was O 0 3.069817751111259e-07
found O 0 1.3309185753485053e-08
in O 0 1.3338345705715682e-10
a O 0 7.583731975735475e-10
homozygous O 0 6.641417371611169e-08
state O 0 9.713737592065286e-10
in O 0 1.2358897238939903e-09
one O 0 5.8270308578300956e-09
family O 0 2.2676989885894727e-07
and O 0 1.561424056717442e-08
in O 0 5.657204704689889e-10
a O 0 1.216102663015306e-09
heterozygous O 0 1.4128263003954089e-08
state O 0 4.610437864815964e-10
in O 0 3.4607067211922526e-10
four O 0 2.2953166034511696e-09
families O 0 1.1284117640286695e-08
. O 0 1.0937068140037809e-08

Pendred B-Disease 0 0.006761595606803894
patients O 0 1.6567422790103592e-05
in O 0 4.742640502541917e-09
three O 0 1.9504264869851795e-09
non O 0 7.804185884197068e-07
- O 0 3.830165587714873e-05
consanguineous O 0 7.478002953575924e-05
families O 0 1.3137233167981321e-07
were O 0 2.3833138129703002e-08
shown O 0 2.97782554170567e-09
to O 0 9.395122180233528e-11
be O 0 2.3355517519974e-10
compound O 0 7.228849963070161e-09
heterozygotes O 0 2.083867300939346e-09
for O 0 1.177596631318778e-10
L236P O 0 6.138792940646454e-08
and O 0 1.1617470541125385e-08
T416P O 0 1.0263464673698763e-06
. O 0 4.553158561293458e-08

In O 0 1.3676773491511085e-08
total O 0 1.100942093046342e-08
, O 0 2.014951316908764e-09
one O 0 7.638125687492447e-10
or O 0 1.0048197829348737e-08
both O 0 1.5457884972036595e-10
of O 0 2.0802354630533593e-11
these O 0 1.3889618621920619e-10
mutations O 0 1.0855945031806868e-09
were O 0 4.489558946829675e-08
found O 0 4.872691761192982e-08
in O 0 7.439475147030805e-10
nine O 0 7.330579476771959e-10
of O 0 2.3704710069849533e-11
the O 0 3.428618500223024e-10
14 O 0 2.2367636631770438e-09
families O 0 1.6631159782676264e-09
analyzed O 0 8.388495587041689e-08
. O 0 3.6301429418017506e-08

The O 0 1.081168843342084e-08
identification O 0 3.680037607978193e-08
of O 0 9.769572928419734e-10
two O 0 2.4712669688398137e-09
frequent O 0 1.793368937796913e-06
PDS B-Disease 0 1.5908348359516822e-05
mutations O 0 1.954307649043585e-08
will O 0 1.0767129410282905e-09
facilitate O 0 3.878834586856783e-09
the O 0 4.0188186112288804e-10
molecular O 0 2.181386236088656e-07
diagnosis O 0 0.00010363005276303738
of O 0 6.062073680368485e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.696846425147669e-06

Insertional O 0 0.00022548188280779868
mutation O 0 2.5450563043705188e-06
by O 0 1.0120769111665595e-08
transposable O 0 5.597486051556189e-06
element O 0 6.855715355413849e-07
, O 0 1.3290971878632263e-08
L1 O 0 1.7563621668159612e-06
, O 0 1.4507089973747611e-09
in O 0 1.856188397431069e-10
the O 0 7.848873773141918e-10
DMD B-Disease 1 0.9999817609786987
gene O 0 4.870712544402522e-08
results O 0 1.1739200722615806e-08
in O 0 1.3223860229061302e-08
X B-Disease 1 0.999920129776001
- I-Disease 1 0.9999909400939941
linked I-Disease 1 0.999996542930603
dilated I-Disease 1 0.9999276399612427
cardiomyopathy I-Disease 1 0.9999991655349731
. O 0 4.512624400376808e-06

X B-Disease 1 0.9995864033699036
- I-Disease 1 0.9999656677246094
linked I-Disease 1 0.9999924898147583
dilated I-Disease 1 0.9999921321868896
cardiomyopathy I-Disease 1 1.0
( O 0 1.9381384674943547e-07
XLDCM B-Disease 0 0.00026137541863135993
) O 0 2.1359232160733654e-09
is O 0 2.4417585731129066e-09
a O 0 1.4345326038167627e-09
clinical O 0 3.495985367862886e-08
phenotype O 0 5.4342837785270603e-08
of O 0 4.2957862267378744e-10
dystrophinopathy B-Disease 0 6.051742093404755e-05
which O 0 1.9221076286157768e-07
is O 0 1.1440500102821716e-08
characterized O 0 2.7649456058043143e-08
by O 0 1.66103952814467e-09
preferential O 0 4.316646482038777e-06
myocardial B-Disease 0 0.022654978558421135
involvement I-Disease 0 5.555794473366404e-07
without O 0 3.495390199503845e-09
any O 0 4.501526706945924e-09
overt O 0 3.4983742125405115e-07
clinical O 0 1.563138198434899e-06
signs O 0 3.867902705678716e-06
of O 0 7.380439228654723e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 3.158855179208331e-05

To O 0 3.712134599709316e-08
date O 0 1.0786912696403306e-07
, O 0 6.877792224635471e-10
several O 0 6.483762138298488e-11
mutations O 0 1.1156887858021491e-08
in O 0 1.3011364208281861e-09
the O 0 3.2211383427238616e-07
Duchenne B-Disease 1 0.9999485015869141
muscular I-Disease 1 0.9095302224159241
dystrophy I-Disease 0 0.033375293016433716
gene O 0 1.3013332136324607e-05
, O 0 3.814642468569218e-06
DMD O 1 0.9999995231628418
, O 0 2.5097645561800164e-07
have O 0 1.3364180873054465e-08
been O 0 2.1101662639466667e-08
identified O 0 1.154305550699064e-06
in O 0 3.0533540140709192e-09
patients O 0 2.1901478408636876e-09
with O 0 6.801164631475842e-10
XLDCM B-Disease 0 0.0004118634096812457
, O 0 1.1982523417941593e-08
but O 0 9.59258783517214e-10
a O 0 2.4666130249428875e-10
pathogenic O 0 2.109030505792475e-09
correlation O 0 5.5230495732416784e-09
of O 0 3.139549384356677e-11
these O 0 6.634194860133391e-10
cardiospecific O 0 1.2989249853490037e-06
mutations O 0 5.984830409033748e-08
in O 0 1.8293796699708764e-08
DMD O 1 0.9999990463256836
with O 0 5.861366147996705e-08
the O 0 9.943034839920983e-09
XLDCM B-Disease 0 7.421339250868186e-05
phenotype O 0 3.0227079150790814e-06
has O 0 5.489999352903396e-07
remained O 0 3.5030012668357813e-07
to O 0 1.2869471044396619e-09
be O 0 2.556098444017607e-08
elucidated O 0 1.0510433412491693e-06
. O 0 4.379648643748624e-08

We O 0 1.1579738838918274e-06
report O 0 1.6193716589896212e-08
here O 0 7.49593609405963e-10
the O 0 1.0549764187239852e-11
identification O 0 1.6733521235323678e-09
of O 0 5.568910610431743e-11
a O 0 3.658891634117367e-09
unique O 0 4.4022360867757016e-08
de O 0 1.044715190801071e-05
novo O 0 3.830084096989594e-06
L1 O 0 7.046636483210023e-07
insertion O 0 1.9115576677108947e-08
in O 0 1.0265134298137468e-09
the O 0 1.6525034118863857e-10
muscle O 0 6.1018328167961045e-09
exon O 0 7.539559199187806e-09
1 O 0 1.0942304840000361e-08
in O 0 1.8641875598746083e-08
DMD O 1 0.9999995231628418
in O 0 3.682396609860916e-08
three O 0 1.220164591586581e-08
XLDCM B-Disease 0 0.00018914755492005497
patients O 0 6.683833930765104e-09
from O 0 4.775467868367578e-11
two O 0 2.3151716654901122e-10
unrelated O 0 7.536816326592088e-08
Japanese O 0 6.127855840531993e-07
families O 0 2.7170733218895293e-08
. O 0 3.114825020134049e-08

The O 0 3.610199694747962e-09
insertion O 0 3.0179212018310864e-08
was O 0 2.438707156215969e-07
a O 0 1.4947289628253202e-08
5 O 0 6.944972597011656e-09
- O 0 7.557457593065919e-07
truncated O 0 3.812558091453866e-08
form O 0 6.547734354711565e-09
of O 0 4.098856809520157e-10
human O 0 7.076724095611553e-09
L1 O 0 9.482828744467042e-08
inversely O 0 1.351592970877391e-07
integrated O 0 2.0519647137007269e-07
in O 0 1.0725520471766004e-09
the O 0 8.008108065560293e-10
5 O 0 7.256519829468289e-09
- O 0 4.893798541161232e-05
untranslated O 0 3.7659854569938034e-05
region O 0 5.694146665291555e-08
in O 0 1.585285513971968e-10
the O 0 7.603410956402712e-11
muscle O 0 2.0881405493611283e-09
exon O 0 1.897165535780232e-09
1 O 0 1.5175803946831934e-09
, O 0 2.349734018469718e-10
which O 0 2.1913180159316425e-09
affected O 0 1.2489659306780254e-09
the O 0 1.309325738108047e-11
transcription O 0 7.376672606085322e-09
or O 0 1.2693513795625222e-08
the O 0 8.734833967238842e-10
stability O 0 1.6605564212568424e-07
of O 0 5.832874461209059e-11
the O 0 9.636655917688586e-10
muscle O 0 1.473164434884211e-08
form O 0 3.5162109335296066e-10
of O 0 8.413625351977316e-11
dystrophin O 0 1.7230529891776314e-08
transcripts O 0 2.660148368249793e-08
but O 0 3.063854947527034e-09
not O 0 3.759758615551334e-10
that O 0 3.549442337269504e-11
of O 0 3.7596637608716676e-11
the O 0 4.643428308526154e-09
brain O 0 3.1891065646050265e-06
or O 0 3.927397074221517e-08
Purkinje O 0 2.5030503820744343e-06
cell O 0 3.312242370157037e-06
form O 0 2.2338825900192205e-08
, O 0 1.5242155981809447e-08
probably O 0 2.7935075763707573e-07
due O 0 2.207123372954811e-09
to O 0 4.4938983090325735e-10
its O 0 6.847359346195958e-10
unique O 0 1.2478610367239185e-09
site O 0 6.638231297984021e-07
of O 0 2.943872645655432e-10
integration O 0 5.603301644896419e-08
. O 0 3.751925348183249e-08

We O 0 5.1726377847671756e-08
speculate O 0 3.0632840264388506e-08
that O 0 1.0652811271993912e-10
this O 0 1.2238267690922733e-11
insertion O 0 1.5054891777666057e-09
of O 0 2.6434140987241506e-10
an O 0 1.0561229668581973e-09
L1 O 0 1.086340716938139e-06
sequence O 0 1.9802016026915226e-08
in O 0 1.0913623782471404e-08
DMD O 1 0.9999974966049194
is O 0 2.81842513771835e-08
responsible O 0 2.4518028496345323e-08
for O 0 1.8455377504000836e-10
some O 0 3.7074728703734294e-11
of O 0 5.0327975294195415e-12
the O 0 2.723155034800584e-11
population O 0 8.025106273956695e-11
of O 0 4.1897464664319983e-11
Japanese O 0 8.451158350908372e-07
patients O 0 1.3964535083843543e-09
with O 0 1.9801126016627535e-10
XLDCM B-Disease 0 1.2315088042669231e-06
. O 0 1.6823993309600382e-09
. O 0 1.563742912935595e-08

Severe O 0 5.085828888695687e-05
early O 0 2.4453472633467754e-06
- O 1 0.9990752935409546
onset O 1 0.9998912811279297
obesity B-Disease 1 1.0
, O 0 0.12674695253372192
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.5077886928338557e-05
red O 0 0.00010225557343801484
hair O 1 0.7996065020561218
pigmentation O 0 0.002277541905641556
caused O 0 9.282479140892974e-07
by O 0 7.77137110219428e-09
POMC O 0 0.0002021724358201027
mutations O 0 2.006397039622243e-07
in O 0 1.6541062963781883e-09
humans O 0 5.18919947012364e-08
. O 0 2.7869607066577373e-08

Sequential O 0 1.0077476872538682e-05
cleavage O 0 0.0001021364878397435
of O 0 5.173335537733692e-09
the O 0 3.9392614170630225e-10
precursor O 0 7.597518170143758e-09
protein O 0 2.5748183585250217e-09
pre O 0 3.088617575031094e-07
- O 0 2.3667578261665767e-06
pro O 0 1.5304752878364525e-06
- O 0 2.5948022539523663e-06
opiomelanocortin O 0 6.821423994551878e-07
( O 0 2.0156269708859753e-10
POMC O 0 4.254432894867932e-08
) O 0 4.660984445625793e-11
generates O 0 6.629742310693132e-10
the O 0 1.0950395451514439e-10
melanocortin O 0 3.3348305805702694e-07
peptides O 0 4.4309953040055916e-08
adrenocorticotrophin O 0 6.538439265568741e-07
( O 0 8.662595085695557e-10
ACTH O 0 3.379008717274701e-08
) O 0 9.293141950417194e-11
, O 0 1.35231451037221e-10
melanocyte O 0 9.544075965095544e-07
- O 0 3.004378595505841e-05
stimulating O 0 2.7784108169726096e-06
hormones O 0 3.410620053045932e-08
( O 0 5.4517685504906765e-11
MSH O 0 3.918253810297756e-08
) O 0 1.28697026993696e-11
alpha O 0 2.0217516896736676e-11
, O 0 3.3454241980812593e-12
beta O 0 3.712615718326484e-12
and O 0 4.65391093718015e-12
gamma O 0 4.33240873731755e-11
as O 0 2.971700663323418e-11
well O 0 4.7139389613981564e-11
as O 0 1.0894785074100355e-11
the O 0 2.577610434123523e-12
opioid O 0 6.015806186532302e-10
- O 0 2.694976464212573e-09
receptor O 0 5.486299192725141e-10
ligand O 0 1.49114876002443e-09
beta O 0 4.378051254860793e-09
- O 0 1.0549578064456e-06
endorphin O 0 2.263070382468868e-05
. O 0 3.524890246353607e-08

While O 0 6.051290313280333e-08
a O 0 2.2444646141650537e-09
few O 0 7.928287470981843e-10
cases O 0 2.2992687753742302e-09
of O 0 3.726377428847627e-09
isolated O 1 0.9996479749679565
ACTH B-Disease 1 0.9978951215744019
deficiency I-Disease 0 0.1939544826745987
have O 0 7.277796587601415e-09
been O 0 7.396273105086948e-08
reported O 0 1.4088028592595947e-06
( O 0 1.7193685364347289e-09
OMIM O 0 3.3464027637819527e-06
201400 O 0 1.8507307686377317e-07
) O 0 7.647718014425209e-10
, O 0 1.3993491920771817e-09
an O 0 4.288559729559438e-09
inherited O 0 0.04303301125764847
POMC O 1 0.7391378283500671
defect O 0 0.05055534839630127
has O 0 2.86188168274748e-07
not O 0 6.614639058710736e-09
been O 0 1.8098401000088415e-08
described O 0 1.9089348768375203e-07
so O 0 6.34812158395448e-09
far O 0 1.7168984456361613e-08
. O 0 1.3321757030837489e-08

Recent O 0 7.60783109399199e-07
studies O 0 3.605783405191687e-08
in O 0 7.282430769528503e-10
animal O 0 2.2459818893594274e-08
models O 0 5.085396637127815e-08
elucidated O 0 6.585273126802349e-08
a O 0 2.959971157068253e-09
central O 0 1.5053283064503375e-09
role O 0 2.676727728356809e-10
of O 0 1.095826554498025e-11
alpha O 0 7.002804447431288e-10
- O 0 2.1096940372444806e-07
MSH O 0 4.4550631628226256e-07
in O 0 4.774202214119505e-11
the O 0 1.460811679954155e-11
regulation O 0 1.5598269897942885e-10
of O 0 4.513334844746808e-11
food O 0 6.968830845721641e-09
intake O 0 1.284453099437144e-09
by O 0 2.894495927663332e-11
activation O 0 2.1471260880367993e-10
of O 0 2.7479386821571694e-11
the O 0 3.4820266114898857e-10
brain O 0 9.567855130399039e-08
melanocortin O 0 2.1397740113116015e-07
- O 0 3.8672246205351257e-07
4 O 0 1.2458283293881323e-08
- O 0 3.03015525560113e-07
receptor O 0 5.238262268392191e-09
( O 0 2.210442107131172e-10
MC4 O 0 7.138694400055101e-07
- O 0 2.401583287792164e-07
R O 0 2.6479892767383717e-07
; O 0 6.505527366806874e-11
refs O 0 6.998054580265034e-09
3 O 0 1.5907807293658038e-09
- O 0 1.3609407290005038e-07
5 O 0 2.3531201986948247e-10
) O 0 1.1320101973855135e-11
and O 0 7.84171824697033e-11
the O 0 2.2311711506128873e-11
linkage O 0 4.2412028733451734e-07
of O 0 2.7715638117875585e-10
human O 0 4.815574357053265e-06
obesity B-Disease 1 0.9999936819076538
to O 0 3.492804490079493e-09
chromosome O 0 1.2918154652652447e-06
2 O 0 5.256918900187202e-09
in O 0 1.2842007457436466e-09
close O 0 1.4846710882920888e-07
proximity O 0 4.82542148461107e-08
to O 0 5.138512726432509e-09
the O 0 9.241709064689019e-10
POMC O 0 4.563531206258631e-07
locus O 0 1.3247490215917423e-08
, O 0 1.0168595965254212e-09
led O 0 6.755797588020584e-10
to O 0 7.236571897273336e-10
the O 0 4.4475700899937465e-10
proposal O 0 4.34680096361717e-08
of O 0 7.229297716015992e-11
an O 0 1.3357142059078342e-09
association O 0 1.8937671431018543e-09
of O 0 2.3277467453564071e-10
POMC O 0 0.00015650260320398957
with O 0 1.155819262521618e-08
human O 0 1.0596520951366983e-05
obesity B-Disease 1 0.9999880790710449
. O 0 6.846764222245838e-07

The O 0 8.97629561791291e-08
dual O 0 3.097815124419867e-07
role O 0 1.475948785412129e-08
of O 0 2.754073913369126e-10
alpha O 0 4.697446875923106e-09
- O 0 7.106999078132503e-07
MSH O 0 7.847157803553273e-07
in O 0 8.33847435544044e-11
regulating O 0 4.614894422161342e-08
food O 0 4.193342206804118e-08
intake O 0 2.494273232400701e-08
and O 0 1.5535006614442182e-09
influencing O 0 3.363325973282372e-08
hair O 0 7.784757326589897e-05
pigmentation O 0 5.918858505538083e-07
predicts O 0 1.2310061947573558e-06
that O 0 4.681130483241702e-10
the O 0 2.8557381459570763e-10
phenotype O 0 2.1677695372090966e-07
associated O 0 7.103110277739688e-08
with O 0 1.0270897021769088e-08
a O 0 1.3019225661992095e-06
defect O 0 0.0010357822757214308
in O 0 2.5065955977510157e-09
POMC O 0 1.3958857380202971e-05
function O 0 5.08260384890491e-08
would O 0 1.5849575873971844e-08
include O 0 8.428832387608054e-08
obesity B-Disease 1 0.9999992847442627
, O 0 2.51075849000415e-09
alteration O 0 2.0191734506624925e-07
in O 0 3.4888225641793724e-09
pigmentation O 0 0.03442095220088959
and O 0 0.0063832406885921955
ACTH B-Disease 1 0.9995549321174622
deficiency I-Disease 1 0.5663524270057678
. O 0 1.0752710721817493e-07

The O 0 7.055930240085218e-08
observation O 0 3.7756230995000806e-06
of O 0 9.388015920208659e-10
these O 0 1.6877482522659193e-08
symptoms O 0 2.0706633563349897e-07
in O 0 1.1695987234272565e-10
two O 0 2.525006037590316e-10
probands O 0 2.359246309424634e-07
prompted O 0 2.4099167106328423e-09
us O 0 6.187737544571803e-10
to O 0 6.640445832095665e-11
search O 0 9.881812035317239e-10
for O 0 1.6366158428482436e-10
mutations O 0 1.3809830612387941e-08
within O 0 9.68770397236085e-10
their O 0 8.774748039286351e-09
POMC O 0 2.13127914321376e-05
genes O 0 1.6324031548720086e-07
. O 0 9.440941539651249e-08

Patient O 0 0.00022405119671020657
1 O 0 1.0932755145631745e-07
was O 0 6.435351451727911e-07
found O 0 1.5138287068339196e-08
to O 0 4.9451837069725e-10
be O 0 6.93897106440744e-10
a O 0 3.4354918909684784e-10
compound O 0 3.4953650640545675e-08
heterozygote O 0 6.725215495606562e-09
for O 0 6.747281899865953e-11
two O 0 4.5278201327159096e-11
mutations O 0 7.984498062718615e-10
in O 0 4.995091840154231e-11
exon O 0 7.920039735154205e-09
3 O 0 7.769311416438995e-09
( O 0 4.540570142097522e-10
G7013T O 0 2.981396107770706e-08
, O 0 3.889315258742698e-10
C7133delta O 0 3.582844598781776e-08
) O 0 7.895942927271804e-11
which O 0 3.719005103874906e-10
interfere O 0 2.2954480538572852e-09
with O 0 3.544699603286183e-11
appropriate O 0 5.148301229773722e-10
synthesis O 0 2.5592923336148488e-09
of O 0 2.7328864171671796e-10
ACTH O 0 4.625782423772762e-07
and O 0 1.746304656435882e-09
alpha O 0 1.2777023883359107e-08
- O 0 2.0321895135566592e-06
MSH O 0 4.228461330058053e-05
. O 0 8.109732618777343e-08

Patient O 0 0.0002294585865456611
2 O 0 3.597848419190086e-08
was O 0 1.9132720296966e-08
homozygous O 0 6.154104426059348e-08
for O 0 2.6736968194995825e-10
a O 0 8.184827815505002e-10
mutation O 0 3.495683742471556e-09
in O 0 8.087214925511788e-11
exon O 0 1.1557884427304543e-08
2 O 0 1.3470590864983478e-08
( O 0 5.665615754324449e-10
C3804A O 0 4.6693731547975403e-08
) O 0 6.115858375288497e-10
which O 0 2.223671557999296e-08
abolishes O 0 5.259145837044343e-06
POMC O 0 1.142834844358731e-05
translation O 0 2.573686117557372e-07
. O 0 6.778093819548303e-08

These O 0 1.0407959649683107e-07
findings O 0 1.4226287703422713e-08
represent O 0 8.179802946095549e-10
the O 0 8.832704012640136e-11
first O 0 4.2655032284066863e-10
examples O 0 6.209115444022473e-09
of O 0 3.861654884751431e-10
a O 0 1.1109587831015233e-05
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999996423721313
within O 0 4.499202788110779e-08
the O 0 3.820060712200757e-09
POMC O 0 5.10866857439396e-06
gene O 0 5.61884156979886e-08
and O 0 8.18851653150432e-09
define O 0 2.016221714029598e-07
a O 0 3.2414209982789544e-08
new O 0 6.080458092583285e-07
monogenic B-Disease 1 0.9990863800048828
endocrine I-Disease 1 0.9347255229949951
disorder I-Disease 0 0.0007717428379692137
resulting O 0 4.576708345638281e-09
in O 0 1.4827112870818837e-09
early O 0 3.3788353448471753e-07
- O 1 0.9997567534446716
onset O 1 0.9998892545700073
obesity B-Disease 1 1.0
, O 1 0.5535557270050049
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 9.354084795631934e-06
red O 0 7.326697414100636e-06
hair O 0 0.002425840590149164
pigmentation O 0 8.550274287699722e-06
. O 0 7.106454535943385e-09
. O 0 2.8132049578744045e-08

A O 0 3.4966569728567265e-06
European O 0 2.368138893871219e-07
multicenter O 0 5.376072658691555e-05
study O 0 2.1510598458007735e-07
of O 0 1.7871915360956336e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 3.687520333528482e-08
classification O 0 3.3027870216528754e-08
of O 0 1.262328991336048e-10
105 O 0 7.069992147279436e-09
mutations O 0 1.471805166630702e-08
and O 0 4.964067379376047e-09
a O 0 3.5758520589013187e-09
general O 0 5.092943289319862e-10
system O 0 8.107482463159954e-10
for O 0 5.420993168248067e-11
genotype O 0 5.242912948233425e-08
- O 0 1.5261201724570128e-07
based O 0 1.1050676818058491e-08
prediction O 0 5.77956484448805e-07
of O 0 2.3973640850272204e-09
metabolic O 0 0.00022018796880729496
phenotype O 0 9.586498890712392e-06
. O 0 2.0632556640975963e-07

Phenylketonuria B-Disease 0 0.0109047656878829
( O 0 2.6649175310922146e-07
PKU B-Disease 0 7.344171535805799e-06
) O 0 9.183762195164036e-09
and O 0 3.208230836548864e-08
mild B-Disease 0 0.0006882288143970072
hyperphenylalaninemia I-Disease 1 1.0
( O 0 4.496811015997082e-05
MHP B-Disease 1 0.9999998807907104
) O 0 9.550971213911907e-08
are O 0 9.030819114741462e-08
allelic B-Disease 0 0.005537630058825016
disorders I-Disease 1 0.9821650385856628
caused O 0 9.457035332616215e-08
by O 0 6.137769181790986e-10
mutations O 0 1.1902138830066633e-08
in O 0 1.6266354929683757e-10
the O 0 3.593483288710786e-10
gene O 0 5.417177462163636e-08
encoding O 0 5.487351018018671e-07
phenylalanine O 0 0.0016922727227210999
hydroxylase O 0 0.003576065879315138
( O 0 9.134466694149523e-08
PAH O 0 4.141693807468982e-06
) O 0 4.42530101452121e-09
. O 0 1.2768400559082238e-08

Previous O 0 1.0626404645108778e-07
studies O 0 6.28204332997484e-09
have O 0 1.4815325632966392e-09
suggested O 0 2.1323531829153808e-09
that O 0 7.385294459316682e-11
the O 0 5.880909648148247e-11
highly O 0 2.2538392485671466e-08
variable O 0 3.4051713555527385e-06
metabolic O 0 0.00012898338900413364
phenotypes O 0 2.427471372357104e-05
of O 0 1.702011559245875e-06
PAH B-Disease 1 0.9997658133506775
deficiency I-Disease 1 0.6250234842300415
correlate O 0 4.947423803969286e-06
with O 0 4.960729143022036e-07
PAH O 0 0.007349252235144377
genotypes O 0 1.6697138562449254e-05
. O 0 1.385397325748272e-07

We O 0 6.420112867999705e-07
identified O 0 1.8705493687320995e-07
both O 0 4.971607570070091e-10
causative O 0 1.009388597594807e-06
mutations O 0 1.2488074219163536e-07
in O 0 3.466568365695366e-09
686 O 0 2.0691069948952645e-05
patients O 0 4.863694016421505e-07
from O 0 1.2107678193373772e-09
seven O 0 5.950964609979792e-09
European O 0 5.981747541738969e-09
centers O 0 7.4520364989894e-08
. O 0 2.4638131534970853e-08

On O 0 1.2010149248453672e-06
the O 0 1.1570252533843473e-09
basis O 0 4.3598018528712146e-09
of O 0 4.505120929088058e-11
the O 0 5.366612362833756e-11
phenotypic O 0 6.659074358594808e-08
characteristics O 0 3.443683027626321e-08
of O 0 4.625764216115158e-10
297 O 0 9.339854045720131e-08
functionally O 0 4.0101900822264724e-07
hemizygous O 0 1.7588326954864897e-05
patients O 0 4.793223951082837e-08
, O 0 1.6072737585304253e-10
105 O 0 1.96788474404741e-09
of O 0 4.0002712947684316e-11
the O 0 8.051508071371671e-11
mutations O 0 1.8387958933274717e-09
were O 0 2.354481498656469e-09
assigned O 0 7.420598580054616e-10
to O 0 8.494041026096966e-10
one O 0 8.928221495452249e-10
of O 0 9.760627028843061e-11
four O 0 6.664760965335859e-10
arbitrary O 0 5.0786599103958e-07
phenotype O 0 1.1423981050029397e-06
categories O 0 3.1590769822287257e-07
. O 0 9.688895374893036e-08

We O 0 2.462202530750801e-07
proposed O 0 4.227545247204034e-08
and O 0 2.3202137100497566e-08
tested O 0 2.279415980410704e-07
a O 0 4.614414406134415e-10
simple O 0 2.1242911873997627e-09
model O 0 1.5951080456488853e-08
for O 0 6.909502830998449e-11
correlation O 0 6.434563992741005e-09
between O 0 5.846822470623181e-10
genotype O 0 9.19684239875096e-08
and O 0 1.5914181084042411e-09
phenotypic O 0 1.6691650728262175e-07
outcome O 0 1.6765564225806884e-07
. O 0 8.085253000444936e-08

The O 0 3.2925473902878366e-08
observed O 0 1.9439805498677742e-07
phenotype O 0 2.970034245208808e-07
matched O 0 4.373329787199509e-08
the O 0 2.1923997339801105e-10
predicted O 0 1.0992827981226583e-07
phenotype O 0 3.0380078896996565e-08
in O 0 4.052974067469961e-10
79 O 0 1.724798970315078e-08
% O 0 7.309271243816085e-11
of O 0 2.7484417519652027e-11
the O 0 8.724676536786546e-10
cases O 0 1.803396543209601e-08
, O 0 2.6233746286408177e-09
and O 0 7.868334428451362e-09
in O 0 3.0494995417740256e-10
only O 0 1.8994057715548962e-10
5 O 0 6.754724557467284e-11
of O 0 1.8908598645173136e-11
184 O 0 2.257129150251558e-09
patients O 0 1.6720791418123326e-09
was O 0 4.094438210699991e-08
the O 0 6.809819375064308e-11
observed O 0 6.444303757291436e-09
phenotype O 0 1.9025867548094766e-09
more O 0 1.0769917596631373e-10
than O 0 7.248217026578629e-10
one O 0 1.2573028174145406e-09
category O 0 3.6677114678695943e-08
away O 0 3.7168301769696654e-09
from O 0 5.164506322596907e-11
that O 0 3.7348715786755804e-10
expected O 0 1.1637252050888947e-08
. O 0 1.250876202618656e-08

Among O 0 6.487556447609677e-08
the O 0 5.851396589484636e-10
seven O 0 2.836694212859925e-10
contributing O 0 4.2518433218674545e-09
centers O 0 1.1032312841052772e-08
, O 0 1.1090744295172428e-10
the O 0 1.2300845238233382e-11
proportion O 0 1.738809873863545e-09
of O 0 9.664224281946687e-11
patients O 0 1.527593829209195e-09
for O 0 3.4877498111818284e-10
whom O 0 6.980271027856588e-09
the O 0 6.62958715702544e-11
observed O 0 2.0128974043132075e-08
phenotype O 0 4.470554770819035e-08
did O 0 2.3225602774346044e-08
not O 0 1.3089874739691254e-09
match O 0 6.662981277827384e-10
the O 0 5.213358217348585e-11
predicted O 0 2.2656275078247745e-08
phenotype O 0 6.0665543699656155e-09
was O 0 2.9780316879168822e-08
4 O 0 7.712287475314383e-10
% O 0 2.711256774645676e-10
- O 0 1.6069342336777481e-06
23 O 0 9.473966500195274e-09
% O 0 9.806382789134815e-11
( O 0 4.1287356866703817e-10
P O 0 1.4783184269617777e-05
< O 0 9.522958066554565e-08
. O 0 2.0712295767388866e-10
0001 O 0 1.9889949243179217e-08
) O 0 5.938191605103782e-11
, O 0 3.176042762120801e-11
suggesting O 0 8.528912021077417e-10
that O 0 1.9321823307993924e-10
differences O 0 1.120753712058331e-09
in O 0 1.5773432907040252e-11
methods O 0 8.200860546203614e-10
used O 0 9.483417384714699e-10
for O 0 6.933371238249109e-11
mutation O 0 3.832921091628805e-09
detection O 0 2.6363272453977515e-08
or O 0 1.5761871452468768e-07
phenotype O 0 7.087160724950081e-07
classification O 0 5.282406618789537e-07
may O 0 1.9305861087559606e-07
account O 0 2.2300682189779764e-08
for O 0 3.225653355531932e-10
a O 0 6.85601075911535e-10
considerable O 0 1.8252171996024913e-09
proportion O 0 3.6137546288728117e-09
of O 0 5.565143901264946e-10
genotype O 0 1.5907922715996392e-05
- O 0 0.0001294814865104854
phenotype O 0 1.3316392141859978e-05
inconsistencies O 0 7.955658475111704e-06
. O 0 2.3734295950816886e-07

Our O 0 2.9774020049444516e-07
data O 0 1.9599937672865053e-07
indicate O 0 4.2286256274337575e-08
that O 0 7.237717647434749e-10
the O 0 8.574649323911387e-10
PAH O 0 4.538731900538551e-06
- O 0 1.6284582216030685e-06
mutation O 0 1.9197678113869188e-08
genotype O 0 4.311707257897979e-08
is O 0 6.33112950954029e-10
the O 0 6.840437244415298e-11
main O 0 3.74559050442258e-08
determinant O 0 8.172589360810889e-08
of O 0 2.1275664563447094e-10
metabolic O 0 1.941138725669589e-05
phenotype O 0 1.5693609611844295e-07
in O 0 1.6289430915250591e-09
most O 0 2.983535196676712e-08
patients O 0 2.88248259039392e-07
with O 0 2.330847109988099e-06
PAH B-Disease 1 0.9995995163917542
deficiency I-Disease 1 0.7439054250717163
. O 0 3.036455495930568e-07

In O 0 3.005822790669299e-08
the O 0 7.716025041126784e-10
present O 0 9.589826710509897e-10
study O 0 9.500327191602764e-10
, O 0 3.212832777599317e-10
the O 0 5.184808832270349e-11
classification O 0 5.571040961882545e-09
of O 0 3.043357788001799e-10
105 O 0 3.515531261655269e-07
PAH O 0 1.1723267334673437e-06
mutations O 0 5.87775339511154e-09
may O 0 9.284059077074858e-10
allow O 0 7.458087480927134e-10
the O 0 3.113687363498485e-10
prediction O 0 8.384982379538997e-07
of O 0 1.0485095430778912e-10
the O 0 2.2420247602905619e-10
biochemical O 0 2.1521714188565966e-08
phenotype O 0 1.1261284349473044e-08
in O 0 1.0787001153422793e-10
> O 0 3.520547853241851e-09
10 O 0 1.1640087782538444e-09
, O 0 3.9221081937768076e-10
000 O 0 2.259515463620687e-09
genotypes O 0 1.609011590630871e-08
, O 0 2.044809210843823e-09
which O 0 2.9480727192776612e-08
may O 0 1.0076005807491129e-08
be O 0 1.9971546638686277e-10
useful O 0 9.972563885796148e-10
for O 0 1.0373361891691246e-10
the O 0 2.2416228595556476e-10
management O 0 1.0680634154880408e-08
of O 0 2.3997143161480494e-10
hyperphenylalaninemia B-Disease 1 0.9999959468841553
in O 0 4.468235914600882e-08
newborns O 0 7.770730007905513e-06
. O 0 4.068623482567091e-08

Somatic O 0 3.557718446245417e-05
instability O 0 8.134353265631944e-06
of O 0 3.5621421368148276e-09
the O 0 3.5445140156298294e-09
CTG O 0 6.386310997186229e-05
repeat O 0 3.241594299652206e-07
in O 0 5.544314451988441e-10
mice O 0 5.943984433542937e-07
transgenic O 0 6.196825665938377e-07
for O 0 2.284202871294383e-08
the O 0 3.3201170026586624e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
region O 0 3.256536729168147e-05
is O 0 7.885645914029737e-08
age O 0 6.0993889938742996e-09
dependent O 0 1.305933317041763e-08
but O 0 3.6202860154155303e-10
not O 0 8.114517391355491e-11
correlated O 0 7.130728230109185e-10
to O 0 1.3459611203359145e-10
the O 0 8.441643217782513e-11
relative O 0 9.33643118372629e-09
intertissue O 0 1.7636556037814444e-07
transcription O 0 1.3541360033286765e-07
levels O 0 1.583347142286584e-08
and O 0 2.8087441705793026e-08
proliferative O 0 0.026557398959994316
capacities O 0 7.018426913418807e-06
. O 0 1.441093644416469e-07

A O 0 1.501998667663429e-06
( O 0 1.0837681863051785e-08
CTG O 0 1.5541675111307995e-06
) O 0 3.118572899918348e-10
nexpansion O 0 1.0293337027178495e-07
in O 0 1.988408743214265e-10
the O 0 5.884929210608902e-10
3 O 0 6.287896070489296e-08
- O 0 0.002817542525008321
untranslated O 0 0.0005915778456255794
region O 0 6.141704034234863e-07
( O 0 5.707809225263816e-10
UTR O 0 1.1392854659675322e-08
) O 0 1.3404444221265521e-11
of O 0 1.096338818340481e-11
the O 0 2.3161268458693485e-09
DM O 1 0.9999997615814209
protein O 0 1.8061042794670357e-07
kinase O 0 2.0579693682520883e-07
gene O 0 2.9723228323064177e-08
( O 0 4.255459595814415e-10
DMPK O 0 2.844312803063076e-07
) O 0 1.9824784869282297e-10
is O 0 6.085835724256583e-10
responsible O 0 6.350691705847566e-08
for O 0 6.59848709005928e-08
causing O 0 0.005512284580618143
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
( O 0 3.373554864083417e-05
DM B-Disease 1 0.9999997615814209
) O 0 3.764247935578169e-07
. O 0 1.9161613806772948e-07

Major O 0 2.6238469672534848e-06
instability O 0 1.0387258953414857e-05
, O 0 3.5317930802136743e-09
with O 0 1.5490173033150256e-10
very O 0 6.598594448625761e-10
large O 0 6.389090922986895e-10
expansions O 0 2.451101543954337e-08
between O 0 2.36607378134579e-09
generations O 0 1.3942605958661147e-09
and O 0 5.845309125618314e-09
high O 0 3.304646156720992e-08
levels O 0 2.7338717401015344e-10
of O 0 4.861950252121883e-12
somatic O 0 7.1848766936000175e-09
mosaicism O 0 3.294237558293389e-07
, O 0 2.2541682409560337e-10
is O 0 2.379514085770751e-10
observed O 0 5.416493031873415e-09
in O 0 1.5423377019985196e-09
patients O 0 2.6707329681130432e-08
. O 0 2.1131345562253046e-08

There O 0 5.974959549348569e-07
is O 0 5.819944526308518e-09
a O 0 1.7983153854927991e-09
good O 0 7.2002279694061144e-09
correlation O 0 3.6879281850588086e-08
between O 0 1.6188922424831276e-09
repeat O 0 7.330069706767972e-08
size O 0 5.994370155804063e-08
( O 0 3.2109703784755084e-10
at O 0 5.8862794638514515e-09
least O 0 3.7848479905733257e-10
in O 0 7.16372794418163e-11
leucocytes O 0 1.3778185348201077e-07
) O 0 1.402127025595945e-10
, O 0 9.340198059426541e-11
clinical O 0 4.068567260873124e-09
severity O 0 9.368615394578228e-08
and O 0 1.3739732906969948e-08
age O 0 9.733679640078208e-09
of O 0 1.172731023402207e-09
onset O 0 5.1298575272085145e-06
. O 0 8.783342053675369e-08

The O 0 4.87511840674415e-07
trinucleotide O 0 0.00011147032637381926
repeat O 0 4.853282916883472e-06
instability O 0 5.773642328676942e-07
mechanisms O 0 6.941439067986721e-08
involved O 0 4.1700285891010935e-08
in O 0 3.117190416901394e-08
DM B-Disease 1 1.0
and O 0 1.3713934094994329e-05
other O 0 8.190082212422567e-08
human O 0 4.438227915670723e-05
genetic B-Disease 1 0.9999998807907104
diseases I-Disease 1 0.9999998807907104
are O 0 3.4600571297005445e-08
unknown O 0 6.877364171486988e-07
. O 0 5.591760299239468e-08

We O 0 1.7795439077872288e-07
studied O 0 1.9376795279413273e-08
somatic O 0 4.911634619020333e-07
instability O 0 7.721279757788579e-07
by O 0 4.352888716141479e-09
measuring O 0 0.0013806885108351707
the O 0 8.958555675064872e-09
CTG O 0 6.687774293823168e-05
repeat O 0 3.2577224828855833e-07
length O 0 1.8114258182322374e-07
at O 0 5.14757978464786e-08
several O 0 2.06938147173652e-10
ages O 0 4.026908140275509e-09
in O 0 6.682144421121805e-11
various O 0 1.6491247256666952e-10
tissues O 0 1.075600941646826e-08
of O 0 7.083522657325148e-11
transgenic O 0 5.981561344015063e-07
mice O 0 8.585578825659468e-07
carrying O 0 7.993374140369269e-08
a O 0 2.5187301133655637e-09
( O 0 2.9363861342446285e-10
CTG O 0 3.075109589190106e-07
) O 0 2.30311270055239e-10
55expansion O 0 3.829503114616273e-08
surrounded O 0 7.97814223574278e-08
by O 0 4.891160809705752e-10
45 O 0 2.1793136184555806e-09
kb O 0 5.566826075664721e-07
of O 0 4.76381656344671e-10
the O 0 4.252289187434144e-09
human O 0 2.05024457500258e-06
DM B-Disease 1 1.0
region O 0 2.395780484221177e-06
, O 0 4.973523259899082e-10
using O 0 9.182110627392603e-10
small O 0 7.372329235977304e-08
- O 0 2.6293821065337397e-05
pool O 0 9.366941640109872e-07
PCR O 0 1.4876433169774828e-06
. O 0 2.4261982645157332e-08

These O 0 7.806673352206417e-08
mice O 0 5.162405614100862e-06
have O 0 4.830464916949495e-09
been O 0 3.040017571009912e-09
shown O 0 4.5820014449304836e-09
to O 0 8.542295204527761e-10
reproduce O 0 3.9606729842489585e-06
the O 0 7.411856683958717e-10
intergenerational O 0 5.892163130738481e-07
and O 0 9.919224552845662e-09
somatic O 0 6.352133397058424e-08
instability O 0 4.89216382959512e-08
of O 0 1.4815769444620486e-10
the O 0 8.018409269894278e-10
55 O 0 2.248467723120484e-08
CTG O 0 5.173405952518806e-06
repeat O 0 6.464274093787026e-08
suggesting O 0 1.3920823604962607e-08
that O 0 3.6078232068526006e-10
surrounding O 0 5.061318475441112e-09
sequences O 0 6.000201668854288e-09
and O 0 1.0048384346816874e-09
the O 0 6.163140831016989e-11
chromatin O 0 4.067923331518841e-09
environment O 0 4.614524584667379e-08
are O 0 8.341035501180372e-11
involved O 0 1.3806715770670053e-09
in O 0 2.5503359424305927e-09
instability O 0 4.232608148413419e-07
mechanisms O 0 1.355324599217056e-07
. O 0 6.589356615904762e-08

As O 0 1.735633148314264e-08
observed O 0 1.1622900863983432e-08
in O 0 7.044987510029799e-11
some O 0 3.988036290092367e-11
of O 0 2.4522387592762485e-11
the O 0 7.568602411467396e-10
tissues O 0 9.701914649440369e-08
of O 0 1.0337246614255946e-08
DM B-Disease 1 1.0
patients O 0 1.5138081835175399e-05
, O 0 1.866723442489615e-09
there O 0 4.595024361009337e-09
is O 0 1.743652000563145e-09
a O 0 5.012110171342954e-10
tendency O 0 7.569573412524733e-09
for O 0 4.521746865826515e-10
repeat O 0 1.4085246391459805e-07
length O 0 1.3293612255438347e-07
and O 0 3.6681784276737517e-09
somatic O 0 4.065728198554552e-09
mosaicism O 0 6.075588743215121e-08
to O 0 3.116866209573743e-10
increase O 0 2.0379875564913164e-09
with O 0 7.003204682831665e-10
the O 0 3.2047722808847823e-10
age O 0 4.4912011887277e-09
of O 0 5.10551670385162e-11
the O 0 3.020937278108704e-09
mouse O 0 1.331273506366415e-05
. O 0 1.3228873285697773e-07

Furthermore O 0 1.0019300589192426e-06
, O 0 3.843755980170727e-09
we O 0 4.363293337750207e-10
observed O 0 1.0144090012431661e-09
no O 0 9.236630210684993e-11
correlation O 0 2.498295126329708e-09
between O 0 1.345450278966709e-10
the O 0 3.405304163650591e-11
somatic O 0 1.3303145252052673e-08
mutation O 0 2.4352761585078042e-08
rate O 0 4.103617357031908e-07
and O 0 1.0741986855578034e-08
tissue O 0 2.84517664113082e-05
proliferation O 0 5.915047222515568e-05
capacity O 0 1.3112575913964974e-07
. O 0 2.7577510053333754e-08

The O 0 2.7101119570716037e-08
somatic O 0 7.510740260840976e-07
mutation O 0 2.865505734916951e-07
rates O 0 3.4898766898550093e-07
in O 0 1.4650844426533638e-10
different O 0 1.0000120870268248e-10
tissues O 0 1.4855854324480333e-08
were O 0 1.3209995763929783e-08
also O 0 2.9842506243937805e-09
not O 0 2.161412715473432e-10
correlated O 0 1.303769869842597e-09
to O 0 2.3229344836561694e-10
the O 0 3.615890087349527e-10
relative O 0 6.714169842325646e-08
inter O 0 1.1820607426216156e-07
- O 0 7.713758350291755e-06
tissue O 0 8.932221930990636e-07
difference O 0 1.1314975623122336e-09
in O 0 3.7786069412293344e-11
transcriptional O 0 5.738737485216916e-09
levels O 0 1.6500664168361823e-09
of O 0 2.2791553366818817e-11
the O 0 1.6969557703472304e-10
three O 0 2.5894247857038977e-10
genes O 0 8.766730674736323e-10
( O 0 5.915514605936423e-11
DMAHP O 0 1.4320337982098863e-07
, O 0 6.10269057510493e-10
DMPK O 0 8.145136689563515e-07
and O 0 1.0256900218053033e-08
59 O 0 1.1157739621125984e-08
) O 0 1.556744871900051e-10
surrounding O 0 8.108322013811176e-09
the O 0 8.152452046772396e-10
repeat O 0 3.174346261403116e-07
. O 0 3.102230250462412e-09
. O 0 1.8898784759358023e-08

A O 0 1.628039058232389e-06
novel O 0 5.418106638899189e-07
missense O 0 2.7844167561852373e-05
mutation O 0 2.710484920953604e-07
in O 0 4.971808742482153e-09
patients O 0 3.847601703910186e-08
from O 0 3.3900376950057876e-10
a O 0 3.2775783864735786e-08
retinoblastoma B-Disease 0 5.110395795782097e-05
pedigree O 0 0.00011054137576138601
showing O 0 2.4387994926655665e-05
only O 0 3.277453686223453e-08
mild O 0 4.598362863816874e-07
expression O 0 6.379510697485102e-09
of O 0 9.939819800575123e-11
the O 0 3.043260532464842e-09
tumor B-Disease 0 4.174249625066295e-05
phenotype O 0 9.638297342462465e-07
. O 0 8.255625516540022e-08

We O 0 4.2423192780915997e-07
have O 0 1.6076302511436324e-09
used O 0 4.6066933601096594e-10
single O 0 8.082315927637751e-10
strand O 0 1.308960762003153e-08
conformation O 0 9.17898113073079e-09
polymorphism O 0 1.0912438064281105e-08
analysis O 0 9.663878586252395e-10
to O 0 2.0425708346927252e-10
study O 0 4.1819242513341237e-10
the O 0 3.543532134386851e-10
27 O 0 2.0464636651951196e-09
exons O 0 2.266265841655013e-09
of O 0 8.470529139215088e-11
the O 0 2.1496666946507759e-10
RB1 O 0 2.2797117082973273e-07
gene O 0 2.313844227330719e-09
in O 0 1.9530016492907976e-10
individuals O 0 3.5549591048678053e-10
from O 0 2.2539445310165718e-10
a O 0 2.0910748688152125e-08
family O 0 2.6830844035430346e-06
showing O 0 0.00040726218139752746
mild O 0 1.6140289517352358e-05
expression O 0 2.4788120001062453e-08
of O 0 2.5977503481655617e-10
the O 0 4.9716097905161405e-09
retinoblastoma B-Disease 0 4.247011020197533e-05
phenotype O 0 5.541990503843408e-06
. O 0 1.5299805511403974e-07

In O 0 2.74340745676227e-08
this O 0 1.4973562389997142e-09
family O 0 5.528153579348327e-08
affected O 0 3.252686298083063e-08
individuals O 0 3.2033133923192736e-09
developed O 0 5.601651537290309e-06
unilateral B-Disease 1 0.9995224475860596
tumors I-Disease 1 1.0
and O 0 3.355152148287743e-05
, O 0 1.1631926533084425e-08
as O 0 9.030725611758328e-10
a O 0 7.370719590227282e-10
result O 0 2.1514591497240332e-10
of O 0 3.2686148926375225e-11
linkage O 0 5.627689461107366e-07
analysis O 0 1.0386378868076918e-08
, O 0 1.3694908540529127e-09
unaffected O 0 1.5217297288927512e-07
mutation O 0 2.8366633486598403e-09
carriers O 0 1.5899193073209972e-09
were O 0 1.4294857741958822e-08
also O 0 7.51423741007784e-08
identified O 0 4.933868922307738e-07
within O 0 1.9675168161370493e-09
the O 0 9.34362898163954e-09
pedigree O 0 3.261916572228074e-05
. O 0 1.3472266857661452e-07

A O 0 3.9087856862352055e-07
single O 0 2.581153069058928e-08
band O 0 8.797472084154379e-09
shift O 0 6.940377161868128e-09
using O 0 4.794538099872625e-09
SSCP O 0 3.650379767350387e-06
was O 0 4.4755033457022364e-08
identified O 0 1.3257803743726981e-08
in O 0 3.3894283213431464e-11
exon O 0 6.792223228302419e-09
21 O 0 2.6564114463667465e-08
which O 0 3.608774612473553e-09
resulted O 0 1.9157322395102483e-09
in O 0 1.5286277799120285e-10
a O 0 1.3582813762624824e-09
missense O 0 4.0276174217979133e-07
mutation O 0 1.97836969029197e-09
converting O 0 1.4852106211549199e-09
a O 0 2.5103610301613344e-09
cys O 0 4.038874521938851e-06
- O 0 9.715893156680977e-07
- O 0 5.22237314726226e-07
> O 0 2.104550089754298e-09
arg O 0 6.742914226975927e-09
at O 0 9.123175548353402e-10
nucleotide O 0 2.6589346280303516e-09
position O 0 1.0313398135508578e-08
28 O 0 8.40395752987888e-10
in O 0 2.6106386150082095e-11
the O 0 9.354549773687992e-11
exon O 0 1.8557803116436844e-07
. O 0 8.632535042352174e-08

The O 0 5.5797421794068214e-08
mutation O 0 3.271158846018807e-07
destroyed O 0 7.348361123149516e-06
an O 0 2.069291848982857e-09
NdeI O 0 2.1754995032097213e-06
restriction O 0 2.2447019887295028e-07
enzyme O 0 2.9460841233230894e-07
site O 0 2.5887663923640503e-06
. O 0 4.696284960914454e-08

Analysis O 0 1.0279799056434058e-07
of O 0 2.971584533995042e-09
all O 0 2.903844276147538e-09
family O 0 2.624531880712766e-08
members O 0 1.7697218690493344e-10
demonstrated O 0 5.172092087946112e-09
that O 0 1.4768089529049178e-10
the O 0 2.827791611981212e-10
missense O 0 1.9063601257585105e-06
mutation O 0 6.319854861658314e-08
co O 0 9.783992709344602e-07
- O 0 5.661458544636844e-06
segregated O 0 6.086670964577934e-06
with O 0 1.2084052514182986e-07
patients O 0 7.813837896719633e-07
with O 0 1.658158794271003e-06
tumors B-Disease 1 1.0
or O 0 0.0011568295303732157
who O 0 4.94198275191593e-06
, O 0 6.361114746056273e-09
as O 0 1.3358618655701093e-09
a O 0 9.411861290331558e-10
result O 0 6.409217601088812e-10
of O 0 6.084660553185017e-11
linkage O 0 2.292822074423384e-07
analysis O 0 1.5132398445416584e-08
had O 0 2.103544289866477e-07
been O 0 8.384892780100017e-09
predicted O 0 4.489421812081673e-08
to O 0 2.3756277500730505e-10
carry O 0 1.514464109675373e-08
the O 0 3.182085039910021e-09
predisposing O 0 3.428090394663741e-06
mutation O 0 5.647867169500387e-07
. O 0 9.20154477057622e-08

These O 0 1.1169536406896441e-08
observations O 0 5.271953185115308e-08
point O 0 4.8287727594242824e-08
to O 0 6.582629996643163e-10
another O 0 1.4063140651998651e-09
region O 0 6.878005276433896e-09
of O 0 2.1375103076426427e-11
the O 0 6.154392551138699e-10
RB1 O 0 1.573524173181795e-06
gene O 0 3.345690835487858e-09
where O 0 9.411520451862998e-10
mutations O 0 2.73544320528174e-09
only O 0 2.1600816968447845e-10
modify O 0 1.6831190663424422e-08
the O 0 4.4384007580333673e-10
function O 0 6.482742787028428e-09
of O 0 2.917420471870713e-11
the O 0 4.2132828476093565e-11
gene O 0 2.4901554152023664e-09
and O 0 6.570164856611882e-09
raise O 0 4.003870568425327e-09
important O 0 1.149088046936697e-09
questions O 0 8.076275204160765e-10
for O 0 4.782213167131566e-11
genetic O 0 1.847240760355362e-08
counseling O 0 1.6943829450610792e-08
in O 0 8.793643035964749e-10
families O 0 2.4333202119919406e-09
with O 0 6.463638513309888e-10
these O 0 1.7469377056045232e-09
distinctive O 0 1.3816462285376474e-07
phenotypes O 0 1.6551048531709966e-07
. O 0 2.462271053715881e-09
. O 0 4.3121517023791966e-08

Maternal B-Disease 0 0.07713237404823303
disomy I-Disease 1 0.6559041738510132
and O 0 0.27128228545188904
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 0.00011035821808036417
with O 0 8.212761137826874e-09
gamete O 0 8.296032660837227e-07
complementation O 0 4.6109136746963486e-05
in O 0 2.8188109624238677e-09
a O 0 3.366514400582332e-09
case O 0 3.909271129032277e-09
of O 0 9.348681551113458e-11
familial O 0 3.3847535974018683e-07
translocation O 0 8.934028414842032e-07
( O 0 1.274664040984419e-09
3 O 0 2.299207491063271e-09
; O 0 4.798716979337314e-10
15 O 0 5.010580839126533e-10
) O 0 2.362527014299065e-11
( O 0 1.511068700721374e-11
p25 O 0 1.4403257475592568e-09
; O 0 2.2964090698462947e-11
q11 O 0 2.6898976379641226e-09
. O 0 8.215008534540047e-11
2 O 0 7.433872406537034e-10
) O 0 1.3995867798044515e-09
. O 0 8.057200240330076e-09

Maternal B-Disease 0 0.05568487197160721
uniparental I-Disease 0 0.3138972818851471
disomy I-Disease 0 0.36848583817481995
( I-Disease 0 2.588401002867613e-06
UPD I-Disease 1 0.9999942779541016
) I-Disease 0 6.453996448385624e-09
for I-Disease 0 6.582315803527194e-10
chromosome I-Disease 0 9.052486348082311e-06
15 I-Disease 0 1.7730279466832144e-08
is O 0 3.24283511154988e-09
responsible O 0 1.52425911892351e-08
for O 0 9.512851617543561e-11
an O 0 7.053982398197434e-11
estimated O 0 5.828220128734074e-09
30 O 0 4.381407181508479e-10
% O 0 2.806265983479328e-11
of O 0 5.1029562520010785e-11
cases O 0 6.605765889844406e-08
of O 0 5.4798019846202806e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.5346325855934992e-05
PWS B-Disease 1 0.9999972581863403
) O 0 2.933448115527426e-07
. O 0 1.9882368462731392e-07

We O 0 1.3555123814512626e-06
report O 0 3.8656086331911865e-08
on O 0 7.788555578258638e-09
an O 0 1.1280147649284089e-10
unusual O 0 3.2875504540896827e-09
case O 0 4.426997435302837e-09
of O 0 3.0372168668968413e-10
maternal B-Disease 0 4.3530445736905676e-07
disomy I-Disease 0 7.030988399492344e-06
15 I-Disease 0 1.830992424345368e-08
in O 0 1.5513931472810327e-08
PWS B-Disease 1 0.9999997615814209
that O 0 2.4412196708567535e-08
is O 0 6.289104792500666e-09
most O 0 1.506103020076921e-10
consistent O 0 5.5042774782521064e-09
with O 0 1.3621126448981613e-10
adjacent O 0 4.433654510194174e-07
- O 0 2.3183217763289576e-06
1 O 0 7.416792180414689e-10
segregation O 0 5.385177193062418e-09
of O 0 4.223855293306045e-11
a O 0 3.2892628620828646e-09
paternal O 0 4.6027372491153073e-07
t O 0 2.388783286733087e-06
( O 0 7.39907024538411e-11
3 O 0 3.355665467719149e-10
; O 0 1.5025394817236304e-10
15 O 0 4.5207984578077287e-10
) O 0 2.6217810908391037e-11
( O 0 2.144976037066204e-11
p25 O 0 1.6837251592960456e-09
; O 0 2.028979415036325e-11
q11 O 0 2.0806025791131333e-09
. O 0 5.446208761750171e-11
2 O 0 1.260829912697048e-10
) O 0 2.955922659420018e-11
with O 0 1.6331140606506978e-10
simultaneous O 0 1.2229750723236066e-07
maternal O 0 1.6921339920372702e-06
meiotic O 0 3.586452521631145e-06
nondisjunction O 0 1.0922892215603497e-05
for O 0 2.06334167529576e-08
chromosome O 0 1.5449091733898968e-05
15 O 0 2.0365436625979783e-07
. O 0 1.6102065103495988e-07

The O 0 7.262782020234226e-08
patient O 0 5.439836741061299e-07
( O 0 3.3794067544334894e-09
J O 0 0.0001385981886414811
. O 0 8.671058870923787e-10
B O 0 1.1040880281143473e-06
. O 0 4.820575189024012e-11
) O 0 1.7632182172655497e-11
, O 0 2.1101027175562947e-11
a O 0 2.8264057760907235e-10
17 O 0 1.029862972679041e-09
- O 0 2.2599999738304177e-07
year O 0 1.4759037547662501e-08
- O 0 2.139779826393351e-05
old O 0 4.7472218284383416e-05
white O 0 1.0172013844567118e-06
male O 0 2.562694305652258e-07
with O 0 5.511644829425677e-08
PWS B-Disease 1 0.9999997615814209
, O 0 3.599077302851583e-08
was O 0 4.2760569840538665e-07
found O 0 7.876667318384989e-09
to O 0 1.1559156964935369e-09
have O 0 2.088360595564609e-08
47 O 0 7.363416543171297e-09
chromosomes O 0 9.358610775223042e-09
with O 0 3.319439390025991e-09
a O 0 9.026427960634464e-08
supernumerary O 0 1.2774615242960863e-05
, O 0 7.323752271304329e-08
paternal O 0 1.7744065189617686e-05
der O 0 0.2713235020637512
( O 0 1.7969611354473614e-09
15 O 0 1.3420344835424203e-09
) O 0 4.3123341703088514e-11
consisting O 0 1.282053768703051e-10
of O 0 8.662309758378228e-11
the O 0 6.501018834370598e-09
short O 0 6.245348686206853e-06
arm O 0 0.00463150255382061
and O 0 2.041341096159499e-09
the O 0 3.3610333960432115e-10
proximal O 0 7.40935774956597e-06
long O 0 1.4996818208601326e-05
arm O 0 3.947909135604277e-05
of O 0 2.0575703640890453e-10
chromosome O 0 8.236576718445576e-07
15 O 0 1.0741842970674043e-08
, O 0 1.4579153440053005e-09
and O 0 1.899650570180711e-08
distal O 0 0.0003174915327690542
chromosome O 0 0.0434420108795166
arm O 1 0.7796913385391235
3p O 0 0.0011124975280836225
. O 0 1.5691440466980566e-06

The O 0 7.530795187449257e-08
t O 0 1.1856938726850785e-05
( O 0 1.7260969042975915e-10
3 O 0 1.3646636598529938e-10
; O 0 2.0780781609386345e-11
15 O 0 6.617964509736396e-11
) O 0 1.3092258180358307e-11
was O 0 1.1043601944038528e-07
present O 0 1.2787794156920995e-09
in O 0 2.092668816011667e-10
the O 0 1.0540315842355596e-10
balanced O 0 3.430898587453157e-08
state O 0 4.398698072449747e-10
in O 0 3.1258917676524334e-10
the O 0 1.0153149432312603e-09
patients O 0 1.138314598136958e-08
father O 0 7.676881352836062e-08
and O 0 3.9004901530859115e-09
a O 0 2.3145691585568784e-08
sister O 0 1.9173388864146546e-05
. O 0 1.5132867758893553e-07

Fluorescent O 0 3.5565203688747715e-06
in O 0 3.960675343250841e-09
situ O 0 5.651526535643825e-08
hybridization O 0 2.079658445452992e-09
analysis O 0 3.407029325330768e-09
demonstrated O 0 1.7337470126221888e-08
that O 0 6.598204205232605e-10
the O 0 1.0189102894742064e-08
PWS B-Disease 1 0.9999986886978149
critical O 0 5.470082555802946e-07
region O 0 7.293294146393237e-08
resided O 0 1.201378836412914e-07
on O 0 2.627241535435587e-08
the O 0 2.4830068556802587e-10
derivative O 0 5.753294658461527e-07
chromosome O 0 3.841197155907139e-07
3 O 0 5.443088202383706e-09
and O 0 1.4230928435665646e-08
that O 0 2.038590185549083e-09
there O 0 1.3640846674434215e-08
was O 0 1.248478724846791e-07
no O 0 2.6625275317826436e-09
deletion O 0 2.2296673396482447e-09
of O 0 3.7802019847710255e-10
the O 0 1.1497949969907495e-07
PWS B-Disease 1 0.9999996423721313
region O 0 6.682051889583818e-07
on O 0 2.8353997549857013e-07
the O 0 9.3335417172824e-10
normal O 0 2.5948610371528957e-08
pair O 0 7.740675656009444e-09
of O 0 7.970768489684588e-11
15s O 0 5.697946114935348e-09
present O 0 3.843799945002502e-09
in O 0 1.2245243929953631e-08
J O 0 0.001058062887750566
. O 0 1.1852745274154586e-07

B O 0 0.0031940657645463943
. O 0 2.8783201742044184e-06

Methylation O 0 9.89669842965668e-07
analysis O 0 3.166780615515563e-08
at O 0 6.101623206689055e-09
exon O 0 6.305211464052718e-09
alpha O 0 1.7996226731042952e-09
of O 0 6.153273723885633e-11
the O 0 4.0351252894588185e-10
small O 0 1.0550287043997741e-07
nuclear O 0 5.125853203935549e-05
ribonucleoprotein O 0 3.8450634747277945e-06
- O 0 7.941596322780242e-07
associated O 0 8.033618570379986e-08
polypeptide O 0 1.3079381915304111e-06
N O 0 2.5601591460144846e-06
( O 0 3.421106176126898e-10
SNRPN O 0 5.1396135347658856e-08
) O 0 3.863981010154838e-11
gene O 0 1.029584084655255e-09
showed O 0 4.7534381764080536e-08
a O 0 1.3298369072600735e-09
pattern O 0 3.7002134831709554e-06
characteristic O 0 6.538002850220437e-08
of O 0 1.688673922917161e-10
only O 0 3.7656171514299785e-09
the O 0 1.5312081602658623e-09
maternal O 0 4.719011030829279e-07
chromosome O 0 1.36453707000328e-06
15 O 0 1.695058671202787e-08
in O 0 1.6403395974862178e-08
J O 0 0.03025199845433235
. O 0 2.2682266376250482e-07

B O 0 0.0014882582472637296
. O 0 1.4183730172590003e-06

Maternal B-Disease 0 0.002392443362623453
disomy I-Disease 0 0.0006405772874131799
was O 0 2.289604253746802e-06
confirmed O 0 4.5637744250370815e-08
by O 0 1.4796622260782044e-10
polymerase O 0 5.325558305457889e-08
chain O 0 4.5540576820712886e-07
reaction O 0 6.541364672152383e-10
analysis O 0 4.449267065886886e-10
of O 0 1.550944789263653e-10
microsatellite O 0 1.5895386695774505e-06
repeats O 0 2.0932742472723476e-07
at O 0 1.0118530013869531e-08
the O 0 1.4174268703204262e-10
gamma O 0 6.080501879779376e-09
- O 0 2.2949770084323973e-07
aminobutyric O 0 3.0854789656586945e-07
acid O 0 1.0064458155767397e-09
receptor O 0 3.080865007554223e-10
beta3 O 0 8.754168945301899e-09
subunit O 0 2.3641790747319646e-09
( O 0 3.532431014363624e-10
GABRB3 O 0 3.4122442116313323e-07
) O 0 1.3567951206994167e-09
locus O 0 2.7512948008734384e-07
. O 0 3.939911508155092e-08

A O 0 2.8487124836829025e-06
niece O 0 0.00013097483315505087
( O 0 9.095242781143043e-09
B O 0 2.554841785240569e-06
. O 0 2.887924066552472e-10
B O 0 1.1489598250591371e-07
. O 0 1.2854542083551301e-11
) O 0 1.0856658454183599e-11
with O 0 3.6149160054232965e-11
45 O 0 2.4621008010150547e-10
chromosomes O 0 1.7975370081302344e-09
and O 0 1.3019432199001812e-09
the O 0 4.56932443271274e-11
derivative O 0 2.5580985152373614e-07
3 O 0 1.1881220451925856e-09
but O 0 5.513072220963977e-09
without O 0 6.714291900244973e-10
the O 0 1.7368807503359562e-09
der O 0 0.00017524459690321237
( O 0 2.2063689764095784e-10
15 O 0 2.37460384688859e-10
) O 0 5.105536132754551e-11
demonstrated O 0 2.6551387755091582e-09
a O 0 8.473829971045177e-10
phenotype O 0 7.893936526670586e-08
consistent O 0 1.023772995267791e-07
with O 0 9.167935854925702e-10
that O 0 2.0648918130916627e-09
reported O 0 2.1700074626096466e-07
for O 0 2.0370151398996228e-10
haploinsufficiency O 0 8.848010679685103e-08
of O 0 2.712343127875272e-10
distal O 0 1.6784822491899831e-06
3 O 0 2.2787183695527347e-07
p O 0 0.00017347697576042265
. O 0 1.4489322097688273e-07

Uniparental B-Disease 1 0.999921441078186
disomy I-Disease 1 0.9999688863754272
associated O 0 0.00011587911285459995
with O 0 5.492963950359808e-08
unbalanced O 0 6.662554369540885e-05
segregation O 0 2.286366225234815e-06
of O 0 1.1123225673870252e-09
non O 0 5.059815748609253e-07
- O 0 1.1304601684969384e-05
Robertsonian O 0 2.9935958991700318e-06
translocations O 0 7.275215011759428e-06
has O 0 1.0796437663884717e-06
been O 0 9.362648256683315e-08
reported O 0 6.022148681950057e-07
previously O 0 1.2527438286724646e-07
but O 0 2.0216814888840418e-08
has O 0 3.22445714573405e-08
not O 0 4.299944400543154e-09
, O 0 1.0270514300136924e-10
to O 0 4.6546880239084487e-10
our O 0 5.658488677617868e-10
knowledge O 0 8.823190095208489e-11
, O 0 2.0202676337399694e-11
been O 0 1.1743914174466852e-10
observed O 0 5.796676472158424e-10
in O 0 3.370578122163792e-11
a O 0 1.3154773936818742e-09
case O 0 1.0005682504754532e-08
of O 0 2.181664449096843e-08
PWS B-Disease 1 0.9999918937683105
. O 0 2.3729181464204885e-07

Furthermore O 0 9.700295777292922e-06
, O 0 3.713395102522554e-08
our O 0 2.858682623951836e-09
findings O 0 4.479512594190993e-10
are O 0 6.838780236551045e-11
best O 0 6.429297649823695e-10
interpreted O 0 2.7462228047170356e-09
as O 0 7.947728031254542e-10
true O 0 4.2624881402275605e-09
gamete O 0 2.930441489468194e-08
complementation O 0 1.7519139419164276e-06
resulting O 0 1.036557861766596e-08
in O 0 8.02949351452753e-09
maternal B-Disease 0 0.001567814964801073
UPD I-Disease 1 0.9999984502792358
15 I-Disease 0 8.860751222528052e-06
and O 0 9.121967013925314e-05
PWS B-Disease 1 0.9999849796295166

Schwartz B-Disease 0 0.2578275501728058
- I-Disease 1 0.9971038699150085
Jampel I-Disease 1 0.9993314743041992
syndrome I-Disease 1 0.9999377727508545
type I-Disease 0 9.113619307754561e-05
2 I-Disease 0 2.2415487421767466e-07
and O 0 6.541096695400483e-07
Stuve B-Disease 1 0.9935566782951355
- I-Disease 1 0.9999994039535522
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999992847442627
: O 0 4.425452448941769e-09
a O 0 3.93233490214584e-09
case O 0 5.78608627677113e-09
for O 0 4.008185727766289e-10
" O 0 6.132567165195724e-08
lumping O 0 6.087316251068842e-07
" O 0 4.046127912715747e-07
. O 0 2.3913688806942446e-08

Recent O 0 5.31392004177178e-07
studies O 0 4.194974323468159e-08
demonstrated O 0 5.433226846207617e-08
the O 0 1.697862267446837e-10
existence O 0 4.405165121568189e-09
of O 0 7.381379535376098e-11
a O 0 3.828069861100403e-09
genetically O 0 2.5269406123129556e-08
distinct O 0 3.6749292497972874e-09
, O 0 1.4013364912912607e-09
usually O 0 9.99703653192796e-10
lethal O 0 1.8945647828338963e-10
form O 0 6.549751019324646e-11
of O 0 2.481135435994375e-11
the O 0 1.1575924663276282e-09
Schwartz B-Disease 0 0.0006352614727802575
- I-Disease 1 0.9991433620452881
Jampel I-Disease 1 0.9995571970939636
syndrome I-Disease 1 0.9998898506164551
( O 0 1.0120537297098053e-08
SJS B-Disease 0 0.001008718740195036
) O 0 8.429788533881322e-10
of O 0 2.1648425274634064e-09
myotonia B-Disease 1 0.6087316274642944
and O 0 3.764574103115592e-06
skeletal B-Disease 1 0.9696614146232605
dysplasia I-Disease 1 0.9997896552085876
, O 0 6.24251015324262e-08
which O 0 2.5555376481634084e-08
we O 0 4.608242232251314e-09
called O 0 2.2782897346473874e-08
SJS B-Disease 0 0.00035693353856913745
type I-Disease 0 1.2802964874936151e-06
2 I-Disease 0 2.1058601973322766e-08
. O 0 2.7491484644315278e-08

This O 0 1.369839878861967e-06
disorder O 0 0.3373646140098572
is O 0 1.153295681177724e-08
reminiscent O 0 9.84237402690269e-08
of O 0 2.731057602289866e-10
another O 0 1.4495700639827191e-08
rare O 0 2.4413483856733365e-07
condition O 0 4.429265118233161e-06
, O 0 2.102434615292026e-10
the O 0 2.5182689267211344e-09
Stuve B-Disease 1 0.7372523546218872
- I-Disease 1 0.9999986886978149
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999971389770508
( O 0 8.385836913760158e-09
SWS B-Disease 0 2.8478967578848824e-05
) O 0 1.3414536148559364e-09
, O 0 3.226361122710131e-10
which O 0 7.468150542422336e-10
comprises O 0 4.013894994159273e-09
campomelia B-Disease 0 3.9463379835069645e-06
at O 0 6.233003659872338e-07
birth O 0 4.1981121512435493e-07
with O 0 5.8687717796601646e-08
skeletal B-Disease 1 0.8351864814758301
dysplasia I-Disease 1 0.9987799525260925
, O 0 5.5298198020636846e-08
contractures B-Disease 0 6.374106305884197e-05
, O 0 1.2628817991355845e-08
and O 0 1.2577111796474583e-08
early B-Disease 0 6.779929861977507e-08
death I-Disease 0 2.2509873076614895e-07
. O 0 4.4944169275140666e-08

To O 0 3.743769028119459e-08
test O 0 2.6916387341202608e-08
for O 0 1.570337887502049e-10
possible O 0 1.2831045559380527e-08
nosologic O 0 1.0918643056356814e-05
identity O 0 6.285401923378231e-07
between O 0 2.793762376995801e-08
these O 0 7.780763411346925e-08
disorders O 0 0.0006223716773092747
, O 0 1.3825847133830393e-09
we O 0 2.1071928646421156e-09
reviewed O 0 3.543736637467987e-09
the O 0 4.9741370744538216e-11
literature O 0 2.114818042908695e-10
and O 0 2.6917490458799875e-10
obtained O 0 3.616303922981956e-10
a O 0 5.742128994512541e-10
follow O 0 2.8341753388616553e-09
- O 0 2.0353429590613814e-06
up O 0 1.8719019578838925e-07
of O 0 1.421235906740037e-10
the O 0 1.9761435543497186e-10
only O 0 7.532482970695753e-10
two O 0 1.7258731943581296e-10
surviving O 0 8.194082568024896e-08
patients O 0 2.2725248349786398e-09
, O 0 4.4336437299286047e-11
one O 0 8.801826628657139e-11
with O 0 4.030286937517502e-10
SJS B-Disease 0 0.00016333274834323674
type I-Disease 0 9.235891411663033e-07
2 I-Disease 0 2.782948982371636e-09
at O 0 1.529758577589746e-07
age O 0 5.620403253914219e-09
10 O 0 4.493563854346405e-10
years O 0 5.069005770685919e-10
and O 0 8.420580344115081e-10
another O 0 1.0151754992193673e-09
with O 0 6.535976759813877e-10
SWS B-Disease 0 1.1793097655754536e-05
at O 0 5.3862070359400605e-08
age O 0 5.141150172249809e-09
7 O 0 2.445729618827386e-09
years O 0 2.2865773718905302e-09
. O 0 1.8501390641745274e-08

Patients O 0 7.058331539155915e-05
reported O 0 1.9670317215059185e-06
as O 0 7.83401166160047e-09
having O 0 2.5237858025661808e-08
either O 0 1.7252585848837043e-07
neonatal O 1 0.9997782111167908
SJS B-Disease 1 0.9999082088470459
or O 0 1.1648681720544118e-05
SWS B-Disease 0 0.004319732077419758
presented O 0 4.804133979519065e-08
a O 0 4.53885817819355e-09
combination O 0 9.185566085534447e-09
of O 0 8.208900920125828e-11
a O 0 1.650687408982776e-08
severe O 0 5.711445965062012e-07
, O 0 1.887222600416294e-09
prenatal O 0 0.0072885118424892426
- O 1 0.9987547397613525
onset O 1 0.9993802309036255
neuromuscular B-Disease 1 0.999996542930603
disorder I-Disease 1 0.9997443556785583
( O 0 1.0634555991373418e-07
with O 0 1.0848584679479245e-05
congenital B-Disease 1 0.9999992847442627
joint I-Disease 0 0.48851969838142395
contractures I-Disease 1 0.999988317489624
, O 0 0.023442814126610756
respiratory O 1 0.9996788501739502
and O 0 2.9881848604418337e-06
feeding O 0 0.0015708355931565166
difficulties O 0 2.88388173430576e-06
, O 0 8.923028982366077e-10
tendency O 0 1.5363841754378882e-08
to O 0 3.5331138015237684e-09
hyperthermia B-Disease 0 0.0003708204021677375
, O 0 1.946655103779449e-08
and O 0 4.2922280840684834e-08
frequent O 0 1.6732433323340956e-06
death O 0 1.0536004992900416e-06
in O 0 4.462050728903932e-09
infancy O 0 2.4792004182927485e-07
) O 0 4.0720821159467846e-10
with O 0 3.3097272145177214e-10
a O 0 5.417092108217503e-09
distinct O 0 4.2234990615952483e-08
campomelic B-Disease 0 0.0004185563884675503
- I-Disease 0 0.009118970483541489
metaphyseal I-Disease 0 0.07203767448663712
skeletal I-Disease 1 0.9546517729759216
dysplasia I-Disease 1 0.9966160655021667
. O 0 1.3001370007259538e-06

The O 0 1.4326575481504733e-08
similarity O 0 1.5813553133625646e-08
of O 0 3.27410737410716e-10
the O 0 1.601897281489073e-09
clinical O 0 3.4300225593142386e-07
and O 0 1.0484985324410445e-08
radiographic O 0 0.00020646204939112067
findings O 0 8.254253316408722e-07
is O 0 6.186751733139317e-08
so O 0 1.8477788188420163e-09
extensive O 0 1.9981053256401538e-08
that O 0 4.2394070476348134e-08
these O 0 3.5862903757788445e-08
disorders O 0 1.203849842568161e-05
appear O 0 9.390580757440148e-09
to O 0 1.4115811852732918e-09
be O 0 1.2421530470874131e-08
a O 0 5.171451267216298e-09
single O 0 2.5295935301983263e-07
entity O 0 6.027054041624069e-06
. O 0 1.2488811762523255e-07

The O 0 8.003652851584775e-09
follow O 0 1.575433472567056e-08
- O 0 2.3421619061991805e-06
up O 0 4.994985047801492e-08
observation O 0 2.22513062908547e-06
of O 0 9.846379267486327e-11
an O 0 4.1712097664792225e-10
identical O 0 6.394186584657291e-07
and O 0 6.864270485351653e-09
unique O 0 5.150739390558101e-09
pattern O 0 4.939560312777758e-06
of O 0 1.1904585095479092e-09
progressive O 0 4.456167152966373e-05
bone B-Disease 1 0.969474196434021
dysplasia I-Disease 1 0.9904138445854187
in O 0 1.714476915992691e-08
the O 0 5.6774642764878536e-09
two O 0 2.3787723790746895e-08
patients O 0 5.783008294457659e-09
( O 0 4.185457189165298e-11
one O 0 3.429344586081129e-10
with O 0 1.7367017823843867e-09
SJS B-Disease 0 0.06210454925894737
type I-Disease 0 3.251959424233064e-05
2 I-Disease 0 3.00715328194201e-08
, O 0 5.4548947581167795e-09
one O 0 6.7515752988356326e-09
with O 0 1.1260640420118762e-08
SWS B-Disease 0 0.0003858903073705733
) O 0 3.4769183088201316e-09
surviving O 0 1.2322495024363889e-07
beyond O 0 6.875909264181246e-08
infancy O 0 4.867313307954646e-08
adds O 0 4.436879752489631e-09
to O 0 3.3259145437725124e-10
the O 0 6.007833813770347e-11
evidence O 0 1.2223092538121705e-09
in O 0 7.304002541674848e-11
favor O 0 3.7096251070956043e-10
of O 0 3.004237691950351e-10
identity O 0 6.927841695869574e-07
. O 0 6.058254342633518e-08

The O 0 1.9418676444615812e-08
hypothesis O 0 1.6624767340545077e-07
that O 0 3.981823315513111e-09
SWS B-Disease 0 1.857352071965579e-05
and O 0 1.572062480192926e-08
SJS B-Disease 0 0.003968583419919014
type I-Disease 0 2.0918680093018338e-05
2 I-Disease 0 9.14598707879577e-09
are O 0 3.106582102674338e-09
the O 0 6.31789620619827e-10
same O 0 3.581943133212917e-07
disorder O 0 3.2521391403861344e-05
should O 0 5.797144098096396e-09
be O 0 4.849646240145944e-10
testable O 0 7.560583270560528e-09
by O 0 4.3620596718030313e-11
molecular O 0 1.3880754323736255e-09
methods O 0 1.8218791808521928e-08
. O 0 3.710271201384785e-09
. O 0 3.1622594320879216e-08

A O 0 7.170503977249609e-07
mouse O 0 2.3208203856484033e-05
model O 0 3.22729283652734e-06
of O 0 7.953816805184033e-08
severe O 1 0.999314546585083
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.2933396100997925
defects O 1 0.9999834299087524
in O 0 2.2354631710186368e-06
hemostasis O 1 0.9886570572853088
and O 0 4.882555003860034e-05
thrombosis B-Disease 0 0.010193724185228348
. O 0 9.046384548128117e-07

von B-Disease 1 0.8875325322151184
Willebrand I-Disease 1 0.8657755851745605
factor I-Disease 0 2.7499685529619455e-05
( I-Disease 0 8.926584200708021e-07
vWf I-Disease 0 0.00407387362793088
) I-Disease 0 0.0005769770359620452
deficiency I-Disease 1 0.999984622001648
causes O 0 0.3617863655090332
severe O 1 0.9997881054878235
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.207862730254419e-06
humans O 0 3.08960625261534e-06
. O 0 4.581440293804917e-07

We O 0 2.844764956932977e-08
generated O 0 9.674432810413691e-09
a O 0 1.8935000234421295e-09
mouse O 0 2.7005198717233725e-06
model O 0 6.920960800016474e-07
for O 0 1.1333334271057538e-09
this O 0 4.4225161310862404e-09
disease O 0 7.46348760571891e-08
by O 0 1.8240669391600406e-11
using O 0 9.780684040450183e-10
gene O 0 5.076044828911108e-08
targeting O 0 1.0148962701350683e-06
. O 0 7.37695700081531e-08

vWf B-Disease 0 0.003542020684108138
- I-Disease 1 0.8320801854133606
deficient I-Disease 0 0.2804695963859558
mice O 0 0.00012115066783735529
appeared O 0 1.1047389989471412e-06
normal O 0 1.1643385278148344e-07
at O 0 1.7157665865852323e-07
birth O 0 2.057509718156325e-08
; O 0 1.1817119505153073e-10
they O 0 6.15630602052164e-10
were O 0 1.6974526673152468e-08
viable O 0 1.3541540511141648e-07
and O 0 1.3419123590097115e-08
fertile O 0 2.0198910988256102e-06
. O 0 5.8881692410750475e-08

Neither O 0 1.338605216005817e-05
vWf O 0 9.092768596019596e-05
nor O 0 7.2158595685323235e-06
vWf O 0 3.731167453224771e-05
propolypeptide O 0 0.0002167369530070573
( O 0 1.9159000430590822e-07
von B-Disease 0 0.1589624583721161
Willebrand I-Disease 0 0.3468962609767914
antigen O 0 0.00017194148676935583
II O 0 0.00038857400068081915
) O 0 4.668204489632899e-09
were O 0 1.2193689613582137e-08
detectable O 0 1.8060751472148695e-07
in O 0 7.00984340018529e-11
plasma O 0 1.2891666756331688e-07
, O 0 4.3098694058052445e-10
platelets O 0 1.7693523091111274e-08
, O 0 2.6740079595022337e-10
or O 0 3.2681568562509256e-09
endothelial O 0 5.185535556506693e-09
cells O 0 7.703466753383736e-10
of O 0 3.499482301161372e-11
the O 0 8.433519438355574e-10
homozygous O 0 5.443412192107644e-07
mutant O 0 1.2606757309185923e-06
mice O 0 2.1350348106352612e-05
. O 0 1.4969235451189888e-07

The O 0 1.115589185474164e-07
mutant O 0 4.260714558768086e-05
mice O 0 0.00907414872199297
exhibited O 0 0.21680884063243866
defects O 1 0.9998520612716675
in O 0 3.552488436753265e-08
hemostasis O 0 0.005506536457687616
with O 0 4.0504740894675706e-08
a O 0 1.2834208007461712e-07
highly O 0 7.065248610160779e-06
prolonged O 0 3.632634980021976e-05
bleeding O 0 0.0003386192547623068
time O 0 2.0985424953323673e-08
and O 0 2.5609246279145736e-08
spontaneous O 0 1.8812977486959426e-07
bleeding O 0 2.883474508053041e-06
events O 0 1.3580353508402254e-09
in O 0 2.0668963762737746e-10
approximately O 0 4.106167406092709e-09
10 O 0 9.144325296972511e-10
% O 0 1.881941269488152e-10
of O 0 8.750909441523902e-10
neonates O 0 2.4607743398519233e-05
. O 0 1.1677591515990571e-07

As O 0 9.267418477065803e-08
in O 0 1.7501560201083066e-09
the O 0 1.8649477517840296e-09
human O 0 1.0278823765474954e-06
disease O 0 2.518674818929867e-06
, O 0 1.3689650801840259e-10
the O 0 2.7055109888540763e-11
factor O 0 6.993700618629362e-10
VIII O 0 8.1573574561844e-07
level O 0 1.782091345603476e-07
in O 0 2.935417187099887e-10
these O 0 6.476769676133642e-10
mice O 0 2.1458474463997845e-07
was O 0 1.48488908280342e-07
reduced O 0 4.27362500943218e-09
strongly O 0 1.440323682544431e-08
as O 0 9.204871864731956e-10
a O 0 8.028969156193e-10
result O 0 8.755133285021088e-10
of O 0 4.2560416996240136e-11
the O 0 5.952107695605946e-10
lack O 0 1.8255167377745352e-09
of O 0 8.038173598956533e-11
protection O 0 5.989796214578291e-09
provided O 0 7.546058222729357e-10
by O 0 1.839616903254182e-09
vWf O 0 1.6665850353092537e-06
. O 0 1.0259525851097351e-07

Defective O 1 0.9934740662574768
thrombosis B-Disease 0 0.005360501352697611
in O 0 3.388767666478998e-08
mutant O 0 1.3337311429495458e-05
mice O 0 0.0003289585292804986
was O 0 7.832758456061129e-06
also O 0 3.873734755188707e-08
evident O 0 1.1904227825709768e-08
in O 0 1.5053706892143026e-10
an O 0 1.2354697820349259e-10
in O 0 1.4134422798850466e-10
vivo O 0 1.6108881482068682e-06
model O 0 1.0423853069596589e-07
of O 0 5.88933435352601e-09
vascular B-Disease 1 0.571447491645813
injury I-Disease 0 8.723006612854078e-05
. O 0 3.255504736898729e-07

In O 0 9.087335328672452e-09
this O 0 3.4689345840277497e-10
model O 0 1.298371046232205e-07
, O 0 5.419673043682849e-10
the O 0 1.3498045736692887e-10
exteriorized O 0 1.3960063824924873e-06
mesentery O 0 3.856848707073368e-06
was O 0 5.501351552084088e-07
superfused O 0 9.705020147521282e-07
with O 0 2.339918037108646e-09
ferric O 0 1.032429054248496e-06
chloride O 0 7.302244142692871e-08
and O 0 6.194589730057487e-09
the O 0 1.3384117425463415e-10
accumulation O 0 2.6666304719924483e-08
of O 0 5.210219478080091e-10
fluorescently O 0 2.8633648980758153e-05
labeled O 0 7.956204171932768e-06
platelets O 0 6.07593108270521e-07
was O 0 6.842965660780465e-08
observed O 0 9.819456359139167e-09
by O 0 3.233482648301589e-10
intravital O 0 2.937902365829359e-07
microscopy O 0 1.3775820661976468e-07
. O 0 8.289470088129747e-08

We O 0 6.335936859613867e-07
conclude O 0 1.2385008574256062e-07
that O 0 4.0541259238580096e-10
these O 0 2.665697107495646e-10
mice O 0 1.441283359326917e-07
very O 0 2.8786644179490395e-09
closely O 0 3.848229823688598e-07
mimic O 0 0.0025172624737024307
severe O 0 0.00011462953261798248
human O 0 0.010870878584682941
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 0.0008522685966454446
will O 0 4.8560928007646e-06
be O 0 3.519032176768633e-08
very O 0 1.1487155671119353e-09
useful O 0 1.2530271265021042e-09
for O 0 5.596126340101648e-11
investigating O 0 2.167846568923437e-09
the O 0 4.489852239997205e-11
role O 0 2.1144268280703926e-10
of O 0 1.3128366449510764e-11
vWf O 0 8.649325700105237e-09
in O 0 6.094710847115437e-10
normal O 0 4.258598096384958e-08
physiology O 0 3.072781495916388e-08
and O 0 7.816369773649967e-09
in O 0 6.73712952092842e-09
disease O 0 7.918598043943348e-07
models O 0 6.624527770782151e-08
. O 0 3.6736047537289096e-09
. O 0 3.4077782373742593e-08

Oral O 0 2.5679795726318844e-05
contraceptives O 0 0.0173545740544796
and O 0 2.006228640993868e-07
the O 0 1.713019059934595e-08
risk O 0 1.2042472917528357e-05
of O 0 3.061875531784608e-06
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 8.414891453867313e-06

Hereditary B-Disease 1 0.9999974966049194
Ovarian I-Disease 1 0.9999947547912598
Cancer I-Disease 0 0.04318588599562645
Clinical O 0 2.381586000410607e-06
Study O 0 3.9019504072257405e-08
Group O 0 6.348208785311726e-07
. O 0 1.2158926665506442e-07

BACKGROUND O 0 0.00041183276334777474
Women O 0 5.531222768695443e-08
with O 0 1.3210619265180412e-09
mutations O 0 2.637800911031718e-08
in O 0 7.408068602998696e-10
either O 0 3.847102547638315e-08
the O 0 5.945768322135336e-09
BRCA1 O 0 1.337482262897538e-05
or O 0 1.9734662259907054e-07
the O 0 3.025181216642636e-09
BRCA2 O 0 2.0232695874256024e-07
gene O 0 1.4482298027473917e-08
have O 0 9.967643599395615e-09
a O 0 1.5590762458828067e-08
high O 0 2.282335799463908e-06
lifetime O 0 5.602851729236136e-07
risk O 0 3.382575232535601e-05
of O 0 1.6908994439290836e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999942779541016
. O 0 9.947133321475121e-07

Oral O 0 0.00011974474909948185
contraceptives O 1 0.9945074915885925
protect O 1 0.8146176338195801
against O 1 0.9551738500595093
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
in O 0 1.83793424923806e-08
general O 0 1.453124554018359e-08
, O 0 2.9947022639476018e-09
but O 0 3.806859716348754e-09
it O 0 5.03567587628595e-09
is O 0 1.7204379032520478e-09
not O 0 1.1233813185240749e-10
known O 0 4.5352038791079963e-10
whether O 0 7.511880562027784e-10
they O 0 4.321173197041617e-09
also O 0 1.663408433216773e-08
protect O 0 1.1800852206533818e-07
against O 0 3.1896032481881775e-08
hereditary B-Disease 0 0.0003969044191762805
forms I-Disease 0 4.1052633605431765e-05
of I-Disease 0 0.00794549286365509
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999814033508301
. O 0 3.491108486741723e-07

METHODS O 0 9.552799156153924e-07
We O 0 4.7650935641740944e-08
enrolled O 0 1.3003755405804895e-08
207 O 0 4.873677426076028e-07
women O 0 3.351732402734342e-07
with O 0 0.00021207737154327333
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 8.739489771869557e-07
161 O 0 3.6082536780668306e-07
of O 0 4.601672376480792e-09
their O 0 7.231307819210997e-08
sisters O 0 3.077145436236606e-07
as O 0 1.4459603514538344e-09
controls O 0 2.7534415494301356e-06
in O 0 6.430339594132306e-10
a O 0 6.323071399805258e-09
case O 0 4.3095038648743866e-08
- O 0 8.092462849162985e-06
control O 0 9.520068147139682e-07
study O 0 1.931333137861202e-08
. O 0 4.9350781239354546e-08

All O 0 1.0773958791787663e-07
the O 0 1.1917927089655223e-08
patients O 0 3.3738114524339835e-08
carried O 0 4.071821990692115e-08
a O 0 1.853974418430937e-09
pathogenic O 0 9.111028020925005e-08
mutation O 0 8.348300717386792e-09
in O 0 3.8903316679217426e-10
either O 0 5.300201610936028e-09
BRCA1 O 0 1.1526429233299496e-07
( O 0 3.2490371504323434e-10
179 O 0 8.99131968878919e-09
women O 0 2.1625357060628403e-09
) O 0 7.667961821056224e-10
or O 0 7.326673312491039e-08
BRCA2 O 0 6.953968068046379e-07
( O 0 6.106218308765676e-10
28 O 0 3.182220353892262e-08
women O 0 3.8588883199963675e-09
) O 0 1.9756998259623515e-09
. O 0 2.393180409399065e-08

The O 0 6.386172657357747e-08
control O 0 9.020677111948316e-07
women O 0 2.2447088632304713e-09
were O 0 2.8227276072101404e-09
enrolled O 0 2.460410764015819e-10
regardless O 0 5.260777924398496e-10
of O 0 1.5491614935303488e-11
whether O 0 4.5849040120060636e-09
or O 0 1.6374324118828554e-08
not O 0 5.406429082199793e-09
they O 0 1.4922526547778148e-09
had O 0 8.184612987349738e-09
either O 0 2.358162554116916e-09
mutation O 0 2.0776690590196267e-08
. O 0 1.0726630250701419e-08

Lifetime O 0 7.817840923962649e-06
histories O 0 3.2695854770281585e-06
of O 0 3.067082365859619e-09
oral O 0 6.55013536743354e-08
- O 0 3.895856025337707e-06
contraceptive O 0 1.8350011714574066e-06
use O 0 6.320068912657462e-09
were O 0 4.862819480422331e-09
obtained O 0 7.278348479466956e-10
by O 0 9.01843599798724e-10
interview O 0 6.698105607938487e-06
or O 0 3.63244225809467e-08
by O 0 3.693358952006065e-10
written O 0 5.833758809359324e-09
questionnaire O 0 6.114822870273429e-09
and O 0 2.9943083568184647e-09
were O 0 1.1786922549106293e-08
compared O 0 2.9323089734134555e-08
between O 0 9.940626988225176e-09
patients O 0 1.232808699569432e-08
and O 0 1.3886031879906113e-08
control O 0 2.5217817892553285e-05
women O 0 3.3319929038100327e-09
, O 0 1.641160957133181e-10
after O 0 7.395303119883678e-11
adjustment O 0 7.93376830898751e-09
for O 0 1.0519609489056947e-10
year O 0 3.0880895063312153e-10
of O 0 9.606059697686575e-11
birth O 0 3.852550989336123e-08
and O 0 6.579319311583731e-09
parity O 0 3.834451831608021e-07
. O 0 2.2486050355041698e-08

RESULTS O 0 4.7197130470522097e-07
The O 0 2.468496740348769e-09
adjusted O 0 2.122978366969619e-05
odds O 0 0.00010158187797060236
ratio O 0 0.006494617089629173
for O 0 0.3096023499965668
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
associated O 0 2.81806524071726e-06
with O 0 3.215807842238405e-09
any O 0 3.6681784276737517e-09
past O 0 8.597301537349722e-09
use O 0 1.5779738626875428e-09
of O 0 1.0647083908965627e-10
oral O 0 1.1132677002478886e-08
contraceptives O 0 8.413775503868237e-06
was O 0 4.822284154215595e-07
0 O 0 5.604370301171002e-08
. O 0 3.777877566335519e-08

5 O 0 8.596469314170463e-08
( O 0 1.3526195719038014e-09
95 O 0 1.7131922547264367e-08
percent O 0 3.427766159802559e-07
confidence O 0 3.441430607153961e-08
interval O 0 4.1302423703371005e-09
, O 0 1.64836616578512e-11
0 O 0 1.0478392459267738e-11
. O 0 3.648154695001793e-12
3 O 0 9.31102157181174e-12
to O 0 1.9636946582690662e-11
0 O 0 7.940526708383189e-11
. O 0 4.055817487413904e-11
8 O 0 6.401080776541335e-10
) O 0 3.7802092012206856e-10
. O 0 3.602605769259526e-09

The O 0 4.7074770748167793e-08
risk O 0 8.438562417723006e-07
decreased O 0 5.16799332217488e-07
with O 0 2.3718471631184457e-10
increasing O 0 4.156667787746926e-10
duration O 0 2.9896687347985562e-09
of O 0 1.4271297685275464e-11
use O 0 6.43809616729385e-10
( O 0 1.9838439224706406e-10
P O 0 4.825950554732117e-07
for O 0 3.9699583898045177e-11
trend O 0 2.4894916350604035e-08
, O 0 4.008443577063758e-11
< O 0 1.246063030535538e-09
0 O 0 4.572445894135413e-11
. O 0 7.834477858126299e-12
001 O 0 4.916967943913164e-10
) O 0 4.996547012942054e-12
; O 0 2.094351601866773e-12
use O 0 2.1069186673106088e-10
for O 0 5.15592679661836e-10
six O 0 8.300410914152678e-10
or O 0 3.032020634563537e-09
more O 0 8.085949965153105e-11
years O 0 4.777082618367956e-10
was O 0 4.9388635403602166e-08
associated O 0 9.012829926824395e-10
with O 0 1.1451535553153036e-10
a O 0 2.5652351354210623e-09
60 O 0 6.7695506977827336e-09
percent O 0 5.75148497716782e-08
reduction O 0 1.4993517538641754e-08
in O 0 6.041036115789211e-09
risk O 0 3.1808008316147607e-07
. O 0 1.3290971878632263e-08

Oral O 0 1.189389149658382e-05
- O 0 0.0005012122564949095
contraceptive O 0 0.0006929304799996316
use O 0 2.9306484066182747e-06
protected O 1 0.9483813047409058
against O 1 0.7651733160018921
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999955892562866
both O 0 3.6422365123911504e-09
for O 0 9.730741767910445e-10
carriers O 0 1.992065179479141e-09
of O 0 8.481829821826992e-11
the O 0 1.8478246710529334e-09
BRCA1 O 0 3.9079358771232364e-07
mutation O 0 3.729783148997967e-09
( O 0 8.143651031300436e-11
odds O 0 2.9122489308974764e-08
ratio O 0 2.1847668563168554e-08
, O 0 1.2863647647076704e-10
0 O 0 7.803253876392802e-11
. O 0 6.033749021250312e-12
5 O 0 1.3071623644611563e-11
; O 0 4.227802569839456e-12
95 O 0 2.084344252750725e-09
percent O 0 2.801791652018437e-07
confidence O 0 3.8327325313503025e-08
interval O 0 1.7561113674346984e-09
, O 0 7.585373301699505e-12
0 O 0 1.337311077848069e-11
. O 0 3.778575976415288e-12
3 O 0 1.5104490574957552e-11
to O 0 1.3481211806609661e-11
0 O 0 1.2914315450363034e-10
. O 0 2.7892750609215256e-11
9 O 0 3.3689984135776285e-10
) O 0 1.4478850410282185e-11
and O 0 1.1145816908308959e-10
for O 0 6.246658051933807e-11
carriers O 0 4.380613372045872e-10
of O 0 3.441852011731861e-11
the O 0 1.4675911597095137e-09
BRCA2 O 0 3.4427179684826115e-07
mutation O 0 2.433408363700096e-09
( O 0 7.65293800553124e-11
odds O 0 4.717184154401366e-08
ratio O 0 1.2008995575740755e-08
, O 0 8.414138136236815e-11
0 O 0 2.968726306451508e-11
. O 0 6.286684280792931e-12
4 O 0 1.4111599042077039e-11
; O 0 7.764899834228345e-12
95 O 0 9.835759984255787e-10
percent O 0 1.431442626653734e-07
confidence O 0 2.8664315365745097e-08
interval O 0 1.5384093998704884e-09
, O 0 1.8127048473370877e-11
0 O 0 1.1710579554680134e-11
. O 0 1.8723867942216366e-12
2 O 0 6.1857723804292775e-12
to O 0 2.496658782491501e-11
1 O 0 1.0206831907444425e-10
. O 0 3.502928155874052e-11
1 O 0 5.062126828825342e-10
) O 0 4.5422937633432525e-10
. O 0 4.927541485955089e-09

CONCLUSIONS O 0 4.942411578667816e-06
Oral O 0 3.8752617115278554e-07
- O 0 1.9810982848866843e-05
contraceptive O 0 6.712954473186983e-06
use O 0 2.0303453140968486e-08
may O 0 7.21345161380782e-09
reduce O 0 9.085705521272303e-09
the O 0 9.860672278705351e-09
risk O 0 0.00018344001728110015
of O 0 0.0005253104027360678
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
in O 0 8.835075959723326e-08
women O 0 2.1911257253037775e-09
with O 0 2.2436505431322473e-10
pathogenic O 0 4.81573003696667e-08
mutations O 0 1.1378826769714578e-08
in O 0 3.2437613706193247e-10
the O 0 4.991001389953453e-09
BRCA1 O 0 1.8598408132675104e-05
or O 0 3.578921905500465e-06
BRCA2 O 0 0.0001934603787958622
gene O 0 6.706779822707176e-05

A O 0 2.339300181120052e-06
Japanese O 0 5.4423608162323944e-06
family O 0 1.3830227771904902e-06
with O 0 2.63936698274847e-07
adrenoleukodystrophy B-Disease 1 0.9999998807907104
with O 0 3.1001260225593796e-08
a O 0 1.841506502842094e-08
codon O 0 1.7956399744889495e-07
291 O 0 4.5890356403788246e-08
deletion O 0 1.1174206804298592e-07
: O 0 2.8150497488610426e-09
a O 0 3.875979981415867e-09
clinical O 0 5.2931021343738394e-08
, O 0 1.8179211469515622e-09
biochemical O 0 1.028872418373794e-07
, O 0 1.9335140155618546e-09
pathological O 0 7.942338129396376e-07
, O 0 5.604827268967938e-09
and O 0 7.941489243989963e-09
genetic O 0 3.2850141451490344e-07
report O 0 2.685183631001564e-07
. O 0 9.844890058730016e-08

We O 0 5.7993918289867e-07
report O 0 1.481572908801354e-08
a O 0 1.5747356751916186e-09
Japanese O 0 2.5297188699369144e-07
family O 0 4.408294671520707e-07
with O 0 1.4099264262767974e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 6.085968379920814e-06
ALD B-Disease 1 0.9999998807907104
) O 0 9.683385648884268e-09
with O 0 1.2496855772425874e-09
a O 0 5.777451406174805e-09
three O 0 2.047572555952115e-09
base O 0 7.998453099844482e-08
pair O 0 2.364018136802315e-08
deletion O 0 1.5547731990750435e-08
( O 0 2.3287724526532827e-10
delGAG O 0 1.5293728949927754e-08
291 O 0 4.069164560860372e-09
) O 0 1.6717753570372196e-10
in O 0 1.8890440600660696e-10
the O 0 1.865610421702968e-08
ALD B-Disease 1 0.9999964237213135
gene O 0 2.424945932943956e-06
. O 0 3.394833356651361e-07

A O 0 3.8001186908331874e-07
variety O 0 5.989740969880586e-08
of O 0 6.185141288028717e-10
phenotypes O 0 1.7119697304224246e-07
were O 0 9.007712797881595e-09
observed O 0 1.63641775685619e-08
within O 0 3.284553184990102e-10
this O 0 5.80390069337966e-10
family O 0 1.6693162763203873e-07
. O 0 4.506236450652068e-08

While O 0 9.666744205105715e-08
the O 0 1.580847674986785e-09
proband O 0 2.3003285605227575e-06
( O 0 2.2683590561456413e-09
patient O 0 2.017987554836509e-07
1 O 0 5.146827963820044e-10
) O 0 6.44748421319008e-10
was O 0 1.2658535979426233e-06
classified O 0 7.732924132142216e-06
as O 0 9.48280742818497e-09
having O 0 5.216586274059409e-09
a O 0 7.990714201433491e-10
rare O 0 3.83243081714113e-09
intermediate O 0 5.139659808861552e-09
type O 0 4.6355376071005594e-07
of O 0 3.761738420759997e-10
adult O 0 1.112387781176949e-05
cerebral O 0 0.000272390287136659
and O 0 1.4113578572505503e-06
cerebello O 0 0.2989332675933838
- O 1 0.9809625148773193
brain O 0 0.007434485480189323
stem O 0 5.946383225818863e-07
forms O 0 1.7458300760608836e-07
, O 0 3.8996962103965416e-08
his O 0 3.4035689822076165e-08
younger O 0 7.613435570874572e-08
brother O 0 4.1182960330843343e-07
( O 0 7.34657834566832e-10
patient O 0 2.805901715419168e-07
2 O 0 6.483422687608709e-09
) O 0 4.348822191246882e-09
and O 0 1.9618674684807047e-07
nephew O 0 5.914302892051637e-05
( O 0 9.75144498482905e-09
patient O 0 8.566554470235133e-07
3 O 0 5.44263123458677e-09
) O 0 4.9869668394819655e-09
had O 0 6.65363984353462e-07
a O 0 2.3446018815320713e-07
childhood O 0 0.0006456722621805966
ALD B-Disease 1 0.9999986886978149
type O 0 0.003214495722204447
. O 0 4.624785390205943e-07

Another O 0 9.70564997260226e-07
nephew O 0 5.712763231713325e-05
( O 0 1.330949039868301e-08
patient O 0 1.0312236327081337e-06
4 O 0 2.1549964035472158e-09
) O 0 1.1175022712750504e-10
of O 0 1.786236991652146e-10
patient O 0 1.0086006341225584e-06
1 O 0 2.0534205447120257e-08
was O 0 7.483865920221433e-05
classified O 0 8.474660717183724e-05
as O 0 1.1421960977031631e-07
having O 0 4.487632665473029e-08
an O 0 1.7774355320909763e-09
adolescent O 0 7.87316878358979e-07
form O 0 1.716040642918415e-08
. O 0 5.325273733092217e-08

The O 0 1.9289180031023534e-08
tau O 0 4.773726303142212e-08
level O 0 4.7969827221550077e-08
in O 0 8.826039343823311e-10
the O 0 4.837176881267169e-09
cerebrospinal O 0 5.675519059877843e-05
fluid O 0 1.1082476021329057e-06
( O 0 1.9319335464729193e-08
CSF O 0 0.002006221329793334
) O 0 6.086312009934147e-10
in O 0 5.446969542077795e-10
patient O 0 2.4350421767849184e-07
1 O 0 4.156883726125216e-09
was O 0 6.802312782383524e-06
as O 0 1.2970265750311682e-08
high O 0 8.719445077076671e-08
as O 0 9.885218338334667e-11
that O 0 7.062976592475678e-11
of O 0 8.760992625811426e-11
patients O 0 9.138052980972589e-09
with O 0 1.79939078748248e-07
Alzheimers B-Disease 1 0.9999887943267822
disease I-Disease 0 0.007762474939227104
( O 0 3.172915485905037e-09
AD B-Disease 0 1.8284328007212025e-06
) O 0 1.772605173755437e-08
. O 0 3.16146362422387e-08

His O 0 3.50311808006154e-07
brain O 0 1.5284040273400024e-06
magnetic O 0 3.4941328408422123e-07
resonance O 0 9.755640348885208e-07
image O 0 2.1862108496861765e-06
( O 0 7.347237263033435e-10
MRI O 0 7.188305630734249e-07
) O 0 2.6157300769824587e-09
showed O 0 1.596438050910365e-05
abnormalities B-Disease 0 0.007454166654497385
in I-Disease 0 1.7267367535822586e-09
the I-Disease 0 1.8714265692665322e-08
bilateral I-Disease 0 0.00061013363301754
cerebellar I-Disease 0 0.057129520922899246
hemispheres I-Disease 0 0.0003768829919863492
and O 0 6.159851182019338e-06
brain O 0 8.108477231871802e-06
stem O 0 9.216579854864904e-08
, O 0 8.156651465363041e-10
but O 0 7.840136317938118e-10
not O 0 1.243852243426602e-09
in O 0 3.1673630385142815e-10
the O 0 3.0291937846982364e-09
cerebral O 0 7.231838026200421e-07
white O 0 3.740635534654757e-08
matter O 0 7.354485909161212e-10
, O 0 5.7836971323332875e-11
where O 0 8.392436745552345e-11
marked O 0 2.222389827721827e-09
reductions O 0 6.164016852494569e-09
of O 0 7.879905755681094e-11
the O 0 3.318761931936365e-09
cerebral O 0 3.5788195873465156e-06
blood O 0 9.399669664844623e-08
flow O 0 5.455054008507432e-08
and O 0 2.6842251088510238e-08
oxygen O 0 9.261367228674544e-10
metabolism O 0 3.667709691512755e-09
were O 0 2.4381097141201735e-09
clearly O 0 7.2663119965454825e-09
demonstrated O 0 8.765476677830009e-10
by O 0 1.4421027740019188e-11
positron O 0 2.020413347736394e-08
emission O 0 3.7820733211901825e-08
tomography O 0 3.624587634476484e-07
( O 0 2.990404368574673e-09
PET O 0 1.2106620488339104e-06
) O 0 2.5306339246355947e-09
. O 0 2.1676118677760314e-08

In O 0 8.349435631771485e-08
patients O 0 9.012115498308049e-08
2 O 0 5.1738289208458355e-09
and O 0 1.116793768574098e-08
3 O 0 2.536790777440956e-09
, O 0 2.8211813440925937e-10
the O 0 1.051128559192982e-10
autopsy O 0 4.0551472920924425e-05
findings O 0 2.5912008538853115e-08
showed O 0 7.903365712991217e-07
massive O 0 3.942523562727729e-06
demyelination B-Disease 1 0.999997615814209
of I-Disease 0 8.620207658793788e-09
the I-Disease 0 4.196871117301271e-08
cerebral I-Disease 0 2.029221286647953e-05
white I-Disease 0 2.0423183855200477e-07
matter I-Disease 0 1.547494354880996e-09
with O 0 9.708268217112348e-11
sparing O 0 1.9183137300871067e-09
of O 0 1.468382776481647e-10
the O 0 2.359089146253268e-09
U O 0 0.05494289845228195
- O 0 0.00015746569260954857
fibers O 0 1.462251702832873e-06
, O 0 1.1279550626852597e-09
compatible O 0 3.878244569932576e-08
with O 0 8.48366266126277e-10
the O 0 1.5971127198532997e-10
findings O 0 4.0700962600226376e-09
of O 0 7.315080097214377e-09
childhood O 0 0.0014914809726178646
ALD B-Disease 1 0.9999961853027344
. O 0 1.1240307458137977e-06

Oleic O 0 0.0020211960654705763
and O 0 2.533011809191521e-07
erucic O 0 0.00016737752594053745
acids O 0 6.939199437283605e-09
( O 0 2.1500440317012703e-10
Lorenzos O 0 2.762784134802132e-08
Oil O 0 1.3779047236539554e-08
) O 0 3.204795109845726e-11
were O 0 1.5184743740181972e-10
administered O 0 4.8529839868916014e-11
to O 0 1.7426660808839145e-11
patients O 0 1.1893096230064515e-10
1 O 0 4.8351059267481844e-11
and O 0 1.845429475899607e-09
4 O 0 2.6613549142240345e-09
, O 0 6.776252337026278e-10
but O 0 4.4764378315242936e-10
sufficient O 0 5.864692620427547e-10
effectiveness O 0 3.3597657989048457e-09
was O 0 2.6068162739534273e-08
not O 0 3.665917291950649e-10
obtained O 0 2.34205255189579e-09
. O 0 1.1921177822671325e-08

The O 0 2.1308052211566064e-08
findings O 0 1.6402863067810358e-08
in O 0 2.733585025005425e-10
this O 0 1.245131081573092e-10
family O 0 7.509348698420126e-09
suggest O 0 5.010832193619308e-09
that O 0 2.9772675991246444e-10
delGAG291 O 0 1.1355479756502973e-07
is O 0 4.157748367816794e-09
part O 0 1.32111732664697e-09
of O 0 6.675558716917607e-11
the O 0 1.1740336480769997e-09
cause O 0 9.842840320573032e-09
of O 0 8.734267753496283e-10
Japanese O 0 2.9962469852762297e-05
ALD B-Disease 1 0.9999958276748657
with O 0 8.033231857496048e-09
phenotypic O 0 7.499131697841221e-07
variations O 0 2.54240217145707e-06
. O 0 2.87342260207879e-07

Moreover O 0 3.6533681395667372e-06
, O 0 2.2553830802962693e-08
although O 0 2.3032105112008594e-09
the O 0 6.256233031631808e-11
scale O 0 1.0133594514627475e-05
of O 0 4.6274737514062636e-11
the O 0 7.30237259549682e-11
study O 0 2.3797866455232963e-10
is O 0 1.0924989801708307e-09
limited O 0 4.984693990905953e-09
, O 0 6.891356929550341e-10
there O 0 4.193708047495193e-09
is O 0 1.2243112079701746e-09
a O 0 1.4836526451844634e-10
possibility O 0 6.145476905139446e-10
that O 0 2.552028033342424e-10
PET O 0 1.8083154600390117e-06
can O 0 2.6434709976541626e-09
detect O 0 6.156597464723745e-06
an O 0 1.3305498924864878e-09
insidious B-Disease 0 5.908473758609034e-05
lesion I-Disease 1 0.5858546495437622
which O 0 2.441741742131853e-07
is O 0 2.49909231087031e-08
undetectable O 0 3.029929374065432e-08
by O 0 3.052209873732892e-11
computed O 0 8.524005501442389e-09
tomogram O 0 1.960440414450204e-07
( O 0 1.7852969103060445e-10
CT O 0 1.0300952908437466e-06
) O 0 5.69114422255268e-10
or O 0 9.022461666674531e-10
MRI O 0 3.132962334007061e-08
analysis O 0 2.874231519456316e-09
, O 0 1.4149884597358664e-09
and O 0 5.942318304086314e-10
that O 0 1.6987108941712847e-10
the O 0 3.2781673209303364e-11
higher O 0 1.0826705088007316e-09
level O 0 9.369804931935732e-10
of O 0 8.673150739268998e-12
tau O 0 9.0363903859636e-11
reflects O 0 5.849653400558097e-11
the O 0 4.981797092906692e-12
process O 0 9.479216717123151e-11
of O 0 5.104961592339308e-11
neuronal B-Disease 0 4.3824357476296427e-07
degeneration I-Disease 0 0.00013791793026030064
in O 0 4.7020077431625396e-07
ALD B-Disease 1 0.9999980926513672
. O 0 2.69883094006218e-06

Lorenzos O 0 0.00013579010555986315
Oil O 0 5.355032953957561e-06
should O 0 3.6637541001027785e-08
be O 0 4.998487179719291e-10
given O 0 3.552612024004809e-11
in O 0 2.6557436805241252e-11
the O 0 2.255345389612362e-11
early O 0 1.4894716571234312e-09
stage O 0 8.723204558691577e-08
. O 0 6.427286480814587e-10
. O 0 7.095077858565446e-09

Nonsense O 0 0.00015080477169249207
mutation O 0 5.012029760109726e-07
in O 0 1.2065100030156373e-09
exon O 0 2.90098913779957e-08
4 O 0 2.439032087409032e-08
of O 0 1.1907401731292566e-09
human O 0 3.6025181060495015e-08
complement O 0 3.978849250074745e-08
C9 O 0 2.647827841428807e-07
gene O 0 2.6448994105976453e-08
is O 0 5.455467189108276e-09
the O 0 1.7930434914603666e-10
major O 0 4.202756365145888e-09
cause O 0 3.704175854934988e-09
of O 0 1.074230815412136e-09
Japanese O 0 6.140565801615594e-06
complement B-Disease 0 2.6488041839911602e-05
C9 I-Disease 0 0.1437303125858307
deficiency I-Disease 0 0.19781087338924408
. O 0 1.7800530827116745e-07

Deficiency B-Disease 1 0.9995604157447815
of I-Disease 0 8.8785041540973e-09
the I-Disease 0 1.4636075684748562e-09
ninth I-Disease 0 1.4849479867962145e-08
component I-Disease 0 1.7813555075463228e-07
of I-Disease 0 2.554199907134347e-10
human I-Disease 0 6.39251940270924e-09
complement I-Disease 0 6.9069798769305635e-09
( O 0 2.4151058930499403e-10
C9 O 0 1.91751361455772e-08
) O 0 9.765618175228141e-11
is O 0 3.82633036366542e-10
the O 0 5.38114657000488e-11
most O 0 2.6295914334895087e-09
common O 0 3.0842309115541866e-06
complement B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999997615814209
in O 0 2.7141970893040934e-09
Japan O 0 8.284048647055897e-08
but O 0 1.0928887794747766e-09
is O 0 1.7027755594423155e-10
rare O 0 1.304398394852413e-10
in O 0 1.5689298818455377e-11
other O 0 4.3820818501627556e-11
countries O 0 3.9463457501831556e-10
. O 0 9.380109133871883e-09

We O 0 1.7359202786337846e-07
studied O 0 5.6549307458908515e-09
the O 0 3.82929243869512e-11
molecular O 0 2.9909006382666803e-09
basis O 0 3.208334931059653e-08
of O 0 1.9055367062037476e-08
C9 B-Disease 1 0.729960560798645
deficiency I-Disease 0 0.024572081863880157
in O 0 1.5303585065851166e-09
four O 0 3.954907512593309e-09
Japanese O 0 9.413194561602722e-07
C9 B-Disease 0 4.4623291614698246e-05
- I-Disease 0 0.12578193843364716
deficient I-Disease 0 0.04672276973724365
patients O 0 5.418902446763241e-07
who O 0 4.933929744765919e-07
had O 0 7.826753426343203e-05
suffered O 0 0.010073659010231495
from O 0 1.8746260366242495e-06
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999985694885254
. O 0 8.116098229038471e-07

Direct O 0 1.0258918337058276e-07
sequencing O 0 5.9380194983305046e-08
of O 0 2.3879356270128937e-09
amplified O 0 3.1004930178823997e-07
C9 O 0 7.740190426375193e-07
cDNA O 0 9.571323289492284e-08
and O 0 7.51629869455428e-09
DNA O 0 3.9738662138688596e-08
revealed O 0 2.0458479355056625e-08
a O 0 1.0708268716186353e-09
nonsense O 0 2.60291610487684e-08
substitution O 0 6.933996155034094e-10
( O 0 1.5697299016181887e-10
CGA O 0 2.8967647835997923e-08
- O 0 2.5940894943232706e-07
- O 0 1.7476325808729598e-07
> O 0 3.5872740333786624e-09
TGA O 0 3.541873283552377e-08
) O 0 4.522909130555419e-11
at O 0 1.0200992828224287e-10
codon O 0 6.578387834466071e-10
95 O 0 1.80994191856243e-10
in O 0 5.7581686814522914e-12
exon O 0 9.147360091610324e-10
4 O 0 2.0157702174117276e-09
in O 0 3.1318359017262765e-10
the O 0 2.475379623501084e-10
four O 0 3.0735591849406774e-09
C9 B-Disease 0 3.349816324771382e-06
- I-Disease 0 0.00018643771181814373
deficient I-Disease 0 4.065865869051777e-05
individuals O 0 7.773521382148374e-09
. O 0 2.0575409820366986e-08

An O 0 3.2880162592618944e-08
allele O 0 1.2646736422539107e-06
- O 0 2.2852261736261426e-06
specific O 0 1.6183188122909087e-08
polymerase O 0 5.984733775221684e-07
chain O 0 9.862508704827633e-06
reaction O 0 4.534687292334638e-09
system O 0 2.4566091383348976e-09
designed O 0 6.799977825266978e-08
to O 0 4.448842405579967e-10
detect O 0 5.615733584818372e-07
exclusively O 0 7.63799867797843e-09
only O 0 3.0233353598418944e-09
one O 0 9.948606383147762e-10
of O 0 5.550226250816692e-11
the O 0 3.1523439414371524e-10
normal O 0 8.950340912861066e-09
and O 0 3.0677127504930013e-10
mutant O 0 7.848189653714144e-09
alleles O 0 2.350017513919056e-09
indicated O 0 1.2250293934812362e-07
that O 0 8.107528537415476e-10
all O 0 1.660642734435669e-10
the O 0 5.800954508417e-11
four O 0 2.0488293006604152e-10
patients O 0 3.1751962170645243e-10
were O 0 1.182437897595534e-10
homozygous O 0 2.797408082955144e-09
for O 0 2.7194138607633533e-10
the O 0 1.557760725967583e-10
mutation O 0 6.49471920688427e-10
in O 0 6.37426222915849e-11
exon O 0 2.1490529356071875e-09
4 O 0 6.449529799112952e-09
and O 0 5.515315137927246e-08
that O 0 2.1713142395185514e-09
the O 0 1.010806507939499e-10
parents O 0 5.903333377688114e-10
of O 0 2.251026275101875e-11
patient O 0 1.7047986133889026e-08
2 O 0 1.6654713164143686e-09
were O 0 1.1719316006519875e-07
heterozygous O 0 6.066482001187978e-07
. O 0 7.816014857553455e-08

The O 0 1.3206871152249278e-08
common O 0 3.774115686638879e-09
mutation O 0 3.666513537226024e-09
at O 0 6.413007902494883e-10
codon O 0 2.694143796944104e-09
95 O 0 1.4036878326351143e-09
in O 0 1.9587567678946982e-11
exon O 0 2.2998039028720996e-09
4 O 0 2.501494567042073e-09
might O 0 8.432011533443529e-09
be O 0 1.1859597748298256e-09
responsible O 0 1.8586666428177523e-08
for O 0 2.903532414499921e-10
most O 0 4.672578324260712e-09
Japanese O 0 5.923894150328124e-06
C9 B-Disease 0 0.0012320317327976227
deficiency I-Disease 0 7.218780228868127e-05
. O 0 1.48326295690282e-09
. O 0 1.6925257639854863e-08

BRCA1 O 0 3.0940889701014385e-05
required O 0 4.1420303631412025e-08
for O 0 1.159090490254755e-09
transcription O 0 9.080379754777823e-07
- O 0 0.00012056798004778102
coupled O 0 4.604910827765707e-06
repair O 0 0.00012490824155975133
of O 0 1.400184856947817e-09
oxidative O 0 7.697421438024321e-07
DNA O 0 2.2517919205711223e-05
damage O 0 0.00015004056331235915
. O 0 3.5383763474783336e-07

The O 0 3.502517529341276e-06
breast B-Disease 1 0.9999926090240479
and I-Disease 1 0.9999827146530151
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
susceptibility O 0 0.0003938563459087163
gene O 0 1.4287260455603246e-05
BRCA1 O 0 4.17557566834148e-05
encodes O 0 5.177622597329901e-07
a O 0 1.71866827258782e-06
zinc O 0 0.08939461410045624
finger O 0 0.0030754313338547945
protein O 0 6.58282459653492e-08
of O 0 1.3846748192491987e-09
unknown O 0 2.3104546187369124e-07
function O 0 8.797123030035436e-08
. O 0 5.677976133711127e-08

Association O 0 4.1539624362485483e-07
of O 0 1.7745291902571125e-09
the O 0 1.7096006832417743e-09
BRCA1 O 0 9.358896591038501e-07
protein O 0 1.1064638982816177e-08
with O 0 7.283666447754911e-10
the O 0 7.301345639199042e-10
DNA O 0 1.1304549616397708e-06
repair O 0 3.640472641563974e-05
protein O 0 2.416804179006249e-08
Rad51 O 0 6.480055958490993e-07
and O 0 7.570623572483726e-10
changes O 0 1.0113657827881539e-10
in O 0 1.1162853627566527e-11
the O 0 3.0502351946321005e-12
phosphorylation O 0 9.587370480845792e-11
and O 0 5.118262480507951e-10
cellular O 0 2.923596831294617e-08
localization O 0 1.3886269023544173e-08
of O 0 4.8858157103426336e-11
the O 0 1.1995499038519597e-10
protein O 0 1.104342395308322e-09
after O 0 6.390979412351783e-10
exposure O 0 2.1230325941701267e-08
to O 0 1.6046464157426499e-09
DNA O 0 1.5985733625711873e-06
- O 0 1.1412740605010185e-05
damaging O 0 2.6641653221304296e-06
agents O 0 2.9486857400229383e-08
are O 0 8.942793727761966e-10
consistent O 0 5.610991138382815e-08
with O 0 1.4083050003943498e-10
a O 0 9.509101284166377e-10
role O 0 1.6005869962754105e-09
for O 0 6.554228826338715e-10
BRCA1 O 0 6.59439791661498e-08
in O 0 6.764965254646427e-10
DNA O 0 4.5888694444329303e-07
repair O 0 0.00022670591715723276
. O 0 1.357112040523134e-07

Here O 0 3.4776169854922045e-07
, O 0 1.2760845713444269e-09
it O 0 1.7252971273862272e-10
is O 0 1.642786323641232e-10
shown O 0 5.089932919588591e-10
that O 0 2.046587482817941e-10
mouse O 0 1.3458362673191004e-06
embryonic O 0 4.951417622578447e-07
stem O 0 5.214370730755036e-07
cells O 0 1.372792439724435e-07
deficient B-Disease 0 1.7046316997948452e-06
in I-Disease 0 4.879504023058701e-10
BRCA1 I-Disease 0 5.088472221359552e-07
are O 0 3.962790984246567e-09
defective O 0 2.8915872007928556e-06
in O 0 2.8801694362812214e-09
the O 0 1.9565520315012463e-09
ability O 0 1.6387946999429914e-08
to O 0 3.646300761328547e-10
carry O 0 5.4371946944797855e-09
out O 0 3.6885736687253257e-09
transcription O 0 6.520331652382083e-08
- O 0 3.92195852327859e-06
coupled O 0 3.371065702140186e-07
repair O 0 1.809620334825013e-05
of O 0 9.265885281273256e-11
oxidative O 0 1.6101688871117403e-08
DNA O 0 6.485020662694296e-07
damage O 0 3.643247328000143e-05
, O 0 3.573615625640514e-09
and O 0 6.392922191622574e-09
are O 0 8.947984575513601e-09
hypersensitive O 0 0.00012168277316959575
to O 0 1.6969639915487278e-08
ionizing O 0 1.1271382618360803e-06
radiation O 0 4.448346828667127e-07
and O 0 2.1350841095113537e-09
hydrogen O 0 2.2545657785144613e-08
peroxide O 0 2.2077661014918704e-06
. O 0 7.477180474779743e-08

These O 0 4.025504907190225e-08
results O 0 1.8083357034015535e-08
suggest O 0 1.4190649544332246e-08
that O 0 9.290276326012759e-10
BRCA1 O 0 1.2259866366548522e-07
participates O 0 7.329282958323802e-09
, O 0 2.9002947266043577e-10
directly O 0 1.4159307060168658e-09
or O 0 1.2128209547768165e-08
indirectly O 0 7.118897116242806e-08
, O 0 6.514221939646347e-10
in O 0 3.299522322031123e-10
transcription O 0 5.281001449475298e-07
- O 0 0.0001030419662129134
coupled O 0 1.0243828910461161e-05
repair O 0 0.00014473039482254535
of O 0 4.723544333451457e-10
oxidative O 0 2.633172186961019e-07
DNA O 0 4.901508418697631e-06
damage O 0 9.034563845489174e-06
. O 0 7.052886719094431e-09
. O 0 1.0007556738855783e-07

Truncation O 0 2.2922149582882412e-05
mutations O 0 1.0698947335185949e-05
in O 0 1.6723925355677238e-08
the O 0 4.648629925441128e-09
transactivation O 0 3.5170858609490097e-05
region O 0 6.296896515323169e-08
of O 0 5.947523584737269e-10
PAX6 O 0 1.2993887139600702e-05
result O 0 5.5540656518360265e-09
in O 0 4.812511500418282e-10
dominant O 0 1.1382470574972103e-06
- O 0 5.41433882972342e-06
negative O 0 9.757287671163795e-07
mutants O 0 9.828648899201653e-07
. O 0 8.222937708524114e-08

PAX6 O 0 0.0008728892426006496
is O 0 8.263045003786829e-08
a O 0 2.2238146879516307e-09
transcription O 0 5.7320566071439316e-08
factor O 0 1.1900050722601918e-08
with O 0 1.0307277253929215e-09
two O 0 5.684623882729056e-10
DNA O 0 1.1935532029383467e-06
- O 0 6.764997579011833e-06
binding O 0 1.5964481292485289e-07
domains O 0 5.868290742228055e-08
( O 0 5.34259414486371e-10
paired O 0 1.0596163058096408e-08
box O 0 1.9964476450695656e-05
and O 0 2.2468045202117537e-08
homeobox O 0 2.6210702941398267e-08
) O 0 2.6857641111099895e-10
and O 0 3.734572096014688e-10
a O 0 1.2620118283734882e-09
proline O 0 2.728941694840614e-07
- O 0 1.7475892377660784e-07
serine O 0 2.8742968538608693e-07
- O 0 1.633627277897176e-07
threonine O 0 6.371432732521498e-07
( O 0 4.4988462954975716e-10
PST O 0 2.1014589890455682e-07
) O 0 1.3446197488775624e-09
- O 0 9.909206255542813e-08
rich O 0 1.0709540809727969e-08
transactivation O 0 3.0366577448148746e-06
domain O 0 3.0058805577937164e-07
. O 0 4.513685780693777e-08

PAX6 O 0 0.0018829259788617492
regulates O 0 0.0001377762237098068
eye O 0 0.0008083728025667369
development O 0 2.2114527098437975e-07
in O 0 2.5504527378927833e-09
animals O 0 1.2725051234951934e-08
ranging O 0 2.8270394025753376e-08
from O 0 2.4539525966815745e-10
jellyfish O 0 8.482869962023187e-10
to O 0 4.109359727499928e-11
Drosophila O 0 1.2192800102894807e-09
to O 0 3.0091756864081276e-10
humans O 0 9.913833309838083e-09
. O 0 5.5534616905106304e-09

Heterozygous O 0 9.127430530497804e-05
mutations O 0 3.141859906463651e-06
in O 0 9.26709642357082e-09
the O 0 2.037583435310353e-09
human O 0 2.0301980541148623e-08
PAX6 O 0 7.958617970871273e-06
gene O 0 4.3629235335629346e-08
result O 0 2.62015431573559e-09
in O 0 1.4079049037718505e-10
various O 0 3.042359697502661e-10
phenotypes O 0 8.163787157400293e-08
, O 0 1.3243541818752647e-09
including O 0 6.079379488710401e-08
aniridia B-Disease 1 0.9999998807907104
, O 0 7.58786263759248e-05
Peters B-Disease 1 0.9999996423721313
anomaly I-Disease 1 0.9999988079071045
, O 0 1.238090362676303e-06
autosomal B-Disease 0 0.016309455037117004
dominant I-Disease 0 0.0003061470633838326
keratitis I-Disease 1 0.8067288994789124
, O 0 5.441335702016659e-07
and O 0 1.1357640232745325e-06
familial B-Disease 0 0.10956118255853653
foveal I-Disease 1 0.9821309447288513
dysplasia I-Disease 1 0.9998241066932678
. O 0 4.500122031458886e-06

It O 0 1.1419357548447806e-07
is O 0 8.337448065276476e-09
believed O 0 7.039904215133674e-09
that O 0 8.668507578413198e-11
the O 0 4.5404985327124336e-11
mutated O 0 8.310458099458629e-09
allele O 0 1.1750154627065967e-08
of O 0 4.718447854656915e-10
PAX6 O 0 1.9879493265761994e-05
produces O 0 2.2917967612556822e-07
an O 0 4.481426896241203e-10
inactive O 0 2.0293541069804633e-08
protein O 0 9.520321420097844e-09
and O 0 2.700525385535002e-07
aniridia B-Disease 1 0.9999998807907104
is O 0 1.4962384966565878e-06
caused O 0 2.613033700527012e-08
due O 0 9.072436690793495e-10
to O 0 1.868358578960283e-09
genetic O 0 9.789303021534579e-07
haploinsufficiency O 0 6.43729290459305e-05
. O 0 3.8728677509425324e-07

However O 0 1.4067337872347707e-07
, O 0 9.420283442196364e-10
several O 0 1.041433883575138e-10
truncation O 0 1.025678599830826e-07
mutations O 0 4.498533883179334e-07
have O 0 2.1901158220316574e-08
been O 0 1.4671972081714557e-08
found O 0 1.2070032973099387e-08
to O 0 5.226643007283371e-10
occur O 0 1.911227565098983e-10
in O 0 9.950974072525653e-11
the O 0 6.885273462486907e-10
C O 0 1.9744422388612293e-05
- O 0 7.803644621162675e-06
terminal O 0 1.854497099884611e-06
half O 0 2.643461005646941e-09
of O 0 2.516404862262789e-10
PAX6 O 0 1.2214123898957041e-06
in O 0 1.775145253013477e-09
patients O 0 2.4120240027514228e-08
with O 0 8.469244860975778e-09
Aniridia B-Disease 1 0.9999996423721313
resulting O 0 1.8066624818402488e-07
in O 0 6.742628122502481e-10
mutant O 0 2.8496472737060685e-08
proteins O 0 1.013055639376148e-09
that O 0 6.715021871883664e-10
retain O 0 5.306351358314032e-09
the O 0 2.980256041951179e-10
DNA O 0 7.435864546323501e-08
- O 0 2.6507484562898753e-07
binding O 0 9.006715373516272e-09
domains O 0 1.7819035136312777e-08
but O 0 1.38364333324148e-08
have O 0 6.6434036050111445e-09
lost O 0 1.3238750540267574e-08
most O 0 4.3046587128170444e-11
of O 0 1.975776833806897e-11
the O 0 1.7415016095867486e-09
transactivation O 0 5.049874289397849e-06
domain O 0 3.5471811088427785e-07
. O 0 6.126698082198345e-08

It O 0 1.642979867710892e-07
is O 0 1.3390820008396531e-08
not O 0 1.1998548821168242e-09
clear O 0 1.8249979305551278e-09
whether O 0 2.863526915586334e-10
such O 0 1.4913187351695e-10
mutants O 0 2.7092797338923447e-08
really O 0 9.147142066012748e-08
behave O 0 7.680188041092606e-09
as O 0 1.692753298643268e-10
loss O 0 1.7535007890145948e-09
- O 0 1.4440996665143757e-07
of O 0 3.0824226504577723e-10
- O 0 4.855458428210113e-06
function O 0 2.3216745859144794e-08
mutants O 0 4.690195343215464e-09
as O 0 5.738887698392148e-10
predicted O 0 1.5901990835232027e-08
by O 0 1.6170960126515865e-09
haploinsufficiency O 0 4.890890068054432e-06
. O 0 5.8072398445574436e-08

Contrary O 0 1.2058317224727944e-06
to O 0 3.0468962908258845e-09
this O 0 1.1981755865253518e-10
theory O 0 1.16882770129223e-09
, O 0 1.706163127446203e-10
our O 0 2.6055407831293564e-10
data O 0 5.338665065579562e-09
showed O 0 3.904258605302857e-08
that O 0 5.150184098634547e-11
these O 0 3.0602773787302695e-11
mutants O 0 1.298161800278308e-09
are O 0 2.0312342086103996e-10
dominant O 0 7.705266824586943e-08
- O 0 5.436071432995959e-07
negative O 0 3.7715558676154615e-08
in O 0 1.0342522671624721e-10
transient O 0 1.564744556148412e-09
transfection O 0 3.4854988228971706e-08
assays O 0 9.210549656302192e-09
when O 0 4.100952355479137e-10
they O 0 2.4349020022462753e-10
are O 0 4.155104385561437e-11
coexpressed O 0 3.953401161993497e-08
with O 0 3.0839752973577106e-10
wild O 0 1.9529593942024803e-07
- O 0 7.056628965074196e-05
type O 0 0.0002714520669542253
PAX6 O 0 0.00012183302169432864
. O 0 2.262398055563608e-07

We O 0 3.1286273838304623e-07
found O 0 3.6137202119590484e-09
that O 0 2.5330326725026e-10
the O 0 1.3797073206145427e-10
dominant O 0 5.524632342712721e-07
- O 0 1.728855295368703e-06
negative O 0 2.337493327786433e-07
effects O 0 4.698847178019605e-08
result O 0 5.726630281088774e-10
from O 0 4.519632237909299e-11
the O 0 1.50719419583778e-11
enhanced O 0 2.9382363209151663e-09
DNA O 0 8.415190322352828e-09
binding O 0 1.3922064612259533e-09
ability O 0 5.093992450078133e-10
of O 0 1.0084565994772365e-11
these O 0 1.8280767177802915e-10
mutants O 0 5.973414829441026e-08
. O 0 1.0723644194854387e-08

Kinetic O 0 1.1448847772044246e-06
studies O 0 2.0661692801127174e-08
of O 0 2.1802522287561743e-10
binding O 0 1.52919852780542e-07
and O 0 1.0636701297528361e-08
dissociation O 0 3.919165436627736e-08
revealed O 0 2.4998838554779468e-08
that O 0 4.2315480980326114e-11
various O 0 2.3017282524406824e-11
truncation O 0 7.102376020640122e-09
mutants O 0 2.1355086587959704e-08
have O 0 1.467761912010701e-09
3 O 0 6.057278012505662e-10
- O 0 1.2264782753845793e-06
5 O 0 7.309250094067465e-09
- O 0 8.803667128631787e-07
fold O 0 2.7152342596536982e-08
higher O 0 4.590992030983898e-10
affinity O 0 7.612669522538695e-11
to O 0 1.8984414734690702e-11
various O 0 2.781529173656594e-11
DNA O 0 1.0173489606302155e-08
- O 0 1.3851562563615971e-08
binding O 0 2.0755808183281488e-09
sites O 0 6.16137398878891e-08
when O 0 3.2250321857496544e-10
compared O 0 1.1238104891120315e-09
with O 0 8.577147325716794e-11
the O 0 2.308192109667928e-10
wild O 0 1.776498379513214e-07
- O 0 3.6991608794778585e-05
type O 0 0.00012658136256504804
PAX6 O 0 6.859927088953555e-05
. O 0 2.252155439919079e-07

These O 0 3.6482457943520785e-08
results O 0 1.0072335854260928e-08
provide O 0 2.1875929956394202e-09
a O 0 7.143401425935281e-10
new O 0 3.59916957348716e-10
insight O 0 2.040313473727906e-09
into O 0 6.028001015012663e-11
the O 0 6.637672356202273e-11
role O 0 8.554425501294816e-10
of O 0 1.772288982238024e-10
mutant O 0 9.839922086030128e-07
PAX6 O 0 2.9923521651653573e-05
in O 0 1.932810711480215e-08
causing O 0 2.5845133677648846e-06
aniridia B-Disease 1 0.9999322891235352
. O 0 6.995414736366001e-08
. O 0 1.342509392543434e-07

Reversal O 0 8.589090430177748e-05
of O 0 7.130359449547541e-07
severe O 1 0.6356935501098633
hypertrophic B-Disease 1 0.9999463558197021
cardiomyopathy I-Disease 1 1.0
and O 0 2.254754690511618e-06
excellent O 0 3.488463335088454e-06
neuropsychologic O 0 1.2324921044637449e-05
outcome O 0 1.3224143913248554e-07
in O 0 2.9813718160909275e-09
very B-Disease 0 1.1305277780593315e-07
- I-Disease 0 0.0013834774727001786
long I-Disease 0 1.3586868590209633e-05
- I-Disease 0 0.0001146945942309685
chain I-Disease 0 0.00010333953105146065
acyl I-Disease 0 2.5372767709086474e-07
- I-Disease 0 1.941080881806556e-06
coenzyme I-Disease 0 1.9218346380966977e-07
A I-Disease 0 2.0471659922804974e-07
dehydrogenase I-Disease 0 0.005120079964399338
deficiency I-Disease 0 0.10523203760385513
. O 0 1.6114140066747495e-07

Very B-Disease 0 6.253508217923809e-06
- I-Disease 0 0.00022320725838653743
long I-Disease 0 5.318154762790073e-06
- I-Disease 0 7.848196401027963e-05
chain I-Disease 0 7.125758565962315e-05
acyl I-Disease 0 1.6987392825740244e-07
- I-Disease 0 4.0652267330187897e-07
coenzyme I-Disease 0 1.7267080210103813e-08
A I-Disease 0 3.1727882543464148e-09
dehydrogenase I-Disease 0 1.9536784634510695e-07
( I-Disease 0 1.7473276159307716e-09
VLCAD I-Disease 0 0.0004975242773070931
) I-Disease 0 3.58378173359597e-07
deficiency I-Disease 0 0.03001919947564602
is O 0 1.1591397175436668e-08
a O 0 1.6510281852788466e-07
disorder O 0 0.0015324740670621395
of O 0 3.5139982590415286e-10
fatty O 0 9.766507247377376e-08
acid O 0 1.315901498877281e-09
beta O 0 7.731901924268314e-11
oxidation O 0 1.8204149299094752e-10
that O 0 5.67621616376357e-10
reportedly O 0 3.799549688210391e-07
has O 0 3.034600792872766e-09
high O 0 7.429439730088916e-09
rates O 0 3.349542865294097e-08
of O 0 1.8138920920840462e-10
morbidity O 0 0.00027418474201112986
and O 0 2.508771217435424e-07
mortality O 0 3.348487371113151e-05
. O 0 7.439169991130257e-08

We O 0 1.5357987592778954e-07
describe O 0 1.9574487808426966e-08
the O 0 8.035230814051886e-11
outcome O 0 8.814347030039471e-10
of O 0 2.3218879943720516e-11
a O 0 1.881565347972014e-09
5 O 0 2.1055939214420505e-09
- O 0 1.930429107233067e-06
year O 0 2.5594596664291203e-08
- O 0 3.4664783015614375e-05
old O 0 0.0014030927559360862
girl O 0 0.06861545890569687
with O 0 2.868961473723175e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.5962526706280187e-07
was O 0 7.993892836566374e-08
first O 0 4.2334960537182553e-10
seen O 0 1.8331419937567262e-07
at O 0 8.155457642544661e-09
5 O 0 1.285937883954702e-10
months O 0 1.332466637027352e-10
of O 0 1.585569002482412e-11
age O 0 1.940775362641034e-08
with O 0 5.508522917807568e-07
severe O 0 0.19660940766334534
hypertrophic B-Disease 1 0.9998735189437866
cardiomyopathy I-Disease 1 1.0
, O 0 0.0005008953739888966
hepatomegaly B-Disease 1 1.0
, O 0 0.0024120111484080553
encephalopathy B-Disease 1 0.5945544242858887
, O 0 3.042786289597643e-08
and O 0 3.635198027041042e-07
hypotonia B-Disease 0 0.20305269956588745
. O 0 5.875984925296507e-07

Biochemical O 0 4.2152838432230055e-05
studies O 0 2.2237345547182485e-06
indicated O 1 0.988519012928009
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 7.324908892769599e-06
by O 0 2.603425919289748e-09
a O 0 1.6701459060186608e-07
stable O 0 0.000223913011723198
yet O 0 6.999645307814717e-08
inactive O 0 9.280809365463938e-08
enzyme O 0 5.5339874904802855e-08
. O 0 1.8427082082439483e-08

Molecular O 0 1.503560724813724e-06
genetic O 0 1.3271892385091633e-06
analysis O 0 7.478848829123308e-08
of O 0 8.151896047081664e-09
her O 0 4.4559513412423257e-07
VLCAD O 0 0.00021067021589260548
gene O 0 5.951761750111473e-07
revealed O 0 3.24185907629726e-06
a O 0 4.0661721101287185e-08
T1372C O 0 5.638766538140771e-07
( O 0 1.8367419807319152e-09
F458L O 0 1.5024282618014695e-07
) O 0 1.7237093974387108e-09
missense O 0 6.766054525542131e-07
mutation O 0 1.0186541743451016e-07
and O 0 1.6072569053449115e-08
a O 0 3.2028572150011314e-07
1668 O 0 0.0007566289277747273
ACAG O 0 0.0012700259685516357
1669 O 0 4.58120703115128e-05
splice O 0 0.00016805704217404127
site O 0 9.663264063419774e-05
mutation O 0 4.759148851007922e-06
. O 0 2.4156983613465854e-07

After O 0 1.1070132188706339e-07
initial O 0 4.97796044385268e-08
treatment O 0 1.816574268787008e-07
with O 0 2.5080588716974717e-09
intravenous O 0 7.372329235977304e-08
glucose O 0 1.8453536540619098e-05
and O 0 1.2926108183819451e-08
carnitine O 0 5.116277179695317e-07
, O 0 1.6012954295874238e-09
the O 0 5.522351465003794e-10
patient O 0 6.18018304976431e-07
has O 0 1.317366304931511e-08
thrived O 0 1.1242788389154157e-07
on O 0 8.751348090640931e-09
a O 0 1.3340623716828759e-08
low O 0 7.622728844580706e-06
- O 0 8.636849997856189e-06
fat O 0 1.0919188042635142e-07
diet O 0 4.239493645030734e-09
supplemented O 0 5.708618022737255e-09
with O 0 9.554024238411785e-10
medium O 0 1.0815939276653808e-05
- O 0 1.769629307091236e-05
chain O 0 1.8205078958999366e-05
triglyceride O 0 2.8380969752106466e-07
oil O 0 1.2005817495719384e-07
and O 0 1.5376145912071593e-09
carnitine O 0 9.639697395869007e-08
and O 0 1.9559065478347293e-09
avoidance O 0 9.172072168439627e-08
of O 0 7.164059345754481e-10
fasting O 0 1.0185001428908436e-06
. O 0 3.552671756779091e-08

Her O 0 1.4988539078331087e-05
ventricular O 0 0.031497739255428314
hypertrophy O 0 0.0003350567421875894
resolved O 0 1.399815118929837e-06
significantly O 0 4.876103787410102e-08
over O 0 1.1736267957473956e-08
1 O 0 2.582968949838005e-09
year O 0 4.536296227541925e-09
, O 0 3.0218305635543175e-09
and O 0 3.4770044621268426e-09
cognitively O 0 6.550035323016346e-07
, O 0 1.47051926191466e-09
she O 0 7.487337860823118e-09
is O 0 1.5105227069156513e-09
in O 0 9.725838884255822e-11
the O 0 2.6061075519834276e-10
superior O 0 9.870551487267676e-09
range O 0 3.845852347694745e-07
for O 0 6.769434346409753e-09
age O 0 6.995468027071183e-08
. O 0 4.032974842971271e-08

Clinical O 0 1.3972895430924837e-05
recognition O 0 1.2464926157917944e-06
of O 0 1.4444759472098667e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.4858370604997617e-06
important O 0 9.538334566627782e-09
because O 0 1.042986919053135e-09
it O 0 1.363363422157704e-09
is O 0 2.100924323400477e-09
one O 0 2.3093149614794584e-10
of O 0 3.615991880923097e-11
the O 0 7.079866692905057e-10
few O 0 8.429427111877885e-08
directly O 0 9.309792972089781e-07
treatable O 0 0.0004376350552774966
causes O 0 2.341147009587985e-08
of O 0 2.349498728904109e-08
cardiomyopathy B-Disease 1 0.9999997615814209
in O 0 2.2182240044799073e-08
children O 0 7.715679117836771e-08
. O 0 1.5749278547971812e-09
. O 0 3.2422679652199804e-08

Cloning O 0 7.863993232604116e-06
of O 0 5.613289832950841e-09
a O 0 1.651792835843935e-08
novel O 0 2.1718538079085192e-08
member O 0 5.71288460982089e-10
of O 0 5.5687298522455464e-11
the O 0 5.169200067989266e-10
low O 0 1.2724536873065517e-06
- O 0 2.4186406335502397e-06
density O 0 2.4211008167185355e-06
lipoprotein O 0 0.00011444124538684264
receptor O 0 3.260171297370107e-07
family O 0 8.016487527129357e-07
. O 0 1.297135980848907e-07

A O 0 4.633318724245328e-07
gene O 0 1.5346479642630584e-07
encoding O 0 1.3997775738516793e-07
a O 0 5.504532651912086e-08
novel O 0 3.5009907151106745e-07
transmembrane O 0 3.0794410577072995e-07
protein O 0 2.4772806028749983e-08
was O 0 3.6967884398109163e-07
identified O 0 2.1647114323286587e-08
by O 0 7.898639381442862e-11
DNA O 0 2.8258519968460405e-09
sequence O 0 5.787816337310403e-10
analysis O 0 3.2741576116990245e-10
within O 0 2.4364724127146076e-10
the O 0 4.946730802757315e-10
insulin B-Disease 0 6.6567758040037e-05
- I-Disease 1 0.9998137354850769
dependent I-Disease 1 0.9999775886535645
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.500490942722536e-07
IDDM B-Disease 0 9.86789382295683e-05
) O 0 8.116212590891791e-09
locus O 0 6.801163863201509e-07
IDDM4 O 0 4.320698280935176e-05
on O 0 2.3459975295736513e-07
chromosome O 0 5.406415948527865e-05
11q13 O 0 1.7343912986689247e-05
. O 0 1.461739742580903e-07

Based O 0 8.651843472762266e-07
on O 0 1.5485942128634633e-07
its O 0 7.637430243789822e-09
chromosomal O 0 0.00041609269101172686
position O 0 3.2948487387329806e-06
, O 0 6.064700408536794e-10
this O 0 2.4060010928028674e-11
gene O 0 7.298031623470536e-10
is O 0 4.012882526271966e-10
a O 0 2.3558280326518855e-10
candidate O 0 1.2970752250041073e-09
for O 0 1.414324074522355e-10
conferring O 0 3.43485311304903e-08
susceptibility O 0 8.19879278424196e-06
to O 0 4.2280721572751645e-06
diabetes B-Disease 1 0.8680620789527893
. O 0 5.625784069707152e-07

The O 0 6.662349338881768e-09
gene O 0 3.6154524707399105e-08
, O 0 7.06947611561759e-10
termed O 0 1.2149213546308602e-07
low O 0 2.4419241526629776e-06
- O 0 4.222776624374092e-06
density O 0 2.26959923566028e-06
lipoprotein O 0 5.025032442063093e-05
receptor O 0 5.5638757601172983e-08
related O 0 9.492618602280345e-08
protein O 0 1.5436862454976108e-08
5 O 0 1.22511711886375e-09
( O 0 1.0184079968222903e-10
LRP5 O 0 3.2721823117753956e-07
) O 0 1.4681894588974842e-10
, O 0 2.2812472397215622e-11
encodes O 0 1.283641803961899e-10
a O 0 3.778652113428649e-10
protein O 0 6.251035800097782e-10
of O 0 1.2328262022354153e-10
1615 O 0 7.548612757091178e-07
amino O 0 1.1889494944128387e-09
acids O 0 7.027178838825421e-11
that O 0 1.4394866375277982e-11
contains O 0 5.201677977240138e-11
conserved O 0 3.278844695753236e-10
modules O 0 1.75123460177673e-09
which O 0 7.662654954998516e-10
are O 0 6.618355169463186e-11
characteristic O 0 5.04291108871513e-10
of O 0 1.657233898721966e-11
the O 0 2.2201518401487874e-10
low O 0 1.1499062111397507e-06
- O 0 1.6358831089746673e-06
density O 0 1.881964863059693e-06
lipoprotein O 0 0.00011654400441329926
( O 0 1.9842394394231633e-08
LDL O 0 1.6066323951235972e-06
) O 0 1.95922211787547e-09
receptor O 0 4.2308766268206455e-08
family O 0 9.236959641611975e-08
. O 0 6.946379471628461e-08

These O 0 4.9009994285142966e-08
modules O 0 1.2390466963552171e-07
include O 0 1.695371287802061e-09
a O 0 1.2228875689856977e-09
putative O 0 1.955232420414177e-08
signal O 0 1.923682546589589e-08
peptide O 0 4.832305666724324e-10
for O 0 1.206161386047011e-11
protein O 0 1.1045650505359106e-10
export O 0 3.7195317936777883e-09
, O 0 4.9827215270470404e-11
four O 0 5.0860388817186575e-11
epidermal O 0 1.4569654815943522e-08
growth O 0 1.607305932793679e-08
factor O 0 2.768749007842075e-09
( O 0 2.8392493911510996e-10
EGF O 0 4.3711697372827985e-08
) O 0 3.15898890379529e-10
repeats O 0 2.5448754215062763e-08
with O 0 7.918675715146151e-10
associated O 0 1.3099397122573464e-08
spacer O 0 3.8137222873046994e-06
domains O 0 2.379948398356646e-07
, O 0 2.587090763839228e-09
three O 0 4.937700248675014e-10
LDL O 0 9.785261454453575e-07
- O 0 1.0375854344601976e-06
receptor O 0 4.876845594026236e-09
( O 0 2.8708002641764097e-10
LDLR O 0 2.7530506940820487e-07
) O 0 2.6628765859015857e-10
repeats O 0 3.660764491542068e-08
, O 0 3.3705860325028425e-10
a O 0 4.6377879314718484e-10
single O 0 2.1166199459798918e-08
transmembrane O 0 1.44981626704066e-08
spanning O 0 2.125901410465758e-08
domain O 0 6.876631175600778e-08
, O 0 1.7931743867549699e-09
and O 0 1.2624693512819363e-09
a O 0 8.943906060210338e-09
cytoplasmic O 0 4.2748419559757167e-07
domain O 0 2.242258716478318e-07
. O 0 4.581505663736607e-08

The O 0 1.4047036422937254e-08
encoded O 0 3.113488489248084e-08
protein O 0 4.3704442731495874e-08
has O 0 4.8255293094712215e-09
a O 0 2.381180252974957e-10
unique O 0 1.0650054171890133e-09
organization O 0 2.329026971281678e-09
of O 0 1.3213685701174427e-10
EGF O 0 5.218255978434172e-07
and O 0 3.1665631894384205e-08
LDLR O 0 1.9266884919488803e-05
repeats O 0 1.652959724651737e-07
; O 0 5.220963661400901e-10
therefore O 0 1.8493337972103063e-09
, O 0 5.046259521357399e-10
LRP5 O 0 1.308902824348479e-06
likely O 0 1.4700375139398147e-08
represents O 0 1.6738723740417072e-09
a O 0 4.4032308355035354e-10
new O 0 1.0156462337818084e-09
category O 0 2.745244742641262e-08
of O 0 2.3187379794009644e-10
the O 0 5.765023569637151e-09
LDLR O 0 6.800888513680547e-05
family O 0 3.4348079225310357e-07
. O 0 9.747952134375737e-08

Both O 0 2.101998148873463e-07
human O 0 1.1611316352855283e-07
and O 0 1.3084814121100408e-08
mouse O 0 8.281359441753011e-06
LRP5 O 0 4.739632004202576e-06
cDNAs O 0 2.5341546461277176e-07
have O 0 8.071151746946725e-09
been O 0 2.09144985774401e-08
isolated O 0 2.278479996675742e-06
and O 0 4.4366910145754446e-10
the O 0 2.296952211766623e-11
encoded O 0 2.202547921825726e-09
mature O 0 1.0175774667331439e-09
proteins O 0 5.1217755731025605e-11
are O 0 7.036687899031335e-11
95 O 0 1.029077600911421e-09
% O 0 1.1205159022864564e-10
identical O 0 3.46272415185922e-08
, O 0 1.8565222692501493e-09
indicating O 0 4.4281907918275465e-08
a O 0 4.898865757496651e-09
high O 0 2.072046214607326e-07
degree O 0 6.216814840698248e-10
of O 0 2.7001496524792223e-11
evolutionary O 0 3.6663458935493054e-09
conservation O 0 3.065563447535169e-08
. O 0 2.1656394455504824e-09
. O 0 1.5262781261071723e-08

The O 0 8.893829317457858e-08
APC B-Disease 0 9.096249300455383e-07
variants O 0 1.0127995864195327e-07
I1307K O 0 7.880117323111335e-07
and O 0 4.6209081006054475e-09
E1317Q O 0 2.3195549658794334e-07
are O 0 1.4096286804488045e-08
associated O 0 2.7555315682548098e-05
with O 1 0.9923608899116516
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 5.396773121901788e-05
but O 0 1.3865710002392007e-07
not O 0 3.8348680675426294e-08
always O 0 2.5763769784248325e-08
with O 0 1.8565142478887964e-10
a O 0 6.4658003395834385e-09
family O 0 7.294546122693646e-08
history O 0 5.52003029952175e-08
. O 0 6.719858447468141e-08

Classical O 0 0.01506023108959198
familial B-Disease 1 0.9999980926513672
adenomatous I-Disease 1 0.9999669790267944
polyposis I-Disease 1 0.9999992847442627
( O 0 1.861615260168037e-06
FAP B-Disease 0 4.247470315021928e-06
) O 0 6.743750891047284e-09
is O 0 5.8415974280023875e-09
a O 0 1.1928410259542943e-08
high O 0 0.0003356458037160337
- O 1 0.9999425411224365
penetrance O 1 0.9998416900634766
autosomal B-Disease 1 0.9999464750289917
dominant I-Disease 1 0.9961435794830322
disease I-Disease 0 0.20898759365081787
that O 0 4.2681751466489e-09
predisposes O 0 1.7621744063944789e-07
to O 0 2.440720070495672e-09
hundreds O 0 8.186861855108418e-09
or O 0 2.598263293407399e-08
thousands O 0 1.9521358751717344e-08
of O 0 6.3109500842983834e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9089428186416626
carcinoma I-Disease 1 1.0
and O 0 2.4018379917833954e-05
that O 0 2.5590887631210535e-08
results O 0 8.546471974568703e-09
from O 0 3.3480707095634443e-10
truncating O 0 1.0219820012480341e-07
mutations O 0 2.1705121255877202e-08
in O 0 4.1357819946519214e-10
the O 0 6.139104224978098e-10
APC B-Disease 0 9.844139015058317e-08
gene O 0 5.893686250146857e-08
. O 0 6.840343047542774e-08

A O 0 7.47977480841655e-07
variant O 0 1.6496147736688727e-06
of O 0 3.3997331616575366e-09
FAP B-Disease 0 1.3642451449413784e-05
is O 0 3.341405999890412e-06
attenuated B-Disease 1 0.9995680451393127
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999639987945557
coli I-Disease 1 0.9999955892562866
, O 0 1.546842156585626e-07
which O 0 2.5784123280914173e-08
results O 0 1.1257461629554655e-08
from O 0 1.335026422744079e-09
germ O 0 0.004907296504825354
- O 0 0.000409079366363585
line O 0 3.110426041530445e-05
mutations O 0 6.871291535759383e-09
in O 0 1.0480316614547291e-10
the O 0 5.912998563006866e-11
5 O 0 4.596696079328666e-10
and O 0 2.509135565986753e-09
3 O 0 4.055835389760176e-10
regions O 0 1.128170223907432e-09
of O 0 1.219788714479364e-10
the O 0 1.6301211491764889e-09
APC B-Disease 0 1.015277106830581e-07
gene O 0 3.334912790364797e-08
. O 0 1.398677529351744e-08

Attenuated B-Disease 1 0.9997559189796448
adenomatous I-Disease 1 0.999996542930603
polyposis I-Disease 1 0.9999881982803345
coli I-Disease 1 0.9999980926513672
patients O 0 0.027868932113051414
have O 0 1.8125560075077374e-07
" O 0 2.5163362806779332e-06
multiple O 0 1.557167161081452e-05
" O 1 0.9992675185203552
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
( O 0 5.256096891059769e-09
typically O 0 2.0576420567408604e-09
fewer O 0 3.790186775542992e-10
than O 0 3.6926828261840683e-10
100 O 0 1.1072107675147436e-09
) O 0 9.444837273386852e-11
without O 0 1.4251883007077026e-10
the O 0 1.3132454845798947e-10
florid O 0 2.224621312052477e-06
phenotype O 0 3.008489812827975e-08
of O 0 1.0933844801774839e-10
classical O 0 3.6690614990675385e-08
FAP B-Disease 0 7.067850447128876e-07
. O 0 2.5086343669045164e-08

Another O 0 1.1923479803499504e-07
group O 0 1.4193821584740363e-07
of O 0 1.5206199632800121e-09
patients O 0 3.752268895595989e-08
with O 0 1.2980899688486147e-09
multiple O 0 2.8662896056630416e-06
adenomas B-Disease 0 0.44753652811050415
has O 0 2.3611270080436952e-05
no O 0 9.205177775584161e-08
mutations O 0 7.995978101860146e-09
in O 0 2.387602060505145e-10
the O 0 2.312056379683014e-10
APC B-Disease 0 3.733441999997922e-09
gene O 0 7.704057836122047e-09
, O 0 9.446985416161624e-10
and O 0 1.998809562309134e-09
their O 0 4.731335323526764e-10
phenotype O 0 3.76943454227785e-08
probably O 0 1.982593822447143e-08
results O 0 6.162344523552576e-10
from O 0 1.0381655257685196e-10
variation O 0 2.883644611983982e-08
at O 0 4.472043144687632e-07
a O 0 5.685190540560825e-09
locus O 0 7.780733568552023e-08
, O 0 3.2683191708571258e-09
or O 0 8.883750401977863e-10
loci O 0 4.606078296554017e-10
, O 0 1.76074571589524e-10
elsewhere O 0 2.0844634907035697e-09
in O 0 5.714886897045801e-11
the O 0 3.8579886507683625e-10
genome O 0 2.0926394483922195e-07
. O 0 5.259569135773745e-08

Recently O 0 3.743970228242688e-05
, O 0 5.0912944971059915e-09
however O 0 9.989983285052517e-10
, O 0 1.4207290899292957e-10
a O 0 7.538289992226055e-10
missense O 0 1.3370245142141357e-06
variant O 0 2.3351324216491776e-06
of O 0 1.9014294583286073e-09
APC B-Disease 0 1.7337413282803027e-07
( O 0 7.426261827703229e-10
I1307K O 0 1.6508856504060532e-08
) O 0 4.0536388135059553e-10
was O 0 5.179321505011103e-08
described O 0 8.724269662252482e-08
that O 0 4.5538747772688737e-10
confers O 0 1.5319296942095662e-09
an O 0 1.929666842981348e-10
increased O 0 6.002086934131512e-07
risk O 0 0.0002912389754783362
of O 0 0.0090358667075634
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.2195521271205507e-06
including O 0 2.4973198620159565e-08
multiple O 0 7.676777045162453e-07
adenomas B-Disease 0 0.00017268907686229795
, O 0 2.4171313839360664e-08
in O 0 1.6105436984048538e-08
Ashkenazim O 0 5.225944551057182e-05
. O 0 1.0700539831987044e-07

We O 0 6.948353075131308e-07
have O 0 8.473975410261403e-10
studied O 0 3.576750839950904e-10
a O 0 2.35825109440313e-10
set O 0 1.703224672411352e-09
of O 0 1.8645947286177744e-10
164 O 0 1.0347653187636752e-06
patients O 0 4.2519911147564926e-08
with O 0 2.9692403202830064e-08
multiple O 1 0.982914924621582
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.007830427028238773
/ I-Disease 1 0.9959115982055664
or I-Disease 0 0.4590747356414795
carcinoma I-Disease 1 1.0
and O 0 2.997550154759665e-07
analyzed O 0 7.768186947032518e-07
codons O 0 2.6979589051734365e-07
1263 O 0 2.683076900211745e-06
- O 0 4.767694008478429e-06
1377 O 0 6.484625032499025e-07
( O 0 1.7459717005507969e-09
exon O 0 2.2102673469248657e-08
15G O 0 1.3520455866000702e-07
) O 0 3.55688534181553e-10
of O 0 1.4873467041320865e-11
the O 0 1.1471494587578235e-10
APC B-Disease 0 3.4603917509201665e-09
gene O 0 1.038577890355441e-09
for O 0 1.2944011418269952e-09
germ O 0 7.146288407966495e-05
- O 0 1.9895956938853487e-05
line O 0 3.703223410411738e-05
variants O 0 1.2626140915017459e-06
. O 0 4.522665619788313e-08

Three O 0 2.07308190169897e-07
patients O 0 1.1730542581744885e-07
with O 0 8.072101320699687e-10
the O 0 3.720899699466429e-10
I1307K O 0 1.0770117597758144e-07
allele O 0 4.486442861661999e-08
were O 0 6.926980322674581e-09
detected O 0 3.323137889310601e-07
, O 0 8.737595369456841e-11
each O 0 3.334182929748408e-11
of O 0 2.339899107806076e-10
Ashkenazi O 0 1.1118765996798174e-06
descent O 0 4.268826614861609e-06
. O 0 1.7265308827063564e-07

Four O 0 1.0632298881319002e-06
patients O 0 1.451414846087573e-06
had O 0 8.769013248866031e-08
a O 0 3.3946804478546255e-08
germ O 0 0.012977121397852898
- O 0 0.0012943802867084742
line O 0 7.177157385740429e-05
E1317Q O 0 7.087992344168015e-07
missense O 0 1.1462711881904397e-06
variant O 0 1.6044918993429746e-07
of O 0 4.75247230458109e-10
APC O 0 1.2616130362630429e-08
that O 0 1.884571609878094e-09
was O 0 2.519544182177924e-07
not O 0 3.3786720088357924e-09
present O 0 7.58192342242836e-10
in O 0 2.4307164614434384e-10
controls O 0 5.807698926219018e-06
; O 0 5.304011119200425e-10
one O 0 7.941909352382481e-10
of O 0 1.581256306448786e-11
these O 0 6.822888920510195e-10
individuals O 0 9.033240266909104e-10
had O 0 6.642127203804193e-08
an O 0 3.493721978387043e-10
unusually O 0 2.6383091267234704e-08
large O 0 4.0186671768083215e-09
number O 0 2.3959925155025985e-09
of O 0 8.018791741726261e-10
metaplastic B-Disease 0 1.9641938706627116e-05
polyps I-Disease 0 1.395891786160064e-06
of I-Disease 0 4.296564770633893e-10
the I-Disease 0 4.005864528977554e-09
colorectum I-Disease 0 1.586492726346478e-05
. O 0 8.47613392807034e-08

There O 0 5.065261916570307e-07
is O 0 2.4546840116101976e-09
increasing O 0 4.1313510945606424e-10
evidence O 0 1.2524392634105652e-09
that O 0 4.3797193649552923e-10
there O 0 1.5929395580371875e-09
exist O 0 8.358928660356924e-09
germ O 0 1.3745227988692932e-05
- O 0 4.532542334345635e-06
line O 0 2.6419309051561868e-06
variants O 0 1.7661920814759924e-09
of O 0 3.2352454049089374e-11
the O 0 1.8838124116182797e-10
APC B-Disease 0 1.5423023969063365e-09
gene O 0 3.915866519932365e-10
that O 0 8.090146608186188e-11
predispose O 0 5.932239699468767e-10
to O 0 1.5606246850374816e-10
the O 0 1.5860417146296157e-10
development O 0 3.889964617087571e-08
of O 0 9.799627775919362e-08
multiple O 1 0.9992682337760925
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9905382394790649
carcinoma I-Disease 1 1.0
, O 0 4.916864781989716e-06
but O 0 1.0122627003283924e-07
without O 0 4.136738507298787e-09
the O 0 8.160790931910356e-10
florid O 0 4.064105269208085e-06
phenotype O 0 6.71049562583903e-08
of O 0 5.065852945462801e-11
classical O 0 2.637845053499177e-09
FAP B-Disease 0 2.1899904112387958e-08
, O 0 4.490967597803319e-10
and O 0 2.3845392327359605e-10
possibly O 0 1.5961025834343445e-09
with O 0 4.2012476830777246e-10
importance O 0 3.3893175555022026e-07
for O 0 0.2133568376302719
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.8639831978362054e-05
in O 0 4.1934261618692403e-10
the O 0 1.5263407204813007e-10
general O 0 3.0192534583584063e-10
population O 0 5.246579282136565e-10
. O 0 5.720517393115188e-10
. O 0 2.0912743536882772e-08

Genomic O 0 2.80758217741095e-06
structure O 0 3.06850040487916e-07
of O 0 1.5153303056791856e-09
the O 0 2.0643179610146944e-08
human O 0 0.01065024919807911
congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.9999709129333496
diarrhea I-Disease 1 1.0
( O 0 1.7306500694758142e-06
CLD B-Disease 0 0.0012717375066131353
) O 0 1.4024547745350446e-08
gene O 0 1.5339252001922432e-07
. O 0 1.1653582987491973e-07

Congenital B-Disease 1 0.9999998807907104
chloride I-Disease 1 0.999994158744812
diarrhea I-Disease 1 1.0
( O 0 5.269498160487274e-06
CLD B-Disease 0 0.0499618761241436
) O 0 4.1681595064346766e-08
is O 0 3.595509312503964e-08
caused O 0 2.8388893014152927e-08
by O 0 2.2285394363219524e-10
mutations O 0 1.4801380565643285e-08
in O 0 1.2539563831737155e-10
a O 0 1.978331942709133e-09
gene O 0 2.5380213486414505e-08
which O 0 7.80990205839771e-09
encodes O 0 3.920848001826016e-08
an O 0 3.4884784838595806e-08
intestinal O 0 0.0017393609741702676
anion O 0 8.034849088289775e-06
transporter O 0 0.0004395893483888358
. O 0 5.347656042431481e-07

We O 0 1.197239953398821e-06
report O 0 2.7456898976652155e-08
here O 0 1.0099436842381238e-09
the O 0 2.8509692870382075e-11
complete O 0 7.606272278692927e-10
genomic O 0 7.497127363365053e-09
organization O 0 2.1248016679464854e-09
of O 0 3.521397062833387e-11
the O 0 1.526160170461921e-10
human O 0 6.406947417048059e-09
CLD B-Disease 0 3.9624760006518045e-07
gene O 0 6.603319668840868e-09
which O 0 2.1124928473170712e-09
spans O 0 2.938775978122976e-08
approximately O 0 4.7490131827032656e-09
39kb O 0 7.083167474775109e-07
, O 0 1.0940754968657984e-09
and O 0 2.122294562312277e-09
comprises O 0 1.1528975996100144e-08
21 O 0 1.3049447744606368e-08
exons O 0 5.585284270637203e-07
. O 0 8.123139139115665e-08

All O 0 2.1082511736381093e-08
exon O 0 9.744826456881128e-07
/ O 0 3.866129191010259e-05
intron O 0 2.8119819035055116e-05
boundaries O 0 1.3766994300112856e-07
conform O 0 2.9454144012674988e-08
to O 0 4.832655942088593e-10
the O 0 6.34452379522088e-10
GT O 0 3.1806841889192583e-06
/ O 0 0.0002928159374278039
AG O 0 0.17095227539539337
rule O 0 8.071875754467328e-07
. O 0 2.2605561866839707e-07

An O 0 1.2838731855424612e-08
analysis O 0 1.3162837930735805e-08
of O 0 4.225549632419501e-10
the O 0 1.8334938012287694e-09
putative O 0 3.059059849874757e-07
promoter O 0 2.4512179152225144e-05
region O 0 3.218503508151116e-08
sequence O 0 1.8894926512302845e-08
shows O 0 1.6905036659409234e-07
a O 0 4.888505156230849e-09
putative O 0 1.6257646962003491e-07
TATA O 0 1.2626583156816196e-05
box O 0 5.02644661537488e-06
and O 0 4.955260202166301e-09
predicts O 0 1.2182954378658906e-07
multiple O 0 2.7893949372526095e-09
transcription O 0 3.5488788796556037e-08
factor O 0 8.405404372524572e-09
binding O 0 1.7269682572873535e-08
sites O 0 1.850299781835929e-06
. O 0 1.1103924890676353e-07

The O 0 1.6127508217778086e-08
genomic O 0 2.4013107235987263e-07
structure O 0 1.16056196475256e-06
was O 0 5.8835105676280364e-08
determined O 0 1.0700535568730629e-08
using O 0 1.3536106679978843e-09
DNA O 0 3.0024306596487804e-08
from O 0 8.567255238567384e-11
several O 0 4.3847737940527765e-11
sources O 0 2.5477139842244867e-10
including O 0 1.1707816660599946e-10
multiple O 0 1.8102915833040356e-09
large O 0 5.029534833056459e-08
- O 0 6.31399016128853e-05
insert O 0 9.275238880945835e-06
libaries O 0 1.620596412976738e-05
and O 0 3.35501448844866e-09
genomic O 0 1.8569515702893113e-08
DNA O 0 4.256535390823046e-08
from O 0 1.2363919887903307e-09
Finnish O 0 2.6698373858380364e-06
CLD B-Disease 0 0.00019872216216754168
patients O 0 6.240164651671876e-08
and O 0 6.4460001780730636e-09
controls O 0 1.4617994565924164e-05
. O 0 4.505037907165388e-07

Exon O 0 1.7278734958381392e-05
- O 0 1.0621987712511327e-05
specific O 0 4.148371246515126e-08
primers O 0 9.5660732313263e-07
developed O 0 6.946578423594474e-08
in O 0 4.8482284159545586e-11
this O 0 1.4050659073727712e-11
study O 0 4.806179412786271e-11
will O 0 1.461564896887424e-10
facilitate O 0 7.808140800591445e-10
mutation O 0 6.752048919977938e-10
screening O 0 1.0711393994000673e-09
studies O 0 2.3227529621916432e-10
of O 0 9.078992418976028e-11
patients O 0 8.811460006086236e-09
with O 0 1.0183812682029725e-09
the O 0 1.4209236098849942e-07
disease O 0 0.0003144673246424645
. O 0 7.45195123386111e-08

Genomic O 0 7.318417942769884e-07
sequencing O 0 3.6583605833584443e-07
of O 0 5.46697753733838e-09
a O 0 7.140274504990884e-08
BAC O 0 2.767431942629628e-05
clone O 0 0.0014749509282410145
H O 1 0.9999985694885254
_ O 0 6.954306996931336e-08
RG364P16 O 0 2.8379483296703256e-07
revealed O 0 1.22832148008456e-07
the O 0 4.102611028677927e-10
presence O 0 2.7749609277094578e-09
of O 0 3.626358588415535e-11
another O 0 2.935340415177734e-09
, O 0 2.605799465094094e-10
highly O 0 2.131803067406679e-10
homologous O 0 3.443232643451921e-10
gene O 0 2.5672517445229914e-09
3 O 0 5.711718875645033e-10
of O 0 5.889081583498879e-11
the O 0 9.85472592418546e-10
CLD B-Disease 0 2.802424660330871e-06
gene O 0 1.9294333242214634e-08
, O 0 1.0175639220122434e-09
with O 0 2.571298451936599e-10
a O 0 2.0203738682056382e-09
similar O 0 1.245084146894726e-09
genomic O 0 8.7980591700898e-09
structure O 0 6.412574293790385e-07
, O 0 1.6323798979200888e-09
recently O 0 2.3938012461144353e-08
identified O 0 9.249741594885563e-08
as O 0 7.318959660551627e-09
the O 0 3.456816330071888e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 8.000128559615405e-07
( O 0 1.614064792931913e-08
PDS B-Disease 0 3.5880743780580815e-06
) O 0 2.4749839955262587e-09
. O 0 2.1908790337477058e-09
. O 0 3.7902772476172686e-08

The O 0 4.427987931876487e-08
APCI1307K O 0 4.8647827497916296e-05
allele O 0 2.6091274776263162e-05
and O 0 6.350864623527741e-06
cancer B-Disease 0 4.401423575473018e-05
risk O 0 9.430176532987389e-07
in O 0 8.154379949054658e-10
a O 0 7.026891513106648e-09
community O 0 1.0848664189211377e-08
- O 0 1.1361896667949622e-06
based O 0 1.0604654931967161e-08
study O 0 9.759589802982305e-10
of O 0 3.395169145825605e-10
Ashkenazi O 0 2.386507844676089e-07
Jews O 0 5.059120766759406e-08
. O 0 2.185783820607412e-08

Mutations O 0 5.0393095989420544e-06
in O 0 8.315183208651433e-09
APC O 0 1.1747778216886218e-06
are O 0 7.258457834780074e-09
classically O 0 2.862267501768656e-05
associated O 0 7.096458830346819e-06
with O 0 0.00016065622912719846
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.99998939037323
polyposis I-Disease 1 0.9999994039535522
( O 0 6.241033929654805e-07
FAP B-Disease 0 1.7584018223715248e-06
) O 0 6.654475193101916e-09
, O 0 1.5319647772571443e-09
a O 0 2.0989867621779013e-08
highly O 0 0.0002698115713428706
penetrant O 1 0.9999103546142578
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999991655349731
disorder I-Disease 1 1.0
characterized O 1 0.5848388671875
by O 0 4.348611128079938e-06
multiple O 0 0.010837447829544544
intestinal O 1 0.8938323855400085
polyps B-Disease 0 0.052878785878419876
and O 0 7.269031243595236e-07
, O 0 1.900736901205846e-09
without O 0 8.574845278275234e-10
surgical O 0 3.8352561659849016e-07
intervention O 0 1.5251490737000495e-08
, O 0 1.4561139793922706e-10
the O 0 5.453245494058123e-11
development O 0 5.980460571208823e-08
of O 0 1.8381382687948644e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.220855381234287e-07
CRC B-Disease 0 1.4289849787019193e-05
) O 0 1.7333503521399507e-08
. O 0 3.689321204092266e-08

APC B-Disease 0 4.947564593749121e-05
is O 0 1.621407506036121e-07
a O 0 1.9556544827992184e-07
tumour O 1 0.9999994039535522
- O 0 3.115368963335641e-05
suppressor O 0 5.115523890708573e-06
gene O 0 1.5766876515499462e-07
, O 0 1.8398800261110182e-09
and O 0 2.2038675329127955e-09
somatic O 0 2.3476223987017875e-07
loss O 0 5.791261514787038e-07
occurs O 0 2.947516186679877e-08
in O 0 4.114118823395074e-08
tumours B-Disease 1 0.9999985694885254
. O 0 1.0324349659640575e-06

The O 0 6.13369053326096e-08
germline O 0 1.490688828198472e-05
T O 0 0.003700480330735445
- O 0 2.245978976134211e-06
to O 0 6.727101098391586e-09
- O 0 2.6612704004946863e-06
A O 0 1.4151295246733753e-08
transversion O 0 2.485829497800296e-07
responsible O 0 1.5901081340530254e-08
for O 0 1.9146828567073726e-10
the O 0 1.6122661539164085e-10
APC O 0 1.4280251647846853e-08
I1307K O 0 4.0550327540245235e-09
allele O 0 1.1169934976962281e-09
converts O 0 1.7260509688199477e-10
the O 0 1.2338353949647995e-10
wild O 0 9.115979082707781e-09
- O 0 6.072056066841469e-07
type O 0 3.1492706398239534e-07
sequence O 0 4.3341406019692386e-09
to O 0 1.2197847176764753e-09
a O 0 3.664753478460625e-08
homopolymer O 0 0.015606946311891079
tract O 1 0.9985625147819519
( O 0 1.3999105874518136e-08
A8 O 0 0.006407842505723238
) O 0 1.0843983488939557e-09
that O 0 7.780637245602406e-10
is O 0 4.2400758459848475e-09
genetically O 0 1.1405600730540755e-07
unstable O 0 0.0025077583268284798
and O 0 2.4679997068233206e-07
prone O 0 1.4874793123453856e-05
to O 0 4.5256318692565856e-09
somatic O 0 8.327636464855459e-07
mutation O 0 5.689249746865244e-07
. O 0 1.097464377153301e-07

The O 0 2.9765324427444284e-08
I1307K O 0 4.783433382726798e-07
allele O 0 2.6544520892457513e-07
was O 0 2.6534902985986264e-07
found O 0 1.2689205242111257e-08
in O 0 9.316076798882023e-10
6 O 0 4.801880493232602e-08
. O 0 4.446870249807944e-08

1 O 0 1.0183064347302206e-07
% O 0 5.415873083336464e-09
of O 0 2.9947921920125964e-10
unselected O 0 5.776165380666498e-06
Ashkenazi O 0 4.926359906676225e-07
Jews O 0 4.101597994576878e-08
and O 0 8.16742851128538e-09
higher O 0 6.516064576800318e-09
proportions O 0 6.462732926593162e-08
of O 0 1.7242050842636303e-10
Ashkenazim O 0 1.570331050970708e-06
with O 0 3.1232669783776146e-08
family O 0 2.0341149138403125e-06
or O 0 4.472892101148318e-07
personal O 0 4.007672941952478e-06
histories O 0 1.2782359135599108e-06
of O 0 4.867171554678862e-09
CRC B-Disease 0 1.6294590750476345e-05
( O 0 2.807505339319505e-09
ref O 0 3.939990619983291e-06
. O 0 4.836132050378694e-10
2 O 0 2.120404962724365e-09
) O 0 2.83718271099076e-09
. O 0 1.332966181877282e-08

To O 0 6.42262349970224e-08
evaluate O 0 1.3826914369019505e-07
the O 0 1.4334815279237745e-10
role O 0 1.0623800728026822e-09
of O 0 6.98940280652316e-11
I1307K O 0 7.609632035610048e-08
in O 0 1.8687542624462594e-09
cancer B-Disease 0 1.0735190159039121e-07
, O 0 3.3564978574318616e-10
we O 0 3.780102453276868e-09
genotyped O 0 2.558411154041096e-07
5 O 0 1.1673839672710074e-09
, O 0 1.1394436505440808e-09
081 O 0 5.213366307543765e-07
Ashkenazi O 0 5.0516380412091166e-08
volunteers O 0 2.774119600701397e-09
in O 0 3.336360077099698e-10
a O 0 2.309470170658301e-09
community O 0 2.0789453714087358e-08
survey O 0 1.932425675477134e-06
. O 0 8.237049797799045e-08

Risk O 0 4.7479963541263714e-05
of O 0 1.2474358435099475e-08
developing O 0 0.00022364269534591585
colorectal B-Disease 1 1.0
, I-Disease 0 1.390820398228243e-05
breast I-Disease 0 0.48330771923065186
and I-Disease 0 2.3623335891898023e-06
other I-Disease 0 2.3738229160130686e-08
cancers I-Disease 0 4.78745459986385e-06
were O 0 8.577519849950477e-08
compared O 0 4.6507697248898694e-08
between O 0 4.211792248298707e-09
genotyped O 0 1.170695554719714e-06
I1307K O 0 1.010804098200424e-07
carriers O 0 1.0499594971236093e-08
and O 0 5.339395037218253e-10
non O 0 1.9207970325396673e-08
- O 0 8.912149382922507e-07
carriers O 0 1.6128153035310788e-08
and O 0 1.0276731687852703e-09
their O 0 1.0844742465154766e-10
first O 0 8.508050375333198e-10
- O 0 1.402491648150317e-06
degree O 0 1.0529797478397995e-08
relatives O 0 2.291568890200324e-08
. O 0 1.3334848780743869e-08

Sperm O 0 2.4278522232634714e-06
DNA O 0 2.1432541075228073e-07
analysis O 0 2.8923039963046904e-08
in O 0 2.445510460802325e-09
a O 0 2.439563218104013e-07
Friedreich B-Disease 1 0.9989449381828308
ataxia I-Disease 1 0.9998231530189514
premutation O 0 0.005009312182664871
carrier O 0 3.532767004799098e-05
suggests O 0 9.313686177847558e-08
both O 0 1.4759817812404208e-09
meiotic O 0 3.5218096172684454e-07
and O 0 2.7570394856013536e-09
mitotic O 0 7.472532814745136e-08
expansion O 0 6.246940387200084e-08
in O 0 9.850065207928083e-10
the O 0 7.493963782856383e-10
FRDA B-Disease 0 2.175835788875702e-06
gene O 0 1.9023360664505162e-07
. O 0 5.014468129616034e-08

Friedreich B-Disease 1 0.9998388290405273
ataxia I-Disease 1 0.9999879598617554
is O 0 3.9274702430702746e-05
usually O 0 1.1701106359396363e-06
caused O 0 4.529658426122296e-08
by O 0 1.847531155840798e-10
an O 0 8.612507929051105e-11
expansion O 0 5.7524939478525994e-08
of O 0 1.5663033092749856e-09
a O 0 2.0843222614530532e-07
GAA O 0 3.94965491068433e-06
trinucleotide O 0 1.8964719856739976e-06
repeat O 0 3.653969926631362e-08
in O 0 4.5062234499404497e-10
intron O 0 1.6578219401708338e-06
1 O 0 2.0366897057755295e-09
of O 0 1.7046539180221032e-10
the O 0 2.2262591770072504e-09
FRDA B-Disease 0 5.472495558933588e-06
gene O 0 2.534142709009757e-07
. O 0 7.281354186261524e-08

Occasionally O 0 6.323849447653629e-06
, O 0 5.369064748350638e-09
a O 0 1.2666564463970076e-09
fully O 0 6.52005560652924e-09
expanded O 0 1.8442718463518304e-09
allele O 0 6.577502631444077e-08
has O 0 8.428028053231174e-08
been O 0 1.737590693551283e-08
found O 0 9.958883495642112e-09
to O 0 1.0434505481882184e-09
arise O 0 7.173603377985671e-10
from O 0 1.5176195369837053e-11
a O 0 2.451959468796616e-10
premutation O 0 2.7200963259588207e-08
of O 0 4.020863850207057e-11
100 O 0 4.83385687033433e-09
or O 0 4.127367780881741e-09
less O 0 5.2654884896696785e-09
triplet O 0 1.715439611871261e-05
repeats O 0 2.498702542652609e-06
. O 0 7.661916612278219e-08

We O 0 1.919553596962942e-06
have O 0 1.138785776788609e-08
examined O 0 3.292170447366516e-08
the O 0 1.18993578879234e-10
sperm O 0 4.382144869197191e-09
DNA O 0 4.897959371419347e-09
of O 0 1.5272259845655611e-10
a O 0 3.877844889643711e-08
premutation O 0 3.936074790544808e-05
carrier O 0 6.801450126658892e-06
. O 0 7.606990948261227e-08

This O 0 3.655050306861085e-08
mans O 0 2.3709642391622765e-06
leucocyte O 0 1.1767033356591128e-05
DNA O 0 1.728950905999227e-06
showed O 0 7.90828948993294e-07
one O 0 1.1492590212824894e-09
normal O 0 3.875757936810942e-09
allele O 0 8.282323271657788e-09
and O 0 4.87868523357804e-10
one O 0 9.92727705595442e-11
allele O 0 9.837636261167404e-10
of O 0 2.0464772237938078e-11
approximately O 0 7.554874947857115e-09
100 O 0 2.3723337960745994e-08
repeats O 0 1.2774327160514076e-06
. O 0 4.434115297158314e-08

His O 0 7.001314088483923e-07
sperm O 0 1.621428964426741e-06
showed O 0 3.252190765579144e-07
an O 0 1.0600235272884007e-10
expanded O 0 2.840371937651298e-09
allele O 0 1.577246422357348e-08
in O 0 7.870491480765907e-10
a O 0 1.3461241898937715e-08
tight O 0 1.7124511941801757e-06
range O 0 4.6856419544383243e-07
centering O 0 1.9772199877365892e-08
on O 0 5.572145855836652e-09
a O 0 3.7947003872496055e-10
size O 0 2.0038903869590285e-09
of O 0 1.3407110144303402e-10
approximately O 0 3.870323084242955e-08
320 O 0 3.1435246228284086e-07
trinucleotide O 0 8.431020432908554e-06
repeats O 0 2.3689256067882525e-06
. O 0 9.145903590024318e-08

His O 0 1.12558495857229e-06
affected O 0 8.030390745261684e-06
son O 0 6.4233856392093e-05
has O 0 5.1311602078385476e-08
repeat O 0 3.498660205991655e-08
sizes O 0 1.6968053628829693e-08
of O 0 2.6129712282774165e-10
1040 O 0 1.4017614091699215e-07
and O 0 2.4264851461452963e-08
540 O 0 1.0122952289748355e-06
. O 0 6.138828467783242e-08

These O 0 1.5701896671771465e-08
data O 0 8.167770459976964e-09
suggest O 0 1.909326696747371e-09
that O 0 6.217428655252988e-11
expansion O 0 5.780791401122087e-09
occurs O 0 6.414182518454936e-10
in O 0 5.928854629466684e-11
two O 0 2.372173013576173e-10
stages O 0 1.4318439411908912e-07
, O 0 1.7493017034908576e-09
the O 0 5.261347607588007e-11
first O 0 1.8009678470765067e-10
during O 0 1.6738141428440656e-10
meiosis O 0 2.172920593457306e-10
followed O 0 1.7222460957366792e-10
by O 0 2.5493560387723768e-11
a O 0 3.6535899305967234e-10
second O 0 1.526871296064769e-09
mitotic O 0 2.851942610959668e-07
expansion O 0 4.6263821218417434e-07
. O 0 7.868877816008535e-08

We O 0 6.592410954908701e-07
also O 0 6.0331832862914325e-09
show O 0 2.564537027183178e-08
that O 0 3.534864345677846e-10
in O 0 9.878169116017688e-11
all O 0 6.330969776202622e-11
informative O 0 1.7211912961556664e-07
carrier O 0 2.1466865973707172e-07
father O 0 1.5378939011156945e-08
to O 0 8.754432179181038e-10
affected O 0 3.689011762730843e-08
child O 0 2.3460310671907791e-07
transmissions O 0 1.0304990610165987e-05
, O 0 2.260756915006823e-09
with O 0 1.7181546463351793e-10
the O 0 7.613017855012671e-11
notable O 0 1.977237928940667e-09
exception O 0 1.189237597287729e-09
of O 0 4.526689439954268e-11
the O 0 1.186472725622778e-10
premutation O 0 1.847357395945437e-07
carrier O 0 1.9264179584865815e-08
, O 0 3.444019028298051e-11
the O 0 2.616844024458387e-12
expansion O 0 9.028761627227766e-10
size O 0 2.4173388624149084e-08
decreases O 0 9.903745734618496e-08
. O 0 1.5496622873811816e-09
. O 0 1.0830388141869207e-08

The O 0 3.108415214114757e-08
R496H O 0 8.812151008896763e-07
mutation O 0 3.0184391874854555e-08
of O 0 5.59183976900357e-10
arylsulfatase O 0 9.006493201013654e-06
A O 0 2.3308686536438472e-07
does O 0 2.066225164298885e-07
not O 0 1.857627012213925e-07
cause O 0 1.8816504962160252e-05
metachromatic B-Disease 1 0.9999923706054688
leukodystrophy I-Disease 1 0.999980092048645
. O 0 3.31062551595096e-06

Deficiency B-Disease 1 0.9986164569854736
of I-Disease 0 6.4881855443843506e-09
arylsulfatase I-Disease 0 7.626731530763209e-05
A I-Disease 0 4.3030317442571686e-07
( O 0 2.4690066879884398e-08
ARSA O 0 0.0008606865885667503
) O 0 3.538535686686828e-09
enzyme O 0 8.543084817347335e-08
activity O 0 4.01878014599788e-06
causes O 0 2.483998287061695e-05
metachromatic B-Disease 1 0.999997615814209
leukodystrophy I-Disease 1 0.9999983310699463
( O 0 4.626987447409192e-06
MLD B-Disease 1 0.9999374151229858
) O 0 1.6241747857748123e-07
. O 0 1.20929186664398e-07

A O 0 3.010281091064826e-07
number O 0 8.097781112326174e-09
of O 0 1.1454249770892488e-09
ARSA O 0 0.030400197952985764
gene O 0 2.9548911584242887e-07
mutations O 0 4.0166395365304197e-07
responsible O 0 1.0002582939705462e-06
for O 0 2.2187217041391705e-07
MLD B-Disease 1 0.9999977350234985
have O 0 1.4348720469570253e-06
been O 0 3.697275019476365e-07
identified O 0 2.4169091830117395e-06
. O 0 7.856925066107578e-08

Recently O 0 2.034074714174494e-05
, O 0 2.8784890027111487e-09
the O 0 1.0723939097845303e-10
R496H O 0 4.024430211302388e-08
mutation O 0 5.8288316395760376e-09
of O 0 2.153208167321452e-10
ARSA O 0 0.00028040417237207294
was O 0 3.638662917637703e-07
proposed O 0 2.482046790319714e-09
to O 0 2.0975410297552344e-09
be O 0 5.507512224056654e-09
a O 0 1.574978925056314e-09
cause O 0 1.0686808771254164e-08
of O 0 2.9503044451928417e-09
MLD B-Disease 1 0.9999974966049194
( O 0 1.351299960816732e-08
Draghia O 0 5.0448247748136055e-06
et O 0 2.6604964205034776e-06
al O 0 4.729156898974907e-06
. O 0 1.4518162227972198e-09
, O 0 1.3997548675703797e-09
1997 O 0 1.8365212683946197e-09
) O 0 3.4173122109848464e-09
. O 0 2.3530866144483298e-08

We O 0 1.3578646758105606e-06
have O 0 6.481160053084523e-09
investigated O 0 2.556430089839523e-08
the O 0 1.5628170979553602e-10
R496H O 0 5.306627315349033e-08
mutation O 0 8.044485966252068e-09
and O 0 9.995301253340472e-10
found O 0 1.2985654773700617e-09
this O 0 3.353475483414137e-11
mutation O 0 1.6375003575319624e-09
at O 0 2.50080778307904e-09
a O 0 3.583633945147824e-10
relatively O 0 2.3039925522994054e-09
high O 0 1.3459899861345548e-09
frequency O 0 1.4955245930536876e-08
in O 0 3.095313449996695e-10
an O 0 6.911031469325479e-11
African O 0 7.395528633935555e-11
American O 0 7.12201200792073e-11
population O 0 6.495360499458869e-11
( O 0 1.0281308790438537e-11
f O 0 7.072287644405151e-08
= O 0 1.1350235418206012e-08
0 O 0 3.4198535669993646e-10
. O 0 4.3984021286247454e-11
09 O 0 7.932779988450989e-10
, O 0 1.4432043060619293e-10
n O 0 1.5389686325306684e-07
= O 0 1.3433418644126505e-07
61 O 0 1.211098776821018e-08
subjects O 0 6.39962252080295e-08
) O 0 6.372566918599887e-09
. O 0 1.74905565586414e-08

The O 0 1.6465342866922583e-07
ARSA O 0 0.0004548550059553236
enzyme O 0 1.472770208010843e-07
activity O 0 5.75284445858415e-07
in O 0 6.198912494426168e-10
subjects O 0 3.4417915628637274e-08
with O 0 3.545507887281474e-09
and O 0 2.4216536331778116e-08
without O 0 5.055237894957543e-10
the O 0 3.346389831904162e-11
R496H O 0 1.2772712665309882e-08
mutation O 0 1.5446398604623823e-09
was O 0 3.7761054727525334e-08
determined O 0 1.2659040748985717e-07
and O 0 7.991174832966408e-09
found O 0 3.2516178638530846e-09
to O 0 8.506103599259518e-10
be O 0 8.935125528353183e-09
normal O 0 9.594774752486046e-08
. O 0 2.3055939379901247e-08

It O 0 1.4613300436394638e-07
is O 0 6.277132591492318e-09
therefore O 0 3.374471257977518e-10
concluded O 0 1.1295568924651889e-09
that O 0 1.1988339487789546e-10
the O 0 6.750165704172417e-11
R496H O 0 1.821295469994766e-08
mutation O 0 2.045854818888415e-09
of O 0 1.1662260046563233e-10
ARSA O 0 0.00020757487800437957
does O 0 1.105227998010605e-08
not O 0 3.032273598879698e-10
negatively O 0 6.907450722515307e-10
influence O 0 1.2157728990214167e-10
the O 0 4.8996088436448204e-11
activity O 0 1.5857021651299874e-07
of O 0 3.4774139123783243e-10
ARSA O 0 0.004430384375154972
and O 0 2.12068922422759e-08
is O 0 8.255826244862874e-09
not O 0 2.866708870286061e-09
a O 0 1.0816287421278048e-08
cause O 0 6.410262187728222e-08
of O 0 1.077272600014112e-07
MLD B-Disease 1 0.9999833106994629

Down O 0 0.00022544836974702775
- O 0 4.619694664143026e-06
regulation O 0 3.1875476480536236e-08
of O 0 9.026248082300015e-10
transmembrane O 0 3.7166941524446884e-07
carbonic O 0 2.418875340026716e-07
anhydrases O 0 1.824087848945055e-05
in O 0 4.2592725435497414e-07
renal B-Disease 1 0.9999843835830688
cell I-Disease 1 0.9999794960021973
carcinoma I-Disease 1 1.0
cell O 1 0.9700329303741455
lines O 0 0.00039564762846566737
by O 0 8.799149853189192e-09
wild O 0 3.85439261663123e-06
- O 0 0.04789886623620987
type O 0 0.31485268473625183
von B-Disease 1 0.9952351450920105
Hippel I-Disease 1 0.995169460773468
- I-Disease 1 0.8875446915626526
Lindau I-Disease 1 0.8544166684150696
transgenes O 0 0.0013210908509790897
. O 0 1.5067157619341742e-06

To O 0 9.274562984273871e-08
discover O 0 1.926598542922875e-07
genes O 0 3.633544309877834e-08
involved O 0 2.867191639666089e-08
in O 0 2.779412078268706e-08
von B-Disease 1 0.9997554421424866
Hippel I-Disease 1 0.9998980760574341
- I-Disease 1 0.9999281167984009
Lindau I-Disease 1 0.9996408224105835
( O 0 2.54369950880573e-07
VHL B-Disease 0 9.164828952634707e-06
) O 0 6.224293525036728e-09
- O 0 4.210018232697621e-06
mediated O 0 4.497007466852665e-06
carcinogenesis O 0 4.4679069105768576e-05
, O 0 4.598206704287122e-09
we O 0 1.3888309169374224e-08
used O 0 2.505665361240972e-05
renal B-Disease 1 0.9998353719711304
cell I-Disease 1 0.9998776912689209
carcinoma I-Disease 1 1.0
cell O 1 0.9923015832901001
lines O 0 0.0779472291469574
stably O 0 0.021379059180617332
transfected O 0 8.789849380264059e-05
with O 0 2.797180442826175e-08
wild O 0 1.2692105428868672e-06
- O 0 0.022909244522452354
type O 0 0.16665957868099213
VHL O 0 0.00018127699149772525
- O 0 2.626039531605784e-05
expressing O 0 2.9624925446114503e-07
transgenes O 0 3.0780734959989786e-05
. O 0 2.5086757204917376e-07

Large O 0 5.995250376145123e-07
- O 0 9.094348570215516e-06
scale O 0 3.6308781545812963e-06
RNA O 0 1.6329007479498614e-08
differential O 0 8.367207371406948e-09
display O 0 5.313281548069426e-08
technology O 0 6.795903839673656e-09
applied O 0 3.75064812541126e-10
to O 0 1.1849485281878458e-10
these O 0 3.7635902727650716e-10
cell O 0 4.450010067102994e-07
lines O 0 2.2673400223993667e-07
identified O 0 3.8074059460768694e-08
several O 0 1.879200961507621e-10
differentially O 0 1.579943500473746e-07
expressed O 0 1.2209602218149485e-09
genes O 0 2.5429431893542187e-09
, O 0 4.923724761241033e-10
including O 0 5.878748599030814e-10
an O 0 2.1671094085906617e-10
alpha O 0 2.0473225337269696e-09
carbonic O 0 9.187721694559059e-09
anhydrase O 0 4.63431781838608e-08
gene O 0 2.0021341029519135e-08
, O 0 1.3638733475929143e-09
termed O 0 8.388565788663982e-07
CA12 O 0 0.0001382183691021055
. O 0 1.6604693087174383e-07

The O 0 4.274156850669897e-08
deduced O 0 8.731877443324265e-08
protein O 0 8.092716718977044e-09
sequence O 0 9.180364912708683e-09
was O 0 4.048944646228847e-08
classified O 0 2.4192374326048594e-07
as O 0 1.6693959548064186e-09
a O 0 3.153044758619217e-08
one O 0 4.859887781094585e-07
- O 0 0.09437590837478638
pass O 0 5.865700131835183e-06
transmembrane O 0 1.030104158417089e-06
CA O 0 5.493631306308089e-06
possessing O 0 2.6420256205028636e-08
an O 0 3.070961818174567e-10
apparently O 0 1.14482494595336e-08
intact O 0 2.3725406084196266e-09
catalytic O 0 5.436748384823886e-09
domain O 0 1.4069559739482429e-08
in O 0 3.02580266398067e-10
the O 0 7.202737295486372e-10
extracellular O 0 2.8210450864207814e-07
CA O 0 3.3095504477387294e-05
module O 0 8.440892088401597e-06
. O 0 6.087803683385573e-08

Reintroduced O 0 3.89226124752895e-06
wild O 0 6.61057038087165e-06
- O 0 0.0009287431603297591
type O 0 0.00014851383457425982
VHL B-Disease 0 6.289170869422378e-06
strongly O 0 1.936774118860285e-08
inhibited O 0 1.3177280600018548e-08
the O 0 3.936435552520656e-11
overexpression O 0 3.2753959544606914e-09
of O 0 9.798548777917304e-11
the O 0 1.9527705841237974e-10
CA12 O 0 3.5061964354099473e-07
gene O 0 2.8085229697438763e-09
in O 0 2.4105634155446864e-10
the O 0 8.261843653656342e-09
parental O 0 0.10492613911628723
renal B-Disease 1 0.9999773502349854
cell I-Disease 1 0.9999587535858154
carcinoma I-Disease 1 1.0
cell O 1 0.9720877408981323
lines O 0 0.061456892639398575
. O 0 1.6347461269106134e-06

Similar O 0 1.4783852009259135e-07
results O 0 1.872504995503732e-08
were O 0 5.53809220704693e-09
obtained O 0 8.202116319466768e-09
with O 0 3.178803220649229e-09
CA9 O 0 5.8262252423446625e-05
, O 0 1.7129070384314105e-09
encoding O 0 9.134741851823946e-09
another O 0 9.927745736604265e-08
transmembrane O 0 1.1852863508465816e-06
CA O 0 6.353206845233217e-05
with O 0 2.02165750806671e-09
an O 0 1.2098029245066755e-09
intact O 0 4.959385933034355e-07
catalytic O 0 5.838726337970002e-07
domain O 0 9.597242751624435e-07
. O 0 8.13141696198727e-08

Although O 0 2.4578318402745936e-07
both O 0 2.443421687203795e-09
domains O 0 1.3844906554538738e-08
of O 0 4.158436373025154e-10
the O 0 2.8564588472335117e-09
VHL B-Disease 0 3.3252331377298106e-07
protein O 0 6.792219564566437e-10
contribute O 0 3.992345898318206e-10
to O 0 7.243362160069822e-11
regulation O 0 1.027506524309274e-09
of O 0 8.307550480868287e-11
CA12 O 0 1.2789645552402362e-05
expression O 0 3.1741276274033225e-08
, O 0 4.22484852657945e-10
the O 0 3.712921983756168e-11
elongin O 0 1.077971418794732e-07
binding O 0 3.8742573593708585e-09
domain O 0 5.314143081136535e-08
alone O 0 4.437634970599902e-08
could O 0 3.3328315662828345e-09
effectively O 0 1.8479314078945208e-08
regulate O 0 4.4154893430459197e-07
CA9 O 0 0.00024299341021105647
expression O 0 8.159987032740901e-07
. O 0 5.003127867553303e-08

We O 0 7.450066732417326e-07
mapped O 0 4.333878678153269e-05
CA12 O 0 0.0004927889094687998
and O 0 7.13823240516831e-08
CA9 O 0 2.6923094992525876e-05
loci O 0 1.4231177658530214e-07
to O 0 2.916210384285023e-09
chromosome O 0 9.981647508539027e-07
bands O 0 1.6786106016297708e-07
15q22 O 0 2.8212762117618695e-06
and O 0 2.384359554241655e-08
17q21 O 0 2.6680579594540177e-06
. O 0 5.223120425057459e-08

2 O 0 5.151882191967161e-07
respectively O 0 1.600817540747812e-07
, O 0 3.0216404933725016e-09
regions O 0 2.9408337098857373e-08
prone O 0 1.7473923435318284e-05
to O 0 8.914727844810955e-10
amplification O 0 6.562202514714954e-08
in O 0 9.752444407595817e-10
some O 0 1.3806689125317462e-09
human O 0 1.502068727177175e-07
cancers B-Disease 0 1.1937459021282848e-05
. O 0 3.7298349297998357e-08

Additional O 0 2.0391862420865436e-08
experiments O 0 1.0008911743852877e-07
are O 0 5.865699592710882e-10
needed O 0 2.132364423923505e-10
to O 0 8.778638926898452e-11
define O 0 1.0549779716484409e-08
the O 0 2.8141036723106083e-10
role O 0 6.798898777304885e-09
of O 0 4.0551081936790467e-10
CA O 0 1.852254536061082e-05
IX O 0 7.75402781982848e-07
and O 0 2.645596453021426e-07
CA O 0 1.886856261990033e-05
XII O 0 2.3009246774563508e-07
enzymes O 0 3.536754666910724e-09
in O 0 9.807374357073684e-11
the O 0 2.3276035612807e-11
regulation O 0 7.00291047373014e-10
of O 0 1.9353948998990234e-10
pH O 0 5.071146915724967e-06
in O 0 3.60994983905627e-10
the O 0 9.253716543033974e-11
extracellular O 0 6.748666070421905e-09
microenvironment O 0 2.9207998863967077e-07
and O 0 7.793860667959507e-09
its O 0 8.780737803526506e-10
potential O 0 1.7555220610532274e-09
impact O 0 4.108454909612647e-09
on O 0 2.9334427154026343e-07
cancer B-Disease 0 1.0167668733629398e-06
cell O 0 4.154505006681575e-07
growth O 0 7.784992135384528e-07
. O 0 4.896196870163294e-08

A O 0 1.0851089626839894e-07
gene O 0 1.0475893930106395e-07
encoding O 0 4.9542329350060754e-08
a O 0 5.541835434996756e-08
transmembrane O 0 3.40166195655911e-07
protein O 0 6.864899315672801e-09
is O 0 9.978119441811373e-10
mutated O 0 1.580137087842104e-08
in O 0 3.2830138607664594e-09
patients O 0 1.145536771218758e-06
with O 0 0.00041223771404474974
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9624038338661194
optic B-Disease 1 0.9999998807907104
atrophy I-Disease 1 0.9995576739311218
( O 0 0.06034102290868759
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 2.444791959987924e-07
. O 0 3.530812193730526e-07

Wolfram B-Disease 1 0.9999985694885254
syndrome I-Disease 1 1.0
( O 0 6.0447200667113066e-06
WFS B-Disease 0 0.027486756443977356
; O 0 2.515098174171726e-07
OMIM O 0 0.001322188414633274
222300 O 0 3.6254907627153443e-06
) O 0 4.3689749595898775e-09
is O 0 1.2733913479223702e-08
an O 0 2.7039366301551127e-08
autosomal B-Disease 1 0.999976396560669
recessive I-Disease 1 0.9999960660934448
neurodegenerative I-Disease 1 0.9999986886978149
disorder I-Disease 1 0.9997311234474182
defined O 0 7.163530881371116e-06
by O 0 3.3131914989326106e-08
young O 0 4.402941726766585e-07
- O 0 0.00019360358419362456
onset O 0 0.00025802807067520916
non O 0 4.030711716040969e-05
- O 0 0.04868120700120926
immune O 0 0.00016594571934547275
insulin B-Disease 0 0.0003586036036722362
- I-Disease 1 0.9966278672218323
dependent I-Disease 1 0.9997321963310242
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0021899878047406673
progressive O 0 0.44416242837905884
optic B-Disease 1 0.9999885559082031
atrophy I-Disease 0 0.021017828956246376
. O 0 1.0376299997005844e-06

Linkage O 0 4.265730967745185e-05
to O 0 3.043616203513011e-08
markers O 0 1.438211984350346e-05
on O 0 1.75634426113902e-07
chromosome O 0 0.00016629800666123629
4p O 0 0.0029956060461699963
was O 0 9.100309398490936e-06
confirmed O 0 9.522576505105462e-08
in O 0 4.55975007751519e-10
five O 0 3.090206313061117e-09
families O 0 1.9598211054017156e-08
. O 0 1.589138065583029e-08

On O 0 1.7334205892893806e-07
the O 0 2.725598358122028e-10
basis O 0 1.9282695440381303e-09
of O 0 6.375806133052109e-11
meiotic O 0 1.5165855074883439e-05
recombinants O 0 0.0846388190984726
and O 0 2.9577986424556002e-05
disease O 0 0.005026674829423428
- O 0 0.0004005599766969681
associated O 0 1.83590964297764e-06
haplotypes O 0 1.947552163983346e-06
, O 0 3.7938048258467916e-09
the O 0 6.502900440352732e-10
WFS B-Disease 0 2.84834385411159e-07
gene O 0 5.9840408184186344e-09
was O 0 8.702610188038307e-09
localized O 0 7.562433523844447e-08
to O 0 5.127978042196446e-09
a O 0 5.216370269067738e-08
BAC O 0 9.379658877151087e-06
/ O 0 1.0473740985617042e-06
P1 O 0 1.8956167195938178e-06
contig O 0 1.0555178420190714e-07
of O 0 1.181022363239137e-10
less O 0 6.871629376625776e-10
than O 0 1.7661955231673687e-09
250 O 0 4.2802916766504495e-08
kb O 0 1.210388472827617e-05
. O 0 1.2021330064726499e-07

Mutations O 0 1.4671891221951228e-05
in O 0 8.930559403097504e-09
a O 0 6.2574563308714914e-09
novel O 0 4.391401020598096e-08
gene O 0 1.271692724458262e-07
( O 0 8.518994953909953e-10
WFS1 O 0 4.912581061944366e-07
) O 0 1.8934412371329756e-10
encoding O 0 4.335265035848579e-09
a O 0 2.1686579643187542e-08
putative O 0 1.0736991384874273e-07
transmembrane O 0 6.3614429279823526e-09
protein O 0 1.5276813147835355e-09
were O 0 4.692485511270661e-09
found O 0 1.5712374734633272e-09
in O 0 9.893385416459566e-11
all O 0 2.5131191572214107e-10
affected O 0 1.0682713380560926e-08
individuals O 0 4.67039296125904e-10
in O 0 7.687673275746931e-10
six O 0 1.4273770609918301e-08
WFS B-Disease 0 2.914846845669672e-06
families O 0 8.527826445003939e-09
, O 0 7.019145265019233e-10
and O 0 5.760327770332196e-10
these O 0 9.489058150347063e-11
mutations O 0 9.871845563225179e-10
were O 0 5.170100347839934e-09
associated O 0 2.698130607825533e-08
with O 0 9.271056811144263e-09
the O 0 2.1751461076746637e-07
disease O 0 0.00020957495144102722
phenotype O 0 1.910079845401924e-06
. O 0 1.3766049278274295e-07

WFS1 O 0 0.0002596801205072552
appears O 0 1.6304862811011844e-06
to O 0 3.772647527711115e-09
function O 0 1.8128874401668327e-08
in O 0 5.458596907814695e-10
survival O 0 7.355818070209352e-07
of O 0 1.6924982249033604e-10
islet O 0 0.008232376538217068
beta O 0 7.105735999601848e-09
- O 0 4.5283542249308084e-07
cells O 0 9.675004797315978e-09
and O 0 9.628717823062516e-10
neurons O 0 3.669963000163534e-09
. O 0 2.696491918641186e-10
. O 0 1.4238476175876258e-08

Stable O 0 7.229858601931483e-05
interaction O 0 2.8585748879095263e-08
between O 0 2.835413681623322e-09
the O 0 1.9180858290557268e-10
products O 0 1.1094504515085646e-07
of O 0 6.857903828150214e-11
the O 0 2.6003093012150202e-09
BRCA1 O 0 2.0508159650489688e-05
and O 0 1.230462345347405e-07
BRCA2 O 0 1.098292432288872e-05
tumor B-Disease 0 1.4384672795131337e-06
suppressor O 0 2.0556606727950566e-07
genes O 0 1.4231633649330888e-08
in O 0 1.4753569477221617e-09
mitotic O 0 5.029025942349108e-06
and O 0 3.1425233260051755e-07
meiotic O 0 4.8630940000293776e-05
cells O 0 2.0235795545886504e-06
. O 0 2.050403651310262e-07

BRCA1 O 0 0.0022786192130297422
and O 0 7.466483111784328e-07
BRCA2 O 0 6.129654593678424e-06
account O 0 3.589883590393583e-08
for O 0 4.955343357870845e-10
most O 0 6.645035077745831e-10
cases O 0 2.7180502293333575e-10
of O 0 3.232100004302296e-11
familial O 0 2.0380584828672e-06
, O 0 2.3537272131335385e-09
early O 0 4.8072873681803685e-08
onset O 0 1.9490056729409844e-05
breast B-Disease 0 0.009967652149498463
and I-Disease 0 0.00012286224227864295
/ I-Disease 1 0.9999979734420776
or I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
and O 0 4.089175664745426e-09
encode O 0 1.1974846891860125e-08
products O 0 1.5841491403989494e-05
that O 0 1.698857610143989e-09
each O 0 2.262494219751332e-10
interact O 0 8.433953535558203e-10
with O 0 1.7139397678889168e-09
hRAD51 O 0 1.7138872863142751e-06
. O 0 5.30692112477027e-08

Results O 0 6.776309078304621e-07
presented O 0 3.3148033651286823e-08
here O 0 4.89107954138035e-09
show O 0 1.9810408957710024e-07
that O 0 5.0843369514552705e-09
BRCA1 O 0 7.437534350174246e-06
and O 0 3.434470841057191e-07
BRCA2 O 0 8.720168807485607e-06
coexist O 0 2.018835857597878e-06
in O 0 9.141970513937281e-10
a O 0 3.2708884489807133e-09
biochemical O 0 5.666486657673886e-08
complex O 0 4.222843017487321e-07
and O 0 6.470784352785586e-09
colocalize O 0 8.810235385681153e-07
in O 0 1.0927220239764779e-09
subnuclear O 0 1.3669962299900362e-06
foci O 0 4.3552412876124436e-07
in O 0 5.362389421392777e-10
somatic O 0 6.008435970983328e-09
cells O 0 1.780741598622626e-08
and O 0 3.3429161661047146e-09
on O 0 1.24893322350772e-08
the O 0 5.6607524223650785e-11
axial O 0 1.4796460723331961e-09
elements O 0 5.271887371094408e-10
of O 0 6.276754810352614e-11
developing O 0 1.430860585571736e-08
synaptonemal O 0 1.1412536196075962e-06
complexes O 0 1.6422544604210998e-06
. O 0 2.3114148817171554e-08

Like O 0 3.85180192097323e-06
BRCA1 O 0 4.148680454818532e-05
and O 0 1.4595180175547284e-07
RAD51 O 0 0.000503496325109154
, O 0 1.2606941268700211e-08
BRCA2 O 0 8.078191058302764e-07
relocates O 0 1.4320460195449414e-07
to O 0 3.4259006742587417e-09
PCNA O 0 8.818222340778448e-06
+ O 0 4.176053991500339e-08
replication O 0 2.818570443707813e-08
sites O 0 8.379748805964482e-08
following O 0 2.316602881746732e-10
exposure O 0 4.715940526978102e-09
of O 0 3.419303729046419e-11
S O 0 1.00384477264015e-06
phase O 0 4.677223941484954e-09
cells O 0 1.1890334272735004e-09
to O 0 5.227639987559485e-10
hydroxyurea O 0 4.969289761902473e-07
or O 0 1.909735658500722e-08
UV O 0 2.9073789846734144e-06
irradiation O 0 1.3303521200214163e-06
. O 0 7.896738196677688e-08

Thus O 0 2.7355446263754857e-07
, O 0 1.0737479350098056e-08
BRCA1 O 0 6.10947552104335e-07
and O 0 3.0124116534580025e-08
BRCA2 O 0 2.1119264204116917e-07
participate O 0 2.68986144469352e-09
, O 0 8.862442446577745e-10
together O 0 2.107152674568624e-09
, O 0 6.582416833822435e-10
in O 0 1.0083878870803531e-10
a O 0 4.587081825491168e-09
pathway O 0 2.7072756481061333e-08
( O 0 6.063936575095852e-10
s O 0 5.65686013942468e-06
) O 0 2.0234657005513412e-10
associated O 0 7.559588510730464e-09
with O 0 3.542072468665225e-10
the O 0 6.555275072761546e-11
activation O 0 3.4789665592782626e-10
of O 0 9.848933474332355e-11
double O 0 1.1097970400442136e-06
- O 0 2.1555770217673853e-05
strand O 0 1.9848221199936233e-06
break O 0 2.577965574346308e-07
repair O 0 0.0001173153577838093
and O 0 1.3527260200874025e-08
/ O 0 3.302176594388584e-07
or O 0 1.5338533776443342e-09
homologous O 0 2.5274660586660502e-08
recombination O 0 1.7348378378301277e-07
. O 0 5.379000000971246e-08

Dysfunction O 0 0.06803940236568451
of O 0 9.355219710016627e-09
this O 0 1.862953125097988e-09
pathway O 0 1.30449478774608e-07
may O 0 1.4697067562963184e-08
be O 0 4.818160315167574e-10
a O 0 1.6846334049969158e-10
general O 0 1.8644595589645263e-10
phenomenon O 0 2.538689436448749e-08
in O 0 1.0864452393288815e-10
the O 0 5.8038872319254864e-11
majority O 0 3.600144626858537e-10
of O 0 9.309286674863415e-11
cases O 0 1.1860734616675472e-08
of O 0 5.086344678773003e-09
hereditary B-Disease 1 0.9744806289672852
breast I-Disease 1 0.9291390180587769
and I-Disease 0 0.024099959060549736
/ I-Disease 1 0.9999995231628418
or I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999938011169434
. O 0 1.149448092263583e-08
. O 0 6.162890286987022e-08

A O 0 1.4113605857346556e-06
novel O 0 3.120010205748258e-07
Arg362Ser O 0 5.153620350029087e-06
mutation O 0 4.506133421955383e-08
in O 0 2.0515276977217667e-10
the O 0 3.4187644382122073e-10
sterol O 0 3.2253512927127304e-06
27 O 0 7.938221102676835e-08
- O 0 5.413012331700884e-06
hydroxylase O 0 7.167849616962485e-06
gene O 0 4.253581309399124e-08
( O 0 1.1924310427957607e-09
CYP27 O 0 1.441089807485696e-06
) O 0 4.4926642961407026e-10
: O 0 8.163215242662503e-11
its O 0 1.864128851281066e-10
effects O 0 4.8565720334181606e-09
on O 0 6.1523879324454356e-09
pre O 0 6.022551133355591e-07
- O 0 2.5331852171461833e-08
mRNA O 0 1.6047925488482662e-10
splicing O 0 1.1364374996603033e-09
and O 0 2.9977353932508777e-10
enzyme O 0 3.3037559354909263e-09
activity O 0 4.9689674597175326e-08
. O 0 1.2501963908562175e-08

A O 0 5.128959514877351e-07
novel O 0 5.683827453140111e-08
C O 0 1.8265436665387824e-06
to O 0 6.068159863481526e-10
A O 0 2.932106113462396e-09
mutation O 0 2.3700348350530476e-09
in O 0 1.0759732688159218e-10
the O 0 2.3179023977970559e-10
sterol O 0 1.5358031077994383e-06
27 O 0 4.7954550552731234e-08
- O 0 4.070035629410995e-06
hydroxylase O 0 5.7511506383889355e-06
gene O 0 2.139434762682413e-08
( O 0 1.7119590467462587e-10
CYP27 O 0 2.613019489672297e-07
) O 0 1.207545452519554e-10
was O 0 7.129031587282952e-09
identified O 0 1.6219087184410341e-09
by O 0 1.9682882060334528e-11
sequencing O 0 2.250002406611884e-09
amplified O 0 3.5127957431768664e-08
CYP27 O 0 1.2230158574766392e-07
gene O 0 8.75819416989998e-09
products O 0 1.7353823977828142e-07
from O 0 2.5243465651136887e-10
a O 0 1.568647967076231e-08
patient O 0 2.3324837457039393e-06
with O 0 8.478203028516873e-08
cerebrotendinous B-Disease 1 0.9999988079071045
xanthomatosis I-Disease 1 0.9999969005584717
( O 0 9.404404011092993e-08
CTX B-Disease 0 0.00015345349675044417
) O 0 2.0945797984950332e-08
. O 0 4.612263282410822e-08

The O 0 1.666622573281984e-08
mutation O 0 5.9434579924300124e-08
changed O 0 1.9842884668719307e-08
the O 0 4.849026735698203e-10
adrenodoxin O 0 3.2429798579869384e-07
cofactor O 0 2.866234716236704e-08
binding O 0 8.669740481082044e-09
residue O 0 6.760714654774347e-08
362Arg O 0 1.3443184343486791e-07
to O 0 2.1990302911945037e-09
362Ser O 0 4.711784526989504e-07
( O 0 1.1775478370168457e-09
CGT O 0 2.591953034425387e-07
362Arg O 0 4.7857696472419775e-08
to O 0 3.018194305592914e-10
AGT O 0 1.3606032212010177e-07
362Ser O 0 3.00933358232669e-08
) O 0 3.398978876134606e-10
, O 0 1.594419041239803e-10
and O 0 1.0399695549168086e-09
was O 0 4.935755555379728e-07
responsible O 0 2.0351219518488506e-06
for O 0 3.263173198320146e-07
deficiency O 0 4.8219157179119065e-05
in O 0 1.0273179529285414e-10
the O 0 2.6408136788447223e-10
sterol O 0 5.226677899372589e-07
27 O 0 1.982072106443411e-08
- O 0 1.6384765899601916e-07
hydroxylase O 0 3.2252756909656455e-07
activity O 0 1.2446567154711374e-07
, O 0 3.444084947790138e-11
as O 0 3.398426332013038e-11
confirmed O 0 3.252465796688142e-10
by O 0 8.469910536823555e-12
expression O 0 1.4110529411581751e-10
of O 0 2.7974788284479413e-12
mutant O 0 2.2132149446463245e-09
cDNA O 0 3.198996623154926e-09
into O 0 1.0536280736772596e-09
COS O 0 7.252403520396911e-06
- O 0 3.40726899139554e-07
1 O 0 2.2242898634061703e-09
cells O 0 1.520870185345302e-08
. O 0 1.2524017378723329e-08

Quantitative O 0 4.593703692989948e-07
analysis O 0 1.1830870505491475e-07
showed O 0 1.5534859585386585e-06
that O 0 5.047126050428119e-10
the O 0 3.5473849552269954e-11
expression O 0 1.1508339836652226e-09
of O 0 3.823702118821437e-11
CYP27 O 0 1.9138090578962874e-07
gene O 0 1.083618750286064e-09
mRNA O 0 3.5994582314735624e-10
in O 0 7.994185174942103e-11
the O 0 3.197299092150274e-10
patient O 0 5.55855130812688e-08
represented O 0 6.073918257243349e-09
52 O 0 8.193379130716494e-08
. O 0 3.9900207582377334e-08

5 O 0 1.3269800547277555e-07
% O 0 3.9433980525416246e-09
of O 0 2.502381080127236e-10
the O 0 2.182158675978485e-09
normal O 0 7.563702553170515e-08
level O 0 1.2172060337434232e-07
. O 0 3.7591600943187586e-08

As O 0 4.45355077260956e-08
the O 0 5.428808513840977e-10
mutation O 0 5.7713278600601825e-09
occurred O 0 6.918582595716316e-09
at O 0 2.4776951601523933e-09
the O 0 2.0834996922181048e-11
penultimate O 0 5.336608488448746e-09
nucleotide O 0 2.4937485409992632e-09
of O 0 5.449252854505815e-11
exon O 0 5.5080060512580076e-09
6 O 0 2.2264077248479452e-09
( O 0 2.811989530115966e-10
- O 0 2.41774046116916e-07
2 O 0 1.5122523233657148e-09
position O 0 6.455277201666831e-09
of O 0 4.30323866817961e-11
exon O 0 8.930286732322656e-09
6 O 0 1.8557868131097166e-08
- O 0 6.031516022630967e-06
intron O 0 1.1720835573214572e-05
6 O 0 1.1771464691889832e-08
splice O 0 5.476314868246845e-07
site O 0 7.370683192675642e-07
) O 0 4.624033100864011e-11
of O 0 5.07814536948592e-12
the O 0 1.674566908749231e-11
gene O 0 8.987354749301346e-10
, O 0 2.358228612386881e-10
we O 0 6.870816138260238e-10
hypothesized O 0 8.557264896680294e-10
that O 0 2.888739525364059e-10
the O 0 1.2142617467070238e-10
mutation O 0 1.7304996546840812e-08
may O 0 1.046426767459252e-08
partially O 0 1.5613532866609603e-07
affect O 0 1.4587304697499803e-09
the O 0 4.044646909062699e-11
normal O 0 4.345718784826147e-10
splicing O 0 5.782508916141182e-10
efficiency O 0 5.455029761236574e-09
in O 0 1.2708084584645007e-10
exon O 0 1.0171840258976772e-08
6 O 0 6.947465891471438e-08
and O 0 1.0617121404266072e-08
cause O 0 6.293649490451969e-10
alternative O 0 1.8794518719111863e-10
splicing O 0 2.489514372427948e-09
elsewhere O 0 2.9856639827130493e-08
, O 0 7.471309682038907e-11
which O 0 2.586571512530611e-10
resulted O 0 4.0313405391678714e-10
in O 0 1.4428766514917868e-10
decreased O 0 1.1871127725271435e-07
transcript O 0 5.422987570113946e-08
in O 0 7.850191607872148e-10
the O 0 3.778192425585303e-09
patient O 0 1.1940039712499129e-06
. O 0 3.8829295334608105e-08

Transfection O 0 3.4953318390762433e-05
of O 0 9.483151153233393e-09
constructed O 0 9.781697372091003e-07
minigenes O 0 7.084455864969641e-05
, O 0 9.690628743896923e-09
with O 0 6.357727677652747e-10
or O 0 3.4860441644468665e-08
without O 0 3.6754321808274426e-10
the O 0 4.6903512324059093e-11
mutation O 0 1.1366759755659928e-09
, O 0 7.688197301014554e-11
into O 0 1.6626013066289858e-10
COS O 0 9.014962415676564e-05
- O 0 4.304322374082403e-06
1 O 0 1.3182854807780586e-09
cells O 0 1.0280162276998794e-09
confirmed O 0 6.39023944870587e-09
that O 0 5.608553899083546e-11
the O 0 3.112771151947413e-11
mutant O 0 2.60116905792529e-08
minigene O 0 4.949387744090927e-07
was O 0 1.2761624645918346e-07
responsible O 0 2.0329261829488132e-08
for O 0 1.8314237626437802e-10
a O 0 7.314504557598411e-10
mRNA O 0 3.6788899704376377e-10
species O 0 4.407808146256187e-11
alternatively O 0 9.715183102443348e-10
spliced O 0 1.8606074547733442e-07
at O 0 1.1439632174869985e-07
an O 0 2.8570457111243286e-10
activated O 0 4.565890066032807e-08
cryptic O 0 3.89692296209887e-08
5 O 0 3.7196790092508536e-10
splice O 0 1.9844102894239768e-07
site O 0 9.71929352999723e-07
88 O 0 6.4293992352304485e-09
bp O 0 1.943094041223503e-08
upstream O 0 3.6592544550018147e-09
from O 0 1.4205828180458013e-10
the O 0 5.769517155695958e-11
3 O 0 2.8076485580896815e-10
end O 0 1.8273490498543765e-09
of O 0 6.284266163003593e-11
exon O 0 6.255692142076441e-08
6 O 0 6.82463934253974e-08
. O 0 2.4706745094249527e-08

Our O 0 2.2294605628303543e-07
data O 0 2.2256362086636727e-08
suggest O 0 4.5812758031615886e-09
that O 0 7.641808019709373e-11
the O 0 5.146099518738012e-11
C O 0 7.832072412838897e-08
to O 0 2.2336929528243843e-10
A O 0 1.6395536039937042e-09
mutation O 0 2.552958955348572e-09
at O 0 4.009243159686093e-09
the O 0 3.0185381971747915e-11
penultimate O 0 1.9233146186792283e-09
nucleotide O 0 1.1322272008840173e-09
of O 0 1.4508596581086497e-11
exon O 0 2.6855198065334207e-09
6 O 0 8.639592929959861e-10
of O 0 3.4528657710808375e-11
the O 0 1.0546831463731365e-10
CYP27 O 0 1.0117665283360111e-07
gene O 0 1.5352700222237559e-09
not O 0 1.0369113345731762e-09
only O 0 7.447084615641586e-10
causes O 0 1.559519269278553e-08
the O 0 1.6900095545224758e-08
deficiency B-Disease 0 0.00016466662054881454
in I-Disease 0 2.3107513125175672e-10
the I-Disease 0 3.6723418750383985e-10
sterol I-Disease 0 1.9393451111682225e-06
27 I-Disease 0 5.162190319651927e-08
- I-Disease 0 4.1576242892915616e-07
hydroxylase I-Disease 0 2.923709416791098e-07
activity I-Disease 0 2.1201397260028898e-07
, O 0 1.6747019049301315e-10
but O 0 4.747778836744487e-10
also O 0 3.3084979200737052e-09
partially O 0 3.0133199402371247e-07
leads O 0 5.618803200491129e-10
to O 0 6.149941667032977e-11
alternative O 0 1.059644039180796e-09
pre O 0 3.941904083148984e-07
- O 0 1.9267044848447767e-08
mRNA O 0 3.0950889073899646e-10
splicing O 0 4.341145776187716e-10
of O 0 1.5950510010021013e-11
the O 0 2.1005026884513e-10
gene O 0 4.7780716272427526e-08
. O 0 2.2795545007170404e-08

To O 0 1.3017458400099713e-07
our O 0 1.2749710620596488e-08
knowledge O 0 7.251854117207301e-10
, O 0 1.0024699126365277e-10
this O 0 2.6136676156696126e-11
is O 0 8.460054323755628e-10
the O 0 3.1781393489138665e-11
first O 0 7.832842152666331e-10
report O 0 6.192168111596175e-09
regarding O 0 1.3788977737405617e-09
effects O 0 1.7130973972712127e-08
on O 0 4.083675264610065e-08
pre O 0 8.743991202209145e-07
- O 0 2.21748788220566e-08
mRNA O 0 1.309081731903916e-10
splicing O 0 4.100483286251233e-10
of O 0 8.294373000927724e-12
a O 0 1.2794544590466472e-10
mutation O 0 5.933439295446874e-10
at O 0 3.4302161111554597e-09
the O 0 1.7453248568610746e-10
- O 0 5.4847005230840296e-06
2 O 0 9.51346024180566e-09
position O 0 3.027560779855776e-08
of O 0 6.304386873656753e-11
a O 0 2.950940602985952e-09
5 O 0 3.490100430880716e-09
splice O 0 4.556113708531484e-06
site O 0 2.294382284162566e-05
. O 0 6.48243627665579e-08

ATM O 0 0.0002485858276486397
germline O 0 5.615389454760589e-05
mutations O 0 5.561621946981177e-06
in O 0 3.9762923620401125e-08
classical O 0 0.40740928053855896
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 0 0.11577767133712769
in O 0 1.0425121210744237e-08
the O 0 3.9512735305891056e-09
Dutch O 0 4.711160272563575e-06
population O 0 6.706439137360576e-08
. O 0 2.922180897257931e-08

Germline O 0 8.078492828644812e-05
mutations O 0 4.76673494631541e-06
in O 0 6.058876511616518e-09
the O 0 2.9653887678726676e-10
ATM O 0 9.268564440390037e-07
gene O 0 1.578167285742893e-08
are O 0 4.143915210974569e-10
responsible O 0 2.3312992425417178e-08
for O 0 1.0676173722856674e-08
the O 0 0.01549846027046442
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.24092556536197662
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999982118606567
T I-Disease 1 0.9999997615814209
) O 0 4.456252611362288e-08
. O 0 4.180947499321519e-08

In O 0 8.390128414248466e-08
our O 0 9.607590278903899e-09
study O 0 6.690284437560479e-10
, O 0 1.757802930990593e-10
we O 0 7.031969451176678e-10
have O 0 3.1891603941014424e-11
determined O 0 8.456020883507165e-10
the O 0 3.9379898647551315e-11
ATM O 0 6.405227281902626e-08
mutation O 0 1.0557665852672926e-09
spectrum O 0 1.0434033193007508e-08
in O 0 1.6062570162844736e-09
19 O 0 1.3144096477901712e-08
classical O 0 1.2475354651542148e-06
A B-Disease 1 0.9999970197677612
- I-Disease 1 0.999996542930603
T I-Disease 1 1.0
patients O 0 1.3966375718155177e-06
, O 0 3.221269917474956e-10
including O 0 1.6182676032538978e-10
some O 0 1.4981781093492685e-10
immigrant O 0 8.825471020657005e-09
populations O 0 1.4875694009930385e-09
, O 0 1.7575715882678367e-10
as O 0 7.8692152793991e-10
well O 0 3.6883487375405366e-09
as O 0 9.266420963882638e-10
12 O 0 2.3853760633407717e-10
of O 0 3.398413148114621e-11
Dutch O 0 8.968951306087547e-07
ethnic O 0 5.62780488877479e-09
origin O 0 4.57853559510113e-08
. O 0 3.2561501939198934e-08

Both O 0 2.406307508806549e-08
the O 0 5.62191182496008e-10
protein O 0 1.0750794698921595e-09
truncation O 0 9.559336433540011e-08
test O 0 1.6484668208249786e-07
( O 0 1.158519669086644e-10
PTT O 0 7.592347195384264e-09
) O 0 1.916501506105117e-11
and O 0 1.8922596128900793e-11
the O 0 2.9272400475788274e-12
restriction O 0 1.3964456258008795e-09
endonuclease O 0 1.1370825347967184e-07
fingerprinting O 0 6.306898114871728e-08
( O 0 1.815878974964491e-10
REF O 0 1.2031858886984992e-07
) O 0 1.50012190169857e-11
method O 0 1.5889363436105697e-10
were O 0 3.5946762233507457e-10
used O 0 2.907929008699739e-09
and O 0 1.6831567251074375e-09
compared O 0 4.838081046898424e-09
for O 0 7.051911138367117e-11
their O 0 3.46151059205102e-11
detection O 0 1.6039487515939754e-09
efficiency O 0 1.057810394833325e-09
, O 0 6.869236950091118e-12
identifying O 0 3.201998111102e-10
76 O 0 8.121908146030421e-10
% O 0 6.506494648617078e-11
and O 0 1.5288764698695445e-09
60 O 0 1.7744343772108095e-09
% O 0 8.091813330501907e-11
of O 0 5.371558406408461e-11
the O 0 7.586783978830169e-10
mutations O 0 3.1616082196705975e-08
, O 0 1.7156471798784878e-09
respectively O 0 5.838826666604291e-08
. O 0 1.0715674392258734e-07

Most O 0 1.9513880999966204e-07
patients O 0 1.2915269564928167e-07
were O 0 5.4323638920550366e-09
found O 0 2.494990214430004e-09
to O 0 6.810134678403301e-10
be O 0 7.451721018014723e-09
compound O 0 2.7173382477485575e-07
heterozygote O 0 6.865811315037718e-07
. O 0 1.5019278265526737e-08

Seventeen O 0 1.2894056453660596e-06
mutations O 0 9.91356046142755e-07
were O 0 5.1164523284796815e-08
distinct O 0 2.598772308459729e-09
, O 0 4.036102563276245e-10
of O 0 1.9640055207159612e-11
which O 0 7.19665793624813e-09
10 O 0 4.893988547749473e-10
were O 0 1.1728480409090025e-08
not O 0 1.707255314897793e-08
reported O 0 1.4706748743265052e-06
previously O 0 5.043536361881706e-07
. O 0 5.388981350051836e-08

Mutations O 0 9.438963388674892e-06
are O 0 1.5883683701645168e-08
small O 0 1.0083042845110413e-08
deletions O 0 5.774435294370051e-07
or O 0 3.1057538762979675e-06
point O 0 1.6573524135310436e-06
mutations O 0 1.3387176522883237e-06
frequently O 0 2.697879040169937e-07
affecting O 0 1.510276348426487e-07
splice O 0 6.456948176492006e-05
sites O 0 2.8484510039561428e-05
. O 0 1.8697575399073685e-07

Moreover O 0 1.904637429106515e-06
, O 0 9.222204333525497e-09
a O 0 1.0965307772892174e-08
16 O 0 2.7725922890908805e-08
. O 0 4.8592617929443804e-08

7 O 0 1.7304025732300943e-06
- O 0 1.3413320630206726e-05
kb O 0 6.387393568729749e-06
genomic O 0 1.2702285800969548e-07
deletion O 0 1.4131099135283876e-07
of O 0 4.183208501817859e-10
the O 0 4.2861858506881845e-10
3 O 0 8.98689234141159e-10
end O 0 4.474886239336229e-09
of O 0 1.761594689564383e-11
the O 0 1.4980745810522222e-11
gene O 0 1.1075318440134652e-09
, O 0 9.301654585458508e-11
most O 0 6.77736061716061e-11
likely O 0 1.2044315544912365e-09
a O 0 1.4361416222907764e-10
result O 0 5.149142917604266e-11
of O 0 4.037184215405221e-12
recombination O 0 2.127234610682649e-09
between O 0 3.852012486760259e-09
two O 0 3.527955483306755e-09
LINE O 0 2.2647414880339056e-05
elements O 0 4.0481261009972513e-08
, O 0 1.961203643929821e-09
was O 0 7.5116297182376e-08
identified O 0 3.5951188692706637e-07
. O 0 3.957278948973908e-08

The O 0 5.238584677158542e-08
most O 0 2.5890356525337666e-09
frequently O 0 4.02019502132589e-08
found O 0 3.0741691414704064e-09
mutation O 0 5.535325087180354e-09
, O 0 8.146747720871872e-10
identified O 0 9.600375960872043e-08
in O 0 1.2129568460750306e-09
three O 0 9.763560626652179e-09
unrelated O 0 1.1797435490734642e-06
Turkish O 0 2.0828623746638186e-05
A B-Disease 1 0.999994158744812
- I-Disease 1 0.9999902248382568
T I-Disease 1 1.0
individuals O 0 3.689631284942152e-07
, O 0 1.4926463620668073e-08
was O 0 3.4016138670267537e-06
previously O 0 4.503263824062742e-07
described O 0 3.330482627461606e-07
to O 0 5.385382806366579e-09
be O 0 2.507376173355169e-08
a O 0 1.1586887893599851e-08
Turkish O 0 8.505528967361897e-06
A B-Disease 1 0.999991774559021
- I-Disease 1 0.999971866607666
T I-Disease 1 0.9999995231628418
founder O 0 5.924764536757721e-06
mutation O 0 2.956204809834162e-07
. O 0 3.333342135647399e-08

The O 0 8.858831002100942e-09
presence O 0 2.4069962023531843e-08
of O 0 1.176620051390742e-10
a O 0 4.100313422128465e-09
founder O 0 3.505313657115039e-07
mutation O 0 1.1331178662032926e-08
among O 0 3.06308201025729e-10
relatively O 0 1.903029511751697e-09
small O 0 3.0568212405768236e-09
ethnic O 0 3.5127269981671816e-09
population O 0 9.236211240271075e-10
groups O 0 5.122843260707555e-10
in O 0 2.400410148428733e-10
Western O 0 3.295618000720424e-09
Europe O 0 2.7226292331761215e-08
could O 0 6.070825619985953e-09
indicate O 0 4.3170538255310476e-09
a O 0 5.688224891109428e-10
high O 0 5.377335021705676e-09
carrier O 0 4.209350645822951e-09
frequency O 0 4.116463614423083e-09
in O 0 1.7423944231875765e-10
such O 0 8.302500908996535e-10
communities O 0 4.561929856095048e-08
. O 0 4.0910425269657935e-08

In O 0 9.073552575955546e-08
patients O 0 5.9148462128177925e-08
of O 0 1.930333115574001e-10
Dutch O 0 4.586945578921586e-06
ethnic O 0 9.205227691211348e-09
origin O 0 9.194172534421341e-09
, O 0 2.6036492961623026e-09
however O 0 4.84747297857524e-10
, O 0 3.509704749049547e-10
no O 0 1.0362747326908561e-09
significant O 0 4.575056722355697e-10
founder O 0 3.110574198217364e-08
effect O 0 7.379191480083591e-09
could O 0 3.7825852672312976e-08
be O 0 1.335314880890337e-08
identified O 0 2.0808742817735038e-07
. O 0 1.959858586531027e-08

The O 0 2.465199955281605e-08
observed O 0 7.155954051540903e-08
genetic O 0 1.6313162376491164e-08
heterogeneity O 0 5.418996451567182e-08
including O 0 6.703162913623828e-09
the O 0 9.44622824405883e-10
relative O 0 3.7393519392026064e-07
high O 0 2.2491870765861677e-07
percentage O 0 4.6569301304089095e-08
of O 0 9.287760560638958e-10
splice O 0 0.00024274700263049453
- O 0 4.036361860926263e-05
site O 0 0.00022866357176098973
mutations O 0 9.641523774917005e-07
had O 0 5.392528237280203e-07
no O 0 2.5753932320071726e-09
reflection O 0 2.034686197305291e-09
on O 0 8.98249208347579e-09
the O 0 1.6808470171270073e-09
phenotype O 0 1.256368250324158e-06
. O 0 4.9609560903718375e-08

All O 0 3.181534964369348e-07
patients O 0 1.390485380170503e-07
manifested O 0 9.244978826927763e-08
classical O 0 1.1930239907087525e-06
A B-Disease 1 0.9999411106109619
- I-Disease 1 0.99996018409729
T I-Disease 1 0.9999997615814209
and O 0 5.919586598679416e-08
increased O 0 2.263398712898379e-08
cellular O 0 4.891580829280429e-07
radioresistant O 0 8.420474273407308e-07
DNA O 0 6.977344924052886e-08
synthesis O 0 1.2968068574537028e-07
. O 0 1.4499288170100044e-07

Determination O 0 1.1525092986630625e-06
of O 0 1.3923976416307937e-09
the O 0 9.500594061462309e-11
genomic O 0 3.0538898077026033e-09
structure O 0 4.3589640341679114e-08
of O 0 2.9059797970742984e-11
the O 0 1.670541899256861e-10
COL4A4 O 0 3.1060687888384564e-07
gene O 0 8.705232978911681e-09
and O 0 1.3511214369543723e-09
of O 0 8.576791499237402e-10
novel O 0 3.693496182677336e-05
mutations O 0 0.04585789516568184
causing O 0 0.006687507499009371
autosomal B-Disease 1 0.9999898672103882
recessive I-Disease 1 0.9999984502792358
Alport I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999990463256836
. O 0 4.0095343138091266e-05

Autosomal B-Disease 1 0.9999942779541016
recessive I-Disease 1 0.9999994039535522
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.1887388356844895e-05
a O 0 1.323259880336991e-06
progressive O 0 0.009589971974492073
hematuric B-Disease 1 0.9996498823165894
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 0.11221378296613693
by O 0 1.3734986623603618e-06
glomerular B-Disease 1 0.9926602244377136
basement I-Disease 1 0.9843398332595825
membrane I-Disease 0 0.015562375076115131
abnormalities I-Disease 1 0.9996628761291504
and O 0 1.6957514503701532e-07
associated O 0 2.807052794651099e-07
with O 0 7.89635823394974e-09
mutations O 0 1.2495461021444498e-07
in O 0 1.4673056103475801e-09
either O 0 6.099482252608368e-09
the O 0 9.449887539147994e-10
COL4A3 O 0 1.6800433513708413e-05
or O 0 1.910890468082016e-08
the O 0 2.3863133691293115e-10
COL4A4 O 0 1.4144771398605371e-07
gene O 0 1.2689246320363168e-09
, O 0 1.3972602241896226e-10
which O 0 1.0845466885678334e-10
encode O 0 4.693880284456498e-10
the O 0 4.393700681060153e-10
alpha3 O 0 1.6872353398866835e-06
and O 0 5.26219556817864e-09
alpha4 O 0 4.679448920796858e-06
type O 0 2.0746118025272153e-05
IV O 0 8.911945769796148e-06
collagen O 0 6.281437890720554e-06
chains O 0 0.00014347188698593527
, O 0 7.390008605057119e-09
respectively O 0 7.175771798983988e-08
. O 0 4.5945181881279495e-08

To O 0 1.4461678965460578e-08
date O 0 5.5101946117019907e-08
, O 0 2.960466594092992e-10
mutation O 0 2.6598004354561056e-10
screening O 0 3.5462381919870722e-09
in O 0 3.7074748826526616e-10
the O 0 1.7738921442855826e-10
two O 0 1.988605946579014e-10
genes O 0 3.3491642792427e-09
has O 0 5.815664039232615e-08
been O 0 2.8346255120936803e-08
hampered O 0 2.507295562281797e-07
by O 0 3.84605680636696e-10
the O 0 3.090493694291041e-10
lack O 0 3.7848263412243455e-10
of O 0 5.865067112531541e-12
genomic O 0 1.0343558010106335e-08
structure O 0 2.069467086585064e-07
information O 0 7.707354399144606e-08
. O 0 3.708454698880814e-08

We O 0 1.3012657973376918e-06
report O 0 2.8785068550973847e-08
here O 0 2.003882615397856e-09
the O 0 3.017030028584777e-11
complete O 0 2.1743269407181742e-09
characterization O 0 1.2656602166316588e-07
of O 0 1.1962621171424104e-10
the O 0 2.5615617960106363e-10
48 O 0 2.382994468419497e-09
exons O 0 2.020173361927391e-09
of O 0 1.6081477816065615e-10
the O 0 1.0795218052805922e-09
COL4A4 O 0 1.0904218470386695e-06
gene O 0 9.730078964764743e-09
, O 0 2.868025539282115e-10
a O 0 3.2873920252640687e-10
comprehensive O 0 2.58882977277608e-08
gene O 0 2.037654311948245e-08
screen O 0 1.3229193427832797e-05
, O 0 1.8942161617019337e-08
and O 0 4.888934146407564e-09
the O 0 3.613957744175167e-11
subsequent O 0 2.5268800940558833e-10
detection O 0 7.1921983924028154e-09
of O 0 4.44777131791696e-11
10 O 0 3.707276985398522e-10
novel O 0 2.2790533904526455e-09
mutations O 0 2.0506963238631215e-08
in O 0 1.4173601181610707e-09
eight O 0 2.0386657695325994e-07
patients O 0 5.1331458053027745e-06
diagnosed O 0 0.0013197013176977634
with O 0 2.146708720829338e-05
autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 0.9999997615814209
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999991655349731
. O 0 3.9068381738616154e-05

Furthermore O 0 2.1585492504527792e-06
, O 0 3.6738097008992554e-08
we O 0 3.3844769209423475e-09
identified O 0 5.642518896564752e-09
a O 0 1.5347247084296356e-10
glycine O 0 1.3926533704022859e-08
to O 0 2.3623297762398465e-10
alanine O 0 8.50563708354457e-09
substitution O 0 2.605675120115336e-10
in O 0 1.0494177749009737e-10
the O 0 6.814276226618787e-11
collagenous O 0 1.8907604726337013e-07
domain O 0 6.9989622986099675e-09
that O 0 5.749537512755865e-10
is O 0 3.119151603669934e-09
apparently O 0 4.007968357200298e-08
silent O 0 1.4821840466083813e-07
in O 0 1.2557586914763164e-10
the O 0 7.242698801812608e-11
heterozygous O 0 9.176425841417313e-09
carriers O 0 1.5657416474468278e-09
, O 0 2.3045187980130777e-10
in O 0 3.374181489768091e-10
11 O 0 1.0638649072802764e-08
. O 0 3.4417915628637274e-08

5 O 0 8.990328836944173e-08
% O 0 2.290864165033213e-09
of O 0 2.0596002681116943e-10
all O 0 5.837073047132435e-10
control O 0 5.29313751940208e-07
individuals O 0 3.549446070394424e-09
, O 0 4.365626526947608e-09
and O 0 8.45060821319521e-09
in O 0 8.953922048249296e-10
one O 0 4.966302480369222e-09
control O 0 4.4904967921866046e-07
individual O 0 1.0557116292275737e-10
homozygous O 0 2.9341424845341635e-09
for O 0 7.55867313184666e-11
this O 0 2.532510867681026e-10
glycine O 0 6.479827163730079e-08
substitution O 0 2.5525466185172263e-08
. O 0 2.1362582813821973e-08

There O 0 1.670730398473097e-06
has O 0 8.461224609845885e-08
been O 0 1.6913380918026633e-08
no O 0 2.0283159596345968e-09
previous O 0 1.1319378767638e-09
finding O 0 3.813558080434376e-10
of O 0 6.810945904489607e-12
a O 0 1.0539512318441524e-10
glycine O 0 1.4361285494146614e-09
substitution O 0 2.748264948948531e-10
that O 0 2.643217589248792e-10
is O 0 2.669808263355833e-10
not O 0 1.083395109735541e-10
associated O 0 2.4935378761803406e-10
with O 0 7.241289512460725e-11
any O 0 2.9745956808824303e-09
obvious O 0 7.2605068623943225e-09
phenotype O 0 2.3890301292794902e-08
in O 0 5.456671225978482e-10
homozygous O 0 8.250577820945182e-07
individuals O 0 5.538274194805126e-08
. O 0 6.047529410579955e-08

Founder O 0 0.00021873746300116181
BRCA1 O 0 0.00016247050371021032
and O 0 3.9696999465377303e-07
BRCA2 O 0 9.690956176200416e-06
mutations O 0 1.9661078454191738e-07
in O 0 9.802315403817374e-09
French O 0 0.00016029922699090093
Canadian O 0 0.010599082335829735
breast B-Disease 1 0.9999978542327881
and I-Disease 1 0.9999964237213135
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 1.7921429389389232e-06
. O 0 1.571580554582397e-07

We O 0 1.8928348026747699e-06
have O 0 1.2153937412051619e-08
identified O 0 2.030430401589456e-08
four O 0 4.082166202290516e-11
mutations O 0 9.337993711611148e-10
in O 0 5.044447498603333e-11
each O 0 7.181649719356642e-11
of O 0 7.306040217258669e-10
the O 0 5.086182568447839e-07
breast B-Disease 1 0.9829549193382263
cancer I-Disease 0 0.002363072242587805
- O 0 0.012840516865253448
susceptibility O 0 7.930167339509353e-05
genes O 0 6.776826353416254e-07
, O 0 2.66544031291005e-08
BRCA1 O 0 1.9222559330955846e-06
and O 0 7.086627817898261e-08
BRCA2 O 0 1.1848783287859987e-06
, O 0 2.435065926675861e-09
in O 0 2.0259383060050595e-09
French O 0 2.197282447014004e-05
Canadian O 0 0.0001757093850756064
breast B-Disease 1 0.9995126724243164
cancer I-Disease 1 0.703300952911377
and O 0 0.1395488977432251
breast B-Disease 1 0.9999991655349731
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 8.517814649167121e-07
from O 0 1.997423382249508e-08
Quebec O 0 3.7701431665482232e-06
. O 0 4.544378100490576e-07

To O 0 1.5542282483238523e-07
identify O 0 1.2133042446293985e-06
founder O 0 4.2570104596961755e-07
effects O 0 4.329652654178062e-07
, O 0 2.032242818472696e-09
we O 0 3.212472954317036e-09
examined O 0 1.0114289494822515e-07
independently O 0 7.096825811458984e-07
ascertained O 0 8.102208994387183e-06
French O 0 1.912905418066657e-06
Canadian O 0 1.276252760362695e-06
cancer B-Disease 0 3.40368433171534e-06
families O 0 1.90891502604984e-09
for O 0 1.1504405761364467e-10
the O 0 9.76785388684398e-11
distribution O 0 5.611355291534892e-08
of O 0 1.0285884644023469e-10
these O 0 3.938713244444614e-10
eight O 0 2.553489863998948e-09
mutations O 0 5.987251228134483e-08
. O 0 2.2903760665826667e-08

Mutations O 0 4.889533101959387e-06
were O 0 7.721465067334066e-08
found O 0 4.210378712343754e-09
in O 0 1.3416781574626668e-10
41 O 0 8.132262641069588e-10
of O 0 1.3911545526656965e-10
97 O 0 1.80714494035783e-07
families O 0 4.195662484107743e-08
. O 0 5.217116694211654e-08

Six O 0 2.0838571401782247e-07
of O 0 2.141495425433959e-09
eight O 0 2.3074493427088782e-09
mutations O 0 1.8286948622048271e-09
were O 0 3.5007678977905243e-09
observed O 0 2.700792656185058e-08
at O 0 7.71435537672005e-08
least O 0 5.291827420705886e-09
twice O 0 2.8862089607173402e-08
. O 0 2.4229843020862063e-08

The O 0 2.6720124424173264e-07
BRCA1 O 0 9.956623216567095e-06
C4446T O 0 1.829821485443972e-06
mutation O 0 2.738488831255381e-07
was O 0 2.779296437438461e-07
the O 0 6.304558541891936e-10
most O 0 7.264548407270865e-10
common O 0 5.824783433361347e-10
mutation O 0 1.2273110305827117e-09
found O 0 2.3889116462783022e-08
, O 0 4.5964945738496965e-10
followed O 0 7.975655136327475e-10
by O 0 3.0437349862744156e-10
the O 0 4.568274647454018e-09
BRCA2 O 0 4.776350124302553e-06
8765delAG O 0 1.8987034309247974e-06
mutation O 0 5.696263656318479e-07
. O 0 2.1095732449794014e-07

Together O 0 1.0229098279523896e-06
, O 0 6.847610922733338e-09
these O 0 1.5979964573809013e-10
mutations O 0 2.919722241756517e-09
were O 0 9.736390360615133e-09
found O 0 1.002665950267101e-08
in O 0 1.436760849182761e-10
28 O 0 1.1606612337899946e-09
of O 0 1.6999351579172206e-11
41 O 0 7.391023792990836e-09
families O 0 1.4362901978870468e-09
identified O 0 1.7080118652756937e-07
to O 0 3.884772503681688e-09
have O 0 7.116192968226187e-09
a O 0 6.319466283599695e-09
mutation O 0 1.5010306242402294e-07
. O 0 3.7997377688725464e-08

The O 0 6.729567303409567e-08
odds O 0 7.762307063785556e-07
of O 0 1.7705692467728795e-10
detection O 0 1.295184848260078e-08
of O 0 1.1505283531443311e-10
any O 0 1.1418607170909922e-09
of O 0 1.98486574398693e-10
the O 0 6.898352999940016e-10
four O 0 2.4921891217388747e-09
BRCA1 O 0 1.5928955576782755e-07
mutations O 0 1.1841771119236455e-08
was O 0 1.9082723667906976e-07
18 O 0 3.6710847695076154e-08
. O 0 6.200846058845855e-08

7x O 0 0.00035434894380159676
greater O 0 3.1755450891068904e-07
if O 0 4.012442644807379e-08
one O 0 1.3048818692240616e-09
or O 0 2.443640623184251e-09
more O 0 8.197404977039469e-10
cases O 0 1.4856567531751352e-07
of O 0 0.00021821500558871776
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
were O 0 4.717535375675652e-06
also O 0 1.738420252195283e-07
present O 0 6.782125971938058e-09
in O 0 2.031111057121393e-09
the O 0 4.3838253027672636e-09
family O 0 5.185821123632195e-07
. O 0 5.401999914056432e-08

The O 0 2.9742567519974727e-08
odds O 0 2.678789314813912e-07
of O 0 1.4741664833284318e-10
detection O 0 1.372079871941878e-08
of O 0 7.927467016166645e-11
any O 0 1.7578205557811089e-09
of O 0 8.111360194629214e-11
the O 0 1.3904841722478523e-09
four O 0 7.749864749939661e-09
BRCA2 O 0 2.1220654389253468e-07
mutations O 0 1.299316831904207e-08
was O 0 4.668260658036161e-07
5 O 0 3.412989002526956e-08
. O 0 7.182330818977789e-08

3x O 0 2.9388142138486728e-05
greater O 0 2.8828262088609335e-07
if O 0 2.054317604915923e-08
there O 0 2.3192257003756822e-09
were O 0 1.4247378832266122e-09
at O 0 4.17292289611737e-09
least O 0 1.480766065320438e-10
five O 0 1.2639818358639587e-10
cases O 0 6.683397169027216e-10
of O 0 3.0796327710191918e-09
breast B-Disease 0 0.29778966307640076
cancer I-Disease 0 2.8361748263705522e-05
in O 0 3.6754410626116396e-09
the O 0 1.7324447654232245e-08
family O 0 2.5629046831454616e-06
. O 0 2.0429320102266502e-07

Interestingly O 0 7.545373819084489e-07
, O 0 5.3222755092008356e-09
the O 0 7.339977931009045e-11
presence O 0 1.2043166464081878e-09
of O 0 8.348993718598763e-11
a O 0 6.020408704898728e-07
breast B-Disease 0 0.04327396675944328
cancer I-Disease 0 2.519059080441366e-06
case O 0 5.072838593633833e-09
< O 0 1.2264133886219497e-07
36 O 0 3.619079480543519e-09
years O 0 3.1394312149934933e-10
of O 0 7.444184157989753e-11
age O 0 1.1691895451804157e-08
was O 0 7.868112561482121e-08
strongly O 0 2.9876678908635768e-09
predictive O 0 2.4449287039374212e-08
of O 0 5.820849358073588e-11
the O 0 1.4862810981952634e-10
presence O 0 1.973206931182858e-09
of O 0 2.0537582051671777e-11
any O 0 6.659702789235666e-10
of O 0 9.602963563226652e-11
the O 0 2.2963882184701134e-10
eight O 0 2.330253323634679e-09
mutations O 0 2.929983011767945e-08
screened O 0 8.243083016168384e-07
. O 0 1.3700277179395925e-07

Carriers O 0 8.587780939706136e-07
of O 0 1.0931139327041706e-09
the O 0 4.830950639522769e-10
same O 0 1.0103136105499289e-09
mutation O 0 4.80645967471105e-09
, O 0 1.4509599077783264e-10
from O 0 3.1068220912588984e-11
different O 0 1.0382150694709935e-10
families O 0 1.3231479911723909e-08
, O 0 1.0883580703335838e-09
shared O 0 4.345744042399957e-10
similar O 0 6.516645556509104e-10
haplotypes O 0 4.388897067997277e-08
, O 0 7.908985688587222e-10
indicating O 0 2.1527011284661057e-08
that O 0 1.057154364048074e-10
the O 0 2.695009666819903e-11
mutant O 0 3.2010718520325554e-09
alleles O 0 3.3044472713683604e-10
were O 0 2.1054866294889507e-08
likely O 0 2.5618529519988442e-08
to O 0 1.6734765795334283e-09
be O 0 3.495672018516416e-08
identical O 0 1.1004807021208762e-07
by O 0 8.708184728867252e-10
descent O 0 1.1623696991591714e-06
for O 0 2.1632284852302064e-09
a O 0 4.182564516952425e-09
mutation O 0 8.926165584455248e-09
in O 0 4.354812899176608e-10
the O 0 5.374328204688084e-10
founder O 0 2.3635767831819976e-07
population O 0 1.4080002941341263e-08
. O 0 3.4984601882115385e-08

The O 0 1.540803573618632e-08
identification O 0 1.8486012720586587e-08
of O 0 5.539610437033105e-10
common O 0 1.895969745646653e-07
BRCA1 O 0 3.200774153810926e-05
and O 0 1.7097703164381528e-07
BRCA2 O 0 1.8683097096072743e-06
mutations O 0 2.8406928365143358e-08
will O 0 1.2139752536555193e-09
facilitate O 0 1.7559917964149463e-08
carrier O 0 1.7055148759936856e-07
detection O 0 1.1127140453481843e-07
in O 0 3.3187745884788455e-09
French O 0 9.975261491490528e-06
Canadian O 0 3.9260732592083514e-05
breast B-Disease 1 0.9996570348739624
cancer I-Disease 1 0.7041050791740417
and O 0 0.14918650686740875
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 4.713155249191914e-06
. O 0 3.9622946701456385e-07

Are O 0 1.7842135946466442e-07
Dp71 O 0 2.820565532601904e-05
and O 0 9.997712169251827e-08
Dp140 O 0 1.2605695701495279e-05
brain O 0 2.483827529431437e-06
dystrophin O 0 6.059358383936342e-07
isoforms O 0 1.6015651027601052e-08
related O 0 9.588517713154943e-08
to O 0 1.9584495802860147e-08
cognitive B-Disease 0 8.6653781181667e-05
impairment I-Disease 0 0.001282219891436398
in O 0 1.0208350431639701e-06
Duchenne B-Disease 1 0.9999710321426392
muscular I-Disease 1 0.9998399019241333
dystrophy I-Disease 1 0.9997135996818542
? O 0 0.0002493689826223999

Molecular O 0 2.8234508135938086e-06
study O 0 3.845657303713779e-08
and O 0 4.591353519600716e-09
neuropsychological O 0 3.504036953927425e-07
analysis O 0 6.726267542944697e-09
were O 0 7.299065796217974e-09
performed O 0 1.940390426113936e-08
concurrently O 0 1.9284609464875757e-09
on O 0 1.045533366550444e-07
49 O 0 3.766890586121008e-06
patients O 0 5.676930641129729e-07
with O 0 8.479834718855273e-07
Duchenne B-Disease 1 0.9999926090240479
muscular I-Disease 1 0.9998506307601929
dystrophy I-Disease 1 0.9995824694633484
( O 0 1.4540471511281794e-06
DMD B-Disease 1 0.9999996423721313
) O 0 3.905003254089934e-08
in O 0 1.2972038998526614e-09
order O 0 4.536520936682109e-09
to O 0 1.5834942246328865e-09
find O 0 1.0583922183116101e-08
a O 0 7.307280336377175e-10
molecular O 0 4.6794279562334395e-09
explanation O 0 2.1348560697020957e-09
for O 0 2.507220542291577e-10
the O 0 1.123576787165348e-09
cognitive B-Disease 0 2.3719815089862095e-07
impairment I-Disease 0 8.234473369839179e-08
observed O 0 2.049296554673674e-08
in O 0 3.3631128992794856e-09
most O 0 7.387812388515158e-07
DMD B-Disease 1 0.9999994039535522
patients O 0 4.032331617054297e-06
. O 0 9.715709126112415e-08

Complete O 0 1.8126078771274479e-07
analysis O 0 1.899212165312747e-08
of O 0 4.4171524771208226e-10
the O 0 1.8324369799316287e-10
dystrophin O 0 1.2229260448748391e-07
gene O 0 2.752317485033018e-08
was O 0 1.9710623178070819e-07
performed O 0 9.770680264864495e-08
to O 0 1.0236119729611914e-09
define O 0 1.4520550983831981e-08
the O 0 2.8697164089486193e-10
localization O 0 3.62107002160883e-08
of O 0 4.7948443826495435e-11
deletions O 0 1.2676746763418123e-08
and O 0 3.838378503928652e-09
duplications O 0 2.5941778503124624e-08
in O 0 8.981871357782722e-10
relation O 0 4.843947465360543e-08
to O 0 2.137630739085239e-09
the O 0 1.1373547659232486e-09
different O 0 5.4229666091032414e-08
DMD B-Disease 1 0.9999833106994629
promoters O 0 1.6926158423302695e-05
. O 0 1.782660632443367e-07

Qualitative O 0 6.798433673793625e-07
analysis O 0 3.970252393514784e-08
of O 0 7.503946908293813e-10
the O 0 8.641505289119777e-10
Dp71 O 0 4.682323151428136e-07
transcript O 0 6.199580298016372e-07
and O 0 1.4692302485741493e-08
testing O 0 9.803587275314385e-09
for O 0 3.738903631145263e-11
the O 0 1.7989585515687523e-11
specific O 0 1.650673070452413e-10
first O 0 2.1567551911072513e-10
exon O 0 1.2700772655804826e-09
of O 0 1.0905310682263192e-10
Dp140 O 0 4.757456295578777e-08
were O 0 2.1197227084712722e-08
also O 0 7.421635750404221e-09
carried O 0 3.3175930980178236e-07
out O 0 1.469213462002017e-08
. O 0 1.4187455654735004e-08

Neuropsychological O 0 9.217161277774721e-05
analysis O 0 4.810621589967923e-07
assessed O 0 6.4735299929452594e-06
verbal O 0 4.243091825628653e-05
and O 0 1.660553152760258e-07
visuospatial O 0 0.00017843795649241656
intelligence O 0 1.0072798204419087e-06
, O 0 5.4764743850910236e-09
verbal O 0 3.814413389591209e-07
memory O 0 1.1153259038110264e-05
, O 0 5.200194497234634e-09
and O 0 5.551354043120682e-09
reading O 0 1.5778639408381423e-06
skills O 0 4.7188220264615666e-07
. O 0 3.297323658557616e-08

Comparison O 0 4.403227080729266e-07
of O 0 7.225041676051092e-10
molecular O 0 5.561032523360154e-08
and O 0 7.488637265851139e-09
psychometric O 0 3.595056477934122e-05
findings O 0 1.5091353944285402e-08
demonstrated O 0 8.860892464213066e-09
that O 0 1.5403787967382954e-10
deletions O 0 9.449297344588103e-09
and O 0 3.143723281695543e-09
duplications O 0 4.42133760714114e-08
that O 0 3.5250902197248024e-09
were O 0 4.130769948318402e-09
localized O 0 3.325188302483184e-08
in O 0 4.883284332457549e-10
the O 0 1.0421254137416014e-10
distal O 0 5.995433980388043e-07
part O 0 8.195380019060394e-08
of O 0 1.1384024278804361e-10
the O 0 3.604265497170189e-11
gene O 0 1.008169103755563e-09
seemed O 0 2.793830278235987e-09
to O 0 7.203022900359457e-11
be O 0 1.8776673271769795e-10
preferentially O 0 5.648161494065107e-09
associated O 0 7.614826991186874e-09
with O 0 9.352703500553616e-09
cognitive B-Disease 0 1.0402802217868157e-05
impairment I-Disease 0 1.3562180356530007e-05
. O 0 1.0277642559231026e-07

Two O 0 4.1078926926729764e-08
altered O 0 5.858231020283711e-07
Dp71 O 0 3.8539074012078345e-06
transcripts O 0 1.0264473075949354e-06
and O 0 1.4432717243550996e-08
two O 0 3.658764402558745e-10
deleted O 0 4.347248605540699e-08
Dp140 O 0 1.8332674045495878e-08
DNA O 0 2.4878481497125904e-09
sequences O 0 8.109632410047141e-10
were O 0 2.1508448355689325e-09
found O 0 2.015108968578261e-09
in O 0 1.0155894875074623e-10
four O 0 3.668598314021665e-09
patients O 0 3.211292209925887e-08
with O 0 1.1532653587664754e-07
severe O 0 0.005051366053521633
cerebral B-Disease 0 0.23034875094890594
dysfunction I-Disease 0 0.0008959501283243299
. O 0 7.722848067714949e-07

These O 0 1.589668485735274e-08
findings O 0 1.6238587141614858e-09
suggest O 0 2.2259960541504142e-09
that O 0 7.675406143992092e-11
some O 0 2.1749928247327688e-11
sequences O 0 5.597186047978653e-10
located O 0 4.174119112576591e-07
in O 0 1.915870101454331e-10
the O 0 5.990109797071597e-11
distal O 0 1.637089610539988e-07
part O 0 3.31816885079661e-08
of O 0 1.5199116965014525e-10
the O 0 5.300327191037901e-11
gene O 0 2.9659048550456646e-09
and O 0 7.907933863293692e-09
, O 0 3.7974443034549665e-10
in O 0 1.2692823181392754e-10
particular O 0 4.693739175110068e-09
, O 0 4.521074070673592e-10
some O 0 6.76297851054386e-10
DMD B-Disease 1 0.9996756315231323
isoforms O 0 2.872066806602902e-09
expressed O 0 2.2418207290542114e-09
in O 0 6.382501749335745e-10
the O 0 2.8840283494702135e-09
brain O 0 3.924966677004704e-06
may O 0 1.0256567151145646e-08
be O 0 1.055617593337388e-09
related O 0 1.116201797657368e-08
to O 0 1.5629161298491567e-09
the O 0 2.5863473140930182e-08
cognitive B-Disease 0 1.5678017007303424e-05
impairment I-Disease 0 2.551316356402822e-06
associated O 0 3.2572253871876455e-07
with O 0 7.150631518015871e-07
DMD B-Disease 1 0.9999994039535522
. O 0 7.495886222841364e-08
. O 0 1.810398231327781e-07

I1307K O 0 0.0001006882666843012
APC O 0 2.393003524048254e-05
and O 0 6.462141044494274e-08
hMLH1 O 0 8.234879942392581e-07
mutations O 0 8.577307397672485e-08
in O 0 5.11155062721258e-10
a O 0 9.465821015908205e-09
non O 0 1.4105357877269853e-06
- O 0 5.0421982450643554e-05
Jewish O 0 3.239905709051527e-06
family O 0 1.5756565971969394e-06
with O 0 9.902045405851823e-08
hereditary B-Disease 1 0.8474620580673218
non I-Disease 1 0.9691311120986938
- I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999983310699463
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 5.908964794798521e-06

We O 0 2.3298640883240296e-07
describe O 0 6.979661293371464e-08
a O 0 1.1709615499455595e-08
French O 0 2.096103798976401e-06
Canadian O 0 1.6344016557923169e-06
hereditary B-Disease 1 0.9567406177520752
non I-Disease 1 0.9930958151817322
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.53482742968481e-06
HNPCC B-Disease 0 0.01677849516272545
) O 0 4.4758106554354526e-08
kindred O 0 3.6930782698618714e-06
which O 0 1.2633039148113312e-07
carries O 0 6.063756785579244e-08
a O 0 4.5437169582385195e-09
novel O 0 4.367977624042396e-08
truncating O 0 5.496002586369286e-07
mutation O 0 2.6414459952661673e-08
in O 0 5.186584495220359e-09
hMLH1 O 0 4.518803962128004e-06
. O 0 1.0683918105769408e-07

Interestingly O 0 2.8436149932531407e-06
, O 0 2.244585672883659e-08
the O 0 2.2960816581374388e-10
I1307K O 0 8.802074802360949e-08
APC O 0 3.026082850965395e-08
polymorphism O 0 8.422146891007287e-08
, O 0 5.423023141659655e-10
associated O 0 3.6163885219764325e-09
with O 0 8.902425463475083e-10
an O 0 2.78902256845015e-09
increased O 0 2.8199256121297367e-06
risk O 0 0.001147799426689744
of O 0 0.0030824949499219656
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.748395205453562e-07
is O 0 2.676483177310729e-07
also O 0 3.4152026984202166e-08
present O 0 3.7097545035891244e-09
in O 0 4.999011204986914e-10
this O 0 2.164437962193233e-09
family O 0 4.2672044742175785e-07
. O 0 7.101552057520166e-08

The O 0 1.2367016744008197e-08
I1307K O 0 2.9631226539095223e-07
polymorphism O 0 1.7096884903367027e-06
has O 0 8.830931363945638e-08
previously O 0 2.1769883673528057e-08
only O 0 8.053938627128332e-10
been O 0 1.0519198845315714e-08
identified O 0 6.10497821185163e-08
in O 0 2.2094556739737925e-10
individuals O 0 3.926883818117233e-10
of O 0 3.11136616470975e-10
self O 0 0.0004821210168302059
- O 0 0.04890519753098488
reported O 0 0.0012385606532916427
Ashkenazi O 0 1.4631277736043558e-06
Jewish O 0 1.2323882003784092e-07
origins O 0 2.3296418305562838e-07
. O 0 4.635890960003053e-08

In O 0 1.5774752171182627e-08
addition O 0 5.205583519796164e-09
, O 0 4.3489362111515106e-10
in O 0 1.0713452347488328e-10
this O 0 2.5952193172251725e-10
family O 0 9.453140847881514e-08
, O 0 5.495882637873706e-10
there O 0 1.4321349661727822e-09
appears O 0 2.352153138929225e-08
to O 0 1.6832018001622373e-09
be O 0 5.3485230466776557e-08
no O 0 2.919740715867647e-08
relationship O 0 7.74838593287086e-09
between O 0 2.2299213864318546e-10
the O 0 4.402296235883618e-11
I1307K O 0 3.5607157222727892e-09
polymorphism O 0 1.9009190665997266e-08
and O 0 1.984666209153829e-09
the O 0 1.052552975333576e-10
presence O 0 4.762165772831395e-09
or O 0 2.4595863123977324e-09
absence O 0 4.937888431477688e-10
of O 0 3.3453129155702754e-10
cancer B-Disease 0 1.672485865356066e-07
. O 0 1.8045447358616684e-09
. O 0 4.6901622141604093e-08

Identification O 0 2.170327434214414e-06
of O 0 6.550307851682646e-09
a O 0 1.598068166686062e-08
novel O 0 4.800909891855554e-08
mutation O 0 3.7621873616444645e-08
of O 0 1.885203521068135e-10
the O 0 1.1815547429350204e-09
CPO O 0 4.509307018452091e-06
gene O 0 5.905622213475681e-09
in O 0 2.2317084291678668e-10
a O 0 1.9912230087015814e-08
Japanese O 0 7.957896741572767e-06
hereditary B-Disease 0 0.0002433845802443102
coproporphyria I-Disease 0 0.0003444382455199957
family O 0 6.724718332407065e-06
. O 0 2.3275232763353415e-07

Hereditary B-Disease 1 0.9954513907432556
coproporphyria I-Disease 0 0.07228803634643555
( O 0 7.657386618120654e-07
HCP B-Disease 0 0.0012234376044943929
) O 0 2.4334930515124142e-08
is O 0 8.180278143754549e-08
an O 0 8.297395481804415e-08
autosomal B-Disease 1 0.9999626874923706
dominant I-Disease 1 0.9999673366546631
disease I-Disease 1 0.9966291785240173
characterized O 0 4.860117405769415e-05
by O 0 1.8968449921885622e-07
a O 0 3.076697248616256e-05
deficiency B-Disease 0 0.20600572228431702
of I-Disease 0 2.0488577501254213e-09
coproporphyrinogen I-Disease 0 6.85203485772945e-05
oxidase I-Disease 0 8.475189133605454e-06
( O 0 1.4486378763223229e-09
CPO O 0 1.7899474187288433e-05
) O 0 6.007137565156029e-10
caused O 0 2.7913429345716168e-09
by O 0 1.3743703397572915e-10
a O 0 9.001421830134859e-10
mutation O 0 6.593477763772171e-09
in O 0 2.1057053323225716e-10
the O 0 1.0676982631352416e-09
CPO O 0 1.6646228687022813e-05
gene O 0 1.1493784768390469e-07
. O 0 4.520509477856649e-08

Only O 0 1.27872695543374e-07
11 O 0 1.3960628209019887e-08
mutations O 0 1.065548449474818e-08
of O 0 8.994827105368586e-11
the O 0 2.0091707464420239e-10
gene O 0 1.4029873263154968e-08
have O 0 5.415614623416332e-09
been O 0 3.4650827984705757e-08
reported O 0 1.5797987771293265e-06
in O 0 1.149540196365706e-08
HCP B-Disease 0 0.02213764376938343
patients O 0 2.442906179567217e-07
. O 0 4.286664534447482e-08

We O 0 7.14233749476989e-07
report O 0 5.004671344011058e-09
another O 0 6.282447895245014e-10
mutation O 0 1.9324448707891406e-09
in O 0 1.2511064406695027e-10
a O 0 8.00020316660266e-09
Japanese O 0 7.835297992642154e-07
family O 0 1.762897170465294e-07
. O 0 5.29222390355244e-08

Polymerase O 0 2.5813511456362903e-05
chain O 0 0.0001251444045919925
reaction O 0 3.147421239191317e-07
- O 0 5.104268439026782e-07
single O 0 7.0713674915623415e-09
strand O 0 3.9109213645360796e-08
conformational O 0 1.269384597435419e-09
polymorphism O 0 6.56663416975789e-08
and O 0 3.221085342897112e-10
direct O 0 4.5757111988287136e-10
sequence O 0 1.2406512484020027e-09
analyses O 0 4.971457912006372e-09
demonstrated O 0 1.1574203817588113e-09
a O 0 3.440252249742315e-10
C O 0 1.348367462128408e-08
to O 0 6.064870827771074e-11
T O 0 1.0669679362251827e-08
substitution O 0 1.8551469388450315e-11
in O 0 9.896796056285684e-12
exon O 0 7.680550639932449e-10
1 O 0 2.067618021239781e-10
of O 0 2.7109247138779047e-11
the O 0 7.171548077611334e-11
CPO O 0 1.0720825827092995e-07
gene O 0 4.0782924259907816e-10
at O 0 1.920135717092819e-10
nucleotide O 0 4.628747385382326e-10
position O 0 3.947620008659669e-09
85 O 0 1.8248135225107376e-09
, O 0 1.6601803265459125e-10
which O 0 1.1193166393752563e-08
lies O 0 1.0083706001751125e-05
in O 0 5.120986967810381e-10
the O 0 1.490278039861792e-10
putative O 0 6.133957342058238e-09
presequence O 0 4.652686413919582e-08
for O 0 1.2599381260525178e-10
targeting O 0 1.2602518140170105e-08
to O 0 1.8394028522550343e-09
mitochondria O 0 1.0565975117060589e-07
. O 0 6.864063806233389e-08

This O 0 9.875542161807971e-09
mutation O 0 2.601064963414501e-08
changes O 0 5.295155980356014e-10
the O 0 5.693997010003393e-11
codon O 0 1.1491625429016494e-09
for O 0 1.2785708256024542e-11
glutamine O 0 4.263925323932938e-10
to O 0 1.0334516575838393e-10
a O 0 1.6365512278682104e-09
termination O 0 7.720150740908593e-09
codon O 0 1.0305689635004e-08
at O 0 1.9191992439715477e-09
amino O 0 7.490762454764877e-10
acid O 0 8.181144650620809e-10
position O 0 3.4012701544128277e-09
29 O 0 8.918116911615925e-09
. O 0 5.5449729252643465e-09

MaeI O 0 1.3310983376868535e-05
restriction O 0 2.1056558807686088e-07
analysis O 0 2.1293507401765055e-08
showed O 0 1.979420432007828e-07
two O 0 2.044527463995749e-10
other O 0 8.445411037172335e-11
carriers O 0 9.526892608135995e-10
in O 0 1.4599990660890683e-10
the O 0 8.770961734683169e-10
family O 0 3.5465521364130836e-07
. O 0 4.49704913307869e-08

The O 0 3.397751058287213e-08
C O 0 0.00010204342106590047
- O 0 0.0002408767759334296
T O 0 0.0007048867410048842
mutation O 0 1.3924940311937917e-08
is O 0 1.7266709173568984e-09
located O 0 1.3022462042044936e-07
within O 0 3.964709116566212e-10
a O 0 3.4452707353693768e-09
recently O 0 6.833313648257899e-08
proposed O 0 3.5862546265974515e-09
putative O 0 1.24266010814722e-08
alternative O 0 1.8988961514310176e-09
translation O 0 1.840557373178342e-09
initiation O 0 4.990761137690924e-10
codon O 0 1.0614043866041811e-08
( O 0 1.8323496886463175e-10
TIC O 0 9.59030970193453e-08
- O 0 4.4048395153595266e-08
1 O 0 2.0748552875815562e-10
) O 0 2.0108106152383343e-11
, O 0 1.033502363551042e-11
supporting O 0 1.8691488634647868e-10
that O 0 1.1626081347637651e-10
TIC O 0 4.174517300725711e-07
- O 0 3.229455671771575e-07
1 O 0 3.956769356605605e-10
is O 0 2.327915360478272e-10
the O 0 2.0056855482009084e-11
real O 0 1.1063184146564708e-08
TIC O 0 7.87713716476901e-08
rather O 0 2.357315731504883e-10
than O 0 2.129377091319995e-10
TIC O 0 8.012010965785521e-08
- O 0 6.25099332296486e-08
2 O 0 1.3119945130313226e-09
. O 0 6.012009778899596e-10
. O 0 5.366024513620005e-09

Human B-Disease 0 8.807732001514523e-07
complement I-Disease 0 1.684669314272469e-06
factor I-Disease 0 0.00042708817636594176
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999585151672363
associated O 0 0.0020816312171518803
with O 0 0.06521087139844894
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999992847442627
. O 0 6.273799044720363e-06

This O 0 3.4156830697185114e-09
study O 0 2.051900427346709e-09
reports O 0 1.990839493259955e-08
on O 0 1.892186674012919e-08
six O 0 3.809903059703856e-09
cases O 0 9.709111736810883e-09
of O 0 1.2246879954602718e-08
deficiency B-Disease 0 0.005576011259108782
in I-Disease 0 2.690927480841765e-10
the I-Disease 0 1.6727162710505894e-10
human I-Disease 0 1.0752845280848078e-09
complement I-Disease 0 4.920626683890816e-10
regulatory I-Disease 0 1.0421696838847083e-09
protein I-Disease 0 3.6271372572116434e-09
Factor I-Disease 0 2.0126018185351313e-08
H I-Disease 1 0.9999939203262329
( O 0 7.395052903369503e-10
FH O 0 1.428612904419424e-06
) O 0 5.8046064482786264e-11
in O 0 1.3784493511914686e-11
the O 0 1.4326225102057055e-11
context O 0 7.95919663509892e-10
of O 0 4.730116853757238e-10
an O 0 5.68583891435992e-06
acute B-Disease 1 0.9999902248382568
renal I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 3.440542741373065e-06

Five O 0 7.281673930492616e-08
of O 0 3.625849065436171e-10
the O 0 2.395073028793604e-10
cases O 0 5.530014779431269e-10
were O 0 1.6140301317690842e-09
observed O 0 7.603593310534507e-09
in O 0 3.898167899585303e-10
children O 0 1.1830527668621471e-08
presenting O 0 4.121793040212651e-07
with O 0 0.00035769245005212724
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 2.5563051167409867e-05
HUS B-Disease 1 0.9998571872711182
) O 0 1.4254800362323294e-06
. O 0 8.500668400301947e-07

Two O 0 5.747273945644338e-08
of O 0 2.1954387197098413e-09
the O 0 2.910248264598181e-09
children O 0 1.2709580232694861e-07
exhibited O 0 2.959889570774976e-05
a O 0 2.2582946712645935e-06
homozygous O 1 0.9935100674629211
deficiency O 1 0.6623139977455139
characterized O 0 1.1914981996596907e-06
by O 0 2.9902331721842756e-09
the O 0 1.3652396990693205e-09
absence O 0 2.4330835124430905e-09
of O 0 3.319207755869691e-11
the O 0 9.908549675197165e-11
150 O 0 9.047552151919547e-10
- O 0 2.4123368191908412e-08
kD O 0 3.2653669990168055e-08
form O 0 2.2576189528944468e-10
of O 0 6.34016519840408e-11
Factor O 0 2.806634213925463e-08
H O 1 0.9999986886978149
and O 0 3.381013513603648e-08
the O 0 1.5043602474840156e-10
presence O 0 4.82873341312029e-09
, O 0 2.109153129925545e-11
upon O 0 9.286457887391908e-12
immunoblotting O 0 2.0463865268993686e-08
, O 0 6.089966725353335e-11
of O 0 5.6252528676803415e-12
the O 0 1.6314827266938892e-10
42 O 0 4.565470224093815e-09
- O 0 3.295185990737082e-08
kD O 0 2.714173490403482e-07
Factor O 0 5.505141587036633e-08
H O 1 0.9999865293502808
- O 0 9.808601362237823e-07
like O 0 1.018598871915799e-09
protein O 0 3.082075983318333e-10
1 O 0 5.3924281706585475e-11
( O 0 1.2826131649823491e-11
FHL O 0 1.819542028158594e-08
- O 0 3.024974759568977e-08
1 O 0 6.790843581905293e-11
) O 0 8.012377220034672e-12
and O 0 4.161131855751066e-11
other O 0 4.3806111515998225e-11
FH O 0 2.670097819645889e-05
- O 0 5.66591961614904e-06
related O 0 3.19428579587111e-07
protein O 0 2.978183477608809e-09
( O 0 1.2308948305062017e-10
FHR O 0 1.046872384335984e-07
) O 0 1.704042601469169e-10
bands O 0 4.426212729669032e-09
. O 0 6.8218777293793664e-09

Southern O 0 6.020609930601495e-07
blot O 0 4.1009865526575595e-05
and O 0 7.337717544686484e-09
PCR O 0 2.654724795547736e-08
analysis O 0 3.0323774047325003e-10
of O 0 1.274234971010424e-11
DNA O 0 3.5123719488439065e-09
of O 0 7.403714447073995e-11
one O 0 2.0059410132944322e-08
patient O 0 1.8218639752376475e-06
with O 0 4.950964438421579e-08
homozygous O 0 0.08661973476409912
deficiency O 0 0.0880432203412056
ruled O 0 1.7729085755036067e-07
out O 0 2.3327714870902128e-08
the O 0 1.4308974838339594e-10
presence O 0 1.2495974255344322e-09
of O 0 8.422757283299553e-12
a O 0 2.171627877523008e-10
large O 0 1.4480633359070794e-09
deletion O 0 6.056946943999719e-09
of O 0 3.36796424083019e-10
the O 0 9.191538086206208e-10
FH O 0 6.153838057798566e-06
gene O 0 5.3516737708037e-09
as O 0 2.852990288459978e-09
the O 0 8.543240004321717e-10
underlying O 0 1.2377524399198592e-05
defect O 0 8.644249646749813e-06
for O 0 3.140942173018857e-09
the O 0 2.858324705812265e-07
deficiency O 0 0.024892538785934448
. O 0 4.578055268211756e-08

The O 0 2.717586511380432e-08
other O 0 2.799618092907963e-09
four O 0 1.924008063980409e-09
children O 0 2.3462924048089917e-08
presented O 0 3.730731634732365e-08
with O 0 1.2152041506396927e-07
heterozygous O 0 0.4151613712310791
deficiency O 1 0.8346644639968872
and O 0 5.1272277090674834e-08
exhibited O 0 3.6561527849698905e-06
a O 0 1.1220375739640076e-08
normal O 0 5.615423503968486e-08
immunoblotting O 0 1.013230189528258e-06
pattern O 0 2.7299310545458866e-07
of O 0 5.5766273543422784e-11
proteins O 0 1.990241443872165e-10
of O 0 1.9149823393682652e-10
the O 0 8.174035670549529e-09
FH O 0 0.0014513307251036167
family O 0 7.862124107305135e-07
. O 0 8.09109934607477e-08

Factor B-Disease 0 0.14291740953922272
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999483823776245
is O 0 9.919133248104117e-08
the O 0 6.330034274526497e-09
only O 0 4.863573849434033e-06
complement B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999998807907104
associated O 0 4.3208310671616346e-06
with O 0 2.3859979592089076e-07
HUS B-Disease 1 0.9997616410255432
. O 0 8.977851280178584e-07

These O 0 7.429624027111004e-09
observations O 0 3.4854455321919886e-08
suggest O 0 6.985345635257545e-09
a O 0 3.228096956409132e-10
role O 0 7.000694468572988e-10
for O 0 7.66519792083642e-10
FH O 0 0.0001269962958758697
and O 0 1.808301242078869e-08
/ O 0 7.830823960830458e-06
or O 0 1.3286387456901139e-07
FH O 0 5.5503685871372e-05
receptors O 0 3.2727482945915654e-09
in O 0 1.7493542725510736e-10
the O 0 4.747914839065004e-10
pathogenesis O 0 2.0527730271169276e-07
of O 0 2.792956532715607e-09
idiopathic O 1 0.869749128818512
HUS B-Disease 1 0.9994321465492249
. O 0 7.327189877059936e-08
. O 0 1.1829381207917322e-07

Further O 0 5.754052523343489e-08
evidence O 0 1.1874112360032996e-08
for O 0 2.643303076421688e-10
a O 0 2.4113142593762404e-09
major O 0 1.0341960177129295e-08
ancient O 0 1.9392311401134066e-07
mutation O 0 4.79284644825384e-05
underlying O 1 0.5657193660736084
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999996423721313
from O 0 4.8746159109214204e-08
linkage O 0 4.049431663588621e-05
disequilibrium O 0 3.958853085350711e-06
studies O 0 1.3246347352335874e-09
in O 0 8.456919886601355e-11
the O 0 1.6630928578731385e-10
Japanese O 0 1.5066159875232188e-08
population O 0 2.0129693467652032e-09
. O 0 8.606965806734479e-09

The O 0 2.0371575374156237e-05
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 0.9999998807907104
( O 0 3.8630627386737615e-05
DM B-Disease 1 1.0
) O 0 8.975524679044611e-08
mutation O 0 9.637417974772688e-08
is O 0 8.844783572214965e-09
an O 0 2.2254356135675835e-09
unstable O 0 9.258765931008384e-05
( O 0 6.293457421868709e-10
CTG O 0 1.1721668897735071e-06
) O 0 6.041931954747781e-10
n O 0 2.783094430469646e-07
repeat O 0 1.1186425297182723e-07
, O 0 5.811710557246386e-10
present O 0 3.9246672578485686e-10
at O 0 8.482582636304414e-09
a O 0 1.7840647015265887e-10
copy O 0 3.6612391340895556e-08
number O 0 7.571330784550412e-10
of O 0 5.2744295042650435e-11
5 O 0 2.701151746720143e-09
- O 0 6.701684014842613e-06
37 O 0 7.082570974148439e-09
repeats O 0 1.6630375299087063e-08
on O 0 8.871952061895172e-09
normal O 0 1.916298675297412e-09
chromosomes O 0 6.345141079222572e-10
but O 0 8.456500777409559e-11
amplified O 0 8.541903850911581e-10
to O 0 1.428497597988354e-10
50 O 0 6.085186243787177e-10
- O 0 2.900319806542484e-08
3000 O 0 9.61081525474583e-09
copies O 0 2.134535392883663e-08
on O 0 5.472975772136124e-06
DM B-Disease 1 0.9999994039535522
chromosomes O 0 6.5852500483742915e-06
. O 0 2.587019025668269e-07

Previous O 0 2.924908528711967e-07
findings O 0 3.376161217261142e-08
in O 0 1.8514371147304587e-09
Caucasian O 0 9.955465429811738e-07
populations O 0 5.377020428909418e-08
of O 0 1.6944048386591248e-09
a O 0 6.917898645042442e-06
DM B-Disease 1 1.0
founder O 0 9.77751478785649e-05
chromosome O 0 3.4231321478728205e-05
raise O 0 4.82168559301499e-07
a O 0 1.5267964670329093e-08
question O 0 2.1859756671460673e-08
about O 0 1.6734382768390788e-09
the O 0 5.134383196381265e-11
molecular O 0 7.152999859094678e-10
events O 0 5.589493867752537e-10
involved O 0 1.081706613170752e-09
in O 0 8.684941654735212e-11
the O 0 3.859489949853412e-10
expansion O 0 2.2264985943820648e-07
mutation O 0 7.19460217624146e-07
. O 0 4.760951100024613e-08

To O 0 7.801939716500783e-08
investigate O 0 2.348735392843082e-07
whether O 0 8.299402054490201e-09
a O 0 2.1476964651157004e-09
founder O 0 3.975693019242499e-08
chromosome O 0 8.830339197629655e-07
for O 0 3.942646209509348e-09
the O 0 2.7252693257651117e-07
DM B-Disease 1 1.0
mutation O 0 3.213333172880084e-07
exists O 0 6.740381586212152e-09
in O 0 1.0923630056058897e-10
the O 0 9.472710116309457e-11
Japanese O 0 4.175353041091512e-08
population O 0 3.4242986224342076e-10
, O 0 8.341862617333717e-11
we O 0 7.438978877338798e-10
genotyped O 0 2.6246571138699437e-08
families O 0 1.4022367988975049e-10
using O 0 5.917255019305401e-10
polymorphic O 0 2.404826204838173e-07
markers O 0 1.9866816728608683e-05
near O 0 3.209571514162235e-05
the O 0 1.6174539485547257e-09
( O 0 5.635030775330563e-10
CTG O 0 1.7397553619957762e-07
) O 0 3.3948843736197887e-10
n O 0 5.51861319308955e-07
repeat O 0 2.8806002205783443e-07
region O 0 5.002049263680419e-08
and O 0 8.472557766481259e-09
constructed O 0 2.0051618776051328e-05
haplotypes O 0 4.013455964013701e-06
. O 0 6.589129952772055e-08

Six O 0 1.997363057171242e-07
different O 0 1.6885041143055446e-09
haplotypes O 0 9.558880975646389e-08
were O 0 2.706950397168839e-08
found O 0 3.046793395355962e-08
and O 0 1.9438581944086764e-07
DM B-Disease 1 0.9999998807907104
alleles O 0 1.042699508957412e-07
were O 0 1.5531037433902384e-07
always O 0 8.88901254825214e-08
haplotype O 0 1.2798361694876803e-06
A O 0 1.9427648112468887e-07
. O 0 1.0894453339460597e-07

To O 0 9.228348574197298e-08
find O 0 3.945626758650178e-08
an O 0 1.1682542433444354e-10
origin O 0 2.3013650707337518e-10
of O 0 6.844078775936069e-11
the O 0 3.027754158502205e-10
( O 0 2.0162113645305624e-10
CTG O 0 2.6453315626895346e-07
) O 0 1.3938716847405885e-10
n O 0 1.45123337347286e-07
repeat O 0 1.4027089711987628e-08
mutation O 0 1.4514092150363922e-09
and O 0 1.3555897515615811e-09
to O 0 5.727985308290329e-10
investigate O 0 6.750033065827665e-08
the O 0 3.8892852827210334e-10
mechanism O 0 5.4903006585504954e-09
of O 0 7.463116930006564e-12
the O 0 2.060640547085768e-11
expansion O 0 2.092797490860221e-09
mutation O 0 1.2397570747779696e-09
in O 0 1.2392080417367168e-10
the O 0 1.3957685007781606e-10
Japanese O 0 1.7529028895069132e-08
population O 0 1.4083802180042682e-10
we O 0 3.615131527467952e-10
have O 0 3.591405298153383e-11
studied O 0 4.581876544840213e-10
90 O 0 7.852812289321776e-10
Japanese O 0 1.598587147100261e-07
DM B-Disease 1 0.9999996423721313
families O 0 1.8373103927160628e-08
comprising O 0 9.920090304760265e-10
190 O 0 9.92870852201122e-09
affected O 0 1.6283692616525514e-08
and O 0 1.3358696371312817e-09
130 O 0 4.394744124169847e-08
unaffected O 0 1.2447177368812845e-06
members O 0 2.981701774373846e-09
. O 0 1.08264428533289e-08

The O 0 2.394773979119691e-08
results O 0 7.947974722810613e-09
suggest O 0 9.119283994607486e-09
that O 0 4.240931494869926e-10
a O 0 9.351897034548529e-10
few O 0 1.44395928547425e-09
common O 0 1.2268381865965239e-09
ancestral O 0 4.0173861748371564e-07
mutations O 0 3.071978582624979e-08
in O 0 2.075921212707499e-09
both O 0 1.7011858588489304e-09
Caucasian O 0 1.9332519229919853e-07
and O 0 1.8813834046227385e-08
Japanese O 0 2.1242318837266794e-07
populations O 0 2.4598583170387656e-09
have O 0 6.967387777834233e-11
originated O 0 1.285177797516468e-10
by O 0 4.164519857435822e-12
expansion O 0 5.303656958055569e-10
of O 0 1.1567195985773271e-11
an O 0 9.218888846751483e-11
ancestral O 0 3.4999024478565843e-07
n O 0 3.5878003927791724e-06
= O 0 2.2714780811838864e-07
5 O 0 3.8593134243924965e-10
repeat O 0 3.371757983927637e-09
to O 0 5.282526638339391e-10
n O 0 3.895548559285089e-07
= O 0 5.006268111173995e-08
19 O 0 1.6653632917140726e-09
- O 0 5.3580905046146654e-08
37 O 0 2.752672978445503e-09
copies O 0 2.1647858616802296e-08
. O 0 2.7036582750383786e-08

These O 0 2.601030146820449e-08
data O 0 1.7316716949267175e-08
support O 0 6.408508723687589e-10
multistep O 0 5.396325519768652e-08
models O 0 2.440573041440075e-07
of O 0 7.669863633097407e-10
triplet O 0 6.52198741590837e-06
repeat O 0 1.3121832864726457e-07
expansion O 0 7.906564292170515e-08
that O 0 6.818547060305491e-09
have O 0 1.0265603922476885e-09
been O 0 5.865588015296908e-10
proposed O 0 5.798335145357214e-10
for O 0 4.530025243809632e-10
both O 0 1.4984539831175425e-08
DM B-Disease 1 1.0
and O 0 1.8432340311846929e-06
Friedreichs B-Disease 0 0.00048651895485818386
ataxia I-Disease 0 0.48513174057006836
. O 0 4.32063096411639e-08
. O 0 1.252660126738192e-07

The O 0 9.748339024895358e-09
molecular O 0 9.638575448889242e-08
basis O 0 3.8712758509973355e-07
of O 0 7.739437933196314e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.8825061205757265e-09
the O 0 9.565802594480033e-10
western O 0 2.4227208683669232e-08
Cape O 0 3.489267612621916e-07
, O 0 3.947514759516935e-09
South O 0 1.9788460647873762e-08
Africa O 0 1.6867762298033995e-08
. O 0 2.528020637271311e-08

Deficiency B-Disease 1 0.9992480874061584
of I-Disease 0 2.549330524459492e-08
the I-Disease 0 3.1346640838592066e-09
sixth I-Disease 0 7.200038254495666e-08
component I-Disease 0 2.413731863271096e-07
of I-Disease 0 2.726945336206654e-10
human I-Disease 0 8.74889494184572e-09
complement I-Disease 0 1.105805669254778e-08
( O 0 4.2589348714372477e-10
C6 O 0 6.066528612791444e-07
) O 0 6.374070715686742e-10
has O 0 8.046388444427066e-09
been O 0 8.489607239425823e-09
reported O 0 1.1940457511627756e-07
in O 0 3.8439942201540234e-11
a O 0 2.389173581196502e-10
number O 0 4.2879355621749937e-10
of O 0 1.753886966215923e-11
families O 0 1.5068875314216967e-10
from O 0 2.0180879536924046e-11
the O 0 5.992280976974129e-11
western O 0 2.980973912158902e-09
Cape O 0 6.64635919633838e-08
, O 0 2.3752664279896862e-09
South O 0 3.18584554293011e-08
Africa O 0 1.7867192170228918e-08
. O 0 1.1261671595264033e-08

Meningococcal B-Disease 1 0.9999063014984131
disease I-Disease 1 0.9728269577026367
is O 0 8.299674902900733e-08
endemic O 0 1.544547103549121e-07
in O 0 1.1449488024339871e-09
the O 0 3.514668833748402e-10
Cape O 0 1.0826234984051553e-06
and O 0 9.264039313450212e-09
almost O 0 5.054138774163164e-10
all O 0 4.97532362531139e-11
pedigrees O 0 5.279319026385565e-08
of O 0 4.900445382816088e-09
total O 1 0.9019671082496643
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.9763255476590302e-09
C6Q0 O 0 2.3005964067124296e-06
) O 0 7.130033785607282e-10
have O 0 1.6582379913643308e-09
been O 0 6.6792207320531816e-09
ascertained O 0 1.0101565095510523e-07
because O 0 8.355752756372681e-10
of O 0 3.5480651749963954e-09
recurrent O 1 0.703277587890625
disease O 0 0.0037815913092345
. O 0 1.2962578921360546e-07

We O 0 6.383853019542585e-07
have O 0 1.3471920246033164e-09
sequenced O 0 4.427310074106572e-09
the O 0 1.765157325861466e-10
expressed O 0 2.356722317298221e-10
exons O 0 1.7284074171897146e-09
of O 0 5.0772479970317974e-11
the O 0 2.863133896635617e-10
C6 O 0 1.2503817004017037e-07
gene O 0 1.0404337391634044e-09
from O 0 6.121573387085633e-11
selected O 0 1.550348183165795e-09
cases O 0 3.9499319370861485e-09
and O 0 3.7079594505939895e-08
have O 0 1.84866806307582e-08
found O 0 3.6963932359412865e-08
three O 0 6.868601798437624e-10
molecular O 0 2.602189624667517e-06
defects O 1 0.5600156784057617
leading O 0 1.3746790727964253e-07
to O 0 1.0319777032918864e-07
total O 0 2.9322693080757745e-05
deficiency O 0 0.0029616118408739567
879delG O 0 6.207590672602237e-07
, O 0 2.360934781009405e-09
which O 0 7.212763719621762e-09
is O 0 3.6974063810646385e-09
the O 0 3.2394828486381755e-10
common O 0 3.2119476855996254e-08
defect O 0 3.757648073587916e-06
in O 0 3.9598421763820113e-10
the O 0 1.0684011453321318e-09
Cape O 0 8.402897719861357e-07
and O 0 4.1926924154722656e-09
hitherto O 0 3.231352607713234e-08
unreported O 0 7.525537526476e-09
, O 0 4.55825460710102e-10
and O 0 3.747030186129763e-10
1195delC O 0 9.103315790071065e-08
and O 0 2.937334153685356e-09
1936delG O 0 1.1876178973579954e-07
, O 0 1.1021812351685867e-09
which O 0 4.97232122143032e-09
have O 0 1.868846855046513e-09
been O 0 7.159036474746472e-09
previously O 0 1.921295478268803e-08
reported O 0 2.6619989057508064e-07
in O 0 1.838633828521452e-10
African O 0 1.9673067619407902e-09
- O 0 2.6716456886788364e-06
Americans O 0 9.420683788619044e-09
. O 0 1.663992499345568e-08

We O 0 3.0292710562207503e-07
also O 0 2.494181305934262e-09
show O 0 2.334079951538115e-08
that O 0 1.4970241712930488e-10
the O 0 1.0780480674821291e-10
879delG O 0 7.622580824317993e-07
and O 0 6.147300268821709e-08
1195delC O 0 7.994240877451375e-05
defects O 0 0.005663446616381407
are O 0 7.451347316944634e-10
associated O 0 2.9417426716804584e-08
with O 0 6.579507605408708e-09
characteristic O 0 0.0009423273731954396
C6 O 0 0.22514890134334564
/ O 0 0.06345314532518387
C7 O 0 9.522421169094741e-05
region O 0 1.4703508099955798e-07
DNA O 0 2.779274836939294e-07
marker O 0 3.5936182030127384e-06
haplotypes O 0 2.1554438944804133e-07
, O 0 7.145063984914657e-10
although O 0 3.153131644673124e-10
small O 0 2.5249542456862173e-09
variations O 0 3.306846707573641e-08
were O 0 1.634006707718072e-08
observed O 0 8.002801621387334e-08
. O 0 2.2861380344352256e-08

The O 0 9.298297243276465e-08
1936delG O 0 1.60328399942955e-05
defect O 0 3.246125197620131e-05
was O 0 3.554088223722829e-08
observed O 0 2.3078774447071737e-08
only O 0 7.025774961810782e-10
once O 0 1.047493025652102e-08
in O 0 1.3240075702469767e-10
the O 0 2.191308523524782e-10
Cape O 0 1.150843829123005e-07
, O 0 7.327532469680875e-10
but O 0 3.889730482153908e-10
its O 0 2.2404005040055353e-10
associated O 0 3.2281726181082604e-09
haplotype O 0 1.5428230426550726e-07
could O 0 6.505462124550832e-08
be O 0 3.4781055813226658e-09
deduced O 0 4.6561041244785883e-08
. O 0 3.7010138953519345e-08

The O 0 1.2927291237474492e-08
data O 0 5.98207989810362e-08
from O 0 2.6667903996191455e-10
the O 0 1.3575866819603988e-10
haplotypes O 0 7.848552030509381e-08
indicate O 0 5.85378039374973e-08
that O 0 4.4196299398002736e-10
these O 0 5.688691739891283e-10
three O 0 5.941105940543423e-10
molecular O 0 3.7117849842616124e-06
defects O 0 0.14590677618980408
account O 0 8.071093304806709e-08
for O 0 1.2293921436423716e-08
the O 0 1.764101256185313e-07
defects O 1 0.7700837850570679
in O 0 6.67903898854405e-10
all O 0 2.616367400509745e-10
the O 0 2.423088119041239e-10
38 O 0 2.9088387254461168e-09
unrelated O 0 6.390739493156161e-09
C6Q0 O 0 1.4756160453543998e-06
individuals O 0 2.0360761965321217e-09
we O 0 9.318817717485217e-09
have O 0 3.330606068718822e-10
studied O 0 3.5990874169833376e-10
from O 0 8.772178122784524e-11
the O 0 2.1676013761684487e-10
Cape O 0 3.00805993447284e-07
. O 0 2.081675276599526e-08

We O 0 1.1198684433111339e-06
have O 0 3.216004129669159e-09
also O 0 3.1487323859380467e-10
observed O 0 2.2342052652390976e-09
the O 0 9.932656780398119e-11
879delG O 0 2.268426442242344e-06
defect O 0 2.730745563894743e-06
in O 0 8.186232802742666e-10
two O 0 1.6643161515617066e-08
Dutch O 1 0.9334274530410767
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999881982803345
deficient I-Disease 1 0.9999995231628418
kindreds O 0 5.156834231456742e-05
, O 0 5.139904946105389e-09
but O 0 5.50497869511446e-10
the O 0 1.2444661967592197e-10
879delG O 0 8.40231280108128e-07
defect O 0 1.736474473545968e-06
in O 0 2.0459474392442445e-10
the O 0 1.3367049134238584e-10
Cape O 0 7.472289809129506e-08
probably O 0 2.980895885684731e-08
did O 0 9.087937069551799e-10
not O 0 9.25816576180516e-11
come O 0 6.31466476330722e-11
from O 0 1.5147218548894337e-11
The O 0 4.086154678506482e-11
Netherlands O 0 1.2554822070853788e-08
. O 0 1.077238742652753e-09
. O 0 2.0225298769105393e-08

Complement B-Disease 1 0.9986276626586914
C7 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 1.5959579968694015e-07
seven O 0 1.0392085414423491e-08
further O 0 1.1657290244215801e-08
molecular O 0 1.0468465006852057e-05
defects O 1 0.9814654588699341
and O 0 4.438193457190209e-08
their O 0 2.388755415694277e-09
associated O 0 2.3822032346743072e-07
marker O 0 0.00014128023758530617
haplotypes O 0 9.451683581573889e-06
. O 0 1.7791400352962228e-07

Seven O 0 7.097124665733645e-08
further O 0 7.049309580509089e-09
molecular O 0 1.3744732996201492e-07
bases O 0 2.8343852136458736e-06
of O 0 7.737792657280806e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 8.214629332314871e-08
described O 0 3.784985437960131e-06
. O 0 1.378550678055035e-07

All O 0 8.423829633841251e-09
these O 0 9.736628170387007e-10
new O 0 1.6963127569269432e-09
molecular O 0 1.4695464187752805e-06
defects O 0 0.003382493741810322
involve O 0 1.2320470865745392e-08
single O 0 9.553103552661923e-08
- O 0 1.5882250181675772e-06
nucleotide O 0 2.321838366015072e-08
events O 0 3.619058830395261e-09
, O 0 6.780476180523465e-11
deletions O 0 1.2930390091980826e-09
and O 0 7.052869399615247e-10
substitutions O 0 3.7131311358962193e-09
, O 0 1.271885097242631e-10
some O 0 1.4999760114542404e-11
of O 0 5.97224179832434e-12
which O 0 1.7649326444768576e-09
alter O 0 1.1514827491510005e-07
splice O 0 9.817041473070276e-07
sites O 0 3.979703251388855e-06
, O 0 1.2289085304928449e-09
and O 0 1.7260123330586907e-09
others O 0 3.951778460020705e-09
codons O 0 1.2774812319094053e-07
. O 0 2.2046336312087078e-08

They O 0 2.4650876184750814e-07
are O 0 2.5271609249699623e-09
distributed O 0 6.192179657915631e-09
along O 0 2.0667407341079524e-08
the O 0 3.0291347208333264e-10
C7 O 0 1.6914115974486776e-07
gene O 0 3.4748102173409734e-09
, O 0 2.3387614067615914e-10
but O 0 3.41052359964511e-11
predominantly O 0 4.1299623443347144e-11
towards O 0 2.48497306065687e-10
the O 0 1.2301414054061155e-10
3 O 0 2.283491618015887e-09
end O 0 8.516160221461178e-08
. O 0 1.802846050225071e-08

All O 0 7.240679167352937e-08
were O 0 1.8494052511641712e-08
found O 0 1.1473578753751212e-09
in O 0 1.7742778080087618e-10
compound O 0 1.1993434156920557e-07
heterozygous O 0 3.3869719118229114e-07
individuals O 0 1.5194320468481237e-08
. O 0 3.636962730979576e-08

The O 0 4.3550710415729554e-07
C6 O 0 0.015986133366823196
/ O 0 0.0031648417934775352
C7 O 0 0.0014416840858757496
marker O 0 0.00025689249741844833
haplotypes O 0 7.531652499892516e-06
associated O 0 9.953158723874367e-07
with O 0 4.77853632219194e-08
most O 0 3.8243246081037796e-07
C7 B-Disease 1 0.969389021396637
defects I-Disease 1 0.9168215394020081
are O 0 5.077388287588747e-09
tabulated O 0 8.526022838850622e-07
. O 0 1.6630145038831756e-09
. O 0 2.121915265718144e-08

A O 0 4.519105914368993e-06
genome O 0 4.463365712581435e-06
- O 0 1.0308253877155948e-05
wide O 0 2.1118779613971128e-07
search O 0 4.61128664142052e-08
for O 0 1.413332340050033e-09
chromosomal O 0 0.00046751025365665555
loci O 0 2.081077809634735e-06
linked O 0 0.005537527147680521
to O 0 1.5047254464661819e-06
mental O 0 0.008602316491305828
health O 0 1.0557256473475718e-06
wellness O 0 5.8343571254226845e-06
in O 0 3.2992031329115434e-09
relatives O 0 4.369760731037786e-08
at O 0 8.615263880074053e-08
high O 0 2.2920664832781767e-06
risk O 0 5.5133505156845786e-06
for O 0 3.5821685173687e-07
bipolar B-Disease 1 0.9999810457229614
affective I-Disease 1 0.9980170726776123
disorder I-Disease 0 0.46975573897361755
among O 0 4.4630721340865875e-09
the O 0 2.0376142995104374e-09
Old O 0 3.968340479332255e-06
Order O 0 3.066323728262432e-08
Amish O 0 9.2618829512503e-06
. O 0 1.0893767665720588e-07

Bipolar B-Disease 1 0.9999794960021973
affective I-Disease 1 0.999920129776001
disorder I-Disease 1 0.9999196529388428
( O 0 2.304913505213335e-05
BPAD B-Disease 1 0.9999996423721313
; O 0 9.385126759298146e-05
manic B-Disease 1 0.9999884366989136
- I-Disease 1 0.9999991655349731
depressive I-Disease 1 0.9999997615814209
illness I-Disease 1 0.9757943153381348
) O 0 9.62372936896827e-09
is O 0 1.7332048685148038e-08
characterized O 0 3.389039093804058e-08
by O 0 2.152353989481881e-10
episodes O 0 5.498058541775208e-08
of O 0 2.4404176457437643e-09
mania B-Disease 0 0.0037076054140925407
and O 0 3.586263801480527e-07
/ O 0 0.0005890765460208058
or O 0 1.5099363963599899e-06
hypomania B-Disease 0 0.0002914798096753657
interspersed O 0 3.044124014195404e-06
with O 0 1.3246320706983283e-09
periods O 0 3.391172853639546e-08
of O 0 1.7145872499568782e-09
depression B-Disease 0 4.7050853027030826e-06
. O 0 3.051207286830504e-08

Compelling O 0 9.125165547629877e-07
evidence O 0 5.8585271744959755e-08
supports O 0 1.158600824169298e-07
a O 0 1.5533317965221727e-09
significant O 0 1.1814421663203234e-09
genetic O 0 3.457682140606266e-08
component O 0 9.515859034081586e-08
in O 0 3.8193159745958383e-10
the O 0 9.49398670790913e-10
susceptibility O 0 3.589192374420236e-07
to O 0 2.0341362372278127e-08
develop O 0 2.8371592634357512e-05
BPAD B-Disease 1 0.9999948740005493
. O 0 1.249171305062191e-06

To O 0 1.67480891377636e-08
date O 0 1.2602811239048606e-07
, O 0 1.0204345146647142e-09
however O 0 1.9353468827532083e-10
, O 0 5.8083499815397843e-11
linkage O 0 2.974954682599673e-08
studies O 0 5.077211429060924e-10
have O 0 8.443482579778561e-10
attempted O 0 7.463757611958499e-08
only O 0 1.012785078025047e-09
to O 0 9.162132164064474e-10
identify O 0 5.9051522782738175e-08
chromosomal O 0 1.110823177441489e-05
loci O 0 2.930083731200739e-08
that O 0 1.994274967387355e-08
cause O 0 1.5911821193981268e-08
or O 0 5.0836677090160265e-09
increase O 0 4.2509431530390884e-09
the O 0 1.8200686513480946e-09
risk O 0 1.2380354519336834e-07
of O 0 1.8452958050474422e-09
developing O 0 5.884031452296767e-06
BPAD B-Disease 1 0.999983549118042
. O 0 7.273760616044456e-07

To O 0 2.59909604949371e-08
determine O 0 1.4924896873935722e-08
whether O 0 5.923389778672572e-09
there O 0 5.6032023465490965e-09
could O 0 8.370272475133334e-09
be O 0 1.816815253796733e-09
protective O 0 8.173225651830762e-09
alleles O 0 8.190793598927826e-10
that O 0 3.3819197442497284e-10
prevent O 0 2.5239060619242082e-08
or O 0 2.3333678100811994e-08
reduce O 0 4.8486523240853785e-08
the O 0 2.2208856975680646e-09
risk O 0 1.1138968147861306e-07
of O 0 1.2583217801065416e-10
developing O 0 2.0230245922903123e-07
BPAD B-Disease 1 0.9999988079071045
, O 0 2.076848026888456e-09
similar O 0 1.9346861612756783e-10
to O 0 2.6845298206623625e-10
what O 0 3.710226570419195e-10
is O 0 4.1291295382883675e-10
observed O 0 6.2484994955980255e-09
in O 0 8.939928797246921e-10
other O 0 3.8437289617831993e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.3714651575801327e-08
we O 0 5.8629762378359374e-08
used O 0 4.23976098318235e-06
mental O 0 0.00020454436889849603
health O 0 2.176577709178673e-07
wellness O 0 1.1306909073027782e-05
( O 0 5.168371841612895e-10
absence O 0 1.3752888827767151e-09
of O 0 1.952450284781193e-10
any O 0 2.047220050371834e-06
psychiatric B-Disease 1 0.8663988709449768
disorder I-Disease 0 0.0006583278300240636
) O 0 4.394027364185149e-10
as O 0 9.968151859496288e-10
the O 0 2.1730366117633793e-10
phenotype O 0 1.94154225141574e-07
in O 0 1.8329341378020558e-09
our O 0 2.269701759871623e-08
genome O 0 3.9400546825163474e-08
- O 0 9.421546565135941e-07
wide O 0 2.497506272902683e-07
linkage O 0 1.9893343505827943e-06
scan O 0 1.5157092093431856e-05
of O 0 4.5880682586485477e-10
several O 0 6.950507946967832e-10
large O 0 8.252960981280921e-09
multigeneration O 0 4.5946590034873225e-06
Old O 0 5.475228590512415e-07
Order O 0 2.2042963010449057e-09
Amish O 0 2.4505411033715063e-07
pedigrees O 0 3.605354095270741e-07
exhibiting O 0 3.1965163316272083e-07
an O 0 7.099433263491051e-10
extremely O 0 3.321246424548008e-07
high O 0 4.5013916860625613e-07
incidence O 0 8.962881111074239e-05
of O 0 1.0282034423880759e-07
BPAD B-Disease 1 0.9999983310699463
. O 0 1.5615246411471162e-06

We O 0 4.876503680861788e-06
have O 0 9.436042169852499e-09
found O 0 1.1400066446398682e-09
strong O 0 1.080118633423055e-10
evidence O 0 5.46976963722301e-10
for O 0 1.207174638029329e-10
a O 0 1.1428956669945478e-09
locus O 0 1.100520634622626e-07
on O 0 5.034027026340482e-07
chromosome O 0 2.6527752197580412e-05
4p O 0 5.635646448354237e-05
at O 0 4.9016069425533715e-08
D4S2949 O 0 5.6135924353384326e-08
( O 0 3.1252597731956655e-10
maximum O 0 3.7363840910131785e-09
GENEHUNTER O 0 7.73551164456876e-07
- O 0 1.1742519490098857e-07
PLUS O 0 2.5392948188596165e-08
nonparametric O 0 2.607120279662922e-07
linkage O 0 4.4489831907412736e-07
score O 0 1.1243342257216682e-08
= O 0 1.470688193450087e-08
4 O 0 1.7500083326904559e-10
. O 0 3.712249257992184e-11
05 O 0 1.4887331367674506e-09
, O 0 1.187287768100731e-10
P O 0 4.4335195070743794e-07
= O 0 2.302850354851671e-09
5 O 0 3.098188372518962e-11
. O 0 1.4709553020075816e-11
22 O 0 8.858416777890454e-11
x O 0 8.170298571030798e-08
10 O 0 3.394948766555217e-10
( O 0 4.9540552216065237e-11
- O 0 1.3863461845176062e-07
4 O 0 2.1618952461555097e-10
) O 0 1.5397554758989074e-11
; O 0 7.396370842183142e-12
SIBPAL O 0 8.304342102860574e-09
Pempirical O 0 3.865695319404949e-09
value O 0 1.6613975750701115e-09
< O 0 5.3347153361471555e-09
3 O 0 1.5835055489077376e-10
x O 0 1.064242880488564e-07
10 O 0 4.733122782596411e-10
( O 0 6.812235497921648e-11
- O 0 1.271289306714607e-06
5 O 0 9.36160482467585e-10
) O 0 4.441328554927182e-11
) O 0 2.4583501900821148e-11
and O 0 3.0960337071839206e-10
suggestive O 0 6.184534413478104e-07
evidence O 0 1.500976232193807e-09
for O 0 1.2532988535873812e-10
a O 0 1.7202181901154745e-09
locus O 0 6.500451377178251e-08
on O 0 1.024092739498883e-06
chromosome O 0 5.528515248443e-05
4q O 0 0.00010138551442651078
at O 0 7.041438010446655e-08
D4S397 O 0 5.135948555334835e-08
( O 0 3.215162303060737e-10
maximum O 0 1.3633434825521817e-08
GENEHUNTER O 0 7.73334306813922e-07
- O 0 2.2021924905857304e-07
PLUS O 0 1.9779593074531476e-08
nonparametric O 0 2.0817437018649798e-07
linkage O 0 2.3385835845601832e-07
score O 0 4.125321861891962e-09
= O 0 4.620757998452518e-09
3 O 0 1.0229381924853342e-10
. O 0 1.4470264396437837e-11
29 O 0 1.8888962616259164e-10
, O 0 2.4366153192345585e-11
P O 0 1.1983121339653735e-07
= O 0 1.9485673075081422e-09
2 O 0 4.931824393317186e-11
. O 0 1.250170713479326e-11
57 O 0 1.9249504767948622e-10
x O 0 7.28732914012653e-08
10 O 0 5.544875114615877e-10
( O 0 1.0942982631156895e-10
- O 0 2.4979087243082176e-07
3 O 0 3.733817421913699e-10
) O 0 1.2687394537747032e-11
; O 0 1.4749222676524454e-11
SIBPAL O 0 1.8551354230567085e-08
Pempirical O 0 1.046077446886784e-08
value O 0 9.266667988505617e-10
< O 0 1.4781123880425184e-08
1 O 0 1.5956329313393525e-10
x O 0 6.547562065861712e-07
10 O 0 3.0032423214976234e-09
( O 0 1.2234679935829718e-10
- O 0 8.365086614503525e-07
3 O 0 4.361080108150617e-10
) O 0 1.0939033533163833e-11
) O 0 2.5312672964628025e-12
that O 0 2.7590672802002558e-11
are O 0 1.7909994320941536e-10
linked O 0 1.146498561865883e-06
to O 0 2.7451559247992918e-08
mental O 0 0.00019726043683476746
health O 0 4.926952215100755e-07
wellness O 0 1.2483847967814654e-05
. O 0 8.98626524303836e-08

These O 0 3.02967499976603e-08
findings O 0 1.591631360042811e-08
are O 0 1.14264508965789e-09
consistent O 0 5.871358510489699e-08
with O 0 5.180323947584498e-10
the O 0 9.518223709203966e-11
hypothesis O 0 2.3924227932070607e-08
that O 0 1.7026456633484344e-10
certain O 0 8.268519896548199e-11
alleles O 0 1.1804870414522384e-09
could O 0 7.966612258769601e-09
prevent O 0 2.92847470717561e-08
or O 0 2.6076218517800953e-08
modify O 0 4.903304215986282e-07
the O 0 3.1124240962299154e-09
clinical O 0 1.6894318832783028e-07
manifestations O 0 4.4151352796006904e-08
of O 0 2.0589572269358314e-09
BPAD B-Disease 1 0.9999997615814209
and O 0 5.7735107361622795e-08
perhaps O 0 1.4386974944713415e-09
other O 0 1.1066195737541307e-09
related O 0 4.674000956583768e-05
affective B-Disease 1 0.9880196452140808
disorders I-Disease 1 0.7682517766952515
. O 0 5.171365842215891e-07

Segregation O 0 0.0003196530742570758
distortion O 0 0.01873805560171604
in O 0 3.171502612531185e-05
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999994039535522
. O 0 3.493102849461138e-05

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.00019136631453875452
DM B-Disease 1 1.0
) O 0 3.360546827479993e-07
is O 0 2.5205486053891946e-07
an O 0 1.7942905827794675e-08
autosomal B-Disease 1 0.9994237422943115
dominant I-Disease 1 0.9997701048851013
disease I-Disease 1 0.9653080701828003
which O 0 2.214803089373163e-06
, O 0 1.744061961517218e-08
in O 0 1.1463909821429752e-09
the O 0 3.0539815121244374e-10
typical O 0 1.595081471350568e-07
pedigree O 0 3.798890020334511e-06
, O 0 2.6858512636174225e-10
shows O 0 5.211653331116395e-09
a O 0 1.259222726091025e-09
three O 0 4.5485359922992075e-10
generation O 0 5.407243985899868e-09
anticipation O 0 7.905611276726177e-09
cascade O 0 1.1251599971728865e-06
. O 0 4.838674527718467e-08

This O 0 7.853310890482135e-09
results O 0 5.137535552535155e-08
in O 0 4.0997054640001807e-08
infertility B-Disease 1 0.9986379742622375
and O 1 0.7188172340393066
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 5.015400574848172e-07
CDM B-Disease 0 1.5069476830831263e-05
) O 0 9.714200555066554e-10
with O 0 1.7713157329790619e-10
the O 0 1.7958773357307223e-10
disappearance O 0 1.126271698126402e-07
of O 0 2.270856613861838e-09
DM B-Disease 1 1.0
in O 0 9.982296944599511e-08
that O 0 4.493722727261229e-08
pedigree O 0 1.1103486031061038e-05
. O 0 2.9102665166647057e-08

The O 0 9.474074857962478e-09
concept O 0 1.158070173090664e-08
of O 0 2.4904012185800184e-10
segregation O 0 7.088885212169771e-08
distortion O 0 4.1961375245591626e-06
, O 0 1.7528654083776019e-09
where O 0 9.799132616450379e-10
there O 0 3.850152419104802e-10
is O 0 9.426066177598003e-11
preferential O 0 2.3527531034517324e-09
transmission O 0 1.228637074746075e-06
of O 0 3.564116363152792e-11
the O 0 4.466559413995874e-11
larger O 0 5.990752338647098e-10
allele O 0 8.31534219258856e-09
at O 0 4.271337061823033e-08
the O 0 6.383356954131614e-09
DM B-Disease 1 0.9999996423721313
locus O 0 5.953884851805924e-07
, O 0 4.0453475236290615e-08
has O 0 2.660858555714185e-08
been O 0 1.874806443424859e-08
put O 0 1.815451433628823e-08
forward O 0 3.5484981619759992e-09
to O 0 1.7246203354304157e-09
explain O 0 2.818108235658201e-08
partially O 0 1.0888552992582845e-07
the O 0 1.2322173836842865e-10
maintenance O 0 4.875099648415926e-07
of O 0 1.864392862316322e-09
DM B-Disease 1 0.9999998807907104
in O 0 8.9695486593655e-09
the O 0 2.7532927049378486e-09
population O 0 2.2343854766404547e-08
. O 0 1.9271197970738285e-08

In O 0 1.492338874697907e-08
a O 0 7.472685581433325e-09
survey O 0 9.914931524690473e-07
of O 0 4.885522209008286e-09
DM B-Disease 1 1.0
in O 0 5.7720356494428415e-08
Northern O 0 3.005035011938162e-07
Ireland O 0 1.688824511347775e-07
, O 0 1.1410486999707814e-09
59 O 0 7.204926433246328e-09
pedigrees O 0 3.8681909586557595e-07
were O 0 1.1707675895422653e-07
ascertained O 0 1.5630399730071076e-06
. O 0 3.2531641380728615e-08

Sibships O 0 6.217903137439862e-05
where O 0 1.4136679737930535e-07
the O 0 1.0170322362057505e-09
status O 0 3.5839091694356284e-09
of O 0 1.3545189969654814e-10
all O 0 5.412132408899595e-10
the O 0 9.533231148939336e-11
members O 0 7.829193543473778e-11
had O 0 3.000049630941248e-08
been O 0 1.5621212767769066e-08
identified O 0 3.0826960539798165e-08
were O 0 3.1829896496304855e-09
examined O 0 3.225958522534711e-08
to O 0 3.9247047278756497e-10
determine O 0 5.566006322510475e-09
the O 0 7.078326813569902e-10
transmission O 0 3.722575456777122e-06
of O 0 3.636334566792243e-10
the O 0 3.408199278354118e-09
DM B-Disease 1 0.9999991655349731
expansion O 0 2.525914908346749e-07
from O 0 2.820370603728861e-09
affected O 0 2.4599440706651876e-08
parents O 0 1.6099807043090664e-09
to O 0 8.07784616974061e-10
their O 0 3.1953255597017005e-09
offspring O 0 3.0756785918129026e-07
. O 0 3.207870236110466e-08

Where O 0 2.165236594464659e-07
the O 0 3.814935034540667e-09
transmitting O 0 0.00031468868837691844
parent O 0 1.7564057088748086e-06
was O 0 1.0343183021177538e-06
male O 0 1.483482208186615e-07
, O 0 3.0236928516558237e-09
58 O 0 3.1389973287332396e-08
. O 0 4.06868565505647e-08

3 O 0 2.203081095331072e-07
% O 0 2.171794744043609e-09
of O 0 1.5217768711828228e-10
the O 0 5.695867666410948e-10
offspring O 0 4.985504986620981e-08
were O 0 1.1070997629758494e-07
affected O 0 6.979394839845554e-08
, O 0 1.4772548739827585e-09
and O 0 6.422890219681676e-09
in O 0 5.183832252342313e-10
the O 0 4.405263653861624e-10
case O 0 5.515575551839902e-09
of O 0 4.491187977073707e-11
a O 0 5.524356083697057e-09
female O 0 2.90258874713345e-08
transmitting O 0 2.043188942479901e-05
parent O 0 9.325275129867805e-08
, O 0 1.9702506293128863e-09
68 O 0 5.0638799820035274e-08
. O 0 6.155019605103007e-08

7 O 0 1.1778269026763155e-06
% O 0 3.4634570766911565e-08
were O 0 5.88477853114e-08
affected O 0 3.8746924246879644e-07
. O 0 4.964846311850124e-08

Studies O 0 1.0054201737830226e-07
on O 0 1.3428110179347641e-08
meiotic O 0 2.3301004148379434e-06
drive O 0 1.934958345373161e-05
in O 0 3.3581851965891474e-08
DM B-Disease 1 0.9999998807907104
have O 0 5.8443756500992095e-08
shown O 0 1.501864765884875e-08
increased O 0 1.635028556989937e-09
transmission O 0 1.0163403203478083e-06
of O 0 4.923309329663006e-11
the O 0 4.227095409814474e-11
larger O 0 1.1413381351133012e-09
allele O 0 8.928481065595406e-09
at O 0 3.3024846857188095e-08
the O 0 7.937446255823488e-09
DM B-Disease 1 0.9999986886978149
locus O 0 7.407460884678585e-07
in O 0 1.8883289598647934e-08
non O 0 2.7622629659163067e-06
- O 0 0.06605417281389236
DM O 1 0.9999992847442627
heterozygotes O 0 8.60574800753966e-06
for O 0 1.5616981485777615e-08
CTGn O 0 1.989948759728577e-05
. O 0 7.026840620483199e-08

This O 0 5.2519379956095236e-09
study O 0 1.6200011332401232e-09
provides O 0 7.772820165286021e-10
further O 0 1.195383930729932e-10
evidence O 0 5.517171719482405e-10
that O 0 3.248820101831029e-10
the O 0 1.7475275670975066e-09
DM B-Disease 1 0.9999996423721313
expansion O 0 1.4554967719959677e-07
tends O 0 1.4490454702809075e-07
to O 0 6.884735004319964e-10
be O 0 4.049282686935385e-09
transmitted O 0 7.50556409911951e-07
preferentially O 0 1.2145476375735598e-06
. O 0 1.0236909986360843e-07

Diagnosis O 0 0.021625539287924767
of O 0 1.7289377183260513e-06
hemochromatosis B-Disease 1 0.9999982118606567
. O 0 1.3608952940558083e-05

If O 0 1.2089442861906718e-05
untreated O 0 0.0013715415261685848
, O 0 2.6604911909089424e-06
hemochromatosis B-Disease 1 1.0
can O 0 0.014294861815869808
cause O 0 8.210490341298282e-05
serious O 0 0.0008856782806105912
illness O 0 8.532989158993587e-05
and O 0 1.2819548089737509e-08
early B-Disease 0 1.1296590685105912e-07
death I-Disease 0 6.518653208331671e-07
, O 0 9.078638285586749e-09
but O 0 6.458725554381317e-09
the O 0 4.255867214197906e-09
disease O 0 9.770313909029937e-07
is O 0 1.2022579598536254e-09
still O 0 1.5327517033369986e-08
substantially O 0 7.75619639625802e-08
under O 0 8.283621610871705e-08
- O 1 0.7455887198448181
diagnosed O 0 0.0014798484044149518
. O 0 1.595525702668965e-07

The O 0 2.4884187155294057e-08
cornerstone O 0 3.4117985592274636e-07
of O 0 1.0140429468341594e-10
screening O 0 8.13235967456194e-09
and O 0 1.1462292226482873e-09
case O 0 6.190452594978524e-10
detection O 0 2.3131117021790715e-09
is O 0 2.4072552284870596e-10
the O 0 2.634624116093498e-11
measurement O 0 1.6307912176216632e-07
of O 0 2.4310181645503803e-10
serum O 0 1.2649978486933833e-07
transferrin O 0 1.949356231989441e-08
saturation O 0 7.860102613221898e-08
and O 0 8.039347854094103e-09
the O 0 5.359161114881772e-09
serum O 0 3.1261447475117166e-06
ferritin O 0 1.5263736713677645e-05
level O 0 2.2589527759464545e-07
. O 0 2.3512157554250734e-08

Once O 0 2.077187446047901e-06
the O 0 2.0743933237810097e-09
diagnosis O 0 9.800253792491276e-06
is O 0 1.404245519864844e-08
suspected O 0 2.7940539439441636e-05
, O 0 9.202308914879609e-10
physicians O 0 9.000237777279096e-10
must O 0 6.638920080348498e-09
use O 0 2.6372777739425146e-08
serum O 0 1.0943945198960137e-05
ferritin O 0 0.00015720944793429226
levels O 0 1.4644791690443526e-06
and O 0 8.635186787842031e-08
hepatic O 0 4.401503611006774e-05
iron O 0 1.936023181769997e-05
stores O 0 6.4599316829117015e-06
on O 0 2.6438185614097165e-06
liver O 0 3.5464950087771285e-06
biopsy O 0 3.177246071572881e-06
specimens O 0 1.3176350677213122e-08
to O 0 2.4441908497152554e-09
assess O 0 2.8340527933323756e-06
patients O 0 1.025054352510324e-08
for O 0 9.275947371323312e-11
the O 0 2.3766702494931735e-10
presence O 0 2.751719208049508e-08
of O 0 7.694982429029551e-09
iron B-Disease 0 0.011230229400098324
overload I-Disease 0 8.147222979459912e-05
. O 0 1.1789074250145859e-07

Liver O 0 0.02432110719382763
biopsy O 0 0.3983440399169922
is O 0 2.1982917530749546e-07
also O 0 4.282298515789762e-09
used O 0 2.7361530818836854e-09
to O 0 7.455953632273804e-10
establish O 0 1.0139879158543863e-08
the O 0 2.437020585333016e-10
presence O 0 2.3144499650129546e-08
or O 0 3.272063153758609e-08
absence O 0 1.3980073765296197e-09
of O 0 5.25940346829401e-10
cirrhosis B-Disease 0 3.250458803449874e-06
, O 0 3.155429806334098e-10
which O 0 6.939252283899577e-09
can O 0 1.5724465285416045e-08
affect O 0 6.678127562054215e-08
prognosis O 0 3.3854842058644863e-06
and O 0 1.2475094735009407e-08
management O 0 1.9243049109718413e-07
. O 0 2.2424888612704308e-08

A O 0 5.834507419422152e-07
DNA O 0 2.6627429861036944e-07
- O 0 3.708865676799178e-07
based O 0 9.45135170127287e-09
test O 0 1.2615409161753632e-08
for O 0 3.070702719876195e-11
the O 0 3.8836274474096655e-11
HFE O 0 1.2040099761634337e-07
gene O 0 1.4089397426531036e-09
is O 0 2.8597499368565593e-10
commercially O 0 9.396134537098533e-09
available O 0 3.337972120931454e-09
, O 0 3.7440439637492773e-10
but O 0 3.4545866167690065e-10
its O 0 1.1663328636224435e-10
place O 0 8.208501434125992e-09
in O 0 9.219591756703949e-11
the O 0 5.964325144880434e-10
diagnosis O 0 2.489424105078797e-06
of O 0 3.9192533662912865e-09
hemochromatosis B-Disease 1 0.9999998807907104
is O 0 1.0507326351216761e-06
still O 0 1.5196761182778573e-07
being O 0 3.096574374694683e-08
evaluated O 0 3.4668684634198144e-07
. O 0 4.606680192864587e-08

Currently O 0 4.125440682400949e-06
, O 0 1.463736776230462e-08
the O 0 1.6941681391102748e-10
most O 0 5.3888192519391254e-11
useful O 0 1.628380874585389e-09
role O 0 2.7974600413926964e-10
for O 0 5.287211293780736e-11
this O 0 1.0711286024811528e-10
test O 0 2.984263502980866e-08
is O 0 2.929589071332117e-10
in O 0 6.845080492007272e-12
the O 0 1.2930032912417122e-11
detection O 0 5.4414894812282455e-09
of O 0 8.945812979277434e-10
hemochromatosis B-Disease 1 1.0
in O 0 1.2056801779181114e-08
the O 0 2.4507449403188275e-09
family O 0 8.289217134915816e-08
members O 0 6.263062291012034e-11
of O 0 1.7909755622991241e-10
patients O 0 1.3108669705275133e-08
with O 0 3.235215983998785e-10
a O 0 6.090149895499053e-08
proven O 0 4.073472155141644e-05
case O 0 1.3825379951981631e-08
of O 0 1.618974676542706e-10
the O 0 5.971580918640029e-08
disease O 0 3.233226379961707e-05
. O 0 2.8082727254741258e-08

It O 0 4.358473404408869e-08
is O 0 2.6375983619431054e-09
crucial O 0 3.3567573609616375e-08
to O 0 1.1325500537395783e-07
diagnose O 1 0.9999741315841675
hemochromatosis B-Disease 1 1.0
before O 0 0.4289571940898895
hepatic B-Disease 1 0.9999880790710449
cirrhosis I-Disease 1 0.9989485144615173
develops O 0 0.00040602852823212743
because O 0 7.800258572387975e-08
phlebotomy O 0 0.0004180866526439786
therapy O 0 3.0663690267829224e-05
can O 0 2.3758489078318235e-06
avert O 0 0.00400127936154604
serious O 1 0.9580909013748169
chronic O 1 0.9999973773956299
disease O 1 0.7856661081314087
and O 0 1.814742205397124e-07
can O 0 5.096271706861444e-07
even O 0 2.0227268748840288e-08
lead O 0 3.4131952819649314e-09
to O 0 1.0188320187509703e-09
normal O 0 6.090556325943908e-08
life O 0 5.589094342894896e-08
expectancy O 0 1.8802252554905863e-07
. O 0 7.289907566487841e-10
. O 0 1.3735881765342128e-08

Prevalence O 0 0.004015911836177111
of O 0 8.406815688033475e-09
the O 0 3.5258298503038077e-09
I1307K O 0 1.0172383326789713e-06
APC B-Disease 0 9.542068113432833e-08
gene O 0 3.4035366525131394e-08
variant O 0 2.681810826743458e-07
in O 0 1.6637949906694871e-09
Israeli O 0 9.903950513034943e-07
Jews O 0 6.855504164349213e-09
of O 0 8.921629407465659e-11
differing O 0 1.967606966246649e-09
ethnic O 0 6.514312644867459e-09
origin O 0 3.304192475184209e-08
and O 0 3.531795584876818e-07
risk O 0 1.1176790394529235e-05
for O 0 9.553790732752532e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 2.388266011621454e-06

BACKGROUND O 0 9.340956603409722e-05
& O 0 1.6220203178818338e-05
AIMS O 0 2.1789526272186777e-06
Israeli O 0 6.685773996650823e-07
Jews O 0 5.092945620788214e-09
of O 0 1.4846292251124993e-10
European O 0 2.862354575583481e-09
birth O 0 6.493944937346896e-08
, O 0 1.2791502301823243e-09
i O 0 6.217366887995013e-08
. O 0 5.145333811795716e-11
e O 0 8.22894374863381e-09
. O 0 1.0321081489461648e-10
, O 0 1.5061892011392075e-10
Ashkenazim O 0 2.1944391193073898e-08
, O 0 4.820457921717036e-10
have O 0 2.4532951670153125e-08
the O 0 8.319899080788673e-08
highest O 1 0.9998680353164673
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0027585835196077824
of O 0 9.719316462764027e-10
any O 0 4.453312385521713e-08
Israeli O 0 1.7192753148265183e-05
ethnic O 0 1.0853263177068584e-07
group O 0 3.923485678569705e-07
. O 0 2.215251626580539e-08

The O 0 7.199626139708926e-08
I1307K O 0 1.8042895817416138e-06
APC B-Disease 0 4.6869067205079773e-07
gene O 0 9.812757895133473e-08
variant O 0 1.3988650380269974e-06
was O 0 1.3791294577458757e-06
found O 0 2.7830989068888812e-08
in O 0 1.022105844405985e-09
6 O 0 3.5420757882320686e-08
. O 0 3.154969974161759e-08

1 O 0 1.0191477883836342e-07
% O 0 1.2921910208518739e-09
of O 0 4.3992493675704125e-11
American O 0 3.4832356443637025e-10
Jews O 0 2.970473644836602e-09
, O 0 4.338563397432438e-10
28 O 0 7.082797681690067e-10
% O 0 7.263117884903636e-11
of O 0 7.346214192516243e-10
their O 0 0.00448732590302825
familial O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.0399518941994756e-05
, O 0 1.7479951708310182e-08
but O 0 6.0899614240383926e-09
not O 0 1.7488612780169888e-09
in O 0 1.1314667258677247e-10
non O 0 7.611722452338654e-08
- O 0 1.8942086171591654e-05
Jews O 0 2.57422613003655e-07
. O 0 3.9629668435736676e-08

We O 0 2.996332852944761e-07
assessed O 0 3.5327252589922864e-07
the O 0 1.480097822081916e-09
I1307K O 0 1.15893828933622e-06
prevalence O 0 8.989041816676036e-06
in O 0 1.0536260752758153e-09
Israeli O 0 7.759539357721223e-07
Jews O 0 2.33103558677783e-09
of O 0 2.929202019830157e-11
differing O 0 4.204253611916897e-10
ethnic O 0 3.153097338781663e-09
origin O 0 1.9670187256792815e-08
and O 0 1.0260112048854353e-07
risk O 0 8.533672371413559e-06
for O 0 2.5966861358028837e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 1.540256221232994e-06

METHODS O 0 1.4445752185565652e-06
DNA O 0 2.716721780871012e-07
samples O 0 2.153123901393883e-08
from O 0 1.7760248827158875e-10
500 O 0 1.529238069508665e-09
unrelated O 0 2.252836805993752e-09
Jews O 0 3.34498895249169e-09
of O 0 4.0732786588115744e-10
European O 0 2.870923765385669e-08
or O 0 2.1057080346054136e-07
non O 0 6.499961386907671e-07
- O 0 1.6191257600439712e-05
European O 0 8.780071780734033e-09
origin O 0 7.00336899583931e-09
, O 0 1.508489999579865e-09
with O 0 5.223244614604994e-10
or O 0 2.938041632205568e-08
without O 0 4.0013722890641645e-10
a O 0 3.2162985608152894e-09
personal O 0 1.2498862815846223e-06
and O 0 8.855977284838445e-07
/ O 0 0.0030325499828904867
or O 0 9.106995548791019e-07
family O 0 1.1476456762693488e-07
history O 0 1.2694578721550442e-08
of O 0 7.767307352857244e-10
neoplasia B-Disease 0 1.8629597207109327e-06
, O 0 1.5331865776957443e-09
were O 0 1.8003650126274806e-08
examined O 0 2.0623191687718645e-07
for O 0 4.0996775418911113e-10
the O 0 2.533303289364852e-10
I1307K O 0 1.5204669523427583e-08
variant O 0 1.9111858762244083e-08
by O 0 2.456087833113685e-10
the O 0 1.362554374884084e-10
allele O 0 3.3170298507911866e-08
- O 0 1.7911709448981128e-07
specific O 0 1.3056892456120295e-08
oligonucleotide O 0 3.7655152596016706e-07
( O 0 2.911664020999183e-09
ASO O 0 1.0877508429985028e-05
) O 0 2.98220059757881e-10
method O 0 9.626520025562968e-09
. O 0 2.5676106574223923e-08

RESULTS O 0 7.967988722157315e-07
In O 0 1.1059232418730858e-09
persons O 0 3.241635626594075e-09
at O 0 6.039633149157453e-08
average O 0 2.2360400180332363e-05
risk O 0 0.0008521118434146047
for O 0 0.028437893837690353
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.464768821321741e-08
I1307K O 0 1.9699180597854138e-07
was O 0 5.234140303400636e-07
found O 0 4.617621840452557e-09
in O 0 5.709943629028658e-10
5 O 0 6.546760467074364e-09
. O 0 3.147943061776459e-08

0 O 0 8.741275792090164e-08
% O 0 5.175849748795258e-10
of O 0 8.780297322541486e-11
120 O 0 3.5962621769414227e-09
European O 0 2.3185313668960816e-09
and O 0 2.3825126316268097e-09
1 O 0 1.0745511147547404e-08
. O 0 2.7275932623638255e-08

6 O 0 4.98201643495122e-07
% O 0 4.6750030513464935e-09
of O 0 3.2277028272353903e-10
188 O 0 2.1572059694108248e-08
non O 0 1.9326843414546602e-07
- O 0 1.0994459671564982e-06
European O 0 2.0776285136747674e-09
Jews O 0 1.8997436956880165e-09
( O 0 1.7735063417845254e-10
P O 0 1.3640296856465284e-06
= O 0 1.032443908144387e-08
0 O 0 9.425639158067156e-10
. O 0 1.3729424541697455e-10
08 O 0 2.059864501191555e-09
) O 0 5.72291825040594e-10
. O 0 3.938189330199293e-09

It O 0 6.669802843362049e-08
occurred O 0 5.745991416006291e-08
in O 0 8.383737037931382e-10
15 O 0 5.706875860767013e-09
. O 0 1.3226761907958462e-08

4 O 0 5.7635645589471096e-08
% O 0 8.977897314466077e-10
of O 0 2.085146499908319e-10
52 O 0 2.7279625669507368e-08
Ashkenazi O 0 1.107507401343355e-07
Israelis O 0 2.0916986613883637e-06
with O 0 1.6854640350061345e-08
familial O 0 0.0033310947474092245
cancer B-Disease 0 1.3452046914608218e-05
( O 0 3.666506653843271e-09
P O 0 0.0007658095564693213
= O 0 2.1015071638430527e-07
0 O 0 2.5566773143026467e-09
. O 0 4.529653874207895e-10
02 O 0 6.322239176625999e-09
) O 0 3.2692012291724026e-11
and O 0 1.346429079340794e-09
was O 0 1.7306537358763308e-07
not O 0 1.7621172299087107e-09
detected O 0 7.00776752182719e-08
in O 0 1.5654454121882821e-10
51 O 0 2.680158139867217e-08
non O 0 3.839134521399501e-08
- O 0 2.113148411808652e-06
European O 0 4.64868366023552e-09
Jews O 0 5.537437175462401e-09
at O 0 3.1211467188541064e-08
increased O 0 2.2462523929789313e-07
cancer B-Disease 0 3.7125566905160667e-06
risk O 0 5.916093073210504e-07
. O 0 1.0514628456803621e-07

Colorectal B-Disease 1 0.8992635011672974
neoplasia I-Disease 0 0.025840630754828453
occurred O 0 3.151924829580821e-05
personally O 0 5.079378024674952e-05
or O 0 1.5901301253506972e-07
in O 0 8.130107143067278e-10
the O 0 1.638618130073155e-10
families O 0 4.412546161791653e-10
of O 0 3.52910964340758e-11
13 O 0 8.42826142211095e-10
of O 0 3.092609154875525e-11
20 O 0 6.076881220451469e-10
Ashkenazi O 0 4.1758605462405285e-09
I1307K O 0 7.812166913367946e-09
carriers O 0 1.43388145801282e-09
, O 0 2.096448015187491e-10
8 O 0 2.375713792357459e-10
of O 0 6.279114034279942e-11
whom O 0 9.380702437056243e-08
also O 0 1.1060355973313563e-06
had O 0 1.0679802471713629e-05
a O 0 1.5863827229622984e-07
personal O 0 7.6063461165176705e-06
or O 0 4.0449583593726857e-07
family O 0 5.65709115107893e-08
history O 0 1.4743337217737462e-08
of O 0 4.38060698826348e-09
noncolonic O 0 0.00017612971714697778
neoplasia B-Disease 0 0.00017128059698734432
. O 0 1.130105218294375e-07

CONCLUSIONS O 0 1.1451348882474122e-06
The O 0 7.873017793258441e-09
I1307K O 0 2.5926303806045325e-06
APC O 0 1.2519607253125287e-06
variant O 0 5.145929208083544e-06
may O 0 2.1795891314013716e-08
represent O 0 4.490736393858441e-10
a O 0 1.2877769961505692e-09
susceptibility O 0 5.993798595227418e-07
gene O 0 6.849396072539093e-07
for O 0 1.1874564052050118e-06
colorectal B-Disease 1 1.0
, I-Disease 0 6.844805966466083e-07
or I-Disease 0 5.741345603382797e-07
other I-Disease 0 4.009061171927897e-08
, I-Disease 0 2.712977789087745e-07
cancers I-Disease 0 3.692630798468599e-06
in O 0 3.088784783500387e-10
Ashkenazi O 0 4.0146090896087117e-08
Jews O 0 2.5105203249609076e-08
, O 0 4.036174061639031e-09
and O 0 8.864577516476402e-09
partially O 0 7.88424415532063e-07
explains O 0 9.10378172847004e-09
the O 0 1.1071024652586914e-10
higher O 0 3.1152289636793284e-08
incidence O 0 0.007202115375548601
of O 0 0.0014362480724230409
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 7.898123044469685e-08
European O 0 1.0920624760046849e-07
Israelis O 0 9.816941201279406e-06
. O 0 1.5479990622679907e-07

Systematic O 0 6.942286177036294e-07
analysis O 0 4.102082939994034e-08
of O 0 3.7004685982111596e-09
coproporphyrinogen O 0 4.726749102701433e-05
oxidase O 0 5.5503685871372e-05
gene O 0 0.00011291608097963035
defects O 1 0.996183454990387
in O 0 4.6561130062627853e-08
hereditary B-Disease 0 0.06897543370723724
coproporphyria I-Disease 0 0.004792022984474897
and O 0 7.081980157863654e-08
mutation O 0 3.58232568942185e-07
update O 0 1.0141463917534566e-06
. O 0 1.94433454225873e-07

Hereditary B-Disease 1 0.9535124897956848
coproporphyria I-Disease 0 0.03712311014533043
( O 0 6.451494414250192e-07
HC B-Disease 1 0.5970426797866821
) O 0 8.367466364234133e-08
is O 0 4.993698894395493e-07
an O 0 2.4883395326469326e-06
acute O 1 0.9998635053634644
hepatic B-Disease 1 0.9999899864196777
porphyria I-Disease 1 0.9999973773956299
with O 0 0.0001299641589866951
autosomal O 1 0.9999356269836426
dominant O 0 0.26260119676589966
inheritance O 0 0.0001492511946707964
caused O 0 2.7100347779196454e-06
by O 0 9.314836901808121e-09
deficient B-Disease 0 6.682818366243737e-06
activity I-Disease 0 1.3786728914055857e-07
of I-Disease 0 3.47086692720211e-10
coproporphyrinogen I-Disease 0 5.076169600215508e-06
III I-Disease 0 7.907438885013107e-06
oxidase I-Disease 0 3.798179932346102e-06
( O 0 5.145770920478299e-09
CPO O 0 8.82176300365245e-06
) O 0 4.935988506815647e-09
. O 0 1.1637451891033379e-08

Clinical O 0 5.759427949669771e-05
manifestations O 0 6.767707873223117e-06
of O 0 7.069722141039847e-09
the O 0 2.207952434218896e-07
disease O 0 0.005991718731820583
are O 0 5.8180242845651264e-09
characterized O 0 3.5134439713147003e-06
by O 0 1.7703794696899422e-07
acute O 0 0.0005769490380771458
attacks O 0 0.0017748220125213265
of O 0 1.7196224462168175e-06
neurological B-Disease 1 0.9999613761901855
dysfunction I-Disease 0 0.011241654865443707
often O 0 3.5494790040502266e-07
precipitated O 0 6.844506117431592e-08
by O 0 5.414950710047606e-10
drugs O 0 5.600488517387703e-09
, O 0 8.548451529977186e-11
fasting O 0 1.2051582842786956e-08
, O 0 3.282210891963899e-10
cyclical O 0 6.18528110862826e-06
hormonal O 0 3.778605730531126e-07
changes O 0 7.42578443180264e-09
, O 0 1.797606508091576e-08
or O 0 3.6672117857960984e-06
infectious B-Disease 0 0.00021548662334680557
diseases I-Disease 0 5.352474909159355e-05
. O 0 3.74173438899561e-08

Skin O 1 0.997994065284729
photosensitivity O 1 0.9739461541175842
may O 0 6.6836209953180514e-06
also O 0 1.527792647948445e-08
be O 0 3.3396403420482557e-09
present O 0 1.3202892112929021e-08
. O 0 3.2436474839414586e-08

The O 0 1.0690257568057859e-07
seven O 0 7.232738852280818e-09
exons O 0 5.6834803530136924e-08
, O 0 5.920596790609522e-10
the O 0 5.291821841835187e-11
exon O 0 2.3548061278688692e-08
/ O 0 5.234018317423761e-06
intron O 0 1.7133630535681732e-05
boundaries O 0 1.6018635733416886e-06
and O 0 1.4181991581097009e-08
part O 0 2.3166659701701064e-09
of O 0 6.58510052042871e-11
3 O 0 2.7200727781284684e-10
noncoding O 0 1.7056247969549077e-08
sequence O 0 1.0403822248150618e-09
of O 0 3.0677755474828317e-11
the O 0 1.0300667957485743e-10
CPO O 0 1.9259445593888813e-07
gene O 0 1.946301564359487e-09
were O 0 1.517149184060429e-09
systematically O 0 8.667610984502971e-08
analyzed O 0 8.85214213042218e-09
by O 0 1.1620251288979588e-10
an O 0 6.824212722689182e-11
exon O 0 5.7682241205725404e-09
- O 0 3.388981610896735e-07
by O 0 7.956802328124013e-09
- O 0 5.524038897419814e-06
exon O 0 2.346772362216143e-06
denaturing O 0 7.16586655471474e-05
gradient O 0 8.039907697821036e-06
gel O 0 1.7081116311601363e-05
electrophoresis O 0 8.128678246066556e-07
( O 0 1.8725683226250567e-09
DGGE O 0 1.5536207342847774e-07
) O 0 9.912499987496659e-11
strategy O 0 2.3603763388280186e-09
followed O 0 7.687493003283308e-11
by O 0 1.0157749641415137e-11
direct O 0 2.023639311676817e-10
sequencing O 0 2.31154584362514e-09
in O 0 4.1033151876312957e-10
seven O 0 6.940784058606653e-10
unrelated O 0 4.2347117812369106e-08
heterozygous O 0 7.515670290558774e-07
HC B-Disease 0 0.015176201239228249
patients O 0 9.849977686826605e-07
from O 0 3.8759573328661645e-09
France O 0 7.474530320905615e-06
, O 0 8.426593645083358e-09
Holland O 0 9.951376341632567e-06
, O 0 1.2756186151818838e-07
and O 0 4.609853476722492e-07
Czech O 0 1.4456293683906551e-05
Republic O 0 1.0181219067817437e-07
. O 0 8.43158147745271e-08

Seven O 0 1.4969977257806022e-07
novel O 0 9.521087918074045e-08
mutations O 0 1.8322296568840102e-07
and O 0 5.270190950312781e-09
two O 0 1.2148687611457376e-10
new O 0 9.016904445324769e-10
polymorphisms O 0 1.397983510287304e-06
were O 0 4.002735636277066e-07
detected O 0 3.2128750717674848e-06
. O 0 3.5837604883681706e-08

Among O 0 3.441634817136219e-07
these O 0 4.277620924142411e-09
mutations O 0 3.411055971014321e-08
two O 0 9.104384468550109e-10
are O 0 1.1927973053715846e-09
missense O 0 6.296884862422303e-07
( O 0 7.526106959865331e-10
G197W O 0 5.54027117516398e-08
, O 0 4.1851080934129925e-10
W427R O 0 6.972407096128563e-09
) O 0 1.3914809582349363e-10
, O 0 1.8390826361791568e-10
two O 0 8.94988735899993e-11
are O 0 2.080070782284338e-09
nonsense O 0 1.412400138178782e-06
( O 0 1.0853640902697137e-10
Q306X O 0 7.1602106466173154e-09
, O 0 9.884030399698318e-11
Q385X O 0 1.5823501398060102e-09
) O 0 5.87084547643002e-11
, O 0 4.834515773821657e-11
two O 0 2.35009563892552e-11
are O 0 7.834362325542799e-11
small O 0 8.010185292839367e-10
deletions O 0 9.818595714250478e-09
( O 0 4.351276006175908e-10
662de14bp O 0 2.1725249155224446e-08
; O 0 2.3462540243990304e-10
1168del3bp O 0 1.3073841387267748e-07
removing O 0 1.309724861897621e-08
a O 0 5.885019138673897e-10
glycine O 0 1.6963005222692118e-08
at O 0 2.419469957715137e-08
position O 0 7.626222320311626e-09
390 O 0 1.864926435501957e-09
) O 0 5.869983665807155e-11
, O 0 7.301885485144766e-11
and O 0 3.567021955586114e-10
one O 0 3.98943045265554e-10
is O 0 4.1719894205982655e-10
a O 0 1.6011877934651864e-10
splicing O 0 5.154139781637923e-09
mutation O 0 6.87008627764385e-09
( O 0 1.7798093554510785e-10
IVS1 O 0 5.29778901636746e-07
- O 0 1.2942953162564663e-06
15c O 0 5.159188845027529e-07
- O 0 1.6641122329019709e-06
- O 0 1.3903490980737843e-06
> O 0 9.737635586759552e-09
g O 0 3.621007849119451e-08
) O 0 7.802211654528435e-11
which O 0 4.693647692732839e-10
creates O 0 5.845294803741297e-10
a O 0 3.105674051262497e-10
new O 0 1.4605400222578169e-09
acceptor O 0 1.6373201461306053e-08
splice O 0 1.964257762665511e-06
site O 0 1.768394395185169e-05
. O 0 1.8706046489569417e-07

The O 0 2.5653589474927685e-08
pathological O 0 9.501166005065897e-07
significance O 0 4.0712009763410606e-08
of O 0 2.741343818613018e-10
the O 0 6.048665457392133e-10
point O 0 1.674665952577925e-07
mutations O 0 1.7291897691507074e-08
G197W O 0 2.0565522618198884e-08
, O 0 3.694937411591326e-10
W427R O 0 2.1644760650474382e-08
, O 0 1.5151394583412525e-09
and O 0 2.3585942088288903e-09
the O 0 2.0027889069407223e-10
in O 0 4.638241346555105e-09
- O 0 3.232702147215605e-05
frame O 0 0.00014150780043564737
deletion O 0 1.359823755819889e-07
390delGly O 0 3.021423253812827e-07
were O 0 1.4891742061706736e-08
assessed O 0 1.9801682071829418e-07
by O 0 2.0665860134272407e-09
their O 0 1.7605014113186712e-09
respective O 0 8.06382294271657e-10
expression O 0 6.885536030232231e-10
in O 0 1.7356999518214344e-11
a O 0 1.2936995918977345e-10
prokaryotic O 0 5.515614631690369e-10
system O 0 4.531572062038691e-10
using O 0 1.2679641780977136e-09
site O 0 7.314409685932333e-06
- O 0 4.351742973085493e-06
directed O 0 3.402469701541122e-07
mutagenesis O 0 3.641298826551065e-05
. O 0 1.9398174799789558e-07

These O 0 3.024997852207889e-08
mutations O 0 5.213903264689179e-08
resulted O 0 7.009970826032941e-09
in O 0 8.665007600328067e-10
the O 0 3.1854721638246986e-10
absence O 0 6.420012077512638e-09
or O 0 5.157148930123867e-09
a O 0 1.5104997252990415e-09
dramatic O 0 2.632116746781321e-08
decrease O 0 8.480063229399093e-08
of O 0 1.1164141833219787e-09
CPO O 0 8.737559255678207e-05
activity O 0 1.99411329049326e-06
. O 0 4.222226479555502e-08

The O 0 1.9277889506952306e-08
two O 0 6.898208115835303e-10
polymorphisms O 0 3.5956404076387116e-07
were O 0 1.2786678382781247e-08
localized O 0 8.333365997259534e-08
in O 0 5.056934870850682e-10
noncoding O 0 1.341014694844489e-07
part O 0 3.015623750712848e-09
of O 0 1.763477211480513e-11
the O 0 1.518204312267457e-11
gene O 0 1.5790870000476076e-10
1 O 0 3.3357410583745306e-11
) O 0 6.416867905090218e-12
a O 0 3.6211492138171764e-10
C O 0 1.226943936671887e-06
/ O 0 1.6941573903750395e-06
G O 0 1.6056276308518136e-07
polymorphism O 0 9.73332987541653e-08
in O 0 1.8330706952340847e-09
the O 0 7.094587139988562e-10
promotor O 0 1.4520129525408265e-06
region O 0 1.2848849983981836e-08
, O 0 1.0359837293583141e-10
142 O 0 1.1057778026568599e-09
bp O 0 1.9892148372946394e-08
upstream O 0 3.471656739861828e-09
from O 0 2.3711494573364078e-11
the O 0 1.0734268508783007e-11
transcriptional O 0 3.3423919187924866e-10
initiation O 0 9.396985967136118e-11
site O 0 6.200999536076779e-08
( O 0 6.331476315457607e-11
- O 0 6.500761173811043e-08
142C O 0 4.806407005730762e-08
/ O 0 8.542205165440464e-08
G O 0 1.1935465948909041e-08
) O 0 2.8170825047690862e-11
, O 0 4.7768615452081775e-11
and O 0 1.3900749995521267e-10
2 O 0 2.3766066892250137e-10
) O 0 2.8880439706391314e-11
a O 0 1.6303410010909403e-10
6 O 0 7.292410564296858e-10
bp O 0 1.4205490117547015e-08
deletion O 0 1.7854613343359915e-09
polymorphism O 0 2.3060689358089803e-08
in O 0 6.681586950385565e-10
the O 0 2.1602093724926164e-10
3 O 0 5.91869997457195e-10
noncoding O 0 1.7791254691701397e-08
part O 0 9.93633730850263e-10
of O 0 2.5920078583485662e-11
the O 0 4.039173509551297e-11
CPO O 0 1.48889938600405e-07
gene O 0 1.348235634246464e-09
, O 0 9.460739136546437e-11
574 O 0 3.140882220975527e-09
bp O 0 2.1199328514853732e-08
downstream O 0 5.845286921157822e-09
of O 0 3.9223530673426765e-11
the O 0 1.4580621432447316e-10
last O 0 2.330200032929497e-09
base O 0 1.5412202625242344e-09
of O 0 6.535571563104359e-12
the O 0 2.1112942991119432e-11
normal O 0 1.955048789525904e-09
termination O 0 7.064286933200492e-10
codon O 0 1.7507469918243146e-09
( O 0 1.0213842271955542e-10
+ O 0 7.327773499099521e-09
574 O 0 1.698758111956522e-08
delATTCTT O 0 4.7434479455432665e-08
) O 0 2.864555481707498e-09
. O 0 1.089313972357786e-08

Five O 0 4.262653305886488e-07
intragenic O 0 6.150511580926832e-06
dimorphisms O 0 9.858907105808612e-06
are O 0 6.783730022164036e-09
now O 0 6.9553522941134815e-09
well O 0 1.5424965749133435e-09
characterized O 0 1.09267297432325e-07
and O 0 7.889011222061981e-09
the O 0 1.324505227717765e-10
high O 0 4.223169014494488e-08
degree O 0 2.394730247434751e-10
of O 0 6.821727210892803e-11
allelic O 0 9.301702874608964e-08
heterogeneity O 0 1.537349163527324e-07
in O 0 6.396288387833238e-09
HC B-Disease 0 0.33272260427474976
is O 0 1.7166469206131296e-06
demonstrated O 0 2.034664561278987e-07
with O 0 5.982999096154629e-10
seven O 0 1.0801103761393094e-10
new O 0 3.7596422503005655e-11
different O 0 1.6083218090656715e-11
mutations O 0 1.8193284379020014e-10
making O 0 4.4734846382787907e-10
a O 0 8.865198575236377e-10
total O 0 3.1624811658303997e-09
of O 0 2.8579069666356816e-10
nineteen O 0 3.83146101512466e-08
CPO O 0 0.00018674480088520795
gene B-Disease 0 3.4978008898178814e-06
defects I-Disease 0 0.005732227116823196
reported O 0 1.2551131476357114e-06
so O 0 3.2053486531680164e-09
far O 0 4.501003125767511e-09
. O 0 5.744856812484045e-10
. O 0 8.943241702752402e-09

Coincidence O 0 1.4409441746465745e-06
of O 0 4.413163168237588e-09
two O 0 5.233268929316637e-09
novel O 0 1.023487925522204e-07
arylsulfatase O 0 5.8315536080044694e-06
A O 0 4.843270229315522e-09
alleles O 0 1.0589293886198448e-08
and O 0 1.5104016926059671e-09
mutation O 0 3.1130255706557364e-08
459 O 0 2.420836722194508e-07
+ O 0 3.302409652405913e-07
1G O 0 9.217586921295151e-06
> O 0 1.2648541769522126e-07
A O 0 4.102059492083754e-08
within O 0 2.4774728935028634e-09
a O 0 2.9472071005898215e-08
family O 0 4.203069693176076e-06
with O 0 8.766871360421646e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999988079071045
: O 0 4.742523262990517e-09
molecular O 0 5.536486380464112e-09
basis O 0 3.406763093849463e-09
of O 0 1.0592762222927377e-09
phenotypic O 0 4.312515557103325e-06
heterogeneity O 0 3.803448998951353e-05
. O 0 7.606706162732735e-07

In O 0 2.0934778888204164e-07
a O 0 6.833887766788393e-08
family O 0 1.0806223826875794e-06
with O 0 1.494566426174515e-08
three O 0 3.311807716954718e-08
siblings O 0 5.208923994359793e-07
, O 0 1.2259867565589389e-09
one O 0 8.895500447358984e-10
developed O 0 1.3056717484971614e-08
classical O 0 1.7351142389543384e-07
late O 0 2.2046348021831363e-05
infantile O 1 0.9997363686561584
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999990463256836
( O 0 4.7473128006458865e-07
MLD B-Disease 1 0.999944806098938
) O 0 1.3495458972556662e-08
, O 0 1.1965045620954129e-09
fatal O 0 4.243160844907834e-08
at O 0 7.16084116447746e-08
age O 0 7.399077350811467e-09
5 O 0 2.369533236290522e-09
years O 0 3.865938680291947e-09
, O 0 1.1640488573050334e-09
with O 0 2.4183890445783618e-09
deficient O 0 8.525871635356452e-06
arylsulfatase O 0 1.2555417470139218e-06
A O 0 1.392810045075521e-08
( O 0 3.4820865635332154e-10
ARSA O 0 1.8099354974765447e-06
) O 0 3.764011671791856e-11
activity O 0 5.5163114076606234e-09
and O 0 2.4921972818781057e-10
increased O 0 1.5670442721216205e-09
galactosylsulfatide O 0 3.866342467517825e-06
( O 0 1.552544759420016e-08
GS O 1 0.999982476234436
) O 0 1.1493626494996079e-08
excretion O 0 1.155537532326889e-07
. O 0 2.7446898087646332e-08

The O 0 2.917614061459517e-08
two O 0 6.257289353328588e-09
other O 0 1.5311759637981481e-09
siblings O 0 8.273327267716013e-08
, O 0 9.137211542942225e-10
apparently O 0 4.568076761302109e-08
healthy O 0 9.650105603498105e-09
at O 0 6.420159071041098e-09
12 O 0 1.5478006376579145e-10
( O 0 1.8825722231108344e-11
1 O 0 1.0484475093663903e-10
/ O 0 4.102044215414935e-08
2 O 0 2.4570623313735496e-10
) O 0 4.4231444895626026e-11
and O 0 1.385295655964569e-09
15 O 0 1.327826321118053e-10
years O 0 8.044017535402403e-11
, O 0 7.658559897372186e-11
respectively O 0 9.80786563076208e-10
, O 0 3.0374962545209883e-09
and O 0 2.1146748352407485e-08
their O 0 6.283697118192322e-09
father O 0 8.74189822752669e-07
, O 0 1.007425254329064e-09
apparently O 0 3.5736583470225014e-08
healthy O 0 4.387463725663565e-09
as O 0 3.9380895766605306e-10
well O 0 2.4477178062198846e-09
, O 0 2.1963547647274595e-10
presented O 0 7.281712566253873e-09
ARSA O 0 0.0007950281142257154
and O 0 7.55549706354941e-07
GS O 1 0.999991774559021
values O 0 8.439739218601972e-08
within O 0 5.391453949954439e-10
the O 0 2.6929866669966884e-10
range O 0 1.4292736238985526e-07
of O 0 7.460509543477656e-09
MLD B-Disease 1 0.9999886751174927
patients O 0 5.273341798783804e-07
. O 0 3.020892336280667e-08

Mutation O 0 1.5202443819362088e-06
screening O 0 1.5727320601399697e-07
and O 0 1.753731493359112e-09
sequence O 0 2.3848358843281403e-09
analysis O 0 4.52689219443414e-09
disclosed O 0 5.155769713383052e-07
the O 0 7.009779978695008e-10
involvement O 0 4.3671445126847175e-08
of O 0 2.1041315911851655e-10
three O 0 4.834490585636786e-10
different O 0 1.1222724971560183e-09
ARSA O 0 0.0003954372077714652
mutations O 0 2.288742706468838e-08
being O 0 2.1141737249763537e-09
the O 0 5.485114445979988e-11
molecular O 0 1.6992919293912223e-09
basis O 0 3.916921897939574e-09
of O 0 1.0411405071408808e-09
intrafamilial O 0 1.7729957107803784e-05
phenotypic O 0 1.1868147339555435e-05
heterogeneity O 0 2.7412652343627997e-05
. O 0 8.174271783900622e-07

The O 0 7.920299793795493e-08
late O 0 1.08753272343165e-06
infantile O 1 0.996442973613739
patient O 0 0.0186541099101305
inherited O 0 0.006030712276697159
from O 0 1.978307153649439e-07
his O 0 1.0501896667847177e-06
mother O 0 2.6549505491857417e-06
the O 0 2.7731658636120926e-10
frequent O 0 2.971291124254094e-08
0 O 0 1.883135247737755e-08
- O 0 1.9084702671534615e-06
type O 0 5.658333066094201e-06
mutation O 0 4.681814047557964e-08
459 O 0 6.140187025494015e-08
+ O 0 3.063505715772408e-08
1G O 0 8.537862186130951e-07
> O 0 2.7078797870672133e-08
A O 0 6.772265237486863e-08
, O 0 1.1339436944979298e-08
and O 0 1.384617398514365e-08
from O 0 8.456542133217226e-09
his O 0 2.339460252187564e-07
father O 0 1.0195323056905181e-06
a O 0 2.7826780879536273e-09
novel O 0 1.779044112026895e-08
, O 0 6.674810704154766e-10
single O 0 3.308901819210064e-09
basepair O 0 3.7465191837782186e-08
microdeletion O 0 3.761928724088648e-08
of O 0 2.2406087402115915e-11
guanine O 0 1.121288284444688e-09
at O 0 1.8435641901959343e-10
nucleotide O 0 4.4791881315120463e-10
7 O 0 1.5865014857396886e-10
in O 0 1.8958831032866996e-11
exon O 0 3.18156923029278e-09
1 O 0 3.0950255691664097e-09
( O 0 4.544720710875083e-10
7delG O 0 9.555982671827223e-08
) O 0 7.897468790041273e-10
. O 0 4.725971169960985e-09

The O 0 6.102626315396265e-08
two O 0 4.5157868555634195e-08
clinically O 0 0.00033077585976570845
unaffected O 0 0.0002718358882702887
siblings O 0 9.885727649816545e-07
carried O 0 6.830941288171744e-07
the O 0 1.997174647883071e-09
maternal O 0 6.653068567175069e-07
mutation O 0 5.723033069671146e-08
459 O 0 9.004555323599561e-08
+ O 0 1.994317528897227e-07
1G O 0 3.2683726658433443e-06
> O 0 5.5448278857284095e-08
A O 0 1.4179914842316066e-07
and O 0 1.3757386341239908e-07
, O 0 3.864066400183219e-09
on O 0 1.937543316898882e-07
their O 0 5.525283341967224e-09
paternal O 0 3.8475945984828286e-07
allele O 0 1.541970817697802e-08
, O 0 1.880706979040525e-10
a O 0 2.0043250392731693e-10
novel O 0 1.7870761537253088e-09
cytosine O 0 6.005800301522868e-09
to O 0 8.311813737282847e-11
thymidine O 0 2.4514848817602797e-08
transition O 0 9.868461603446121e-09
at O 0 2.369085816411598e-09
nucleotide O 0 4.30051860789149e-09
2435 O 0 9.76186953494107e-08
in O 0 3.945470686272934e-11
exon O 0 3.2954734496826177e-09
8 O 0 2.368638618577279e-09
, O 0 9.700235059639795e-11
resulting O 0 5.201935757148668e-11
in O 0 5.750255306635754e-12
substitution O 0 1.5111818740809468e-10
of O 0 8.169522697221154e-11
alanine O 0 2.113552284299658e-07
464 O 0 2.1097678271075893e-08
by O 0 3.820447069813326e-09
valine O 0 2.2097058263170766e-06
( O 0 2.432016144027216e-09
A464V O 0 7.910274746336654e-08
) O 0 2.985901748076003e-09
. O 0 1.1357706775072529e-08

The O 0 2.520032182928844e-07
fathers O 0 8.726930218472262e-07
genotype O 0 9.098556574826944e-07
thus O 0 8.383597815964094e-09
was O 0 5.559208560157458e-08
7delG O 0 2.260466317238752e-06
/ O 0 1.7431664673495106e-05
A464V O 0 3.1359809327113908e-06
. O 0 1.8208721996870736e-07

Mutation O 0 3.624840701377252e-06
A464V O 0 3.2130128602148034e-06
was O 0 1.0372915539846872e-06
not O 0 1.816541583821163e-09
found O 0 1.5646459683438252e-09
in O 0 3.1255936727703215e-10
18 O 0 9.787108901093688e-09
unrelated O 0 1.9049135744353407e-06
MLD B-Disease 1 0.9999984502792358
patients O 0 8.963683626461716e-07
and O 0 4.601075520582754e-09
50 O 0 1.3860654846098441e-08
controls O 0 7.231097242765827e-06
. O 0 1.7075899449991994e-07

A464V O 0 2.4718805434531532e-05
, O 0 1.2905857715850289e-08
although O 0 1.6430630189745443e-09
clearly O 0 1.596033349926529e-08
modifying O 0 2.0040046422309388e-07
ARSA O 0 0.019289575517177582
and O 0 3.6869548694085097e-06
GS O 1 0.999998927116394
levels O 0 1.6990634321700782e-07
, O 0 7.435105864317393e-10
apparently O 0 1.3837145651507399e-08
bears O 0 9.483404284083008e-09
little O 0 9.076486229275815e-10
significance O 0 1.8124300948940686e-09
for O 0 5.257216884047011e-10
clinical O 0 3.5664132980173235e-08
manifestation O 0 4.901148642488806e-08
of O 0 2.544408239657514e-09
MLD B-Disease 1 0.999993085861206
, O 0 2.021218747927378e-08
mimicking O 0 6.269052619245485e-07
the O 0 1.3202137161272276e-08
frequent O 0 3.4348120152571937e-06
ARSA O 0 0.006325932219624519
pseudodeficiency O 0 2.786092591122724e-05
allele O 0 5.905477792111924e-06
. O 0 2.472381481766206e-07

Our O 0 1.158620079877437e-06
results O 0 4.544317633303763e-08
demonstrate O 0 2.4331079373496323e-08
that O 0 2.181233665909943e-10
in O 0 3.3798030346643415e-11
certain O 0 2.4837740197902747e-10
genetic O 0 2.0769131481301883e-07
conditions O 0 7.971136255946476e-06
MLD B-Disease 1 0.999994158744812
- O 0 0.005556363146752119
like O 0 1.4783174719923409e-06
ARSA O 0 0.19085419178009033
and O 0 1.5269471305145998e-06
GS O 1 0.9999626874923706
values O 0 5.6213707466667984e-08
need O 0 6.575013311582723e-10
not O 0 1.2274414817881052e-10
be O 0 1.702937929559667e-10
paralleled O 0 3.525791214542551e-08
by O 0 4.128139163839251e-09
clinical O 0 5.0030801503453404e-05
disease O 0 5.740521373809315e-05
, O 0 3.367450207569789e-10
a O 0 1.393231863211497e-09
finding O 0 9.25729182199575e-09
with O 0 1.910040570152205e-09
serious O 0 1.7818261710544903e-07
diagnostic O 0 1.9288647763460176e-06
and O 0 1.4817679527823202e-08
prognostic O 0 5.954618245596066e-05
implications O 0 2.612476350805082e-07
. O 0 8.372176552029487e-08

Moreover O 0 3.2971652217383962e-06
, O 0 1.8378852217892927e-08
further O 0 4.4633978291130916e-08
ARSA O 0 0.007349812425673008
alleles O 0 2.29914135729814e-07
functionally O 0 2.7120518097945023e-07
similar O 0 5.849034145910537e-09
to O 0 2.010141608721483e-09
A464V O 0 1.2154011130860454e-07
might O 0 9.146806867477153e-09
exist O 0 1.4367450562602357e-09
which O 0 7.825748937762e-10
, O 0 5.763995530871924e-11
together O 0 1.1020818285745193e-10
with O 0 2.259311904229122e-10
0 O 0 2.632327777973842e-08
- O 0 6.366756133502349e-05
type O 0 0.002070804126560688
mutations O 0 7.99549127350474e-07
, O 0 9.915194887355483e-09
may O 0 6.762313375929807e-08
cause O 0 1.8006879543008836e-08
pathological O 0 3.610343583204667e-06
ARSA O 1 0.9800916314125061
and O 0 0.0001347798970527947
GS O 1 0.9999997615814209
levels O 0 2.6318818981962977e-06
, O 0 5.159704330459647e-10
but O 0 2.6588978241370853e-10
not O 0 7.526623768683294e-10
clinical O 0 7.188317496797936e-09
outbreak O 0 7.293530757124245e-08
of O 0 1.9215425084428972e-10
the O 0 2.5593230645881704e-08
disease O 0 6.925602519913809e-06
. O 0 4.3885498013374047e-10
. O 0 2.143547916944044e-08

Human O 0 0.003346939804032445
MLH1 O 1 0.9996235370635986
deficiency O 1 0.9992027878761292
predisposes O 0 0.00017819703498389572
to O 0 5.557787403631664e-07
hematological B-Disease 1 0.9538252353668213
malignancy I-Disease 0 0.435145765542984
and O 0 1.5447666328327614e-06
neurofibromatosis B-Disease 1 0.9151347875595093
type I-Disease 0 0.00021909081260673702
1 I-Disease 0 3.363172709214268e-07
. O 0 2.1524182614029996e-07

Heterozygous O 0 0.00017150038911495358
germ O 0 0.032084815204143524
- O 0 0.011812903918325901
line O 0 7.519411883549765e-05
mutations O 0 1.1336327787603295e-07
in O 0 1.9747381507784212e-10
the O 0 1.4178244689411201e-10
DNA O 0 9.023438565236575e-07
mismatch O 0 0.00017408044368494302
repair O 0 0.00012396277452353388
genes O 0 4.4257507170186727e-07
lead O 0 2.594354384655162e-07
to O 0 3.0587177661800524e-06
hereditary B-Disease 1 0.9999910593032837
nonpolyposis I-Disease 1 0.999998927116394
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 1.1740245099645108e-05

The O 0 1.7202755486778187e-07
disease O 0 6.658419442828745e-05
susceptibility O 0 5.51957873540232e-06
of O 0 4.959543886684514e-09
individuals O 0 6.800015626140521e-07
who O 0 1.2492641872086097e-06
constitutionally O 0 3.4374410461168736e-05
lack O 0 1.0655935511749703e-07
both O 0 2.1125694527057703e-09
wild O 0 2.612453897654632e-07
- O 0 5.446645445772447e-05
type O 0 1.8963339243782684e-05
alleles O 0 3.16607398076485e-08
is O 0 5.011848003277919e-08
unknown O 0 3.344815979744453e-07
. O 0 2.9130099221674755e-08

We O 0 2.4327216578967636e-06
have O 0 6.380922457083216e-09
identified O 0 2.3225426915018943e-08
three O 0 2.926461573071748e-10
offspring O 0 1.706177954474697e-08
in O 0 3.711580376375423e-09
a O 0 5.64675929126679e-06
hereditary B-Disease 1 0.9999974966049194
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.01677928864955902
who O 0 1.5866120520513505e-05
developed O 0 2.2779589926358312e-05
hematological B-Disease 1 0.6392331719398499
malignancy I-Disease 0 0.0031234584748744965
at O 0 1.3653598216478713e-06
a O 0 7.715763139515275e-09
very O 0 1.8902739373771738e-09
early O 0 6.965598098318537e-10
age O 0 3.4825133887750326e-09
, O 0 2.7614219244576077e-10
and O 0 1.9379298166199987e-09
at O 0 3.403212289754265e-08
least O 0 5.295187066600704e-10
two O 0 3.871712325742571e-11
of O 0 2.1802094851697262e-11
them O 0 3.5153457922376674e-10
displayed O 0 2.227250490705046e-07
signs O 0 2.45587301606065e-07
of O 0 5.735255048655574e-10
neurofibromatosis B-Disease 0 0.0001522828679298982
type I-Disease 0 6.54053701509838e-06
1 I-Disease 0 1.9941838402814938e-08
( O 0 5.423935967030502e-09
NF1 B-Disease 0 4.1524194784869906e-06
) O 0 8.476533253087837e-09
. O 0 3.925854130670814e-08

DNA O 0 1.0651124284777325e-06
sequence O 0 6.499780624835694e-08
analysis O 0 2.4699110312553785e-08
and O 0 1.1053222781498562e-09
allele O 0 4.036345302438349e-08
- O 0 2.9046884719718946e-07
specific O 0 7.57813989338274e-09
amplification O 0 8.552100894121395e-08
in O 0 2.788831166000705e-09
two O 0 6.3307585840277625e-09
siblings O 0 4.593029245825164e-07
revealed O 0 7.499947685118968e-08
a O 0 1.3791747299762847e-08
homozygous O 0 1.281147251575021e-05
MLH1 O 0 0.0004045322129968554
mutation O 0 5.163726868318008e-08
( O 0 8.736833478906192e-10
C676T O 0 2.017400646536771e-07
- O 0 9.632906767365057e-06
- O 0 2.2035334040992893e-05
> O 0 2.367721236851139e-07
Arg226Stop O 0 1.932045961439144e-06
) O 0 7.469608043209064e-09
. O 0 1.2736706800353659e-08

Thus O 0 2.509482044388278e-07
, O 0 4.4044341507287754e-09
a O 0 3.845061158358476e-09
homozygous O 0 1.8707310118770692e-06
germ O 0 0.012965722940862179
- O 0 0.020027993246912956
line O 0 0.01474930439144373
MLH1 O 0 0.03602505847811699
mutation O 0 6.729901542712469e-07
and O 0 3.789510927276751e-08
consequent O 0 2.7774154659709893e-05
mismatch O 1 0.9986849427223206
repair O 1 0.9999823570251465
deficiency O 1 0.9973589777946472
results O 0 6.777680283676091e-08
in O 0 1.8271398838365371e-09
a O 0 7.559015813285441e-08
mutator O 0 0.2156895101070404
phenotype O 0 1.7498818124295212e-05
characterized O 0 2.660483914951328e-06
by O 0 1.1491241735939184e-07
leukemia B-Disease 1 0.6032996773719788
and O 0 2.7096007215732243e-06
/ O 1 0.999951958656311
or O 1 0.9987745881080627
lymphoma B-Disease 1 1.0
associated O 0 0.0001177931044367142
with O 0 7.111432864803646e-07
neurofibromatosis B-Disease 1 0.7649766802787781
type I-Disease 0 5.852732283528894e-05
1 I-Disease 0 9.248823573670961e-08
. O 0 8.278738583555878e-09
. O 0 5.749017262246525e-08

Missense O 0 0.0008917348459362984
mutations O 0 1.3499879969458561e-05
in O 0 6.4419931611325865e-09
the O 0 3.83278742077664e-10
most O 0 1.0934678856822089e-10
ancient O 0 3.001591752926913e-10
residues O 0 7.62514584806695e-09
of O 0 5.742772229977433e-11
the O 0 5.455089713279904e-10
PAX6 O 0 1.1284588254056871e-05
paired O 0 3.473811105436653e-08
domain O 0 2.571467661027782e-08
underlie O 0 1.2374913183066383e-07
a O 0 4.714087786794607e-09
spectrum O 0 2.085057815293112e-07
of O 0 1.5473535341925526e-08
human O 0 0.001374082057736814
congenital B-Disease 1 0.999997615814209
eye I-Disease 1 0.9980630278587341
malformations I-Disease 1 0.9959806203842163
. O 0 2.1011674107285216e-06

Mutations O 0 2.25803887587972e-05
of O 0 1.2005468619236126e-08
the O 0 3.79389897275928e-09
human O 0 7.36880068075152e-08
PAX6 O 0 0.0001437945757061243
gene O 0 1.1924374121008441e-05
underlie O 0 0.10870104283094406
aniridia B-Disease 1 0.9999998807907104
( O 0 0.0002225625212304294
congenital B-Disease 1 0.9999978542327881
absence I-Disease 0 1.5428290680574719e-06
of I-Disease 0 1.894330692309154e-09
the I-Disease 0 3.454549091230774e-09
iris I-Disease 0 0.00024980775197036564
) O 0 5.626398902336405e-09
, O 0 8.701178666470355e-10
a O 0 8.45262260185109e-09
rare O 0 1.1312552032904932e-06
dominant O 0 0.003670095233246684
malformation B-Disease 1 0.9366915822029114
of I-Disease 0 5.6099289658106954e-09
the I-Disease 0 8.28569213240371e-08
eye I-Disease 0 0.004452385473996401
. O 0 3.8456286688415275e-07

The O 0 1.839140573167697e-08
spectrum O 0 3.3656016285021906e-07
of O 0 2.4676307663895614e-09
PAX6 O 0 0.00020685353956650943
mutations O 0 2.0249638055247488e-06
in O 0 1.5286241250578314e-07
aniridia B-Disease 1 0.9999998807907104
patients O 0 4.6943509914854076e-06
is O 0 4.056007529840144e-09
highly O 0 4.75693662238541e-09
biased O 0 1.57887399154788e-07
, O 0 4.568551370542906e-10
with O 0 1.6253545731537145e-10
92 O 0 3.2928848536784017e-09
% O 0 6.049482442760379e-11
of O 0 2.2497729373904818e-11
all O 0 5.8594746832341116e-09
reported O 0 8.17489308246877e-06
mutations O 0 3.1092099561647046e-08
leading O 0 9.691977886916447e-09
to O 0 2.0550925405871112e-09
premature O 0 2.578176250267461e-08
truncation O 0 1.9389851502182864e-07
of O 0 1.355220047294381e-09
the O 0 5.945027803377911e-10
protein O 0 4.617797699779658e-09
( O 0 2.0381188403639783e-10
nonsense O 0 2.1863202448457741e-07
, O 0 3.139309992516992e-11
splicing O 0 4.1198860989410946e-10
, O 0 7.642668442553457e-11
insertions O 0 5.327516205966276e-09
and O 0 4.3536668714594384e-10
deletions O 0 1.327224441460828e-09
) O 0 2.992787961897392e-10
and O 0 3.883816823702091e-09
just O 0 3.627893363500334e-08
2 O 0 1.4109567958442426e-09
% O 0 1.4649866042493187e-10
leading O 0 1.0637588587769642e-09
to O 0 1.374328428838112e-10
substitution O 0 3.727470276881917e-10
of O 0 9.188624167100201e-11
one O 0 4.606948156293811e-10
amino O 0 1.7654602779693107e-10
acid O 0 1.0302553948848825e-10
by O 0 4.669321873596033e-11
another O 0 8.029275577747796e-10
( O 0 4.5851286656350965e-10
missense O 0 1.8477767582680826e-07
) O 0 2.0149821811088486e-09
. O 0 1.3188546255094025e-08

The O 0 1.9016445307329377e-08
extraordinary O 0 2.7779439193409416e-08
conservation O 0 7.2872698986259365e-09
of O 0 6.636659971581693e-11
the O 0 2.0685962665023538e-10
PAX6 O 0 1.664362912379147e-06
protein O 0 7.52355600042165e-09
at O 0 6.788506201615974e-09
the O 0 1.0354285484570624e-10
amino O 0 8.125409234338576e-10
acid O 0 5.921794166141581e-10
level O 0 7.625839404390433e-10
amongst O 0 8.79085415572689e-11
vertebrates O 0 2.3105850566196295e-09
predicts O 0 2.3570714802190196e-07
that O 0 7.963980031000517e-10
pathological O 0 2.7122175083604816e-07
missense O 0 1.640133632463403e-06
mutations O 0 2.165306653978405e-07
should O 0 8.298582088173134e-08
in O 0 6.827992060642885e-10
fact O 0 7.383639921698659e-09
be O 0 2.6325988500275344e-08
common O 0 2.3213899691398865e-09
even O 0 2.677545962725958e-09
though O 0 6.533147911547132e-10
they O 0 4.081646409748174e-10
are O 0 7.668719131936896e-11
hardly O 0 1.8575742055659816e-09
ever O 0 2.4973043633025327e-09
seen O 0 1.2180258579519432e-07
in O 0 8.773509030390869e-09
aniridia B-Disease 1 0.9999896287918091
patients O 0 4.1516256032991805e-07
. O 0 3.034405793300721e-08

This O 0 1.0242726666831459e-08
indicates O 0 6.143947217651657e-08
that O 0 5.647932121988219e-10
there O 0 6.242385497401415e-10
is O 0 2.407806454218786e-10
a O 0 2.5571489370435074e-10
heavy O 0 2.849419615813531e-07
ascertainment O 0 1.7362244761898182e-06
bias O 0 3.4596985187818063e-06
in O 0 9.955877233736032e-10
the O 0 1.1775090624777107e-10
selection O 0 2.54686383094338e-10
of O 0 1.4295661876495558e-10
patients O 0 1.2095306978210374e-09
for O 0 1.0008879142153759e-10
PAX6 O 0 8.858316959958756e-07
mutation O 0 1.8056189876602957e-09
analysis O 0 2.1489874324487346e-09
and O 0 1.3204353166429428e-08
that O 0 1.0087539692449354e-09
the O 0 2.0280761514612777e-09
missing O 0 4.0908793152993894e-07
PAX6 O 0 0.00020273182599339634
missense O 0 4.952824019710533e-05
mutations O 0 1.753926653691451e-06
frequently O 0 1.337070557383413e-06
may O 0 1.8702905890677357e-07
underlie O 0 9.762921763467602e-06
phenotypes O 0 7.86609325587051e-06
distinct O 0 2.0838810144141462e-07
from O 0 9.687656898904606e-08
textbook O 0 0.0027334284968674183
aniridia B-Disease 1 0.9999585151672363
. O 0 2.7693795345840044e-06

Here O 0 2.738666466939321e-07
we O 0 9.728464256397729e-09
present O 0 1.019520134981633e-09
four O 0 8.250580219026915e-10
novel O 0 4.6814925269700325e-08
PAX6 O 0 2.6083162083523348e-05
missense O 0 1.62314950102882e-06
mutations O 0 1.265805167349754e-07
, O 0 6.199813995522163e-09
two O 0 5.081454701461041e-10
in O 0 2.2322714787748055e-09
association O 0 3.742574694598488e-09
with O 0 1.27375021641285e-09
atypical O 0 1.2957156059201225e-06
phenotypes O 0 6.957444043109717e-07
ectopia B-Disease 0 8.599832653999329e-06
pupillae I-Disease 0 2.2685395379085094e-05
( O 0 4.566071076794742e-09
displaced B-Disease 0 9.434280912046233e-08
pupils I-Disease 0 2.49409239927445e-08
) O 0 1.0090623447922553e-08
and O 0 1.0459913028171286e-05
congenital B-Disease 1 0.9999903440475464
nystagmus I-Disease 0 0.0001363757037324831
( O 0 2.738429261128772e-09
searching B-Disease 0 3.310769329800678e-07
gaze I-Disease 0 7.330229436774971e-07
) O 0 5.148458326331706e-10
, O 0 1.138166449976552e-09
and O 0 6.902884042148116e-09
two O 0 4.5886983102150225e-10
in O 0 1.133095617333879e-09
association O 0 5.945027803377911e-10
with O 0 1.6584901507687988e-10
more O 0 2.7806301705624037e-09
recognizable O 0 2.806112934194971e-05
aniridia B-Disease 1 0.9999700784683228
phenotypes O 0 2.4867142201401293e-05
. O 0 2.2513651742883667e-07

Strikingly O 0 4.434153743204661e-05
, O 0 4.998444680381908e-08
all O 0 6.140006281185606e-10
four O 0 2.6368676686594483e-10
mutations O 0 2.9530293765844817e-09
are O 0 5.057552709963886e-10
located O 0 2.0372606002183602e-07
within O 0 4.068495540465733e-10
the O 0 2.6273741515758786e-10
PAX6 O 0 2.552742444095202e-06
paired O 0 1.232408930462725e-08
domain O 0 4.417266197265235e-08
and O 0 1.120656012432164e-08
affect O 0 1.0280304607590551e-08
amino O 0 1.7567135246476795e-10
acids O 0 3.647224189329279e-11
which O 0 2.077262944988334e-10
are O 0 4.493698815832836e-11
highly O 0 4.9754939751567306e-11
conserved O 0 3.113461433112974e-10
in O 0 5.325377291920397e-11
all O 0 4.39345539116065e-11
known O 0 1.1612856232190438e-09
paired O 0 2.4389517072620492e-09
domain O 0 1.1474394767674312e-08
proteins O 0 2.9900848463881857e-09
. O 0 1.7518502204438846e-08

Our O 0 2.9411924060696037e-06
results O 0 9.422412716730832e-08
support O 0 8.02869681848506e-09
the O 0 3.8714781380733143e-10
hypothesis O 0 9.507672871222894e-09
that O 0 1.8748046171079835e-10
the O 0 6.770589644489178e-11
under O 0 4.6404161069268923e-10
- O 0 1.2572800756061042e-07
representation O 0 4.710878798164231e-09
of O 0 6.37116581714281e-10
missense O 0 1.3734586900682189e-05
mutations O 0 3.0187331390152394e-07
is O 0 2.5408208870203453e-08
caused O 0 1.0019088669821485e-08
by O 0 4.317134150166879e-10
ascertainment O 0 6.128754193923669e-06
bias O 0 5.268326276564039e-05
and O 0 5.056882557141762e-08
suggest O 0 1.5138343911758056e-08
that O 0 4.689012511605029e-10
a O 0 5.553797977064789e-10
substantial O 0 6.865894075502865e-09
burden O 0 6.443138289569106e-08
of O 0 9.871224948554413e-10
PAX6 B-Disease 0 0.12379465252161026
- I-Disease 1 0.898867666721344
related I-Disease 1 0.6154248118400574
disease I-Disease 0 0.1680937260389328
remains O 0 3.609634632084635e-06
to O 0 4.1719836474385374e-09
be O 0 1.9062564859950726e-08
uncovered O 0 5.985441021039151e-06
. O 0 3.402859993784091e-09
. O 0 2.3600804865964164e-08

The O 0 2.928329578821831e-08
chromosomal O 0 0.00013715910608880222
order O 0 4.6469040171359666e-08
of O 0 4.397724961968663e-10
genes O 0 3.872102283253298e-08
controlling O 0 1.4001161616761237e-05
the O 0 2.540824439734024e-09
major O 0 2.0888027307819357e-08
histocompatibility O 0 5.472404041029222e-07
complex O 0 6.047228851002728e-08
, O 0 1.0424733298819433e-10
properdin O 0 3.451442154300821e-08
factor O 0 6.201398949912118e-09
B O 0 1.8517828721087426e-05
, O 0 2.3638783375190542e-08
and O 0 2.2869201075081946e-06
deficiency B-Disease 0 1.640186928852927e-05
of I-Disease 0 3.1113524950887594e-11
the I-Disease 0 2.5958779570345314e-10
second I-Disease 0 3.5301903622553255e-09
component I-Disease 0 3.561940076224346e-08
of I-Disease 0 3.0859342858846617e-10
complement I-Disease 0 6.889693793254992e-08
. O 0 4.922847196553448e-08

The O 0 6.702065746821972e-08
relationship O 0 1.1619270168239382e-07
of O 0 2.3852941843927056e-10
the O 0 9.554693841673512e-11
genes O 0 1.4286402061358672e-09
coding O 0 1.3755151684335942e-08
for O 0 2.616132865895793e-10
HLA O 0 1.522246435570196e-07
to O 0 6.039926891965308e-10
those O 0 1.300612256782685e-10
coding O 0 4.012425058874669e-09
for O 0 1.6778031741715438e-10
properdin O 0 1.585194127073919e-07
Factor O 0 7.4240000813574625e-09
B O 0 2.221251804712665e-07
allotypes O 0 4.3050883391515526e-07
and O 0 3.17079980050039e-08
for O 0 3.808757043088917e-08
deficiency B-Disease 0 6.836631655460224e-05
of I-Disease 0 5.362314758894371e-11
the I-Disease 0 1.7419923836747842e-10
second I-Disease 0 6.724496959265025e-09
component I-Disease 0 5.995650553813903e-08
of I-Disease 0 1.4316343943665544e-10
complement I-Disease 0 8.301761056372925e-09
( O 0 6.132047092322068e-10
C2 O 0 2.8792655371034925e-07
) O 0 1.5139831055499542e-10
was O 0 3.6491485388978617e-09
studied O 0 6.796470053416215e-10
in O 0 5.933029068039275e-11
families O 0 6.323079837500245e-10
of O 0 3.015915572834871e-10
patients O 0 1.6759376819663885e-07
with O 0 5.350757703581621e-08
connective O 1 0.998963475227356
tissue O 1 0.9999219179153442
disorders O 1 0.850342869758606
. O 0 6.253688411561598e-07

Patients O 0 7.474352059944067e-06
were O 0 1.6126245228065272e-08
selected O 0 1.3047674052302227e-09
because O 0 3.53672563457863e-10
they O 0 1.7134486884895495e-10
were O 0 9.33617738674286e-10
heterozygous O 0 1.9142866847232654e-08
or O 0 1.8482380070850013e-08
homozygous O 0 3.485868364805356e-05
for O 0 0.0014534038491547108
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
. O 0 3.3467813409515657e-07

12 O 0 3.36929161903754e-07
families O 0 2.9489388708725528e-08
with O 0 1.988887721182664e-09
15 O 0 4.1651535553910435e-09
matings O 0 3.542354534147307e-05
informative O 0 0.09111612290143967
for O 1 0.631509006023407
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
were O 0 2.0394494981701428e-07
found O 0 4.923231955444862e-08
. O 0 3.048496566293579e-08

Of O 0 4.355016613999396e-08
57 O 0 2.3999254494810884e-07
informative O 0 1.1031409030692885e-06
meioses O 0 1.5499845176236704e-05
, O 0 1.5651145934825195e-09
two O 0 1.7240825087028178e-11
crossovers O 0 1.3501972873086743e-08
were O 0 2.910055663107869e-08
noted O 0 4.738935643899822e-08
between O 0 8.258616901457572e-08
the O 0 5.343096927390434e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999953508377075
gene O 0 2.0287581392608445e-08
and O 0 2.447325675447587e-09
the O 0 3.514890045686059e-10
HLA O 0 1.6089277323771967e-06
- O 0 2.7267926725471625e-06
B O 0 6.095792173255177e-07
gene O 0 2.6644528805519485e-09
, O 0 7.210074204344608e-11
with O 0 7.815493044405208e-12
a O 0 4.168694209272239e-11
recombinant O 0 1.9775726889381673e-10
fraction O 0 1.4480855403675719e-09
of O 0 2.1898335922365675e-10
0 O 0 2.0863380356672678e-08
. O 0 3.404328907663512e-08

035 O 0 0.02667882852256298
. O 0 1.7473006664658897e-05

A O 0 1.0845735687325941e-06
lod O 0 9.452235826756805e-05
score O 0 6.09825150377219e-08
of O 0 9.538469319947396e-11
13 O 0 6.15652917534959e-10
was O 0 1.5215830817538745e-09
calculated O 0 7.162204607169542e-09
for O 0 1.6006846959015775e-09
linkage O 0 0.0019517672481015325
between O 0 0.009091499261558056
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
and O 0 6.6888969918466046e-09
HLA O 0 2.5507031296001514e-06
- O 0 6.4536634454270825e-06
B O 0 8.590976108280302e-07
at O 0 1.7594642409690664e-09
a O 0 3.326350653254373e-11
maximum O 0 1.0359778312984957e-10
likelihood O 0 1.0527397009685302e-10
value O 0 3.7110337025580975e-10
of O 0 3.345251809935834e-12
the O 0 3.0969755839688196e-12
recombinant O 0 2.1087601109748277e-10
fraction O 0 8.954844088471248e-10
of O 0 3.1875566075534323e-10
0 O 0 2.9220135644436596e-08
. O 0 2.492076056626047e-08

04 O 0 0.0003431013901717961
. O 0 1.8140186739401543e-06

18 O 0 1.4681386346637737e-06
families O 0 4.613407256215396e-08
with O 0 1.0025621444142985e-09
21 O 0 1.8336755447379005e-09
informative O 0 5.8926861612462744e-08
matings O 0 8.757995715313882e-07
for O 0 1.3891665595622271e-09
both O 0 3.2058544707780356e-10
properdin O 0 1.0609271328121395e-07
Factor O 0 6.512685502002569e-09
B O 0 1.8832903947441082e-07
allotype O 0 1.6768267130373715e-07
and O 0 6.740368707625066e-09
HLA O 0 3.3965573038585717e-06
- O 0 2.3275077182915993e-05
B O 0 5.470679752761498e-06
were O 0 1.3906519491513336e-08
found O 0 1.156657347678447e-08
. O 0 1.1235045782598263e-08

Of O 0 4.219119276172023e-08
72 O 0 5.455718792291009e-07
informative O 0 1.7268238252654555e-06
meioses O 0 4.095311669516377e-05
, O 0 2.5735076292221493e-09
three O 0 4.5369946688467166e-10
recombinants O 0 6.362482736221864e-07
were O 0 6.293210930152782e-08
found O 0 1.0846740394754306e-08
, O 0 3.614936822105008e-11
giving O 0 1.3524556474742155e-11
a O 0 1.0465908521772871e-11
recombinant O 0 8.539195045509373e-11
fraction O 0 5.335292763142263e-10
of O 0 2.056424475149754e-10
0 O 0 1.7979285615865592e-08
. O 0 4.797019315105899e-08

042 O 0 0.0018090670928359032
. O 0 8.518014510627836e-06

A O 0 8.911198392524966e-07
lod O 0 2.9396189347608015e-05
score O 0 8.042540855512925e-08
of O 0 1.0058830157699816e-10
16 O 0 2.2214735606596037e-10
between O 0 2.0291510138825686e-10
HLA O 0 3.2446718023493304e-07
- O 0 1.547903138998663e-06
B O 0 2.4910218598961364e-07
and O 0 2.979596569474552e-10
Factor O 0 7.790735279122885e-10
B O 0 2.3646448354952554e-08
allotypes O 0 2.274772370469691e-08
was O 0 8.21810441919979e-09
calculated O 0 8.210036206435234e-09
at O 0 3.0955686902700563e-09
a O 0 2.033870433182372e-10
maximum O 0 8.007557950051591e-10
likelihood O 0 3.5332736736393144e-10
value O 0 5.855516072017508e-10
of O 0 2.891178399119787e-12
the O 0 2.622284984640788e-12
recombinant O 0 7.071009749948232e-11
fraction O 0 4.507719197910376e-10
of O 0 2.990254432955197e-10
0 O 0 3.352508315401792e-08
. O 0 3.610015397725874e-08

04 O 0 0.0005083055002614856
. O 0 3.392530061319121e-06

A O 0 5.609386022342733e-08
crossover O 0 8.260665396164768e-08
was O 0 7.299096296264906e-07
shown O 0 1.3002490639735242e-08
to O 0 1.7503830607168425e-09
have O 0 1.0370182490504476e-09
occurred O 0 7.534149970567228e-10
between O 0 1.464589213795442e-11
genes O 0 7.322959599820322e-11
for O 0 2.069569862706011e-11
Factor O 0 8.162596154548396e-10
B O 0 4.865995606451179e-08
and O 0 8.019082065047201e-10
HLA O 0 2.781478372071433e-07
- O 0 1.0285687494615559e-05
D O 0 2.7688645332091255e-06
, O 0 3.129626280351516e-10
in O 0 4.63191568433885e-11
which O 0 3.5930467490175033e-09
HLA O 0 4.3750792428909335e-06
- O 0 2.0088289602426812e-05
D O 0 3.551639565557707e-06
segregared O 0 9.330814805252885e-07
with O 0 2.078103911173912e-09
HLA O 0 2.6001180231105536e-06
- O 0 3.2327327517123194e-06
A O 0 1.2522563963557332e-07
and O 0 6.623201187494487e-08
B O 0 5.643028544000117e-06
. O 0 2.202465054779168e-08

These O 0 9.046797977418919e-09
studies O 0 6.446058131714949e-10
suggest O 0 1.2164413920601191e-09
that O 0 2.3355014103221272e-11
the O 0 9.187357472018043e-12
genes O 0 1.2018561146298623e-10
for O 0 7.415316971570718e-11
Factor O 0 1.319161953006187e-07
B O 1 0.7984669804573059
and O 1 0.7903262376785278
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
are O 0 4.266881070691397e-09
located O 0 1.208932047802591e-07
outside O 0 9.097081310471822e-09
those O 0 3.360448377898173e-11
for O 0 1.2519442427194605e-10
HLA O 0 6.298843118202058e-07
, O 0 7.697283366248087e-10
that O 0 3.304579665464047e-10
the O 0 6.104561994790814e-11
order O 0 5.011517867359316e-10
of O 0 3.003846824056744e-11
genese O 0 7.42131334163787e-08
is O 0 1.8868087092727137e-09
HLA O 0 1.2766261647811916e-07
- O 0 5.027564498050197e-07
A O 0 4.350160054400476e-08
, O 0 1.2101144530873853e-09
- O 0 5.186261091694178e-07
B O 0 1.3083063095109537e-06
, O 0 5.285025750367822e-10
- O 0 5.133887270858395e-07
D O 0 1.766096033861686e-07
, O 0 1.0610228667884414e-10
Factor O 0 2.072479299286556e-09
B O 0 1.020918625727063e-05
allotype O 0 0.0006198397604748607
, O 0 0.0016800761222839355
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
, O 0 9.755495300467487e-10
that O 0 6.222755644103017e-11
the O 0 1.9943290074930786e-11
genes O 0 4.88192686276534e-09
coding O 0 6.295723778748652e-06
for O 0 0.00037568469997495413
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
and O 0 5.76028647003568e-09
Factor O 0 3.9634260318166525e-09
B O 0 2.4211485083469597e-07
allotypes O 0 4.2756326479320705e-08
are O 0 1.6329178287310953e-10
approximately O 0 1.2350179767750546e-09
3 O 0 1.5058883029439585e-09
- O 0 1.586754933668999e-06
- O 0 1.2331540801824303e-06
5 O 0 1.0355575286169483e-09
centimorgans O 0 2.3279088878780385e-08
from O 0 4.690772076321181e-11
the O 0 4.93526851330639e-11
HLA O 0 6.713504063782239e-08
- O 0 4.471441528153264e-08
A O 0 5.011902892704256e-09
and O 0 3.5265494968683697e-09
HLA O 0 5.15579472448735e-07
- O 0 1.7852223663794575e-06
B O 0 7.668861456977538e-08
loci O 0 2.8839225452159667e-10
, O 0 2.238341595406368e-10
and O 0 3.6755512522468337e-10
that O 0 1.1412025491264188e-10
the O 0 1.7097596949344762e-10
apparent O 0 1.8561902237479444e-08
lack O 0 2.1977208941592608e-10
of O 0 7.419940530051239e-12
recombinants O 0 5.415545345499595e-08
between O 0 8.346510288470554e-11
the O 0 6.155691928411144e-11
Factor O 0 4.369725026265314e-09
B O 0 3.3535081911395537e-06
gene O 0 6.610664513573283e-06
and O 1 0.9802108407020569
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
gene O 0 1.214750966482825e-07
suggests O 0 3.393644831817255e-08
that O 0 8.891666847254953e-10
these O 0 1.8609279395231937e-10
two O 0 3.137162751798428e-10
genes O 0 2.8660268824864943e-08
lie O 0 7.903117875684984e-06
in O 0 5.48588119375637e-10
close O 0 1.355104899403159e-07
proximity O 0 3.0983585475041764e-08
to O 0 2.950597322026738e-09
one O 0 5.515785606036161e-09
another O 0 1.9673002782383264e-08
. O 0 3.51500055728593e-08

Distribution O 0 1.03151671737578e-06
of O 0 5.026607574620812e-09
emerin O 0 3.48007888533175e-05
and O 0 9.301064096689515e-08
lamins O 0 5.838929064339027e-05
in O 0 1.4143057835980244e-09
the O 0 1.2923880854387448e-09
heart O 0 1.9263357842191908e-07
and O 0 8.841827270344993e-10
implications O 0 2.9826801029031458e-09
for O 0 2.1823376439300546e-09
Emery B-Disease 0 0.02004080079495907
- I-Disease 1 0.9999375343322754
Dreifuss I-Disease 1 0.9999685287475586
muscular I-Disease 1 0.9989327788352966
dystrophy I-Disease 1 0.9880951642990112
. O 0 3.3016870020219358e-06

Emerin O 0 0.0008594769169576466
is O 0 3.728619049070403e-07
a O 0 2.5525320523911432e-08
nuclear O 0 7.129983714548871e-06
membrane O 0 6.1356302261117435e-09
protein O 0 2.093839768235739e-09
which O 0 2.2745370031884704e-09
is O 0 6.474673241996243e-09
missing O 0 5.625357957228516e-09
or O 0 2.2852257863803516e-09
defective O 0 1.2680828831435065e-06
in O 0 5.338369302165802e-09
Emery B-Disease 0 0.13921144604682922
- I-Disease 1 0.9999661445617676
Dreifuss I-Disease 1 0.9999939203262329
muscular I-Disease 1 0.9998579025268555
dystrophy I-Disease 1 0.9991727471351624
( O 0 2.129831500496948e-06
EDMD B-Disease 1 0.9999943971633911
) O 0 1.2685399042311474e-07
. O 0 8.897629300008703e-08

It O 0 2.8550448405439965e-07
is O 0 1.1925112453070597e-08
one O 0 9.610572337948042e-10
member O 0 8.460340761295981e-11
of O 0 2.518535553719392e-11
a O 0 1.2455171116698693e-08
family O 0 1.5606833869696857e-07
of O 0 1.0625563762189927e-09
lamina O 0 0.0005251231486909091
- O 0 0.0006747513543814421
associated O 0 2.2073460570481984e-07
proteins O 0 1.2567561435972152e-09
which O 0 5.290633486865204e-10
includes O 0 3.068205689515935e-09
LAP1 O 0 8.304629091071547e-07
, O 0 5.190372021068868e-10
LAP2 O 0 3.51762395212063e-07
and O 0 7.091397691283419e-09
lamin O 0 1.1452131730038673e-05
B O 0 3.1280505936592817e-06
receptor O 0 1.8808236745826434e-08
( O 0 3.3509277574950147e-09
LBR O 0 2.3311383756663417e-06
) O 0 2.2058523896362203e-09
. O 0 9.962815461506125e-09

A O 0 4.849285915042856e-07
panel O 0 6.589029766246313e-08
of O 0 2.811764432397723e-10
16 O 0 2.0242734155573316e-09
monoclonal O 0 2.093370028433128e-07
antibodies O 0 2.4804247544807367e-08
( O 0 1.3290349376582355e-10
mAbs O 0 7.616569597246325e-09
) O 0 1.6590628870716273e-10
has O 0 1.5122176844073465e-09
been O 0 1.4020155036931214e-09
mapped O 0 1.7648025050220895e-06
to O 0 6.0905538390443326e-09
six O 0 3.091566724844341e-10
specific O 0 3.159971173616327e-10
sites O 0 2.5770455991391827e-08
throughout O 0 2.82310314014822e-10
the O 0 6.901573756934454e-11
emerin O 0 4.7479652209858614e-08
molecule O 0 7.258772471985253e-10
using O 0 9.67610769286864e-10
phage O 0 1.3065611703666491e-08
- O 0 3.963080175140021e-08
displayed O 0 9.092119945819377e-09
peptide O 0 5.379097167690361e-10
libraries O 0 3.2372099445510116e-10
and O 0 4.546940046701309e-10
has O 0 1.1338372463143287e-09
been O 0 2.766831486145094e-10
used O 0 4.697158217936703e-10
to O 0 3.888677435615051e-10
localize O 0 1.6095045793917961e-06
emerin O 0 5.250475624052342e-06
in O 0 2.2570172397706756e-09
human O 0 3.219246380581353e-08
and O 0 6.470195046404115e-08
rabbit O 0 0.0018111279932782054
heart O 0 2.0954577848897316e-05
. O 0 1.194017187344798e-07

Several O 0 2.2399203203349316e-07
mAbs O 0 3.4777208384184632e-06
against O 0 1.179801056849783e-08
different O 0 1.225876844479501e-09
emerin O 0 1.3545458159569534e-06
epitopes O 0 3.863010988425231e-06
did O 0 5.8906632460775654e-08
not O 0 6.381259964882702e-10
recognize O 0 2.5831363714701183e-09
intercalated O 0 2.525994746704896e-09
discs O 0 2.6607514882925898e-05
in O 0 7.153330816578318e-09
the O 0 1.974137475713178e-08
heart O 0 1.6434576082247077e-06
, O 0 3.8579298089480574e-10
though O 0 6.854193324024038e-10
they O 0 5.236431288579979e-10
recognized O 0 7.187751505099982e-10
cardiomyocyte O 0 2.003379329096333e-08
nuclei O 0 1.1789974552200988e-09
strongly O 0 8.239827486988816e-09
, O 0 6.941419661288251e-10
both O 0 1.3056829228919042e-10
at O 0 1.5561445820821973e-07
the O 0 2.190532200074813e-09
rim O 0 1.3616615888167871e-06
and O 0 5.0254382877312764e-09
in O 0 8.923097261082091e-10
intranuclear O 0 1.1610657111305045e-06
spots O 0 8.426924864579632e-07
or O 0 1.800448217181838e-07
channels O 0 1.3600418924397673e-06
. O 0 1.4668704295672796e-07

A O 0 2.753284206846729e-06
polyclonal O 0 4.158709998591803e-05
rabbit O 0 4.418388198246248e-05
antiserum O 0 1.5504190741921775e-05
against O 0 1.8995093498119786e-08
emerin O 0 1.1544152584974654e-05
did O 0 6.17341981978825e-08
recognize O 0 1.6125907720265786e-08
both O 0 8.137305274047435e-10
nuclear O 0 4.001585239166161e-06
membrane O 0 6.143148212345295e-09
and O 0 5.301826200287962e-10
intercalated O 0 1.316858067035298e-09
discs O 0 3.452602641118574e-06
but O 0 8.538910911681796e-09
, O 0 3.807204204675507e-11
after O 0 1.2134183415002386e-11
affinity O 0 3.605942974771459e-11
purification O 0 4.085151383836916e-10
against O 0 9.773779702237917e-11
a O 0 5.228686927871706e-10
pure O 0 8.830220110667142e-09
- O 0 3.438862279381283e-07
emerin O 0 3.2033096886152634e-07
band O 0 3.5456162450486772e-09
on O 0 6.873441371624267e-09
a O 0 9.902698661079512e-10
western O 0 3.1042426407168477e-09
blot O 0 7.945601100800559e-05
, O 0 3.4943168358836374e-09
it O 0 2.403742094259087e-09
stained O 0 4.217427340336144e-05
only O 0 2.4307642565446486e-09
the O 0 1.0102442216108898e-09
nuclear O 0 8.730952686164528e-06
membrane O 0 7.663962975357208e-08
. O 0 2.0783666343504592e-08

These O 0 2.9712685645222336e-08
results O 0 1.276036698527605e-08
would O 0 2.4385657937386895e-09
not O 0 3.229427003592633e-10
be O 0 2.8129337747984096e-10
expected O 0 3.049640762142758e-09
if O 0 6.602484670104047e-10
immunostaining O 0 1.0102489511609747e-07
at O 0 5.823741933141946e-09
intercalated O 0 1.5707219969129937e-09
discs O 0 1.4811681694482104e-06
were O 0 1.8421903291709896e-07
due O 0 3.0906897041660386e-09
to O 0 3.8047379136152415e-10
a O 0 3.417299110353156e-09
product O 0 1.6967267413292575e-07
of O 0 2.7121036319521785e-11
the O 0 5.938735614385848e-11
emerin O 0 7.140220503742967e-08
gene O 0 4.7619477250293585e-09
and O 0 1.3233449003280384e-08
, O 0 4.813778264889379e-10
therefore O 0 9.498659636619777e-10
, O 0 8.108019117214482e-11
cast O 0 1.189335074869291e-09
some O 0 2.1324862709004577e-10
doubt O 0 1.0891990642747373e-09
upon O 0 4.644983009338688e-11
the O 0 6.68117575153282e-11
hypothesis O 0 4.3955573403309245e-08
that O 0 5.63439179757097e-08
cardiac B-Disease 0 0.0015755046624690294
defects I-Disease 1 0.5418195724487305
in O 0 1.0437700126431082e-07
EDMD B-Disease 1 0.9999998807907104
are O 0 6.887380550324451e-07
caused O 0 1.6838937710872415e-07
by O 0 7.022827874791915e-10
absence O 0 3.34476579766374e-09
of O 0 2.9986849114926883e-10
emerin O 0 2.0194424905639607e-06
from O 0 3.1484759244193583e-09
intercalated O 0 3.2936407023953507e-07
discs O 0 4.124259066884406e-05
. O 0 2.456807806083816e-07

Although O 0 1.209320714679052e-07
emerin O 0 5.425069048214937e-06
was O 0 6.72175559657262e-08
abundant O 0 1.1749117234671758e-09
in O 0 1.4081975863167173e-10
the O 0 1.1693042367699746e-10
membranes O 0 6.3898619728774975e-09
of O 0 4.344738804840098e-11
cardiomyocyte O 0 1.575572383671897e-07
nuclei O 0 6.657522089170698e-09
, O 0 8.279255059306934e-10
it O 0 3.21623727650433e-09
was O 0 1.6691873838681204e-07
absent O 0 1.1815209921550718e-09
from O 0 2.518006983476262e-11
many O 0 3.22229430638199e-11
non O 0 8.724648559166326e-09
- O 0 2.8590629881364293e-06
myocyte O 0 8.776817594480235e-06
cells O 0 9.536842426882686e-09
in O 0 8.139773299831177e-10
the O 0 9.402947753756052e-09
heart O 0 2.720403017519857e-06
. O 0 3.724858288478572e-08

This O 0 7.2867134548459944e-09
distribution O 0 6.502683191911274e-08
of O 0 4.0185504923684334e-10
emerin O 0 4.4113912736065686e-06
was O 0 2.3340717802966537e-07
similar O 0 1.1098494345773702e-09
to O 0 4.054149238541527e-10
that O 0 4.324122448995382e-10
of O 0 3.5342964666007504e-11
lamin O 0 1.5286809684766922e-06
A O 0 9.884779217372852e-08
, O 0 6.039880817709786e-10
a O 0 4.6222717320354434e-10
candidate O 0 1.9032437847954498e-09
gene O 0 5.456101792589152e-09
for O 0 1.057879006616247e-09
an O 0 2.877709404103257e-09
autosomal O 0 3.1071882403921336e-05
form O 0 5.404214675763797e-07
of O 0 1.2918338825329556e-06
EDMD B-Disease 1 0.9999991655349731
. O 0 4.734414233098505e-06

In O 0 4.156980892844331e-08
contrast O 0 2.742872027283738e-07
, O 0 2.9627685194100195e-08
lamin O 0 0.0008776003960520029
B1 O 1 0.585821270942688
was O 0 2.172315134885139e-06
absent O 0 2.436446955300653e-08
from O 0 5.426810667508164e-10
cardiomyocyte O 0 1.0818458662242847e-07
nuclei O 0 3.62889496230423e-09
, O 0 3.18941761889846e-10
showing O 0 9.84904033884959e-08
that O 0 5.819555948249899e-09
lamin O 0 4.528233694145456e-05
B1 O 0 0.001108374330215156
is O 0 1.3038103041651539e-08
not O 0 2.5540486392472417e-10
essential O 0 1.1019809370571565e-10
for O 0 1.8577814633879974e-11
localization O 0 4.923286223146306e-09
of O 0 7.918762867653584e-11
emerin O 0 4.839191092287365e-07
to O 0 2.0772084052822493e-09
the O 0 6.054509338326852e-09
nuclear O 0 0.00020691686950158328
lamina O 0 4.9285499699180946e-06
. O 0 3.489875766149453e-08

Lamin O 1 0.8102031946182251
B1 O 1 0.9971645474433899
is O 0 8.744657975512382e-07
also O 0 1.2020296935588703e-07
almost O 0 2.135036325512374e-08
completely O 0 7.408548867715581e-07
absent O 0 6.570318333842806e-08
from O 0 5.1200421680164254e-09
skeletal O 0 0.00043899050797335804
muscle O 0 2.23505185203976e-06
nuclei O 0 2.8522796924335125e-07
. O 0 6.940764052387749e-08

In O 0 6.132065095698636e-07
EDMD B-Disease 1 0.9999914169311523
, O 0 1.0157396701515609e-08
the O 0 4.513438234265976e-11
additional O 0 1.3894839445693918e-10
absence O 0 1.4301013706585763e-09
of O 0 3.461023689865783e-10
lamin O 0 0.0022492657881230116
B1 O 0 0.49703091382980347
from O 0 4.494048155834207e-08
heart O 0 5.9394256822997704e-05
and O 0 7.700182322878391e-07
skeletal O 0 0.008012327365577221
muscle O 0 5.154122959538654e-07
nuclei O 0 3.159956563081323e-08
which O 0 7.295047055322357e-08
already O 0 6.38538111275011e-08
lack O 0 5.689366755490255e-09
emerin O 0 3.07312643599289e-06
may O 0 4.450128443522772e-08
offer O 0 1.897114909610309e-09
an O 0 5.6584206070686704e-11
alternative O 0 1.1974086167043652e-09
explanation O 0 1.0241978376512861e-09
of O 0 3.107444163097384e-11
why O 0 1.9125558914367957e-09
these O 0 6.051362883008338e-11
tissues O 0 1.997666254638375e-09
are O 0 5.723679169511442e-11
particularly O 0 4.21376711301491e-10
affected O 0 3.741454257522037e-09
. O 0 5.859147056419545e-10
. O 0 1.4501978284897632e-08

Genetic O 0 6.2652370615978725e-06
mapping O 0 2.4910650608944707e-06
of O 0 3.138409088165872e-09
the O 0 7.315414940478604e-09
copper B-Disease 0 4.782792166224681e-05
toxicosis I-Disease 0 6.600127380806953e-05
locus O 0 1.8042123883788008e-07
in O 0 3.376262824872356e-09
Bedlington O 0 1.8334494598093443e-06
terriers O 0 2.4718115128052887e-06
to O 0 2.5644439460847934e-08
dog O 0 0.00015258607163559645
chromosome O 0 5.322619927028427e-06
10 O 0 1.7407785435352707e-08
, O 0 9.271370893237929e-10
in O 0 2.4850771440654285e-10
a O 0 8.145057961428392e-09
region O 0 1.084877254697858e-07
syntenic O 0 3.3505830288049765e-06
to O 0 5.1897512953758e-09
human O 0 2.497643869503463e-08
chromosome O 0 1.3198382475820836e-05
region O 0 7.700226092310913e-07
2p13 O 0 5.503731244971277e-06
- O 0 3.6062814615434036e-05
p16 O 0 1.0928049960057251e-05
. O 0 1.722874571896682e-07

Abnormal O 1 0.9978193044662476
hepatic B-Disease 1 0.9993721842765808
copper I-Disease 0 0.03346036747097969
accumulation I-Disease 0 2.6501382308197208e-05
is O 0 3.6518105162031134e-07
recognized O 0 1.3502351237093535e-07
as O 0 3.68383723525767e-07
an O 0 3.3445328881498426e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.409062969694787e-07
man O 0 0.00026069526211358607
, O 0 1.1009317013588316e-08
mouse O 0 1.375907777401153e-05
, O 0 9.997212835344271e-09
rat O 0 5.0178117817267776e-05
and O 0 2.1814425110733282e-07
dog O 0 0.0008896856452338398
. O 0 1.7066831503598223e-07

The O 0 1.3630241824102995e-07
major O 0 4.630403509509051e-07
cause O 0 5.196757228986826e-07
of O 0 2.6180474677062193e-08
hepatic B-Disease 1 0.9756848812103271
copper I-Disease 0 0.14860749244689941
accumulation I-Disease 0 1.0623141861287877e-05
in O 0 4.63541383055599e-08
man O 0 1.5277499187504873e-05
is O 0 8.289434916264327e-09
a O 0 4.294355093747981e-09
dysfunctional O 0 4.881724748884153e-07
ATP7B O 0 4.7923331294441596e-06
gene O 0 2.0788313292996463e-07
, O 0 8.564584597081648e-09
causing O 0 7.554200465165195e-07
Wilson B-Disease 0 2.9807319151586853e-05
disease I-Disease 0 4.3324245780240744e-05
( O 0 1.6470014685410206e-08
WD B-Disease 0 0.0007811147952452302
) O 0 2.289987222070522e-08
. O 0 5.183917295425999e-08

Mutations O 0 1.7616161130717956e-05
in O 0 1.7946362618204148e-08
the O 0 8.519173699816918e-10
ATP7B O 0 8.87703299667919e-06
genes O 0 2.5992992647161373e-08
have O 0 6.430944221591517e-09
also O 0 2.104096452626436e-09
been O 0 5.105940115157637e-09
demonstrated O 0 6.1961609176819366e-09
in O 0 2.545198218850686e-10
mouse O 0 9.416153261554427e-06
and O 0 7.964808190763506e-08
rat O 0 0.00013111703447066247
. O 0 1.198761339082921e-07

The O 0 3.770620793375201e-08
ATP7B O 0 3.096154614468105e-06
gene O 0 1.5569149525163084e-07
has O 0 3.8038422189856647e-08
been O 0 4.397970432279408e-09
excluded O 0 7.915629929300394e-09
in O 0 6.887292819390822e-11
the O 0 2.9286434388708926e-11
much O 0 1.4386590807546895e-09
rarer O 0 1.405253442499088e-07
human O 0 8.268119700005627e-07
copper B-Disease 0 0.14569619297981262
overload I-Disease 0 0.04745522141456604
disease O 0 3.616065441747196e-05
non B-Disease 0 8.105052984319627e-07
- I-Disease 0 0.05775413289666176
Indian I-Disease 0 1.9529609289747896e-06
childhood I-Disease 0 0.000220075438846834
cirrhosis I-Disease 0 0.00020851752196904272
, O 0 1.86469528706823e-09
indicating O 0 1.6576765915488068e-07
genetic O 0 3.670969874747243e-07
heterogeneity O 0 3.3208741569978883e-06
. O 0 4.977765684088808e-07

By O 0 8.640095927603397e-08
investigating O 0 1.8886248653871007e-07
the O 0 4.3936942972777615e-09
common O 0 8.117289667097793e-07
autosomal O 1 0.820501983165741
recessive O 1 0.8541799783706665
copper B-Disease 1 0.7233580350875854
toxicosis I-Disease 0 0.005008568521589041
( O 0 5.615495624056166e-09
CT B-Disease 0 3.0702543881488964e-05
) O 0 1.3331129533611374e-09
in O 0 5.420055515514832e-10
Bedlington O 0 1.5843718301766785e-06
terriers O 0 8.125452950480394e-06
, O 0 1.9177548438165104e-08
we O 0 6.150278863970016e-08
have O 0 1.3262855258489026e-09
identified O 0 1.7853557521263497e-09
a O 0 4.70269552466096e-11
new O 0 7.332841278628877e-11
locus O 0 6.6323764258413576e-09
involved O 0 2.0676790057905237e-08
in O 0 6.178061653372424e-07
progressive O 1 0.9996970891952515
liver B-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
. O 0 1.391850787513249e-06

We O 0 1.0353312518418534e-07
examined O 0 8.253184802242686e-08
whether O 0 9.552237889565163e-10
the O 0 6.248210282500111e-10
WD B-Disease 0 1.582950062584132e-05
gene O 0 5.426060312174741e-08
ATP7B O 0 6.349241630232427e-06
was O 0 2.5389323354829685e-07
also O 0 1.6459392737644407e-09
causative O 0 1.9732830480734265e-08
for O 0 2.0880040751958262e-10
CT B-Disease 0 1.0200097676715814e-05
by O 0 1.105800895295772e-09
investigating O 0 4.4710663615887825e-08
the O 0 2.6878357317627888e-09
chromosomal O 0 0.0016887640813365579
co O 0 6.436059629777446e-05
- O 0 1.2180543308204506e-05
localization O 0 1.1621524436122854e-06
of O 0 6.154251552814571e-10
ATP7B O 0 4.293941401556367e-06
and O 0 2.523423248135259e-09
C04107 O 0 7.20252169017499e-09
, O 0 1.980542292667753e-11
using O 0 3.61755070343861e-11
fluorescence O 0 5.859236984484539e-10
in O 0 3.212683938325078e-11
situ O 0 2.639717333607905e-09
hybridization O 0 5.079459075574277e-10
( O 0 2.2561251478148137e-10
FISH O 0 1.0678536277453077e-08
) O 0 1.8734900297801005e-09
. O 0 1.110574210372306e-08

C04107 O 0 3.500832826830447e-05
is O 0 1.209409532521022e-07
an O 0 8.303894794003952e-10
anonymous O 0 1.5392791041790588e-08
microsatellite O 0 8.381285624636803e-06
marker O 0 3.7123143556527793e-05
closely O 0 4.905609785055276e-07
linked O 0 6.037685579940444e-06
to O 0 1.9942522300198107e-08
CT B-Disease 0 0.001151634263806045
. O 0 2.0054176275152713e-07

However O 0 2.5980136797443265e-07
, O 0 3.8797391965772476e-08
BAC O 0 2.1809028112329543e-06
clones O 0 4.062021616846323e-07
containing O 0 5.30616190985711e-08
ATP7B O 0 2.8380603907862678e-05
and O 0 1.1610714167886727e-08
C04107 O 0 9.533280831419688e-08
mapped O 0 7.958921742101666e-06
to O 0 6.5081899869312565e-09
the O 0 2.957527556191053e-09
canine O 0 8.25961342343362e-06
chromosome O 0 2.158040842914488e-06
regions O 0 4.549920618046599e-08
CFA22q11 O 0 1.4497602478513727e-06
and O 0 1.4186752217426601e-08
CFA10q26 O 0 1.9009138441106188e-06
, O 0 1.5607891645785799e-09
respectively O 0 1.514082192954902e-09
, O 0 1.0564831648407491e-10
demonstrating O 0 1.7306637234426603e-09
that O 0 6.377852690420127e-10
WD B-Disease 0 7.396776254608994e-06
cannot O 0 6.880576997048138e-09
be O 0 2.6361171925892712e-11
homologous O 0 9.036618120461526e-10
to O 0 2.487174466381248e-09
CT B-Disease 0 0.0001712797675281763
. O 0 1.031509384574747e-07

The O 0 1.8607281049298763e-07
copper O 0 5.654244432662381e-06
transport O 0 8.464468947977366e-08
genes O 0 2.2782808528631904e-08
CTR1 O 0 2.0905099518131465e-06
and O 0 9.533587252974485e-09
CTR2 O 0 2.4862993086571805e-06
were O 0 3.785306645909259e-08
also O 0 2.2220170148301577e-09
excluded O 0 1.552639439239556e-08
as O 0 4.228420114049669e-10
candidate O 0 5.586627271902955e-10
genes O 0 4.1734221634115443e-10
for O 0 8.080430768941937e-11
CT B-Disease 0 2.5779931092984043e-05
since O 0 1.1025287349752944e-08
they O 0 2.2063026960950083e-09
both O 0 1.2944252614222052e-10
mapped O 0 1.5293870092136785e-05
to O 0 9.247201404605221e-08
canine O 0 0.00011866920976899564
chromosome O 0 5.11251091666054e-05
region O 0 3.717088020493975e-06
CFA11q22 O 0 4.447781975613907e-05
. O 0 3.6334165542939445e-07

2 O 0 1.8508467292122077e-06
- O 0 5.8473091485211626e-05
22 O 0 1.802365403591466e-07
. O 0 3.223067679414271e-08

5 O 0 5.9270369092701e-06
. O 0 6.979194608902617e-07

A O 0 7.47856233829225e-07
transcribed O 0 1.2759741139234393e-06
sequence O 0 1.7518325989840378e-07
identified O 0 3.37219120183363e-07
from O 0 2.7026758608883483e-10
the O 0 2.542534516258854e-10
C04107 O 0 1.2293597251300525e-07
- O 0 7.383804359051283e-07
containing O 0 8.58839044326487e-08
BAC O 0 1.6847960750965285e-06
was O 0 3.656114131445065e-07
found O 0 2.55515630875891e-09
to O 0 8.573793758293036e-11
be O 0 1.0156844115760677e-10
homologous O 0 2.5532645442361e-10
to O 0 7.764563297874005e-11
a O 0 4.5769327217115574e-10
gene O 0 6.088451520724902e-09
expressed O 0 6.460323387358358e-10
from O 0 1.698707702280089e-10
human O 0 6.649653716550574e-09
chromosome O 0 9.167347911898105e-07
2p13 O 0 6.08760672093922e-07
- O 0 3.312839453428751e-06
p16 O 0 1.53099335875595e-07
, O 0 2.021514733385743e-09
a O 0 1.844504105008582e-09
region O 0 7.856067796296884e-09
devoid O 0 2.2119245102203422e-08
of O 0 4.860255600758201e-11
any O 0 1.274629957137563e-09
positional O 0 9.334226547252911e-08
candidate O 0 1.7398332374796155e-07
genes O 0 1.9695008290909755e-07
. O 0 1.1908205976851605e-07

Molecular O 0 2.1573298170096677e-07
analysis O 0 4.858501867488485e-08
of O 0 6.569021437918821e-10
the O 0 5.291168614363073e-10
APC B-Disease 0 1.3203647952764186e-08
gene O 0 1.182982156677781e-09
in O 0 3.09963776867761e-10
205 O 0 6.048703760086482e-09
families O 0 3.517145019671375e-09
: O 0 3.383280877677919e-10
extended O 0 1.4088813671264688e-08
genotype O 0 1.8229466149932705e-06
- O 0 1.5892606825218536e-05
phenotype O 0 3.105221537680336e-07
correlations O 0 1.1160042134861214e-07
in O 0 7.683202407626766e-10
FAP B-Disease 0 2.5494570010664575e-08
and O 0 2.7352553555459735e-09
evidence O 0 1.5669248121241708e-09
for O 0 1.4702659922871675e-10
the O 0 1.3412994326333916e-10
role O 0 9.019347491090457e-10
of O 0 7.812427094133767e-11
APC B-Disease 0 2.3584783903629614e-08
amino O 0 7.524585954321594e-10
acid O 0 5.935770763798587e-10
changes O 0 4.67406691129213e-09
in O 0 4.704802904598182e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
predisposition O 0 0.04670381546020508
. O 0 1.6377297242797795e-06

BACKGROUND O 0 2.8425407435861416e-05
/ O 0 3.711807949002832e-05
AIMS O 0 1.972674908756744e-06
The O 0 8.88786877428771e-10
development O 0 1.8461632578237186e-07
of O 0 1.13049691208289e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3571388396703696e-07
a O 0 9.363663622252716e-09
variable O 0 7.69596795180405e-07
range O 0 8.387885941374407e-07
of O 0 2.3361632628393636e-09
extracolonic O 0 0.00012058085849275813
manifestations O 0 3.7041274481453e-05
in O 0 1.730897679408372e-06
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999409914016724
polyposis I-Disease 1 0.999997615814209
( O 0 1.117533656724845e-07
FAP B-Disease 0 1.6959259596660559e-07
) O 0 1.383312686620286e-09
is O 0 9.394983679911206e-10
the O 0 3.399554249217118e-11
result O 0 8.529753986463717e-11
of O 0 1.1894631113396059e-11
the O 0 5.483600240552278e-10
dominant O 0 3.67309917237435e-06
inheritance O 0 2.4701548682060093e-06
of O 0 9.880019206320867e-06
adenomatous B-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999772310256958
coli I-Disease 1 0.9999924898147583
( O 0 1.0927271887339884e-07
APC B-Disease 0 4.6429440203610284e-07
) O 0 2.932698972557546e-09
gene O 0 1.851216211434803e-07
mutations O 0 1.1449087651271839e-06
. O 0 1.9535070805432042e-07

In O 0 2.0131086131414122e-08
this O 0 1.655292014568488e-10
study O 0 2.1776255798577893e-10
, O 0 3.9283500063991283e-11
direct O 0 3.4374186830277154e-10
mutation O 0 7.168297067039475e-10
analysis O 0 5.488748344717465e-10
of O 0 5.840333078266369e-11
the O 0 3.510749191359963e-10
APC B-Disease 0 5.875713249281489e-09
gene O 0 1.750366407371473e-09
was O 0 2.9405869739207446e-08
performed O 0 1.345077116354787e-08
to O 0 2.4329616099549867e-10
determine O 0 9.382095100818333e-09
genotype O 0 1.949834540937445e-06
- O 0 9.376332855026703e-06
phenotype O 0 2.217471433141327e-07
correlations O 0 8.485579883199534e-08
for O 0 2.2826556200783443e-09
nine O 0 4.407291420704951e-09
extracolonic O 0 5.396335041041311e-07
manifestations O 0 7.964641213220602e-08
and O 0 1.884269629215396e-09
to O 0 3.002908754989875e-10
investigate O 0 1.680543171289628e-08
the O 0 3.748273635917343e-10
incidence O 0 7.41698568162974e-06
of O 0 2.7964144888592557e-10
APC B-Disease 0 7.403937019034856e-08
mutations O 0 1.275423500146644e-08
in O 0 4.041257994913394e-09
non O 0 4.176467700744979e-05
- O 1 0.9998730421066284
FAP O 1 0.9996658563613892
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 1.6367725947930012e-06

METHODS O 0 1.0331411885999842e-06
The O 0 1.3555276900945046e-09
APC B-Disease 0 3.8795466394958567e-08
gene O 0 1.3429468204151362e-08
was O 0 1.701764240635839e-08
analysed O 0 2.2214290851252372e-08
in O 0 5.57278057033983e-10
190 O 0 8.027533304755252e-09
unrelated O 0 3.009425597610971e-08
FAP B-Disease 0 8.785151095480614e-08
and O 0 9.793980737526908e-09
15 O 0 1.66932974110523e-08
non O 0 4.9761019909055904e-05
- O 1 0.9999260902404785
FAP O 1 0.9998327493667603
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 5.266340394882718e-07
using O 0 8.260366257673013e-08
denaturing O 0 0.00037459167651832104
gradient O 0 4.776105561177246e-05
gel O 0 1.6083607988548465e-05
electrophoresis O 0 3.181546901487309e-07
, O 0 1.163464991016383e-09
the O 0 3.478015792035549e-11
protein O 0 3.539296911103662e-10
truncation O 0 4.8739281055532047e-08
test O 0 1.3594799952443282e-07
, O 0 1.0044737958070371e-10
and O 0 1.5536985586983576e-10
direct O 0 1.924334691594254e-09
sequencing O 0 1.0692990315419593e-07
. O 0 3.438117346377112e-08

RESULTS O 0 1.1980819181189872e-05
Chain O 0 6.023049081704812e-06
terminating O 0 1.9682315155478136e-07
signals O 0 7.379997413181627e-08
were O 0 7.0521064543527245e-09
only O 0 2.6634353056387283e-10
identified O 0 1.0874212108546999e-07
in O 0 3.237951018419949e-10
patients O 0 1.5989454205111997e-09
belonging O 0 9.501708753134608e-09
to O 0 1.0174300291154736e-09
the O 0 1.2513313718542918e-09
FAP B-Disease 0 2.351628403118866e-08
group O 0 1.588912779126872e-09
( O 0 6.112135103597538e-11
105 O 0 2.918096653203861e-09
patients O 0 1.5341109493860472e-09
) O 0 3.9543854302159787e-10
. O 0 1.0559805474485984e-08

Amino O 0 2.4770710638222226e-07
acid O 0 7.405699165019541e-09
changes O 0 3.3939195898113894e-10
were O 0 8.44275760414348e-10
identified O 0 3.3213154893019237e-08
in O 0 5.653633672331182e-10
four O 0 3.0948310580924954e-09
patients O 0 3.1007036938035526e-09
, O 0 1.133466931424465e-10
three O 0 8.115074584535975e-11
of O 0 8.053412797748294e-11
whom O 0 1.0025225094523194e-08
belonged O 0 5.613249598468428e-08
to O 0 2.373110818965074e-09
the O 0 9.177943960381185e-10
non O 0 5.079517677586409e-07
- O 0 2.5376122721354477e-05
FAP O 0 3.5872898251909646e-07
group O 0 2.4600902293059335e-07
of O 0 4.229782007314498e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 1.3686601050721947e-05
. O 0 2.0135853162628337e-07

Genotype O 0 0.001604907913133502
- O 0 0.001252453657798469
phenotype O 0 5.459036401589401e-06
correlations O 0 6.8457402448984794e-06
identified O 0 2.889348706958117e-06
significant O 0 2.967938073084042e-08
differences O 0 4.15509703088901e-06
in O 0 3.773179990673725e-09
the O 0 1.209876754337813e-09
nature O 0 9.2195165279918e-08
of O 0 6.442674865825282e-11
certain O 0 7.199262852530808e-10
extracolonic O 0 8.91481079179357e-07
manifestations O 0 1.4670173698050348e-07
in O 0 1.8927561740156307e-09
FAP B-Disease 0 1.7413503883290105e-07
patients O 0 2.8273186014615703e-09
belonging O 0 7.284295833187571e-09
to O 0 7.024555936929744e-10
three O 0 2.871557214234599e-09
mutation O 0 9.000451228757811e-08
subgroups O 0 3.035471252132993e-07
. O 0 6.925820628111978e-08

CONCLUSIONS O 0 5.902589236939093e-06
Extended O 0 2.8206096658323077e-07
genotype O 0 1.0632405064825434e-05
- O 0 4.191181869828142e-05
phenotype O 0 7.353692694778147e-07
correlations O 0 7.016407153059845e-07
made O 0 2.020413347736394e-08
in O 0 2.5511567858238493e-10
this O 0 7.825700504282551e-11
study O 0 4.304537559729482e-10
may O 0 7.360355436247801e-09
have O 0 7.259464696041107e-10
the O 0 3.899192427270215e-11
potential O 0 3.6568664762981484e-10
to O 0 1.743029331979784e-10
determine O 0 1.2097383095266423e-09
the O 0 5.180667006499107e-11
most O 0 4.100168468634813e-11
appropriate O 0 3.628297939872738e-10
surveillance O 0 6.950785973458551e-07
and O 0 7.258219025807477e-10
prophylactic O 0 2.1845839626166708e-07
treatment O 0 1.3272781984596804e-08
regimens O 0 8.069903856267047e-09
for O 0 3.6828495808549633e-10
those O 0 1.855693820829174e-09
patients O 0 2.6134361341689782e-09
with O 0 2.0215870644157974e-10
mutations O 0 7.742657004428111e-08
associated O 0 1.648875667115135e-07
with O 0 3.508336376967236e-08
life O 0 3.3898779747687513e-06
threatening O 0 0.0004293968959245831
conditions O 0 8.297960448544472e-06
. O 0 1.3791830610898614e-07

This O 0 4.183450030836866e-09
study O 0 3.4684930483308563e-09
also O 0 9.123402033850425e-10
provided O 0 3.82975456902912e-10
evidence O 0 1.871365062910968e-09
for O 0 4.6381151697083567e-10
the O 0 1.3661904940676095e-09
pathological O 0 3.23581093653047e-06
nature O 0 7.201370522125217e-08
of O 0 5.8124616231225446e-11
amino O 0 4.428650501875353e-10
acid O 0 1.732654575370418e-10
changes O 0 4.153583033073005e-11
in O 0 8.606793056031847e-11
APC O 0 5.246161283167794e-09
associated O 0 1.819169814787358e-09
with O 0 4.3595999033030353e-10
both O 0 8.60318594142484e-10
FAP B-Disease 0 1.0354912660659465e-07
and O 0 2.0130164202214473e-08
non O 0 4.006697781733237e-05
- O 1 0.9998873472213745
FAP O 1 0.9998594522476196
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 9.673569365986623e-06
. O 0 8.908511262006868e-09
. O 0 9.058265959538403e-08

Inherited B-Disease 1 0.9999480247497559
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999798536300659
and O 0 0.019606992602348328
cancer B-Disease 0 0.14850498735904694
risk O 0 2.3322925244428916e-06
of O 0 6.048262446434194e-10
the O 0 4.280012344537454e-09
APC O 0 1.2137255680499948e-06
I1307K O 0 1.5899465779511956e-06
polymorphism O 0 5.86580608796794e-06
. O 0 1.742151027883665e-07

Germ O 0 0.010432466864585876
- O 0 0.0012954081175848842
line O 0 3.6076573451282457e-05
and O 0 3.0352318436399628e-09
somatic O 0 1.84290485094607e-08
truncating O 0 1.8151611413941282e-07
mutations O 0 5.349747667082738e-08
of O 0 1.1980477720996419e-10
the O 0 2.2926202603024137e-10
APC B-Disease 0 3.1167846081814332e-09
gene O 0 7.807098301171322e-10
are O 0 9.697053576784853e-11
thought O 0 8.291850539521306e-10
to O 0 1.8142666258214035e-09
initiate O 0 0.00015094404807314277
colorectal B-Disease 1 0.9999998807907104
tumor I-Disease 0 0.18141043186187744
formation O 0 1.697669540590141e-05
in O 0 8.397080819122493e-05
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999986886978149
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
and O 0 5.838728611706756e-05
sporadic O 1 0.9963557720184326
colorectal O 1 0.9999998807907104
carcinogenesis O 1 0.7984864711761475
, O 0 4.401959188271576e-07
respectively O 0 4.1174322973347444e-07
. O 0 1.0938948946659366e-07

Recently O 0 1.677609543548897e-05
, O 0 8.320133026984422e-09
an O 0 8.452248345669489e-10
isoleucine O 0 0.00017965983715839684
- O 0 9.877383126877248e-05
- O 0 4.896384780295193e-05
> O 0 8.035105025783196e-08
lysine O 0 2.3678634875068383e-07
polymorphism O 0 2.3579819696806226e-07
at O 0 2.9630001563418773e-08
codon O 0 4.0911046994551725e-08
1307 O 0 8.190238531824434e-08
( O 0 2.088968026336957e-10
I1307K O 0 3.947981497276487e-09
) O 0 2.5103967515871517e-11
of O 0 5.460820597796845e-12
the O 0 3.689541033802257e-11
APC B-Disease 0 1.889935097310058e-09
gene O 0 1.824893569590813e-09
has O 0 4.862726665777473e-09
been O 0 2.0151744717367137e-09
identified O 0 3.1254463461749538e-09
in O 0 6.506196970068601e-11
6 O 0 4.873290659901386e-10
% O 0 1.249842312978089e-10
- O 0 2.1290395579853794e-06
7 O 0 1.3984027269486887e-08
% O 0 6.578534245127443e-11
of O 0 3.7917752271354743e-11
the O 0 3.678428450726301e-09
Ashkenazi O 0 1.2140272076521796e-07
Jewish O 0 5.07859176934744e-08
population O 0 3.550544747099593e-08
. O 0 3.4955785821466634e-08

To O 0 6.78440557067006e-08
assess O 0 1.1194210856046993e-06
the O 0 3.337921050672321e-09
risk O 0 6.220391668421144e-08
of O 0 4.164172826004453e-11
this O 0 4.333634007203102e-10
common O 0 1.839666907699211e-08
APC B-Disease 0 7.99134625140141e-08
allelic O 0 4.267819235792558e-07
variant O 0 2.6462743335287087e-05
in O 0 7.167776061578479e-07
colorectal O 1 0.9999994039535522
carcinogenesis O 0 0.003573694732040167
, O 0 1.4354972677210753e-07
we O 0 3.518468716379175e-08
have O 0 4.919575302686496e-10
analyzed O 0 2.367202212028019e-09
a O 0 7.559484149766149e-10
large O 0 1.8806864954257208e-09
cohort O 0 6.809995234391408e-09
of O 0 4.957630972413085e-10
unselected O 0 3.3536871342221275e-06
Ashkenazi O 0 8.221641678574088e-07
Jewish O 0 3.0476306278615084e-07
subjects O 0 5.819697435072158e-07
with O 0 1.447064601478587e-08
adenomatous B-Disease 0 7.576020288979635e-05
polyps I-Disease 0 4.710307257482782e-05
and O 0 3.497873422020348e-07
. O 0 2.1018156814989197e-07
or O 1 0.9990007281303406
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.7590723544458342e-08
for O 0 8.504416060262088e-10
the O 0 3.703349182870852e-09
APC O 0 3.744690957319108e-07
I1307K O 0 3.8971836602286203e-07
polymorphism O 0 2.937083536380669e-06
. O 0 1.4925102220786357e-07

The O 0 1.0065061673003584e-07
APC O 0 5.36879042556393e-07
I1307K O 0 2.5756898480722157e-07
allele O 0 1.1715695791281178e-07
was O 0 4.0746812146608136e-08
identified O 0 2.0155905389174222e-08
in O 0 1.027478657711356e-10
48 O 0 6.070648983502736e-10
( O 0 1.1479959344251611e-11
10 O 0 1.3358324862933202e-11
. O 0 4.764593233841374e-12
1 O 0 3.393730088618874e-11
% O 0 9.262665287557148e-12
) O 0 1.0820460846772129e-11
of O 0 4.5030333628570673e-11
476 O 0 7.909128640903873e-08
patients O 0 2.1658141946545584e-08
. O 0 1.7273766417247316e-08

Compared O 0 6.690685268040397e-07
with O 0 3.262862868780303e-09
the O 0 1.0516840870389288e-10
frequency O 0 3.613501320387513e-08
in O 0 6.523696582938499e-10
two O 0 1.581341446676987e-10
separate O 0 1.9899690784086488e-09
population O 0 9.9943286979709e-10
control O 0 1.9316854604767286e-07
groups O 0 2.2006245714578654e-09
, O 0 2.457418712964454e-10
the O 0 1.0736034977698594e-10
APC O 0 5.250115453492299e-09
I1307K O 0 6.212290681872901e-09
allele O 0 7.766407961184996e-09
is O 0 9.596101691045078e-10
associated O 0 1.0160996488650653e-09
with O 0 2.5730154118441817e-10
an O 0 7.519330991190287e-11
estimated O 0 3.437278195406179e-08
relative O 0 2.82767160797448e-07
risk O 0 3.7565367705383323e-08
of O 0 4.81034601040875e-10
1 O 0 5.0226425685195863e-08
. O 0 8.058971445734642e-08

5 O 0 1.1194551916560158e-06
- O 0 3.160991764161736e-05
1 O 0 1.2311407715515088e-07
. O 0 3.748477794829341e-08

7 O 0 2.8286956421652576e-06
for O 0 3.559733272595622e-07
colorectal B-Disease 1 0.9999995231628418
neoplasia I-Disease 0 0.05345490947365761
( O 0 2.301902846113535e-08
both O 0 1.1113031384013539e-08
P O 0 0.03767907992005348
= O 0 2.4410996957158204e-06
. O 0 3.7496561411387574e-09
01 O 0 1.6420869997091359e-07
) O 0 1.7552441722301637e-09
. O 0 2.3097138424077457e-08

Furthermore O 0 6.557872893608874e-07
, O 0 3.4099159051947936e-09
compared O 0 6.0871627738379175e-09
with O 0 9.358391839242586e-10
noncarriers O 0 1.2805511687474791e-05
, O 0 8.487579528093647e-10
APC O 0 8.926199335235196e-09
I1307K O 0 1.517135572726147e-08
carriers O 0 3.3372973273770867e-09
had O 0 1.5273490250322652e-09
increased O 0 3.5010197518836605e-10
numbers O 0 1.998161414107358e-09
of O 0 6.161568477658363e-10
adenomas B-Disease 0 0.2723456919193268
and O 0 0.0009731097961775959
colorectal B-Disease 1 1.0
cancers I-Disease 0 0.002939101541414857
per O 0 3.432600976793765e-07
patient O 0 4.491684649110539e-06
( O 0 1.8049647332318841e-09
P O 0 0.05647607147693634
= O 0 1.3436510926112533e-06
. O 0 1.3560681466628921e-09
03 O 0 3.3252758324664455e-09
) O 0 5.623571400215077e-11
, O 0 9.286551388987263e-11
as O 0 1.9616852586779032e-10
well O 0 1.6558550086642754e-09
as O 0 3.781434887439872e-10
a O 0 7.406952828858948e-10
younger O 0 1.4014566174225251e-09
age O 0 2.8011242214631693e-09
at O 0 1.9260878048044106e-07
diagnosis O 0 6.8019817263120785e-06
. O 0 5.478566578176469e-08

We O 0 3.885167529915634e-07
conclude O 0 2.1506901148882207e-08
that O 0 2.5947294313155567e-10
the O 0 2.4903820672328436e-10
APC O 0 2.4594935865707157e-08
I1307K O 0 5.162367600064499e-08
variant O 0 2.005281913852741e-07
leads O 0 4.9155541859136065e-09
to O 0 3.04485148205913e-09
increased O 0 1.0890189514611848e-06
adenoma B-Disease 1 0.9999991655349731
formation O 0 2.5937285386135045e-07
and O 0 1.0930227389849279e-08
directly O 0 1.5317075385823387e-09
contributes O 0 3.141199966805175e-09
to O 0 4.6066933601096594e-10
3 O 0 8.121040506736676e-10
% O 0 1.3385265118515122e-10
- O 0 5.38336109912052e-07
4 O 0 1.0364882285784915e-09
% O 0 5.003616271315181e-11
of O 0 9.4243043924358e-11
all O 0 1.4505021184163525e-08
Ashkenazi O 0 0.0004326838534325361
Jewish O 1 0.7699978947639465
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999996542930603
. O 0 9.658502904130728e-07

The O 0 9.406409873236043e-09
estimated O 0 9.63923767471897e-08
relative O 0 1.2203013000089413e-07
risk O 0 7.515269828672899e-08
for O 0 9.32233401584881e-10
carriers O 0 2.632543605329829e-08
may O 0 3.043945540071036e-09
justify O 0 1.2606075294741004e-08
specific O 0 3.219146282873453e-09
clinical O 0 1.6188242968340205e-09
screening O 0 1.294860552114585e-09
for O 0 1.0011246692753772e-10
the O 0 2.445727301236822e-11
360 O 0 3.4199856280281438e-09
, O 0 5.694582999593578e-11
000 O 0 1.167085039721627e-10
Americans O 0 4.0080921220875254e-11
expected O 0 9.81226322416262e-10
to O 0 3.5881206339460903e-10
harbor O 0 6.839859878482457e-08
this O 0 4.8024043075578504e-11
allele O 0 4.296558664407257e-09
, O 0 5.860410490221568e-10
and O 0 3.7594932722484486e-10
genetic O 0 2.8005100460859467e-09
testing O 0 2.573351842727334e-08
in O 0 1.9194107414577388e-10
the O 0 1.2030143548003025e-10
setting O 0 1.155632389782113e-07
of O 0 2.7224084098165235e-10
long O 0 2.7087793341706856e-07
- O 0 1.1758417713281233e-05
term O 0 1.3870445059183112e-07
- O 0 1.5278313014732703e-07
outcome O 0 2.004027832569477e-09
studies O 0 2.422672340518517e-10
may O 0 4.537583364605524e-10
impact O 0 1.8167495285936752e-09
significantly O 0 3.793655309891619e-07
on O 1 0.9689558148384094
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
prevention O 0 1.1238473689445527e-06
in O 0 3.4372482637934354e-10
this O 0 4.657689234299767e-10
population O 0 6.5860237263848376e-09
. O 0 1.0136474770661152e-08

Localization O 0 2.8439179004635662e-05
of O 0 7.584964656359716e-09
human O 0 5.9353808978812594e-08
BRCA1 O 0 6.903162557136966e-06
and O 0 6.780705774644957e-08
its O 0 1.730304965974483e-08
loss O 0 8.3672908601784e-08
in O 0 3.046065399914255e-09
high O 0 1.5140763025556225e-06
- O 0 0.00014879136870149523
grade O 0 1.0476815077709034e-05
, O 0 4.888449200990408e-09
non B-Disease 0 2.840953129634727e-06
- I-Disease 1 0.9254857301712036
inherited I-Disease 1 0.9997488856315613
breast I-Disease 1 0.9997705817222595
carcinomas I-Disease 1 0.9999990463256836
. O 0 1.8656031897990033e-05

Although O 0 8.962592090711041e-08
the O 0 6.991019985136404e-10
link O 0 3.079385351156816e-07
between O 0 5.863197038991075e-09
the O 0 7.878831809193798e-09
BRCA1 O 0 0.0005299669574014843
tumour B-Disease 1 0.9999992847442627
- O 0 2.38870779867284e-05
suppressor O 0 9.506445167062338e-06
gene O 0 9.435643733013421e-06
and O 0 0.0001030873681884259
hereditary B-Disease 1 0.9999949932098389
breast I-Disease 1 0.9999997615814209
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.107537284246064e-06
established O 0 3.0328664024636964e-08
, O 0 1.1192647919600063e-09
the O 0 8.60717053186022e-11
role O 0 7.954162661860664e-09
, O 0 4.529083497128994e-10
if O 0 2.249894298644861e-10
any O 0 4.212866722141939e-10
, O 0 8.897430014975782e-11
of O 0 2.40934425188577e-11
BRCA1 O 0 4.313895374252752e-08
in O 0 1.7258905415928893e-09
non B-Disease 0 1.05144508779631e-05
- I-Disease 1 0.9547505974769592
familial I-Disease 1 0.7929754257202148
cancers I-Disease 0 0.010065216571092606
is O 0 1.3337957227577135e-07
unclear O 0 1.4561493344444898e-07
. O 0 3.264912606937287e-08

BRCA1 O 0 0.0005836248747073114
mutations O 0 5.877128842257662e-06
are O 0 1.1073273853412502e-08
rare O 0 1.9141552343171497e-08
in O 0 3.72873776299798e-09
sporadic B-Disease 0 0.027269823476672173
cancers I-Disease 0 0.04621264338493347
, O 0 1.5158050814534363e-08
but O 0 4.797428676539539e-09
loss O 0 1.123626702792535e-08
of O 0 2.1946590378352226e-10
BRCA1 O 0 7.981968224157754e-07
resulting O 0 6.025650645113956e-09
from O 0 8.52192039157984e-10
reduced O 0 8.406174423214452e-09
expression O 0 1.6579573269837056e-08
or O 0 1.350666067878592e-08
incorrect O 0 1.148115757132473e-06
subcellular O 0 8.19622800918296e-06
localization O 0 7.652415092707088e-07
is O 0 1.4140117965411036e-09
postulated O 0 7.713847338663982e-10
to O 0 2.6029531308147114e-10
be O 0 2.4272744925113443e-10
important O 0 1.0378527204313315e-10
in O 0 1.678171213104207e-10
non B-Disease 0 3.3566821002750657e-06
- I-Disease 1 0.818332850933075
familial I-Disease 1 0.9997990727424622
breast I-Disease 1 0.9999910593032837
and I-Disease 1 0.9999613761901855
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999992847442627
. O 0 2.214676442235941e-06

Epigenetic O 0 3.214705429854803e-05
loss O 0 3.141862543998286e-05
, O 0 2.9338975693349312e-08
however O 0 2.25035434731069e-09
, O 0 2.1724326781935588e-09
has O 0 1.653842041093867e-08
not O 0 4.912711903948264e-10
received O 0 6.65286922774122e-11
general O 0 1.0994260363217379e-10
acceptance O 0 1.9011503482602166e-09
due O 0 8.868936141048778e-10
to O 0 3.0190119848505503e-10
controversy O 0 2.7349944531351866e-09
regarding O 0 2.0992021454446785e-09
the O 0 1.8611161223258677e-10
subcellular O 0 3.555770717866835e-06
localization O 0 2.6358327431807993e-07
of O 0 2.9728755568392273e-10
BRCA1 O 0 3.540529291967687e-08
proteins O 0 9.103185982795026e-10
, O 0 3.7185440837639305e-10
reports O 0 4.15020551258749e-09
of O 0 5.0165455123263314e-11
which O 0 3.8003829416766166e-08
have O 0 7.154299819234211e-09
ranged O 0 1.5059121949434484e-08
from O 0 3.4199365561704553e-11
exclusively O 0 2.4072797089047526e-09
nuclear O 0 1.1208322575839702e-05
, O 0 6.762768817170084e-11
to O 0 3.967430550755324e-11
conditionally O 0 1.1445415992739072e-07
nuclear O 0 6.75371029501548e-06
, O 0 2.1412972089907e-11
to O 0 1.80515220826738e-11
the O 0 1.4091164346474727e-10
ER O 0 1.415614974575874e-06
/ O 0 6.738564479746856e-07
golgi O 0 1.7002109586883307e-07
, O 0 1.06051345483138e-09
to O 0 4.496410466181544e-10
cytoplasmic O 0 5.6721631835898734e-08
invaginations O 0 2.2956315604005795e-07
into O 0 6.324852863670571e-10
the O 0 1.0368560454665499e-09
nucleus O 0 4.349123017277634e-08
. O 0 2.3831910667126976e-08

In O 0 3.604779408306058e-08
an O 0 9.181042592842914e-10
attempt O 0 1.389774837434743e-07
to O 0 1.3915752994364539e-08
resolve O 0 8.271920819424849e-07
this O 0 2.799072085224452e-10
issue O 0 1.0145299000896557e-07
, O 0 4.4482911798482405e-10
we O 0 1.2893106582367864e-09
have O 0 3.440449314329186e-10
comprehensively O 0 1.0336279956391081e-06
characterized O 0 3.726528419178976e-08
19 O 0 8.200051304640965e-09
anti O 0 9.115884722632472e-07
- O 0 3.844114689854905e-05
BRCA1 O 0 4.733506557386136e-06
antibodies O 0 3.1380312748297e-07
. O 0 2.8990752909408002e-08

These O 0 1.3179266566964998e-08
reagents O 0 1.0335890721080432e-07
detect O 0 2.2930386478492437e-07
a O 0 1.4419336835658214e-09
220 O 0 1.2421909723059343e-08
- O 0 2.7701378257916076e-07
kD O 0 4.204634933557827e-07
protein O 0 5.036549843850935e-09
localized O 0 7.832547055386385e-09
in O 0 6.370773353303605e-11
discrete O 0 2.7906363442298243e-08
nuclear O 0 3.476797792245634e-05
foci O 0 2.906450902173674e-07
in O 0 3.4165481554992994e-10
all O 0 2.572446144988305e-10
epithelial O 0 1.6856594697856053e-07
cell O 0 9.920503543980885e-06
lines O 0 1.1042628102586605e-05
, O 0 9.969406411514115e-10
including O 0 2.62585619914546e-10
those O 0 2.37839775651949e-10
derived O 0 1.5611791859271307e-09
from O 0 3.983000596008424e-09
breast B-Disease 0 0.00011452989565441385
malignancies I-Disease 0 4.139488373766653e-05
. O 0 3.0304499887279235e-07

Immunohistochemical O 0 0.0004799326998181641
staining O 0 5.658301233779639e-05
of O 0 3.269212101031371e-08
human O 0 8.698529541106836e-07
breast O 0 7.382970215985551e-05
specimens O 0 2.081061893477454e-06
also O 0 3.4842400964407716e-07
revealed O 0 1.6262953067780472e-05
BRCA1 O 0 5.7553654187358916e-05
nuclear O 0 0.0004056809120811522
foci O 0 9.482107998337597e-06
in O 0 3.995130626321952e-08
benign O 1 0.8570365905761719
breast O 0 0.03130970895290375
, O 0 8.443088006515609e-08
invasive B-Disease 0 0.0011356204049661756
lobular I-Disease 1 0.9990548491477966
cancers I-Disease 0 0.16600720584392548
and O 0 2.651967179190251e-06
low B-Disease 0 0.05232781171798706
- I-Disease 1 0.9195507168769836
grade I-Disease 1 0.5746834874153137
ductal I-Disease 1 0.9991145730018616
carcinomas I-Disease 1 0.9999985694885254
. O 0 9.968928679882083e-06

Conversely O 0 7.824583008186892e-06
, O 0 4.439294087887902e-08
BRCA1 O 0 1.5026690789454733e-06
expression O 0 4.2730405880320177e-07
was O 0 1.6624196632619714e-06
reduced O 0 7.709589056048571e-08
or O 0 1.8085225406139216e-07
undetectable O 0 3.758543925869162e-06
in O 0 3.314787333508207e-10
the O 0 8.930874789703225e-11
majority O 0 1.5620421622841718e-10
of O 0 6.422944814898912e-11
high O 0 2.323707349205506e-06
- O 0 0.0006171247805468738
grade O 0 3.272797403042205e-05
, O 0 1.1873795280337163e-08
ductal B-Disease 0 0.015653742477297783
carcinomas I-Disease 1 0.9999997615814209
, O 0 3.0861084354683044e-08
suggesting O 0 5.260492486058865e-08
that O 0 1.6154590998240792e-09
absence O 0 1.117257730776089e-09
of O 0 8.414796637268296e-11
BRCA1 O 0 3.520906091125653e-07
may O 0 3.879818688545811e-09
contribute O 0 6.652073891721955e-10
to O 0 7.449670325065938e-10
the O 0 2.252912995048817e-10
pathogenesis O 0 1.4035145490254308e-08
of O 0 2.2755936024410062e-11
a O 0 4.1980757758963705e-10
significant O 0 7.955645031643144e-10
percentage O 0 4.293423216950032e-08
of O 0 4.532836772597193e-09
sporadic B-Disease 1 0.7359427213668823
breast I-Disease 1 0.9842126965522766
cancers I-Disease 0 0.008052513003349304
. O 0 1.4492052002879063e-08
. O 0 1.0763791635781672e-07

